<SEC-DOCUMENT>0001193125-20-197435.txt : 20200723
<SEC-HEADER>0001193125-20-197435.hdr.sgml : 20200723
<ACCEPTANCE-DATETIME>20200723064832
ACCESSION NUMBER:		0001193125-20-197435
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		43
FILED AS OF DATE:		20200723
DATE AS OF CHANGE:		20200723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annexon, Inc.
		CENTRAL INDEX KEY:			0001528115
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				275414423
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-239647
		FILM NUMBER:		201042698

	BUSINESS ADDRESS:	
		STREET 1:		180 KIMBALL WAY
		STREET 2:		SUITE 200
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650)-822-5500

	MAIL ADDRESS:	
		STREET 1:		180 KIMBALL WAY
		STREET 2:		SUITE 200
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d773514ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the U.S. Securities and Exchange Commission on July 23, 2020. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-239647 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:3.00pt solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No. 2 </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES ACT
OF 1933 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Annexon, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Exact name of
registrant as specified in its charter) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><FONT STYLE="white-space:nowrap">27-5414423</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Primary Standard Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Classification Code Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Identification Number)</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>180 Kimball
Way, Suite 200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>South San Francisco, California 94080 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">822-5500</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Douglas Love, Esq. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Annexon, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>180 Kimball
Way, Suite 200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>South San Francisco, California 94080 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">822-5500</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>Copies to:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kathleen M. Wells</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Brian J. Cuneo</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>140 Scott Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park,
California 94025</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">328-4600</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Charles S. Kim</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kristin VanderPas</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Michael
Tenta</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>David Peinsipp</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>4401 Eastgate
Mall</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92121</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">550-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this
Registration Statement. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If any of the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this
form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration
statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and
&#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">Large&nbsp;accelerated&nbsp;filer&nbsp;&nbsp;&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Accelerated filer&nbsp;&nbsp;&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer&nbsp;&nbsp;&#9745;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9745; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><B>Title&nbsp;of&nbsp;each&nbsp;class&nbsp;of securities&nbsp;to&nbsp;be&nbsp;registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>to be</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>registered<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed maximum<BR>aggregate offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>price per share</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed&nbsp;maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>aggregate&nbsp;offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>price<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount&nbsp;of<BR>registration&nbsp;fee<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.001 par
value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman" ALIGN="center">14,375,000</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman" ALIGN="center">$16.00</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman" ALIGN="center">$230,000,000</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman" ALIGN="center">$29,854</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Includes 1,875,000 shares of common stock that the underwriters have the option to purchase.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(a)
under the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The registrant previously paid a total of $23,884 in connection with the previous filing of the registration
statement. </P></TD></TR></TABLE>  <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the
Registration Statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="line-height:5.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Arial Narrow" ALIGN="justify"><FONT COLOR="#cc062a"><B>The information in this preliminary prospectus is not complete and
may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers
to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#cc062a"><B>SUBJECT TO COMPLETION, DATED JULY 23, 2020 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000
Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g16w09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This is an initial public offering of shares of common stock of Annexon, Inc. We are offering 12,500,000&nbsp;shares of our
common stock. We currently expect the initial public offering price to be between $15.00 and $16.00 per share of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. Our common stock has been approved for listing
on the Nasdaq Global Select Market under the symbol &#147;ANNX.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company&#148;
as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Annexon, Inc., before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">See the section titled &#147;Underwriting&#148; for a description of the compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>Investing in our common stock involves risks. See &#147;<A HREF="#toc773514_2">Risk&nbsp;Factors</A>&#148; beginning on
page&nbsp;12 to read about factors you should consider before buying shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities nor passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted the underwriters the option for a period of 30 days to purchase up to an additional 1,875,000&nbsp;shares
from us at the initial price to the public less the underwriting discounts and commissions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters expect
to deliver the shares against payment in New York, New York on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>BofA&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Cowen</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_4">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_9">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_10">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_13">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_14">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_18">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_22">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc773514_23">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Annexon,&#148; &#147;Annexon Biosciences,&#148; the Annexon logo and other trademarks, trade names or service marks of
Annexon, Inc. appearing in this prospectus are the property of Annexon, Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and
trade names in this prospectus may be referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any
indicator that their respective owners will not assert their rights thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither we nor the underwriters have
authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility
for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to
do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results
of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For investors outside the United States: Neither we nor the
underwriters have done anything that would permit this offering or possession or distribution of this prospectus or any free writing prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose
is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus and any such free writing prospectus outside the United
States. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This summary highlights selected information contained in greater detail elsewhere in this prospectus. This summary is not
complete and does not contain all of the information you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus. You should carefully consider, among other things,
the sections titled &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial
statements and the related notes included elsewhere in this prospectus. Unless the context otherwise requires, the terms &#147;Annexon,&#148; the &#147;company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references in this
prospectus refer to Annexon, Inc. and its consolidated subsidiary. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical
complement-mediated disorders of the body, brain and eye. Our pipeline is based on our platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by
aberrant activation of C1q, the initiating molecule of the classical complement pathway. Evidence suggests that potent and selective inhibition of C1q can prevent tissue damage triggered in antibody-mediated autoimmune disease and preserve loss of
functioning synapses associated with cognitive and functional decline in complement-mediated neurodegeneration. Our upstream complement approach targeting C1q acts as an &#147;on/off switch&#148; designed to block all downstream components of the
classical complement pathway that lead to excess inflammation, tissue damage and patient disability in a host of complement-mediated disorders, while preserving the normal immune function of the lectin and alternative complement pathways involved in
the clearance of pathogens and damaged cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pipeline of product candidates is designed to block the activity of C1q
and the entire classical complement pathway in a broad set of complement-mediated diseases. Our first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative
disorders. Our second product candidate, ANX007, is an antigen-binding fragment, or Fab, formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. We are also developing ANX009, an investigational,
subcutaneous formulation of a Fab designed for the treatment of systemic autoimmune diseases. We have completed Phase 1b safety and dose-ranging clinical trials for ANX005 and ANX007 in patients with Guillain-Barr&eacute; Syndrome, or GBS, and
glaucoma, respectively. Both ANX005 and ANX007 were well-tolerated and showed full inhibition of C1q and the classical complement pathway in the Phase 1b trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on learnings from our initial trials, we are advancing our current programs while evaluating additional orphan and large
market indications. We are also developing novel product candidates designed to inhibit C1q and other components of the early classical complement cascade with the goal of further broadening our portfolio. Finally, we are leveraging our disciplined
development strategy in early clinical trials utilizing established biomarkers to enhance patient selection, measure target engagement and assess our product candidates&#146; potential to meaningfully impact the disease process and improve the
probability of technical success over shorter development timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We hold worldwide development and commercialization
rights, including through exclusive licenses, to all of our product candidates, which allows us to strategically maximize value from our product portfolio over time. Our patent portfolio includes patent protection for our upstream complement
platform and each of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The complement system is an integral component of the immune system that
consists of many circulating and locally-produced molecules. This system evolved to enhance, or complement, other components of the </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
adaptive and innate immune systems. The complement system rapidly responds to pathogens, damaged cells and unwanted tissue components to facilitate their removal by the immune system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are three main complement pathways&#151;the classical, lectin and alternative pathways. Each pathway is initiated by
different molecules that respond to distinct triggers. The classical pathway is initiated by C1q, which recognizes antibody complexes, specific pathogens, damaged cells or unwanted cellular components. While the lectin and alternative pathways are
initiated by distinct molecules, all three pathways converge downstream on common pathway components known as C3 and C5. Specific activated components of the complement cascade, triggered by any of the pathways, have important immune functions that
contribute to three key outcomes involving immune cell recruitment and inflammation, directed immune cell attack and membrane damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The classical complement cascade has a well-established role in augmenting antibody function within the immune system. C1q
recognizes antibodies bound to pathogens or cells and activates the classical pathway to trigger their removal and clearance by the immune system. C1q can also directly recognize pathogens, damaged cells or unwanted cellular components leading to
similar downstream clearance. A more recent finding made by the laboratory of the late Dr.&nbsp;Ben Barres, our scientific founder, is that C1q also directly interacts with neuronal connections, or synapses, during early development. Recognition of
weaker synapses by C1q triggers the classical complement cascade and directs immune cells to &#147;prune&#148; the synapses away from neurons, thereby reinforcing stronger synapses to establish appropriate neuronal connections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of its central role in immune function, aberrant activation of C1q and the classical complement cascade can lead to
damage of healthy tissue and destruction of functioning synapses. We are focused on two distinct disease processes involving C1q as a key mediator of tissue damage: antibody-mediated autoimmune disease and complement-mediated neurodegeneration. To
our knowledge, our two clinical-stage product candidates, ANX005 and ANX007, are the first clinical-stage product candidates designed to inhibit C1q and the entire classical complement pathway. By inducing full inhibition of C1q and the classical
cascade, we seek to block upstream tissue-damaging components of the classical pathway as well as the downstream membrane attack complex, while leaving the lectin and alternative pathways intact to perform their normal immune functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our approach has broad utility for the treatment of antibody-mediated autoimmune disease and complement-mediated
neurodegeneration, in which full inhibition of the entire classical complement cascade may be beneficial. Our initial indications represent our beachhead within both disease areas, and we will selectively pursue both orphan and larger patient
population diseases with clear biological evidence of classical complement activation. We are also developing novel product candidates targeting C1q and additional components of the classical complement cascade, and will utilize different drug
modalities to target these components. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are deploying a disciplined, biomarker-driven development strategy designed to
establish confidence that each of our product candidates is engaging the specific target at a well-tolerated therapeutic dose in the intended patient tissue. We design small, early-stage clinical trials to rigorously evaluate the product candidate
using target engagement and pharmacodynamic biomarkers. We are utilizing sensitive, specific assays for C1q and activation of downstream classical complement components to select patients who may be more likely to respond to anti-C1q therapy and
evaluate target engagement in patient tissues. We will also employ biomarkers, such as neurofilament light chain, or NfL, to provide <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in small patient
trials. We believe that this development strategy allows us to make rational decisions regarding our therapeutic pipeline, increasing the probability of technical success over shorter development timelines for product candidates we advance into
later stage trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Annexon was <FONT STYLE="white-space:nowrap">co-founded</FONT> by Dr.&nbsp;Ben Barres, former member
of the National Academy of Sciences, Chair of Neurobiology at Stanford University and a pioneer in complement-mediated neurodegeneration, and Dr.&nbsp;Arnon </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Rosenthal, a world-renowned scientist and industry executive. We have assembled a seasoned and accomplished management team that has been involved in the development, approval and
commercialization of numerous marketed drugs, and has been studying the complement pathway and autoimmune and neurodegenerative disorders for decades. Our team is further supported by an experienced scientific advisory board and leading healthcare
investors that share our commitment to advancing transformative medicines for patients suffering from debilitating autoimmune and neurodegenerative diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
pipeline is focused on antibody-mediated autoimmune and complement-mediated neurodegenerative disorders for which there is significant unmet medical need. Our product candidates are summarized below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g98f32.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">We have activated investigational new drug applications for these indications. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Following the activation of an investigational new drug application, we intend to initiate a Phase 2 clinical
trial in this disease indication. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our first clinical-stage product candidate is ANX005, an
investigational monoclonal antibody designed to block C1q and activation of the classical complement cascade. For GBS, ANX005 is designed to act early in the disease course to prevent nerve damage and irreversible neurological disability in GBS
patients. In the Phase&nbsp;1b dose-ranging trial in GBS patients, treatment with ANX005 was well-tolerated and resulted in full and prolonged C1q engagement and classical cascade inhibition in the blood and cerebrospinal fluid, or CSF. While our
Phase 1b trial was not powered to show statistical significance, we did observe a significant reduction in NfL, a well-accepted marker of nerve damage in neurodegenerative disease that has been shown to correlate with disease severity and clinical
outcomes. Patients treated with ANX005 also showed positive numerical trends across key GBS outcome measures. GBS is a rare, acute, antibody-mediated autoimmune disease impacting the peripheral nervous system. There are currently no approved
therapies for GBS in the United States, but intravenous immunoglobulin, or IVIg, and plasma exchange are the current standards of care in the Western world and parts of Asia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have initiated a Phase 1b drug-drug interaction, or DDI, trial, to assess any potential pharmacokinetic, or PK, interaction
between ANX005 and co-administered IVIg and to evaluate the safety of this combination in GBS patients. This trial is being conducted in the United States, Europe and Bangladesh. We anticipate that the results from the DDI trial will provide data on
the combined use of ANX005 and IVIg in GBS patients in the Western world. However, this trial will provide no evidence of the efficacy of ANX005 as a monotherapy, nor is the trial powered to show a statistically significant efficacious outcome with
the combined administration of ANX005 and IVIg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we intend to advance ANX005 into a Phase 2/3 trial in GBS
patients in developing countries in early 2021. This randomized Phase 2/3 trial will be statistically powered to evaluate the efficacy of ANX005 in </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
improving disability in GBS patients. ANX005 has received both Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, or FDA, for the treatment of GBS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beyond GBS, we intend to study ANX005 in patients with Huntington&#146;s disease, or HD, as well as patients with amyotrophic
lateral sclerosis, or ALS&#151;two neurodegenerative disorders where aberrant classical complement activation has been shown to be associated with synapse loss, elevated levels of NfL and disease progression. We plan to initiate Phase&nbsp;2a trials
in patients with HD and ALS in 2020 to assess ANX005&#146;s safety, tolerability, target engagement and impact on disease-related biomarkers such as NfL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also intend to study ANX005 in patients with warm autoimmune hemolytic anemia, or wAIHA, an antibody-mediated autoimmune
disease characterized by the premature destruction of red blood cells. The classical complement pathway plays an important role in wAIHA through the removal of red blood cells labeled by activated complement components in the spleen or liver
(extra-vascular hemolysis) and less common destruction of red blood cells in the blood vessels by the classical complement generated membrane attack complex (intravascular hemolysis). Following the activation of an investigational new drug
application, or IND, for wAIHA in 2020, we plan to initiate a Phase&nbsp;2 trial in patients with the primary diagnosis of wAIHA. We intend to conduct a non-interventional screening study in wAIHA patients to utilize complement activation markers to
identify and select patients who may be more likely to respond to our anti-C1q therapy in the planned Phase 2 trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
second clinical-stage product candidate is ANX007, an investigational C1q Fab designed for intravitreal administration in patients with complement-mediated neurodegenerative ophthalmic disorders. Consistent with the results we observed in
preclinical studies, in the Phase 1b trial with intravitreal administration in glaucoma patients, ANX007 was well-tolerated and showed full target engagement and inhibition of C1q in the eye for at least four weeks. We believe inhibition of C1q may
provide neuroprotective benefit by preventing the aberrant loss of functioning synapses in the retina in a variety of ophthalmic disorders, including glaucoma and geographic atrophy, or GA. Based on a range of considerations, including preclinical
data, clinical results observed to date, proximate clinical validation and an established, objective clinical and regulatory path, we plan to advance ANX007 into a Phase 2 trial in patients with GA in 2021 with the goal of protecting against the
loss of photoreceptor neurons in a well-defined patient population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our preclinical pipeline includes ANX009, an
investigational C1q Fab designed for subcutaneous delivery. We are developing ANX009 to enable chronic dosing for patients with antibody-mediated autoimmune disorders where anti-C1q may have a disease-modifying effect and where we can utilize our
targeted biomarker-driven approach. These disorders may include autoimmune hemolytic anemias and a subset of lupus nephritis patients who are selected for pathogenic anti-C1q antibodies, or PACA, and who have a high risk of renal flare. We intend to
select our initial lead autoimmune disease indication and commence a first-in-human, or FIH, clinical trial in 2020. We are developing additional next generation product candidates, including ANX105, an investigational monoclonal antibody with
enhanced dosing and PK properties designed for chronic neurodegenerative diseases, and small molecules designed for chronic autoimmune and neurodegenerative diseases. We intend to advance both ANX105 and our small molecule candidates through IND
enabling studies in 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal is to develop disease-modifying medicines for patients suffering from classical complement-mediated diseases. Key
elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leveraging our distinct approach of inhibiting C1q and aberrant upstream classical complement activity
to address a broad range of well characterized classical complement-mediated diseases</I></B><B>. </B>By inhibiting C1q and the early classical cascade, we believe our product candidates are uniquely designed to address a wide range of
antibody-mediated autoimmune diseases as well as complement-mediated neurodegenerative disorders. We believe full classical complement inhibition may result in clinical </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
benefit by blocking aberrant upstream immune cell activation in our targeted indications and potentially provide safety advantages by leaving the lectin and alternative pathways intact to perform
their normal immune functions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advancing ANX005 through clinical development in multiple autoimmune and neurodegenerative indications
of high unmet need</I></B><B>.</B> Our Phase 1b trial in patients with GBS demonstrated full target engagement of C1q in serum and the CSF, as well as a significant reduction in NfL, a well-accepted biomarker shown to be elevated in patients with
GBS, HD and ALS and correlated with disease severity and clinical course and outcomes. We intend to advance ANX005 into a Phase&nbsp;2/3 trial in patients with GBS in early 2021, and into Phase 2a trials in patients with HD and ALS in 2020. We also
intend to advance ANX005 into a Phase&nbsp;2 trial in patients with wAIHA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Evaluating ANX007 as an agent for neuroprotective benefit in ophthalmic indications</I></B><B>.</B> We
are developing ANX007 in neurodegenerative ophthalmic indications, such as glaucoma and GA. ANX007 reduced retinal damage in animal models of glaucoma and GA. In our Phase 1b trial in glaucoma patients, intravitreal administration of ANX007 resulted
in full target engagement of C1q at both low and high doses. Based on this clinical dosing data, our preclinical data in glaucoma and GA, and proximate clinical validation from downstream complement approaches, we believe that ANX007 may provide
neuroprotective benefit in patients with these and other complement-mediated ophthalmic disorders. We plan to advance ANX007 into a Phase 2 trial in patients with GA in 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expanding our autoimmune and neurodegenerative portfolios informed by data from our beachhead
indications. </I></B>Our initial indications represent our beachhead within antibody-mediated autoimmune and complement-mediated neurodegenerative diseases. We intend to leverage learnings from our initial indications to inform selection of
additional orphan and larger patient populations involving related biological mechanisms. In our autoimmune portfolio, potential indications include antibody-mediated autoimmune disorders such as wAIHA, Cold Agglutinin Disease, or CAD, and lupus
nephritis, (specifically in lupus nephritis patients with endogenous PACA). In our neurodegenerative portfolio, potential indications include complement-mediated neurodegeneration disorders in the eye and brain such as glaucoma, GA, HD, ALS,
frontotemporal dementia and Alzheimer&#146;s disease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Developing additional product candidates that are designed to inhibit activation of the classical
complement cascade</I></B><B>.</B> We have secured broad intellectual property protection for our upstream complement platform and intend to leverage our intellectual property and know-how to protect and enhance our leading position in developing
novel therapeutics that target the classical complement cascade. We are developing product candidates, such as ANX009, to modulate the classical pathway with the potential to become tailored therapeutics for a large range of indications using
different molecular modalities, dosing regimens and tissue localization strategies. In addition, we are developing next generation product candidates, including ANX105, an investigational monoclonal antibody, and small molecule modulators of the
classical pathway, for the treatment of chronic autoimmune and neurodegenerative diseases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Maximizing the value of our product candidates</I></B><B>. </B>We currently hold worldwide development
and commercialization rights, including through exclusive licenses, to all of our product candidates. We intend to pursue independent development and commercialization in select indications and markets that we can address with a focused sales and
marketing organization. We may opportunistically explore licensing agreements, collaborations or partnerships to develop our product candidates in larger market indications where we could accelerate development utilizing the resources of larger
biopharmaceutical companies. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Preliminary Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June 30, 2020, we had approximately $124.7&nbsp;million in cash and cash equivalents. This estimate of our cash and cash
equivalents is preliminary and subject to completion, including the completion of customary financial statement closing and review procedures for the quarter ended June&nbsp;30, 2020. As a result, the unaudited preliminary cash and cash equivalents
set forth above reflects our preliminary estimate with respect to such information, based on information currently available to management, and may vary from our actual financial position as of June&nbsp;30, 2020. Further, this preliminary estimate
is not a comprehensive statement or estimate of our financial results or financial condition as of and for quarter ended June&nbsp;30, 2020. The unaudited preliminary cash and cash equivalents included herein has been prepared by, and is the
responsibility of, management. KPMG LLP, our independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to the unaudited preliminary cash and cash equivalents. Accordingly, KPMG LLP
does not express an opinion or any other form of assurance with respect thereto. This estimate should not be viewed as a substitute for financial statements prepared in accordance with accounting principles generally accepted in the United States
and they are not necessarily indicative of the results to be achieved in any future period. Accordingly, you should not draw any conclusions based on the foregoing estimate and should not place undue reliance on this preliminary estimate. We assume
no duty to update this preliminary estimate except as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common
stock.&nbsp;These risks are more fully described in the section titled &#147;Risk Factors&#148; immediately following this prospectus summary. These risks include, among others, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved
for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to
assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary
capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business is heavily dependent on the successful development, regulatory approval and commercialization of
our two clinical-stage product candidates, ANX005 and ANX007, each of which is in early stages of clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Public health crises such as pandemics or similar outbreaks could materially and adversely affect our
preclinical and clinical trials, business, financial condition and results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that
any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates may cause undesirable and unforeseen side effects or have other properties that could
halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties
to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all,
would materially and adversely affect our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any collaboration arrangements that we may enter into in the future may not be successful, which could
adversely affect our ability to develop and commercialize our product candidates. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our current and any future product candidates or products could be alleged to infringe patent rights and other
proprietary rights of third parties, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and/or limit our ability to commercialize our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were incorporated under the laws of the State of Delaware on March&nbsp;3, 2011. Our principal executive offices are located
at 180 Kimball Way, Suite 200, South San Francisco, California 94080, and our telephone number is (650) <FONT STYLE="white-space:nowrap">822-5500.</FONT> Our corporate website address is www.annexonbio.com. Information contained on, or accessible
through, our website shall not be deemed incorporated into and is not a part of this prospectus or the registration statement of which it forms a part. We have included our website in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will
remain an emerging growth company until the earliest of (i)&nbsp;the last day of the fiscal year following the fifth anniversary of the consummation of this offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross
revenue of at least $1.07&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act
of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter
of such year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. An emerging growth company may take advantage of
specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will present in this prospectus only two years of audited consolidated financial statements, plus unaudited
condensed consolidated financial statements for any interim period, and related management&#146;s discussion and analysis of financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will avail ourselves of the exemption from the requirement to obtain an attestation and report from our
auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will provide less extensive disclosure about our executive compensation arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will not require stockholder <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, the information contained herein
may be different than the information you receive from our competitors that are public companies or other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for
complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to avail
ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common&nbsp;stock&nbsp;offered&nbsp;by&nbsp;us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12,500,000&nbsp;shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The underwriters have been granted an option to purchase up to 1,875,000 additional shares of common stock from us at any
time within 30 days from the date of this prospectus.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">33,758,687&nbsp;shares (or 35,633,687&nbsp;shares if the underwriters exercise their option to purchase additional shares
in full).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the net proceeds from this offering will be approximately $175.9&nbsp;million (or approximately
$202.9&nbsp;million if the underwriters exercise in full their option to purchase up to 1,875,000 additional shares of common stock), based on an assumed initial public offering price of $15.50 per share, the midpoint of the price range set forth on
the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the advancement
of: ANX005 for the treatment of GBS and wAIHA; ANX009 for the treatment of systemic autoimmune diseases; ANX005 for the treatment of HD and ALS; ANX007 for the treatment of GA; our next generation product candidates; our other research and
development activities; and the remainder for working capital and other general corporate purposes. See the section titled &#147;Use of Proceeds&#148; for additional information.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directed shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At our request, the underwriters have reserved for sale, at the initial public offering price, up to 1% of the shares offered
hereby for directors, officers, employees, business associates and other persons related to us who have expressed an interest in purchasing common stock in the offering. Shares purchased by our directors and officers will be subject to the 180-day
lock-up restriction described in the &#147;Underwriting&#148; section of this prospectus. See &#147;Underwriting&#151;Directed Share Program&#148; for more information.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You should read the section titled &#147;Risk Factors&#148; for a discussion of factors to consider carefully, together
with all the other information included in this prospectus, before deciding to invest in our common stock.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ANNX&#148;</P></TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this
offering is based on 13,117,963 shares of our common stock as of March 31, 2020 (after giving effect to the conversion of all of our shares of redeemable convertible preferred stock outstanding as of March 31, 2020 into an aggregate of 12,684,214
shares of our common stock immediately prior to the completion of this offering), plus 8,140,724 shares of our common stock issuable pursuant to the conversion of our Series D redeemable convertible preferred stock issued and sold in June 2020, and
excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,136,390 shares of our common stock issuable upon the exercise of outstanding stock options as of March 31,
2020, with a weighted-average exercise price of $5.45 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">892,730 shares of our common stock issuable upon the exercise of outstanding stock options granted subsequent
to March 31, 2020, with a weighted-average exercise price of $13.32 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,375,868 shares of our common stock reserved for future issuance under our 2020 Incentive Award Plan, or the
2020 Plan, from which we will grant options to purchase an aggregate of 448,821 shares of our common stock with an exercise price per share equal to the initial public offering price to certain officers and employees upon the pricing of this
offering, which will become effective on the date immediately prior to the date our registration statement relating to this offering becomes effective, as well as any future increases in the number of shares of common stock reserved for issuance
under the 2020 Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">337,586 shares of our common stock reserved for future issuance under our Employee Stock Purchase Plan, or the
ESPP, which will become effective on the date immediately prior to the date our registration statement relating to this offering becomes effective, as well as any future increases in the number of shares of common stock reserved for issuance under
the ESPP. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise indicated, all information in this prospectus assumes or gives
effect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the
completion of this offering and the adoption of our amended and restated bylaws immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of (i)&nbsp;all of our shares of redeemable convertible preferred stock outstanding as of
March&nbsp;31, 2020 into 12,684,214 shares of our common stock and (ii)&nbsp;all of our shares of Series&nbsp;D redeemable convertible preferred stock issued and sold in June 2020 into 8,140,724&nbsp;shares of our common stock, immediately prior to
the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-8.81</FONT></FONT> reverse stock
split of our common stock effected on July&nbsp;17, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase up to 1,875,000 additional shares of our common
stock. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables set forth our summary consolidated statements of operations and consolidated balance sheet data. The
summary consolidated statements of operations data for the years ended December&nbsp;31, 2018 and 2019 and the consolidated balance sheet data as of December 31, 2019 are derived from our audited consolidated financial statements appearing elsewhere
in this prospectus. The summary consolidated statements of operations data for the three months ended March 31, 2019 and 2020 and the consolidated balance sheet data as of March&nbsp;31, 2020 are derived from our unaudited interim condensed
consolidated financial statements appearing elsewhere in this prospectus. The unaudited interim condensed consolidated financial statements were prepared on a basis consistent with our audited consolidated financial statements and include, in
management&#146;s opinion, all adjustments, consisting only of normal recurring adjustments that we consider necessary for a fair presentation of the financial information set forth in those statements. Our historical results are not necessarily
indicative of the results that may be expected for any period in the future and our interim results are not necessarily indicative of our expected results for the year ending December 31, 2020. You should read the following summary consolidated
financial data together with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and the related notes included elsewhere in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on remeasurement of redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders,
basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">402,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing pro forma net loss per&nbsp;share attributable to common
stockholders, basic and diluted (unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,452,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,117,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">See Notes 2 and 11 to our audited consolidated financial statements and Notes 2 and 10 to our unaudited
interim condensed consolidated financial statements included elsewhere in this prospectus for explanations of the calculations of our basic and diluted net loss per share, basic and diluted pro forma net loss per share and the weighted-average
number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;March 31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As</B><br><B>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;
(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112,422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The pro forma column reflects: (i)&nbsp;the conversion of all of our shares of redeemable convertible
preferred stock outstanding as of March&nbsp;31, 2020 into 12,684,214 shares of our common stock, which will occur immediately prior to the completion of this offering, (ii)&nbsp;the issuance and sale of 71,719,859&nbsp;shares of our Series D
redeemable convertible preferred stock in June 2020 for aggregate net proceeds of approximately $96.7 million, and the conversion of such shares into 8,140,724 shares of our common stock, which will occur immediately prior to the completion of this
offering, and (iii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation in Delaware, which will be in effect immediately prior to the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The pro forma as adjusted column reflects: (i)&nbsp;the pro forma adjustments set forth in footnote (1) above
and (ii)&nbsp;the sale of 12,500,000 shares of our common stock in this offering at an assumed initial public offering price of $15.50 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The pro forma as adjusted information discussed above is illustrative only and will depend on the actual
initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $15.50 per share, the midpoint of the price range set forth on the cover page of
this prospectus, would increase or decrease, as applicable, each of our pro forma as adjusted cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by approximately $11.6 million, assuming the number of shares
of common stock offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or
decrease of 1.0&nbsp;million shares of common stock offered by us would increase or decrease, as applicable, each of our pro forma as adjusted cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by
approximately $14.4 million, assuming the assumed initial public offering price of $15.50 per share remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">We define working capital as current assets less current liabilities. See our unaudited interim condensed
consolidated financial statements and the related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as
well as the other information in this prospectus, including our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; before deciding
whether to invest in our common stock. Many of the following risks and uncertainties are, and will be, exacerbated by the coronavirus disease 2019, or COVID-19, pandemic and any worsening of the global business and economic environment as a result.
The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations and prospects. In such an event, the market price of our common stock could decline
and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have
incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biopharmaceutical company, and we have only a limited operating history upon which you can
evaluate our business and prospects. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We have no products approved for commercial sale and have not generated any revenue from sales
of our product candidates and have incurred losses in each year since our inception in March 2011. We have only a limited operating history upon which you can evaluate our business and prospects. In addition, we have not yet demonstrated an ability
to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical, biopharmaceutical and biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have had significant operating losses since our inception. Our net loss for the years ended December&nbsp;31, 2018 and 2019
was approximately $18.3&nbsp;million and $37.2 million, respectively, and $8.7 million and $12.3 million for the three months ended March 31, 2019 and 2020, respectively. As of March 31, 2020, we had an accumulated deficit of $114.9 million.
Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur losses for the
foreseeable future, and we anticipate these losses will increase as we continue to develop our product candidates, conduct clinical trials and pursue research and development activities. Even if we achieve profitability in the future, we may not be
able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#146; equity and working capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on
acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development
activities. Our product candidates will require additional clinical development, and we intend to conduct additional research and development activities to discover and develop new product candidates, including conducting preclinical studies and
clinical trials, all of which will require substantial additional funds. We will continue to expend significant resources for the foreseeable future in connection with these activities. These expenditures will include costs associated with
conducting preclinical studies and clinical trials, obtaining regulatory approvals and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome
of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or any future product candidates.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March 31, 2020, we had capital resources consisting of cash and cash
equivalents of approximately $33.3&nbsp;million. In June 2020, we issued and sold an aggregate of 71,719,859 shares of our Series&nbsp;D redeemable convertible preferred stock for net proceeds of approximately $96.7 million. We expect our existing
capital resources, which includes the net proceeds from the Series D financing, together with the proceeds from this offering, will fund our planned operating expenses through 2023. However, our operating plans may change as a result of many factors
currently unknown to us, and we may need to seek additional funds sooner than planned through public or private equity offerings or debt financings or other sources, such as strategic collaborations. Such financing may result in dilution to our
stockholders, imposition of burdensome debt covenants and repayment obligations, or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if
we believe we have sufficient funds for our current or future operating plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future capital requirements depend on
many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of researching and developing our current product candidates or any
other future product candidates we choose to pursue, and conducting preclinical studies and clinical trials, including our planned clinical trials of ANX005 and ANX007 and any delays related to the COVID-19 pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates or any
future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and characteristics of any additional product candidates we develop or acquire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty and/or other payments we are required to make pursuant to our
current or any future license or collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates or any future product candidates and any products we
successfully commercialize; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of building a sales force in anticipation of product commercialization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of commercialization activities of our product candidates, if approved for sale, including marketing,
sales and distribution costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish strategic collaborations, licensing or other arrangements and the financial terms of
any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual
property portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and amount of sales of any future approved products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional funds may not be available when we need them, on terms that are acceptable to us, or at all.
Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from
the ongoing COVID-19 pandemic. If adequate funds are not available to us on a timely basis, we may be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our
product candidates or any future product candidate; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, limit, reduce or terminate our research and development activities; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities
or other activities that may be necessary to commercialize our product candidates or any future product candidate, or reduce our flexibility in developing or maintaining our sales and marketing strategy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish
rights to some of our technologies or product candidates that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and
until our product candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities. We will be required to seek additional funding in
the future and currently intend to do so through public or private equity offerings or debt financings, credit or loan facilities, collaborations or a combination of one or more of these funding sources. Our ability to raise additional funds will
depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer
dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing
stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity
securities received any distribution of our corporate assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Due to the significant resources required for the development of our
product candidates, we must prioritize development of certain product candidates and/or certain disease indications. We may expend our limited resources on candidates or indications that do not yield a successful product and fail to capitalize on
product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are currently focused on developing product candidates to address classical complement-mediated autoimmune and
neurodegenerative diseases. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between aggressively advancing our two clinical-stage product candidates, ANX005 and ANX007, in identified
indications and exploring additional indications or mechanisms as well as developing future product candidates. However, due to the significant resources required for the development of our product candidates, we must focus on specific diseases and
disease pathways and decide which product candidates to pursue and the amount of resources to allocate to each such product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward
particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, any decision to delay, terminate or collaborate with third
parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product
candidates or misread trends in the autoimmune or neurodegenerative or pharmaceutical, biopharmaceutical or biotechnology industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we
may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have
greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest
additional resources to retain development and commercialization rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our operating results may fluctuate significantly, which makes our future operating
results difficult to predict and could cause our operating results to fall below expectations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our quarterly and
annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to
predict, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development and, if approved, commercialization
activities relating to our product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and status of enrollment for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary
depending on the quantity of production and the terms of our agreements with manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing and amount of any milestone, royalty or other payments due under any collaboration or license
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies and clinical trials for our product candidates or
competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of receipt of approvals for our product candidates from regulatory authorities in the United States
and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future
drugs that compete with our products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for our product candidates, if approved, which may vary significantly over time.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The cumulative effects of these factors could result in large fluctuations and unpredictability in our
quarterly and annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our
past results as an indication of our future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This variability and unpredictability could also result in our
failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any
forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or
earnings guidance we may provide. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business is heavily dependent on the successful development, regulatory approval and commercialization of our two clinical-stage
product candidates, ANX005 and ANX007, each of which is in early stages of clinical development. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no
products approved for sale, and our two clinical-stage product candidates are in early stages of clinical development. The success of our business, including our ability to finance our company and generate revenue in the future, will primarily
depend on the successful development, regulatory approval and commercialization of our product candidates and, in particular, the advancement of our current clinical-stage product candidates, ANX005 and ANX007. However, given our stage of
development, it may be many years, if we succeed at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. We cannot be certain that our product candidates will receive
regulatory approval or be successfully commercialized even if we receive regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While inhibition of the complement pathway has been validated as a
therapeutic approach, C1q inhibition is a novel therapeutic approach, which exposes us to certain risks. For example, we may discover unforeseen safety events or that our product candidates do not possess certain properties required for therapeutic
effectiveness, or that even if found to be effective in one type of disease, a product candidate, or the therapeutic approach, is not effective in other diseases. In addition, given the novel nature of this therapeutic approach, designing
preclinical studies and clinical trials to demonstrate the effect of the product candidates is complex and exposes us to risks, including that our biomarker-driven approach may not translate into therapeutic effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the future, we may also become dependent on other product candidates that we may develop or acquire. The clinical and
commercial success of our product candidates and future product candidates will depend on a number of factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the COVID-19 pandemic, which may result in clinical site closures, delays to patient enrollment, patients
discontinuing their treatment or follow up visits or changes to trial protocols; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise any additional required capital on acceptable terms, or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to complete an investigational new drug application, or IND, enabling studies and successfully
submit INDs or comparable applications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost
more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we are required by the U.S. Food and Drug Administration, or FDA, or similar foreign regulatory
agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications
of our product candidates by the FDA and similar foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the
safety, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our
product candidates or future approved products, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and
maintain compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of third parties with whom we contract to manufacture adequate clinical trial and commercial
supplies of our product candidates or any future product candidates remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing
practices, or cGMPs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates
or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party
payors and adequate market share and revenue for any approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience of our treatment or dosing regimen; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates
or any future product candidates, if approved, including relative to alternative and competing treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product
candidates or any future product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients&#146; willingness to enroll or continue to participate in a clinical trial during the COVID-19
pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient demand for our product candidates, if approved, including patients&#146; willingness to pay <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and enforce intellectual property rights in and to our product candidates or any
future product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to avoid third-party patent interference, intellectual property challenges or intellectual
property infringement claims. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These factors, many of which are beyond our control, could cause us to
experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates.
Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials,
business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2020, the World Health Organization declared
COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19. In response to the COVID-19 pandemic, &#147;shelter in place&#148; orders and other public health guidance measures have been implemented across
much of the United States and Europe, including in the locations of our offices, clinical trial sites, key vendors and partners. We expect that our clinical development program timelines will be negatively affected by COVID-19, which could
materially and adversely affect our business, financial condition and results of operations. Further, due to &#147;shelter in place&#148; orders and other public health guidance measures, we have implemented a work-from-home policy for all staff
members excluding those necessary to maintain minimum basic operations. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay or otherwise adversely impact our business. For example, with our
personnel working from home, some of our research activities that require our personnel to be in our laboratories will be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of the COVID-19 pandemic, or similar pandemics, and related &#147;shelter in place&#148; orders and other public
health guidance measures, we have and may in the future experience disruptions that could materially and adversely impact our clinical trials, business, financial condition and results of operations. Potential disruptions include but are not limited
to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with
clinical site initiation and recruiting clinical site investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of
contracting COVID-19 or other health conditions or being forced to quarantine; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy,
safety and translational data collection, processing and analyses, due to limitations on travel imposed or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and
clinical study endpoints; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of
hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff
and unforeseen circumstances at contract research organizations, or CROs, and vendors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing
organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical
trials and pre-clinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit
disruptions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways
in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These and other factors arising from the COVID-19 global pandemic could worsen in countries that are
already afflicted with COVID-19, could continue to spread to additional countries or could return to countries where the pandemic has been partially contained, each of which could further adversely impact our ability to conduct clinical trials and
our business generally, and could materially and adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The COVID-19 global pandemic continues to rapidly evolve. The extent to which the outbreak may affect our clinical trials,
business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel
restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken
in the United States and other countries to contain and treat the disease. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of
our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are at an early stage of clinical development of our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize our product candidates, and we may
fail to do so for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our product candidates may not successfully complete preclinical studies or clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may on further study be shown to have harmful side effects or other characteristics that
indicate it does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors may develop therapeutics that render our product candidates obsolete or less attractive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market for a product candidate may change so that the continued development of that product candidate is
no longer reasonable or commercially attractive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing
capabilities, or successfully market such approved product candidate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or
third-party payors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of these events occur, we may be forced to abandon our development efforts
for a product candidate or candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Failure of a product candidate may occur at any stage of preclinical or clinical development, and
we may never succeed in developing marketable products or generating product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be successful in our
efforts to further develop our current and future product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may
never receive such regulatory approval for any of our product candidates. Each of our product candidates will require significant additional clinical development, management of preclinical, clinical and manufacturing activities, regulatory approval,
adequate manufacturing supply, a commercial organization and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not demonstrate the efficacy and safety necessary
to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with
statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA or other regulatory agencies may not agree with our clinical development plan and require that we conduct additional
clinical trials to support our regulatory submissions. We have not yet conducted an end of Phase 2 meeting with the FDA to discuss the registration pathway for ANX005, and our current clinical development plans for ANX005 in Guillain-Barre Syndrome,
or GBS, may change as a result of future interactions with the FDA. For example, the FDA may require that we conduct more than one pivotal trial in order to gain approval in GBS. Furthermore, any approval of ANX005 for GBS may be limited to ANX005
in combination with the existing standard of care. While not approved for use in GBS in the United States due to differing levels of efficacy in GBS patients, IVIg has developed as the standard of care in the Western world and parts of Asia for
patients with GBS and has been shown to be a reasonably effective treatment in some GBS patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of our product
candidates successfully completes clinical trials, we plan to seek regulatory approval to market our product candidates in the United States, the European Union and in additional foreign countries where we believe there is a viable commercial
opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates
successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries
regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. We may also rely on collaborators or partners to conduct the required activities to support an
application for regulatory approval and to seek approval for one or more of our product candidates. We cannot be sure that any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
collaborators or partners will conduct these activities successfully or do so within the timeframe we desire. Even if we or any future collaborators or partners are successful in obtaining
approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be
negatively affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we receive regulatory approval to market any of our product candidates, we cannot assure you
that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. Any approval we may obtain could be for indications or patient populations that
are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be
subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a Risk Evaluation and
Mitigation Strategy, or REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the
timelines we expect, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical testing is expensive and can take many years to complete, and its outcome
is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an IND or a clinical trial application, or CTA, will result in the FDA or
other regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. For example, prior to the authorization of our IND for HD, the FDA placed the Phase&nbsp;2a trial on clinical hold in order to obtain
additional information on our preclinical data package; we provided the required information and the clinical hold was lifted in March 2020. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials.
A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the COVID-19 pandemic, which may result in clinical site closures, delays to patient enrollment, patients
discontinuing their treatment or follow up visits or changes to trial protocols; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology or other <I>in vivo</I> or <I>in vitro</I> data to
support the initiation or continuation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining regulatory authorization to commence a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can
be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining institutional review board, or IRB, approval at each trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including
after review of an IND or amendment, or equivalent foreign application or amendment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new safety findings that present unreasonable risk to clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a negative finding from an inspection of our clinical trial operations or study sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruiting an adequate number of suitable patients to participate in a trial; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">having subjects complete a trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing subject safety concerns that arise during the course of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding a sufficient number of clinical trial sites; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining sufficient product supply of product candidates for use in preclinical studies or clinical trials
from third-party suppliers. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may experience numerous adverse or unforeseen events during, or as a
result of, preclinical studies and clinical trials which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical
trials or require that we submit additional data or information before allowing a clinical trial to be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies of our product candidates may produce negative or inconclusive results, and we may decide, or
regulators may require us, to conduct additional clinical trials or abandon drug development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we
anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality
controls or be unable to provide us with sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our investigators might have to suspend or terminate clinical trials of our product candidates for
various reasons, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that the
participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical
trials of our product candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators may revise the requirements for approving our product candidates or such requirements may not be as
we anticipate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any future collaborators may conduct clinical trials in ways they view as advantageous to them but that are
suboptimal for us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are required to conduct additional clinical trials or other testing of our
product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately
positive or if there are safety concerns, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur unplanned costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval in some countries and not in others; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety
warnings, including boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to additional post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the product removed from the market after obtaining marketing approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or
delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being
conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical
trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues
or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, conducting clinical trials in foreign countries, as we plan to do for certain of our product candidates, presents
additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs and
managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and
may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship
may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or
rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we experience delays in the completion, or termination, of any preclinical study or clinical trial of our product
candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our clinical trials
may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may materially and adversely affect our business, financial
condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product
candidates. If one or more of our product candidates proves to be ineffective, unsafe or commercially unviable, our business, financial condition, results of operations and prospects may be materially and adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or
otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to initiate or continue clinical trials on a timely basis or at
all for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical
power for a given trial. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may
experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity and difficulty of diagnosing the disease under investigation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility and exclusion criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existing body of safety and efficacy data with respect to the study drug and safety concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that enrolled subjects will drop out before completion of the trial, including as a result of contracting
COVID-19 or other health conditions or being forced to quarantine; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and efficacy of approved medications or therapies, or other clinical trials, for the disease or
condition under investigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate being
studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same
therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted
by one of our competitors. Because the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who
are available for our clinical trials in such clinical trial site. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and
adversely affect our ability to advance the development of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our product candidates may cause undesirable and
unforeseen side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to
interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. If unacceptable side effects arise in the development of our
product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical
trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in
potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect
profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of
these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, early clinical trials may only include a limited number of subjects and limited duration of exposure to our
product candidates. In particular, we are pursuing a novel approach to inhibiting upstream </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
molecules of the classical complement pathway, primarily C1q, and as a result, our product candidates may cause unforeseen safety events when evaluated in larger patient populations. Further,
clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of our product candidates receives marketing approval, and we or others later identify undesirable and unforeseen side
effects caused by such product, a number of potentially significant negative consequences could result, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against
its manufacture or distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to conduct additional clinical trials or post-approval studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a product or change the way such product is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing
processes for the product or any component thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require the addition of labeling statements, such as a &#147;black box&#148;
warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to implement a REMS or create a Medication Guide outlining the risks of such side effects
for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to fines, injunctions or the imposition of criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product may become less competitive; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if
approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates prove to be unsafe, our business, financial
condition, results of operations and prospects may be materially and adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">Interim&nbsp;&#147;top-line&#148;&nbsp;and&nbsp;preliminary</FONT> data from studies or trials that we
announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may
<FONT STYLE="white-space:nowrap">publish&nbsp;interim&nbsp;&#147;top-line&#148;&nbsp;or&nbsp;preliminary</FONT> data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially
change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publish
such data.&nbsp;As a result, the <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once
additional data have been received and fully evaluated. Preliminary <FONT STYLE="white-space:nowrap">or&nbsp;&#147;top-line&#148;&nbsp;data&nbsp;also</FONT> remain subject to audit and verification procedures that may result in the final data being
materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could
significantly harm our business prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, others, including regulatory agencies, may not accept or agree with
our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product
candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions,
views, activities or otherwise regarding a particular product candidate or our business. If the <FONT STYLE="white-space:nowrap">top-line</FONT> data that we report differ from final results, or if others, including regulatory authorities, disagree
with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Clinical trials of ANX005 in combination with IVIg in patients with GBS will provide no evidence of the efficacy of ANX005. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While not approved for use in GBS in the United States due to differing levels of efficacy in GBS patients, IVIg has developed
as the standard of care in the Western world and parts of Asia for patients with GBS and has been shown to be a reasonably effective treatment in some but not all GBS patients. We have initiated a Phase 1b drug-drug, or DDI, interaction trial
evaluating ANX005 with IVIg. The purpose of our DDI clinical trial is to assess safety and if there are any pharmacokinetic or pharmacodynamic effects on ANX005&#146;s dosing profile by administering the two drug products in combination. Any
objective responses observed in this trial will be in patients receiving ANX005 together with IVIg, and attribution of objective responses to the effects of ANX005 as a monotherapy will not be possible. Moreover, the trial is not powered to show a
statistically significant efficacious outcome with the combined administration of ANX005 and IVIg. As a result, this clinical trial evaluating ANX005 with IVIg will provide no evidence of the efficacy of ANX005, which may not be fully understood by
investors or market participants, potentially leading to negative effects on our stock price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if our current or future product
candidates obtain regulatory approval, they may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if one or more of our product candidates receive FDA or other regulatory approvals, the commercial success of any of our
current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. Our product candidates may not be commercially successful. For a variety of
reasons, including, among other things, competitive factors, pricing or physician preference, reimbursement by insurers, the degree and rate of physician and patient adoption of our current or future product candidates, if approved, will depend on a
number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product is approved and patient demand for approved products that treat
those indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety and efficacy of our product as compared to other available therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage and adequate reimbursement from managed care plans, insurers and other healthcare
payors for any of our product candidates that may be approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance by physicians, operators of clinics and patients of the product as a safe and effective treatment;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">physician and patient willingness to adopt a new therapy over other available therapies to treat approved
indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overcoming any biases physicians or patients may have toward particular therapies for the treatment of
approved indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proper training and administration of our product candidates by physicians and medical staff;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">public misperception regarding the use of our therapies, if approved for commercial sale;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient satisfaction with the results and administration of our product candidates and overall treatment
experience, including, for example, the convenience of any dosing regimen; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement
levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors, physicians and patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue and profitability that our products may offer a physician as compared to alternative therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling for our
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of physicians, operators of clinics and patients to utilize or adopt our products as a
solution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any FDA requirement to undertake a REMS; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales, marketing and distribution efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity about our products or favorable publicity about competitive products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among
physicians and patients. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have received Orphan Drug designation for ANX005 for the treatment of GBS, and we may seek Orphan Drug designation for certain future
product candidates. We may be unable to obtain such designations or to maintain the benefits associated with Orphan Drug designation, including market exclusivity, which may cause any revenue from product sales to be reduced. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have received Orphan Drug designation in the United States for ANX005 for the treatment of GBS. Although we may seek Orphan
product designation for some or all of our other product candidates, we may never receive such designations. Under the Orphan Drug Act, the FDA may designate a drug or biologic product as an Orphan Drug if it is intended to treat a rare disease or
condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered
from sales in the United States. Orphan Drug designation must be requested before submitting a biologics license application, or BLA. In the European Union, the EMA&#146;s Committee for Orphan Medicinal Products, or COMP, grants Orphan Drug
designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union.
Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in
the European Union would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be
of significant benefit to those affected by the condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, Orphan Drug designation entitles a party
to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and application fee waivers. After the FDA grants Orphan Drug designation, the generic identity of the drug and its potential orphan use are
disclosed publicly by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if a product receives the first FDA approval for the indication
for which it has orphan designation, the product is entitled to Orphan Drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited
circumstances, such as a showing of clinical superiority over the product with Orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity the orphan patient population. Exclusive marketing rights in the United
States may also be unavailable if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. In the
European Union, Orphan Drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if
the Orphan Drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable to not justify maintenance of market exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we obtain Orphan Drug designation, we may not be the first to obtain marketing approval for any particular orphan
indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain Orphan Drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from competition because
different drugs with different active moieties can be approved for the same condition. Even after an Orphan Drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that
the later drug is clinically superior in that it is safer, more effective or makes a major contribution to patient care. Orphan Drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug
or biologic any advantage in the regulatory review or approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A Breakthrough Therapy designation by the FDA, even if
granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may seek a Breakthrough Therapy designation for our product candidates if the clinical data support such a designation for
one or more product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary
clinical evidence indicates that the drug, or biologic in our case, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while
minimizing the number of patients placed in ineffective control regimens. Biologics designated as breakthrough therapies by the FDA may also be eligible for priority review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product
candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result
in a faster development process, review or approval compared to drugs considered for approval under <FONT STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if
one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A Fast Track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or
regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA has granted Fast Track designation for ANX005 in GBS, and, in the future, we may seek Fast Track designation for other
of our product candidates. If a drug or biologic, in our case, is intended for the treatment of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
serious or life-threatening condition and the biologic demonstrates the potential to address unmet medical needs for this condition, the biologic sponsor may apply for Fast Track designation. The
FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Fast Track designation may not result
in a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many
biologics that have received Fast Track designation have failed to obtain approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we obtain regulatory approval for a
product candidate, our products will remain subject to regulatory scrutiny. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If one of our product candidates is
approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of <FONT STYLE="white-space:nowrap">post-marketing</FONT> studies and
submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA and comparable foreign regulatory
authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. We and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and
adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality
control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will have to comply with requirements concerning advertising and promotion for our products. Promotional
communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#146;s approved label. We may not promote our products <FONT
STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the
approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful
post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a
regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or
labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or
enforcement authority may, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose civil or criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any of our clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve pending applications or supplements to approved applications submitted by us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose restrictions on our operations, including closing our contract manufacturers&#146; facilities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize or detain products, or require a product recall. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any government investigation of alleged violations of law could require us to expend significant time and resources in
response, and could generate negative publicity. Any failure to comply with ongoing regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is
withdrawn, the value of our company and our operating results will be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, the policies of the
FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of
government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we are unable to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Disruptions at the&nbsp;FDA&nbsp;and other government agencies caused by funding shortages or global health concerns could hinder their
ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability of the&nbsp;FDA&nbsp;to review and/or approve new products can be affected by a variety of factors,
including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#146;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#146;s ability
to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political
process, which is inherently fluid and unpredictable. Disruptions at the&nbsp;FDA&nbsp;and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would
adversely affect our business.&nbsp;For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the&nbsp;FDA, have had to
furlough critical&nbsp;FDA&nbsp;employees and stop critical activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Separately, in response to the COVID-19 pandemic,
on March&nbsp;10, 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities, and subsequently, on March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections
of domestic manufacturing facilities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged&nbsp;government&nbsp;shutdown&nbsp;occurs, or if
global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory
authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We
have conducted, and in the future plan to conduct, clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have conducted clinical trials of our product candidates outside the United States, and plan to continue to do so in the
future. For example, we conducted our Phase 1b clinical trial of ANX005 in Bangladesh. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, any comparable foreign regulatory
authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the
application on the basis of foreign data alone unless (i)&nbsp;the data are applicable to the U.S. population and U.S. medical practice; (ii)&nbsp;the trials were performed pursuant to good clinical practice, or GCP, requirements; and (iii)&nbsp;if
necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection. Many foreign regulatory authorities have similar requirements. In addition, foreign trials are subject to the applicable local
laws of the foreign jurisdictions where the trials are conducted. There can be no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any
comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we
may develop not receiving approval or clearance for commercialization in the applicable jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If the product candidates
that we develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for our product candidates and adversely affect our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any
other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or any future collaborators&#146; ability to develop,
manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals
have been received. In order to market and sell product candidates in the European Union, or EU, and many other jurisdictions, we and any future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory
requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement
before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other
country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or any future collaborators fail to comply with the regulatory requirements in international
markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Patient Protection and Affordable Care Act, signed into law on March&nbsp;23, 2010, includes a subtitle called
the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT>
reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a
biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still
market a competing version of the reference product if the FDA approves a full Biologics License Application, or BLA, for the competing product containing the sponsor&#146;s own <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and data from
adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning
are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is a risk that any of our product candidates approved as a biological product under a BLA would not
qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference
products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation.
Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number
of marketplace and regulatory factors that are still developing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on third-party suppliers to manufacture our product
candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at
acceptable quality levels or prices, or at all, would materially and adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not have
nor do we plan to build or acquire the infrastructure or capability internally to manufacture supplies of our product candidates or the materials necessary to produce our product candidates for use in the conduct of our preclinical studies or
clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a preclinical, clinical or commercial scale. The facilities used by our contract manufacturers to manufacture our product
candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing processes of, and are completely dependent on, our contract manufacturing
partners for compliance with the regulatory requirements, known as cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable
regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture of our product candidates. In addition, we have limited control over the ability of our contract manufacturers to
maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds these facilities inadequate for the manufacture of our product candidates or if such facilities are subject
to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently intend to supply our product candidates in all territories for our clinical development programs. We currently
rely on third parties at key stages in our supply chain. For instance, the supply chains for our two clinical-stage product candidates involve several manufacturers that specialize in specific operations of the manufacturing process, specifically,
raw materials manufacturing, drug substance manufacturing and drug product manufacturing. As a result, the supply chain for the manufacturing of our product candidates is complicated, and we expect the logistical challenges associated with our
supply chain to grow more complex as our product candidates are further developed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not have any control over the
process or timing of the acquisition or manufacture of materials by our manufacturers. We generally do not begin preclinical or clinical trials unless we believe we have access to a sufficient supply of a product candidate to complete such study. In
addition, any significant delay in, or quality control problems with respect to, the supply of a product candidate, or the raw material components thereof, for an ongoing study could considerably delay completion of our preclinical or clinical
trials, product testing and potential regulatory approval of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not yet engaged any
manufacturers for the commercial supply of our product candidates. Although we intend to enter into such agreements prior to commercial launch of any of our product candidates, we may be unable to enter into any such agreement or do so on
commercially reasonable terms, which could have a material adverse impact upon our business. Moreover, if there is a disruption to one or more of our third-party manufacturers&#146; or suppliers&#146; relevant operations, or if we are unable to
enter into arrangements for the commercial supply of our product candidates, we will have no other means of producing our product candidates until they restore the affected facilities or we or they procure alternative manufacturing facilities or
sources of supply. Our ability to progress our preclinical and clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business challenge, disruption or
failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory or reputational issues. Additionally, any damage to or
destruction of our third-party manufacturers&#146; or suppliers&#146; facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, to manufacture our product candidates in the quantities which
we believe would be required to meet anticipated market demand, our third-party manufacturers would likely need to increase manufacturing capacity and we may need to secure alternative sources of commercial supply, which could involve significant
challenges and may require additional regulatory approvals. In addition, the development of commercial-scale manufacturing capabilities may require us and our third-party manufacturers to invest substantial additional funds and hire and retain the
technical personnel who have the necessary manufacturing experience. Neither we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. If our manufacturers
or we are unable to purchase the raw materials necessary for the manufacture of our product candidates on acceptable terms, at sufficient quality levels or in adequate quantities, if at all, the commercial launch of our product candidates would be
delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of such product candidates, if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on third parties in the conduct of all of our preclinical studies and clinical trials. If these third parties do not
successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently do not have the ability to independently conduct preclinical studies or clinical trials that comply with the
regulatory requirements known as good laboratory practice, or GLP, requirements or GCP requirements, respectively. The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring,
recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical
trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct <FONT STYLE="white-space:nowrap">GLP-compliant</FONT> preclinical studies and
<FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence
over their actual performance. The third parties with whom we contract for execution of our <FONT STYLE="white-space:nowrap">GLP-compliant</FONT> preclinical studies and our <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials play
a significant role in the conduct of these studies and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability
to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our <FONT STYLE="white-space:nowrap">GLP-compliant</FONT> preclinical studies and
<FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable
laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of the
third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive
position. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected
deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLPs or GCPs, or for any other reason, we may need to
enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result we may not be able to
obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our business, financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to
generate revenues could be delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are not successful in identifying, developing and commercializing additional
product candidates, our ability to expand our business and achieve our strategic objectives would be impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although a substantial amount of our effort will focus on the continued development and potential approval of our current
product candidates, a key element of our strategy is to identify, develop and commercialize a portfolio of products that address classical complement-mediated autoimmune and neurodegenerative diseases. A component of our strategy is to evaluate our
product candidates in multiple indications based, in part, on our evaluation of certain biomarkers in a disease area. For example, we intend to evaluate ANX005 in neurodegenerative diseases, including amyotrophic lateral sclerosis, or ALS, and
Huntington&#146;s disease, or HD; however, we have not yet evaluated ANX005 in these patient populations and we may find that while we have seen promising results in one neurodegenerative disease, that effect is not replicated across other
neurodegenerative or autoimmune diseases. Even if we successfully identify product candidates, we may still fail to yield product candidates for development and commercialization for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render our product candidates obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates we develop may be covered by third parties&#146; patents or other exclusive rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may be shown to have harmful side effects or other characteristics that indicate it is
unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be accepted as safe and effective by physicians and patients.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We therefore cannot provide any assurance that we will be able to successfully identify or acquire
additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire,
develop or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunities may be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We face significant competition in an environment of rapid technological and scientific change, and our product candidates, if approved,
will face significant competition, which may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pharmaceutical, biopharmaceutical and biotechnology industries in particular are characterized by rapidly advancing
technologies, intense competition and a strong emphasis on developing proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing and marketing of healthcare products competitive with those that we are
developing. We face competition from a number of sources, such as pharmaceutical, biopharmaceutical and biotechnology companies, generic drug companies and academic and research institutions, many of which have greater financial resources, marketing
capabilities, sales forces, manufacturing capabilities, research and development capabilities, clinical trial expertise, intellectual property portfolios, experience in obtaining patents and regulatory approvals for product candidates and other
resources than we do. Some of the companies also have a broad range of other product offerings, large direct sales forces and long-term customer relationships with our target physicians, which could inhibit our market penetration efforts. Mergers
and acquisitions in the pharmaceutical, biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites
and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain alternative treatments offered by competitors may be available at
lower prices and may offer greater efficacy or better safety profiles. Furthermore, currently approved products could be discovered to have application for the intended indication of our product candidates, which could give such products significant
regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, European Medicines Agency, or EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours and
may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. For additional information
regarding our competition, see the section of this prospectus captioned &#147;Business&#151;Competition.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The successful
commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and
adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid,
private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement
for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be
particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Even if we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment
rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be
available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third-party payors increasingly are challenging prices charged for pharmaceutical, biopharmaceutical and biotechnology
products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a
third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product
candidates, pricing of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing
marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully
commercialize our product candidates and may not be able to obtain a satisfactory financial return on our investment in the development of product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United
States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs
increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will
decide with respect to the coverage and reimbursement for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No uniform policy for coverage and
reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates
to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short
notice, and we believe that changes in these rules and regulations are likely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outside the United States, international
operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put
pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own
prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge for our product candidates. Accordingly, in markets
outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce
healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience
pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare
costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We previously identified a material weakness in our internal control over financial reporting and may identify additional material
weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, we were a private company and had limited accounting and financial reporting personnel and other
resources with which to address our internal controls and procedures. In connection with the audit of our consolidated financial statements for the year ended December&nbsp;31, 2018, we and our independent registered public accounting firm
identified a material weakness in our internal control over financial reporting. The material weakness that was identified related to an inadequate number of qualified personnel within our accounting function, which impacted our ability to perform
effective reviews over <FONT STYLE="white-space:nowrap">non-routine</FONT> transactions. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility
that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have implemented measures designed to improve our internal control over financial reporting to address the underlying
causes of this material weakness, including the hiring of accounting personnel and establishing new accounting and financial reporting policies, processes and controls to have in place an appropriate level of internal control over financial
reporting. As a result of these measures, we remediated the material weakness as of December&nbsp;31, 2019. However, we can give no assurance that additional material weaknesses in our internal control over financial reporting will not be identified
in the future. Our failure to implement and maintain effective internal control over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet
our reporting obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective internal control over financial reporting is necessary for us to provide reliable
and timely financial reports and, together with adequate disclosure controls and procedures, are designed to reasonably detect and prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
implementation, could cause us to fail to meet our reporting obligations. For as long as we are an &#147;emerging growth company&#148; under the JOBS Act, our independent registered public
accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404. We could be an &#147;emerging growth
company&#148; for up to five years. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#146;s assessment might not. Undetected material weaknesses in our internal
control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may
not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently do not have a marketing or sales organization. In order to commercialize our product candidates in the United
States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties to perform these services, and we may
not be successful in doing so. If any of our product candidates receive regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate,
which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical, biopharmaceutical and biotechnology products, and there are significant risks involved in building and managing a
sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and
marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct
sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at
all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing our product candidates or any future product candidates, either on our own or through arrangements with one or more third
parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will need
to increase the size of our organization, and we may experience difficulties in managing growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June 30,
2020, we had 30 full-time employees. We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize our two
clinical-stage product candidates or any future product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy
requires that we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manage our clinical trials effectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify, recruit, retain, incentivize and integrate additional employees, including sales personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manage our internal development and operational efforts effectively while carrying out our contractual
obligations to third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to improve our operational, financial and management controls, reports systems and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we fail to attract and retain senior management and key scientific personnel, our business may be materially
and adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our success depends in part on our continued ability to attract, retain and motivate
highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
management, particularly our President and Chief Executive Officer, Douglas Love, Esq., Executive Vice President and Chief Medical Officer, Sanjay Keswani, MBBS, BSc, FRCP, and Executive Vice
President and Chief Scientific Officer, Ted Yednock, Ph.D., as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our
product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the
limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and
retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other
confidential information, or that their former employers own their research output. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If product liability lawsuits are brought
against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an
even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted under state consumer
protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require
significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our current or future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our current or any future product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are unable to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to
protect against potential product liability claims, the commercialization of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance covering our clinical trials.
Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance
coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that
exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain
approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability
to develop and commercialize our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we have not entered into any collaboration agreements
to date, we may seek collaboration arrangements for the commercialization, or potentially for the development, of certain of our product candidates depending on the merits of retaining commercialization rights for ourselves as compared to entering
into collaboration arrangements. For example, certain of the disease areas that we believe our product candidates address, including, among others, ophthalmic indications, require large, costly and later-stage clinical trials, which a collaboration
partner may be better positioned to finance and/or conduct. In addition, a component of our strategy is to maximize the commercial value of our current and future product candidates, which may also strategically align with partnering commercial
rights with partners that have larger and established sales organizations. To the extent that we decide to enter into collaboration agreements, we may face significant competition for appropriate collaborators. Moreover, collaboration arrangements
are complex and time-consuming to negotiate, document, implement and maintain and challenging to manage. We may not be successful in our efforts to enter into collaboration agreements. The terms of collaborations or other arrangements that we may
establish may not be favorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The success of our collaboration arrangements will depend heavily on the efforts
and activities of our collaborators. Collaborations are subject to numerous risks, which may include risks that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to
continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of
funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our products or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with marketing, manufacturing and distribution rights to one or more products may not commit
sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual
property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and collaborators that cause the delay or termination of the research,
development or commercialization of our current or future product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated, and, if terminated, this may result in a need for additional capital to
pursue further development or commercialization of the applicable current or future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering
products that result from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise with respect to the ownership of any intellectual property developed pursuant to our
collaborations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators&#146; sales and marketing activities or other operations may not be in compliance with
applicable laws resulting in civil or criminal proceedings. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Unfavorable global economic or political conditions
could adversely affect our business, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is susceptible to
general conditions in the global economy and in the global financial markets. A global financial crisis or a global or regional political disruption could cause extreme volatility in the capital and credit markets. A severe or prolonged economic
downturn, including a recession or depression resulting from the current COVID-19 pandemic, or political disruption could result in a variety of risks to our business, including weakened demand for our product candidates or any future product
candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply
disruption, or cause our customers to delay making payments for our potential products. Any of the foregoing could materially and adversely affect our business, financial condition, results of operations and prospects, and we cannot anticipate all
of the ways in which the political or economic climate and financial market conditions could adversely impact our business. <B><I> </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters, and our business
continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our corporate
headquarters and other facilities are located in the San Francisco Bay Area, which has experienced both severe earthquakes and the effects of wildfires. We do not carry earthquake insurance. Earthquakes, wildfires or other natural disasters could
severely disrupt our operations, and could materially and adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our
headquarters, that damaged critical infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business
continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business
continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen
and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Significant disruptions of information technology systems, breaches of data security and other incidents could materially adversely
affect our business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We collect and maintain information in digital
and other forms that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal
information. It is critical that we do so in a secure manner to maintain the privacy, security, confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to
safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools and monitoring to provide security for our information technology systems and the processing, transmission and storage of
digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may have access to our confidential information. Our internal information technology systems and
infrastructure, and those of any future collaborators and our contractors, consultants, vendors and other third parties on which we rely, are vulnerable to damage or unauthorized access or use resulting from computer viruses, malware, natural
disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, denial or degradation of service attacks, ransomware, hacking, phishing and other social engineering attacks, attachments to
emails, persons inside our organization or persons with access to systems inside our organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The risk of a security
breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and
intrusions from around the world have increased. The prevalent use of mobile devices that access confidential information also increases the risk of lost or stolen devices, security incidents and data security breaches, which could lead to the loss
of confidential information or other intellectual property. As a result of the COVID-19 pandemic, we may face increased risks of a security breach or disruption due to our reliance on internet technology and the number of our employees who are
working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. The costs to us to investigate, mitigate and remediate security incidents, breaches, disruptions, network security problems, bugs, viruses,
worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be
successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our
operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security
measures and lead to regulatory scrutiny. Moreover, if a computer security breach affects our systems or results in the unauthorized access to or unauthorized use, disclosure, release or other processing of personally identifiable information or
clinical trial data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws, and our reputation could be materially damaged. We would also be exposed
to a risk of loss, governmental investigations or enforcement, or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or
criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and any future collaborators are subject to or affected by federal, state and foreign data protection laws and regulations
which address privacy and data security. In the United States, numerous federal and state laws and regulations, including the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, or HITECH, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, including Section&nbsp;5
of the Federal Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information, may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
apply to our operations and the operations of any future collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain
clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and other privacy and data security laws. Depending on the facts and circumstances, we could be subject to significant administrative,
civil and criminal penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Further, various states have implemented similar
privacy laws and regulations. For example, California also recently enacted the California Consumer Privacy Act of 2018, or CCPA. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain
personal information sharing and receive detailed information about how their personal information is used. The CCPA also provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to
increase data breach litigation. The CCPA went into effect on January 1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July 1, 2020. The CCPA has been amended from time to time, and it remains
unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and as a result may increase our compliance costs and potential liability.
Many similar privacy laws have been proposed at the federal level and in other states. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Foreign data protection laws,
including Regulation 2016/679, known as the General Data Protection Regulation, or GDPR, may also apply to health-related and other personal information data subjects in the EU or the United Kingdom, or UK. The GDPR went into effect on May&nbsp;25,
2018. Companies that must comply with the GDPR face increased compliance obligations and risk, including robust regulatory enforcement of data protection requirements as well as potential fines for noncompliance of up to &#128;20&nbsp;million or 4%
of annual global revenue of the noncompliance company, whichever is greater. The GDPR imposes numerous requirements for the collection, use, storage and disclosure of personal information of EU or UK data subjects, including requirements relating to
providing notice to and obtaining consent from data subjects, personal data breach notification, cross-border transfers of personal information, and honoring and providing for the rights of EU or UK individuals in relation to their personal
information, including the right to access, correct and delete their data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compliance with U.S. and foreign data
protection laws and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our
partners&#146; or suppliers&#146; ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and/or enforcement actions, fines, civil or
criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the
providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#146; privacy rights, failed to comply with data protection laws or breached our
contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our employees and independent contractors, including principal investigators, consultants, any future commercial
collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to the risk that our employees and independent contractors, including principal investigators,
consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized
activities that violate the laws and regulations of the FDA and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state
healthcare fraud and abuse, data privacy laws and other similar <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws
also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in
regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in
controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. In addition, we are subject to the risk that a person
or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact
on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and
other U.S. healthcare programs, other sanctions, imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business
and our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business involves the use of hazardous materials, and we and our third-party manufacturers and
suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our research and development activities and our third-party manufacturers&#146; and suppliers&#146; activities involve the
controlled storage, use and disposal of hazardous materials owned by us, including the components of our product candidates and other hazardous compounds. We and any third-party manufacturers and suppliers are subject to numerous federal, state and
local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes;
the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our
operations also produce hazardous waste. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#146; facilities pending their use and disposal. We generally contract with third
parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, and environmental
damage resulting in costly <FONT STYLE="white-space:nowrap">clean-up</FONT> and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot guarantee that the safety procedures utilized by our third-party manufacturers for handling and disposing of these
materials comply with the standards prescribed by these laws and regulations, nor can we eliminate the risk of accidental contamination or injury from these materials. Under certain environmental laws, we could be held responsible for costs relating
to any contamination at our current or past facilities and at third-party facilities. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable
authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of
such changes and cannot be certain of our future compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compliance with applicable environmental laws and
regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination
from hazardous materials or wastes. Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological
or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the
event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on
our business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our current and any future product candidates or products could be alleged to infringe patent rights and other proprietary rights of
third parties, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and/or limit our ability to commercialize our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success depends on our ability to develop, manufacture and market our current and any future product candidates
that may be approved for sale, and to use our proprietary technology without infringing the patents and other proprietary rights of third parties. Intellectual property disputes can be costly to defend and may cause our business, operating results
and financial condition to suffer. We operate in an industry with extensive intellectual property litigation. As the pharmaceutical, biopharmaceutical and biotechnology industries expand and more patents are issued, the risk increases that there may
be patents issued to third parties that relate to our products and technology of which we are not aware or that we may need to challenge to continue our operations as currently contemplated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Whether merited or not, we may face allegations that we have infringed the trademarks, copyrights, patents and other
intellectual property rights of third parties, including patents held by our competitors or by <FONT STYLE="white-space:nowrap">non-practicing</FONT> entities. We may also face allegations that our employees have misappropriated the intellectual
property rights of their former employers or other third parties. Litigation may make it necessary to defend ourselves by determining the scope, enforceability and validity of third-party proprietary rights, or to establish our proprietary rights.
Regardless of whether claims that we are infringing patents or other intellectual property rights have merit, the claims can be time consuming, divert management attention and financial resources and are costly to evaluate and defend. Results of any
such litigation are difficult to predict and may require us to stop treating certain conditions, obtain licenses or modify our products and features while we develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> substitutes, or may result
in significant settlement costs. For example, litigation can involve substantial damages for infringement, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#146;s
attorneys&#146; fees. We may also be prohibited from selling or licensing our products unless the third party licenses rights to us, which it is not required to do at a commercially reasonable price or at all. If a license is available from a third
party, we may have to pay substantial royalties or upfront fees or grant cross-licenses to intellectual property rights for our products. We may also have to redesign our products so they do not infringe third-party intellectual property rights,
which may not be possible or may require substantial monetary expenditures and time, during which our products may not be available for manufacture, use or sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we have reviewed certain third-party patents and patent filings that we believe may be relevant to our product
candidates, we have not conducted a freedom-to-operate search or analysis for any of our product candidates, and we may not be aware of patents or pending or future patent applications that, if issued, would block us from commercializing our product
candidates. Thus, we cannot guarantee that our product candidates, or our commercialization thereof, do not and will not infringe any third party&#146;s intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, patent applications in the United States and many international jurisdictions are typically not published until
18 months after the filing of certain priority documents (or, in some cases, are not published until they issue as patents), and publications in the scientific literature often lag behind actual discoveries. Therefore, we cannot be certain that
others have not filed patent applications or made public disclosures relating to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
technology or our contemplated technology. A third party may have filed, and may in the future file, patent applications covering our product candidates or technology similar to ours. Any such
patent application may have priority over our patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to
ours, depending on whether the timing of the filing date falls under certain patent laws, we may have to participate in a priority contest (such as an interference proceeding) declared by the United States Patent and Trademark Office, or USPTO, to
determine priority of invention in the United States. The costs of patent litigation and other proceedings could be substantial, and it is possible that such efforts would be unsuccessful if it is determined that the other party had independently
arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such invention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may be subject to legal proceedings and claims in the ordinary course of business with respect to
intellectual property. We may receive claims from third parties asserting infringement of their intellectual property rights. Future litigation may be necessary to establish our intellectual property rights or to defend ourselves by determining the
scope, enforceability and validity of third-party intellectual property rights. There can be no assurance with respect to the outcome of any current or future litigation brought by or against us, and the outcome of any such litigation could have a
material adverse impact on our business, operating results and financial condition. Litigation is inherently unpredictable, and outcomes are uncertain. Further, as the costs and outcome of these types of claims and proceedings can vary
significantly, it is difficult to estimate potential losses that may occur. Accordingly, we are unable at this time to estimate the effects of these potential future lawsuits on our financial condition, operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can. Even if
resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In
addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on
the price of our common stock. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to obtain, maintain and enforce intellectual property protection directed to our current and any future technologies
that we develop, others may be able to make, use or sell products substantially the same as ours, which could adversely affect our ability to compete in the market. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates
in every country or territory in which we may sell our products. In addition, we cannot be sure that any of our pending patent applications or pending trademark applications will issue or that, if issued, they will issue in a form that will provide
adequate protection. The U.S. Patent and Trademark Office, or USPTO, international patent offices or judicial bodies may deny or significantly narrow claims made under our patent applications, and our issued patents may be successfully challenged,
may be designed around or may otherwise be of insufficient scope to provide us with protection for our products. Further, the USPTO, international trademark offices or judicial bodies may deny our trademark applications and, even if published or
registered, these trademarks may not effectively protect our brand and goodwill. Like patents, trademarks also may be successfully opposed or challenged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be certain that the steps we have taken will prevent unauthorized use or unauthorized reverse engineering of our
technology. Moreover, third parties may independently develop technologies that are competitive with ours and such competitive technologies may or may not infringe our intellectual property. The enforcement of our intellectual property rights also
depends on the success of any legal actions we may take against these infringers in the respective country or forum, but these actions may not be successful. As with all granted intellectual property, such intellectual property may be challenged,
invalidated or circumvented, may not provide protection and/or may not prove to be enforceable in actions against specific alleged infringers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The market for pharmaceuticals and biopharmaceuticals is highly competitive
and subject to rapid technological change. Our success depends, in part, upon our ability to maintain a competitive position in the development and protection of technologies and any future products for use in these fields and upon our ability to
obtain, maintain and enforce our intellectual property rights. We seek to obtain and maintain patents and other intellectual property rights to restrict the ability of others to market products that misappropriate our technology and/or infringe our
intellectual property to unfairly and illegally compete with any future products. If we are unable to protect our intellectual property and proprietary rights, our competitive position and our business could be harmed, as third parties may be able
to make, use or sell products that are substantially the same as any future products we may sell without incurring the sizeable development and licensing costs that we have incurred, which would adversely affect our ability to compete in the market.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We use a combination of patents, trademarks, <FONT STYLE="white-space:nowrap">know-how,</FONT> confidentiality procedures
and contractual provisions to protect our proprietary technology. However, these protections may not be adequate and may not provide us with any competitive advantage. For example, patents may not issue from any of our currently pending or any
future patent applications, and our issued patents and any future patents that may issue may not survive legal challenges to their scope, validity or enforceability, or provide significant protection for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we or any future collaborators we may have were to initiate legal proceedings against a third party to enforce a patent
covering one of our product candidates or future product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or
unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including obviousness or lack of novelty, enablement or written description. Grounds for an
unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims
before the USPTO even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art
of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product
candidates. Such a loss of patent protection would have a material adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if our patents
are determined by a court to be valid and enforceable, they may not be interpreted sufficiently broadly to prevent others from marketing products similar to ours or designing around our patents. For example, third parties may be able to make
products that are similar to ours but that are not covered by the claims of our patents. Third parties may assert that we or our licensors were not the first to make the inventions covered by our issued patents or pending patent applications. The
claims of our issued patents or patent applications when issued may not cover our product candidates or any future products that we develop. We may not have freedom to commercialize unimpeded by the patent rights of others. Third parties may have
patents that dominate, block or are otherwise relevant to our technology. There may be prior public disclosures or other art that could be deemed to invalidate one or more of our patent claims. Further, we may not develop additional proprietary
technologies in the future, and, if we do, they may not be patentable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent law can be highly uncertain and involve
complex legal and factual questions for which important principles remain unresolved. In the United States and in many international jurisdictions, policies regarding the breadth of claims allowed in patents can be inconsistent. The U.S. Supreme
Court and the Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, international courts have made, and will likely continue to make,
changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and international legislative
bodies. Those changes may materially affect the patents and patent applications of our licensors, our existing or future patents and patent applications and our ability to obtain additional patents in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent reform legislation in the United States could increase the
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. For example, on September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into
law. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system
from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> system to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system. Under a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the
patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law
associated with the Leahy-Smith Act, and in particular, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> provisions, only became effective on March&nbsp;16, 2013. The Leahy-Smith Act and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, which could have a material adverse effect on our business and financial
condition. Any future changes in the patent laws of the United States, or even the possibility of such changes, may further increase these uncertainties and costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have a number of international patents and patent applications, and expect to continue to pursue patent
protection in many of the significant markets in which we intend to do business. The laws of some international jurisdictions may not protect intellectual property rights to the same extent as laws in the United States, and many companies have
encountered significant difficulties in obtaining, protecting and defending such rights in international jurisdictions. If we encounter such difficulties or we are otherwise precluded from effectively protecting our intellectual property rights in
international jurisdictions, our business, financial condition, results of operations and prospects could be materially and adversely affected. Earlier patent filings in certain international countries may also permit third parties to allege
priority to certain technology in those countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent terms may be shortened or lengthened by, for example, terminal
disclaimers, patent term adjustments, supplemental protection certificates and patent term extensions. Patent term extensions and supplemental protection certificates, and the like, may be impacted by the regulatory process and may not significantly
lengthen patent term. <FONT STYLE="white-space:nowrap">Non-payment</FONT> or delay in payment of patent fees or annuities, delay in patent filings or delay in extension filing (including any patent term extension or adjustment filing), whether
intentional or unintentional, may also result in the loss of patent rights important to our business. Certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. In addition, many
countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the protection afforded by patents, we rely on confidentiality agreements to protect confidential
information and proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and
development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology that is not covered by patents. We seek to protect our proprietary technology and processes, in part, by entering into
confidentiality agreements with our employees, consultants, scientific advisors and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or
proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information
technology systems. Agreements or security measures may be breached, and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is
difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by
competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
using that technology or information to compete with us. We rely on trade secret protection, which would be subject to the risks identified above with respect to confidential information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we review our
competitors&#146; products, and may in the future seek to enforce our patents or other rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent misappropriation of our
intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Our competitors may also independently develop similar technology. Any inability to meaningfully protect
our intellectual property could result in competitors offering products competitive to our products. In addition, we may need to defend our patents from third-party challenges, such as interferences, derivation proceedings, <FONT
STYLE="white-space:nowrap">re-examination</FONT> proceedings, post-grant review, inter partes review, third-party submissions, oppositions, nullity actions or other patent proceedings. We may need to initiate infringement claims or litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adverse proceedings such as litigation can be expensive, time consuming and may divert the efforts of our technical and
managerial personnel, which could in turn materially and adversely affect our business, financial condition, results of operations and prospects, whether or not we receive a determination favorable to us. In addition, in an infringement proceeding,
a court or other judicial body may decide that the patent we seek to enforce is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that the patent in question does not cover the
technology in question or that stopping the other party would harm the public interest. An adverse result in any litigation could put one or more of our patents at risk of being invalidated or interpreted narrowly. Some of our competitors may be
able to devote significantly more resources to intellectual property litigation, and may have significantly broader patent portfolios to assert against us if we assert our rights against them. Further, because of the substantial discovery required
in connection with intellectual property litigation, there is a risk that some of our confidential information could be disclosed or otherwise compromised during litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to correctly estimate or control our future operating expenses in relation to obtaining intellectual
property, enforcing intellectual property and/or defending intellectual property, which could affect operating expenses. Our operating expenses may fluctuate significantly in the future as a result of a variety of factors, including the costs of
preparing, filing, prosecuting, defending and enforcing patent and trademark claims and other intellectual property-related costs, including adverse proceedings and litigation costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We license patent rights from third-party owners. Such licenses may be subject to early termination if we fail to comply with our
obligations in our licenses with third parties, which could result in the loss of rights or technology that are material to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a party to licenses that give us rights to third-party intellectual property that are necessary or useful for our
business, and we may enter into additional licenses in the future. Under these license agreements we are obligated to pay the licensor fees, which may include annual license fees, milestone payments, royalties, a percentage of revenues associated
with the licensed technology and a percentage of sublicensing revenue. In addition, under certain of such agreements, we are required to diligently pursue the development of products using the licensed technology. If we fail to comply with these
obligations and fail to cure our breach within a specified period of time, the licensor may have the right to terminate the applicable license, in which event we could lose valuable rights and technology that are material to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the licensor retains control of prosecution of the patents and patent applications licensed to us, we may have limited or
no control over the manner in which the licensor chooses to prosecute or maintain its patents and patent applications and have limited or no right to continue to prosecute any patents or patent applications that the licensor elects to abandon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our intellectual property agreements with third parties may be subject to
disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of
any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, any of which could have a
material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, while it
is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an
agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or
defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We jointly own
certain patent rights with third parties. Our ability to <FONT STYLE="white-space:nowrap">out-license</FONT> these patent rights, or to prevent the third party from <FONT STYLE="white-space:nowrap">out-licensing</FONT> these patent rights, may be
limited in certain countries. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We jointly own certain patents and patent applications with third parties, and may
jointly own patents and patent applications with third parties in the future. Unless we enter into an agreement with the joint owner, we will be subject to certain default rules pertaining to joint ownership. Certain countries require the consent of
all joint owners to license jointly owned patents, and if we are unable to obtain such consent from the joint owner, we may not be able to license our rights under these patents and patent applications. In certain other countries, including the
United States, the joint owner could license its rights under these patents and patent applications to another party without our consent and without any duty of accounting to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also be subject to claims that former employees, any future collaborators or other third parties have an ownership
interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we
may lose valuable intellectual property rights and could even face litigation for infringing patents that we had regarded as ours. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against
such claims, litigation could result in substantial costs and distraction to management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to
protect our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Filing, prosecuting and defending patents on
product candidates in all countries throughout the world would be prohibitively expensive, and the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.
Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and may export otherwise infringing products to territories where we have patent protection but
enforcement is not as strong as that in the United States. These products may compete with any future products we may sell, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals and biopharmaceuticals, which could make it difficult for us to
stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and
attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a
significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If our trademarks and trade names are
not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or
conflict with third-party rights. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition with potential partners, physicians or patients in our markets of interest. In addition, third
parties may file first for our trademarks in certain countries. If they succeeded in registering such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our future
products in those countries. In such cases, over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then our commercial success abilities may be impacted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling,
packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and
requirements of comparable foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Manufacturers and manufacturers&#146; facilities are required
to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to
continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of
regulatory compliance, including manufacturing, production and quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will have to comply with requirements
concerning advertising and promotion for any future products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in
the product&#146;s approved label. We may not promote products for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to
the approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful
post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a
regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or
labeling of a product, such regulatory agency may impose restrictions on that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among
other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose civil or criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve pending applications or supplements to approved applications submitted by us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose restrictions on our operations, including closing our contract manufacturers&#146; facilities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize or detain products, or require a product recall. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any government investigation of alleged violations of law could require us to expend significant time and resources in
response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from any future products. If regulatory sanctions
are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be
enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action,
either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of
Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and
approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose restrictions
on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize
our product candidates and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, the European Union and other
jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been
and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Reconciliation Act, or collectively the Affordable Care Act, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the Affordable Care
Act, those of greatest importance to the pharmaceutical, biopharmaceutical and biotechnology industries include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, <FONT STYLE="white-space:nowrap">non-deductible</FONT> fee payable by any entity that manufactures
or imports certain branded prescription drugs and biologic agents (other than those designated as Orphan Drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part&nbsp;D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirements to report certain financial arrangements with physicians and teaching hospitals, including
reporting &#147;transfers of value&#148; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to
23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer
Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a licensure framework for follow on biologic products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare&nbsp;and Medicaid Innovation at the Centers for Medicare&nbsp;&amp;
Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its enactment, there have been judicial, Congressional and executive branch challenges to certain aspects of the
Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the
implementation of certain provisions of the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal
legislation, it has enacted laws that modify certain provisions of the Affordable Care Act such as removing penalties for not complying with the Affordable Care Act&#146;s individual mandate to carry health insurance and delaying the implementation
of certain fees mandated by the Affordable Care Act. On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of
the Affordable Care Act, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the Affordable Care Act are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld
the District Court&#146;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On March 2, 2020, the
United States Supreme Court granted the petitions for writs of certiorari to review this case, although it is unclear when a decision will be made or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal or
replace the Affordable Care Act will impact the law or our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, other legislative changes have been
proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These
reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional action is taken by Congress. The Coronavirus Aid, Relief, and Economic Security Act, or
CARES Act, which was signed into law on March 27, 2020, designed to provide financial support and resources </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to individuals and businesses affected by the COVID-19 pandemic, suspended these reductions from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030. In
addition, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers,
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and
other health care funding, which could negatively affect our customers and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example,
CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted
in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and
review the relationship between pricing and manufacturer patient programs. At the federal level, the Trump administration&#146;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to
reduce drug prices, increase competition, lower out-of-pocket drug costs for patients and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to
Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses and place limits on pharmaceutical
price increases. The Trump administration previously released a &#147;Blueprint,&#148; or plan, to lower drug prices and reduce out of pocket costs of prescription drugs that contained proposals to increase drug manufacturer competition, increase
the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or
HHS, has solicited feedback on some of these measures and has implemented others under its existing authority. While some measures may require additional authorization through additional legislation to become effective, Congress and the Trump
administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which
could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. Individual states in the United States have also
become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other
restrictions could materially and adversely affect our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine
what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably
commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or
obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for
national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however,
the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those
wishing to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our
product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative or judicial action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with
generic versions of such drugs, which may result in a material decline in sales of affected products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the
Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application, or ANDA, seeking approval of a generic version of an approved, small molecule
innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit a new drug application, or NDA, under section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA&#146;s prior approval of the small
molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some
circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug,
which would be listed with the product in the FDA publication, &#147;Approved Drug Products with Therapeutic Equivalence Evaluations,&#148; known as the Orange Book. If there are patents listed in the Orange Book for a product, a generic or
505(b)(2) applicant that seeks to market its product before expiration of the patents must include in their applications what is known as a &#147;Paragraph IV&#148; certification, challenging the validity or enforceability of, or claiming <FONT
STYLE="white-space:nowrap">non-infringement</FONT> of, the listed patent or patents. Notice of the certification must be given to the patent owner and NDA holder and if, within 45 days of receiving notice, either the patent owner or NDA holder sues
for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, if we choose
to develop a small molecule product candidate, and the product is approved, competitors could file ANDAs for generic versions of our small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products. If there are patents
listed for our small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the
patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such
patents, or the outcome of any such suit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be successful in securing or maintaining proprietary patent
protection for products and technologies we develop or license. Moreover, if any of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents that are listed in the Orange Book are successfully challenged by way of a Paragraph IV
certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business operations and current and future relationships with investigators,
healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants,
third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we
conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal civil and criminal Anti-Kickback Statute, which prohibits, among other things, persons or
entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in
return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such
as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal false claims laws, including the False Claims Act, which can be enforced through
whistleblower actions, and civil monetary penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for
payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an
obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for
purposes of the False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment
for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the HITECH and its implementing regulations, which also imposes certain obligations,
including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities, such as health plans, healthcare
clearinghouses and healthcare providers, as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers
of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of
value to physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Effective January 1, 2022, the U.S. federal physician
transparency reporting requirements will extend to include transfers of value made during the previous year to certain non-physician providers such as physician assistants and nurse practitioners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may
apply to our business practices, including but not limited to, research, distribution, sales and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to
comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other
potential referral sources; state and local laws that require the registration of pharmaceutical sales representatives; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which
requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy, security and disposal of personal information and health information in certain circumstances,
many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S.
companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international
organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">similar data protection and healthcare laws and regulations in the European Union and other jurisdictions,
including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal data, including the GDPR, which imposes obligations and restrictions on the collection and use
of personal data relating to individuals located in the European Union and European Economic Area (including with regard to health data). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare
laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, such as the provision of stock options to physicians who may influence the ordering, prescribing or use of
our product candidates, if approved, as compensation for consulting services, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If
our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties,
damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and
the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that
may be brought against us, our business may be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in tax laws and regulations may have a material adverse effect on
our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New income, sales, use or other tax laws, statutes,
rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our
business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the U.S. government recently enacted significant tax reform,
and certain provisions of the new law may adversely affect us. Changes include, but are not limited to, a federal corporate tax rate decrease to 21% for tax years beginning after December&nbsp;31, 2017, a reduction to the maximum deduction allowed
for net operating losses generated in tax years after December&nbsp;31, 2017, eliminating carrybacks of net operating losses, and providing for indefinite carryforwards for losses generated in tax years after December&nbsp;31, 2017. The legislation
is unclear in many respects and could be subject to potential amendments and technical corrections, and will be subject to interpretations and implementing regulations by the Treasury and Internal Revenue Service, any of which could mitigate or
increase certain adverse effects of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation. Generally, future changes in applicable U.S. tax laws and regulations, or
their interpretation and application could have an adverse effect on our business, financial conditions and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money
laundering laws and regulations.&nbsp;Compliance with these legal standards could impair our ability to compete in domestic and international markets.&nbsp;We can face criminal liability and other serious consequences for violations, which can harm
our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to export control and import laws and regulations, including the U.S. Export
Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended,
or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.
Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of
value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory
approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our
employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines
and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading price of our common stock following this offering could be highly volatile and could be subject to wide
fluctuations in response to various factors, some of which are beyond our control. In particular, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of the COVID-19 pandemic.
These factors include those discussed in this &#147;Risk Factors&#148; section of this prospectus and others such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results from, and any delays in, our clinical trials for our two clinical-stage product candidates or any
other future clinical development programs, including any delays related to the COVID-19 pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of regulatory approval or disapproval of our current or any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure or discontinuation of any of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination of any of our existing license agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements relating to any future licensing, collaboration or development agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the commercialization of our current or any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">public misperception regarding the use of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquisitions and sales of new products or product candidates, technologies or businesses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing and supply issues related to our product candidates for clinical trials or future product
candidates for commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quarterly variations in our results of operations or those of our competitors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in earnings estimates or recommendations by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of new products or product candidates, significant contracts,
commercial relationships, acquisitions or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments with respect to intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commencement of, or involvement in, litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates or guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any major changes in our board of directors or management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new legislation or regulation in the United States relating to the sale or pricing of pharmaceuticals;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA or other U.S. or foreign regulatory actions affecting us or our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product liability claims or other litigation or public concern about the safety of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical, biopharmaceutical and biotechnology sectors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions in the United States and abroad, including as a result of an economic recession or
depression and market volatility related to the COVID-19 pandemic and global health concerns. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These
broad market fluctuations may adversely affect the trading price or liquidity of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>An active, liquid and orderly
market for our common stock may not develop, and you may not be able to resell your common stock at or above the public offering price. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for shares of our common stock, and an active public market for our
shares may not develop or be sustained after this offering. We and the representatives of the underwriters will determine the initial public offering price of our common stock through negotiation. This price will not necessarily reflect the price at
which investors in the market will be willing to buy and sell our shares following this offering. In addition, an active trading market may not develop following the consummation of this offering or, if it is developed, may not be sustained. The
lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our
ability to acquire other product candidates, businesses or technologies using our shares as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If securities or
industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts
publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the trading price for our stock would be
negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or
if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility
in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an &#147;emerging growth company,&#148; and as a result of the reduced
disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain
exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of
Section&nbsp;404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. In addition, as an &#147;emerging growth company,&#148; the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such
pronouncements are made applicable to private companies. We have elected to use this extended transition period under the JOBS Act. As a result, our consolidated financial statements may not be comparable to the financial statements of issuers who
are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some
investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an
emerging growth company. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year following the fifth anniversary of the consummation of this offering, (2)&nbsp;the last day of the fiscal year in which
we have total annual gross revenue of at least $1.07&nbsp;billion, (3)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT>
under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business
day of the second fiscal quarter of such year, or (4)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will incur significant costs as a result of operating as a public company, and our management will devote substantial time to new
compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that could materially and adversely affect
our business, financial condition, results of operations and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will incur significant legal,
accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of The Nasdaq Stock
Market LLC and the rules of the Securities and Exchange Commission, or SEC, require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and
voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting
requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to
satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more
difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#146; and officers&#146; insurance, on
acceptable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After this offering, we will be subject to Section&nbsp;404 and the related rules of the SEC, which
generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Beginning with the second annual report that we will be required to file
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
with the SEC, Section&nbsp;404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth
company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being
required to comply with the auditor attestation requirements of Section&nbsp;404. Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to
include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must
provide the required reports. Furthermore, if we identify any material weaknesses, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not
be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could materially and adversely affect our business, financial condition, results of operations and prospects, cause investors to lose
confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In
order to report our results of operations and financial statements on an accurate and timely basis, we will depend in part on CROs to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate
and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market or other adverse consequences that would materially and adversely affect our business, financial condition, results of operations and
prospects. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Purchasers in this offering will experience immediate and substantial dilution in the book value of their
investment. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial public offering price of our common stock is substantially higher than the pro forma
net tangible book value per share of our common stock before giving effect to this offering. Accordingly, if you purchase our common stock in this offering, you will incur immediate substantial dilution of approximately $6.48 per share, based on an
assumed initial public offering price of $15.50 per share, the midpoint of the estimated price range set forth on the cover of this prospectus, and our pro forma as adjusted net tangible book value as of March&nbsp;31, 2020. In addition, following
this offering, purchasers in this offering will have contributed approximately 44.7% of the total gross consideration paid by stockholders to us to purchase shares of our common stock through March&nbsp;31, 2020, but will own only approximately
37.0% of the shares of common stock outstanding immediately after this offering. Furthermore, if the underwriters exercise their option to purchase additional shares or outstanding options are exercised, you could experience further dilution. For a
further description of the dilution that you will experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock
price may decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may from time to time issue additional shares of common stock at a discount from the current
trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into
financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional
dilution and, as a result, our stock price may decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our principal stockholders and management own a significant percentage of
our stock and will be able to exert significant control over matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of
June&nbsp;30, 2020, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 74.6% of our voting stock and, upon the closing of this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
offering, that same group will hold approximately 47.7% of our outstanding voting stock (assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of
outstanding options). Therefore, even after this offering these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example,
these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition
proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sales of a
substantial number of shares of our common stock in the public market could cause our stock price to fall. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If
our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the <FONT STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this
prospectus lapse, the trading price of our common stock could decline. Immediately after this offering, based upon the number of shares outstanding as of March 31, 2020 (including the conversion of all of our shares of redeemable convertible
preferred stock outstanding as of March&nbsp;31, 2020 into 12,684,214 shares of our common stock), plus 8,140,724 shares of our common stock issuable pursuant to the conversion of our Series D redeemable convertible preferred stock issued and sold
in June 2020, immediately prior to the completion of this offering, we will have outstanding a total of 33,758,687&nbsp;shares of common stock, assuming no exercise of the underwriters&#146; option to purchase additional shares. Of these shares,
substantially all of the shares of our common stock sold in this offering (excluding any shares sold to our director or officers in the directed share program), plus any shares sold upon exercise of the underwriters&#146; option to purchase
additional shares, will be freely tradable, without restriction, in the public market immediately following this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering will expire 180&nbsp;days from the
date of this prospectus. Based upon the number of shares outstanding as of March 31, 2020, plus 8,140,724 shares of our common stock issuable pursuant to the conversion of our Series D redeemable convertible preferred stock issued and sold in June
2020, after the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, up to approximately 21,258,687 additional shares of common stock will be eligible for sale in the public market, approximately 11,732,146 of which shares are held by
directors, executive officers and other affiliates and will be subject to Rule&nbsp;144 under the Securities Act of 1933, as amended, or the Securities Act. J.P. Morgan Securities LLC, BofA Securities, Inc. and Cowen and Company, LLC may, however,
in their sole discretion, permit our officers, directors and other stockholders who are subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as of March 31, 2020, approximately
2,461,332 shares of common stock that are either subject to outstanding options or reserved for future issuance under our equity incentive plans, plus 942,043 shares reserved for future issuance under a June 2020 amendment to our equity incentive
plan, will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule&nbsp;144 and Rule&nbsp;701 under the Securities
Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After this offering, the holders of approximately 20,824,938 shares of our common stock, or approximately 98.0% of our total
outstanding shares of common stock as of March 31, 2020 (including the shares of our common stock issuable pursuant to the conversion of our Series D redeemable convertible preferred stock issued and sold in June 2020), will be entitled to rights
with respect to the registration of their shares under the Securities Act, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. Registration of these shares under the Securities Act would result in the shares
becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have broad discretion to determine how to use the funds raised in this offering,
and may use them in ways that may not enhance our operating results or the price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
management will have broad discretion over the use of proceeds from this offering, and we could spend the proceeds from this offering in ways our stockholders may not agree with or that do not yield a favorable return, if at all. We currently expect
to use the net proceeds of this offering, together with our existing cash and cash equivalents, to fund the advancement of ANX005 for the treatment of GBS and wAIHA; ANX009 for the treatment of systemic autoimmune diseases; ANX005 for the treatment
of HD and ALS; ANX007 for the treatment of geographic atrophy; our next generation product candidates; our other research and development activities; and the remainder for working capital and other general corporate purposes. However, our use of
these proceeds may differ substantially from our current plans. If we do not invest or apply the proceeds of this offering in ways that improve our operating results, we may fail to achieve expected financial results, which could cause our stock
price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an
&#147;ownership change,&#148; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#146;s ability to use its <FONT
STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards, or NOLs, and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research and development tax credits) to offset its post-change income or
taxes may be limited. We may have experienced ownership changes in the past and may experience ownership changes as a result of this offering and/or subsequent shifts in our stock ownership (some of which are outside our control). As a result, our
ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and tax credits to offset future taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain
profitability, we may be unable to use a material portion of our NOLs and tax credits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provisions in our charter documents and
under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws, both of which will become effective
immediately prior to the completion of this offering, will contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions will include the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders
to change the membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect
director candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exclusive right of our board of directors to elect a director to fill a vacancy, however occurring,
including by an expansion of the board of directors, which prevents stockholders from being able to fill vacancies on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine
the price and other terms of those shares, including voting or other rights or preferences, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt,
amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an
annual or special meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may
delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of
directors or to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise
attempting to obtain control of us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also subject to the anti-takeover provisions contained in
Section&nbsp;203 of the Delaware General Corporation Law. Under Section&nbsp;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three
years or, among other exceptions, the board of directors has approved the transaction. For a description of our capital stock, see the section titled &#147;Description of Capital Stock.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>As a California-domiciled public company, we will be required to have at least two or three women on our board of directors by the end
of 2021, depending on the size of our board at the time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our success depends in part on our continued ability to
attract, retain and motivate highly qualified individuals to our board of directors. As a public company headquartered in California, we will be required to have two or three women on our board of directors by the end of 2021, depending on the size
of our board of directors at the time. While we currently have two women on the board of directors, recruiting and retaining board members carries uncertainty, and failure to comply with this California requirement will result in financial
penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful
third-party claims against us and may reduce the amount of money available to us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated
certificate of incorporation and amended and restated bylaws will provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as permitted by Section&nbsp;145 of the Delaware General Corporation Law, our amended and restated bylaws to be
effective immediately prior to the completion of this offering and our indemnification agreements that we have entered into with our directors and officers will provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors and officers for serving us in those capacities or for serving other business
enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not
opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#146;s conduct was unlawful; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is
permitted by applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a
proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to
proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into
indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification
obligations to directors, officers, employees and agents. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we maintain a directors&#146; and
officers&#146; insurance policy, such insurance may not be adequate to cover all liabilities that we may incur, which may reduce our available funds to satisfy third-party claims and may adversely impact our cash position. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our amended and restated certificate of incorporation and amended and restated bylaws will provide that the Court of Chancery of the
State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that the Court
of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any
derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate
of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability
or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject
matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws will also provide that the federal district
courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our
amended and restated certificate of incorporation and amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal
securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that
a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue
other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision that will be contained
in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could
adversely affect our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We do not currently intend to pay dividends on our common stock, and,
consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to
invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation
in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to securities litigation, which is expensive and could divert our management&#146;s attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities
class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our
management&#146;s attention from other business concerns. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Participation in this offering by our existing stockholders and/or their
affiliated entities may reduce the public float for our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent certain of our existing
stockholders and their affiliated entities participate in this offering, such purchases would reduce the non-affiliate public float of our shares, meaning the number of shares of our common stock that are not held by officers, directors and
controlling stockholders. A reduction in the public float could reduce the number of shares that are available to be traded at any given time, thereby adversely impacting the liquidity of our common stock and depressing the price at which you may be
able to sell shares of common stock purchased in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains forward-looking statements about us and our industry that involve substantial risks and
uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of
management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148;
&#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;due,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148;
&#147;positioned,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the potential market size and size of the potential patient populations for our
product candidates and any future product candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our clinical and regulatory development plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations with regard to the results of our clinical studies, preclinical studies and research and
development programs, including the timing and availability of data from such studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of commencement of future nonclinical studies and clinical trials and research and development
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to acquire, discover, develop and advance product candidates into, and successfully complete,
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intentions and our ability to establish collaborations and/or partnerships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and expectations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intentions with respect to the commercialization of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential effects of COVID-19 on our preclinical and clinical programs and business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model and strategic plans for our business and product candidates,
including additional indications for which we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates, including the projected terms of patent protection; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our
ability to obtain additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future financial performance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors and our industry, including competing products.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have based these forward-looking statements largely on our current expectations, estimates,
forecasts and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking
statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
prospectus, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all.
You should refer to the section titled &#147;Risk Factors&#148; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward- looking statements. Furthermore, if our
forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or
otherwise. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act do not protect any forward-looking statements that we make in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the
registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by
these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains estimates, projections and other information concerning our industry, our business, as well as data
regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or
circumstances may differ materially from events and circumstances that are assumed in this information. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in
the section titled &#147;Risk Factors.&#148; Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third
parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of
data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the net proceeds to us from this offering will be approximately $175.9&nbsp;million (or approximately
$202.9&nbsp;million if the underwriters exercise in full their option to purchase up to 1,875,000 additional shares of common stock), based on an assumed initial public offering price of $15.50 per share, the midpoint of the price range set forth on
the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase or decrease in the assumed initial public offering price of $15.50 per share, the midpoint of the price
range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by approximately $11.6&nbsp;million, assuming that the number of shares of common stock offered by us, as set
forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million&nbsp;shares of
common stock offered by us would increase or decrease, as applicable, the net proceeds to us by approximately $14.4&nbsp;million, assuming the assumed initial public offering price of $15.50 per share remains the same, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal purposes of this
offering are to obtain additional capital to support our operations, to create a public market for our common stock and to facilitate our future access to the public markets. We currently intend to use the net proceeds from this offering, together
with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $60.0 million to $70.0 million to advance ANX005 for the treatment of Guillain-Barr&eacute;
Syndrome, or GBS, and warm autoimmune hemolytic anemia, or wAIHA, and to advance ANX009 for the treatment of systemic autoimmune diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $10.0 million to $20.0 million to advance ANX005 for the treatment of Huntington&#146;s disease,
or HD, and amyotrophic lateral sclerosis, or ALS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $15.0 million to $25.0 million to advance ANX007 for the treatment of geographic atrophy, or GA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $20.0 million to $30.0 million to advance our next generation product candidates, including
ANX105 and small molecule modulators of the classical pathway; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $65.0 million to $75.0 million to fund our other research and development activities, including
research and development personnel costs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based upon our current operating plan, we believe that the anticipated net proceeds from this offering, together with our
existing cash and cash equivalents, which includes the net proceeds of approximately $96.7 million from the Series D financing, will enable us to fund our operating expenses and capital expenditure requirements through 2023. In particular, we expect
that the net proceeds from this offering, together with our existing cash and cash equivalents, will allow us to complete our Phase 1b drug-drug interaction and Phase&nbsp;2/3 trials of ANX005 in GBS, our planned Phase 2 trial of ANX005 in wAIHA,
our planned Phase&nbsp;2a trials of ANX005 in HD and ALS, our Phase&nbsp;2 trial of ANX007 in GA and our first-in-human trial of ANX009. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This expected use of the net proceeds from this offering represents our intentions based on our current plans and business
conditions, which could change in the future as our plans and business conditions evolve. Further, due to the uncertainties inherent in the drug development process, it is difficult to estimate with certainty the exact amounts of the net proceeds
from this offering that may be used for the above purposes. We may also use a portion of the remaining net proceeds and our existing cash and cash equivalents to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in complementary
businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management will have broad discretion over the use of the net proceeds
from this offering, and our investors will be relying on the judgment of our management regarding the application of the net proceeds of this offering. The amounts and timing of our expenditures will depend upon numerous factors including the
results of our research and development efforts, the timing and success of our preclinical studies and ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions, the amount of cash obtained
through any future collaborations and other factors described in the section titled &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
expected net proceeds from this offering will not be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of our product
candidates. We expect to finance our cash needs through a combination of equity offerings, debt financings and potential collaborations, and license and development agreements. We have based these estimates on assumptions that may prove to be
incorrect, and we could expend our available capital resources at a rate greater than we currently expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pending the
use of the net proceeds from this offering as described above, we intend to invest the net proceeds in a variety of capital preservation instruments, including short-term, interest-bearing obligations, investment-grade instruments, certificates of
deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid cash dividends on our capital stock, and we do not currently intend to pay any cash dividends
on our capital stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination related to dividend policy will be made at the
discretion of our board of directors, subject to applicable laws, and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. In addition, our ability to pay cash
dividends on our capital stock may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our cash and cash equivalents and our capitalization as of March 31, 2020 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma basis, to reflect: (i)&nbsp;the conversion of all of our shares of redeemable convertible
preferred stock outstanding as of March 31, 2020 into 12,684,214 shares of our common stock, which will occur immediately prior to the completion of this offering, (ii)&nbsp;the issuance and sale of 71,719,859 shares of our Series D redeemable
convertible preferred stock in June 2020 for aggregate net proceeds of approximately $96.7 million, and the conversion of such shares into 8,140,724 shares of our common stock, which will occur immediately prior to the completion of this offering,
and (iii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation in Delaware, which will be in effect immediately prior to the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma as adjusted basis, to reflect (i)&nbsp;the pro forma adjustments set forth above and (ii)&nbsp;the
sale of 12,500,000&nbsp;shares of our common stock in this offering at an assumed initial public offering price of $15.50 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read this table together with the sections titled &#147;Selected
Consolidated Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus. The pro
forma information below is illustrative only and our capitalization following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;March 31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Actual&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Pro&nbsp;Forma&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value, per share; 119,155,472 shares
authorized, 111,748,065 issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value, no shares authorized, issued and outstanding, actual; 5,000,000
shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share; 150,000,000 shares authorized, 433,749 shares issued and
outstanding, actual;&nbsp;300,000,000 shares authorized and 21,258,687&nbsp;shares issued and outstanding, pro forma;&nbsp;300,000,000&nbsp;shares authorized and 33,758,687&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112,422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">304,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Each $1.00 increase or decrease in the assumed initial public offering price of $15.50 per share, the
midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, each of pro forma as adjusted cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total
stockholders&#146; equity and total capitalization by approximately $11.6&nbsp;million, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million&nbsp;shares of common stock offered by us would increase or decrease, as applicable, each of pro
forma as adjusted cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by approximately $14.4&nbsp;million, assuming that the assumed initial public
offering price of $15.50 per share remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock issued and outstanding, pro forma and pro forma as adjusted, in the table above is
based on 13,117,963 shares of our common stock outstanding as of March 31, 2020 (after giving effect to the conversion of all of our shares of redeemable convertible preferred stock outstanding as of March 31, 2020 into an aggregate of 12,684,214
shares of our common stock immediately prior to the completion of this offering), plus 8,140,724 shares of our common stock issuable pursuant to the conversion of our Series&nbsp;D redeemable convertible preferred stock issued and sold in June 2020,
and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,136,390 shares of our common stock issuable upon the exercise of outstanding stock options as of March 31,
2020, with a weighted-average exercise price of $5.45 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">892,730 shares of our common stock issuable upon the exercise of outstanding stock options granted subsequent
to March 31, 2020, with a weighted-average exercise price of $13.32 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,375,868&nbsp;shares of our common stock reserved for future issuance under the 2020 Plan, from which we will
grant options to purchase an aggregate of 448,821 shares of our common stock with an exercise price per share equal to the initial public offering price to certain officers and employees upon the pricing of this offering, which will become effective
on the date immediately prior to the date our registration statement relating to this offering becomes effective, as well as any future increases in the number of shares of common stock reserved for issuance under the 2020 Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">337,586&nbsp;shares of our common stock reserved for future issuance under the ESPP, which will become
effective on the date immediately prior to the date our registration statement relating to this offering becomes effective, as well as any future increases in the number of shares of common stock reserved for issuance under the ESPP.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our historical net tangible book value (deficit) as of March&nbsp;31, 2020 was $(115.3)&nbsp;million, or $(265.88) per share
of our common stock. Our historical net tangible book value (deficit) represents our total tangible assets less capitalized deferred offering costs, total liabilities and redeemable convertible preferred stock. Historical net tangible book value
(deficit) per share is our historical net tangible book value (deficit) divided by the number of shares of our common stock outstanding as of March&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pro forma net tangible book value as of March 31, 2020 was $125.7 million, or $5.91 per share of our common stock, based
on the total number of shares of our common stock outstanding as of March&nbsp;31, 2020. Pro forma net tangible book value per share represents our total tangible assets less capitalized deferred offering costs and our total liabilities, divided by
the number of outstanding shares of common stock, after giving effect to&nbsp;(i)&nbsp;the conversion of all of our shares of redeemable convertible preferred stock outstanding as of March&nbsp;31, 2020 into an aggregate of 12,684,214&nbsp;shares of
common stock and (ii)&nbsp;the issuance of 71,719,859 shares of our Series&nbsp;D redeemable convertible preferred stock in June 2020 for aggregate net proceeds of approximately $96.7&nbsp;million, and the conversion of such shares into 8,140,724
shares of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After giving effect to the sale of 12,500,000&nbsp;shares of common stock in this
offering at an assumed initial public offering price of $15.50 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us, our pro forma as adjusted net tangible book value as of March&nbsp;31, 2020 would have been $304.5&nbsp;million, or $9.02 per share. This represents an immediate increase in pro forma as adjusted net tangible book value of
$3.11 per share to our existing stockholders and an immediate dilution of $6.48 per share to new investors participating in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed&nbsp;initial&nbsp;public&nbsp;offering&nbsp;price&nbsp;per&nbsp;share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(265.88)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in net tangible book value per share as of March&nbsp;31, 2020 attributable to
the pro forma transactions described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">271.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of March&nbsp;31, 2020, before giving effect to
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase or decrease in the assumed initial public offering price of
$15.50 per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by $0.34 per share and the
dilution per share to new investors participating in this offering by $0.66 per share, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, an increase of 1.0&nbsp;million in the number of shares of common stock offered by us would increase the pro forma as adjusted net tangible
book value after this offering by $0.15 per share and decrease the dilution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
per share to new investors participating in this offering by $0.15 per share, and a decrease of 1.0&nbsp;million shares of common stock offered by us would decrease the pro forma as adjusted net
tangible book value by $0.17 per share, and increase the dilution per share to new investors in this offering by $0.17 per share, assuming that the assumed initial public offering price of $15.50 per share remains the same and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters
exercise in full their option to purchase additional shares of common stock from us, the pro forma as adjusted net tangible book value per share after giving effect to this offering would be $9.30 per&nbsp;share, representing an immediate increase
to existing stockholders of $3.39 per share, and dilution to new investors participating in this offering of $6.20 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes on the pro forma as adjusted basis described above, the differences between the number of
shares purchased from us, the total consideration paid and the average price per share paid to us by existing stockholders and by investors purchasing shares in this offering at the assumed initial public offering price of $15.50 per share, the
midpoint of the price range set forth on the cover page on this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,258,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">239,766,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,758,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">433,516,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A $1.00 increase or decrease in the assumed initial public offering price of $15.50
per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the total consideration paid by new investors by $12.5&nbsp;million and, in the case of an increase, would increase
the percentage of total consideration paid by new investors to 46.2% and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors to 43.1%, assuming that the number of shares offered by us, as set forth
on the cover page of this prospectus, remains the same. Similarly, an increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us would increase or decrease, as applicable, the total consideration paid by new investors by
$15.5&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors to 46.6% and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors to
42.6%, assuming that the assumed initial public offering price of $15.50 per share remains the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters
exercise their option to purchase additional shares in full, our existing stockholders would own 59.7% and our new investors would own 40.3% of the total number of shares of our common stock outstanding upon the completion of this offering. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock issued and outstanding, pro forma and pro forma as adjusted, in the table above
is based on 13,117,963 shares of our common stock outstanding as of March&nbsp;31, 2020 (after giving effect to the conversion of all of our shares of redeemable convertible preferred stock outstanding as of March&nbsp;31, 2020 into an aggregate of
12,684,214 shares of our common stock immediately prior to the completion of this offering), plus 8,140,724 shares of our common stock issuable pursuant to the conversion of our Series&nbsp;D redeemable convertible preferred stock issued and sold in
June 2020, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,136,390 shares of our common stock issuable upon the exercise of outstanding stock options as of
March&nbsp;31, 2020, with a weighted-average exercise price of $5.45 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">892,730 shares of our common stock issuable upon the exercise of outstanding stock options granted subsequent
to March&nbsp;31, 2020, with a weighted-average exercise price of $13.32 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,375,868 shares of our common stock reserved for future issuance under the 2020 Plan, from which we will
grant options to purchase an aggregate of 448,821 shares of our common stock with an exercise price per share equal to the initial public offering price to certain officers and employees upon the pricing of this offering, which will become effective
on the date immediately prior to the date our registration statement relating to this offering becomes effective, as well as any future increases in the number of shares of common stock reserved for issuance under our 2020 Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">337,586 shares of our common stock reserved for future issuance under the ESPP, which will become effective on
the date immediately prior to the date our registration statement relating to this offering becomes effective, as well as any future increases in the number of shares of common stock reserved for issuance under the ESPP. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that any outstanding options are exercised, new options or other equity awards are issued under our equity
incentive plans, or we issue additional shares in the future, there will be further dilution to new investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_9"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables set forth our selected consolidated statements of operations and consolidated balance sheet data. The
selected consolidated statements of operations data for the years ended December&nbsp;31, 2018 and 2019 and the selected consolidated balance sheet data as of December&nbsp;31, 2018 and 2019 are derived from our audited consolidated financial
statements appearing elsewhere in this prospectus. The selected consolidated statements of operations data for the three months ended March 31, 2019 and 2020 and the selected consolidated balance sheet data as of March 31, 2020 are derived from our
unaudited interim condensed consolidated financial statements appearing elsewhere in this prospectus. The unaudited interim condensed consolidated financial statements were prepared on a basis consistent with our audited consolidated financial
statements and include, in management&#146;s opinion, all adjustments, consisting only of normal recurring adjustments that we consider necessary for a fair presentation of the financial information set forth in those statements. Our historical
results are not necessarily indicative of the results that may be expected for any period in the future and our interim results are not necessarily indicative of our expected results for the year ending December 31, 2020. You should read the
following selected consolidated financial data together with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and the related notes
included elsewhere in this prospectus. The selected consolidated financial data included in this section are not intended to replace the consolidated financial statements and are qualified in their entirety by the consolidated financial statements
and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on remeasurement of redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders,
basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">402,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing pro forma net loss per&nbsp;share attributable to common
stockholders, basic and diluted (unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,452,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,117,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">See Notes 2 and 11 to our audited consolidated financial statements and Notes 2 and 10 to our unaudited
interim condensed consolidated financial statements included elsewhere in this prospectus for explanations of the calculations of our basic and diluted net loss per share, basic and diluted pro forma net loss per share and the weighted-average
number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112,422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">We define working capital as current assets less current liabilities. See our audited consolidated financial
statements and our unaudited interim condensed consolidated financial statements and related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>You should read the following discussion and analysis of our financial condition and results of operations together with
our consolidated financial statements and the related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our
plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual
results could differ materially from the results described in or implied by these forward-looking statements. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical
complement-mediated disorders of the body, brain and eye. Our pipeline is based on our platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by
aberrant activation of C1q, the initiating molecule of the classical complement pathway. Evidence suggests that potent and selective inhibition of C1q can prevent tissue damage triggered in antibody-mediated autoimmune disease and preserve loss of
functioning synapses associated with cognitive and functional decline in complement-mediated neurodegeneration. Our upstream complement approach targeting C1q acts as an &#147;on/off switch&#148; designed to block all downstream components of the
classical complement pathway that lead to excess inflammation, tissue damage and patient disability in a host of complement-mediated disorders, while preserving the normal immune function of the lectin and alternative complement pathways involved in
the clearance of pathogens and damaged cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pipeline of product candidates is designed to block the activity of C1q
and the entire classical complement pathway in a broad set of complement-mediated diseases. Our first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative
disorders. Our second product candidate, ANX007, is an antigen-binding fragment, or Fab, formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. We are also developing ANX009, an investigational,
subcutaneous formulation of a Fab designed for the treatment of systemic autoimmune diseases. We have completed Phase 1b safety and dose-ranging clinical trials for ANX005 and ANX007 in patients with Guillain-Barr&eacute; Syndrome, or GBS, and
glaucoma, respectively. Both ANX005 and ANX007 were well-tolerated and showed full inhibition of C1q and the classical complement pathway in the Phase 1b trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on learnings from our initial trials, we are advancing our current programs while evaluating additional orphan and large
market indications. In particular, we intend to advance ANX005 into multiple Phase&nbsp;2 trials in 2020 and 2021 including in patients with GBS, warm autoimmune hemolytic anemia, Huntington&#146;s disease and amyotrophic lateral sclerosis. We plan
to advance ANX007 into a Phase 2 trial in patients with GA in 2021. Additionally, we are developing novel product candidates designed to inhibit C1q and other components of the early classical complement cascade with the goal of further broadening
our portfolio. Finally, we are leveraging our disciplined development strategy in early clinical trials utilizing established biomarkers to enhance patient selection, measure target engagement and assess our product candidates&#146; potential to
meaningfully impact the disease process and improve the probability of technical success over shorter development timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We hold worldwide development and commercialization rights, including through exclusive licenses, to all of our product
candidates, which allows us to strategically maximize value from our product portfolio over time. Our patent portfolio includes patent protection for our upstream complement platform and each of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were incorporated in March 2011 and commenced operations later that year. To date, we have focused primarily on performing
research and development activities, hiring personnel and raising capital to support and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
expand these activities. We do not have any products approved for sale, and we have not generated any revenue from product sales. We have incurred net losses each year since our inception. Our
net losses were $18.3&nbsp;million and $37.2 million for the years ended December&nbsp;31, 2018 and 2019, respectively, and $8.7 million and $12.3 million for the three months ended March 31, 2019 and 2020, respectively. As of March 31, 2020, we had
an accumulated deficit of $114.9&nbsp;million and cash and cash equivalents of $33.3&nbsp;million. In June 2020, we issued and sold 71,719,859 shares of our Series D redeemable convertible preferred stock for net proceeds of approximately $96.7
million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to incur significant and increasing losses in the foreseeable future as we continue to invest in
research and development activities related to developing our product candidates, particularly as they advance into later stages of development and as we conduct larger clinical trials, engage in other research and development activities, seek
regulatory approvals for any product candidates that successfully complete clinical trials, prepare for commercialization, hire additional personnel, protect our intellectual property and incur additional expenses as a result of operating as a
public company. We also expect to increase the size of our administrative function to support the growth of our business. Our net losses may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on a variety of factors, including: the
timing and cost of, and level of investment in, research and development; the number and timing of the clinical trials we commence; the cost of manufacturing our product candidates; the timing and cost of commercialization activities relating to our
product candidates, if approved; and expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have funded our operations to date primarily from the issuance and sale of equity securities. From our inception through
June 30, 2020, we have raised aggregate net cash proceeds of approximately $233.8&nbsp;million from the sale of our equity securities. We do not expect to generate revenue from any product candidates that we develop until we obtain regulatory
approval for one or more of such product candidates and commercialize our products or enter into collaboration agreements with third parties. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we
expect to finance our operations through public or private equity offerings or debt financings, credit or loan facilities, collaborations or a combination of one or more of these funding sources. As a result, we will need to raise additional
capital. Additional funds may not be available to us on acceptable terms or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in,
the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or
terminate our product development programs, commercialization efforts or other operations. Based upon our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, which
includes the net proceeds of approximately $96.7 million from the Series D financing, will enable us to fund our operating expenses and capital expenditure requirements through 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The global COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> situation closely. The extent of the impact of the COVID-19 on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments,
including the duration and spread of the outbreak and its impact on our clinical trial enrollment, trial sites, contract research organizations, or CROs, third-party manufacturers, and other third parties with whom we do business, as well as its
impact on regulatory authorities and our key scientific and management personnel. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent possible, we are conducting business
as usual, with necessary or advisable modifications to employee travel and the majority of our employees working remotely. We will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that
alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. At this point, the extent to which
the COVID-19 pandemic may affect our business, operations and clinical development timelines and plans, including the resulting impact on our expenditures and capital needs, remains uncertain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Operating Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
product candidates are not approved for commercial sale. We have not generated any revenue from sales of our product candidates and do not expect to do so in the foreseeable future and until we complete clinical development, submit regulatory
filings and receive approvals from applicable regulatory bodies for such product candidates, if ever. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses account for a significant portion of our operating expenses. Research and development
expenses consist primarily of direct and indirect costs incurred for the development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Direct
expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">professional services agreements with third party contract organizations, investigative clinical trial sites
and consultants that conduct research and development activities on our behalf; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contract manufacturing costs to produce clinical trial materials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory supplies and materials. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indirect expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensation and personnel-related expenses (including stock-based compensation); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated expenses for facilities and depreciation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other indirect costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We record research and development expenses as incurred. Payments made to other entities are under agreements that are
generally cancelable by us. Advance payments for goods or services to be received in future periods for use in research and development activities are deferred as prepaid expenses. The prepaid amounts are then expensed as the related services are
performed. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest
in research and development activities related to developing our product candidates, particularly as they advance into later stages of development and as we conduct larger clinical trials, engage in other research and development activities and seek
regulatory approvals for any product candidates that successfully complete clinical trials and as we incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary
clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist primarily of compensation and personnel-related expenses (including stock-based
compensation) for our personnel in executive, finance and other administrative functions. General and administrative expenses also include professional fees paid for accounting, legal and tax services, allocated expenses for facilities and
depreciation and other general and administrative costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our general and administrative expenses to increase substantially
for the foreseeable future as we continue to support our research and development activities, grow our business and, if any of our product candidates receive marketing approval, commercialization activities. We will also incur additional expenses as
a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, Sarbanes-Oxley Act and the Nasdaq Stock Market, additional insurance expenses, investor relations activities and other
administrative and professional services. We also expect to increase the size of our administrative function to support the growth of our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain (Loss) on Remeasurement of Redeemable Convertible Preferred Stock Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain (loss) on remeasurement of redeemable convertible preferred stock liability consists of gains and losses from the
remeasurement to fair value of the redeemable convertible preferred stock liability related to our Series C redeemable convertible preferred stock. We remeasured the liability each reporting period from the date of issuance (December 2018) until the
second closing of our Series C redeemable convertible preferred stock which occurred in August 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income, net, primarily consists of <FONT STYLE="white-space:nowrap">non-recurring</FONT> income from research grants and
interest income earned on our cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Three Months Ended March&nbsp;31, 2019 and 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables summarize our results of operations for the periods presented. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months<BR>Ended March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on remeasurement of redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I></I></B><B>Three&nbsp;Months<BR>Ended</B><B><I> </I></B><B>March&nbsp;31,</B><B><I></I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical and clinical outside services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory supplies and materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indirect costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and personnel-related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;10,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><I>Not meaningful</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses increased by $5.5&nbsp;million, or 120%, from $4.7&nbsp;million for the three months ended
March&nbsp;31, 2019 to $10.2&nbsp;million for the three months ended March&nbsp;31, 2020. The increase was primarily due to an increase of $2.0&nbsp;million in direct clinical outside services related to our Phase 1b drug-drug interaction trial and
planning activities for our Phase 2/3 GBS and Phase 2 HD clinical trials. In addition, preclinical expenses were higher due to toxicology studies to support ANX009. Contract manufacturing expenses increased by $2.1&nbsp;million primarily due to the
manufacturing of ANX005 to support the initiation of multiple clinical trials and ANX105 cell line development. Direct professional services costs increased by $0.2&nbsp;million related to external research and development capabilities during the
three months ended March&nbsp;31, 2020. Compensation and personnel-related expenses increased by $1.2&nbsp;million due to an increase in headcount and related employee costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I></I></B><B>Three&nbsp;Months<BR>Ended</B><B><I> </I></B><B>March 31,</B><B><I></I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and personnel-related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><I>Not meaningful</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses increased by $0.8&nbsp;million, or 55%, from $1.4&nbsp;million for the three months ended
March 31, 2019 to $2.2&nbsp;million for the three months ended March 31, 2020. The increase was primarily due to an increase of $0.5&nbsp;million in professional services for public company readiness efforts including accounting, legal and audit
fees, and an increase of $0.2&nbsp;million in compensation and personnel-related expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Loss on Remeasurement of Redeemable Convertible Preferred Stock Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the three months ended March&nbsp;31, 2019, we recorded a loss on remeasurement of redeemable convertible preferred stock
liability related to the change in the fair value of the liability. The liability was recognized in connection with the initial closing of our Series C redeemable convertible preferred stock financing in December 2018 and was settled upon completion
of the second closing in August 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income, net, decreased by $0.1&nbsp;million from $0.2&nbsp;million for the three months ended March 31, 2019 to
$0.1&nbsp;million for the three months ended March 31, 2020. The decrease was primarily driven by lower interest income as a result of lower cash balance and interest rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2018 and 2019 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables summarize our results of operations for the periods presented. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;15,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;8,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on remeasurement of redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><I>Not meaningful</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical and clinical outside services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;2,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory supplies and materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indirect costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and personnel-related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;15,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;24,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><I>Not meaningful </I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses increased by $9.0&nbsp;million, or 58%,
from $15.5&nbsp;million for the year ended December&nbsp;31, 2018 to $24.5&nbsp;million for the year ended December&nbsp;31, 2019. The increase was primarily due to $3.7&nbsp;million in additional contract manufacturing costs to support continued
advancement of our product candidates through clinical trials. Preclinical and clinical outside services increased by $2.7&nbsp;million primarily related to our Phase 1b clinical trials for ANX005 in GBS and ANX007 in glaucoma. Compensation and
personnel-related expenses increased by $2.0&nbsp;million due to growth in the number of research and development employees. In addition, laboratory supplies and materials increased by $0.6&nbsp;million due to activities associated with our ongoing
clinical trials and research programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and personnel-related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses increased by $4.4&nbsp;million, or 121%, from
$3.6&nbsp;million for the year ended December&nbsp;31, 2018 to $8.0&nbsp;million for the year ended December&nbsp;31, 2019. The increase was primarily due to $2.5&nbsp;million in additional professional service fees for accounting, legal and tax
services. Compensation and personnel-related expenses increased by $1.7&nbsp;million primarily related to $1.0&nbsp;million in additional stock-based compensation expense as well as growth in the number of general and administrative employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gain (loss) on Remeasurement of Redeemable Convertible Preferred Stock Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the year ended December 31, 2019, we recorded a loss on remeasurement of redeemable convertible preferred stock liability
of $5.7&nbsp;million related to the change in fair value of the liability. The liability was recognized in connection with the initial closing of our Series C redeemable convertible preferred stock financing in December 2018 and was settled upon
completion of the second closing in August 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income, net, increased by $0.4 million, or 73%, from $0.6&nbsp;million for the year ended December&nbsp;31, 2018 to
$1.0&nbsp;million for the year ended December 31, 2019. The increase was primarily due to interest income from increased investments in money market funds resulting from the Series C redeemable convertible preferred stock financing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of
Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to our significant research and development expenditures, we have generated operating losses since
our inception. We have funded our operations primarily through the sale of equity securities. From our inception through March&nbsp;31, 2020, we have raised aggregate net cash proceeds of $137.1&nbsp;million from the sale of our equity securities.
As of March 31, 2020, we had available cash and cash equivalents of $33.3&nbsp;million and an accumulated deficit of $114.9&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, we issued and sold 71,719,859 shares of our Series D
redeemable convertible preferred stock for net proceeds of approximately $96.7 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical Cash Flows </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in operating activities for the three months ended March 31, 2020 was $10.0&nbsp;million, which consisted of a net
loss of $12.3&nbsp;million, partially offset by $0.8&nbsp;million in non-cash charges and a net change of $1.5&nbsp;million in our net operating assets and liabilities. The non-cash charges consisted of stock-based compensation of $0.7&nbsp;million
and depreciation and amortization of $0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in operating activities for the three months ended
March 31, 2019 was $6.0&nbsp;million, which consisted of a net loss of $8.7&nbsp;million and a net change of $0.7&nbsp;million in our net operating assets and liabilities, partially offset by $3.4&nbsp;million in non-cash charges. The non-cash
charges consisted of depreciation and amortization of $0.1&nbsp;million and stock-based compensation of $0.5&nbsp;million as well as an increase of $2.8 million loss on remeasurement of redeemable convertible preferred stock liability related to the
change in fair value of the liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in operating activities for the year ended December 31, 2019 was
$28.4&nbsp;million, which consisted primarily of a net loss of $37.2&nbsp;million and a net change of $0.6&nbsp;million in our net operating assets and liabilities, partially offset by $8.2 million in non-cash charges. The <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges pertained to the loss on remeasurement of the redeemable convertible preferred stock liability of $5.7&nbsp;million, stock-based compensation of $2.0&nbsp;million and depreciation and amortization
of $0.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in operating activities for the year ended December&nbsp;31, 2018 was $17.2&nbsp;million,
which consisted primarily of a net loss of $18.3 million, partially offset by $0.6&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> charges and a net change of $0.5&nbsp;million in net operating assets and liabilities. The <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges consisted of depreciation and amortization of $0.5&nbsp;million and stock-based compensation of $0.4&nbsp;million, partially offset by the gain on remeasurement of redeemable convertible preferred
stock liability of $0.3&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There was no cash used in investing activities for the three months ended March&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in investing activities for the years ended December&nbsp;31, 2018 and 2019 was $17,000 and $0.3&nbsp;million,
respectively, related to purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in financing activities for the three months ended March 31, 2020 was $0.6 million, which consisted of payments for
deferred offering costs of $0.6 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash provided by financing activities for the three months ended March 31,
2019 was $3,000, which consisted of proceeds from the exercise of stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash provided by financing activities
for the year ended December 31, 2019 was $28.4 million, which consisted of net proceeds received from the sale and issuance of our Series C redeemable convertible preferred stock of $30.0 million, partially offset by payments for deferred offering
costs of $1.6 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash provided by financing activities for the year ended December&nbsp;31, 2018 was
$58.5&nbsp;million which consisted of aggregate net proceeds received from the sale and issuance of our Series B and Series C redeemable convertible preferred stock of $58.3&nbsp;million and proceeds from the exercise of stock options of
$0.1&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We use our cash to fund operations, primarily to fund our clinical trials, research and development expenditures and related
personnel costs. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to our product candidates, particularly as they advance
into later stages of development and as we conduct larger clinical trials, engage in other research and development activities, seek regulatory approvals for any product candidates that successfully complete clinical trials and as we incur expenses
associated with hiring additional personnel to support our research and development efforts. In addition, we expect our general and administrative expenses to increase substantially for the foreseeable future as we continue to support our research
and development activities and to grow our business and as we expect to engage in commercialization activities, if any of our product candidates receive marketing approval. We will also incur additional expenses as a result of operating as a public
company and also expect to increase the size of our administrative function to support the growth of our business. The timing and amount of our operating expenditures will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of researching and developing our current product candidates or any
other future product candidates we choose to pursue, and conducting preclinical studies and clinical trials, including our planned clinical trials of ANX005 and ANX007; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our lead product candidates or
any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and characteristics of any additional product candidates we develop or acquire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty and/or other payments we are required to make pursuant to our
current or any future license or collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our lead product candidates or any future product candidates and any products we
successfully commercialize; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of building a sales force in anticipation of product commercialization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of commercialization activities of our product candidates, if approved for sale, including marketing,
sales and distribution costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish strategic collaborations, licensing or other arrangements and the financial terms of
any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual
property portfolio; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and amount of sales of any future approved products. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Without giving effect to the anticipated net proceeds from this offering, we
believe that our existing cash and cash equivalents, which includes the net proceeds of approximately $96.7 million from the Series D financing, will enable us to fund our operating expenses and capital expenditure requirements through 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based upon our current operating plan, we believe that the net proceeds from this offering, together with our existing cash
and cash equivalents, which includes the net proceeds of approximately $96.7 million from the Series D financing, will enable us to fund our operating expenses and capital expenditure requirements through 2023. We have based this estimate on
assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We expect to continue to expend significant resources for the foreseeable future. Until such time, if ever, as we can generate
substantial product revenue, we will be required to seek additional funding in the future and currently intend to do so through public or private equity offerings or debt financings, credit or loan facilities, collaborations or a combination of one
or more of these funding sources. Additional funds may not be available to us on acceptable terms or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, we could be forced to delay, limit, reduce or terminate
our product development programs, commercialization efforts or other operations. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our
stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive
covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Other Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our contractual obligations and other commitments as of December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments&nbsp;Due&nbsp;by&nbsp;Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;to&nbsp;3<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;to&nbsp;5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contractual obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The obligations noted above represent operating lease obligations related to our currently
occupied premises in South San Francisco, California. We also enter into contracts in the normal course of business with various third parties for preclinical studies, clinical trials and other services. These contracts generally provide for
termination upon notice, and therefore we believe that our noncancelable obligations under these agreements are not material. These payments are not included in the table above. This table also does not include any milestone or royalty payments to
third parties as the amounts, timing and likelihood of such payments are not known at this time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the audit of our financial statements for the year ended December&nbsp;31, 2018, a material weakness was identified in
our internal control over financial reporting. Under standards established by the Public Company Accounting Oversight Board, a material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that
there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. The material weakness that was identified related to an inadequate number
of qualified personnel within our accounting function, which impacted our ability to perform effective reviews over <FONT STYLE="white-space:nowrap">non-routine</FONT> transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have implemented measures designed to improve our internal control over
financial reporting to address the underlying causes of this material weakness, including the hiring of accounting personnel and establishing new accounting and financial reporting policies, processes and controls to have in place an appropriate
level of internal control over financial reporting. As a result of these measures, we remediated the material weakness as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, and our independent registered public accounting firm, were not required to perform an evaluation of our internal control
over financial reporting as of December&nbsp;31, 2019 in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified all, or that we will not in the future have additional, material weaknesses.
Material weaknesses may still exist when we report on the effectiveness of our internal control over financial reporting as required by reporting requirements under Section&nbsp;404 of the Sarbanes-Oxley Act after the completion of this offering.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have not engaged in any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as
defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Beneficial Conversion Feature (Series&nbsp;D Redeemable Convertible Preferred Stock) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, we issued and sold 71,719,859 shares of our Series&nbsp;D redeemable convertible preferred stock for net proceeds
of approximately $96.7&nbsp;million. In connection with the issuance and sale of our Series&nbsp;D redeemable convertible preferred stock, we are assessing the related accounting impacts, which could result in the recognition of a beneficial
conversion feature of up to approximately $6.3&nbsp;million. A beneficial conversion feature represents the intrinsic value of the conversion feature, as determined by comparing the effective conversion price at the commitment date with the
estimated fair value of our common stock. If applicable, the beneficial conversion feature would be recorded in additional paid-in capital as of June&nbsp;30, 2020 resulting in a discount to the carrying value of the Series&nbsp;D redeemable
convertible preferred stock. All outstanding shares of Series&nbsp;D redeemable convertible preferred stock will convert into shares of our common stock upon consummation of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Polices and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management&#146;s discussion and analysis of our financial condition and consolidated results of operations is based on our
consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that
affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates
are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While our significant accounting policies are described in the notes to our consolidated financial statements included
elsewhere in this prospectus, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued and Prepaid Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research
institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on our behalf. In recording service fees as either prepaid or accrued costs, we estimate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the period over which services will be performed and the level of effort to be expended in each period. These estimates of the expense are based on communications with and information provided by
the third-party service providers at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the amounts recorded accordingly. The estimates are trued up to reflect
the best information available at the time of the financial statement issuance. We have not experienced any material differences between accrued or prepaid costs and actual costs incurred since inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We defer and capitalize <FONT STYLE="white-space:nowrap">non-refundable</FONT> advance payments for goods or services that
will be used or rendered for future research and development activities as prepaid expenses until the related goods are delivered or services are performed. We evaluate such payments for current or long-term classification based on when such
services are expected to be received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid research and development costs were $1.1&nbsp;million, $1.1 million and
$0.8 million as of December&nbsp;31, 2018 and 2019, and March 31, 2020, respectively. Accrued research and development expenses were $0.8&nbsp;million, $0.5&nbsp;million and $1.7 million as of December&nbsp;31, 2018 and 2019, and March 31, 2020,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain a stock-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The
plan allows for the issuance of incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted stock units and other forms of equity awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recognize stock-based compensation expense for stock options on a straight-line basis over the requisite service period and
account for forfeitures as they occur. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. This model utilizes inputs which are highly subjective assumptions
and generally require significant judgment. These assumptions include: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Fair Value of Common Stock</I>&#151;See the
subsection titled &#147;&#151;Common Stock Valuations&#148; below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Term</I>&#151;The expected term represents
the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Volatility</I>&#151;Because we have been privately held and do not have any trading history for our common stock,
the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the
similar size, stage in life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Risk-Free Interest Rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at
the time of grant for periods corresponding with the expected term of the option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Dividend Yield</I>&#151;We have never
paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See Note 9 to our audited consolidated financial statements and Note 8 to our unaudited interim condensed consolidated
financial statements included elsewhere in this prospectus for more information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options.
Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation
could be materially different. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recorded stock-based compensation expense of $0.4&nbsp;million and
$2.0 million for the years ended December&nbsp;31, 2018 and 2019, respectively. For the three months ended March 31, 2019 and 2020, we recorded stock-based compensation expense of $0.5 million and $0.7 million, respectively. As of March 31, 2020, we
had $7.4 million of total unrecognized stock-based compensation cost which we expect to recognize over an estimated weighted-average period of 2.2 years. We expect to continue to grant stock options and other equity-based awards in the future, and
to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
intrinsic value of all outstanding options as of March 31, 2020 was $21.5 million based on an assumed initial public offering price of $15.50 per share, the midpoint of the price range set forth on the cover of this prospectus, of which
approximately $10.9 million is related to vested options and approximately $10.6 million is related to unvested options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Valuations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Historically, for all periods prior to this offering, fair values of the shares of common stock underlying our share-based
awards were estimated on each grant date by our board of directors. Our board of directors considered, among other things, valuations of our common stock which were prepared by an independent third-party valuation firm in accordance with the
guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For our valuations performed prior to December 31, 2018, we used the option pricing method, or OPM, backsolve method. In an
OPM framework, the backsolve method for inferring the equity value implied by a recent financing transaction involves making assumptions for the expected time to liquidity, volatility and risk-free interest rate and then solving for the value of
equity such that value for the most recent financing equals the amount paid. This method was selected as we concluded that the contemporaneous financing transaction was an arms-length transaction. Furthermore, as of the valuation dates prior to
December 31, 2018, we were at an early stage of development and future liquidity events were difficult to forecast. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For
our valuations performed subsequent to December&nbsp;31, 2018, we used a Probability Weighted Expected Return Method, or PWERM, whereby our total equity value was estimated under various exit scenarios and allocated to our different classes of
equity. The PWERM included two scenarios, initial public offering, or IPO, or staying private, that considered our estimate of the timing of each scenario and were weighted based on our estimate of the probability of each event occurring. The equity
value under the IPO scenario was based on our estimate and recent IPO values of comparable companies. The OPM was utilized to estimate our equity value under the staying private scenario. The equity value under all scenarios was reduced by a
discount for lack of marketability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the absence of a public trading market, our board of directors with input from
management considered numerous objective and subjective factors to determine the fair value of common stock. The factors included, but were not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contemporaneous valuations performed by an independent third-party valuation firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">important developments in our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our redeemable convertible preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights, preferences and privileges of our redeemable convertible preferred stock relative to those of our
common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of marketability of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual operating results; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for our securityholders, such as an IPO or a sale of our
company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trends, developments and conditions in the life sciences and biotechnology industry sectors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the economy in general; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stock price performance and volatility of comparable public companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For valuations after the completion of this offering, the fair value of each share of underlying common stock will be based on
the closing price of our common stock as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The obligation to issue additional shares of Series C redeemable convertible preferred stock at a future date was determined to
be a freestanding financial instrument that should be accounted for as a liability. At issuance, we recorded the redeemable convertible preferred stock liability on the balance sheet at its estimated fair value, using the Black-Scholes option
pricing model, with an expected term based on the expected contractual closing date. The other inputs to the Black-Scholes option pricing model, including volatility and risk-free interest rate, were estimated using a similar methodology as
described above for our stock option grants. During 2019, in light of our progress towards an IPO, the liability was remeasured using a PWERM. The PWERM included two scenarios, IPO or staying private, that were weighted based on our estimate of the
probability of each event occurring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The liability is subject to remeasurement at each balance sheet date, with changes
in fair value recognized in gain (loss) on remeasurement of redeemable convertible preferred stock liability in the statements of the operations. Upon settlement of the redeemable convertible preferred stock liability, which occurred in August 2019,
we remeasured the liability and reclassified the final value to the carrying value of the Series C redeemable convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income
Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recognize deferred income taxes for temporary differences between the basis of assets and liabilities for
financial statement and income tax purposes. In evaluating our valuation allowance, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning
strategies and recent financial performance. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. The deferred
tax assets were primarily comprised of federal and state tax net operating losses and tax credit carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of
December&nbsp;31, 2019, we had $89.8&nbsp;million of federal and $65.8&nbsp;million of state net operating loss, or NOL, carryforwards available to offset future taxable income. Under the Tax Cuts and Jobs Act of 2017, or the Tax Act, federal net
operating losses generated after December&nbsp;31, 2017 will be carried forward indefinitely with the yearly net operating loss utilization limited to 80 percent of taxable income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have $46.8 million of such federal NOLs that do not expire. If not utilized, the federal carryforward losses generated
prior to 2018 and the state carryforward losses will expire in various amounts, beginning in 2031. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, substantial changes in our ownership may limit the amount of
NOL and research and development credit carryforwards that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
could be used annually in the future to offset taxable income. The tax benefits related to future utilization of federal and state NOL carryforwards, credit carryforwards, and other deferred tax
assets may be limited or lost if cumulative changes in ownership exceeds fifty percent within any three-year period. We have not completed a Section&nbsp;382/383 analysis under the Code regarding the limitation of NOL and credit carryforwards. If a
change in ownership were to have occurred, the annual limitation may result in the expiration of NOL carryforwards and credits before utilization. If eliminated, the related asset would be removed from the deferred tax asset schedule with a
corresponding reduction in the valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We record unrecognized tax benefits as liabilities and adjust these
liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different
from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See Note 2 to our audited consolidated financial statements and Note 2 to our unaudited interim condensed consolidated
financial statements included elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate
sensitivities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We held cash and cash equivalents of $43.9&nbsp;million and $33.3 million as of December&nbsp;31, 2019 and March 31, 2020,
respectively. We generally hold our cash in interest-bearing money market accounts. We believe that historical fluctuations in interest rates have not had a material effect on our results of operations during the periods presented. Due to the low
risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our reporting currency is the U.S. dollar. The functional currency of the subsidiary located in Australia is the Australian
Dollar. Balance sheets prepared in the functional currencies are translated to the reporting currency at exchange rates in effect at the end of the accounting period, except for stockholders&#146; equity accounts, which are translated at rates in
effect when these balances were originally recorded. Revenue and expense accounts are translated using a weighted-average rate during the year. The resulting foreign currency translation adjustments are recorded as a separate component of
accumulated other comprehensive loss in the consolidated balance sheets. Foreign exchange translation losses for the years ended December&nbsp;31, 2018 and 2019 and the three months ended March 31, 2019 and 2020 were not material. Gains and losses
resulting from exchange-rate changes on transactions denominated in a currency other than the local currency are included in earnings as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effects of Inflation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We believe that inflation has not had
a material effect on our results of operations during the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to be an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay
adopting new or revised accounting standards issued subsequent to the enactment of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have
different effective dates for public and private companies until the earlier of the date that we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the
JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will remain an emerging growth company until the earliest of (i)&nbsp;the last day of the fiscal year following the fifth
anniversary of the consummation of this offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large
accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded
$700.0&nbsp;million as of the last business day of the second fiscal quarter of such year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during
the prior three-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Our pipeline is based on our platform technology addressing well-researched
classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Evidence suggests that potent and selective
inhibition of C1q can prevent tissue damage triggered in antibody-mediated autoimmune disease and preserve loss of functioning synapses associated with cognitive and functional decline in complement-mediated neurodegeneration. Our upstream
complement approach targeting C1q acts as an &#147;on/off switch&#148; designed to block all downstream components of the classical complement pathway that lead to excess inflammation, tissue damage and patient disability in a host of
complement-mediated disorders, while preserving the normal immune function of the lectin and alternative complement pathways involved in the clearance of pathogens and damaged cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a
broad set of complement-mediated diseases. Our first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. Our second product candidate, ANX007, is an
antigen-binding fragment, or Fab, formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. We are also developing ANX009, an investigational, subcutaneous formulation of a Fab designed for the treatment
of systemic autoimmune diseases. We have completed Phase 1b safety and dose-ranging clinical trials for ANX005 and ANX007 in patients with Guillain-Barr&eacute; Syndrome, or GBS, and glaucoma, respectively. Both ANX005 and ANX007 were well-tolerated
and showed full inhibition of C1q and the classical complement pathway in the Phase 1b trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on learnings from
our initial trials, we are advancing our current programs while evaluating additional orphan and large market indications. We are also developing novel product candidates designed to inhibit C1q and other components of the early classical complement
cascade with the goal of further broadening our portfolio. Finally, we are leveraging our disciplined development strategy in early clinical trials utilizing established biomarkers to enhance patient selection, measure target engagement and assess
our product candidates&#146; potential to meaningfully impact the disease process and improve the probability of technical success over shorter development timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Annexon was <FONT STYLE="white-space:nowrap">co-founded</FONT> by the late Dr.&nbsp;Ben Barres, former member of the National
Academy of Sciences, Chair of Neurobiology at Stanford University and a pioneer in complement-mediated neurodegeneration, and Dr.&nbsp;Arnon Rosenthal, a world-renowned scientist and industry executive. We have assembled a seasoned and accomplished
management team that has been involved in the development, approval and commercialization of numerous marketed drugs, and has been studying the complement pathway and autoimmune and neurodegenerative disorders for decades. Our team is further
supported by an experienced scientific advisory board and leading healthcare investors that share our commitment to advancing transformative medicines for patients suffering from debilitating autoimmune and neurodegenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We hold worldwide development and commercialization rights, including through exclusive licenses, to all of our product
candidates, which allows us to strategically maximize value from our product portfolio over time. Our patent portfolio includes patent protection for our upstream complement platform and each of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pipeline is focused on antibody-mediated autoimmune and complement-mediated neurodegenerative disorders for which there is
significant unmet medical need. Our product candidates are summarized below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g98f32.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">We have activated investigational new drug applications for these indications. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Following the activation of an investigational new drug application, we intend to initiate a Phase 2 clinical
trial in this disease indication. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our first clinical-stage product candidate is ANX005, an
investigational monoclonal antibody designed to block C1q and activation of the classical complement cascade. For GBS, ANX005 is designed to act early in the disease course to prevent nerve damage and irreversible neurological disability in GBS
patients. In the Phase&nbsp;1b dose-ranging trial in GBS patients, treatment with ANX005 was well-tolerated and resulted in full and prolonged C1q engagement and classical cascade inhibition in the blood and cerebrospinal fluid, or CSF. While our
Phase 1b trial was not powered to show statistical significance, we did observe a significant reduction in neurofilament light chain, or NfL, a well-accepted marker of nerve damage in neurodegenerative disease that has been shown to correlate with
disease severity and clinical outcomes. Patients treated with ANX005 also showed positive numerical trends across key GBS outcome measures. GBS is a rare, acute, antibody-mediated autoimmune disease impacting the peripheral nervous system. There are
currently no approved therapies for GBS in the United States, but intravenous immunoglobulin, or IVIg, and plasma exchange are the current standards of care in the Western world and parts of Asia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have initiated a Phase 1b drug-drug interaction, or DDI, trial to assess any potential pharmacokinetic, or PK, interaction
between ANX005 and co-administered IVIg and to evaluate the safety of this combination in GBS patients. This trial is being conducted in the United States, Europe and Bangladesh. We anticipate that the results from the DDI trial will provide data on
the combined use of ANX005 and IVIg in GBS patients in the Western world. However, this trial will provide no evidence of the efficacy of ANX005 as a monotherapy, nor is the trial powered to show a statistically significant efficacious outcome with
the combined administration of ANX005 and IVIg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we intend to advance ANX005 into a Phase 2/3 trial in GBS
patients in developing countries in early 2021. This randomized Phase 2/3 trial will be statistically powered to evaluate the efficacy of ANX005 in improving disability in GBS patients. ANX005 has received both Orphan Drug and Fast Track
designations from the U.S. Food and Drug Administration, or FDA, for the treatment of GBS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beyond GBS, we intend to study
ANX005 in patients with Huntington&#146;s disease, or HD, as well as patients with amyotrophic lateral sclerosis, or ALS&#151;two neurodegenerative disorders where aberrant classical complement activation has been shown to be associated with synapse
loss, elevated levels of NfL and disease progression. We plan to initiate Phase 2a trials in patients with HD and ALS in 2020 to assess ANX005&#146;s safety, tolerability, target engagement and impact on disease-related biomarkers such as NfL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also intend to study ANX005 in patients with warm autoimmune hemolytic anemia, or wAIHA, an antibody-mediated autoimmune
disease characterized by the premature destruction of red blood cells. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
classical complement pathway plays an important role in wAIHA through the removal of red blood cells labeled by activated complement components in the spleen or liver (extra-vascular hemolysis)
and less common destruction of red blood cells in the blood vessels by the classical complement generated membrane attack complex (intravascular hemolysis). Following the activation of an IND for wAIHA in 2020, we plan to initiate a Phase 2 trial in
patients with the primary diagnosis of wAIHA. We intend to conduct a non-interventional screening study in wAIHA patients to utilize complement activation markers to identify and select patients who may be more likely to respond to our anti-C1q
therapy in the planned Phase 2 trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our second clinical-stage product candidate is ANX007, an investigational C1q Fab
designed for intravitreal administration in patients with complement-mediated neurodegenerative ophthalmic disorders. Consistent with the results we observed in preclinical studies, in the Phase 1b trial with intravitreal administration in glaucoma
patients, ANX007 was well-tolerated and showed full target engagement and inhibition of C1q in the eye for at least four weeks. We believe inhibition of C1q may provide neuroprotective benefit by preventing the aberrant loss of functioning synapses
in the retina in a variety of ophthalmic disorders, including glaucoma and geographic atrophy, or GA. Based on a range of considerations, including preclinical data, clinical results observed to date, proximate clinical validation and an
established, objective clinical and regulatory path, we plan to advance ANX007 into a Phase 2 trial in patients with GA in 2021 with the goal of protecting against the loss of photoreceptor neurons in a well-defined patient population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our preclinical pipeline includes ANX009, an investigational C1q Fab designed for subcutaneous delivery. We are developing
ANX009 to enable chronic dosing for patients with antibody-mediated autoimmune disorders where <FONT STYLE="white-space:nowrap">anti-C1q</FONT> may have a disease-modifying effect and where we can utilize our targeted biomarker-driven approach.
These disorders may include autoimmune hemolytic anemias and a subset of lupus nephritis patients who are selected for pathogenic <FONT STYLE="white-space:nowrap">anti-C1q</FONT> antibodies, or PACA, and who have a high risk of renal flare. We
intend to select our initial lead autoimmune disease indication and commence a first-in-human, or FIH, clinical trial in 2020. We are developing additional next generation product candidates, including ANX105, an investigational monoclonal antibody
with enhanced dosing and PK properties designed for chronic neurodegenerative diseases, and small molecules designed for chronic autoimmune and neurodegenerative diseases. We intend to advance both ANX105 and our small molecule candidates through
IND enabling studies in 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal is to develop disease-modifying medicines for patients suffering from classical complement-mediated diseases. Key
elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leveraging our distinct approach of inhibiting C1q and aberrant upstream classical complement activity
to address a broad range of well-characterized classical complement-mediated diseases</I></B><B>. </B>By inhibiting C1q and the early classical cascade, we believe our product candidates are uniquely designed to address a wide range of
antibody-mediated autoimmune diseases and complement-mediated neurodegenerative disorders. We believe full classical complement inhibition may result in clinical benefits by blocking aberrant upstream immune cell activation in our targeted
indications, as well as potentially provide safety advantages by leaving the lectin and alternative pathways intact to perform their normal immune functions. We believe our two clinical-stage product candidates, ANX005 and ANX007, are the first and
leading clinical-stage product candidates designed to inhibit C1q and the entire classical complement pathway. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advancing ANX005 through clinical development in multiple autoimmune and neurodegenerative indications
of high unmet need</I></B><B>.</B> Our Phase 1b trial in patients with GBS demonstrated full target engagement of C1q in serum and the CSF, as well as a significant reduction in NfL, a well-accepted biomarker shown to be elevated in patients with
GBS, HD and ALS and correlated with disease severity and clinical course and outcomes. We intend to advance ANX005 into a Phase 2/3 trial in patients with GBS in early 2021, and into Phase 2a trials in patients with HD and ALS in 2020. We also
intend to advance ANX005 into a Phase 2 trial in patients with wAIHA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Evaluating ANX007 as an agent for neuroprotective benefit in ophthalmic indications</I></B><B>.</B> We
are developing ANX007 in neurodegenerative ophthalmic indications, such as glaucoma and GA. ANX007 reduced retinal damage in animal models of glaucoma and GA. In our Phase 1b trial in glaucoma patients, intravitreal administration of ANX007 resulted
in full target engagement of C1q at both low and high doses. Based on this clinical dosing data, our preclinical data in glaucoma and GA, and proximate clinical validation from downstream complement approaches, we believe that ANX007 may provide
neuroprotective benefit in patients with these and other complement-mediated ophthalmic disorders. We plan to advance ANX007 into a Phase 2 trial in patients with GA in 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expanding our autoimmune and neurodegenerative portfolios informed by data from our beachhead
indications. </I></B>Our initial indications represent our beachhead within antibody-mediated autoimmune and complement-mediated neurodegenerative diseases. We intend to leverage learnings from our initial indications to inform selection of
additional orphan and larger patient populations involving related biological mechanisms. In our autoimmune portfolio, potential indications include antibody-mediated autoimmune disorders such as wAIHA, Cold Agglutinin Disease, or CAD, and lupus
nephritis, (specifically in lupus nephritis patients with endogenous PACA). In our neurodegenerative portfolio, potential indications include complement-mediated neurodegeneration disorders in the eye and brain such as glaucoma, GA, HD, ALS,
frontotemporal dementia and Alzheimer&#146;s disease. We plan to efficiently prosecute these broad opportunities utilizing our disciplined, biomarker-driven development strategy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Developing additional product candidates that are designed to inhibit activation of the classical
complement cascade</I></B><B>.</B> We have secured broad intellectual property protection for our upstream complement platform and intend to leverage our intellectual property and <FONT STYLE="white-space:nowrap">know-how</FONT> to protect and
enhance our leading position in developing novel therapeutics that target the classical complement cascade. We are developing product candidates, such as ANX009, to modulate the classical pathway with the potential to become tailored therapeutics
for a large range of indications using different molecular modalities, dosing regimens and tissue localization strategies. In addition, we are developing next generation product candidates, including ANX105, an investigational monoclonal antibody,
and small molecule modulators of the classical pathway, for the treatment of chronic autoimmune and neurodegenerative diseases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Maximizing the value of our product candidates</I></B><B>. </B>We currently hold worldwide development
and commercialization rights, including through exclusive licenses, to all of our product candidates. We intend to pursue independent development and commercialization in select indications and markets that we can address with a focused sales and
marketing organization. We may opportunistically explore licensing agreements, collaborations or partnerships to develop our product candidates in larger market indications where we could accelerate development utilizing the resources of larger
biopharmaceutical companies. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of the Complement System and C1q Biology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Complement System&#151;three main complement pathways </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The complement system is an integral component of the immune system that consists of many circulating and locally-produced
molecules. This system evolved to enhance, or complement, other components of the adaptive and innate immune systems. The complement system, also known as the complement cascade, rapidly responds to pathogens, damaged cells and unwanted tissue
components to facilitate their removal by the immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are three main complement pathways (also called
cascades)&#151;the classical, lectin and alternative pathways. Each pathway is initiated by different molecules that respond to distinct triggers. When activated, the initiating molecules set in motion a cascade of enzymatic reactions that greatly
amplify, or complement, an inflammatory response. The classical pathway is initiated by C1q, which recognizes antibody complexes, specific pathogens, damaged cells or unwanted cellular components. The lectin pathway is triggered by carbohydrates on
the surface of pathogens or cells. The alternative pathway amplifies the action of the other two pathways and also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
self-activates to eliminate pathogens or cells that are not specifically shielded by the body&#146;s built-in self-protective systems. While these three pathways are initiated by distinct
molecules, they converge downstream on common pathway components known as C3 and C5. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>The three main pathways of the complement cascade are
activated by independent molecules but converge&nbsp;at C3 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g32p90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Aberrant activation of the complement system can result in a range of diseases
characterized by an attack on healthy tissue, such as red blood cells, nerve cells or kidney components. A broad range of diseases are known to be associated with pathological activation of the complement cascade, including antibody-mediated
autoimmune disorders such as GBS, wAIHA, CAD and lupus nephritis, and complement-mediated neurodegeneration disorders in the eye and brain such as glaucoma, GA, HD, ALS, frontotemporal dementia and Alzheimer&#146;s disease. We believe intervening in
the activation of the complement cascade offers a potent and selective mechanism for specifically slowing or reversing these disease processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Specific activated components of the complement cascade have important immune functions that contribute to three key outcomes:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Immune cell recruitment and inflammation</I></B><B>.</B> Specific activated molecules from the cascade
serve as soluble signals to make blood vessels leaky and attract immune cells into tissues. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Directed immune cell attack</I></B><B>. </B>Several complement components, including C1q, bind directly
to the pathogen and serve as receptors that direct immune cell attack and pathogen engulfment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Membrane damage</I></B><B>.</B> Downstream components of the cascade directly puncture the pathogen or
cell surface, causing membrane damage and lysis. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Aberrant activation of the initiating molecule, C1q, can lead to three main
outcomes </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g21m00.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Broad potential for Classical Complement pathway targeted therapeutics in Autoimmune and
Neurodegenerative Diseases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The classical complement cascade has a well-established role in augmenting antibody
function within the immune system. C1q recognizes antibodies bound to pathogens or cells and activates the classical pathway to trigger their removal and clearance by the immune system. C1q can also directly recognize pathogens, damaged cells or
unwanted cellular components leading to similar downstream clearance. A more recent finding made by the laboratory of Dr.&nbsp;Ben Barres, our scientific founder, is that C1q also directly interacts with neuronal connections, or synapses, during
early development. Recognition of weaker synapses by C1q triggers the classical complement cascade and directs immune cells to &#147;prune&#148; the synapses away from neurons, thereby reinforcing stronger synapses to establish appropriate neuronal
connections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of its central role in immune function, aberrant activation of C1q can lead to damage of healthy
tissue and destruction of functioning synapses. We are focused on two distinct disease processes involving C1q as a key mediator of tissue damage: antibody-mediated autoimmune disease and complement-mediated neurodegeneration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Our platform targets two disease processes </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g23r02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In antibody-mediated autoimmune disease, self-reactive antibodies bind to cells or tissues,
activating C1q and leading to damaging inflammatory responses. We have observed that inhibition of C1q was protective in several animal models of antibody-mediated autoimmune disease, including neuromyelitis optica, or NMO, and two variants of GBS.
In NMO, auto-antibodies recognize cells within the central nervous system, or CNS, and can lead to rapid localized destruction of the optic nerve and regions of the spinal cord, while in GBS pathogenic antibodies react with components of the
peripheral nerve system, or PNS, to cause widespread peripheral nerve damage and paralysis. This disease process is also evident in antibody-mediated autoimmune disease involving blood components, such as wAIHA and CAD, characterized by
auto-reactive antibodies that trigger destruction of red blood cells, and systemic lupus erythematosus, or SLE, where endogenous pathogenic antibodies against C1q itself drive aberrant C1q activation and are highly associated with kidney damage, or
lupus nephritis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In complement-mediated neurodegeneration, aberrant activation of C1q at synapses in aging and disease
can lead to excessive synapse loss and neuronal damage, driving disease progression in multiple neurodegenerative disorders regardless of the initiating factor. In animal models, C1q accumulated on synapses with age, building up to <FONT
STYLE="white-space:nowrap">300-fold</FONT> higher levels than in younger animals. It did not activate with normal aging, but other inflammatory stimuli, including misfolded proteins, metabolic dysfunction or increases in intraocular pressure,
appeared to aberrantly reactivate C1q&#146;s developmental role in synapse elimination. Complement activation and aberrant synapse pruning in disease may lead to neuroinflammation, loss of synaptic neuronal connections and neurodegeneration. In
support of this hypothesis, we and other investigators have observed that C1q inhibition was protective in numerous models of neurodegenerative disease, including diseases of the eye, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
glaucoma and <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, chronic diseases of the CNS, such as frontotemporal dementia, Alzheimer&#146;s, HD and Spinal Muscular
Atrophy, or SMA, and acute injury, such as traumatic brain injury and stroke. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Synaptic loss is a pathogenic driver of disability in many
neurodegenerative diseases, protected with C1q&nbsp;inhibition </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g82q36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our differentiated approach to treating complement-mediated autoimmune and neurodegenerative disease through
inhibition of C1q </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that in order to selectively inhibit aberrant activation of the classical complement
pathway implicated in driving certain complement-mediated autoimmune and neurodegenerative diseases, it is important to target the early components of the classical cascade, particularly C1q, C4 and C3. Activated fragments of C4 and C3 induce
vascular leakiness and immune cell recruitment into the tissue, while other fragments of C4 and C3, as well as C1q, work together to direct immune cell attack to the cell or synapse surface. Furthermore, C1q inhibition blocks downstream classical
pathway activation of C5 and its membrane damaging effects. We believe that inhibition of C1q does not block the activity of these components in the lectin or alternative complement pathways, and both of these pathways will continue to perform their
normal immune functions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our novel upstream complement platform is designed to completely inhibit classical complement activity for the treatment of
antibody-mediated autoimmune disease and complement-mediated neurodegeneration. We believe there are potential advantages to our approach of upstream inhibition of the classical complement cascade, which include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Full inhibition of the classical cascade while preserving healthy immune function of the other
complement pathways</I></B><B>.</B> Inhibition of C1q fully inhibits the classical cascade, including components downstream of C1q such as C4, C3, C5 and the downstream membrane attack complex. As a result, we believe our approach is designed to
block all classical complement activity that can contribute to disease pathology, including immune cell recruitment, directed immune cell attack and membrane damage. By targeting upstream tissue-damaging components of the classical complement
pathway, our approach leaves the lectin and alternative pathways to perform their normal immune function, which may aide both clinical improvement and safety. Our approach is also distinct from inhibiting C3 or C5. Inhibition of C5 will not affect
the upstream components of the classical pathway involved in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
pathology (C1q, C4 and C3), while inhibition of C3 will block downstream components in all three complement pathways. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Broad applicability across many indications</I></B><B>. </B>We believe our approach has broad utility
for the treatment of diseases in which full inhibition of the entire classical complement cascade may be beneficial. We believe our approach is distinguishable from those that target only downstream complement components. Our initial indications
represent our beachhead within antibody-mediated autoimmune and complement-mediated neurodegenerative diseases, and we will selectively pursue both orphan and larger patient population diseases with clear biological evidence of classical complement
activation. We are also developing novel product candidates targeting C1q and early components of the classical complement cascade, and will utilize different modalities to target these components of the classical complement pathway.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Disciplined, biomarker-driven development strategy for our product candidates</I></B><B>.</B> We are
deploying a disciplined, biomarker-driven development strategy designed to establish confidence that our product candidates are engaging the specific target at a well-tolerated therapeutic dose in the intended patient tissue. We design small,
early-stage clinical trials to rigorously evaluate our product candidates using target engagement and pharmacodynamic biomarkers. We are utilizing sensitive, specific assays for C1q and activation of downstream classical complement components to
evaluate target engagement in patient tissues that are most relevant for the diseases that we are treating, such as CSF for neurological diseases and aqueous humor for ocular diseases. In neurodegenerative diseases, we are measuring our product
candidate&#146;s impact on NfL, a sensitive marker of neurodegeneration, to provide proof-of-concept in small patient trials. We believe that this development strategy allows us to make rational decisions regarding our therapeutic pipeline,
increasing the probability of technical success over shorter development timelines for product candidates we advance into later stage trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
pipeline is focused on antibody-mediated autoimmune and complement-mediated neurodegenerative disorders for which there is significant unmet medical need. Our product candidates are summarized in the table below.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g98f32.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">We have activated investigational new drug applications for these indications. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Following the activation of an investigational new drug application, we intend to initiate a Phase 2 clinical
trial in this disease indication. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our First Product Candidate, ANX005 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ANX005 is an investigational humanized recombinant monoclonal antibody that is designed to potently bind and inhibit C1q. Our
investigational new drug, or IND, application for ANX005 in GBS was authorized to proceed in February 2019. We have completed a Phase 1b clinical trial for ANX005 in patients with GBS in which ANX005 was well-tolerated and achieved full target
engagement and C1q suppression in the PNS and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
CNS. A Phase&nbsp;1b drug-drug interaction, or DDI, trial is ongoing to assess the concomitant use of ANX005 and IVIg in GBS patients, and we anticipate reporting data from this DDI trial in
2020. Further, we plan to advance ANX005 into a Phase&nbsp;2/3 trial in GBS patients in early 2021. ANX005 has been granted Orphan Drug and Fast Track designations from the FDA for the treatment of GBS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Separately, our IND applications for ANX005 in HD and in ALS were authorized to proceed in March and May 2020, respectively,
and we expect to initiate Phase&nbsp;2a trials in patients with HD and ALS in 2020. We anticipate reporting data from both the HD and ALS trials in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>ANX005 for the Treatment of GBS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of Guillain-Barr&eacute; Syndrome </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GBS is a severe acute inflammatory disease typically triggered by a preceding infection, in which aberrant auto-antibodies that
recognize neurons or associated cells cause neuronal injury and acute paralytic neuropathy. In 2011, the estimated annual incidence of GBS was approximately 12,000 in North America and Europe. In 2004, the annual economic cost of GBS in the United
States was $1.7&nbsp;billion, largely due to the permanent disability and mortality it can cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are currently no
FDA-approved therapies for the treatment of GBS. Treatment guidelines published by the American Academy of Neurology recommend early initiation of IVIg or plasma exchange in patients diagnosed with GBS. IVIg and plasma exchange are the established
standards of care in the Western world and parts of Asia. Although IVIg and plasma exchange have been shown to provide some benefit, significant unmet need still exists, and many patients, despite receiving the standard of care, are left with
residual neurological disability, accompanied by chronic pain and fatigue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The clinical course of GBS usually involves
rapidly progressive weakness in the limbs culminating in neuromuscular paralysis within two to four weeks of onset. According to 2011 estimates, 20 to 30&nbsp;percent of patients require mechanical ventilation, over 20&nbsp;percent have permanent
motor or sensory disability and 2 to 17 percent of cases result in death globally. Many patients with GBS require extensive monitoring and supportive care and will seek treatment in a hospital within a few days of onset of the disease. Because
approximately a quarter of patients need artificial ventilation due to respiratory muscle weakness, and many develop autonomic disturbances, admission in an intensive care unit is frequently necessary. Symptoms peak within four weeks as the
auto-antibody response declines, followed by a recovery period that can last months or years, as the nervous system repairs itself. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>C1q is a key driver of pathogenesis in GBS </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GBS is an acute, autoimmune disease driven by antibodies that lead to activation of the classical complement cascade.
Pathological nerve-targeting auto-antibodies, which may be triggered by an infection, lead to the activation of C1q and the classical complement cascade. Studies have shown that pathogenic auto-antibodies are present in the serum and CSF and that
activated components of the complement cascade are deposited on peripheral nerve tissue from GBS patients. Peripheral nerve roots are immersed in CSF as they emerge from the spinal cord and are prominent sites of damage in GBS. The figure below
illustrates the activation of the classical complement pathway within peripheral nerves in a GBS patient. The left image shows a low magnification view of a peripheral nerve from a GBS patient with numerous individual nerve fibers coated with
membrane-damaging complement activation products <FONT STYLE="white-space:nowrap">(C5b-9;</FONT> dark staining). The middle image shows<I> </I>a<I> </I>high magnification view of an individual nerve fiber with deposition of C3d (dark staining), a
complement activation product that directs immune cell attack. The right image shows a high power image of an individual nerve fiber being probed by an infiltrating immune cell (macrophage). </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g28x11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that by blocking the activity of C1q early in the onset of the disease, we can
minimize the neuronal damage caused by these pathogenic auto-antibodies, in turn reducing the patients&#146; symptoms and accelerating their neurological recovery. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Neurofilament light chain (NfL), a marker of neurodegeneration, is highly elevated in GBS </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NfL, an intracellular neuron-specific protein, has emerged as a well-accepted biomarker of nerve damage in disorders
characterized by damaged or degenerating nerves. NfL is a subunit of neurofilaments, which are cylindrical proteins exclusively located in the cytoplasm of nerve cells and are released into the CSF and blood when nerves are damaged (illustration
below). Recent ultrasensitive techniques (e.g., single-molecule array technology) have made it possible to accurately and quantitatively detect longitudinal changes of NfL in both blood and CSF, with very low analytical variation. These assay
properties, in addition to neuron-specificity, position NfL as an important decision-enabling tool in proof-of-concept studies of neuroprotective agents across a wide variety of diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Neurofilament Light Chain (NfL) is released from damaged nerve cells </B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g52p85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Elevated NfL levels correlate with current patient disability and predict patient outcomes
in autoimmune neurological diseases such as GBS, multiple sclerosis, or MS, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy as well as in chronic neurodegenerative diseases such as Huntington&#146;s disease,
amyotrophic lateral sclerosis, spinal muscular atrophy, or SMA, frontotemporal dementia, and Alzheimer&#146;s disease. Moreover, effective treatments for MS (e.g., ocrelizumab, natalizumab and fingolimod) and SMA (e.g., nusinersen) that prevent
neurological disability in patients have been shown to significantly reduce NfL levels in these same patients. In patients with GBS, NfL is very highly elevated (in some instances, greater than 100 fold above normal). Retrospective and prospective
studies in GBS patients have shown that NfL levels in CSF and serum may correlate with disease course, severity and prognosis in GBS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Development in GBS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As illustrated below, in a mouse model of severe GBS, ANX005 treatment blocked complement deposition on nerve terminals (left
panel) and protected respiratory and motor function (right panel) when compared to an irrelevant immunoglobulin G, or IgG, isotype control antibody. A p-value is a measure of the statistical significance of the observed result. By convention, a
p-value lower than 0.05 is considered statistically significant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Respiratory and motor function </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g773514g36c17.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g773514g20t78.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;** p &lt; 0.01</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">*** p &lt;
0.001</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1a Trial in Healthy Volunteers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ANX005 was initially evaluated in a Phase 1a dose-escalation single-dose trial designed to assess safety, pharmacokinetics and
pharmacodynamics. This trial was conducted in 27 healthy volunteers in Australia. The dosing levels of ANX005 delivered in this trial ranged from 1 mg/kg to 8.2 mg/kg. We terminated the trial in healthy volunteers and transitioned our clinical
development to evaluate ANX005 directly in patients with GBS based on guidance from the FDA in order to expediently advance this program in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1b Trial in GBS Patients </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have closely coordinated our clinical efforts with leading researchers of the International GBS Outcome Study, or IGOS, in
pursuing a novel therapy for GBS. With the goal of aiding the development of effective treatments for GBS, practitioners established IGOS in May 2012, and have collected natural history data from over 1,750 newly-diagnosed GBS patients worldwide.
IGOS is a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset as well as the subtype, course and outcome of GBS. IGOS was established to help develop a
better understanding of the mechanism of disease progression and recovery and to conduct selective therapeutic trials to improve patient outcomes. This natural history database is an invaluable resource to clinical development, facilitating the
design of clinical trials, optimal selection of endpoints, and patient follow-up for one to three years. We initiated our GBS clinical development in Bangladesh, a country where the incidence of GBS is several times higher than in North America and
Europe and where 17% of patients die from the disease and 20% suffer permanent disability and are unable to walk. Additionally, our site in Bangladesh is well situated to conduct clinical research in GBS in a manner compliant with good clinical
practice, or GCP, requirements. As of March 2017, Bangladesh had enrolled more patients in IGOS than any other country, representing approximately 15% of all enrolled patients worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conducted a Phase 1b placebo-controlled, dose escalation trial (n=31) of ANX005 in GBS patients at a tertiary care hospital
in Bangladesh, in compliance with GCP as described above. The trial objectives included safety and tolerability, dosing levels and target engagement, and included a follow up of eight weeks. The dosing levels of ANX005 delivered in this trial ranged
from 3 mg/kg to 75 mg/kg. ANX005 was well tolerated, and no drug-related serious adverse events or drug-related discontinuations occurred. The most common adverse events were acute infusion-related reactions, or IRRs, which occurred in the majority
of patients and presented as low grade, <FONT STYLE="white-space:nowrap">non-serious,</FONT> transient skin rash. These acute IRRs were mitigated by standard anti-inflammatory <FONT STYLE="white-space:nowrap">pre-medications</FONT> and slowly
administering ANX005 until saturation of endogenous C1q was reached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Results from the Phase 1b trial showed increasing
serum levels of ANX005 and its duration in the circulation at increasing dose levels, and that the drug was present in the serum for up to three weeks at a dose of 75 mg/kg (left panel). When ANX005 was present in the circulation C1q function was
fully inhibited, and rapidly returned to normal levels as ANX005 serum levels declined (right panel showing data from a patient receiving 75 mg/kg). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g88d44.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Much of the proximal weakness in GBS patients is due to involvement of
peripheral nerve roots that are immersed in CSF as they exit the spinal cord. Hence, we believe product candidate levels and target inhibition in CSF may be an important contributor to efficacy. We observed that ANX005 entered the CSF of GBS
patients treated with doses of 18-75&nbsp;mg/kg of ANX005, resulting in full engagement of C1q inhibition in the CSF (as shown below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Inhibition
of C1q Observed in CSF at 18-75 mg/kg </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g89g55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the Phase 1b trial in GBS patients, ANX005 treatment at doses that engaged C1q in both
serum and CSF (i.e., 18-75 mg/kg dose) resulted in a statistically significant early decline in serum NfL levels compared to placebo (2-4 week post treatment p-value &lt;0.05, left panel below). In this Phase 1b trial, we also explored the
administration of ANX005 on multiple validated clinical disability measures including GBS-Disability Score, or GBS-DS, Medical Research Council Muscle Strength Scale, or MRC, and Inflammatory Rasch-built Overall Disability Scale, or I-RODS, over an
eight-week period. We observed that early decline in NfL correlated with improvement in the GBS-DS at the end of the study (2-8 week post treatment p-value &lt;0.05; right panel below). We believe these results suggest that ANX005 had a rapid impact
on the disease process by ameliorating antibody-induced nerve damage, likely within the first two weeks of dosing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g773514g90w00.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g773514g28y21.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:8.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman" ALIGN="justify">*&#8195;&#8201;&#8201;r is a statistical measure for the correlation of two variables
that ranges from -1 to 1. The closer r is to 1 or -1, the more closely the variables are related. A correlation of 0.431 is considered moderate correlation.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Though the trial was not powered for statistical significance, treatment
with ANX005 resulted in consistent, positive numerical trends, including an improvement in MRC score and the number of days of ventilation. We observed a dose-dependent trend for improvement in MRC within the first week of treatment (as shown
below). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g36m63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Early improvement in MRC is known to have strong prognostic implications on long-term
functional recovery (modified Erasmus GBS Outcome Score). In line with this published data, we found that early improvement in MRC correlated with patients&#146; disability scores at the end of the Phase&nbsp;1b trial (GBS-DS at week eight). This
result is important because <FONT STYLE="white-space:nowrap">GBS-DS</FONT> is typically used as the primary endpoint in GBS registrational studies. In addition, using a responder analysis, 28% of patients treated with high dose ANX005 <FONT
STYLE="white-space:nowrap">(18-75&nbsp;mg/kg)</FONT> improved by at least three points on <FONT STYLE="white-space:nowrap">GBS-DS</FONT> by week 8 compared to 0% of placebo-treated patients (as shown below). Patients treated with ANX005 showed a
trend of improvement on GBS-DS when using a mean analysis. Both results are promising but not statistically significant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g773514g91c19.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g773514g93s80.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on the results of the Phase 1b trial, we selected the 75 mg/kg dose of ANX005 for
ongoing development in GBS. Following the completion of the Phase 1b treatment cohorts (through 75 mg/kg), two unblinded exploratory cohorts were enrolled to establish higher dose and multiple dose safety and PK/PD to inform subsequent chronic
dosing trials. These two exploratory cohorts were a single dose of 100 mg/kg, and two doses of 75 mg/kg separated by one week (150 mg/kg total). At these higher dose levels, ANX005 was well-tolerated, and no drug-related serious adverse events or
drug-related discontinuations occurred; moreover, we did not reach a maximum tolerated dose. Similarly, we observed full inhibition of C1q in serum and CSF, a reduction in NfL and trends of improvement in clinical measures when compared to placebo;
however, there was no additional impact on these clinical measures beyond that seen at 75 mg/kg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The results of the Phase
1b dose ranging trial in GBS showed that ANX005 was well-tolerated, fully inhibited C1q in the blood and CSF at target doses, and demonstrated an early reduction in NfL levels. Drug treatment was associated with a trend for early improvement in MRC,
and early changes in MRC significantly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
correlated with improved clinical measures in GBS patients. An additional key learning from the study is the importance of using baseline MRC for patient stratification at the time of
hospitalization and study entry. Accounting for baseline MRC strengthened the impact of ANX005 treatment in the biomarker and clinical measures, demonstrating that MRC will be an important stratification tool in future GBS trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing Development of ANX005 for GBS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on results from our Phase 1b trial and initial feedback from the FDA, we intend to initiate a Phase&nbsp;2/3 trial of
ANX005 in GBS in early 2021 and anticipate reporting data from this trial in 2023. A Phase 1b DDI trial evaluating ANX005 in combination with IVIg is ongoing. ANX005 has received both Orphan Drug and Fast Track designations from the FDA for the
treatment of GBS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>ANX005 for Future Autoimmune Indications </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beyond GBS, we also intend to study ANX005 in specific subsets of patients with autoimmune hemolytic anemias, or AIHA,
characterized by the presence of auto-antibodies that bind red blood cells and activate the classical complement pathway. The temperature at which these auto-antibodies bind to red blood cells determines whether the hemolytic anemia is labelled
&#147;cold&#148; or &#147;warm.&#148; In both cases, the antibodies trigger classical complement activation, which tags red blood cells with complement components (e.g., C3d, C4d) for removal in the spleen or liver (via extra-vascular hemolysis) or,
less commonly, leads to their direct lysis within blood vessels by the C5b-9 membrane attack complex (intravascular hemolysis). The &#147;cold&#148; forms of AIHA are known to be complement-mediated disorders, whereas complement is hypothesized to
play a dominant role in a subset of patients with the &#147;warm&#148; form of AIHA. It is estimated that less than 5,000 people have the cold form while approximately 30,000 people have the warm form of AIHA in the United States. There are no
approved treatments for AIHA in the United States; however, blood transfusions, steroids, rituximab, chemotherapies and splenectomies are currently used to treat patients with AIHA. It is estimated that up to 30% of patients require second-line
treatment when treated with the standard of care treatment and approximately 11% of cases after symptom onset result in death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have found that ANX005 inhibited complement deposition on human red blood cells (left panel) and prevented direct red blood
cell lysis (right panel) induced by sera from CAD patients as <I>ex vivo</I> models of extravascular and intravascular lysis, respectively. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g37x35.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g773514g43r37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have observed in both preclinical studies and in our Phase 1b trial in patients with GBS
that treatment with ANX005 resulted in near complete inhibition of C1q, as measured in serum by the same ex vivo hemolysis assay used for hemolytic anemia conditions. Thus, we believe that ANX005 may be able to achieve near complete suppression of
complement-mediated hemolysis in patients with wAIHA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We plan to initiate a Phase 2 trial in wAIHA patients who are
enriched for complement-mediated pathology in 2020. This open label trial will evaluate safety, tolerability, PK, pharmacodynamic impact and efficacy, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
measured by biomarkers of hemolysis and changes in hemoglobin. We anticipate reporting data from this trial in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>ANX005 for the Treatment of Huntington&#146;s Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of Huntington&#146;s Disease </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">HD is an orphan hereditary neurodegenerative disease that is fatal and for which there are no approved treatments that can
reverse or slow its course of progression. HD symptoms typically begin to manifest between the ages of 30 to 50 and progress as a devastating neurodegenerative disorder characterized by abnormal involuntary movements, known as chorea, spreading to
all muscles, progressive dementia and psychiatric manifestations such as depression and psychosis. Ultimately, affected individuals succumb to cardio-respiratory complications. Life expectancy after symptom onset is approximately 10 to 20 years.
Some of the symptoms of HD such as chorea and depression can be managed with medications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approximately 25,000 to 35,000
people in the United States have HD. Estimates project that approximately 75,000 people in the United States and other major market countries will have HD by 2025. Because HD is a genetic disease in which an individual with a single copy of the
dysfunctional gene will develop the disease, every child of a parent with HD has a 50&nbsp;percent chance of inheriting the faulty gene and developing the disease. There are an estimated 200,000 individuals in the United States who have a
50&nbsp;percent risk of developing HD because of their family relationship to HD patients. It is estimated that only five to seven percent of these <FONT STYLE="white-space:nowrap">at-risk</FONT> individuals have voluntarily undergone genetic
testing due to the devastating nature of the disease and the lack of any effective treatments. The development of a disease-modifying therapy could encourage <FONT STYLE="white-space:nowrap">at-risk</FONT> patients to seek out testing and thereby
both provide hope to gene carriers and expand the number of patients who may benefit from treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>C1q is a key driver of
pathogenesis in HD </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">HD is caused by a genetic mutation, specifically, by expansion of the number of
cytosine-adenine-guanine, or CAG, nucleotide sequences within the DNA of the huntingtin gene, which leads to production of a mutant huntingtin protein that is thought to be neurotoxic and promote the degeneration of neurons. Above a threshold of 35
CAG repeats, the age of disease onset is inversely correlated with the number of CAG repeats. The classical complement cascade is activated in HD patients and is associated with progressive synapse loss. We hypothesize that C1q plays an important
role in the degenerative process by tagging weakened synapses and triggering a neuroinflammatory response that leads to aberrant synapse loss and progressive neuronal destruction. As shown below, we observed that increased complement activation in
HD patients (as measured by the complement activation marker C4a in CSF) was associated with disease progression. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Increased Complement Activation Marker C4a in the CSF of HD Patients </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g26o17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>NfL is elevated in HD patients </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Both CSF (shown below) and plasma levels were found to be elevated in HD patients compared to healthy controls, consistent with
observations in other neurodegenerative diseases. Furthermore, plasma NfL is increased with advancing disease severity and increases at an earlier age with a greater number of the CAG repeats. NfL levels in both plasma and CSF correlate better than
levels of the mutant huntingtin, or mHTT, protein itself, with clinical functional/cognitive measures such as total Unified Huntington&#146;s Disease Rating Scale and with brain volume measures as determined by MRI. In addition, while CSF mHTT
levels accurately differentiate controls and HD mutation carriers, only NfL in CSF and plasma is able to distinguish presymptomatic from symptomatic (manifest) HD patients, suggesting that NfL might be one of the earliest detectable abnormalities in
the progression to manifest HD. Of note, NfL levels were shown to reflect future patient outcomes as well as current disability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Increased Nfl in
the CSF with Disease Progression </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g75k69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Progressive synapse loss in HD patients </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As shown below, researchers observed in post-mortem tissue from HD patients that the number of synapses on neurons connecting
specific regions of the brain (the cortex and striatum) were reduced compared to healthy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
controls, with patients more advanced in the disease process (Huntington&#146;s disease stage 4) showing greater loss of synapses than earlier stage patients (Huntington&#146;s disease stage 2).
These results are consistent with our hypothesis that complement activation leads to synapse elimination and neuronal damage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Progressive Synapse
Loss in Huntington&#146;s Disease </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Synapse number (% Control) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:4%" ALIGN="center">


<IMG SRC="g773514g10j85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>ANX005 protected against synapse loss and reduced NfL in a preclinical model of HD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In transgenic mouse models of HD, we assessed the potential of peripherally administered ANX005 to inhibit activation of the
classical complement cascade and protect against synapse loss. As shown below, ANX005 treatment reduced the amount of activated complement factor C3d that was deposited on synapses in the striatum (the same region of the brain as affected in HD
patients; left panel), reduced CSF levels of NfL (middle panel), and reduced the loss of synapses (right panel). We believe these three lines of evidence support the hypothesis that ANX005 blocks complement-mediated neurodegeneration in HD and can
lead to preservation of neuronal synapses. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g773514g25h63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Development of ANX005 in HD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our IND application for ANX005 in HD was activated in March 2020. We intend to initiate a three-month Phase&nbsp;2a trial in HD
patients in 2020. This open-label trial will evaluate ANX005&#146;s ability to inhibit C1q in the CSF and to reduce levels of serum and CSF NfL, a marker of neurodegeneration with prognostic significance. We anticipate reporting data from this trial
in 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>ANX005 for the Treatment of ALS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of ALS </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ALS is a devastating neurodegenerative disease with no curative treatment that affects about 30,000 patients worldwide. There
are rare familial forms of ALS (e.g., due to DNA mutations in the SOD1 and C9ORF72 genes), but the majority of ALS cases are considered sporadic. The disease is a motor neuron disease impacting both the central and peripheral nervous systems. ALS
causes progressive weakness of limb, respiratory, swallowing and speaking muscles, and death typically occurs within two to five years after symptom onset. There is evidence that neurodegeneration begins peripherally, at the neuromuscular junction,
or NMJ, and then proceeds proximally to involve the peripheral motor nerves, ventral nerve roots, spinal cord and brain motor cortex (&#147;dying back&#148; neurodegeneration). The NMJ is a specialized synapse between peripheral motor nerve and
muscle fiber. As illustrated below, &#147;dying back&#148; of the peripheral nerve in ALS is associated with C1q / classical complement deposition on the NMJ. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g35y96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>C1q involvement in ALS </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C1q and classical pathway activation is elevated in ALS patients. Specifically, C1q deposition has been noted in NMJs and C4d
levels are increased in the CSF of ALS patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As shown below in a preclinical model of ALS, muscle levels of C1q (at NMJs)
increased with age (left panel) and were observed to correlate with decline in muscle strength (right panel). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g22x55.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">* p &lt; 0.05</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g45j64.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal with our C1q inhibitor is to prevent loss of NMJs and hence prevent &#147;dying
back&#148; neurodegeneration of motor nerves in patients with ALS. Of note, there is significant overlap in the peripheral nerve structures that are involved in both GBS and ALS; therefore, we believe our ANX005 pharmacokinetics and pharmacodynamics
data in GBS patients can be extrapolated to ALS patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Likewise, in an experimental model of SMA, another peripheral
nerve degenerative disease that is pathologically similar to ALS, we found that treatment with anti-C1q antibody (mouse precursor of ANX005) protected against synapse loss and improved motor function. The same peripheral nerve pathway is involved in
GBS and ALS, as illustrated below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>The same peripheral nerve pathway is involved in GBS and ALS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g09l31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>NfL is elevated in ALS patients </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ALS patients have substantial elevations of NfL in both CSF and serum compared with controls and pre-symptomatic mutation
carriers. In ALS patients, serum levels of NfL increase in the year prior to onset of disease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
symptoms (see below). In addition, it has been observed that NfL levels in ALS patients correlate both with current disability and future patient outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Serum NfL Elevated in ALS Patients a Year Prior to Symptom Onset </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g54u14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Development of ANX005 in ALS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our IND application for ANX005 in ALS was activated in May 2020. We intend to initiate a three-month, open-label Phase&nbsp;2a
trial in ALS patients in 2020 to evaluate ANX005&#146;s ability to inhibit C1q in the CSF and to reduce NfL levels in serum and CSF in ALS patients. We anticipate reporting data from this trial in 2021. Based on the results of this trial, we will
evaluate whether to initiate a potential registrational program for ALS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If either of the HD or ALS Phase 2a trials are
successful, we will consider <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies in other CNS neurodegenerative indications, such as Alzheimer&#146;s disease, frontotemporal dementia and
progressive multiple sclerosis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Second Product Candidate, ANX007 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ANX007 is an investigational monoclonal antibody antigen-binding fragment, or Fab, that is designed to potently bind to C1q and
inhibit activation of the classical complement cascade. We activated an IND for ANX007 in 2018 and are developing ANX007 as an intravitreal injection for ophthalmic indications such as glaucoma and geographic atrophy. We have conducted a Phase 1b
trial of ANX007 in patients with glaucoma, and based on these and preclinical study results, we believe ANX007 may have potential to treat patients with GA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>ANX007 for the Treatment of Ophthalmic Diseases, including Glaucoma and Geographic Atrophy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of Glaucoma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Glaucoma is a major cause of blindness and results from progressive loss of neurons in the retina called Retinal Ganglion
Cells, and optic nerve degeneration. A frequent risk factor for glaucoma is elevated intraocular pressure, or IOP, but there are patients with &#147;normotensive&#148; glaucoma who have normal IOP. Patients with glaucoma have progressive loss of
peripheral vision, which can eventually result in functional blindness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is estimated that over three million people in
the United States have glaucoma but only half of these people have been diagnosed. More than 120,000 people in the United States are blind due to glaucoma, accounting for 9 to 12% of all cases of blindness. The worldwide prevalence of glaucoma has
been estimated to be over 60&nbsp;million people. Glaucoma is a disease that is more frequently found in older adults with rates increasing several fold between ages 50 and 70. Similar to other neurodegenerative diseases, the overall prevalence of
glaucoma is projected to increase as populations age worldwide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Glaucoma is one of the largest segments of the global ophthalmic market and
has a significant impact on the quality of life. Patients&#146; ability to perform daily activities becomes increasingly limited as the disease progresses. Individuals with glaucoma are more likely to experience falls, to be involved in motor
vehicle collisions, to suffer depression and to require admission to a nursing home. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The goal of existing therapies for
glaucoma is reduction of IOP. <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> treatments are typically administered in the form of eye drops, and patients may require surgery to facilitate drainage of fluid in the eye. However, approximately
ten percent of people who receive appropriate treatment nevertheless continue to experience progressive vision loss. The optic nerve damage observed in glaucoma is believed to be irreversible, highlighting the need for neuroprotective therapies that
can slow or stop the damage to optic nerves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Role of C1q in Glaucoma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C1q, the initiating molecule of the classical complement cascade, has been implicated in the progression of neurodegenerative
disease, including glaucoma. The lab of our scientific founder, Dr.&nbsp;Ben Barres, reported that C1q accumulated on retinal neurons and their synapses early in the disease process in a chronic mouse model of glaucoma, before the onset of other
observable changes. C1q accumulation continued as synapses were lost, followed by loss of the optic nerve. Subsequent studies showed that genetic deletion of C1q protected against optic nerve damage in a chronic mouse model of glaucoma at 12 months
of age (left panel, figure below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using pharmacological inhibition of C1q with ANX007, we observed these findings in a
different mouse model of glaucoma involving acute elevation of IOP. In this model, animals received an intravitreal injection of the <FONT STYLE="white-space:nowrap">M1-Fab</FONT> murine precursor of ANX007 at the time of IOP elevation, followed by
a second dose one week later, and their retinas were examined at week 2. As shown in the right panel of the figure below, intravitreal administration of ANX007 protected against optic nerve damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>C1q Inhibition was Protective in Both Acute and Chronic Models of Glaucoma </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g33c68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:24%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">* p &lt; 0.05 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:24%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">** p &lt; 0.001 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Independent investigators observed elevated levels of C1q and other
components of the classical complement cascade in the inner retinal synapse layer of 34 out of 34 human donor eyes from patients with glaucoma, as illustrated below. C1q was not found in donor eyes from individuals who did not have glaucoma. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g02r42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of Geographic Atrophy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GA is an advanced, vision-threatening form of <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD,
and is a chronic, progressive disease of the macula that results in loss of central vision. The disease typically affects one eye first, with a high likelihood of it occurring in the second eye over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are two forms of AMD, &#147;dry&#148; AMD and &#147;wet&#148; AMD. Dry AMD is the most common form, representing
approximately 85% to 90% of all AMD cases. Geographic atrophy represents the advanced form of dry AMD and is characterized by progressive atrophy of retinal pigment epithelial cells, overlying photoreceptors and underlying choriocapillaries. An
early feature of the disease is the presence of drusen, which is comprised of extracellular yellow deposits at the back of the retina. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GA accounts for about ten percent of legal blindness related to AMD. Approximately one million individuals in the United
States and five million individuals worldwide suffer from geographic atrophy. As with AMD, the prevalence of geographic atrophy increases with age. There are no approved therapies to prevent either the onset or progression of geographic atrophy.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Role of C1q and Complement in Geographic Atrophy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman" ALIGN="justify">Genome-wide association studies have strongly implicated multiple components of the complement cascade in AMD and geographic
atrophy. For example, specific alleles of the gene for C3 can increase the likelihood of developing AMD by 50&nbsp;percent. Histopathological investigations have also observed the presence of complement components in geographic atrophy. These
studies largely point to a role of excessive C3 activity in disease, but do not indicate how C3 is being activated (classical, lectin or alternative pathways). We have identified a potential dual role of C1q and the classical cascade as an important
complement-activating system in geographic atrophy. First, we found that C1q strongly accumulated on photoreceptor cell synapses with normal age or disease, as shown below (left panels), implicating C1q&#146;s role in excessive synapse pruning and
complement-mediated neurodegeneration. Second, C1q and C1q ligands, such as <FONT STYLE="white-space:nowrap">C-reactive</FONT> protein, also accumulated in the retina below photoreceptor cells in association with drusen (extracellular membrane and
protein debris associated with geographic atrophy; right panel). These results suggest that the photoreceptor neurons and pigmented retinal epithelial cells &#150; cell types that are both lost in GA &#150; are sandwiched between deposits of C1q and
that the classical complement cascade may have an ongoing and pathogenic role in GA by activating C3. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g54i19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman" ALIGN="justify">In support of this hypothesis, we found that either deletion or pharmacologic inhibition
of C1q was protective in an animal model of photoreceptor neuron loss induced by photo-oxidation, as shown below. Further, components of the classical complement cascade have been associated with photoreceptor cells in human GA tissue (C4 and C3)
and implicated in photoreceptor cell targeting with an <I>in vitro</I> assay. Finally, C1q is locally produced within the retina during disease by infiltrating immune cells, indicating that its pathogenic role may be amenable to local inhibition of
C1q. As described above, we believe inhibition of C1q would block all key components of the classical cascade, including C1q, C4, C3 involved in immune cell attack and synapse pruning, as well as C5 involved in direct membrane damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman" ALIGN="justify">As shown below, C1q inhibition was protective of photoreceptor cells and retinal function in a model of GA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>C1q Inhibition Protective of Photoreceptor Cells and Retinal Function in Model of GA-like damage </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g93e09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:24%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">* p &lt; 0.05 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Development of ANX007 for Ophthalmic Diseases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have completed a Phase 1b trial of ANX007 in patients with glaucoma. Based on our Phase 1b clinical results in glaucoma, our
preclinical data showing protection in three retinal neurodegeneration animal models (glaucoma, optic neuritis and GA), and our knowledge of C1q biology in this setting, we plan to advance ANX007 in GA and are planning a Phase&nbsp;2 trial. Our
rationale to pursue ANX007 for GA includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The classical complement pathway is implicated in GA by human genetics, and C1q and C4 are associated with
pathology in human GA tissue. C1q is produced locally in the eye by infiltrating immune cells and may be more amenable to local inhibition by intravitreal administration of ANX007. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential role of C1q in GA may be dual-purpose, resulting in both complement-mediated neurodegeneration
and localized tissue damage unique to the eye. Local administration of ANX007 has been shown to be protective in animal photoreceptor neuron loss and achieved complete C1q inhibition in patients for <FONT STYLE="white-space:nowrap">1-2</FONT>
months. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There is a well-established clinical and regulatory path for development. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1b Trial in Glaucoma </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We completed single ascending dose (n=9) and sham-controlled multiple dose (n=17) studies of intravitreal ANX007 in patients
with glaucoma to evaluate safety, tolerability, pharmacokinetics and target engagement. These patients had aqueous humor taps so that ocular fluid could be analyzed for levels of ANX007 and free C1q immediately prior to first dose (day 1) and prior
to second dose (day 29). The studies showed that ANX007 was well-tolerated at all doses (1&nbsp;mg, 2.5&nbsp;mg, 5&nbsp;mg) and achieved complete suppression of C1q at 2.5&nbsp;mg and 5&nbsp;mg, as illustrated below. We believe these results suggest
that ANX007 can be dosed monthly or potentially less frequently in future Phase 2 efficacy trials. We are exploring further development of ANX007 that could enable patients to be dosed as infrequently as every six months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Free C1q Levels in Aqueous Humor </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g18a54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Planned Phase 2 Trial in Geographic Atrophy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We plan to initiate a randomized, controlled Phase 2 trial in GA patients who are at a high risk of progression in 2021 and
anticipate reporting data from this trial in 2023. Prior natural history data similar to that found in other recent large Phase 3 trials may provide a wealth of natural history data from nearly 2,000 patients on how to successfully enrich fast
progressors of GA to enable an efficacy <FONT STYLE="white-space:nowrap">read-out</FONT> within a <FONT STYLE="white-space:nowrap">one-year</FONT> time period. Our Phase 2 GA trial would be designed to show clinical effect on slowing of GA lesion
growth, leveraging the natural history data and patient selection criteria of prior GA trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Third Product Candidate, ANX009 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ANX009 is designed to potently bind to C1q and inhibit activation of the classical complement cascade. ANX009 is a Fab designed
for subcutaneous delivery, and was well tolerated in preclinical toxicology studies. We intend to select our initial lead autoimmune disease indication and commence a Phase 1 FIH clinical trial in 2020. We anticipate reporting data from the FIH
trial in 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Future ANX009 Indications<U></U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing ANX009 to potentially enable chronic dosing in autoimmune hemolytic anemias, such as wAIHA and CAD. In
addition, we are evaluating ANX009 as a treatment option for a subset of lupus nephritis patients who are at a high risk of renal flare due to pathogenic <FONT STYLE="white-space:nowrap">anti-C1q</FONT> antibodies in the circulation, and who may
likely respond to treatment with our <FONT STYLE="white-space:nowrap">anti-C1q</FONT> approach. For this purpose, we have identified a plasma biomarker that identifies lupus nephritis patients with ongoing early classical complement cascade
activation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g34v86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have observed that daily subcutaneous administration of ANX009 fully inhibited C1q
functional activity in the serum of <FONT STYLE="white-space:nowrap">non-human</FONT> primates. Its activity occurred rapidly after the first dose and this activity rapidly reversed after dosing was stopped. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g02e84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that ANX009&#146;s inhibitory activity and its on/off function may benefit
patients with hematological autoimmune disorders. Importantly, the use of plasma biomarkers that define an active </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
complement signature will allow us to take a precision medicine approach to identify patients appropriate for anti-C1q therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Next Generation Product Candidates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing additional next generation product candidates, including ANX105, an investigational monoclonal antibody, and
small molecule modulators of the classical pathway. ANX105 has been designed with enhanced dosing and PK properties facilitating use in chronic neurodegenerative diseases. Our small molecule program is targeting compounds suitable for oral dosing
for the treatment of chronic autoimmune and neurodegenerative diseases. We intend to advance both ANX105 and our small molecule candidates through IND enabling studies in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining
patent protection in the United States and internationally for our product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. Our policy is to seek to protect our proprietary
and intellectual property position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important for the development and implementation of our business. We
also rely on the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is
not patentable, we rely on confidentiality agreements to protect our interests. We generally require our employees, consultants, scientific advisors and contractors to enter into confidentiality agreements prohibiting the disclosure of confidential
information and requiring disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our patent portfolio includes patents and patent applications that are licensed to us in whole or in part from a number of
partners, including Stanford University and the University of California, and patents and patent applications that are owned by us. Our proprietary technology has been primarily developed by <FONT STYLE="white-space:nowrap">in-house</FONT> research
and development programs, and to a lesser extent through acquisitions, relationships with academic research centers and contract research organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For our product candidates, we will, in general, initially pursue patent protection covering compositions of matter and
methods of use. Throughout the development of our product candidates, we seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including by protecting inventions related to additional
methods of use, processes of making, formulation and dosing regimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We hold worldwide development and commercialization
rights, including through exclusive licenses, to all of our product candidates, which allows us to strategically maximize value from our product portfolio over time. Our patent portfolio includes patent protection for our upstream complement
platform and each of our product candidates. In total, our patent portfolio, including patents licensed from our partners, comprises 11 different patent families as of May 31, 2020, filed in various jurisdictions worldwide. Our patent portfolio
includes issued patents and patent applications in the United States and in many international countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One patent
family, which we exclusively license from Stanford University, includes nine granted U.S. patents covering various methods of treating neurodegeneration and related medical conditions by inhibiting the C1 complex or its components, such as by using
an <FONT STYLE="white-space:nowrap">anti-C1q</FONT> antibody. The U.S. patents in this family, which include claims broadly covering uses of ANX005, ANX007, ANX009 and ANX105 will expire between 2026 and 2030, absent any disclaimers, extensions or
adjustments of patent term. There are no pending applications or foreign patents in this family. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Two other patent
families, which we own, are directed to <FONT STYLE="white-space:nowrap">anti-C1q</FONT> antibodies and methods of using them. These families include four granted U.S. patents, two pending U.S. patent applications, four granted foreign
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
patents and 27 pending foreign patent applications. The granted patents in these families cover ANX005, ANX007, ANX009 and ANX105 and will expire between 2034 and 2037, absent any disclaimers,
extensions or adjustments of patent term. Another patent family that we own, which includes one pending U.S. patent application and 13 pending foreign patent applications, includes claims directed to antibody fragments of <FONT
STYLE="white-space:nowrap">anti-C1q</FONT> antibodies, including ANX007 and ANX009 and methods of using them. Patents that may be issued from these applications would expire in 2036, absent any disclaimers, extensions or adjustments of patent term.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our patent portfolio also includes six patent families, owned by us solely or jointly with the University of California
or The J. David Gladstone Institutes, directed to the treatment of certain medical conditions using <FONT STYLE="white-space:nowrap">anti-C1q</FONT> antibodies, including ANX005, ANX007, ANX009 and ANX105. These families include six pending U.S.
patent applications, one granted foreign patent, and 15 pending foreign patent applications. Patents that may be issued from these applications would expire between 2034 and 2039, absent any disclaimers, extensions or adjustments of patent term.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November&nbsp;2011, we and The Board of Trustees of the Leland Stanford Junior University, or Stanford, entered into an
exclusive licensing agreement, or the Stanford Agreement. Under the Stanford Agreement, Stanford granted to us an exclusive, worldwide, royalty-bearing, sublicensable license, under certain patent rights, or the Licensed Patents, to make, use, offer
for sale, sell, import and otherwise commercialize products covered by the Licensed Patents for human or animal diseases, disorders or conditions. We are required to meet certain development and funding diligence milestones for the licensed
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Stanford Agreement, we are obligated to pay Stanford an upfront payment, license maintenance fees
ranging from the single digit to tens of thousands of dollars per year, and milestone payments totaling up to $675,000. We also agreed to make royalty payments at a rate equal to a low single-digit percentage of worldwide net sales of licensed
products and a portion of certain sublicensing income we receive from sublicensees at a rate in the low double digit percentages, subject to a specified maximum total payment. Additionally, in accordance with the terms of the Stanford Agreement,
upon closing our first financing event that raised at least $2.0&nbsp;million, we granted Stanford $150,000 in shares of our redeemable convertible preferred stock. We may also have to pay a fee to Stanford if we assign our rights under the Stanford
Agreement to a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may terminate the Stanford Agreement in its entirety, or as to a particular Licensed
Patent or licensed product, for convenience on thirty days&#146; prior written notice. Stanford may terminate the Stanford Agreement for our breach that remains uncured for forty-five days or if we provide any false report, are delinquent on any
report or payment, fail to achieve a milestone or fail to diligently develop and commercialize a licensed product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term and Term Extensions
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The terms of individual patents are determined based primarily on the date of filing of the patent application or
the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing
date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In addition, in certain instances, the term of a U.S. patent can be extended to recapture a portion of the United States Patent and Trademark Office, or USPTO,
delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period
cannot extend the patent term beyond 14 years from FDA approval for the product covered by that patent. In addition, only one patent applicable to an approved drug may receive the extension, and the extension applies only to coverage for the
approved drug, methods for using it and methods of manufacturing it, even if the claims cover other products or product candidates. Where one patent covers multiple products or product candidates, it may only receive an extension for one of the
covered products; any extension related to a second product or product candidate must be applied to a different patent. The duration of foreign patents varies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent
application, such as a Patent Cooperation Treaty, or PCT, application. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and various foreign jurisdictions, must be timely paid in order for the patent to remain in force
during this period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The actual protection afforded by a patent may vary on a product by product basis, from
country to country, and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal remedies in a particular country and the validity and
enforceability of the patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our patents and patent applications may be subject to procedural or legal challenges by
others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which
could materially harm our business. For more information, see the section titled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks and <FONT STYLE="white-space:nowrap">Know-How</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the ongoing development and advancement of our products and services in the United States and various
international jurisdictions, we seek to create protection for our marks and enhance their value by pursuing trademarks and service marks where available and when appropriate. In addition to patent and trademark protection, we rely upon <FONT
STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality agreements with our commercial
partners, collaborators, employees and consultants, and invention assignment agreements with our employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements,
to grant us ownership of technologies that are developed by our employees and through relationships with third parties. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may
otherwise become known or be independently discovered by competitors. To the extent that our contractors, commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may
arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. For more information, see the section titled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
hold worldwide commercialization rights, including through exclusive licenses, to our product candidates. Given our stage of development, we have not yet established a commercial organization or distribution capabilities. Should any of our product
candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the
full commercial value of our programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our success as a company will depend on our ability to deliver reliable, high-quality preclinical and clinical drug supply. We
do not currently own or operate facilities for product manufacturing, storage and distribution, or testing. We contract with third parties for the manufacture of our product candidates. Because we rely on contract manufacturers, we employ personnel
with extensive technical, manufacturing, analytical and quality experience. Our staff has strong project management discipline to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our
regulatory submissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Manufacturing is subject to extensive regulation that imposes various procedural and
documentation requirements and that governs record keeping, manufacturing processes and controls, personnel, quality control </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and quality assurance, and more. Our systems and our contractors are required to be in compliance with these regulations, and compliance is assessed regularly through monitoring of performance
and a formal audit program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current supply chains for our lead drug candidates involve several manufacturers that
specialize in specific operations of the manufacturing process, specifically, raw materials manufacturing, drug substance manufacturing and drug product manufacturing. We currently operate under work order programs for our drug candidates with
master services agreements in place that include specific supply timelines, volume and quality specifications. We intend to establish long-term supply agreements in the future. We believe our current manufacturers have the scale, the system, and the
experience to supply our currently planned clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not currently require commercial manufacturing
capabilities. Should our needs change, we will need to scale up our manufacturing processes to enable commercial launch. To ensure continuity in our supply chain, we plan to establish supply arrangements with alternative larger scale suppliers for
certain portions of our supply chain, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pharmaceutical, biopharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense
competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our executive and scientific team, research, clinical capabilities, development experience and scientific knowledge provide us with
competitive advantages, we face potential competition from many different sources, including pharmaceutical, biopharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.
Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our competitors may have significantly greater financial resources, established presence in the market, expertise in research
and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific,
sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guillain-Barr&eacute; Syndrome </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are currently no approved therapies for GBS in the United States. IVIg and plasma exchange are the current standards of
care in the Western world and parts of Asia. Hansa Biopharma AB began an open label Phase&nbsp;2 trial in GBS patients in the second quarter of 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warm Autoimmune Hemolytic Anemia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are currently no approved therapies for wAIHA in the United States. Rigel is running a Phase 3 clinical trial of
Tavalisse in wAIHA. Apellis is running a Phase&nbsp;2 clinical trial using APL-2 in cold agglutinin disease, or CAD, and wAIHA. Other companies who have trials ongoing or planned in these rare anemias include Alexion in Phase 2 with SYNT001, Momenta
in Phase&nbsp;2 with Nipocalimab and Immunovant with <FONT STYLE="white-space:nowrap">IMVT-1401.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Huntington&#146;s Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no known cures for HD. Companies such as Ionis, Takeda, Wave Life Sciences, Voyager Therapeutics, uniQure and Hoffman
La Roche are conducting clinical trials with products that are gene silencing in order to attempt to lower the level of the mutant huntingtin protein in patients to investigate whether this will translate to benefits for people with HD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amyotrophic Lateral Sclerosis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no known cures for ALS. The drug riluzole is currently approved for treatment and has shown modest affect in slowing
the progression of the disease. Alexion has initiated a Phase 3 trial of Ultomiris, a long acting C5 inhibitor for ALS. We are aware that Zilucoplan, a C5a inhibitor from Ra Pharma, a subsidiary of UCB, will be included in the HEALY ALS platform
trial. There are many companies conducting clinical trials in ALS patients including MediciNova, Astellas, Biogen, Mitsubishi Tanabe, Ono Pharmaceuticals and others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Glaucoma </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There
are many approved treatments to relieve increased intraocular pressure in glaucoma. There are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> treatments currently available for the retinal degeneration that is observed in glaucoma patients.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Geographic Atrophy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No <FONT STYLE="white-space:nowrap">FDA-approved</FONT> treatment is currently available for GA. We are aware of a number of
companies developing products for the treatment of GA. Those products in clinical development include: APL-2, a C3 inhibitor in Phase 3 trials being developed by Apellis; and Zimura, a C5 inhibitor in Phase&nbsp;2/3 clinical trials, is being
developed by IVERIC bio, previously Ophthotech Corporation. Other products that do not target the complement cascade that are in Phase 2 clinical trials are being developed by Allergan PLC and Regenerative Patch Technologies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively
regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing,
post-approval monitoring and post-approval reporting of biological product candidates such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval
requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with
applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S.
Biologics Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, our product candidates are regulated as biologic pharmaceuticals, or
biologics. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s Good
Laboratory Practice requirements, or GLP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an Investigational New Drug application, or IND, which must become effective before
clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board, or IRB, or ethics committee at each clinical site before the trial
is commenced; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency
of the proposed biologic product candidate for its intended purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of a biologics license application, or BLA, after completion of all
required clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities at which the proposed products is produced to assess compliance with current Good Manufacturing Practices, or cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological
product&#146;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCP; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the BLA to permit commercial marketing of the product for specific indication(s)
for use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to beginning the first clinical trial with a product candidate in
the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and
the protocol(s) for clinical trials. The IND also includes results of animal and <I>in vitro</I> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product; chemistry, manufacturing and
controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by
the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the
FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified
investigators in accordance with GCP, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things,
the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product
development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical
trial begins at that site, and must monitor the trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an
unacceptable health risk or that the trial is unlikely to meet its stated objective(s). Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a Data Safety Monitoring
Board, which provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for
subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be
combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1&#151;The investigational product is initially introduced into healthy human subjects or patients with
the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible,
to gain early evidence on effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2&#151;The investigational product is administered to a limited patient population with a specified
disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning
larger and more expensive Phase 3 clinical trials. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3&#151;The investigational product is administered to an expanded patient population to further evaluate
dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit
ratio of the investigational product and to provide an adequate basis for product approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In some
cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 trials may also be
made a condition to approval of the BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrent with clinical trials, companies may complete additional animal
studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMPs. The manufacturing process must be
capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be
selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BLA Submission and Review by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results
of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from preclinical
studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls and proposed labeling, among other things. Data
can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of the product or from a number of alternative sources, including studies and trials initiated by investigators. The submission of a BLA requires
payment of a substantial user fee to the FDA, and the sponsor of an approved BLA is also subject to an annual program fee. A waiver of user fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on BLAs for
products designated as Orphan Drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once a BLA has been submitted, the FDA&#146;s goal is to review standard applications within ten months after it accepts the
application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. Priority review designation will direct overall attention and resources to the evaluation of applications for
products that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions. In both standard and priority reviews, the review process is often significantly extended
by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facilities in which it is manufactured, processed, packed or held meet standards
designed to assure the product&#146;s continued safety, purity and potency. The FDA may also convene an Advisory Committee to provide clinical insight on application review questions. The FDA is not bound by recommendations of an Advisory Committee,
but it considers such recommendations when making decisions regarding approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before approving a BLA, the FDA will
typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with and adequate to assure consistent
production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites and/or the sponsor&#146;s headquarters to assure compliance with GCP. If the FDA determines
that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested
additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the FDA evaluates a BLA and conducts inspections of clinical trial
sites and manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product
with specific prescribing information for specific indications. A Complete Response Letter indicates that the BLA is not ready for approval in its present form and ends the current review cycle, and will describe all of the deficiencies that the FDA
has identified in the BLA, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may
recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not
satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail
limitations on the indicated uses for which such product may be marketed. Additionally, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety
strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or
elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate
controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches
the marketplace. The FDA may also require one or more Phase 4 post-marketing studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further marketing of the product
based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which could impact the timeline for regulatory
approval or otherwise impact ongoing development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#146;s review and approval of
new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate
the potential to address unmet medical needs for the disease or condition. For a Fast Track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a
schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of
the application. A Fast Track designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six months after the FDA accepts the application for filing. Priority review is
granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious disease or condition. If criteria are not met for priority review, the
application is subject to the standard FDA review period of 10 months after FDA accepts the application for filing. Priority review does not change the scientific/medical standard for approval or the quality of evidence necessary to support
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint
that is reasonably likely to predict clinical benefit or a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other
clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required
to verify the biologic&#146;s clinical benefit in relationship to the surrogate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. The FDA may withdraw approval of a drug or indication approved under accelerated approval
if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, a
sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition
and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. If the FDA designates a product candidate as a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team
throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary
for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an
efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more
efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough Therapy designation also comes with all of the benefits of Fast Track designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards
for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time
period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act, the FDA may grant Orphan designation to a drug or biologic intended to treat a rare disease or
condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation
that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan Drug designation must be requested before submitting a BLA. After the FDA
grants Orphan Drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a product that has Orphan Drug designation subsequently receives the first FDA approval for a particular active ingredient
for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for
seven years, except in limited circumstances, such as a showing of clinical superiority to the product with Orphan Drug exclusivity or if the FDA finds that the holder of the Orphan Drug exclusivity has not shown that it can assure the availability
of sufficient quantities of the Orphan Drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan Drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same
disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of Orphan Drug designation are tax credits for certain research and development activities and a waiver of the BLA application user
fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A designated Orphan Drug may not receive Orphan Drug exclusivity if it is approved for a use that is broader than
the indication for which it received Orphan designation. In addition, Orphan Drug exclusive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates
that its product is clinically superior to the approved product with Orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by
the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to
the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and their subcontractors
are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and
documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA
regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money
and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur
after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements,
may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program.
Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds on clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those
claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity,
warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and
approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties. Physicians may believe that such &#147;off-label&#148; uses are the best treatment for many patients in varied circumstances. The
FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively
the Affordable Care Act, signed into law in 2010, includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an
<FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically
meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical study or studies. Interchangeability requires that a
product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an
individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.
However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval
pathway that are still being developed by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the BPCIA, an application for a biosimilar product may not be
submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the
reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing
product containing that applicant&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars
approved as interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted,
adds six months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary
completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought
to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result,
the ultimate impact, implementation and impact of the BPCIA is subject to significant uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Healthcare Laws and Compliance Requirements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and
by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state fraud and abuse laws, including false claims, civil
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
monetary penalties laws and consumer protection and transparency laws as well as similar foreign laws in the jurisdictions outside the United States. For example, the federal Anti-Kickback
Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for
purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge
of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a
false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute. The federal civil and criminal false claims laws, including the civil False Claims Act, prohibit, among other things, any individual or
entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the
federal government. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal civil and criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud
any healthcare benefit program. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have
committed a violation. The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance
Program, with specific exceptions, to report annually to Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians, as defined by such law, and teaching hospitals, and
applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as
state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT
STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance
guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug
manufacturers to file reports relating to pricing and marketing information or that require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require
the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted
by HIPAA, thus complicating compliance efforts. Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, significant administrative, civil and criminal penalties, damages,
fines, disgorgement, additional reporting obligations, contractual damages, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and individual imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Data Privacy and Security Laws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pharmaceutical, biopharmaceutical and biotechnology companies may be subject to U.S. federal and state health information
privacy, security and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. State laws may be more stringent, broader in scope or offer greater individual
rights with respect to protected health information, or PHI, than HIPAA, and state laws may differ from each other, which may complicate compliance efforts. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured
PHI, a complaint about privacy practices or an audit by the Department of Health and Human Services, or HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations
if required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA <FONT STYLE="white-space:nowrap">non-compliance.</FONT> In addition, California enacted the
California Consumer Privacy Act, or CCPA, which creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA went into effect on January&nbsp;1,
2020, and the California Attorney General may bring enforcement actions for violations beginning July&nbsp;1, 2020. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this
legislation or how it will be interpreted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">European Union member states, the United Kingdom, Switzerland and other
jurisdictions have also adopted data protection laws and regulations, which impose significant compliance obligations. In the EEA and the United Kingdom, the collection and use of personal data, including clinical trial data, is governed by the
provisions of the General Data Protection Regulation, or GDPR. The GDPR became effective on May&nbsp;25, 2018, repealing its predecessor directive and increasing responsibility and liability of pharmaceutical companies in relation to the processing
of personal data of EU data subjects. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on
the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data
relates, the information provided to the individuals, the transfer of personal data out of the European Economic Area, or EEA, or the United Kingdom, security breach notifications, security and confidentiality of the personal data and imposition of
substantial potential fines for breaches of the data protection obligations. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing
personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Coverage and Reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors,
such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. No uniform policy exists for coverage and
reimbursement for products exists among U.S. third-party payors. Therefore, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. The process for determining whether a third-party payor will provide coverage for a product typically is separate from the process for setting the
price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which
might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication, or place products at certain formulary levels that result in lower reimbursement levels and higher cost-sharing obligation
imposed on patients. One third-party payor&#146;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service. As a result, the coverage determination
process will often require us to provide scientific and clinical support for the use of our product candidates to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied
consistently or obtained in the first instance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In international markets, reimbursement and healthcare payment systems
vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their
national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect
controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products.
Furthermore, there can be no assurance that a product will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
considered medically reasonable and necessary for a specific indication, that a product will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be
established even if coverage is available or that the third-party payors&#146; reimbursement policies will not adversely affect the ability to sell a product profitably. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare Reform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the
United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Affordable Care Act was signed into law, which
substantially changed the way healthcare is financed by both governmental and private insurers in the United States and significantly affected the pharmaceutical industry. The Affordable Care Act contains a number of provisions, including those
governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the Affordable Care Act increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1%
to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70&nbsp;percent <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or importers who sell certain &#147;branded prescription drugs&#148; to specified
federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; expanded eligibility
criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center
for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the Affordable
Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated the
<FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
&#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the Affordable
Care Act, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the Affordable Care Act are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District
Court&#146;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On March 2, 2020, the United States
Supreme Court granted the petitions for writs of certiorari to review this case, although it is unclear when a decision will be made or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal or replace the
Affordable Care Act will impact the law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other legislative changes have been proposed and adopted since the Affordable
Care Act was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2030 absent additional congressional
action. The Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which was signed into law on March 27, 2020, designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended
these reductions from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their
marketed products, which has resulted in several Congressional inquiries and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform
government program reimbursement methodologies for pharmaceutical products. At the federal level, the Trump administration&#146;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to
reduce drug prices, increase competition, lower out-of-pocket drug costs for patients and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to
Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses and place limits on pharmaceutical
price increases. Further, the Trump Administration previously released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating
power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. Individual states in the United States have also become
increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems
and publication of discounts and list prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our corporate headquarters are located in South San Francisco, California, where we lease approximately 12,300 square feet of
office, research and development, engineering and laboratory space pursuant to a lease agreement which commenced on July&nbsp;1, 2017 and expires on June&nbsp;30, 2024 with an option to extend for five years. We believe that our existing facilities
are sufficient for our near-term needs but expect to need additional space as we grow. We believe that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June 30,
2020, we had 30 full-time employees, 23 of whom were primarily engaged in research and development activities. A total of 12 employees have an M.D., Ph.D. or Pharm.D. degree. Substantially all of our employees are located in South San Francisco,
California. None of our employees is represented by a labor union, and we consider our employee relations to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are not currently a party to any material legal proceedings. We may, however, in the ordinary course of business face
various claims brought by third parties, and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our
products. Any of these claims could subject us to costly litigation, and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, may be inadequately
capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our operations, cash flows
and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding our executive officers and directors as of July&nbsp;20, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Position(s)</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Executive&nbsp;Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Love, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanjay Keswani, MBBS, BSc, FRCP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief Medical Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Lew</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Overdorf</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief Business Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ted Yednock, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief Scientific Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William D. Young(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">75</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman and Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jung E. Choi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emmett Cunningham, M.D., Ph.D., M.P.H.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">59</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol Gallagher, Pharm.D.(1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Campbell Murray, M.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">44</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Muneer A. Satter(1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ricky Sun, Ph.D.(1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas G. Wiggans(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">68</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Member of our audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Member of our compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Member of our nominating and corporate governance committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Murray is expected to resign from our Board of Directors prior to the effectiveness of the
registration statement of which this prospectus is a part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Douglas Love, Esq.</I></B> has served as our President and Chief Executive Officer and as a member of our board of
directors since December 2014. Prior to joining Annexon, from 2008 to April<I> </I>2013, he served as Head of Operations&nbsp;&amp; Strategic Alliances for Elan Pharmaceuticals, Inc., a biopharmaceutical company, where he led the Tysabri<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> multiple sclerosis franchise, and Elan&#146;s Alzheimer&#146;s Immunotherapy Program, which was licensed to Johnson&nbsp;&amp; Johnson. From 2006 to 2008, he served as Head of Strategic
Alliances, Business Development&nbsp;&amp; Business Integration for Elan. Prior to joining Elan, Mr.&nbsp;Love served as an associate at the law firm Orrick, Herrington&nbsp;&amp; Sutcliffe LLP, Corporate Counsel at Amgen, Inc. and as Section
Corporate Counsel at Genentech, Inc., where he led the BioOncology Healthcare Law Group. Mr.&nbsp;Love received a B.S. in business administration from the University of Southern California and a J.D. with great distinction from McGeorge School of
Law. We believe that Mr.&nbsp;Love is qualified to serve on our board of directors due to the valuable expertise and perspective he brings in his capacity as our President and Chief Executive Officer and because of his extensive experience and
knowledge of our industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sanjay Keswani, MBBS, BSc, FRCP</I></B> has served as our Executive Vice President and
Chief Medical Officer since June 2019. Prior to that, Dr.&nbsp;Keswani was Chief Executive Officer at Rheos Medicines, Inc., a privately-held biopharmaceutical company, from September 2018 to June 2019. From June 2015 to September 2018,
Dr.&nbsp;Keswani was Senior Vice President&nbsp;&amp; Global Head of Neuroscience, Ophthalmology and Rare Diseases for the Roche Pharma Research and Early Development division of F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd., a
publicly-held </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
pharmaceutical company. Prior to Roche, he was Vice President, Exploratory and Clinical Translational Research at Bristol-Myers Squibb Company, a publicly-held pharmaceutical company, where he
was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology from March 2011 to June 2015. Prior to joining Bristol-Myers Squibb, Dr.&nbsp;Keswani held research and development leadership
roles at Eli Lilly&nbsp;&amp; Company, a publicly-held pharmaceutical company, and Amgen Inc., a publicly-held biopharmaceutical company, and also served as Assistant Professor in Neurology at Johns Hopkins University. Dr.&nbsp;Keswani received his
MBBS in medicine at St. Bartholomew&#146;s Hospital, London and completed his medical residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins University School of Medicine. In addition, Dr.&nbsp;Keswani
received a first class honors degree from St. Mary&#146;s Hospital, London in Pathology&nbsp;&amp; Basic Medical Sciences (Immunology) and was elected as a Fellow of the Royal College of Physicians. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jennifer Lew</I></B> has served as our Executive Vice President and Chief Financial Officer since June 2019. Previously,
from October 2013 to May 2019, Ms.&nbsp;Lew held various roles at Aduro Biotech, Inc., a publicly-held immunotherapy company, most recently as Chief Financial Officer. Prior to that, Ms.&nbsp;Lew held various roles at Dynavax Technologies
Corporation, a publicly-held biopharmaceutical company, from 2004 to October 2013, most recently as Vice President of Finance and Principal Accounting Officer, where she oversaw accounting and finance operations. Prior to joining Dynavax,
Ms.&nbsp;Lew held positions as Assistant Controller and Director of Finance at QRS Corporation, a publicly-held technology company, from 2000 to 2004. Ms.&nbsp;Lew was a member of the audit practice at Ernst&nbsp;&amp; Young LLP from 1994 to 1999.
She received a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Michael Overdorf </I></B>has served as our Executive Vice President and Chief Business Officer since July 2020. Prior to
joining Annexon, from 2001 to July 2020, Mr. Overdorf held various executive leadership roles at Eli Lilly&nbsp;&amp; Company, a publicly-held pharmaceutical company, most recently in Corporate Business Development and Corporate Strategy where he
led teams focused on accessing innovative medicines and led the development and execution of the company&#146;s global strategy. Mr.&nbsp;Overdorf also served as a Global Biologics Platform Team Leader, leading two Phase&nbsp;3 clinical development
teams working on biologic molecules targeting autoimmune diseases and as the Chief Operating Officer of the Bio-Medicines Business Unit of Lilly. Mr.&nbsp;Overdorf also held multiple commercial leadership roles at Lilly, including Chief Marketing
Officer of the United Kingdom and General Manager of the Czech &amp; Slovak Republics. Mr.&nbsp;Overdorf is an adjunct lecturer in Medicine in the Division of Clinical Pharmacology at the Indiana University School of Medicine. Mr.&nbsp;Overdorf
received a B.A. in Economics from Wabash College and an M.B.A. from Harvard Business School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Ted Yednock,
Ph.D.</I></B><B> </B>has served as our Executive Vice President and Chief Scientific Officer since November 2013. Previously, Dr.&nbsp;Yednock was Chief Scientific Officer for Prothena Corporation plc, a publicly-held biotechnology company spun out
from Elan Pharmaceuticals, Inc., until 2013, and served in several roles of increasing responsibility from 1996 to 2013 at Elan Pharmaceuticals, Inc., a biopharmaceutical company, including Head of Global Research from 2007 to<I> </I>2013. From 1990
to 1996, Dr.&nbsp;Yednock was a Scientist at Athena Neurosciences, Inc., a privately-held pharmaceutical company. While at Athena, he was the scientific inventor of Tysabri<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a monoclonal
antibody for the treatment of multiple sclerosis. In addition to his work in multiple sclerosis, Dr.&nbsp;Yednock has contributed to the invention or progression of numerous drugs in the areas of Alzheimer&#146;s disease, Parkinson&#146;s disease,
amyloidosis, rheumatoid arthritis, psoriasis and Crohn&#146;s disease. Dr.&nbsp;Yednock received his B.S. in biology and chemistry from the University of Illinois and his Ph.D. in anatomy and cell biology from the University of California, San
Francisco. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>William D. Young </I></B>has served as Chairman of our board of directors since March 2017 and as a member of our board
of directors since December 2014. Since December 2018, he has been a Senior Advisor at Blackstone Life Sciences, following Blackstone&#146;s acquisition of Clarus Ventures, LLC, a healthcare and life sciences venture capital firm where
Mr.&nbsp;Young served as Venture Partner since 2010. Mr.&nbsp;Young served from 1999 until 2009 as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Chairman of the board of directors and Chief Executive Officer of Monogram Biosciences, Inc., then a publicly-held biotechnology company, which was acquired by Laboratory Corporation of America
in June 2009. From 1980 to 1999, Mr.&nbsp;Young was employed at Genentech, Inc., most recently as Chief Operating Officer, where he was responsible for all Product Development, Manufacturing and Commercial functions. Prior to joining Genentech,
Mr.&nbsp;Young worked at Eli Lilly&nbsp;&amp; Company for 14 years. Mr.&nbsp;Young has been Chairman of the board of directors of NanoString Technologies, Inc., a publicly-held biotechnology company, since March 2010. He has served as a director of
Theravance Biopharma., Inc., a publicly-held biopharmaceutical company, since October 2013 and lead independent director since April 2014. Mr.&nbsp;Young served as a director of Innoviva, Inc., a publicly-held biopharmaceutical company, from April
2001 to June 2014, prior to Theravance&#146;s <FONT STYLE="white-space:nowrap">spin-off</FONT> from Innoviva. In addition, Mr.&nbsp;Young has been a member of the board of directors of Vertex Pharmaceuticals Incorporated, a publicly-held
biopharmaceutical company, since May 2014 and is also a member of the board of directors of Praxis Precision Medicines, Inc., a privately-held pharmaceutical company, and SJF Pharmaceuticals Inc., a privately-held pharmaceutical company, both Clarus
portfolio companies. He was a member of the board of directors of BioMarin, Inc., a publicly-held biotechnology company, until November 2015 and Biogen Idec Inc., a publicly-held biotechnology company, until June 2014, having served as a director
since 1997 and as Chairman of the board of directors since 2010. Mr.&nbsp;Young is also a Trustee of Montage Health, a nonprofit company. Mr.&nbsp;Young received his B.S. in Chemical Engineering from Purdue University, his M.B.A. from Indiana
University and an honorary Doctorate of Engineering from Purdue University. Mr.&nbsp;Young was elected to The National Academy of Engineering in 2003 for his contributions to biotechnology. We believe that Mr.&nbsp;Young is qualified to serve on our
board of directors due to his demonstrated leadership in his field, his experience as an executive and a board member of biotechnology and pharmaceutical companies and his experience as an investor in life sciences companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jung E. Choi </I></B>has served as a member of our board of directors since June 2020. Since April 2015, Ms. Choi has
served as Chief Business and Strategy Officer of Global Blood Therapeutics, Inc., a publicly-held biopharmaceutical company, responsible for corporate strategy, business development, patient advocacy, and government affairs. From April 2014 to March
2015, Ms. Choi served as Senior Vice President, Corporate Development for InterMune, Inc., a biotechnology company (acquired by Roche Holding AG in 2014), and served as an adviser on strategy and business development to InterMune from March 2013 to
April 2014. Prior to joining InterMune, from February 2011 to March 2013, Ms. Choi led corporate and business development for Chimerix, Inc., a biopharmaceutical company, as a consultant and Senior Vice President, Corporate Development. Prior to
that, from August 2001 to August 2010, Ms. Choi held various management positions at Gilead Sciences, Inc., a publicly-held biopharmaceutical company, including leadership of business development, licensing, and mergers and acquisition activities.
During her tenure at Gilead Sciences, Ms. Choi built and oversaw the corporate development group, and led the U.S. commercial launch of Hepsera<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of the hepatitis B virus. Ms.
Choi received her B.A. in human biology and an M.B.A. from Stanford University. We believe that Ms. Choi is qualified to serve on our board of directors due to her experience as an executive of biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Emmett Cunningham, M.D., Ph.D., M.P.H. </I></B>has served as a member of our board of directors since December 2014. He
is a Senior Managing Director of Blackstone Life Sciences, having joined as part of its acquisition of Clarus Ventures, LLC, in December 2018. Dr.&nbsp;Cunningham was a Managing Director at Clarus from January 2017 to November 2018, where he led
investments in the medical technology and biotechnology space including partnerships with pharmaceutical companies, and a Partner from December 2008 to December 2016. Prior to joining Clarus, Dr.&nbsp;Cunningham was the Senior Vice President,
Medical Strategy at Eyetech Pharmaceuticals, Inc., a privately-held pharmaceutical company, from February 2004 to December 2005, where he helped lead the team that developed Macugen, a treatment for
<FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration. Dr.&nbsp;Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications. Dr.&nbsp;Cunningham previously served as
a member of the board of directors of Restoration Robotics, Inc., a publicly-held medical device company. He is also a member of the board of directors of Galera Therapeutics, Inc., a privately-held biotechnology company, Graybug Vision, Inc., a
privately-held clinical-stage pharmaceutical company, Lumos Pharma, Inc., a privately-held clinical-stage biopharmaceutical company, and SFJ Pharmaceutical, Inc., a privately-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
held pharmaceutical company, and serves on the Scientific Advisory Board of Aerie Pharmaceuticals, Inc., a publicly-held ophthalmic pharmaceutical company. Dr.&nbsp;Cunningham is the founder and
Chairman of the Ophthalmology Innovation Summit symposium held in conjunction with the annual meetings of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Dr.&nbsp;Cunningham received his B.S. in
Science from Drexel University and a B.A. in human biology, M.D. and M.P.H. in public health from Johns Hopkins University and a Ph.D. in neuroscience from the University of California, San Diego for work done at The Salk Institute. We believe that
Dr.&nbsp;Cunningham is qualified to serve on our board of directors due to his educational background, his medical and scientific expertise, his experience as a board member of biotechnology and pharmaceutical companies and his experience as an
investor in life sciences companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Carol Gallagher, Pharm.D. </I></B>has served<B><I> </I></B>as a member of our
board of directors since October 2018. Since October 2014, Dr.&nbsp;Gallagher has served as a partner with New Enterprise Associates, Inc., a venture capital firm. Prior to joining New Enterprise Associates, Dr.&nbsp;Gallagher served as a venture
partner with Frazier Healthcare Partners, a venture capital firm, from October 2013 to July 2014. Dr.&nbsp;Gallagher served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, Inc., a privately-held biopharmaceutical company,
from 2008 to 2011, when the company was acquired by Gilead Sciences, Inc. From 2007 to 2008, Dr.&nbsp;Gallagher was the President and Chief Executive Officer of Metastatix, Inc., a privately-held biopharmaceutical company. Prior to that time
starting in 1989, she served in various roles at pharmaceutical companies, Eli Lilly&nbsp;&amp; Company, Amgen Inc., Agouron Pharmaceuticals, Inc., Pfizer Inc., Biogen Idec Pharmaceuticals Inc., CancerVax Corp. and Anadys Pharmaceuticals, Inc.
Dr.&nbsp;Gallagher also serves as Chairman of the board of directors of Millendo Therapeutics, Inc., a publicly-held biopharmaceutical company, since 2012, lead director at Atara Bio, Inc., a publicly-held immunotherapy company, since 2012, and as a
director and chair of the Nominating and Corporate Governance Committee of Turning Point Therapeutics, a publicly-held oncology company, since August 2019. She also serves as a director to the following private companies: Metacrine, Inc. (since
November 2017), PIONYR Immunotherapeutics Inc. (since December 2017), Qpex (since August 2018), XOC Pharmaceuticals (since October 2018) and Chromacode (since December 2018). From November 2011 to March 2018, Dr.&nbsp;Gallagher served as a member of
the board of directors of AnaptysBio, Inc., a publicly-held biopharmaceutical company. Dr.&nbsp;Gallagher attended Vanderbilt University and received B.S. and Doctor of Pharmacy degrees from the University of Kentucky. We believe that
Dr.&nbsp;Gallagher is qualified to serve on our board of directors due to her educational background, her experience as an executive and a board member of biotechnology and pharmaceutical companies and her experience as an investor in life sciences
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Campbell Murray, M.D. </I></B>has served as a member of our board of directors since December 2014.
Dr.&nbsp;Murray has served as a Managing Director at the Novartis Venture Fund since August 2005. Previously, Dr.&nbsp;Murray served as the Director of Special Projects at the Novartis Institutes for BioMedical Research from July 2004 until July
2005. Currently, Dr.&nbsp;Murray serves as a member of the boards of directors of Expansion Therapeutics, Lemonaid Health, Renovacor and TScan Therapeutics. Dr.&nbsp;Murray received a bachelor of human biology from the University of Auckland Medical
School, an M.B.A. from Harvard Business School, an M.P.P. from the John F. Kennedy School of Government, and an MBChB (M.D.) from the University of Auckland Medical School. We believe that Dr. Murray is qualified to serve on our board of directors
due to his extensive investment experience in the biotechnology sector. Dr. Murray has notified us that he will resign from our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a
part. Dr. Murray&#146;s resignation is not due to any disagreement with the company or any matters relating to our operations, policies or practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Muneer A. Satter</I></B> has served as a member of our board of directors since December 2014. Mr.&nbsp;Satter has been
Founder and Managing Partner of Satter Medical Technology Partners, L.P. since 2016, and Chairman of Satter Investment Management, LLC since 2012, and he also manages the Satter Foundation. Prior to Satter Investment Management, Mr.&nbsp;Satter was
a partner at Goldman Sachs where he spent 24 years in various roles, most recently as the Global Head of the Mezzanine Group in the Merchant Banking Division, where he raised and managed over $30&nbsp;billion of assets and was also Chairman of the
Risk Committee overseeing $80 billion of assets. He is the Chairman of the board of directors of Aerpio Pharmaceuticals, a publicly-held </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
biopharmaceutical company. Mr.&nbsp;Satter was Chairman of the board of directors of Akebia Therapeutics, Inc. from May 2013 to December 2018 and was Co-Chairman and a director of Vital
Therapies, Inc. from October 2012 to October 2018. He also serves as Vice Chairman of the Goldman Sachs Foundation and GS Gives, is a director of World Business Chicago and Accelerate Institute, is on the Board of Advisors of the American Enterprise
Institute, is on the board of directors of the Navy SEAL Foundation, Northwestern Medical Group and is on the Board of Trustees of Northwestern University where he is Chairman of the Finance Committee, as well as on the Board of Trustees of the US
Olympic and Paralymic Foundation. Mr.&nbsp;Satter received a B.A. in Economics from Northwestern University, a J.D. from Harvard Law School and an M.B.A. from Harvard Business School. We believe that Mr.&nbsp;Satter is qualified to serve on our
board of directors due to his experience in the financial industry, his experience as a board member of biotechnology and pharmaceutical companies and his experience as an investor in life sciences companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Ricky Sun, Ph.D. </I></B>has served as a member of our board of directors since December 2018. Since August 2016,
Dr.&nbsp;Sun has been a partner at Bain Capital Life Sciences, L.P. Prior to joining Bain Capital, he was a Director of Corporate Development and Strategy at Biogen Inc., a publicly-held biotechnology company, from January 2013 to July 2016. Prior
to Biogen, Dr.&nbsp;Sun served as a Vice President at BlackRock, Inc., as a member of the Fundamental Equity division of BlackRock&#146;s Alpha Strategies Group and senior analyst for BlackRock&#146;s Fundamental Large Cap Growth equity team,
covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel LLC and Alyeska Investment Group, L.P. in Chicago from May 2010 to December 2011, and worked as a pharmaceuticals equity research analyst on Wall Street
from September 2006 to July 2007, spending time at Lehman Brothers Holdings Inc. and Morgan Stanley. Dr.&nbsp;Sun began his career as a senior scientist at Ironwood Pharmaceutical, Inc. from January 2002 to July 2009, where he was involved in the
discovery and development of the drug Linzess for irritable bowel syndrome. Dr. Sun serves as a director of Arcutis Biotherapeutics, Inc., a publicly-held biopharmaceutical company, and, since December 2019, Dr. Sun has also served as a director of
Savara, Inc., a publicly-held biopharmaceutical company. Dr.&nbsp;Sun received a B.A. in chemistry, <I>summa cum laude</I>, from Berea College, an M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar, and
a Ph.D. degree in Chemistry and Chemical Biology from Harvard University. He was also an NIH post-doctoral fellow in Biological Chemistry&nbsp;&amp; Molecular Pharmacology at Harvard Medical School. We believe that Dr.&nbsp;Sun is qualified to serve
on our board of directors due to his educational background and his experience in the financial industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Thomas G.
Wiggans</I></B> has served as a member of our board of directors since February 2017. Mr.&nbsp;Wiggans founded Dermira, Inc., a publicly-held pharmaceutical company, in August 2010 and has served as its Chief Executive Officer since September 2010
and on its board of directors since October 2014. Mr.&nbsp;Wiggans has also served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx
Pharmaceuticals from March 2005 until its acquisition by Amgen Inc. in October 2013, Sangamo Biosciences, Inc. from June 2008 until June 2012, Somaxon Pharmaceuticals, Inc. from June 2008 until May 2012 and as Chairman of the board of directors of
Excaliard Pharmaceuticals, Inc. from October 2010 until its acquisition by Pfizer, Inc. in December 2011. From October 2007, Mr.&nbsp;Wiggans served as Chairman of the board of directors of Peplin, Inc. and in July 2007, he became its Chief
Executive Officer, and he served in these positions until Peplin&#146;s acquisition by LEO Pharma A/S in November 2009. Previously, Mr.&nbsp;Wiggans served as Chief Executive Officer of Connetics Corporation from July 1994, and as Chairman of the
board of directors of Connetics from January 2006, and he served in these positions until December 2006 when Connetics was acquired by Stiefel Laboratories, Inc. From 1992 to 1994, Mr.&nbsp;Wiggans served as President and Chief Operating Officer of
CytoTherapeutics Inc. From 1980 to 1992, Mr.&nbsp;Wiggans served at Ares-Serono S.A. in various management positions including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations.
Mr.&nbsp;Wiggans began his career with Eli Lilly&nbsp;&amp; Company. In addition, Mr.&nbsp;Wiggans is a member of the board of directors of the Biotechnology Innovation Organization and is a member of the board of trustees of the University of
Kansas Endowment Association. Mr.&nbsp;Wiggans received a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University. We believe that Mr.&nbsp;Wiggans is qualified to serve on our board of directors due to his
experience as an executive and a board member of biotechnology and pharmaceutical companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors currently consists of nine members, and after the resignation of Dr. Murray, our board of
directors will consist of eight members. Our board of directors has determined that all of our directors, other than Mr.&nbsp;Love, qualify as independent directors in accordance with The Nasdaq Stock Market LLC, or Nasdaq, Marketplace Rules or the
Nasdaq Listing Rules. Mr.&nbsp;Love is not considered independent by virtue of his position as our President and Chief Executive Officer. Under the Nasdaq Listing Rules, the definition of independence includes a series of objective tests, such as
that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his or her family members has engaged in various types of business dealings with us. In addition, as required by the
Nasdaq Listing Rules, our board of directors has made a subjective determination as to each independent director that no relationships exists that, in the opinion of our board of directors, would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#146;s relationships as they may relate to us
and our management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with our amended and restated certificate of incorporation, which will be effective immediately prior to the
completion of this offering, our board of directors will be divided into three classes with staggered three-year terms. At each annual general meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from
the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;I directors will be Dr. Gallagher, Mr. Satter and Dr. Sun, and their terms will expire at the
annual meeting of stockholders to be held in 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;II directors will be Ms.&nbsp;Choi, Mr.&nbsp;Love and Mr.&nbsp;Young, and their terms will
expire at the annual meeting of stockholders to be held in 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;III directors will be Dr. Cunningham and Mr. Wiggans, and their terms will expire at the annual
meeting of stockholders to be held in 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that any additional directorships resulting from
an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors
into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Arrangements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The election of the members of our board of directors is currently governed by the amended and restated voting
agreement that we entered into with certain holders of our common stock and convertible preferred stock and the related provisions of our amended and restated certificate of incorporation. Pursuant to our amended and restated voting agreement and
amended and restated certificate of incorporation, our current directors were elected as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dr.&nbsp;Cunningham, Dr.&nbsp;Gallagher, Dr.&nbsp;Murray, Mr.&nbsp;Satter and Dr.&nbsp;Sun were elected as the
designees of Clarus Lifesciences III, L.P., New Enterprise Associates 15, L.P., Novartis Bioventures Ltd., entities affiliated with Mr.&nbsp;Satter and Bain Capital Life Sciences Fund, L.P., respectively; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mr.&nbsp;Love was elected and designated as our then-serving and current Chief Executive Officer; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ms. Choi, Mr.&nbsp;Wiggans and Mr.&nbsp;Young were elected as the designees of the (i)&nbsp;holders of a
majority of the shares of common stock held by stockholders who are our employees, consultants or advisors at the time of such vote and (ii)&nbsp;holders of at least 60% of the shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT>
redeemable convertible preferred stock, Series&nbsp;B redeemable convertible preferred stock, Series&nbsp;C redeemable convertible preferred stock and Series&nbsp;D redeemable convertible preferred stock on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated voting agreement
will terminate and the provisions of our current amended and restated certificate of incorporation by which our directors were elected will be amended and restated in connection with this offering. After this offering, the number of directors will
be fixed by our board of directors, subject to the terms of our amended and restated certificate of incorporation and amended and restated bylaws that will become effective immediately prior to the completion of this offering. Each of our current
directors will continue to serve as a director until the election and qualification of his or her successor, or until his or her earlier death, resignation or removal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leadership Structure of the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws and corporate governance guidelines provide our board of directors with flexibility to combine
or separate the positions of Chairman of the board of directors and Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has
concluded that our current leadership structure is appropriate at this time. However, our board of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Risk assessment and oversight are an integral part of our governance and management processes. Our board of directors
encourages management to promote a culture that incorporates risk management into our corporate strategy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations. Management discusses
strategic and operational risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior
management reviews these risks with the board of directors at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or
eliminate such risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors does not have a standing risk management committee, but rather administers
this oversight function directly through our board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. While our board of directors is
responsible for monitoring and assessing strategic risk exposure, our audit committee is responsible for overseeing our major financial risk exposures and the steps our management has taken to monitor and control these exposures. The audit committee
also approves or disapproves any related person transactions. Our nominating and corporate governance committee monitors the effectiveness of our corporate governance guidelines. Our compensation committee assesses and monitors whether any of our
compensation policies and programs has the potential to encourage excessive risk-taking. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance
committee. Our board of directors may establish other committees to facilitate the management of our business. The composition and functions of each committee are described below. Members </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
serve on these committees until their resignation or until otherwise determined by our board of directors. Each committee intends to adopt a written charter that satisfies the applicable rules
and regulations of the SEC and Nasdaq Listing Rules, which we will post on our website at www.annexonbio.com upon the completion of this offering. The reference to our website address does not constitute incorporation by reference of the information
contained at or available through our website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit committee oversees our corporate accounting and financial reporting process. Among other matters, the audit
committee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoints our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluates the independent registered public accounting firm&#146;s qualifications, independence and
performance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determines the engagement of the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews and approves the scope of the annual audit and <FONT STYLE="white-space:nowrap">pre-approves</FONT>
the audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> fees and services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews and approves all related party transactions on an ongoing basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishes procedures for the receipt, retention and treatment of any complaints received by us regarding
accounting, internal accounting controls or auditing matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discusses with management and the independent registered public accounting firm the results of the annual
audit and the review of our quarterly financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approves the retention of the independent registered public accounting firm to perform any proposed
permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discusses on a periodic basis, or as appropriate, with our management&#146;s policies and procedures with
respect to risk assessment and risk management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consults with management to establish procedures and internal controls relating to cybersecurity;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is responsible for reviewing our financial statements and our management&#146;s discussion and analysis of
financial condition and results of operations to be included in our annual and quarterly reports to be filed with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investigates any reports received through the ethics helpline and reports to the board of directors
periodically with respect to any information received through the ethics helpline and any related investigations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews the audit committee charter and the audit committee&#146;s performance on an annual basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit committee consists of Mr. Satter, Dr. Gallagher and Dr. Sun. Our board of directors has
determined that all members are independent under the Nasdaq Listing Rules and <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3(b)(1)</FONT> of the Exchange Act. The chair of our audit committee is Mr. Satter. Our board of directors has determined
that Mr.&nbsp;Satter is an audit committee financial expert as such term is currently defined in Item&nbsp;407(d)(5) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> Our board of directors has also determined that each member of our
audit committee can read and understand fundamental consolidated financial statements, in accordance with applicable requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation
Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee oversees policies relating to compensation and benefits of our officers and
employees. The compensation committee reviews and approves or recommends corporate goals and objectives </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
relevant to compensation of our executive officers (other than our Chief Executive Officer), evaluates the performance of these officers in light of those goals and objectives and approves the
compensation of these officers based on such evaluations. The compensation committee also reviews and approves or makes recommendations to our board of directors regarding the issuance of stock options and other awards under our stock plans to our
executive officers (other than our Chief Executive Officer). The compensation committee reviews the performance of our Chief Executive Officer and makes recommendations to our board of directors with respect to his compensation, and our board of
directors retains the authority to make compensation decisions relative to our Chief Executive Officer. The compensation committee will review and evaluate, on an annual basis, the compensation committee charter and the compensation committee&#146;s
performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee consists of&nbsp;Mr. Wiggans, Dr. Cunningham&nbsp;and&nbsp;Dr. Sun. Our board of
directors has determined that all members are independent under the Nasdaq Listing Rules and are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT>
promulgated under the Exchange Act. The chair of our compensation committee is Mr.&nbsp;Wiggans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The nominating and corporate governance committee is responsible for making recommendations to our board of
directors regarding candidates for directorships and the size and composition of our board of directors. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance policies and making
recommendations to our board of directors concerning governance matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our nominating and corporate governance
committee consists of&nbsp;Mr. Young, Dr. Gallagher and Mr. Satter. Our board of directors has determined that all members of the nominating and corporate governance committee are independent under the Nasdaq Listing Rules. The chair of our
nominating and corporate governance committee is Mr. Young. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the members of the compensation committee is currently, or has been at any time, one of our executive officers or
employees. None of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of
directors or on our compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Diversity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon consummation of this offering, our nominating and corporate governance committee will be responsible for reviewing with
the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates
and current members), the nominating and corporate governance committee, in recommending candidates for election, and the board of directors, in approving (and, in the case of vacancies, appointing) such candidates, may take into account many
factors, including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personal and professional integrity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ethics and values; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience in corporate management, such as serving as an officer or former officer of a publicly held
company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">professional and academic experience relevant to our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience as a board member of another publicly held company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strength of leadership skills; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience in finance and accounting and/or executive compensation practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to devote the time required for preparation, participation and attendance at board of directors
meetings and committee meetings, if applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">background, gender, age and ethnicity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conflicts of interest; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to make mature business judgments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the consummation of this offering, our board of directors will evaluate each individual in the context of the board
of directors as a whole, with the objective of ensuring that the board of directors, as a whole, has the necessary tools to perform its oversight function effectively in light of our business and structure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we intend to adopt a written code of business conduct and ethics that applies to all of our
directors, officers and employees, including those officers responsible for financial reporting. The full text of our code of business conduct and ethics will be posted on our website at www.annexonbio.com upon the completion of this offering. Any
substantive amendment to, or waiver of, a provision of the code of business conduct and ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar
functions will be disclosed on our website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and our amended and restated bylaws, both of which will become effective
immediately prior to the completion of this offering, limit our directors&#146; liability, and provide that we may indemnify our directors and officers to the fullest extent permitted under Delaware General Corporation Law, or the DGCL. The DGCL
provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for any: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transaction from which the director derives an improper personal benefit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payment of dividends or redemption of shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach of a director&#146;s duty of loyalty to the corporation or its stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These limitations of liability do not apply to liabilities arising under federal securities laws and do not affect the
availability of equitable remedies such as injunctive relief or recession. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The DGCL and our amended and restated bylaws
provide that we will, in certain situations, indemnify our directors and officers and may indemnify other employees and other agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to
advancement, direct payment or reimbursement of reasonable expenses (including attorneys&#146; fees and disbursements) in advance of the final disposition of the proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have entered, and intend to continue to enter, into separate indemnification agreements with our directors and
officers. These indemnification agreements, among other things, require us to indemnify our directors and officers for certain expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or officer in any
action or proceeding arising out of their services as a director or officer, or any other company or enterprise to which the person provides services at our request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also maintain a directors&#146; and officers&#146; insurance policy
pursuant to which our directors and officers are insured against liability for actions taken in their capacities as directors and officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and
these indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or control persons, in the opinion of the SEC, such indemnification is against public policy, as expressed in the Securities Act and is
therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This section discusses the material components of the executive compensation program for our executive officers who are named
in the &#147;2019 Summary Compensation Table&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This discussion may contain forward-looking statements that are
based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ materially from the currently planned
programs summarized in this discussion. As an &#147;emerging growth company&#148; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure
requirements applicable to emerging growth companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2019 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information concerning the compensation of our named executive officers for the applicable years
shown. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name&nbsp;and&nbsp;Principal&nbsp;Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive&nbsp;
Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Love, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,841,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,388,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">517,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanjay Keswani, M.B.B.S., F.R.C.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,244,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,251</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,620,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President and Chief Medical
Officer</I><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP><I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Lew<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,036,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,308,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President and Chief <BR>Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lesley Stolz<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">973,637</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,452</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,317,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Executive Vice President and Chief Business Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Amounts reflect the full grant-date fair value of option awards granted during 2019 computed in accordance
with ASC Topic 718, rather than the amounts paid to or realized by the named individual. In accordance with ASC Topic 718, no amount for Dr.&nbsp;Keswani&#146;s performance-based option has been included because the satisfaction of the required
performance condition was not considered probable as of the grant date. Assuming full attainment of the performance condition, the grant date fair value of Dr.&nbsp;Keswani&#146;s performance-based option would have been $311,046. See Note 9 of the
audited financial statements included in this prospectus for the assumptions used in calculating these amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Amounts represent the annual performance-based cash bonuses earned by our named executive officers based on
the achievement of certain corporate performance objectives during 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Amounts represent relocation reimbursements made to Dr.&nbsp;Keswani in connection with the commencement of
his employment with us, including moving expenses and closing costs on the sale of his home in Massachusetts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Keswani commenced employment effective June&nbsp;17, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Ms.&nbsp;Lew commenced employment effective June&nbsp;3, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Ms. Stolz commenced employment effective May&nbsp;6, 2019 and terminated on October&nbsp;11, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Represents the new hire option award granted to Ms.&nbsp;Stolz, which was subsequently forfeited in its
entirety upon Ms.&nbsp;Stolz&#146; termination in October 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Represents severance benefits of (i)&nbsp;a cash payment of $175,000 and (ii)&nbsp;six months of continued
healthcare premiums. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to the Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Salaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
named executive officers each receive a base salary to compensate them for services rendered to our company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the
executive&#146;s skill set, experience, role and responsibilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For fiscal year 2019, Mr. Love&#146;s annual base salary was $397,762, a
merit increase of 3.5% over his fiscal 2018 annual base salary. Dr. Keswani&#146;s and Ms. Lew&#146;s annual base salaries for 2019 were $380,000 and $350,000, respectively, each of which were negotiated in connection with the commencement of their
employment with the company during 2019. In December 2019, our board of directors approved increasing the base salaries of our named executive officers. Subject to the consummation of this offering, the annual base salaries for Mr. Love, Dr. Keswani
and Ms. Lew will be $502,300, $407,800 and $371,900, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Bonuses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain an annual performance-based cash bonus program in which each of our named executive officers participated in 2019.
Each named executive officer&#146;s target bonus is expressed as a percentage of base salary which can be achieved by meeting certain performance goals discussed below at target level. The 2019 annual bonus for Mr. Love was targeted at 40% of his
base salary, which was unchanged from his 2018 level. The 2019 annual bonuses for Dr. Keswani and Ms. Lew were targeted at 35% of their respective base salaries and were negotiated in connection with the commencement of their employment with the
company during 2019. Dr. Keswani&#146;s and Ms. Lew&#146;s 2019 annual bonuses will be prorated to reflect the length of their employment during 2019. In December 2019, in connection with this offering, our board of directors approved increasing the
target bonuses of our named executive officers as follows for fiscal 2020, subject to the consummation of this offering: Mr. Love: 50%; Dr. Keswani: 40%; and Ms. Lew: 40%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For 2019, our named executive officers are eligible to earn annual cash bonuses based on the achievement of certain corporate
objectives approved by the compensation committee and the board of directors. The goals under our 2019 bonus program were set with respect to research and development activities and corporate activities. Full achievement of all goals could result in
up to 120% of target. In the case of our named executive officers other than our Chief Executive Officer, annual bonuses were also based on individual achievement, with corporate achievement weighted 80% and individual achievement weighted 20%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2020, our board of directors reviewed and approved overall achievement of our 2019 corporate goals at 95% of target.
Based on this determination and the determination of individual achievement of 100% of target for each of Dr. Keswani and Ms. Lew, the board of directors approved the 2019 annual bonuses set forth above in the Summary Compensation Table in the
column titled &#147;Non-Equity Incentive Plan Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted stock options to our employees, including our named executive officers, in order to attract and retain them, as
well as to align their interests with the interests of our stockholders. In order to provide a long-term incentive, these stock options generally vest over four years subject to continued service to the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2019, we granted to Mr. Love an option to purchase 537,844 shares of our common stock, which vests as to 1/48th of
the shares subject to the option on each monthly anniversary of December 12, 2018, subject to continued service. In May 2019, in connection with her commencement of employment with us, we granted to Ms. Stolz an option to purchase 155,793 shares of
common stock, which was subsequently forfeited in its entirety upon her termination in October 2019. In June 2019, in connection with their commencement of employment with us, we granted to Dr. Keswani an option to purchase 186,951 shares of common
stock and Ms. Lew an option to purchase 155,793 shares of common stock, each of which vests as to 25% of the shares subject to the option on the first anniversary of the applicable named executive officer&#146;s employment commencement date, and as
to 1/36th of the remaining shares subject to the option on each monthly anniversary thereafter, subject to continued service. We also granted to Dr.&nbsp;Keswani a performance-based option to purchase 46,737 shares of common stock that vests in full
upon the successful completion of a development milestone approved by our Chief Executive Officer and board of directors, subject to continued service through such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, we granted to Mr. Love an option to purchase 414,301 shares of
our common stock and to each of Dr.&nbsp;Keswani and Ms.&nbsp;Lew an option to purchase 68,104 shares of our common stock. Each option vests as to 1/48th of the shares subject to the option on each monthly anniversary of the grant date, subject to
continued service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we have adopted the 2020 Incentive Award Plan, referred to below as
the 2020 Plan, in order to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of our company and certain of its affiliates and to enable us to obtain and retain
services of these individuals, which is essential to our long-term success. The 2020 Plan will be effective on the date immediately prior to the date the registration statement relating to this offering becomes effective. For additional information
about the 2020 Plan, please see the section titled &#147;Equity Incentive Plans&#148; below<I>.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Release Agreement with Ms. Stolz </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lesley Stolz, our former Executive Vice President and Chief Business Officer, commenced employment effective May 6, 2019 and
terminated on October 11, 2019. Ms. Stolz&#146; 2019 base salary ($350,000), target bonus (35% of base salary) and option to purchase common stock were negotiated in connection with the commencement of her employment with us. Ms. Stolz was not
eligible to receive an annual bonus for 2019 as she terminated employment in October 2019. Ms. Stolz&#146;s option to purchase 155,793 shares of common stock was forfeited in its entirety upon her termination. In connection with her termination of
employment in October 2019, we entered into a release agreement with Ms. Stolz, pursuant to which she was entitled to receive, in exchange for a release of all potential claims against us, a lump sum payment equal to six&nbsp;months of her
then-current base salary and payment of premiums for continued health benefits for up to six&nbsp;months following the date of her termination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other
Elements of Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retirement Savings and Health and Welfare Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain
eligibility requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees. Currently, we do not match contributions made by participants in the 401(k) plan. We believe that
providing a vehicle for <FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings through our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our
named executive officers, in accordance with our compensation policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our full-time employees, including our
named executive officers, are eligible to participate in our health and welfare plans, including: medical, dental and vision benefits; basic and supplemental life and accidental death and dismemberment insurance; and medical and dependent care
flexible spending accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Perquisites and Other Personal Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the commencement of his employment with us in June 2019, we reimbursed Dr.&nbsp;Keswani for certain
relocation expenses, including moving expenses and closing costs on his home in Massachusetts pursuant to his offer letter, which provided for up to $100,000 for expenses incurred to relocate to the San Francisco Bay Area. Such amounts are subject
to repayment (i) in full, in the event Dr. Keswani resigns prior to the first anniversary of his employment commencement date or (ii) with respect to 50% in the event Dr.&nbsp;Keswani resigns between the first and second anniversaries of his
employment commencement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the number of shares of common stock underlying outstanding option awards for each named
executive officer as of December&nbsp;31, 2019 other than Ms. Stolz. Ms. Stolz did not hold </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
any outstanding stock options as of December 31, 2019 as her stock option was forfeited in connection with her termination in October 2019. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name&nbsp;and&nbsp;Principal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting</B><br><B>Commencement</B><br><B>Date<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>(Exercisable)</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>(Unexercisable)</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity</B><br><B>Incentive</B><br><B>Plan</B><br><B>Awards:</B><br><B>Number&nbsp;
of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Unearned</B><br><B>Options</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Douglas Love, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/12/2014</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman"><I>President and <BR>Chief&nbsp;Executive&nbsp;Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8/11/2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6/8/2016</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94,849</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13,550</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1.86</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6/8/2026</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/11/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/11/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/11/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/12/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Sanjay Keswani, M.B.B.S., F.R.C.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/21/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/17/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/21/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman"><I>Executive Vice President and Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6/21/2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">46,737</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7.49</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6/21/2029</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jennifer Lew</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/21/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/3/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">7.49<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/21/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman"><I>Executive Vice President and Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Except as otherwise indicated, 1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares
subject to each option vest on each monthly anniversary of the vesting commencement date, subject to continued service with us. All of the named executive officers&#146; equity awards will be subject to certain acceleration in connection with a
change in control in accordance with the terms of their new employment agreements, which will become effective as of immediately prior to the effectiveness of the registration statement relating to this offering, as described below, which will
generally supersede the terms of their offer letters. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Pursuant to the terms of the named executive officer&#146;s offer letter, the shares subject to the option
will vest in full in the event of a termination of the executive&#146;s employment by us without &#147;cause&#148; or the executive&#146;s resignation for &#147;good reason&#148; (each, as defined in the offer letter), in each case, that occurs
within 12 months following a &#147;change of control&#148; of us (as defined in the offer letter). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">25% of the shares subject to the option vest on the <FONT STYLE="white-space:nowrap">12-month</FONT>
anniversary of the vesting commencement date and 1/36<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the remaining shares subject to the option vest on each monthly anniversary thereafter, subject to continued service with us.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">100% of the shares subject to the option vest upon the successful completion of a development milestone,
subject to continued service with us. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Offer Letters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As
of March 31, 2020, we were party to offer letters with each of our named executive officers. In connection with the offering, we have entered into new employment agreements with each of our named executive officers, which will become effective as of
immediately prior to the effectiveness of the registration statement relating to this offering and generally supersede the terms of such offer letters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Mr.</I><I></I><I>&nbsp;Love</I>. We entered into an offer letter with Mr.&nbsp;Love in December 2014 setting forth the
terms of his employment as our President and Chief Executive Officer, including his initial base salary, target bonus, initial stock option grants and benefit plan participation eligibility. Mr.&nbsp;Love&#146;s offer letter provides that in the
event that Mr.&nbsp;Love&#146;s employment is terminated by us without Cause (as defined in the offer letter), then subject to his execution of a release of claims in favor of us, Mr.&nbsp;Love will receive severance payments equal to nine months of
his then-current base salary. In addition, in the event that Mr.&nbsp;Love is terminated by us without Cause or resigns for Good Reason (as defined in the offer letter), in each case, within 12 months following a &#147;change of control&#148; (as
defined in the offer letter), his initial option grants will vest in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Dr. Keswani and Ms. Lew</I>. We entered
into offer letters with Dr. Keswani and Ms. Lew in connection with their commencement of employment with us in June 2019, which provide for initial base salary, target bonus and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
initial stock option grants as described above. Each of their offer letters also provides that in the event that the named executive officer&#146;s employment is terminated by us without Cause
(as defined in the offer letter) any time other than during the period commencing three months prior to and ending 12 months following a change in control, then subject to the execution of a release of claims in favor of us, the named executive
officer will receive severance payments equal to nine months of his or her then-current base salary and nine months of premium reimbursement for continuing healthcare coverage under COBRA. In addition, in the event that the named executive officer
is terminated by us without Cause or resigns for Good Reason (as defined in the offer letter), in each case, during the period commencing three months prior to and ending 12 months following a change in control, the named executive officer will
receive severance payments equal to 12 months of the executive&#146;s then-current base salary and the executive&#146;s target bonus, 12 months of premium reimbursement for continuing healthcare coverage under COBRA, and the executive&#146;s initial
time-based option will vest in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of our named executive officers&#146; offer letters: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Cause&#148; means (i)&nbsp;the executive&#146;s failure to perform the executive&#146;s assigned duties or
responsibilities as an officer of us (other than a failure resulting from the executive&#146;s Disability (as defined in the offer letter) after notice thereof from us describing the executive&#146;s failure to perform such duties or
responsibilities, (ii)&nbsp;the executive&#146;s engaging in any act of dishonesty, fraud or misrepresentation, (iii)&nbsp;the executive&#146;s violation of any federal or state law or regulation applicable to our business or our affiliates,
(iv)&nbsp;the executive&#146;s breach of any confidentiality agreement or invention assignment agreement between the executive and us (or any affiliate of us), or (v)&nbsp;the executive&#146;s commission of, or entering a plea of nolo contendere to,
any crime or committing any act of moral turpitude; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Good Reason&#148; for the executive to terminate the
executive&#146;s employment shall mean the occurrence of any of the following events without the executive&#146;s consent: (i)&nbsp;a material reduction in the executive&#146;s salary or benefits (excluding the substitution of substantially
equivalent compensation and benefits), other than as a result of a reduction in compensation affecting our employees, or our successor entity, generally; (ii)&nbsp;a material diminution in the executive&#146;s duties or responsibilities, provided
however, that, a mere change in title or reporting relationship alone shall not constitute &#147;Good Reason,&#148; and (iii)&nbsp;relocation of the executive&#146;s place of employment to a location more than 50 miles from our office location. If
any of the events set forth above shall occur, the executive shall give prompt written notice of such event to us, or our successor entity, upon becoming aware of such event, and if such event is not cured within thirty (30)&nbsp;days from such
notice the executive may exercise his or her rights to resign for Good Reason, provided that if the executive has not exercised such right within forty-five (45)&nbsp;days of the date of such notice the executive shall be deemed to have agreed to
the occurrence of such event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>New Employment Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we have entered into new employment agreements with each of our named executive officers,
which will become effective as of immediately prior to the effectiveness of the registration statement relating to this offering and supersede in their entirety their offer letters (other than with respect to the relocation expense provisions in
Dr.&nbsp;Keswani&#146;s offer letter). Each employment agreement sets forth the named executive officer&#146;s base salary and annual target bonus, as described above, and standard benefit plan participation. In addition, pursuant to the employment
agreements, in the event the executive is terminated without Cause or resigns for Good Reason (each, as defined in the employment agreements), in each case, other than during the period commencing three months prior to and ending 12&nbsp;months
following a change in control, the executive will receive (i)&nbsp;a lump sum cash payment equal to nine months of base salary, in the case of our executive vice presidents, or 12&nbsp;months of base salary, in the case of our CEO, and
(ii)&nbsp;payment or reimbursement of COBRA premiums for nine months, in the case of our executive vice presidents, or 12&nbsp;months, in the case of our CEO. In the event the executive is terminated without Cause or resigns for Good Reason, in each
case, during the period commencing three months prior to and ending 12 months following a change in control, the executive will receive (i) a lump sum cash payment equal to 12 months of base salary plus the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
executive&#146;s target annual bonus, in the case of our executive vice presidents, or 18 months of base salary plus 1.5 times the executive&#146;s target annual bonus, in the case of our CEO,
(ii) payment or reimbursement of COBRA premiums for 12 months, in the case of our executive vice presidents, or 18 months, in the case of our CEO, and (iii) and full acceleration of all unvested equity awards. The foregoing severance payments and
benefits are subject to the executive&#146;s execution of a release of claims in favor of us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The definitions of Cause
and Good Reason under our named executive officers&#146; new employment agreements are substantially the same as under their offer letters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity
Compensation Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following summarizes the material terms of the 2020 Plan, in which our named executive officers
will be eligible to participate following the consummation of this offering, our 2011 Equity Incentive Plan, referred to as the 2011 Plan, under which we have previously made periodic grants of equity and equity-based awards to our named executive
officers and other key employees, and the Employee Stock Purchase Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Incentive Award Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted the 2020 Plan, which will be effective on the date immediately prior to the date our registration statement
relating to this offering becomes effective. The principal purpose of the 2020 Plan is to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance
bonus awards. The material terms of the 2020 Plan are summarized below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Share Reserve</I>. Under the 2020 Plan,
3,375,868 shares of our common stock will be initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, or SARs, restricted stock awards, restricted stock unit
awards, performance bonus awards, performance stock unit awards, dividend equivalents or other stock or cash based awards. The number of shares initially reserved for issuance or transfer pursuant to awards under the 2020 Plan will be increased by
(i)&nbsp;the number of shares represented by awards outstanding under our 2011 Plan, or 2011 Plan Awards, that become available for issuance under the counting provisions described below following the effective date and (ii)&nbsp;an annual increase
on the first day of each fiscal year beginning in 2021 and ending in 2030, equal to the lesser of (A) 4% of the shares of stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (B)&nbsp;such smaller
number of shares of stock as determined by our board of directors; provided, however, that no more than 20,255,212 shares of stock may be issued upon the exercise of incentive stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following counting provisions will be in effect for the share reserve under the 2020 Plan: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that an award (including a 2011 Plan Award) expires, lapses or is terminated, converted into an
award in respect of shares of another entity in connection with a <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar event, exchanged for cash, surrendered, repurchased or canceled, in any case, in a manner that results in the Company
acquiring the underlying shares at a price not greater than the price paid by the participant or not issuing the underlying shares, such unused shares subject to the award at such time will be available for future grants under the 2020 Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent shares are tendered or withheld to satisfy the grant, exercise price or tax withholding
obligation with respect to any award under the 2020 Plan or 2011 Plan Award, such tendered or withheld shares will be available for future grants under the 2020 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent shares subject to stock appreciation rights are not issued in connection with the stock
settlement of SARs on exercise thereof, such shares will be available for future grants under the 2020 Plan; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment of dividend equivalents in cash in conjunction with any outstanding awards or 2011 Plan Awards
will not be counted against the shares available for issuance under the 2020 Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares issued in assumption of, or in substitution for, any outstanding awards of any entity acquired in any
form of combination by us or any of our subsidiaries will not be counted against the shares available for issuance under the 2020 Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the sum of the grant date fair value of all equity-based awards and the maximum that may become payable pursuant
to a cash-based award to any individual for services as a non-employee director during any calendar year may not exceed $1,000,000 for the individual&#146;s first year of service and $700,000 for each year thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration</I>. The compensation committee of our board of directors is expected to administer the 2020 Plan unless our
board of directors assumes authority for administration. The board of directors may delegate its powers to a committee, which, to the extent required to comply with Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> is intended to be comprised of <FONT
STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act. The 2020 Plan provides that the board or compensation committee may delegate its
authority to grant awards other than to individuals subject to Section&nbsp;16 of the Exchange Act or officers or directors to whom authority to grant awards has been delegated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the terms and conditions of the 2020 Plan, the administrator has the authority to select the persons to whom awards
are to be made, to determine the number of shares to be subject to awards and the terms and conditions of awards, and to make all other determinations and to take all other actions necessary or advisable for the administration of the 2020 Plan. The
administrator is also authorized to adopt, amend or rescind rules relating to administration of the 2020 Plan. Our board of directors may at any time remove the compensation committee as the administrator and revest in itself the authority to
administer the 2020 Plan. The full board of directors will administer the 2020 Plan with respect to awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility</I>. Awards under the 2020 Plan may be granted to individuals who are then our officers, employees or
consultants or are the officers, employees or consultants of certain of our subsidiaries. Such awards also may be granted to our directors. However, only employees of our company or certain of our subsidiaries may be granted incentive stock options,
or ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Awards</I>. The 2020 Plan provides that the administrator may grant or issue stock options, SARs, restricted
stock, restricted stock units, performance bonus awards, performance stock units, other stock- or cash-based awards and dividend equivalents, or any combination thereof. Each award will be set forth in a separate agreement with the person receiving
the award and will indicate the type, terms and conditions of the award. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Nonstatutory Stock Options</I>, or NSOs, will provide for the right to purchase shares of our common stock
at a specified price which may not be less than fair market value on the date of grant, and usually will become exercisable (at the discretion of the administrator) in one or more installments after the grant date, subject to the participant&#146;s
continued employment or service with us and/or subject to the satisfaction of corporate performance targets and individual performance targets established by the administrator. NSOs may be granted for any term specified by the administrator that
does not exceed ten years. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Incentive Stock Options</I>, or ISOs, will be designed in a manner intended to comply with the provisions
of Section&nbsp;422 of the Code and will be subject to specified restrictions contained in the Code. Among such restrictions, ISOs must have an exercise price of not less than the fair market value of a share of common stock on the date of grant,
may only be granted to employees, and must not be exercisable after a period of ten years measured from the date of grant. In the case of an ISO granted to an individual who owns (or is deemed to own) at least 10% of the total combined voting power
of all classes of our capital stock, the 2020 Plan provides that the exercise price must be at least 110% of the fair market value of a share of common stock on the date of grant and the ISO must not be exercisable after a period of five years
measured from the date of grant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted Stock</I> may be granted to any eligible individual and made subject to such restrictions as may
be determined by the administrator. Restricted stock typically may be forfeited for no consideration or repurchased by us at the original purchase price if the conditions or restrictions on vesting are not met. In general, restricted stock may not
be sold or otherwise transferred until restrictions are removed or expire. Purchasers of restricted stock, unlike recipients of options, will have voting rights and will have the right to receive dividends, if any, prior to the time when the
restrictions lapse; however, extraordinary dividends will generally be placed in escrow, and will not be released until restrictions are removed or expire. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted Stock Units</I> may be awarded to any eligible individual, typically without payment of
consideration, but subject to vesting conditions based on continued employment or service or on performance criteria established by the administrator. Like restricted stock, restricted stock units may not be sold, or otherwise transferred or
hypothecated, until vesting conditions are removed or expire. Unlike restricted stock, stock underlying restricted stock units will not be issued until the restricted stock units have vested, and recipients of restricted stock units generally will
have no voting or dividend rights prior to the time when vesting conditions are satisfied. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock Appreciation Rights</I>, or SARs, may be granted in connection with stock options or other awards, or
separately. SARs granted in connection with stock options or other awards typically will provide for payments to the holder based upon increases in the price of our common stock over a set exercise price. The exercise price of any SAR granted under
the 2020 Plan must be at least 100% of the fair market value of a share of our common stock on the date of grant. SARs under the 2020 Plan will be settled in cash or shares of our common stock, or in a combination of both, at the election of the
administrator. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Performance Bonus Awards and Performance Stock Units</I> are denominated in cash or shares/unit
equivalents, respectively, and may be linked to one or more performance or other criteria as determined by the administrator. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Stock- or Cash-Based Awards</I> are awards of cash, fully vested shares of our common stock and other
awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock- or cash-based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as
standalone payments and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise payable to any individual who is eligible to receive awards. The administrator will determine the terms and conditions of other stock- or
cash-based awards, which may include vesting conditions based on continued service, performance and/or other conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend Equivalents</I> represent the right to receive the equivalent value of dividends paid on shares of
our common stock and may be granted alone or in tandem with awards other than stock options or SARs. Dividend equivalents are converted to cash or shares by such formula and such time as determined by the administrator. In addition, dividend
equivalents with respect to an awards subject to vesting will either (i)&nbsp;to the extent permitted by applicable law, not be paid or credited or (ii)&nbsp;be accumulated and subject to vesting to the same extent as the related award.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any award may be granted as a performance award, meaning that the award will be subject to vesting
and/or payment based on the attainment of specified performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Change in Control</I>. In the event of a change
in control, unless the administrator elects to terminate an award in exchange for cash, rights or other property, or cause an award to accelerate in full prior to the change in control, such award will continue in effect or be assumed or substituted
by the acquirer, provided that any performance-based portion of the award will be subject to the terms and conditions of the applicable award agreement. In the event the acquirer refuses to assume or replace awards granted, prior to the consummation
of such transaction, awards issued under the 2020 Plan (other than any portion subject to performance-based vesting) will be subject to accelerated vesting such that 100% of such awards will become vested and exercisable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or payable, as applicable. The administrator may also make appropriate adjustments to awards under the 2020 Plan and is authorized to provide for the acceleration,
<FONT STYLE="white-space:nowrap">cash-out,</FONT> termination, assumption, substitution or conversion of such awards in the event of a change in control or certain other unusual or nonrecurring events or transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Adjustments of Awards</I>. The administrator has broad discretion to take action under the 2020 Plan, as well as make
adjustments to the terms and conditions of existing and future awards, to prevent the dilution or enlargement of intended benefits and facilitate necessary or desirable changes in the event of certain transactions and events affecting our common
stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders
known as &#147;equity restructurings,&#148; the administrator will make equitable adjustments to the 2020 Plan and outstanding awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Amendment and Termination</I>. The administrator may terminate, amend or modify the 2020 Plan at any time and from time to
time. However, we must generally obtain stockholder approval to the extent required by applicable law, rule or regulation (including any applicable stock exchange rule), and generally no amendment may materially and adversely affect any outstanding
award without the affected participant&#146;s consent. Notwithstanding the foregoing, an option may be amended to reduce the per share exercise price below the per share exercise price of such option on the grant date and options may be granted in
exchange for, or in connection with, the cancellation or surrender of options having a higher per share exercise price without receiving additional stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No incentive stock options may be granted pursuant to the 2020 Plan after the tenth anniversary of the effective date of the
2020 Plan, and no additional annual share increases to the 2020 Plan&#146;s aggregate share limit will occur from and after such anniversary. Any award that is outstanding on the termination date of the 2020 Plan will remain in force according to
the terms of the 2020 Plan and the applicable award agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2011 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors adopted, and our stockholders approved, the 2011 Plan effective as of July&nbsp;31, 2011. The 2011 Plan
was subsequently amended on multiple occasions to increase the number of shares issuable thereunder. The 2011 Plan provides for the grant of ISOs, NSOs, SARs, restricted stock, and restricted stock units. As of March 31, 2020, options to purchase
2,136,390 shares of our common stock at a weighted-average exercise price per share of $5.45 remained outstanding under the 2011 Plan. Following this offering and in connection with the effectiveness of our 2020 Plan, no further awards will be
granted under the 2011 Plan. However, all outstanding awards will continue to be governed by their existing terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration</I>. Our board of directors or a committee thereof appointed by our board of directors has the authority to
administer the 2011 Plan and the awards granted under it. The administrator&#146;s authority includes the authority to select the service providers to whom awards will be granted under the 2011 Plan, the number of shares to be subject to those
awards under the 2011 Plan, and the terms and conditions of the awards granted. The administrator also has the authority to institute and determine the terms and conditions of a program under which all outstanding awards are surrendered or cancelled
in exchange for awards of the same or a different type or in exchange for cash, participants would have the opportunity to transfer any outstanding awards to a financial institution or other person selected by the administrator, or the exercise
price of the award is reduced or increased. In addition, the administrator has the authority to construe and interpret the 2011 Plan and to adopt rules for the administration, interpretation and application of the 2011 Plan that are consistent with
the terms of the 2011 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Awards</I>. The 2011 Plan provides that the administrator may grant or
issue options, including ISOs and NSOs, SARs, restricted stock and restricted stock units to employees, consultants and directors; provided that only employees may be granted ISOs. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock Options</I>. The 2011 Plan provides for the grant of ISOs or NSOs. ISOs may be granted only to
employees. NSOs may be granted to employees, directors or consultants. The exercise price of ISOs granted to employees who at the time of grant own stock representing more than 10% of the voting power of all classes of our common stock may not be
less than 110% of the fair market value per share of our common stock on the date of grant, and the exercise price of ISOs granted to any other employees may not be less than 100% of the fair market value per share of our common stock on the date of
grant. The exercise price of NSOs to employees, directors or consultants may not be less than 100% of the fair market value per share of our common stock on the date of grant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock Appreciation Rights</I>. The 2011 Plan provides for the grant of SARs. Each SAR will be governed by a
SAR agreement. The exercise price of SARs may not be less than 100% of the fair market value per share of our common stock on the date of grant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted Stock Awards</I>. The 2011 Plan provides for the grant of restricted stock awards. Each
restricted stock award will be governed by a restricted stock award agreement, which will detail the restrictions on transferability, risk of forfeiture and other restrictions the administrator approves. In general, restricted stock may not be sold,
transferred, pledged, hypothecated, margined or otherwise encumbered until restrictions are removed or expire. Holders of restricted stock, unlike recipients of other equity awards, will have voting rights and will have the right to receive
dividends, if any, prior to the time when the restrictions lapse. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted Stock Units</I>. The 2011 Plan provides that we may issue restricted stock unit awards which may
be settled in either cash of common stock. Each restricted stock unit award will be governed by a restricted stock unit award agreement that will set forth any vesting conditions based on continued employment or service or on performance criteria
established by the administrator. Unlike restricted stock, stock underlying restricted stock units will not be issued until the restricted stock units have vested, and recipients of restricted stock units generally will have no rights as a
stockholder prior to the time when vesting conditions are satisfied. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Adjustments of Awards</I>. In
the event of any dividend or other distribution, recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">spin-off,</FONT>
combination, repurchase, exchange of shares or other change in the corporate structure of the company affecting shares of common stock, the administrator will make adjustments to the number and class of shares available for issuance under the 2011
Plan and the number, class and price of shares subject to outstanding awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Change in Control</I>. In the event of a
merger or change in control, the administrator has discretion to determine the treatment of each outstanding award, and may provide that the awards will be assumed or substituted, that the awards will terminate or accelerate in full immediately
prior to the change in control, or that the awards will terminate in exchange for cash or other property, or any combination of the foregoing. The administrator is not obligated to treat all outstanding awards in the same manner. In addition, in the
event of a change in control where the acquirer does not assume or replace awards, prior to the consummation of such transaction, awards issued under the 2011 Plan will accelerate in full and any awards subject to performance-based vesting will be
deemed achieved at 100% of target levels and all other terms and conditions met. Awards will be considered assumed for this purpose if, following the merger or change in control, the award represents the right to purchase or receive the per share
consideration received in the merger or change in control by holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Amendment and Termination</I>.
Our board of directors may amend or terminate the 2011 Plan at any time, but no amendment will impair the rights of a holder of an outstanding award without the holder&#146;s consent. An amendment of the 2011 Plan will be subject to the approval of
our stockholders, where such approval by our stockholders of an amendment is required by applicable law. Following this offering and in connection with the effectiveness of our 2020 Plan, no further awards will be granted under the 2011 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted the Employee Stock Purchase Plan, which we refer to as our ESPP, which will be effective on the date
immediately prior to the date the registration statement relating to this offering becomes effective. The ESPP is designed to allow our eligible employees to purchase shares of our common stock, at periodic intervals, with their accumulated payroll
deductions. The ESPP is intended to qualify under Section&nbsp;423 of the Code. The material terms of the ESPP are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration</I>. Subject to the terms and conditions of the ESPP, our compensation committee will administer the ESPP.
Our compensation committee can delegate administrative tasks under the ESPP to the services of an agent and/or employees to assist in the administration of the ESPP. The administrator will have the discretionary authority to administer and interpret
the ESPP. Interpretations and constructions of the administrator of any provision of the ESPP or of any rights thereunder will be conclusive and binding on all persons. We will bear all expenses and liabilities incurred by the ESPP administrator.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Share Reserve</I>. The maximum number of our shares of our common stock which will be authorized for sale under
the ESPP is equal to the sum of (i) 337,586 shares of common stock and (ii)&nbsp;an annual increase on the first day of each year beginning in 2021 and ending in 2030, equal to the lesser of (A) 1% of the shares of common stock outstanding (on an as
converted basis) on the last day of the immediately preceding fiscal year and (B)&nbsp;such number of shares of common stock as determined by our board of directors; provided, however, no more than 3,713,455 shares of our common stock may be issued
under the ESPP. The shares reserved for issuance under the ESPP may be authorized but unissued shares or reacquired shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility</I>. Employees eligible to participate in the ESPP for a given offering period generally include employees who
are employed by us or one of our subsidiaries on the first day of the offering period, or the enrollment date. Our employees (and, if applicable, any employees of our subsidiaries) who customarily work less than five months in a calendar year or are
customarily scheduled to work less than 20 hours per week will not be eligible to participate in the ESPP. Finally, an employee who owns (or is deemed to own through attribution) 5% or more of the combined voting power or value of all our classes of
stock or of one of our subsidiaries will not be allowed to participate in the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Participation</I>. Employees will
enroll under the ESPP by completing a payroll deduction form permitting the deduction from their compensation of at least 1% of their compensation but not more than 15% of their compensation. Such payroll deductions may be expressed as either a
whole number percentage or a fixed dollar amount, and the accumulated deductions will be applied to the purchase of shares on each purchase date. However, a participant may not purchase more than 50,000 shares in each offering period and may not
accrue the right to purchase shares of common stock at a rate that exceeds $25,000 in fair market value of shares of our common stock (determined at the time the option is granted) for each calendar year the option is outstanding (as determined in
accordance with Section&nbsp;423 of the Code). The ESPP administrator has the authority to change these limitations for any subsequent offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Offering</I>. Under the ESPP, participants are offered the option to purchase shares of our common stock at a discount
during a series of successive offering periods, the duration and timing of which will be determined by the ESPP administrator. However, in no event may an offering period be longer than 27 months in length. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The option purchase price will be the lower of 85% of the closing trading price per share of our common stock on the first
trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless a participant has previously canceled his or her participation in the ESPP before the purchase date, the participant
will be deemed to have exercised his or her option in full as of each purchase date. Upon exercise, the participant will purchase the number of whole shares that his or her accumulated payroll deductions will buy at the option purchase price,
subject to the participation limitations listed above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A participant may cancel his or her payroll deduction authorization at any
time prior to the end of the offering period. Upon cancellation, the participant will have the option to either (i)&nbsp;receive a refund of the participant&#146;s account balance in cash without interest or (ii)&nbsp;exercise the participant&#146;s
option for the current offering period for the maximum number of shares of common stock on the applicable purchase date, with the remaining account balance refunded in cash without interest. Following at least one payroll deduction, a participant
may also decrease (but not increase) his or her payroll deduction authorization once during any offering period. If a participant wants to increase or decrease the rate of payroll withholding, he or she may do so effective for the next offering
period by submitting a new form before the offering period for which such change is to be effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A participant may
not assign, transfer, pledge or otherwise dispose of (other than by will or the laws of descent and distribution) payroll deductions credited to a participant&#146;s account or any rights to exercise an option or to receive shares of our common
stock under the ESPP, and during a participant&#146;s lifetime, options in the ESPP shall be exercisable only by such participant. Any such attempt at assignment, transfer, pledge or other disposition will not be given effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Adjustments upon Changes in Recapitalization, Dissolution, Liquidation, Merger or Asset Sale</I>. In the event of any
increase or decrease in the number of issued shares of our common stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the common stock, or any other increase or decrease in the number of shares
of common stock effected without receipt of consideration by us, we will proportionately adjust the aggregate number of shares of our common stock offered under the ESPP, the number and price of shares which any participant has elected to purchase
under the ESPP and the maximum number of shares which a participant may elect to purchase in any single offering period. If there is a proposal to dissolve or liquidate us, then the ESPP will terminate immediately prior to the consummation of such
proposed dissolution or liquidation, and any offering period then in progress will be shortened by setting a new purchase date to take place before the date of our dissolution or liquidation. We will notify each participant of such change in writing
at least 10 business days prior to the new exercise date. If we undergo a merger with or into another corporation or sell all or substantially all of our assets, each outstanding option will be assumed or an equivalent option substituted by the
successor corporation or the parent or subsidiary of the successor corporation. If the successor corporation refuses to assume the outstanding options or substitute equivalent options, then any offering period then in progress will be shortened by
setting a new purchase date to take place before the date of our proposed sale or merger. We will notify each participant of such change in writing at least 10 business days prior to the new exercise date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Amendment and Termination</I>. Our board of directors may amend, suspend or terminate the ESPP at any time. However, the
board of directors may not amend the ESPP without obtaining stockholder approval within 12 months before or after such amendment to the extent required by applicable laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
have not historically maintained a formal <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program. However, we have granted stock options to certain of our directors from time to time, and we provide reimbursement to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable expenses incurred in attending meetings of our board of directors and committees of our board of directors. In January 2019, we granted to Messrs. Wiggans and Young
options to purchase 6,808 and 21,788 shares of common stock, respectively, which vest as to 1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares subject to the option on each monthly anniversary of December 12, 2018, subject to
continued service. Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received no other compensation from us during the year ended December&nbsp;31, 2019. Mr.&nbsp;Love receives no additional compensation for his service as director.
His compensation as our President and Chief Executive Officer is set forth in the Summary Compensation Table above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Director Compensation Table </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or&nbsp;Paid&nbsp;in&nbsp;Cash</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other<BR>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emmett Cunningham, M.D., Ph.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol Gallagher, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Campbell Murray, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Muneer Satter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ricky Sun, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas G. Wiggans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Young</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019, Mr.&nbsp;Wiggans held options to purchase an aggregate of 22,665
shares of our common stock, and Mr.&nbsp;Young held options to purchase an aggregate of 72,532 shares of our common stock. No other <FONT STYLE="white-space:nowrap">non-employee</FONT> director held any options to purchase shares of our common stock
or any other equity award as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, we granted to each of Messrs. Wiggans and Young an
option to purchase 9,080 shares of our common stock, which vests on the first anniversary of the grant date, subject to the director&#146;s continued service on such vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We approved a compensation program for our non-employee directors, or the Director Compensation Program, to be effective in
connection with the consummation of this offering. Pursuant to the Director Compensation Program, our non-employee directors will receive cash compensation as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each non-employee director will receive an annual cash retainer in the amount of $35,000 per year.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The non-executive chair will receive an additional annual cash retainer in the amount of $30,000 per year.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The chairperson of the audit committee will receive additional annual cash compensation in the amount of
$15,000 per year for such chairperson&#146;s service on the audit committee. Each non-chairperson member of the audit committee will receive additional annual cash compensation in the amount of $7,500 per year for such member&#146;s service on the
audit committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The chairperson of the compensation committee will receive additional annual cash compensation in the amount
of $10,000 per year for such chairperson&#146;s service on the compensation committee. Each non-chairperson member of the compensation committee will receive additional annual cash compensation in the amount of $5,000 per year for such member&#146;s
service on the compensation committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The chairperson of the nominating and corporate governance committee will receive additional annual cash
compensation in the amount of $8,000 per year for such chairperson&#146;s service on the nominating and corporate governance committee. Each non-chairperson member of the nominating and corporate governance committee will receive additional annual
cash compensation in the amount of $4,000 per year for such member&#146;s service on the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Director Compensation Program, each non-employee director will automatically be granted an option to purchase 20,000
shares of our common stock upon the director&#146;s initial appointment or election to our board of directors, referred to as the Initial Grant, and an option to purchase 10,000 shares of our common stock automatically on the date of each annual
stockholder&#146;s meeting thereafter, referred to as the Annual Grant. The Initial Grant will vest in substantially equal monthly installments for three years from the date of grant, subject to continued service through each applicable vesting
date. The Annual Grant will vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder&#146;s meeting to the extent unvested as of such date, subject to continued service through each applicable
vesting date. Each Initial Grant and Annual Grant will vest in full in the event of a change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following includes a summary of transactions since January&nbsp;1, 2016 and any currently proposed transactions to which
we were or are expected to be a participant in which (i)&nbsp;the amount involved exceeded or will exceed $120,000, and (ii)&nbsp;any of our directors, executive officers or holders of more than 5% of our capital stock, or any affiliate or member of
the immediate family of the foregoing persons, had or will have a direct or indirect material interest, other than compensation and other arrangements that are described under the section titled &#147;Executive and Director Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redeemable Convertible Preferred Stock Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B Redeemable Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2016, we entered into a Series B redeemable convertible preferred stock purchase agreement with various investors,
pursuant to which we issued an aggregate of 38,778,090 shares of Series&nbsp;B redeemable convertible preferred stock at $1.15 per share for gross proceeds of approximately $44.6&nbsp;million in two closings. The first closing occurred in June 2016,
at which time we issued 26,974,965 shares of our Series&nbsp;B redeemable convertible preferred stock for gross proceeds of approximately $31.0&nbsp;million. The second closing occurred in February 2018, at which time we issued an additional
11,803,125 shares of our Series&nbsp;B redeemable convertible preferred stock for gross proceeds of approximately $13.6&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below sets forth the number of shares of our Series&nbsp;B redeemable convertible preferred stock purchased by our
executive officers, directors, holders of more than 5% of our capital stock and their affiliated entities or immediate family members. Each share of Series B redeemable convertible preferred stock in the table below will convert into 0.1135074
shares of our common stock immediately prior to the completion of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name<SUP STYLE="font-size:85%; vertical-align:top">(1)
</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B<BR>Redeemable<BR>Convertible<BR>Preferred&nbsp;Stock</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Cash<BR>Purchase&nbsp;Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with New Enterprise
Associates<SUP STYLE="font-size:85%; vertical-align:top">(2) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,039,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,145,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novartis Bioventures Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(3) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,406,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,667,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clarus Lifesciences III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,370,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,626,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trusts and Other Entities affiliated with Muneer A. Satter<SUP
STYLE="font-size:85%; vertical-align:top">(5) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,016,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,619,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">For additional information regarding these stockholders and their equity holdings, see the section titled
&#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with New Enterprise Associates became beneficial owners of (in the aggregate) more than
5% of our outstanding capital stock upon the closing of the Series&nbsp;B redeemable convertible preferred stock financing. Dr.&nbsp;Carol Gallagher was designated to serve as a member of our board of directors by New Enterprise Associates 15, L.P.
Dr.&nbsp;Gallagher is a partner at New Enterprise Associates, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Novartis Bioventures Ltd. beneficially owned more than 5% of our outstanding capital stock at the time of the
Series&nbsp;B redeemable convertible preferred stock financing. Dr.&nbsp;Campbell Murray is currently, and was at the time of the Series&nbsp;B redeemable convertible preferred stock financing, a member of our board of directors. Dr.&nbsp;Murray was
designated to serve as a member of our board of directors by Novartis Bioventures Ltd. Dr.&nbsp;Murray is a Managing Director at Novartis Venture Fund, and, in such capacity, employed by a corporation that is an affiliate of Novartis Bioventures
Ltd. Dr.&nbsp;Murray is expected to resign from our board of directors prior to the effectiveness of the registration statement of which this prospectus is a part. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Clarus Lifesciences III, L.P. beneficially owned more than 5% of our outstanding capital stock at the time of
the Series B redeemable convertible preferred stock financing. Dr.&nbsp;Emmett Cunningham is currently, and was at the time of the Series B redeemable convertible preferred stock financing, a member of our board of directors. Dr.&nbsp;Cunningham was
designated to serve as a member of our board of directors by Clarus Lifesciences&nbsp;III, L.P. Dr.&nbsp;Cunningham is a Senior Managing Director of Blackstone Life Sciences, having joined as part of its acquisition of Clarus Ventures, LLC in
December 2018. Dr.&nbsp;Cunningham was a Managing Director at Clarus Ventures, LLC from January 2017 to November 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Trusts and other entities affiliated with Muneer A. Satter beneficially owned (in the aggregate) more than 5%
of our outstanding capital stock at the time of the Series B redeemable convertible preferred stock financing. Mr.&nbsp;Satter is currently, and was at the time of the Series B redeemable convertible preferred stock financing, a member of our board
of directors. Mr.&nbsp;Satter was designated to serve as a member of our board of directors by trusts and other entities affiliated with Mr.&nbsp;Satter. Mr.&nbsp;Satter is the founder and managing partner of Satter Medical Technology Partners, L.P.
and Chairperson of Satter Investment Management LLC. Mr.&nbsp;Satter also manages the Satter Foundation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series C Redeemable Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2018, we entered into a Series C redeemable convertible preferred stock purchase agreement with various investors,
pursuant to which we issued an aggregate of 55,555,546 shares of Series C redeemable convertible preferred stock at $1.35 per share for gross proceeds of approximately $75.0 million in two closings. The first closing occurred in December 2018, at
which time we issued 33,333,329 shares of our Series C redeemable convertible preferred stock for gross proceeds of approximately $45.0 million. The second closing occurred in August 2019, at which time we issued an additional 22,222,217 shares of
our Series C redeemable convertible preferred stock for gross proceeds of approximately $30.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below
sets forth the number of shares of our Series C redeemable convertible preferred stock purchased by our executive officers, directors, holders of more than 5% of our capital stock and their affiliated entities or immediate family members. Each share
of Series C redeemable convertible preferred stock in the table below will convert into 0.1135074 shares of our common stock immediately prior to the completion of this offering. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;C<BR>Redeemable<BR>Convertible<BR>Preferred&nbsp;Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Cash<BR>Purchase&nbsp;Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Bain Capital Life Sciences Investors, LLC<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,222,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clarus Lifesciences III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,148,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,299,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 15, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,925,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Satter Medical Technology Partners,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,537,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,474,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novartis Bioventures Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,444,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,407,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">For additional information regarding these stockholders and their equity holdings, see the section titled
&#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with Bain Capital Life Sciences Investors, LLC became beneficial owners of (in the
aggregate) more than 5% of our outstanding capital stock upon the closing of the Series C redeemable convertible preferred stock financing. Dr.&nbsp;Ricky Sun was designated to serve as a member of our board of directors by Bain Capital Life
Sciences Fund, L.P. Dr.&nbsp;Sun is a partner with Bain Capital Life Sciences, LP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Clarus Lifesciences III, L.P. beneficially owned more than 5% of our outstanding capital stock at the time of
the Series C redeemable convertible preferred stock financing. Dr.&nbsp;Emmett Cunningham is currently, and was at the time of the Series C redeemable convertible preferred stock financing, a member of our board of directors. Dr.&nbsp;Cunningham was
designated to serve as a member of our board of directors by Clarus Lifesciences III, L.P. Dr.&nbsp;Cunningham is a Senior Managing Director of Blackstone Life Sciences, having joined as part of its acquisition of Clarus Ventures, LLC in December
2018. Dr.&nbsp;Cunningham was a Managing Director at Clarus Ventures, LLC from January 2017 to November 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with New Enterprise Associates 15, L.P. beneficially owned (in the aggregate) more than
5% of our outstanding capital stock at the time of the Series C redeemable convertible preferred stock financing. Dr.&nbsp;Carol Gallagher is currently, and was at the time of the Series C redeemable convertible preferred stock financing, a member
of our board of directors. Dr.&nbsp;Gallagher was designated to serve as a member of our board of directors by New Enterprise Associates 15, L.P. Dr.&nbsp;Gallagher is a partner at New Enterprise Associates, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Trusts and other entities affiliated with Muneer A. Satter beneficially owned (in the aggregate) more than 5%
of our outstanding capital stock at the time of the Series C financing. Mr.&nbsp;Muneer Satter is currently, and was at the time of the Series C redeemable convertible preferred stock financing, a member of our board of directors. Mr.&nbsp;Satter
was designated to serve as a member of our board of directors by trusts and other entities affiliated with Mr. Satter. Mr.&nbsp;Satter is the founder and managing partner of Satter Medical Technology Partners, L.P. and Chairperson of Satter
Investment Management LLC. Mr.&nbsp;Satter also manages the Satter Foundation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Novartis Bioventures Ltd. beneficially owned more than 5% of our outstanding capital stock at the time of the
Series C redeemable convertible preferred stock financing. Dr.&nbsp;Campbell Murray is currently, and was at the time of the Series C redeemable convertible preferred stock financing, a member of our board of directors. Dr.&nbsp;Murray was
designated to serve as a member of our board of directors by Novartis Bioventures Ltd. Dr.&nbsp;Murray is a Managing Director at Novartis Venture Fund, and, in such capacity, employed by a corporation that is an affiliate of Novartis Bioventures
Ltd. Dr.&nbsp;Murray is expected to resign from our board of directors prior to the effectiveness of the registration statement of which this prospectus is a part. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series D Redeemable Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, we entered into a Series D redeemable convertible preferred stock purchase agreement with various investors,
pursuant to which we issued an aggregate of 71,719,859 shares of Series D redeemable convertible preferred stock at $1.4222 per share for gross proceeds of approximately $102.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below sets forth the number of shares of our Series D redeemable convertible preferred stock purchased by our
executive officers, directors, holders of more than 5% of our capital stock and their affiliated entities or immediate family members. Each share of Series D redeemable convertible preferred stock in the table below will convert into 0.1135074
shares of our common stock immediately prior to the completion of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D<BR>Redeemable<BR>Convertible<BR>Preferred&nbsp;Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Cash<BR>Purchase Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redmile Group, LLC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,062,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zone II Healthcare Holdings, LLC<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,195,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Bain Capital Life Sciences Investors, LLC<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,812,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,812,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Satter Medical Technology Partners, L.P.
<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,812,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clarus Lifesciences III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,109,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 15,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,039,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,899,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">For additional information regarding these stockholders and their equity holdings, see the section titled
&#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Redmile Biopharma Investments II, L.P. became a beneficial owner of more than 5% of our outstanding capital
stock upon the closing of the Series&nbsp;D redeemable convertible preferred stock financing. Redmile Group, LLC is the investment manager to Redmile Biopharma Investments II, L.P. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Zone II Healthcare Holdings, LLC became a beneficial owner of more than 5% of our outstanding capital stock
upon the closing of the Series&nbsp;D redeemable convertible preferred stock financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with Bain Capital Life Sciences Investors, LLC beneficially owned more than 5% of our
outstanding capital stock at the time of the Series&nbsp;D redeemable convertible preferred stock financing. Dr.&nbsp;Sun is currently, and was at the time of the Series&nbsp;D redeemable convertible preferred stock financing, a member of our board
of directors. Dr.&nbsp;Ricky Sun was designated to serve as a member of our board of directors by Bain Capital Life Sciences Fund, L.P. Dr. Sun is a partner with Bain Capital Life Sciences, LP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Citadel Multi-Strategy Equities Master Fund Ltd. beneficially owned more than 5% of our outstanding capital
stock at the time of the Series D redeemable convertible preferred stock financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Trusts and other entities affiliated with Muneer A. Satter beneficially owned (in the aggregate) more than 5%
of our outstanding capital stock at the time of the Series&nbsp;D redeemable convertible preferred stock financing. Mr. Muneer Satter is currently, and was at the time of the Series D redeemable convertible preferred stock financing, a member of our
board of directors. Mr. Satter was designated to serve as a member of our board of directors by trusts and other entities affiliated with Mr. Satter. Mr. Satter is the founder and managing partner of Satter Medical Technology Partners, L.P. and
Chairperson of Satter Investment Management LLC. Mr. Satter also manages the Satter Foundation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Clarus Lifesciences III, L.P. beneficially owned more than 5% of our outstanding capital stock at the time of
the Series D redeemable convertible preferred stock financing. Dr. Emmett Cunningham is currently, and was at the time of the Series D redeemable convertible preferred stock financing, a member of our board of directors. Dr. Cunningham was
designated to serve as a member of our board of directors by Clarus Lifesciences III, L.P. Dr. Cunningham is a Senior Managing Director of Blackstone Life Sciences, having joined as part of its acquisition of Clarus Ventures, LLC in December 2018.
Dr. Cunningham was a Managing Director at Clarus Ventures, LLC from January 2017 to November 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with New Enterprise Associates 15, L.P. beneficially owned (in the aggregate) more than
5% of our outstanding capital stock at the time of the Series D redeemable convertible preferred stock financing. Dr. Carol Gallagher is currently, and was at the time of the Series D redeemable convertible preferred stock financing, a member of our
board of directors. Dr. Gallagher was designated to serve as a member of our board of directors by New Enterprise Associates 15, L.P. Dr. Gallagher is a partner at New Enterprise Associates, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, we entered into an amended and restated investors&#146; rights agreement with the purchasers of our outstanding
redeemable convertible preferred stock, including entities with which certain of our directors are affiliated. Following the consummation of this offering, the holders of approximately 20,824,938 shares of our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
common stock, including the shares of common stock issuable upon the conversion of our Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series B, Series C and Series D redeemable
convertible preferred stock, are entitled to rights with respect to the registration of their shares under the Securities Act. For a more detailed description of these registration rights, see the section titled &#147;Description of Capital
Stock&#151;Registration Rights.&#148; The investors&#146; rights agreement also provides for a right of first refusal in favor of certain holders of redeemable convertible preferred stock with regard to certain issuances of our capital stock. The
rights of first refusal will not apply to, and will terminate upon the consummation of, this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, we entered into an amended and restated voting agreement with certain holders of our common stock and redeemable
convertible preferred stock. Upon the conversion of all outstanding shares of redeemable convertible preferred stock into common stock in connection with the consummation of this offering, the amended and restated voting agreement will terminate.
For a description of the amended and restated voting agreement, see the section titled &#147;Management&#151;Board Composition&#151;Voting Arrangements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, we entered into an amended and restated right of first refusal and
<FONT STYLE="white-space:nowrap">co-sale</FONT> agreement with certain holders of our common stock and redeemable convertible preferred stock. This agreement provides for rights of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT>
relating to the shares of our common stock held by the parties to the agreement. Upon the consummation of this offering, the amended and restated right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement will terminate.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officer and Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See the section titled &#147;Executive and Director Compensation&#148; for information regarding the compensation of our
directors and named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into offer letter agreements with our executive officers that, among other things, provide for certain
compensatory and change in control benefits, as well as severance benefits. For a description of these agreements with our named executive officers, see the section titled &#147;Executive and Director Compensation&#151;Executive Compensation
Arrangements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into indemnification agreements with certain of our current directors and officers, and intend to enter into
new indemnification agreements with each of our current directors and officers before the completion of this offering. Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our
directors and officers to the fullest extent permitted by applicable law. See the section titled &#147;Management&#151;Limitation on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors adopted a written related person transaction policy, to be effective upon the consummation of this
offering, setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount
involved exceeds $120,000 and a related person had or will have a direct or indirect material interest, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
without limitation purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and
employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including but not limited to whether the transaction is on terms comparable to
those that could be obtained in an arm&#146;s length transaction with an unrelated third party and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption
of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth, as of June 30, 2020, information regarding beneficial ownership of our capital stock by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The percentage ownership information under the column titled &#147;Before Offering&#148; is based on 21,258,687 shares of
common stock outstanding as of June 30, 2020 assuming the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 20,824,938 shares of common stock upon the completion of this offering. The percentage
ownership information under the column titled &#147;After Offering&#148; is based on the sale of 12,500,000 shares of common stock in this offering. The percentage ownership information assumes no exercise of the underwriters&#146; option to
purchase additional shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table does not reflect any shares of common stock that may be purchased
pursuant to our directed share program described under &#147;Underwriting&#151;Directed Share Program.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beneficial
ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security. In addition, shares of common
stock issuable upon the exercise of stock options or warrants that are currently exercisable or exercisable within 60 days of June 30, 2020 are included in the following table. These shares are deemed to be outstanding and beneficially owned by the
person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. The information
contained in the following table does not necessarily indicate beneficial ownership for any other purpose. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares
shown as beneficially owned by them, subject to applicable community property laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise noted below, the address for each beneficial owner listed
in the table below is c/o Annexon, Inc., 180 Kimball Way, Suite 200, South San Francisco, California 94080. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned<BR>(#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares&nbsp;Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before&nbsp;Offering<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After&nbsp;Offering<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater than 5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Bain Capital Life Sciences Investors, LLC<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,841,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clarus Lifesciences III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,530,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with New Enterprise
Associates<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,497,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novartis Bioventures Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,107,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trusts and Other Entities affiliated with Muneer A. Satter<SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,754,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redmile Group, LLC<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,596,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zone II Healthcare Holdings, LLC<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,157,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Love, Esq.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanjay Keswani, MBBS, BSc, FRCP<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Lew<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Young<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">*<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Campbell Murray, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,107,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Muneer Satter<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,754,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jung E. Choi<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emmett Cunningham, M.D., Ph.D.,
M.P.H.<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">*<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol Gallagher, Pharm.D.<SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ricky Sun<SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas G. Wiggans<SUP STYLE="font-size:85%; vertical-align:top">(19)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (12&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(20)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,704,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 2,288,169 shares of common stock issuable upon the conversion of the Series C redeemable
convertible preferred stock directly held by Bain Capital Life Sciences Fund, L.P., or BCLS, (ii)&nbsp;234,216&nbsp;shares of common stock issuable upon the conversion of the Series C redeemable convertible preferred stock directly held by BCIP Life
Sciences Associates, or BCIPLS, and together with BCLS, the Bain Capital Life Sciences Entities, and (iii)&nbsp;289,600&nbsp;shares of common stock issuable upon the conversion of the Series&nbsp;D redeemable convertible preferred stock directly
held by BCLS and (iv)&nbsp;29,643&nbsp;shares of common stock issuable upon the conversion of the Series&nbsp;D redeemable convertible preferred stock directly held by BCIPLS. Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey
Schwartz and Adam Koppel, is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, each of Bain Capital Life Sciences Investors, LLC,
Mr.&nbsp;Schwartz and Dr.&nbsp;Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. The address of the Bain Capital Life Sciences Entities is c/o Bain Capital Life Sciences, LP,
200 Clarendon Street, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 643,208 shares of common stock issuable upon the conversion of the Series A-1 redeemable
convertible preferred stock, (ii) 950,134 shares of common stock issuable upon the conversion of the Series B redeemable convertible preferred stock, (iii)&nbsp;697,860 shares of common stock issuable upon the conversion of the Series C redeemable
convertible preferred stock and (iv)&nbsp;239,433 shares of common stock issuable upon the conversion of the Series D redeemable convertible preferred stock, collectively, the Clarus Shares, directly held by Clarus Lifesciences III, L.P. The address
for Clarus Lifesciences III, L.P. is 101 Main Street, Suite 1210, Cambridge, Massachusetts 02142. Clarus Lifesciences III, L.P. is the record owner of the Clarus Shares. Clarus Ventures III GP, L.P. is the sole general partner of Clarus Lifesciences
III, L.P. Blackstone Clarus III L.L.C. is the sole general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P. The sole general partner of Blackstone Holdings II L.P. is Blackstone
Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Class&nbsp;C common stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group
Management L.L.C. is wholly-owned by Blackstone&#146;s senior managing directors and controlled by its founder, Stephen&nbsp;A. Schwarzman. Each of such entities and Mr. Schwarzman may be deemed to beneficially own the shares beneficially owned by
Clarus Lifesciences III, L.P., but each (other than Clarus Lifesciences III, L.P.) disclaims beneficial ownership of such shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i)&nbsp;1,974 shares of common stock issuable upon the conversion of the Series&nbsp;B
redeemable convertible preferred stock directly held by NEA Ventures 2016, L.P., or Ventures&nbsp;16, (ii)&nbsp;1,591,599&nbsp;shares of common stock issuable upon the conversion of the Series&nbsp;B redeemable convertible preferred stock directly
held by New Enterprise Associates 15, L.P., or NEA&nbsp;15, (iii)&nbsp;672,636 shares of common stock issuable upon the conversion of the Series C redeemable convertible preferred stock directly held by NEA&nbsp;15 and (iv)&nbsp;231,452 shares of
common stock issuable upon the conversion of the Series D redeemable convertible preferred stock directly held by NEA 15. The securities directly held by NEA 15 are indirectly held by NEA Partners 15, L.P., or Partners&nbsp;15, which is the sole
general partner of NEA&nbsp;15; NEA 15 GP, LLC, or NEA&nbsp;15 LLC, which is the sole general partner of Partners 15; and each of the individual managers of NEA&nbsp;15 LLC. The individual Managers of NEA 15 LLC, or the NEA&nbsp;15 Managers, are
Forest Baskett, Anthony&nbsp;A. Florence, Mohamad Makhzoumi, Joshua Makower, Scott&nbsp;D. Sandell and Peter Sonsini. Partners&nbsp;15, NEA&nbsp;15 LLC and the NEA&nbsp;15 Managers share voting and dispositive power with regard to the shares owned
directly by NEA&nbsp;15. The securities directly held by Ventures 16 are indirectly held by Karen&nbsp;P. Welsh, the general partner of Ventures 16. All indirect holders of the above referenced shares disclaim beneficial ownership of all applicable
shares except to the extent of their actual pecuniary interest therein. The address for the above referenced entities is 1954 Greenspring Drive, Suite 600, Timonium, Maryland 21093. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 648,613 shares of common stock issuable upon the conversion of the Series A-1 redeemable
convertible preferred stock, (ii) 954,154 shares of common stock issuable upon the conversion of the Series B redeemable convertible preferred stock and (iii)&nbsp;504,477 shares of common stock issuable upon the conversion of the Series C
redeemable convertible preferred stock directly held by Novartis Bioventures Ltd. The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of
directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Dr. Campbell Murray, a member of our board of directors, is also an employee of a corporation that is
affiliated with Novartis Bioventures Ltd. Dr. Murray disclaims beneficial ownership of the securities held by Novartis Bioventures Ltd. except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of
Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a Swiss corporation and an indirectly owned subsidiary of Novartis AG. The address for Novartis Bioventures Ltd. is Lichtstrasse 35, CH-4056 Basel. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 108,102 shares of common stock issuable upon the conversion of the Series A-1 redeemable
convertible preferred stock directly held by the Muneer A. Satter Revocable Trust for which Muneer A. Satter serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (ii) 243,229 shares of common stock
issuable upon the conversion of the Series A-1 redeemable convertible preferred stock directly held by various other trusts and other entities for which Muneer A. Satter serves as trustee, investment advisor or manager and, in such capacity, has
sole voting and dispositive power over all such shares, (iii) 131,898 shares of common stock issuable upon the conversion of the Series B redeemable convertible preferred stock directly held by the Muneer A. Satter Revocable Trust for which Muneer
A. Satter serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (iv) 324,011 shares of common stock issuable upon the conversion of the Series B redeemable convertible preferred stock directly held by
various other trusts and other entities for which Muneer A. Satter serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, (v) 628,494 shares of common stock issuable upon
the conversion of the Series C redeemable convertible preferred stock directly held by Satter Medical Technology Partners, L.P., or SMTP, for which Muneer A. Satter has sole voting and dispositive power over all such shares, and (vi)&nbsp;319,244
shares of common stock issuable upon the conversion of the Series D redeemable convertible preferred stock directly held by SMTP for which Muneer&nbsp;A. Satter has sole voting and dispositive power over all such shares, collectively, the Satter
Investors. Mr.&nbsp;Satter disclaims beneficial ownership of all shares included in clauses&nbsp;(ii), (iv), (v) and (vi) of this footnote&nbsp;(5), except to the extent of his pecuniary interest. The address of the Satter Investors is c/o Satter
Management Co., L.P., 676 North Michigan Avenue, Suite 4000, Chicago, Illinois 60611. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,596,222 shares of common stock issuable upon the conversion of the Series D redeemable
convertible preferred stock directly held by Redmile Biopharma Investments II, L.P. Redmile Group, LLC is the investment manager to Redmile Biopharma Investments II, L.P. and, in such capacity, exercises shared voting and dispositive power over the
securities held by Redmile Biopharma Investments II, L.P. and may be deemed to beneficially own such securities. Jeremy Green serves as the managing member of Redmile Group, LLC and as such shares voting and dispositive power over the securities
held by Redmile Biopharma Investments II, L.P. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any. The address for each of the
above person and entities is Letterman Digital Arts Center, One Letterman Drive, Building D, Suite D3-300, San Francisco, California 94129. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 840,795 shares of common stock issuable upon the conversion of the Series C redeemable
convertible preferred stock directly held by Citadel Multi-Strategy Equities Master Fund Ltd., or Citadel, and (ii) 319,244 shares of common stock issuable upon the conversion of the Series&nbsp;D redeemable convertible preferred stock directly held
by Citadel. Citadel Advisors LLC, or Citadel Advisors, acts as the portfolio manager of Citadel. Citadel Advisors Holdings LP, or CAH, is the sole member of Citadel Advisors, and Citadel GP LLC, or CGP, is the general partner of CAH. Kenneth Griffin
owns a controlling interest in CGP and may be deemed to share voting and dispositive power over shares held by Citadel. The address for this entity is c/o Citadel Advisors, 601&nbsp;Lexington Avenue, New York, New York 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,157,261 shares of common stock issuable upon the conversion of the Series D redeemable
convertible preferred stock directly held by Zone Healthcare Holdings II, LLC, or ZHH II. Farallon Capital Management, L.L.C., or FCM, as the manager of ZHH&nbsp;II, may be deemed to beneficially own such shares of common stock acquirable by
ZHH&nbsp;II. Each of Philip&nbsp;D. Dreyfuss, Michael&nbsp;B. Fisch, Richard B. Fried, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J.M. Spokes, John R. Warren and Mark D. Wehrly, the Managing
Members, as a senior managing member or managing member, as the case may be, of FCM, in each case with the power to exercise investment discretion, may be deemed to beneficially own such shares of common stock acquirable by ZHH II. Each of FCM and
the Managing Members disclaims beneficial ownership of any such shares of common stock. The address for each of the entities and individuals identified in this footnote is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San
Francisco, California 94111. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 524,851 shares of common stock that may be acquired pursuant to the exercise of stock options
within 60 days of June&nbsp;30,&nbsp;2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 57,364 shares of common stock that may be acquired pursuant to the exercise of stock options
within 60 days of June&nbsp;30,&nbsp;2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 48,276 shares of common stock that may be acquired pursuant to the exercise of stock options
within 60 days of June&nbsp;30,&nbsp;2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 54,092 shares of common stock that may be acquired pursuant to the exercise of stock options
within 60 days of June&nbsp;30,&nbsp;2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of the shares described in footnote (4) above. Dr. Murray disclaims beneficial ownership of all such
shares except to the extent of his pecuniary interests therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of the shares described in footnote (5) above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,513 shares of common stock that may be acquired pursuant to the exercise of stock options
within 60 days of June 30, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Cunningham, a member of our board of directors, is an employee of The Blackstone Group Inc. or one
of its affiliates. Dr.&nbsp;Cunningham disclaims beneficial ownership of any shares of common stock owned directly or indirectly by The Blackstone Group Inc. or its affiliates. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Does not include the shares of common stock held by NEA&nbsp;15 or Ventures&nbsp;16 described in footnote (3)
above. Dr. Gallagher, a member of our board of directors, is employed as a Partner at New Enterprise Associates, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Does not include the shares of common stock held by the Bain Capital Life Sciences Entities described in
footnote (1) above. Ricky Sun is a Partner of Bain Capital Life Sciences, LP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 16,712 shares of common stock that may be acquired pursuant to the exercise of stock options
within 60 days of June&nbsp;30,&nbsp;2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Includes (i) 3,862,222&nbsp;shares held by our current directors and executive officers and (ii)&nbsp;842,195
shares subject to options exercisable within 60&nbsp;days of June&nbsp;30, 2020. Does not include Mr. Overdorf as he joined the Company on July 20, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The following summary describes our capital stock and the material provisions of our amended and restated certificate of
incorporation and our amended and restated bylaws, which will become effective immediately prior to the completion of this offering, the amended and restated investors&#146; rights agreement to which we and certain of our stockholders are parties
and of the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of
incorporation, amended and restated bylaws and amended and restated investors&#146; rights agreement, copies of which have been filed as exhibits to the registration statement of which this prospectus is part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the
completion of this offering and the filing of our amended and restated certificate of incorporation, our authorized capital stock will consist of&nbsp;300,000,000&nbsp;shares of common stock, par value $0.001 per share,
and&nbsp;5,000,000&nbsp;shares of preferred stock, par value $0.001 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March 31, 2020, we had 13,117,963 shares of common stock outstanding, held of record by 44 stockholders, assuming the
conversion of all of our outstanding shares of redeemable convertible preferred stock into 12,684,214 shares of common stock immediately prior to the completion of this offering. In June 2020, we issued and sold 71,719,859 shares of our
Series&nbsp;D redeemable convertible preferred stock to 22 stockholders. The shares of our Series&nbsp;D redeemable convertible preferred stock are convertible into 8,140,724 shares of our common stock immediately prior to the completion of this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders,
including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative
vote of holders of 66 2/3% of the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, including the
provisions relating to amending our amended and restated bylaws, the classified board and director liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled
to receive dividends as may be declared from time to time by our board of directors out of legally available funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in
the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of
preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund
provisions applicable to our common stock. The rights, preferences and privileges of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the
future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and Nonassessable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully
paid and nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, all of our currently outstanding shares of redeemable convertible preferred stock will
convert into common stock and we will not have any shares of preferred stock outstanding. Immediately prior to the completion of this offering, our amended and restated certificate of incorporation will be amended and restated to delete all
references to such shares of redeemable convertible preferred stock. From and after the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up
to&nbsp;5,000,000&nbsp;shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights,
terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock
could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying,
deferring or preventing a change in control of our company or other corporate action. Immediately after consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March 31, 2020, we had outstanding options to purchase an aggregate of 2,136,390 shares of our common stock, with a
weighted-average exercise price of $5.45 per share. For additional information regarding terms of our equity incentive plans, see the section titled &#147;Executive and Director Compensation&#151;Equity Incentive Plans.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon
the completion of this offering and subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into in connection with this offering and federal securities laws, certain holders of shares of our common stock, including those
shares of our common stock that will be issued upon the conversion of our redeemable convertible preferred stock in connection with this offering, will initially be entitled to certain rights with respect to registration of such shares under the
Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities possess registration rights pursuant to the terms of our amended and restated investors&#146; rights agreement and are described in
additional detail below. The registration of shares of our common stock pursuant to the exercise of the registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the
applicable registration statement is declared effective. We will pay the registration expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered pursuant to the demand, piggyback and Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registrations described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, in an underwritten offering, the managing
underwriter, if any, has the right, subject to specified conditions and limitations, to limit the number of shares the holders may include. The demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights described
below will terminate upon the earliest of (i)&nbsp;with respect to each stockholder, such date, on or after the closing of this offering, on which all registrable shares held by such stockholder may immediately be sold during any 90-day period
pursuant to Rule 144 of the Securities Act, or Rule&nbsp;144, and (ii)&nbsp;the occurrence of a deemed liquidation event, as defined in our amended and restated certificate of incorporation, as currently in effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, holders of approximately 20,824,938 shares of our common stock issuable upon conversion
of outstanding redeemable convertible preferred stock will be entitled to certain demand registration rights. Beginning 180 days following the effectiveness of the registration statement of which this prospectus is a part, certain major investors
holding, collectively, 60% of registrable securities may, on not more than two occasions, request that we register all or a portion of their shares, subject to certain specified exceptions. If any of these holders exercises its demand registration
rights, then holders of approximately 20,824,938 shares of our common stock issuable upon the shares of our redeemable convertible preferred stock in connection with this offering will be entitled to register their shares, subject to specified
conditions and limitations in the corresponding offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, holders of approximately 20,824,938 shares of our common stock issuable upon conversion of
outstanding redeemable convertible preferred stock are entitled to their rights to notice of this offering and to include their shares of registrable securities in this offering. The requisite percentage of these stockholders are expected to waive
all such stockholders&#146; rights to notice of this offering and to include their shares of registrable securities in this offering. In the event that we propose to register any of our securities under the Securities Act in another offering, either
for our own account or for the account of other security holders, the holders of registrable securities will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their shares in such registration, subject to
specified conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, the holders of approximately 20,824,938 shares of our common stock issuable upon
conversion of outstanding redeemable convertible preferred stock will initially be entitled to certain <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights. Certain major investors holding at least 30% of registrable securities
may, on not more than two registrations on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> within any <FONT STYLE="white-space:nowrap">12-month</FONT> period, request that we register all or a portion of their shares on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> if we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> subject to specified exceptions. Such request for registration on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> must cover securities with an aggregate offering price which equals or exceeds $1.0&nbsp;million, net of selling expenses. The right to have such shares registered on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of
Provisions of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated
bylaws that will become effective immediately prior to the completion of this offering contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy
contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best
interest or in our best interests, including transactions that might result in a premium over the market price for our shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an
unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed &#147;interested
stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly-held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction
in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or
within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction
resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts
that might result in a premium over the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability to authorize undesignated preferred stock will make it possible for our board of directors to issue preferred stock
with voting or other rights or preferences that could impede the success of any attempt to effect a change in control of our company. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or
management of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Stockholder Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation will provide that a special meeting of stockholders may be called at any
time by our board of directors, but such special meetings may not be called by the stockholders or any other person or persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for
Advance Notification of Stockholder Nominations and Proposals </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws will establish
advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation will eliminate the right of stockholders to act by written consent
without a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board; Election and Removal of Directors; Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective upon the consummation of this offering, our board of directors will be divided into three classes, divided as nearly
as equal in number as possible. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting
of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock
outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation will provide for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 66 2/3% of
the voting power of the then outstanding voting stock. For more information on the classified board, see the section titled &#147;Management&#151;Board Composition.&#148; Furthermore, any vacancy on our board of directors, however occurring,
including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies shall be filled by the stockholders.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us because it
generally makes it more difficult for stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that, unless we consent in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or
proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our stockholders; any action asserting a claim against us arising pursuant to the Delaware
General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); or any action asserting a claim against us that is governed by the internal affairs
doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that, the
exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court
of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of
incorporation and amended and restated bylaws will also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our
directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from
bringing such claims in state or federal court, subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any action the subject matter of which is
within the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the
state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and restated bylaws and
having service of process made upon such stockholder in any such action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of incorporation and amended
and restated bylaws will contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal
securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The amendment of any of the above provisions in our amended and restated certificate of incorporation, except for the provision
making it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended
and restated bylaws could have the effect of discouraging others from attempting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts.
These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For a discussion of limitation on liability and indemnification, see the section titled &#147;Management&#151;Limitation on
Liability and Indemnification Matters.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our common stock has been approved for listing on the Nasdaq Global Select Market under the trading symbol &#147;ANNX.&#148;
</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon completion of this offering, the transfer agent and registrar for our common stock will be Computershare, Inc. The
transfer agent and registrar&#146;s address is 462 South 4th Street, Louisville, Kentucky 40202. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock, and a liquid trading market for our common stock
may not develop or be sustained after this offering. Future sales of our common stock, including shares issued upon the exercise of outstanding options, in the public market after the completion of this offering, or the perception that those sales
may occur, could adversely affect the prevailing market price for our common stock from time to time or impair our ability to raise equity capital in the future. As described below, only a limited number of shares of our common stock will be
available for sale in the public market for a period of several months after the completion of this offering due to contractual and legal restrictions on resale described below. Future sales of our common stock in the public market either before or
after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price of our common stock at such time and our ability to raise equity capital at a time and price we deem appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale of Restricted Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on the number of shares of our common stock outstanding as of March&nbsp;31, 2020, upon the closing of this offering and
(i)&nbsp;assuming&nbsp;the conversion of all of our redeemable convertible preferred stock outstanding as of March&nbsp;31, 2020 into 12,684,214 shares of our common stock immediately prior to the completion of this offering, (ii)&nbsp;assuming the
conversion of all of our Series&nbsp;D redeemable convertible preferred stock issued and sold in June 2020 into 8,140,724 shares of our common stock immediately prior to the completion of this offering, (iii)&nbsp;assuming no exercise of the
underwriters&#146; option to purchase additional shares of common stock and (iv)&nbsp;assuming no exercise of outstanding options, we will have outstanding an aggregate of approximately&nbsp;33,758,687 shares of common stock. Of these shares, all of
the&nbsp;12,500,000 shares of common stock to be sold in this offering (excluding any shares sold to affiliates in the directed share program) will be freely tradable in the public market without restriction or further registration under the
Securities Act, unless the shares are held by any of our &#147;affiliates&#148; as such term is defined in Rule&nbsp;144 of the Securities Act, or Rule&nbsp;144, or subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. All remaining
shares of common stock held by existing stockholders immediately prior to the consummation of this offering will be &#147;restricted securities,&#148; as such term is defined in Rule&nbsp;144. These restricted securities were issued and sold by us
in private transactions and are eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule&nbsp;144 or Rule&nbsp;701
of the Securities Act, or Rule&nbsp;701, which rules are summarized below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements referred to below and the provisions of Rule 144 and Rule 701, based on the number of shares of our common stock outstanding (calculated as of March 31, 2020 on the basis of the assumptions
described above), the shares of our common stock (excluding the shares sold in this offering) that will be available for sale in the public market are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="74%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Approximate&nbsp;Number&nbsp;of&nbsp;Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>First&nbsp;Date&nbsp;Available&nbsp;For&nbsp;Sale&nbsp;Into&nbsp;Public&nbsp;Market</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21,258,687 shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">181 days after the date of this prospectus, upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements referred to below, subject in some cases to applicable volume, manner of sale and other limitations under Rule 144 and Rule 701.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may issue shares of common stock from time to time as consideration for future
acquisitions, investments or other corporate purposes. In the event that any such acquisition, investment or other transaction is significant, the number of shares of common stock that we may issue may in turn be significant. We may also grant
registration rights covering those shares of common stock issued in connection with any such acquisition and investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the shares of common stock reserved for future issuance under our 2020 Plan will become eligible for sale in the
public market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, a registration statement under the Securities Act or an exemption from registration, including Rule
144 and Rule 701. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Rule 144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange
Act for at least 90 days, and we are current in our Exchange Act reporting at the time of sale, a person (or persons whose shares are required to be aggregated) who is not deemed to have been one of our &#147;affiliates&#148; for purposes of Rule
144 at any time during the 90 days preceding a sale and who has beneficially owned restricted securities within the meaning of Rule 144 for at least six months, including the holding period of any prior owner other than one of our
&#147;affiliates,&#148; is entitled to sell those shares in the public market (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to below, if applicable) without complying with the manner of sale, volume limitations
or notice provisions of Rule 144, but subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior
owner other than &#147;affiliates,&#148; then such person is entitled to sell such shares in the public market without complying with any of the requirements of Rule 144 (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement
referred to below, if applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule 144, as currently in effect, once we have been subject to the
public company reporting requirements of the Exchange Act for at least 90 days, our &#147;affiliates,&#148; as defined in Rule 144, who have beneficially owned the shares proposed to be sold for at least six months, are entitled to sell in the
public market, upon expiration of any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and within any three-month period, a number of those shares of our common stock that does not exceed the greater of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of common stock then outstanding, which will equal approximately&nbsp;337,586
shares of common stock immediately upon the completion of this offering (calculated as of March 31, 2020 on the basis of the assumptions described above); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on Nasdaq during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such sales under Rule 144 by our
&#147;affiliates&#148; or persons selling shares on behalf of our &#147;affiliates&#148; are also subject to certain manner of sale provisions, notice requirements and requirements related to the availability of current public information about us.
Notwithstanding the availability of Rule 144, the holders of substantially all of our restricted securities have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as referenced above and their restricted securities will become
eligible for sale (subject to the above limitations under Rule 144) upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule 701 as currently in effect, any of our employees, directors, officers, consultants or advisors
who acquired common stock from us in connection with a written compensatory stock or option plan or other written agreement in compliance with Rule 701 before the effective date of the registration statement of which this prospectus is a part (to
the extent such common stock is not subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement) and who are not our &#147;affiliates&#148; as defined in Rule 144 during the immediately preceding 90 days, is entitled to rely on Rule 701
to resell such shares beginning 90 days after the date of this prospectus in reliance on Rule 144, but without complying with the notice, manner of sale, public information requirements or volume limitation provisions of Rule 144. Persons who are
our &#147;affiliates&#148; may resell those shares beginning 90 days after the date of this prospectus without compliance with minimum holding period requirements under Rule 144 (subject to the terms of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to below, if applicable). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we, our directors, our executive officers and holders of substantially
all of our other outstanding shares of common stock or securities convertible into or exchangeable for shares of our common stock outstanding upon the completion of this offering, have agreed, subject to certain limited
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
exceptions, with the underwriters not to directly or indirectly offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of any shares of our common stock or any securities convertible into or exchangeable for shares of common stock during the period from the date of this
prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC, BofA Securities, Inc. and Cowen and Company, LLC, and certain other limited exceptions. These
agreements are described in the section titled &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the restrictions contained in the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, we have entered into agreements with certain security holders, including the amended and restated investors&#146; rights agreement, our standard form of option agreement,
our standard form of restricted stock agreement and our standard form of restricted stock purchase agreement, that contain market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions or incorporate market
<FONT STYLE="white-space:nowrap">stand-off</FONT> provisions from our equity incentive plan imposing restrictions on the ability of such security holders to offer, sell or transfer our equity securities for a period of 180 days following the date of
this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, the holders of approximately 20,824,938 shares of our common stock will be entitled to
rights with respect to the registration of their shares under the Securities Act, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described under <FONT STYLE="white-space:nowrap">&#147;&#151;Lock-Up</FONT> Agreements&#148;
above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates, immediately upon the effectiveness of the
registration statement of which this prospectus is a part. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. The requisite percentage of these stockholders will waive all
such stockholders&#146; rights to notice of this offering and to include their shares of registrable securities in this offering. See the section titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to file with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the
Securities Act covering the shares of common stock reserved for issuance under our 2020 Plan and our ESPP. Such registration statement is expected to be filed and become effective as soon as practicable after the completion of this offering.
Accordingly, shares registered under such registration statement will be available for sale in the open market following its effective date, subject to Rule&nbsp;144 volume limitations and the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements described above, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following discussion is a summary of the material U.S. federal
income tax consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of
all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the
U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in
effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that
discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This
discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This
discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment
income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a
conversion transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes
(and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all
of the interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an entity treated as a
partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner
level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THIS DISCUSSION IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S.
FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner
of our common stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof, or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (i)&nbsp;is subject to the primary supervision of a U.S. court and all substantial decisions of
which are subject to the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (ii)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal
income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As described in the section titled &#147;Dividend Policy,&#148; we do not currently intend to pay any cash dividends on our
capital stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or
accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#147;&#151;Sale or Other Taxable
Disposition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussion below on effectively connected income, dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable
documentation) certifying qualification for the lower treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund
of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable tax
treaties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a
permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any
such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax
at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors
regarding any applicable tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussion below regarding backup withholding, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will
not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183&nbsp;days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real
property holding corporation, or USRPHC, for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in the
first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at
a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower
rate specified by an applicable income tax treaty), which may be offset by certain U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United
States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC.
Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business
assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup
Withholding </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payments of dividends on our common stock will not be subject to backup withholding, provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any distributions on
our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or
conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting if the applicable withholding agent receives the certification described above or the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships with the United States generally will not be subject to backup withholding or information reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Copies of information returns that are filed with the IRS may also be made
available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a
refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Withholding taxes may be imposed under Sections&nbsp;1471 to 1474 of the Code (such Sections commonly referred to as the
Foreign Account Tax Compliance Act, or FATCA) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a
30% withholding tax may be imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT
STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (ii)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to
the diligence and reporting requirements in (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States
persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT>
foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments
of dividends on our common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019, proposed Treasury Regulations eliminate FATCA
withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to
their investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan
Securities LLC, BofA Securities, Inc. and Cowen and Company, LLC are acting as joint <FONT STYLE="white-space:nowrap">book-running</FONT> managers of the offering and as representatives of the underwriters. We have entered into an underwriting
agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting
discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters are committed to purchase all the shares of common stock offered by us
if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters propose to offer the common stock directly to the public at the initial public offering
price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. After the initial offering of the shares
to the public, if all of the shares of common stock are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. Sales of shares made outside of the United States may be made by
affiliates of the underwriters. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have an option to buy up to&nbsp;1,875,000 additional shares of
common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this option to purchase additional
shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the
underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise
of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option&nbsp;to<BR>Purchase<BR>Additional&nbsp;Shares<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Full<BR>Option&nbsp;to<BR>Purchase<BR>Additional&nbsp;Shares<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the total expenses of this offering, including registration, filing and
listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $4.3&nbsp;million. We have agreed to reimburse the underwriters for expenses relating to the clearance of
this offering with the Financial Industry Regulatory Authority, Inc. in an amount up to $35,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A prospectus in electronic format may be made available on the web sites
maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account
holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We<I> </I>have agreed that we will not, subject to certain exceptions, (i)&nbsp;offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or file with, or submit to, the Securities and Exchange
Commission a registration statement under the Securities Act of 1933, as amended, or the Securities Act, relating to, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock, or
publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (ii)&nbsp;enter into any swap, hedging, or other agreement that transfers, in whole or in part, any of the economic consequences associated with the ownership
of any shares of common stock or any such other securities, whether any such transaction is to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise, in each case without the prior written consent of
J.P. Morgan Securities LLC, BofA Securities, Inc. and Cowen and Company, LLC for a period of 180&nbsp;days after the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our directors and executive officers, and substantially all of our securityholders have entered into <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each of these persons or entities, with limited exceptions, for a period of 180&nbsp;days after the date of this
prospectus, may not, without the prior written consent of J.P. Morgan Securities LLC, BofA Securities, Inc. and Cowen and Company, LLC, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock
(including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such directors, executive officers, managers and members in accordance with the rules and regulations of the SEC and securities
which may be issued upon exercise of a stock option or warrant); (ii)&nbsp;enter into any hedging, swap, or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or such
other securities, whether any such transaction described in clause&nbsp;(i) or&nbsp;(ii) above is to be settled by delivery of common stock or such other securities, in cash or otherwise; (iii)&nbsp;make any demand for or exercise any right with
respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock; or (iv) publicly disclose the intention to undertake any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions described in the immediately preceding paragraph do not apply to, subject to certain additional limitations,
among other items: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:-4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;the securities to be sold by the securityholder pursuant to
the underwriting agreement for this offering; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:-4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)&nbsp;&nbsp;&nbsp;transfers of shares of our common
stock as a bona fide gift or gifts; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:-4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;transfers or dispositions of shares of our common
stock to any trust for the direct or indirect benefit of the securityholder or the immediate family of the securityholder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:-4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv)&nbsp;&nbsp;transfers or dispositions of shares of our common stock to any corporation, partnership,
limited liability company or other entity all of the beneficial ownership interests of which are held by the securityholder or the immediate family of the securityholder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:-4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v)&nbsp;&nbsp;&nbsp;transfers or dispositions of shares of our common stock by will, other testamentary
document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the securityholder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:-4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi)&nbsp;&nbsp;&nbsp;distributions of shares of our common stock to partners, members or stockholders of the
securityholder; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="right">(vii)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers to the securityholder&#146;s affiliates or to any investment fund or other entity controlled or
managed by, controlling or managing, or under common control with, the securityholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="right">(viii)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction
made to all holders of our common stock and involving a change of control of our company approved by the board of directors of our company, provided that in the event that the tender offer, merger, consolidation or other such transaction is not
completed, the common stock owned by the securityholder shall remain subject to the restrictions contained in the lock-up agreement; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that in the case of any transfer or distribution pursuant to clauses (ii), (iii), (iv), (v), (vi) or (vii) above, each transferee,
donee or distributee shall execute and deliver to the representatives a lock-up agreement; and provided, further, that in the case of any transfer, disposition or distribution pursuant to clauses (ii), (iii), (iv), (v), (vi) or (vii) above, no
filing by any party under Section 16 of the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution and any such transfer or distribution shall not involve a
disposition for value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, securityholders may, subject to certain additional limitations, without the prior
written consent of J.P. Morgan Securities LLC, BofA Securities, Inc. and Cowen and Company, LLC (i)&nbsp;exercise on a cash basis of any option to purchase shares of common stock granted under any stock incentive plan or stock purchase plan,
provided that the underlying shares of common stock shall continue to be subject to the restrictions on transfer set forth in the lock-up agreement; (ii)&nbsp;establish a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the
transfer of common stock, provided that such plan does not provide for any transfers of common stock during the lock-up period; (iii)&nbsp;transfer or dispose of shares of common stock acquired in this offering or on the open market following this
offering; (iv) transfer or surrender to us shares of common stock (or any security convertible into common stock) (A) pursuant to a right of first refusal described in this prospectus with respect to transfers of such shares of common stock or other
securities, or (B) to us for purposes of exercising or settling (including for the payment of tax withholdings due as a result of such exercise or settlement) on a &#147;net exercise,&#148; &#147;net settlement&#148; or &#147;cashless&#148; basis
any equity award, provided such equity award was granted under our stock incentive plan or stock purchase plan; and (v) transfer or dispose of securities by operation of law pursuant to a qualified domestic order or in connection with a divorce
settlement or other court order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have agreed to indemnify the underwriters against certain liabilities, including
liabilities under the Securities Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our common stock has been approved for listing on the Nasdaq Global Select
Market under the trading symbol &#147;ANNX.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, the underwriters may engage in
stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in
progress. These stabilizing transactions may include making short sales of the common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and
purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase
additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares,
in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the
underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open
market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the
Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common
stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding
a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them
at any time. The underwriters may carry out these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. The initial public offering price will be
determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information set forth in this prospectus and otherwise available to the representatives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our prospects and the history and prospects for the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our prospects for future earnings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the general condition of the securities markets at the time of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors deemed relevant by the underwriters and us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither we nor the underwriters can assure investors that an active trading market will develop for shares of our common
stock, or that the shares will trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At our request, the underwriters have reserved up to 1% of the shares of common stock offered hereby, at the initial public
offering price, to offer to directors, officers, employees, business associates and other persons related to us. The underwriters will receive the same underwriting discount on any shares purchased pursuant to this program as they will on any other
shares sold to the public in this offering. The number of shares of common stock available for sale to the general public will be reduced to the extent these individuals purchase such reserved shares. Any reserved shares that are not so purchased
will be offered by the underwriters to the general public on the same basis as the other shares offered by this prospectus. Shares purchased by our directors and officers will be subject to the 180-day lock-up restriction described in the
&#147;Underwriting&#148; section of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time
to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees
and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions
in our debt or equity securities or loans, and may do so in the future.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the
securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material
or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction.
Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a
solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the European Economic Area and the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to each member state of the European Economic Area and the United Kingdom, or each, a &#147;Relevant State,&#148;
no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State
or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation), except that offers of shares may be made to the public in that Relevant
State at any time under the following exemptions under the Prospectus Regulation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:-4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;to any legal entity which is a qualified investor as defined under the
Prospectus Regulation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:-4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;(ii)&nbsp;&nbsp;to fewer than 150 natural or legal persons (other than
qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:-4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii)&nbsp;&nbsp;in any other circumstances falling within Article&nbsp;1(4) of the Prospectus Regulation,
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article&nbsp;3 of
the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to
and with each of the underwriters and the Company that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares being offered to a financial intermediary as that term is used
in the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they
been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances
in which the prior consent of the underwriters have been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes
of this provision, the expression an &#147;offer to the public&#148; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be
offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer
subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which have not
resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this
document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to section 3A.3 of National Instrument
<FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI
<FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective
Investors in Switzerland </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss
Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance
prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility
in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither this document nor any other offering or marketing material relating to the offering, the Company or the shares have
been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA and the offer of
shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to
acquirers of shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority,
or DFSA. This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying
any documents in connection with Exempt Offers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this document
relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you should
consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to its use in the Dubai International Financial Centre, or DIFC,
this document is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The
interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United
Arab Emirates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the
United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities.
Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed
with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in Australia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001
(Cth), or the Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a
disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or
more of the categories of investors, available under section 708 of the Corporations Act, or Exempt Investors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe
for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required under Chapter
6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As any offer of shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations
Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By
applying for the shares you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those shares to investors in Australia except in circumstances where
disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and
Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other
entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the
registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than
(i)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder; or (ii)&nbsp;in other circumstances which do not result in
the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, or the CO or which do not constitute an offer to the public within the meaning of the CO. No
advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which
are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or
only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of
Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause
the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or
invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="right">(i)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of
Singapore, as modified or amended from time to time, or the SFA) pursuant to Section 274 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="right">(ii)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any
person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="right">(iii)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person
which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(i)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(ii)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">securities or securities-based derivatives
contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust
has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(A)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(B)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="right">(C)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="right">(D)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="right">(E)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Bermuda </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of
Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are
permitted to do so under applicable Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Saudi Arabia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of
Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as
amended by resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended (the &#147;CMA Regulations&#148;). The CMA does not make any representation as to the accuracy or completeness of this
document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the
accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the British Virgin Islands </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or
subscription by or on behalf of the Company. The shares may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), or BVI Companies, but only where the offer will be made to, and received by, the
relevant BVI Company entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in China </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus will not be circulated or distributed in the PRC and the shares will not be offered or sold, and will not be
offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus nor any
advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Korea </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea
and the decrees and regulations thereunder, or the FSCMA, and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold
to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign
Exchange Transaction Law of Korea and the decrees and regulations thereunder, or the FETL. The shares have not been listed on any of the securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the
purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased
the shares pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Malaysia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be
registered with the Securities Commission of Malaysia, or Commission, for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the
offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or
indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services License; (iii)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that
the shares may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse
exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies)
per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a
corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign
currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and
(xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the shares is made by a holder of a Capital Markets Services License who carries on the
business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or
purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Taiwan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant
securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a
registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in South Africa </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to restrictions under the securities laws of South Africa, no &#147;<I>offer to the public</I>&#148; (as such term is
defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted),</FONT> or the South African Companies Act) is being made in connection with the issue of the shares in South Africa.
Accordingly, this document does not, nor is it intended to, constitute a &#147;<I>registered prospectus</I>&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not
been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not offered, and the offer shall not be transferred, sold, renounced or
delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96(1) applies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">96(1)(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">the offer, transfer, sale, renunciation or delivery is to:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) persons whose ordinary business, or part of whose
ordinary business, is to deal in securities, as principal or agent;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) the South African Public Investment Corporation;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) persons or entities regulated by the Reserve Bank of South Africa;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) authorised financial service providers under South
African law;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) financial institutions recognised as
such under South African law;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi) a wholly-owned
subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorized portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under
South African law); or</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vii) any combination of the
person in (i) to (vi); or</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">96(1)(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or
greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information made available in this prospectus should not be considered as
&#147;<I>advice</I>&#148; as defined in the South African Financial Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Israel </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not taken any action to permit a public offering of our shares outside the United States. Solicitation
of our shares, however, will be made in certain countries in a manner that will not require the publication of a prospectus under the laws of the country. Persons outside the United States who come into possession of this prospectus must inform
themselves about and observe any restrictions relating to the offering of our shares and the distribution of this prospectus outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the above, the offering of our shares is available to investors listed in the First Supplement of the Israeli
Securities Law of 1968, as amended. A prospectus has not been prepared or filed, and will not be prepared or filed, in Israel relating to the shares offered hereunder. The shares cannot be resold in Israel other than to investors listed in the First
Supplement of the Israeli Securities Law of 1968, as amended purchasing for their own account and not for distribution or resale purposes. No action will be taken in Israel that would permit an offering of the shares offered hereunder, or the
distribution of any offering document or any other material to the public in Israel. This registration statements has not been reviewed or approved by the Israel Securities Authority. Any materials provided to an investor in Israel may not be
reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been provided directly by the Issuer or the Dealer(s). The shares will not be traded on the TASE. Nothing in the above should be
considered as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
rendering of a recommendation or advice, including investment advice or investment marketing under the Israeli Law For Regulation of Investment Advice, Investment Marketing and Investment
Portfolio Management, 1995, to purchase any shares and in purchasing the shares, the investors acknowledge that they have expertise and experience in financial and business matters so as to be capable of evaluating the risks and merits of the
purchase of the shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Latham&nbsp;&amp;
Watkins LLP. Certain legal matters in connection with this offering will be passed upon for the underwriters by Cooley LLP, San Diego, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The consolidated financial statements of Annexon, Inc. as of December&nbsp;31, 2018 and 2019, and for each of the years in the
<FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2019, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing
elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_22"></A>WHERE YOU CAN
FIND ADDITIONAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have filed with the SEC a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1,</FONT> including exhibits and schedules, under the Securities Act, with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement,
does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits.
Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the
registration statement. Each of these statements is qualified in all respects by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You may read our SEC
filings, including this registration statement, over the Internet at the SEC&#146;s website at www.sec.gov. Upon the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act and we will file
reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for review at the SEC&#146;s website referred to above. We also maintain a website at www.annexonbio.com, at which,
following the completion of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on or accessible through our website
is not a part of this prospectus or the registration statement of which it forms a part, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc773514_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Financial Statements as of and for the Years Ended December&nbsp;31, 2018 and
2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_3">Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_4">Consolidated Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_5">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_6">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_7">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Financial Statements as of and for the Three Months Ended March&nbsp;31,
2019 and 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_8">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_9">Condensed Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_10">Condensed Consolidated Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_11">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and
 Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_12">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin773514_13">Notes to Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the Stockholders and Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Annexon, Inc.: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Opinion on the Consolidated
Financial Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have audited the accompanying consolidated balance sheets of Annexon, Inc. and its subsidiary (the Company) as
of December&nbsp;31, 2018 and 2019, the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders&#146; deficit, and cash flows for each of the years in the two-year period ended
December&nbsp;31, 2019, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of
December&nbsp;31, 2018 and 2019, and the results of its operations and its cash flows for each of the years in the two-year period ended December&nbsp;31, 2019, in conformity with U.S.&nbsp;generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis for Opinion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These consolidated
financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material
misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe
that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ KPMG LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have served as the Company&#146;s auditor since 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 26, 2020, except as to
note&nbsp;12, which is as of July&nbsp;19, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_2"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value, 119,155,472 shares authorized as of
December&nbsp;31, 2018 and 2019, respectively; 89,525,848 and 111,748,065 shares issued and outstanding as of December&nbsp;31, 2018 and 2019, respectively; liquidation preference of $107,814 and $137,814 as of December&nbsp;31, 2018 and 2019,
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (Deficit) Equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 150,000,000 shares authorized as of December&nbsp;31, 2018 and
2019, respectively; 432,309 and 433,749&nbsp;shares issued and outstanding as of December&nbsp;31, 2018 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_3"></A>Consolidated Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on remeasurement of redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">402,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing pro forma net loss per share attributable to common
stockholders, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,452,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_4"></A>Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:400pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_5"></A>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,389,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $22</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,803,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $217 and
redeemable convertible preferred stock liability of $5,400</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,333,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,525,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series C redeemable convertible preferred stock, including the value of the redeemable
convertible preferred stock liability of $10,810, net of issuance costs of $3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,222,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,748,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">143,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:90pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_6"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the exercise common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of fair value of redeemable convertible preferred stock liability upon issuance of
redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of redeemable convertible preferred stock liability to redeemable convertible
preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_7"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Annexon,
Inc. (the &#147;Company&#148;) is a clinical-stage biopharmaceutical company targeting C1q and initiating molecules of the classical complement pathway to develop transformative therapies for autoimmune and neurodegenerative disorders of the body,
eye and brain. The Company is located in South San Francisco, California and was incorporated in Delaware in March 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s wholly-owned subsidiary, Annexon Biosciences Australia Pty Ltd (the &#147;Subsidiary&#148;), is a
proprietary limited company incorporated in 2016 and domiciled in Australia. The Subsidiary is also engaged in research and development activities in support of its parent company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since
inception, the Company has been involved primarily in performing research and development activities, hiring personnel, and raising capital to support and expand these activities. The Company has experienced losses and negative cash flows from
operations since its inception and, as of December&nbsp;31, 2019, had an accumulated deficit of $102.6&nbsp;million and cash and cash equivalents of $43.9&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has historically funded its operations through the issuance of shares of its redeemable convertible preferred
stock. The Company intends to raise additional capital through public or private equity offerings or debt financings, credit or loan facilities, collaborations or a combination of one or more of these funding sources. If financing is not available
at adequate levels, the Company may need to reevaluate its operating plans. Based on projected activities, management believes that cash and cash equivalents on hand is sufficient to support operations for at least the next 12 months following
issuance of these consolidated financial statements. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of Presentation and Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of
America (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including but not limited to the fair value of common stock, redeemable convertible preferred stock, redeemable convertible preferred stock liability,
stock options, income taxes, clinical trial accruals and stock-based compensation. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when
facts and circumstances dictate. Actual results could differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The consolidated financial statements include the operations of Annexon, Inc. and its wholly owned subsidiary and include the
results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s chief operating decision maker is its Chief Executive Officer. The Chief Executive Officer
reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#146;s resources. Accordingly, the Company has determined that it operates in one segment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company considers all highly liquid instruments with an original maturity of three months or less at time of purchase to be
cash equivalents. Cash equivalents, which includes amounts invested in money market funds, are stated at fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the
straight-line method over the estimated useful lives of the respective assets. Depreciation begins at the time the asset is placed in service. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost
and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The useful lives of the property and equipment are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shorter of remaining lease term or estimated useful life</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in
circumstances indicate that the carrying amount of these assets may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows the asset is expected to
generate over its remaining life. When indications of impairment are present and the estimated undiscounted future cash flows from the use of these assets is less than the assets&#146; carrying value, the related assets will be written down to fair
value. There were no impairments of the Company&#146;s long-lived assets for the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Commitments and Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are
recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred offering costs, consisting of legal, accounting, audit and filing fees relating to an IPO, are capitalized. The
deferred offering costs will be offset against offering proceeds upon the completion of the offering. In the event the offering is terminated or delayed, deferred offering costs will be expensed. As of December&nbsp;31, 2019, $2.3&nbsp;million of
deferred offering costs were capitalized, which are included in other long-term assets in the accompanying consolidated balance sheets. No amounts were deferred as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The obligation to issue additional shares of the Company&#146;s Series C redeemable convertible preferred stock at a future
date was determined to be a freestanding financial instrument that should be accounted for as a liability. At initial recognition, the Company recorded the redeemable convertible preferred stock liability on the balance sheet at its estimated fair
value. The liability is subject to remeasurement at each balance sheet date, with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
changes in fair value recognized as gain (loss) on remeasurement of redeemable convertible preferred stock liability on the consolidated statement of operations. Upon settlement of the redeemable
convertible preferred stock liability in August 2019, the Company remeasured the liability and reclassified the final value associated with the redeemable convertible preferred stock liability to the carrying value of the Series C redeemable
convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax
rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred taxes to the amounts expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained
upon examination based solely on their technical merit, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#146;s policy is to recognize interest and penalties related to the
underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Translation of Foreign Currencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s reporting currency is the U.S. dollar. The functional currency of the Company&#146;s subsidiary located in
Australia is the Australian Dollar. Balance sheets prepared in the functional currencies are translated to the reporting currency at exchange rates in effect at the end of the accounting period, except for stockholders&#146; equity accounts, which
are translated at rates in effect when these balances were originally recorded. Revenue and expense accounts are translated using a weighted-average rate during the year. The resulting foreign currency translation adjustments are recorded as a
separate component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. Foreign exchange translation losses for the years ended December&nbsp;31, 2018 and 2019 totaled $40,000 and $14,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gains and losses resulting from exchange rate changes on transactions denominated in a currency other than the local currency
are included in earnings as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses consist primarily of direct and indirect costs incurred for the development of the
Company&#146;s product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Direct expenses include (i)&nbsp;preclinical and clinical outside service costs
associated with discovery, preclinical and clinical testing of the Company&#146;s product candidates; (ii)&nbsp;professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct
research and development activities on the Company&#146;s behalf; (iii)&nbsp;contract manufacturing costs to produce clinical trial materials; and (iv)&nbsp;laboratory supplies and materials. Indirect expenses include (A)&nbsp;compensation and
personnel-related expenses (including stock-based compensation), (B) allocated expenses for facilities and depreciation; and (C)&nbsp;other indirect costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs are expensed as incurred. Payments made to
third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts
with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#146;s behalf. In accruing service fees, the Company estimates the period over which services will be
performed and the level of effort to be expended in each period. These estimates are based on the Company&#146;s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of
the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not
experienced any material differences between accrued costs and actual costs incurred since its inception. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for stock-based compensation arrangements with employees and
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options. The fair value
method requires the Company to estimate the fair value of stock-based payment awards to employees on the date of grant using the Black-Scholes option pricing model. The fair value of awards to <FONT STYLE="white-space:nowrap">non-employees</FONT> is
estimated at each measurement date, which is the date on which the award vests. Total expenses for <FONT STYLE="white-space:nowrap">non-employee</FONT> share based awards has been immaterial to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company grants certain employees performance-based stock options. For awards that include performance conditions, no
compensation cost is recognized until the performance goals are probable of being met, at which time the cumulative compensation expense from the service inception date would be recognized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes option
pricing model and recognized as expense on a straight-line basis (for all but performance based awards for which the accelerated method is used) over the requisite service period, which is the vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Determining the appropriate fair value model and related assumptions requires judgment, including estimating the fair value of
the underlying common stock, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting for <FONT STYLE="white-space:nowrap">Non-Recurring</FONT> Grant Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-recurring</FONT> grant income is recognized when the research and development activities
have been undertaken and the Company has completed its assessment of whether such activities meet the relevant qualifying criteria. Grants received from government and other agencies in advance of the specific research and development costs to which
they relate are deferred and recognized in the consolidated statement of operations in the period they are earned and when the related research and development costs are incurred. <FONT STYLE="white-space:nowrap">Non-recurring</FONT> grant income
recognized in other income, net for the years ended December&nbsp;31, 2018 and 2019 was $35,000 and $190,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common
stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss
per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss Per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In contemplation of the IPO, the Company has computed the unaudited pro&nbsp;forma basic and diluted net loss per share
attributable to common stockholders, to give effect&nbsp;to the conversion of the redeemable convertible preferred stock into shares of common stock. The unaudited pro forma net loss per share attributable to common stockholders does not include the
shares expected to be sold and related proceeds to be received from the IPO. The unaudited pro forma net loss per share attributable to common stockholders for the year ended December&nbsp;31, 2019 was computed using the weighted-average number of
shares of common stock outstanding, including the pro forma effect of the conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock, as if such conversion had occurred at the beginning of the period,
or their issuance dates if later. The net loss attributable to common stockholders was adjusted to exclude the impact of the remeasurement of the redeemable convertible preferred stock liability and accretion on the redeemable convertible preferred
stock as the underlying shares would have converted into common stock upon an IPO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash. The
Company&#146;s cash is deposited with high credit quality financial institutions. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is expected to be an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the
&#147;JOBS Act&#148;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company
has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging
growth company or (ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2016, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update
(&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases </I>(Topic 842), which supersedes the guidance in former ASC 840<I>, Leases</I>. This standard requires lessees to apply a dual approach, classifying leases as
either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or
on a straight-line basis over the term of the lease. A lessee is also required to record a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater
than 12 months regardless of their classification. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases today. This standard </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
is effective for annual reporting periods, and interim periods within those years, for public entities beginning after December&nbsp;15, 2018 and for private entities beginning after
December&nbsp;15, 2020. Originally, a modified retrospective transition approach was required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. In July 2018, the
FASB issued guidance to permit an alternative transition method for Topic 842, which allows transition to the new lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.
Entities may elect to apply either approach. There are also a number of optional practical expedients that entities may elect to apply. The Company plans to adopt Topic 842 on January&nbsp;1, 2021, and is currently assessing the impact of this
standard on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2016, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2016-16,</FONT> <I>Intra-Entity Transfers of Assets Other Than Inventory</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2016-16&#148;).</FONT> This standard requires entities to recognize current and
deferred income tax consequences of intercompany asset transfers other than inventory at the transaction date. For public business entities, the amendments in this standard are effective for annual reporting periods beginning after December&nbsp;15,
2017, including interim reporting periods within those annual reporting periods. For all other entities, the amendments are effective for annual reporting periods beginning after December&nbsp;15, 2018, and interim reporting periods within annual
periods beginning after December&nbsp;15, 2019. Early adoption is permitted for all entities as of the beginning of an annual reporting period for which financial statements (interim or annual) have not been issued or made available for issuance.
The Company adopted this standard on January&nbsp;1, 2019. There were no current or deferred income tax consequences of adopting the standard because the Company had no intra-entity transfers of assets for the year ended December&nbsp;31, 2019 or
prior years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Improvements
to Nonemployee Share-Based Payment Accounting </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2018-07&#148;).</FONT> This standard simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based
payments to employees, with certain exceptions. Some of the areas of simplification apply only to nonpublic entities. This guidance is effective for annual reporting periods, and interim periods within those years, for public entities beginning
after December&nbsp;15, 2018. For all other entities, the amendments are effective for annual periods beginning after December&nbsp;15, 2019, and interim periods within annual periods beginning after December&nbsp;15, 2020. Early adoption is
permitted for any entity in any interim or annual period for which financial statements have not been issued or made available for issuance, but not before an entity adopts ASC 606. The Company adopted this standard on January&nbsp;1, 2020 and the
adoption of this standard is not expected to have a material impact on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August
2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Disclosure Framework &#150; Changes to the Disclosure Requirements for Fair Value Measurement </I>(&#147;ASU
<FONT STYLE="white-space:nowrap">2018-13&#148;),</FONT> which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure
requirements. This standard is effective for all entities for fiscal years beginning after December&nbsp;15, 2019, with early adoption permitted. The Company adopted this standard on January&nbsp;1, 2020 and the adoption of this standard is not
expected to have a material impact on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2018, the FASB issued ASU No.
2018-15, <I>Customer&#146;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</I> (&#147;ASU 2018-15&#148;). The standard requires implementation costs incurred by customers in cloud computing
arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2)&nbsp;for which exercise of the renewal option is
controlled by the cloud service provider. The effective date of this pronouncement is for fiscal years beginning after December&nbsp;15, 2020, and interim periods within annual periods beginning after December&nbsp;15, 2021, and early adoption is
permitted. The standard can be adopted either using the prospective or retrospective transition approach. The Company is currently evaluating the impact of this pronouncement on the Company&#146;s consolidated financial statements and disclosures.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions
in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Level</I><I></I><I>&nbsp;1 Inputs:</I> Unadjusted quoted prices in active markets for identical assets or
liabilities accessible to the reporting entity at the measurement date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Level</I><I></I><I>&nbsp;2 Inputs:</I> Other than quoted prices included in Level&nbsp;1 inputs that are
observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Level</I><I></I><I>&nbsp;3 Inputs:</I> Unobservable inputs for the asset or liability used to measure fair
value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On a recurring basis, the Company measures certain financial assets and liabilities at fair value. The following tables
summarize the fair value of the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has an operating account invested in money market funds with maturities of less
than three months and is classified as cash and cash equivalents on the Company&#146;s balance sheet. The money market funds are valued using Level&nbsp;1 inputs that are based on quoted prices in active markets for identical assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the years ended December&nbsp;31, 2018 and 2019, the Company recognized no material realized gains or losses on financial
instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s Level&nbsp;3 liabilities include the redeemable convertible preferred stock liability.
The Company initially estimated the fair value of the redeemable convertible preferred stock liability using the Black-Scholes option pricing model with an expected term of 0.65 years, the fair value of the Series C redeemable convertible preferred
stock of $1.19, expected volatility of 77.7% and risk-free interest rate of 2.47% as of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
December&nbsp;7, 2018. The liability was remeasured at December&nbsp;31, 2018 using the Black-Scholes option pricing model with an expected term of 0.58 years, the fair value of the Series C
redeemable convertible preferred stock of $1.20, expected volatility of 77.7% and risk-free interest rate 2.56%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
August 2019, the redeemable convertible preferred stock liability was settled upon the completion of the second closing of the Company&#146;s Series C redeemable convertible preferred stock financing. In light of the Company&#146;s progress towards
an IPO, the liability was remeasured at the settlement date using a probability-weighted expected return method (&#147;PWERM&#148;) whereby the Company&#146;s total equity value was estimated under various exit scenarios and allocated to the
Company&#146;s different classes of equity. The PWERM included two scenarios, IPO or staying private, that considered an estimate of the timing of each scenario and were weighted based on the Company&#146;s estimate of the probability of each event
occurring. The equity value under the IPO scenario was based on recent IPO values of comparable companies. The equity value under the staying private scenario was based on the recent Series C redeemable convertible preferred stock financing. The
liability was remeasured to its fair value of $10.8&nbsp;million upon settlement and the carrying value of the liability was reclassified to the carrying value of the Series C redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recorded a gain of $0.3&nbsp;million and a loss of $5.7&nbsp;million in the consolidated statements of operations
for the years ended December&nbsp;31, 2018 and 2019, respectively, for the change in the fair value of the liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
changes in the carrying value of the liability were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification to redeemable convertible preferred stock upon settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There were no transfers between Levels&nbsp;1, 2 or 3 for the periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses and other current assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Property and Equipment, Net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, net consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total depreciation expense recognized for the years ended December&nbsp;31, 2018 and 2019 was
$488,000 and $493,000, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Accrued Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company
leases its offices and laboratory in South San Francisco, California under a <FONT STYLE="white-space:nowrap">7-year</FONT> noncancelable lease agreement that ends in June 2024 with a <FONT STYLE="white-space:nowrap">5-year</FONT> renewal option.
Rent expense is recognized on a straight-line basis over the <FONT STYLE="white-space:nowrap">non-cancelable</FONT> term of the lease and, accordingly, the Company records the difference between cash rent payments and the recognition of rent expense
as a deferred rent liability on the accompanying consolidated balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total rent expense was $353,000 for each of
the years ended December&nbsp;31, 2018 and 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future minimum lease payments under noncancelable operating leases as of
December&nbsp;31, 2019 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024 and thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License and Other Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2011, the Company entered into an exclusive licensing agreement (the &#147;Stanford Agreement&#148;) with The Board
of Trustees of the Leland Stanford Junior University (&#147;Stanford&#148;) whereby the Company was granted an exclusive, worldwide, royalty-bearing, sublicensable license, under certain patent rights (the &#147;Licensed Patents&#148;), to make,
use, offer for sale, sell, import and otherwise commercialize products covered by the Licensed Patents for human or animal diseases, disorders or conditions. Under the Stanford Agreement, the Company made an upfront payment and is obligated to pay
Stanford annual license maintenance fees, potential future milestone payments totaling up to $600,000, and royalty payments at a rate equal to a low single-digit percentage of worldwide net sales of licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2016, the Company entered into a Sponsored Research Agreement with a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">not-for-profit</FONT></FONT> entity to perform research on multiple sclerosis. The Sponsored Research Agreement was amended in March 2019. Under the terms of the Sponsored Research Agreement, the Company may receive up to
$651,000, which was amended from $693,000, in funding. If within 15 years of the end of the Sponsored Research Agreement the Company files a marketing authorization application for a product treating multiple sclerosis, the Company will be obligated
to pay milestone payments up to four times the amounts received under the Sponsored Research Agreement. The Company has received $455,000 in funding to date, including $190,000 received during the year ended December&nbsp;31, 2019, which was
recorded as other income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees and Indemnifications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for
general indemnification. The Company&#146;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action
related to its indemnification obligations. As of December&nbsp;31, 2019, the Company did not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Redeemable Convertible Preferred Stock and Stockholder&#146;s Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2018, redeemable convertible preferred stock consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Carrying<BR>Value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,398,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,398,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,778,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,778,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,962,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,333,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,155,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,525,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019, redeemable convertible preferred stock consisted of the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Carrying<BR>Value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,398,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,398,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,778,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,778,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,962,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,555,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,155,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,748,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">143,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">137,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2016, the Company issued 26,974,965 shares of Series B redeemable convertible
preferred stock for $1.15 per share to a group of investors in the first closing of its Series B redeemable convertible preferred stock financing. In February 2018, the Company issued 11,803,125 additional shares of Series B redeemable convertible
preferred stock in a second closing on the same terms as the initial closing in June 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2018, the Company
issued 33,333,329 shares of Series C redeemable convertible preferred stock for $1.35 per share in the first closing of its Series C redeemable convertible preferred stock financing. Investors in the Series C redeemable convertible preferred stock
financing also received freestanding rights to purchase an additional 22,222,217 shares of Series C redeemable convertible preferred stock on the same terms as the first closing upon completion of certain defined milestones or waiver of the
milestones by the holders of at least 60% of the outstanding redeemable convertible preferred stock, voting as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, including certain Series C investors. Additionally, the
investors had the right to purchase their second closing shares upon providing notice to the Company prior to July&nbsp;31, 2019. If the milestones were met by July&nbsp;31, 2019, then the investors were obligated to participate in the second
closing on the same terms as the first closing. In August 2019, the term was extended to August&nbsp;31, 2019. The investors&#146; rights to purchase Series C redeemable convertible preferred stock represented a freestanding financial instrument
accounted for as a liability measured at fair value at inception and remeasured at fair value each reporting date. Changes in fair value are recognized in the statement of operations. The proceeds from the initial closing of the Series C redeemable
convertible preferred stock of $44.8&nbsp;million were allocated to the redeemable convertible preferred stock liability at its fair value of $5.4&nbsp;million and to the carrying value of the Series C redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2019, upon achieving certain defined milestones, the Company
completed the second closing (&#147;Second Closing&#148;) of its Series C redeemable convertible preferred stock financing and issued 22,222,217 shares of Series C redeemable convertible preferred stock at $1.35 per share for gross proceeds of
$30.0&nbsp;million. The redeemable convertible preferred stock liability was settled upon the Second Closing and the fair value of the liability of $10.8&nbsp;million was reclassified to the carrying value of the Series C redeemable convertible
preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Significant provisions of the redeemable convertible preferred stock are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Dividends</I>&#151;The holders of Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series B and Series C redeemable
convertible preferred stock are entitled to receive noncumulative dividends, in preference to any dividends payable to holders of Series A redeemable convertible preferred stock or common stock, at the annual dividend rate of $0.063 per share for
Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, $0.069 per share for Series B redeemable convertible preferred stock and $0.081 per share for Series C redeemable convertible preferred stock, as adjusted for
any stock splits, stock dividends, recapitalization, or the like, if declared by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of
Series A redeemable convertible preferred stock are entitled to receive noncumulative dividends, in preference to any dividends payable to holders of common stock, if declared by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of redeemable convertible preferred stock are also entitled to participate in dividends on common stock, when and
if declared by the Board of Directors, based on the outstanding redeemable convertible preferred stock (on an <FONT STYLE="white-space:nowrap">as-if</FONT> converted to common stock basis) and common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Conversion</I>&#151;At the option of the holder, each share of redeemable convertible preferred stock is convertible,
subject to adjustment for anti-dilution protection, into 0.1135074 shares of common stock. Each share automatically converts into the number of shares of common stock into which the shares are convertible at the then applicable conversion ratio upon
(i)&nbsp;the closing of the sale of the Company&#146;s common stock in a public offering provided the offering price per share is not less than $23.79 (as adjusted for recapitalization), and the aggregate net proceeds are greater than
$50&nbsp;million (&#147;Qualified Public Offering&#148;) or (ii)&nbsp;upon receipt of the written consent of the holders of at least 60% of the outstanding redeemable convertible preferred stock, voting as a single class on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis, including certain Series C investors, for the conversion of all then outstanding redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Liquidation</I>&#151;In the event of any liquidation, dissolution or winding up of the Company, including a merger or
acquisition where the beneficial owners of the Company&#146;s common and redeemable convertible preferred stock own less than majority of the surviving entity, or a sale of all or substantially all assets, the holders of Series C, Series B and
Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock will be entitled to receive a per share amount equal to $1.35, $1.15 and $1.05 for Series C, Series B and Series <FONT STYLE="white-space:nowrap">A-1</FONT>
redeemable convertible preferred stock, respectively (subject to adjustment for recapitalizations, stock dividends or the like), plus all declared but unpaid dividends (if any). The holders of Series C redeemable convertible preferred stock are also
entitled to an additional amount per share if the liquidation event occurs before a certain date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After payment of the
full liquidation preference of Series C, Series B and Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, the holders of Series A redeemable convertible preferred stock will be entitled to receive an amount
equal to $0.98 per share, as adjusted, plus all declared but unpaid dividends prior to and in preference to any distribution to the holders of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After payment of the full liquidation preference of Series C, Series B,
Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series A redeemable convertible preferred stock, distributions by the Company shall be distributed with equal priority, subject to the provisions outlined below, among holders of the redeemable
convertible preferred stock and common stock, with redeemable convertible preferred stock being treated on an as converted basis. Upon receipt by the Series C, Series B, Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series A redeemable
convertible preferred stock holders of their per share aggregate distribution threshold amounts of $1.35, $2.30, $2.10 and $1.97 for holders of Series C, Series B, Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series A redeemable
convertible preferred stock, respectively, any remaining proceeds available for distribution will be distributed among holders of common stock in proportion to the number of common shares held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Voting</I>&#151;The holders of redeemable convertible preferred stock are entitled to the number of votes equal to the
number of shares of common stock into which each share of Series C, Series B, Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series A redeemable convertible preferred stock could be converted on the record date for the vote or consent of the
stockholders, except as otherwise required by law, and have voting rights and powers equal to the voting rights and powers of the common stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of Series C redeemable convertible preferred stock, voting as a separate class, are entitled to elect one member
of the Board of Directors. The holders of Series B redeemable convertible preferred stock, voting as a separate class, are entitled to elect one member of the Board of Directors. The holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT>
redeemable convertible preferred stock, voting as a separate class, are entitled to elect three members of the Board of Directors. The holders of common stock, voting as a separate class, are entitled to elect one member of the Board of Directors.
Any additional members of the Board of Directors shall be elected by the holders of common stock and redeemable convertible preferred stock voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Redemption</I>&#151;All redeemable convertible preferred stock shall be redeemed at the election of the holders of at least
60% of the then outstanding shares of redeemable convertible preferred stock, voting as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, including certain Series C investors, at any time after the fifth anniversary of
the date of the filing of the Fifth Amended and Restated Certificates of Incorporation. The Company shall redeem the outstanding shares of redeemable convertible preferred stock by paying in cash, in three equal annual installments, an amount per
share equal to the Series C original issue price, with respect to Series C redeemable convertible preferred stock, Series B original issue price, with respect to Series B redeemable convertible preferred stock, Series
<FONT STYLE="white-space:nowrap">A-1</FONT> original issue price, with respect to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, and the Series A original issue price, with respect to the Series A
redeemable convertible preferred stock, plus an amount equal to all declared and unpaid dividends thereon, whether or not earned. Funds available for such redemption shall be used to redeem all shares of Series C, Series B and Series <FONT
STYLE="white-space:nowrap">A-l</FONT> redeemable convertible preferred stock, on a pari passu basis, before any shares of Series A redeemable convertible preferred stock are redeemed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Classification</I>&#151;The Company has classified the redeemable convertible preferred stock as mezzanine equity on the
consolidated balance sheets as the stock is contingently redeemable with passage of time or upon deemed liquidation events, such as a change in control. Because the redeemable convertible preferred stock becomes redeemable at any time after the
fifth anniversary of the date of the filing of the Fifth Amended and Restated Certificate of Incorporation at the election of the holders of at least 60% of the then outstanding shares of redeemable convertible preferred stock, voting as a single
class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, including certain Series C investors, the carrying values of the redeemable convertible preferred stock are adjusted to redemption value over the period from the date of
issuance to the earliest redemption date using the effective interest rate method. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of the Company&#146;s common stock have one vote for each share of common stock. Common stockholders are entitled
to dividends when, as, and if declared by the Board of Directors, subject to the prior rights of the redeemable convertible preferred stockholders. The holders have no preemptive or other subscription rights and there are no redemption or sinking
fund provisions with respect to such shares. As of December&nbsp;31, 2019, no dividends had been declared by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company reserved the following shares of common stock for issuance as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock outstanding on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,161,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,684,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">705,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options available for future grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,757,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common stock reserved</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,624,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,145,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2011, the Company adopted the 2011 Equity Incentive Plan (the &#147;Plan&#148;). The Plan provides for granting stock
options, stock bonuses, and rights to acquire restricted stock to employees, directors and consultants. As of December&nbsp;31, 2019, there were 2,577,260 shares authorized under the Plan. Both incentive and nonqualified stock options can be granted
under terms of the Plan and conditions established by the Board of Directors. Incentive stock options can only be granted to employees. The exercise price for incentive stock options cannot be less than the fair market value of the related common
stock on the grant date. Stock options granted under the Plan generally vest over four years and expire no later than 10 years from the date of grant. The exercise price for rights to acquire restricted stock cannot be less than the fair market
value of the related common stock on the grant date. The terms and conditions governing restricted stock is at the sole discretion of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock option activity under the 2011 Equity Incentive Plan (the &#147;Plan&#148;) was as follows:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Available<BR>for<BR>Grant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">820,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional shares authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,403,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,757,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">705,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional shares authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,588,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(285,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">771,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total intrinsic value of options exercised during the years ended
December&nbsp;31, 2018 and 2019 was $200,000 and $8,000, respectively. The intrinsic value is the difference between the estimated fair value of the Company&#146;s common stock at the time of exercise, as determined by the Board of Directors, and
the exercise price of the stock option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The weighted-average grant date fair value of options granted to employees during
the years ended December&nbsp;31, 2018 and 2019 was $2.91 and $5.72&nbsp;per share, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2019, the
Company granted options to purchase 46,737&nbsp;shares of the Company&#146;s common stock to one of its officers that will vest if the Company achieves a certain milestone related to its product candidate. The total grant date fair value of this
award was $311,000 and no associated expense was recognized during the year ended December&nbsp;31, 2019 as the achievement of the performance condition was not yet considered probable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options Granted to Employees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To determine the value of stock option awards for stock-based compensation purposes, the Company uses the Black-Scholes option
pricing model and the assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Fair Value of Common Stock</I>&#151;The grant date fair market value of the shares of common stock underlying stock options
has historically been determined by the Company&#146;s Board of Directors. Because there has been no public market for the Company&#146;s common stock, the Board of Directors exercises reasonable judgment and considers a number of objective and
subjective factors to determine the best estimate of the fair market value, which include contemporaneous valuations performed by an independent third-party, important developments in the Company&#146;s operations, sales of redeemable convertible
preferred stock, the rights, preferences and privileges of the Company&#146;s redeemable convertible preferred stock relative to those of its common stock, lack of marketability of its common stock, actual operating results, financial performance,
the progress of clinical development, the likelihood of achieving a liquidity event for the Company&#146;s security holders, the trends, development and conditions in the life sciences and biotechnology sectors, the economy in general, the stock
price performance and volatility of comparable public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Term</I>&#151;The Company&#146;s expected
term represents the period that the Company&#146;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end
of the contractual term). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Volatility</I>&#151;Because the Company is privately held and does not have any
trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life science companies over a period equal to the expected term of the stock option grants. The comparable
companies were chosen based on the similar size, stage in the life cycle, or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price
becomes available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Risk-Free Interest Rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury zero
coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Dividend
Yield</I>&#151;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of each award issued during the years ended December&nbsp;31,
2018 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.08</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">6.02-6.08</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">76%-77%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">72%-77%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.49%-2.87%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.48%-2.61%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019, the total unrecognized stock-based compensation cost related to
outstanding unvested employee stock options that are expected to vest was $6.4&nbsp;million, which the Company expects to recognize over an estimated weighted-average period of 2.3 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total stock-based compensation expense recognized for options granted was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For financial reporting purposes, loss before provision for income taxes, includes the following components (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For each of the years ended December&nbsp;31, 2018 and 2019, the Company incurred
insignificant amounts for an income tax provision. The U.S. federal and California deferred tax assets generated from the Company&#146;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the
benefit will be realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Reconciliation of income tax computed at federal statutory rates to the
reported provision for income taxes was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax provision at U.S. statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Tax Assets and Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tax effects of temporary differences that give rise to significant portions of the Company&#146;s deferred tax assets and
liabilities are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred Tax Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other intangibles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant improvement allowances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred Tax Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019, the Company had $89.8&nbsp;million of federal and
$65.8&nbsp;million of state net operating loss carryforwards available to offset future taxable income. Under the Tax Cuts and Jobs Act of 2017 (the &#147;Tax Act&#148;), net operating losses generated after December&nbsp;31, 2018 will be carried
forward indefinitely with the yearly net operating loss utilization limited to 80&nbsp;percent of taxable income. The Company has $46.8&nbsp;million of such federal NOLs that do not expire. If not utilized, the federal carryforward losses generated
prior to 2018 and the state carryforward losses will expire in various amounts beginning in 2031. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019, the Company had $3.1&nbsp;million of federal
and $2.5&nbsp;million of state credit carryforwards available to offset future taxable income. If not utilized, these credit carryforwards will expire in various amounts for federal purposes beginning in 2031. The state credits do not expire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some or all
of the deferred tax assets will not be realized. Management believes that, based on available evidence, both positive and negative, it is more likely than not that the deferred tax assets will not be utilized; therefore, a full valuation allowance
has been recorded. The Company&#146;s valuation allowance increased by $6.4&nbsp;million and $10.4&nbsp;million for the years ended December&nbsp;31, 2018 and 2019, respectively. The changes in the 2018 and 2019 valuation allowance were primarily
due to the addition of the current year loss carryforwards and research and development credits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Utilization of the net
operating loss carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. Any annual limitation may result in the
expiration of net operating losses and credits before utilization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Uncertain Tax Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has the following activity relating to the gross amount of unrecognized tax benefits (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on tax positions related to prior year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on tax positions related to current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of these uncertain tax positions will impact the Company&#146;s effective tax rate if
assessed. The Company&#146;s policy is to classify interest and penalties associated with unrecognized tax benefits as income tax expense. The Company had no interest or penalty accruals associated with uncertain tax benefits in its consolidated
balance sheet and consolidated statement of operations for the year ended December&nbsp;31, 2019. The Company files income tax returns in California, Massachusetts, Pennsylvania and in Australia. The Company is not currently under examination by any
major tax jurisdictions nor has it been in the past. The tax years 2011 through 2019 remain effectively open for examination by the Internal Revenue Service and most state tax authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next 12 months
due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not
anticipate any significant changes to unrecognized tax benefits over the next 12 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Net Loss and Unaudited Pro Forma Net Loss Per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due
to their anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT>
basis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,161,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,684,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">705,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,867,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,691,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss Per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the computation of unaudited pro forma basic and diluted net loss per share during the year
ended December&nbsp;31, 2019 (in thousands, except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on remeasurement of the redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion to redemption value on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss used in computing pro forma net loss per share attributable to common stockholders, basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock used in computing net loss per share attributable to
common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,018,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock used in computing pro forma net loss per share
attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,452,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluated its consolidated financial statements for subsequent events through February&nbsp;26, 2020, the date the
consolidated financial statements were available to be issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2020, the Company&#146;s board of directors approved an amendment to the Company&#146;s certificate of incorporation to
effect a reverse split of shares of the Company&#146;s common stock on an one-for-8.81 basis, which was effected on July 17, 2020 (the &#147;Reverse Stock Split&#148;). The number of authorized shares and the par values of the common stock and
redeemable convertible preferred stock were not adjusted as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the conversion ratio for the Company&#146;s outstanding redeemable convertible preferred stock was
proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. All references to common stock and options to purchase common stock share data, per share
data and related information contained in the consolidated financial statements have been retroactively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_8"></A>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>March&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, less accumulated depreciation of $1,304 and $1,435 as of December 31, 2019
and March 31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value, 119,155,472 shares authorized as of
December&nbsp;31, 2019 and March&nbsp;31, 2020; 111,748,065 shares issued and outstanding as of December&nbsp;31, 2019 and March&nbsp;31, 2020; liquidation preference of $137,814 as of December&nbsp;31, 2019 and March&nbsp;31, 2020, no shares issued
and outstanding as of March&nbsp;31, 2020, pro forma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">143,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (Deficit) Equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 150,000,000 shares authorized as of December&nbsp;31, 2019 and
March&nbsp;31, 2020; 433,749&nbsp;shares issued and outstanding as of December&nbsp;31, 2019 and March&nbsp;31, 2020; 13,117,963&nbsp;shares issued and outstanding as of March&nbsp;31, 2020, pro forma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112,422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_9"></A>Condensed Consolidated Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on remeasurement of convertible redeemable preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing pro forma net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,117,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:230pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_10"></A>Condensed Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,658</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:459pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_11"></A>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Redeemable Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,525,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,082</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(65,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of March&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,525,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,344</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(72,653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Redeemable Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,748,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">143,984</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,748,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,263</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(112,422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:86pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">F-31</FONT> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_12"></A>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on remeasurement of redeemable convertible preferred stock liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering cost payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin773514_13"></A>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Annexon, Inc. (the &#147;Company&#148;) is a clinical-stage biopharmaceutical company targeting C1q and initiating molecules of
the classical complement pathway to develop transformative therapies for autoimmune and neurodegenerative disorders of the body, brain and eye. The Company is located in South San Francisco, California and was incorporated in Delaware in March 2011.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s wholly-owned subsidiary, Annexon Australia Pty Ltd (the &#147;Subsidiary&#148;), is a proprietary
limited company incorporated in 2016 and domiciled in Australia. The Subsidiary is also engaged in research and development activities in support of its parent company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since inception, the Company has been involved primarily in performing research and development activities, conducting clinical
trials, hiring personnel, and raising capital to support and expand these activities. The Company has experienced losses and negative cash flows from operations since its inception and, as of March&nbsp;31, 2020, had an accumulated deficit of
$114.9&nbsp;million and cash and cash equivalents of $33.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has historically funded its
operations through the issuance of shares of its redeemable convertible preferred stock. In June 2020, the Company completed a Series&nbsp;D redeemable convertible preferred stock financing raising net proceeds of $96.7&nbsp;million (Note&nbsp;11).
Based on projected activities, management projects that cash on hand and the proceeds from the Series&nbsp;D financing are sufficient to support operations for at least the next 12&nbsp;months following issuance of these condensed consolidated
financial statements. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
Basis of Presentation and Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of
America (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including but not limited to the fair value of common stock, redeemable convertible preferred stock, redeemable convertible preferred stock liability,
stock options, income taxes, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances
dictate. Actual results could differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The consolidated financial statements include the operations of Annexon, Inc. and its wholly owned subsidiary and include the
results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Condensed Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The interim condensed consolidated balance sheet as of March&nbsp;31, 2020, and the interim condensed consolidated statements
of operations, comprehensive loss, changes in redeemable convertible preferred stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and stockholders&#146; deficit and cash flows for the three months ended March&nbsp;31, 2019 and 2020 are unaudited. These unaudited interim condensed consolidated financial statements have been
prepared on the same basis as the Company&#146;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of the
Company&#146;s consolidated financial information.&nbsp;The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three-month periods are also unaudited. The
condensed consolidated results of operations for the three months ended March&nbsp;31, 2020 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2020 or for any other future annual or interim period. The
condensed consolidated balance sheet as of December&nbsp;31, 2019 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction
with the Company&#146;s audited consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma
Consolidated Balance Sheet Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In contemplation of the Company&#146;s planned initial public offering
(&#147;IPO&#148;), the unaudited pro forma stockholders&#146; equity in the condensed consolidated balance sheet reflects shares of the Company&#146;s common stock outstanding as of March&nbsp;31, 2020 and assumes the conversion of outstanding
shares of redeemable convertible preferred stock into common stock immediately prior to the completion of the IPO. The shares of common stock issuable and the proceeds expected to be received in the IPO are excluded from such pro forma financial
information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred offering costs, consisting of legal, accounting, audit and filing fees relating to an IPO, are capitalized. The
deferred offering costs will be offset against offering proceeds upon the completion of the offering. In the event the offering is terminated or delayed, deferred offering costs will be expensed. As of December&nbsp;31, 2019 and March&nbsp;31, 2020,
$2.3&nbsp;million and $2.9&nbsp;million, respectively, of deferred offering costs were capitalized, which are included in other long-term assets in the accompanying condensed consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The obligation to issue additional shares of Series C redeemable convertible preferred stock at a future date was determined to
be a freestanding financial instrument that should be accounted for as a liability. At initial recognition, the Company recorded the redeemable convertible preferred stock liability on the balance sheet at its estimated fair value. The liability is
subject to remeasurement at each balance sheet date, with changes in fair value recognized as loss on remeasurement of convertible redeemable preferred stock liability on the statement of operations. Upon settlement of the redeemable convertible
preferred stock liability in August 2019, the Company remeasured the liability and reclassified the final value associated with the redeemable convertible preferred stock liability to the carrying value of the Series C redeemable convertible
preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s reporting currency is the U.S. dollar. The functional currency of the subsidiary located in Australia is the
Australian Dollar. Balance sheets prepared in the functional currencies are translated to the reporting currency at exchange rates in effect at the end of the accounting period, except for stockholders&#146; equity accounts, which are translated at
rates in effect when these balances were originally recorded. Revenue and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
expense accounts are translated using a weighted-average rate during the year. The resulting foreign currency translation adjustments are recorded as a separate component of accumulated other
comprehensive loss in the accompanying consolidated balance sheets. Foreign exchange translation losses for the three months ended March&nbsp;31, 2019 and 2020 totaled $6,000 and $11,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gains and losses resulting from exchange-rate changes on transactions denominated in a currency other than the local currency
are included in earnings as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses consist primarily of direct and indirect costs incurred for the development of the
Company&#146;s product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Direct expenses include (i)&nbsp;preclinical and clinical outside service costs
associated with discovery, preclinical and clinical testing of the Company&#146;s product candidates; (ii)&nbsp;professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct
research and development activities on the Company&#146;s behalf; (iii)&nbsp;contract manufacturing costs to produce clinical trial materials; and (iv)&nbsp;laboratory supplies and materials. Indirect expenses include (A)&nbsp;compensation and
personnel related expenses (including stock-based compensation), (B) allocated expenses for facilities and depreciation; and (C)&nbsp;other indirect costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are
generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts
with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#146;s behalf. In accruing service fees, the Company estimates the period over which services will be
performed and the level of effort to be expended in each period. These estimates are based on the Company&#146;s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of
the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not
experienced any material differences between accrued costs and actual costs incurred since its inception. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Stock-Based</FONT> Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for stock-based compensation
arrangements using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options. The fair value method requires the Company to estimate the fair value of
stock-based payment awards on the date of grant using the Black-Scholes option pricing model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company grants certain
employees performance-based stock options. For awards that include performance conditions, no compensation cost is recognized until the performance goals are probable of being met, at which time the cumulative compensation expense from the service
inception date would be recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation costs are based on the fair value of the underlying option
calculated using the Black-Scholes option-pricing model and recognized as expense on a straight-line basis (for all but performance-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
based awards for which the accelerated method is used) over the requisite service period, which is the vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price
volatility, expected dividend yield, expected term, risk-free rate of return, and the estimated fair value of the underlying common stock. The Company accounts for forfeitures as they occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common
stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss
per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss Per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In contemplation of the IPO, the Company has computed the unaudited pro forma basic and diluted net loss per share attributable
to common stockholders, to give effect to the conversion of the redeemable convertible preferred stock into shares of common stock. The unaudited pro forma net loss per share attributable to common stockholders does not include the shares expected
to be sold and related proceeds to be received from the IPO. The unaudited pro forma net loss per share attributable to common stockholders for the three months ended March&nbsp;31, 2020 was computed using the weighted-average number of shares of
common stock outstanding, including the pro forma effect of the conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock, as if such conversion had occurred at the beginning of the period, or their
issuance dates if later. The net loss attributable to common stockholders was adjusted to exclude accretion on the redeemable convertible preferred stock as the underlying shares would have converted into common stock upon an IPO. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is expected to be emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the
&#147;JOBS Act&#148;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company
has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging
growth company or (ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or
revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Recently Adopted Accounting Pronouncements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2018, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update
(&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Improvements to Nonemployee Share-Based Payment Accounting</I>. This standard simplifies the accounting for share-based payments to nonemployees by aligning it with the
accounting for share-based payments to employees, with certain exceptions. The Company adopted this standard on January&nbsp;1, 2020 and the adoption of this standard did not have a material impact on its condensed consolidated financial statements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2018, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Disclosure Framework &#150; Changes to the Disclosure Requirements for Fair Value Measurement</I>, which eliminates certain disclosure requirements for fair value measurements for all
entities, requires public entities to disclose certain new information and modifies some disclosure requirements. This standard is effective for all entities for fiscal years beginning after December&nbsp;15, 2019, with early adoption permitted. The
Company adopted this standard on January&nbsp;1, 2020 and the adoption of this standard did not have a material impact on its condensed consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases </I>(Topic 842),
which supersedes the guidance in former ASC 840, Leases. This standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed
purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less may
be accounted for similar to existing guidance for operating leases today. In November 2019, the FASB issued ASU No. <FONT STYLE="white-space:nowrap">2019-10,</FONT><I>&nbsp;Financial Instruments &#151; Credit Losses (Topic 326), Derivatives and
Hedging (Topic 815), and Leases (Topic 842),</I>&nbsp;delaying the effective implementation date for Topic 842 by one year for entities that have not yet adopted the standard. This standard is effective for annual reporting periods, and interim
periods within those years, for public entities beginning after December&nbsp;15, 2018 and for private entities beginning after December&nbsp;15, 2020. Originally, a modified retrospective transition approach was required for leases existing at, or
entered into after, the beginning of the earliest comparative period presented in the financial statements. In July 2018, the FASB issued guidance to permit an alternative transition method for Topic 842, which allows transition to the new lease
standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Entities may elect to apply either approach. There are also a number of optional practical expedients that entities may
elect to apply. The Company plans on adopting Topic 842 on January&nbsp;1, 2021 and is currently assessing the impact of this standard on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-15,</FONT> <I>Customer&#146;s Accounting
for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</I>. The standard requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the
cloud computing arrangements plus any optional renewal periods (1)&nbsp;that are reasonably certain to be exercised by the customer or (2)&nbsp;for which exercise of the renewal option is controlled by the cloud service provider. The effective date
of this pronouncement is for fiscal years beginning after December&nbsp;15, 2020, and interim periods within annual periods beginning after December&nbsp;15, 2021, and early adoption is permitted. The standard can be adopted either using the
prospective or retrospective transition approach. The Company is currently evaluating the impact of this pronouncement on the Company&#146;s consolidated financial statements and disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions
in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible
to the reporting entity at the measurement date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2 Inputs: Other than quoted prices included in Level&nbsp;1 inputs that are observable for the
asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent
that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On a recurring basis, the Company measures certain financial assets and liabilities at fair value. The following tables
summarize the fair value of the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December&nbsp;31, 2019 and March&nbsp;31, 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has an operating account invested in money market funds with maturities of less
than three months and is classified as cash and cash equivalents on the Company&#146;s balance sheet. The money market funds are valued using Level&nbsp;1 inputs that are based on quoted prices in active markets for identical assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the three months ended March&nbsp;31, 2019 and 2020, the Company recognized no material realized gains or losses on
financial instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s Level&nbsp;3 liabilities include the redeemable convertible preferred stock
liability which was settled in August 2019 upon the completion of the second closing of the Company&#146;s Series C redeemable convertible preferred stock financing. The liability was remeasured at March&nbsp;31, 2019 using a probability-weighted
expected return method (&#147;PWERM&#148;) whereby the Company&#146;s total equity value was estimated under various exit scenarios and allocated to the Company&#146;s different classes of equity. The PWERM included two scenarios, IPO or staying
private, that considered an estimate of the timing of each scenario and were weighted based on the Company&#146;s estimate of the probability of each event occurring. The equity value under the IPO scenario was based on recent IPO values of
comparable companies and weighted 35%. The equity value under the staying private scenario was based on the recent Series C redeemable convertible preferred stock financing and was weighted 65%. The liability was remeasured to its fair value of
$7.9&nbsp;million as of March&nbsp;31, 2019. The Company recorded a loss of $2.8&nbsp;million in the condensed consolidated statements of operations for the three months ended March&nbsp;31, 2019 for the change in the fair value of the liability.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The changes in the carrying value of the liability were as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value as of March&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses and other current assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company leases its offices and laboratory in South San Francisco, California under a
<FONT STYLE="white-space:nowrap">7-year</FONT> noncancelable agreement that ends in June 2024 with a <FONT STYLE="white-space:nowrap">5-year</FONT> renewal option. Rent expense is recognized on a straight-line basis over the <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> term of the lease and, accordingly, the Company records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability on the accompanying balance sheet.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total rent expense was $88,000 for the three months ended March&nbsp;31, 2019 and 2020, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2011, the Company entered into an exclusive licensing agreement (the &#147;Stanford Agreement&#148;) with the
Leland Stanford Junior University (&#147;Stanford&#148;) whereby the Company was granted an exclusive, worldwide, royalty-bearing, sublicensable license, under certain patent rights (the &#147;Licensed Patents&#148;), to make, use, offer for sale,
sell, import and otherwise commercialize products covered by the Licensed Patents for human </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or animal diseases, disorders or conditions. Under the Stanford Agreement, the Company made an upfront payment and is obligated to pay Stanford annual license maintenance fees, potential future
milestone payments totaling up to $600,000, and royalty payments at a rate equal to a low single-digit percentage of worldwide net sales of licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2016 and amended in March 2019, the Company entered into a Sponsored Research Agreement with a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> entity to perform research on multiple sclerosis. Under the terms of the Sponsored Research Agreement, the Company may receive up to $651,000, which was amended
from $693,000, in funding. If within 15 years of the end of the Sponsored Research Agreement the Company files a marketing authorization application for a product treating multiple sclerosis, the Company will be obligated to pay milestone payments
up to four times the amounts received under the Sponsored Research Agreement. The Company has received $455,000 in funding to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No funding was received for the three months ended March&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees and Indemnifications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for
general indemnification. The Company&#146;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action
related to its indemnification obligations. As of March&nbsp;31, 2020, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Redeemable Convertible Preferred Stock and Stockholder&#146;s Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2019, redeemable convertible preferred stock consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Carrying<BR>Value</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,398,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,398,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,778,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,778,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,962,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,555,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,155,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,748,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">143,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">137,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2020, redeemable convertible preferred stock consisted of the following:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Carrying<BR>Value</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,398,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,398,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,778,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,778,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,962,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,555,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,155,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,748,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">137,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has reserved the following shares of common stock for issuance as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock outstanding on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,684,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,136,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options available for future grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common stock reserved</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,145,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock option activity under the Plan is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR></B><br><B>Available<BR>for<BR>Grant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise<BR>Price&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B><br><B>(in Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic</B><br><B>Value</B><br><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(129,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances as of March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,136,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total intrinsic value of options exercised during the three months ended March&nbsp;31,
2019 was $8,000. The intrinsic value is the difference between the estimated fair value of the Company&#146;s common stock at the time of exercise, as determined by the Board of Directors, and the exercise price of the stock option.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation recognized for options granted was as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2020, the total unrecognized stock-based compensation cost related to
outstanding unvested stock options that are expected to vest was $7.4&nbsp;million, which the Company expects to recognize over an estimated weighted-average period of 2.2 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To determine the value of stock option awards for stock-based compensation purposes, the Company uses the Black-Scholes
option-pricing model and the assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Term</I>&#151;The Company&#146;s expected term represents the
period that the Company&#146;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual
term). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Volatility</I>&#151;Because the Company is privately held and does not have any trading history for
its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life science companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen
based on the similar size, stage in the life cycle, or area of specialty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Risk-Free Interest Rate</I>&#151;The
risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Dividend</I>&#151;The Company has never paid dividends on its common stock and has no plans to pay dividends on
its common stock. Therefore, the Company used an expected dividend yield of zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Fair Value of Common Stock </I>- The
grant date fair market value of the shares of common stock underlying stock options has historically been determined by the Company&#146;s Board of Directors. Because there has been no public market for the Company&#146;s common stock, the Board of
Directors exercises reasonable judgment and considers a number of objective and subjective factors to determine the best estimate of the fair market value, which include contemporaneous valuations performed by an independent third-party, important
developments in the Company&#146;s operations, sales of convertible preferred stock, actual operating results, financial performance, the conditions in the life sciences industry, the economy in general, the stock price performance and volatility of
comparable public companies, and the lack of liquidity of the Company&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of each award
issued during the three months ended March&nbsp;31, 2019 and 2020 was estimated on the date of grant using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model with the following assumptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended June&nbsp;30,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">6.02-6.08</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5.00-6.08</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">77%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">85%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.61%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.64%-1.45%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the three months ended March&nbsp;31, 2019 and 2020, the Company incurred insignificant amounts for an income tax
provision. The U.S. federal and California deferred tax assets generated from the Company&#146;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Net Loss and Unaudited Pro Forma Net Loss Per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for
the periods presented due to their anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT>
basis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,161,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,684,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,603,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,136,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,765,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,820,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro forma Net Loss per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the computation of unaudited pro forma basic and diluted net loss per share during the three
months ended March&nbsp;31, 2020 (in thousands, except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion to redemption value on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss used in computing pro forma net loss per share attributable to common stockholders, basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock used in computing net loss per share attributable to
common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,684,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock used in computing pro forma net loss per share
attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,117,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Series D Redeemable Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, the Company entered into a Series D redeemable convertible preferred stock purchase agreement with various
investors, pursuant to which the Company issued and sold an aggregate of 71,719,859 shares of Series&nbsp;D redeemable convertible preferred stock at $1.4222 per share for gross proceeds of $102.0&nbsp;million. The Company incurred issuance costs of
$5.3 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2020, the Company&#146;s board of directors approved an amendment to the Company&#146;s certificate of incorporation to
effect a reverse split of shares of the Company&#146;s common stock on an one-for-8.81 basis, which was effected on July 17, 2020 (the &#147;Reverse Stock Split&#148;). The number of authorized shares and the par values of the common stock and
redeemable convertible preferred stock were not adjusted as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the conversion ratio for the Company&#146;s outstanding redeemable convertible preferred stock was
proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. All references to common stock and options to purchase common stock share data, per share
data and related information contained in the consolidated financial statements have been retroactively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000 Shares </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g773514g21m47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:160pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="bottom"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>BofA&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Cowen</B></TD></TR>
</TABLE>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (the 25th day after the date of this prospectus), all dealers that buy, sell or trade shares of our common
stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their
unsold allotments or subscriptions. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by
Annexon, Inc., or the Registrant, in connection with the sale of our common stock being registered. All amounts are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority,
or FINRA, filing fee and the Nasdaq Global Select Market, or Nasdaq, listing fee. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>ITEM</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>Paid or to be<BR>Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">770,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As permitted by Section&nbsp;102 of the Delaware General Corporation Law, we have adopted provisions in our amended and
restated certificate of incorporation and amended and restated bylaws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting
on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for
breach of fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission.
Our amended and restated certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As permitted by Section&nbsp;145 of the Delaware General Corporation Law, our amended and restated bylaws provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may indemnify our directors, officers and employees to the fullest extent permitted by the Delaware General
Corporation Law, subject to limited exceptions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the
fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and our amended and restated bylaws provide for the indemnification
provisions described above and elsewhere herein. We have entered or will enter into, and intend to continue to enter into, separate indemnification agreements with our directors and officers that may be broader than the specific indemnification
provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require us, among other things, to indemnify our officers and directors against certain liabilities that may arise by reason of their status or
service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against
them as to which they could be indemnified. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses
incurred, arising under the Securities Act of 1933, as amended, or the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have purchased and currently
intend to maintain insurance on behalf of each and every person who is or was a director or officer of the company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to
certain exclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The form of underwriting agreement for this initial public offering provides for indemnification by
the underwriters of us and our officers and directors who sign this registration statement for specified liabilities, including matters arising under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since June&nbsp;30, 2016, we have made the following sales of unregistered securities: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Plan-Related Issuances </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">1.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Since June&nbsp;30, 2016, we have granted to our directors, employees and consultants options to purchase
3,253,095 shares of our common stock with per share exercise prices ranging from $1.86 to $14.45 under our 2011 Equity Incentive Plan, as amended, or the 2011 Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">2.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Since June&nbsp;30, 2016, we have issued to certain of our directors, employees and consultants an aggregate
of 94,752 shares of our common stock at per share purchase prices ranging from $1.41 to $1.86 pursuant to exercises of options under the 2011 Plan for an aggregate purchase price of $150,088. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">3.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Since June&nbsp;30, 2016, we have issued to our consultants 8,513 shares of restricted common stock at a price
per share of $1.86 (including <FONT STYLE="white-space:nowrap">non-cash</FONT> issuances as consideration for services) under the 2011 Plan for an aggregate purchase price $15,750. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale of Preferred Stock </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">4.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Between June 2016 and February 2018, we issued and sold an aggregate of 38,778,090 shares of Series B
redeemable convertible preferred stock at $1.15 per share for gross proceeds of approximately $44.6&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">5.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Between December 2018 and August 2019, we issued and sold an aggregate of 55,555,546 shares of Series C
redeemable convertible preferred stock at $1.35 per share for gross proceeds of approximately $75.0&nbsp;million. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">6.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In June 2020, we issued and sold an aggregate of 71,719,859 shares of Series&nbsp;D redeemable convertible
preferred stock at $1.4222 per share for gross proceeds of approximately $102.0 million. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
offers, sales and issuances of the securities described in paragraphs&nbsp;(1) through (3) were deemed to be exempt from registration under Rule&nbsp;701 promulgated under the Securities Act as transactions under compensatory benefit plans and
contracts relating to compensation, or under Section&nbsp;4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. The recipients of such securities were our directors, employees or bona fide consultants and
received the securities under our equity incentive plans. Appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions had adequate access, through employment, business
or other relationships, to information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The offers, sales and issuances of the securities described in
paragraphs&nbsp;(4) through (6) were deemed to be exempt under Section&nbsp;4(a)(2) of the Securities Act or Rule 506 of Regulation&nbsp;D under the Securities Act as a transaction by an issuer not involving a public offering. The recipients of
securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions.
Each of the recipients of securities in these transactions was an accredited investor within the meaning of Rule&nbsp;501 of Regulation&nbsp;D under the Securities Act and had adequate access to information about us. No underwriters were involved in
these transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
exhibits listed below are filed as part of this registration statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit <BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporated&nbsp;by&nbsp;Reference</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filed<BR>Herewith</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520195043/d773514dex11.htm">Form of Underwriting Agreement </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/20/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520195043/d773514dex31.htm">Sixth Amended and Restated Certificate of Incorporation, as amended, currently in effect </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/20/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520195043/d773514dex32.htm">Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the completion of this offering</A></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/20/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520195043/d773514dex33.htm">Bylaws, currently in effect</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/20/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520195043/d773514dex34.htm">Form of Amended and Restated Bylaws, to be in effect immediately prior to the completion of this offering</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/20/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits&nbsp;3.1 through 3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex42.htm">Form of Common Stock Certificate </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d773514dex51.htm">Opinion of Latham&nbsp;&amp; Watkins&nbsp;LLP</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex101.htm">Amended and Restated Investors&#146; Rights Agreement, dated June&nbsp;
30, 2020, by and among the Registrant and the investors listed therein </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex102.htm">Exclusive (Equity) Agreement, dated November&nbsp;
21, 2011, by and between the Registrant and The Board of Trustees of the Leland Stanford Junior University </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex103.htm">Lease, dated December&nbsp;19, 2016, by and between the Registrant and Bayside Acquisition, LLC </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit <BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporated&nbsp;by&nbsp;Reference</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filed<BR>Herewith</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4(a)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520195043/d773514dex104a.htm">2011 Equity Incentive Plan, as amended</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/20/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.4(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4(b)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex104b.htm">Form of Stock Option Agreement under 2011 Equity Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.4(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5(a)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d773514dex105a.htm">2020 Incentive Award Plan</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5(b)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex105b.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.5(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5(c)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex105c.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2020 Incentive Award Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.5(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5(d)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex105d.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2020 Incentive Award Plan
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.5(d)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d773514dex106.htm">Employee Stock Purchase Plan</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1528115/000119312520186799/d773514dex107.htm">Employment Agreement by and between the Registrant and Douglas Love, Esq. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex108.htm">Employment Agreement by and between the Registrant and Sanjay Keswani, MBBS, BSc, FRCP </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex109.htm">Employment Agreement by and between the Registrant and Jennifer Lew </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex1010.htm">Employment Agreement by and between the Registrant and Ted Yednock, Ph.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520195043/d773514dex1011.htm">Employment Agreement by and between the Registrant and Michael Overdorf</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/20/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520195043/d773514dex1012.htm"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/20/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1528115/000119312520186799/d773514dex1012.htm">Form of Indemnification and Advancement Agreement for directors and officers </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001528115/000119312520186799/d773514dex211.htm">List of subsidiaries </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d773514dex231.htm">Consent of KPMG LLP, independent registered public accounting firm</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d773514dex51.htm">Consent of Latham&nbsp;&amp; Watkins&nbsp;LLP (included in Exhibit&nbsp;5.1)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1528115/000119312520186799/d773514ds1.htm#ii773514_sig">Power of Attorney (reference is made to the signature page of the initial filing of the Registration Statement) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">07/02/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Certain portions of this document that constitute confidential information have been redacted in accordance
with Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> Item 601(b)(10). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial Statement Schedules. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is
shown in the consolidated financial statements or notes thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting
agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned Registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">1.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this Registration Statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">2.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Amendment
No.&nbsp;2 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California on July 23, 2020. </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ANNEXON, INC.</B></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Douglas Love,
Esq.</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Douglas Love, Esq.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, as amended, this
Amendment No.&nbsp;2 to the Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> has been signed by the following persons in the capacities and on the dates indicated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Douglas Love, Esq.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Douglas Love, Esq.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director <I>(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">July 23, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jennifer Lew</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jennifer Lew</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President and Chief Financial Officer <I>(Principal Financial and Accounting Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">July 23, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">William D. Young</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">July 23, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-bottom:0pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jung E. Choi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">July 23, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Emmett Cunningham, M.D., Ph.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">July 23, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carol Gallagher, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">July 23, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Campbell Murray, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">July 23, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Muneer A. Satter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 23, 2020</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ricky Sun, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 23, 2020</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Thomas G. Wiggans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 23, 2020</P></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*By:</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer Lew</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jennifer Lew</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-Fact</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d773514dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Scott Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park,
California 94025</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +1.650.328.4600 Fax: +1.650.463.2600</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g773539v2.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:20pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;23, 2020</P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">180 Kimball Way, Suite 200</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">South San Francisco, California
94080</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beijing</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brussels</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Century City</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dubai</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D&#252;sseldorf</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frankfurt</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamburg</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Kong</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Los Angeles</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Milan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moscow</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Munich</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orange County</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paris</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Riyadh</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seoul</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silicon Valley</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tokyo</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Washington, D.C.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-239647)</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Up to 14,375,000 Shares of Common Stock of Annexon, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as special
counsel to Annexon, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the proposed issuance of up to 14,375,000 shares of common stock, par value $0.001 per share (the &#147;<B><I>Shares</I></B>&#148;). The
Shares are included in a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), filed with the Securities and Exchange Commission (the
&#147;<B><I>Commission</I></B>&#148;) on July&nbsp;2, 2020 (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-239647)</FONT> (as amended, the &#147;<B><I>Registration Statement</I></B>&#148;). This opinion is being furnished in connection
with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectus (the
&#147;<B><I>Prospectus</I></B>&#148;), other than as expressly stated herein with respect to the issue of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we
have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual
matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), and we express no opinion with respect to any other laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have
been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the
form of underwriting agreement most recently filed as an exhibit to the Registration Statement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued,
fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>July 23, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page 2 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g773539v1_page1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be
relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus under
the heading &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Latham&nbsp;&amp; Watkins LLP</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5.(A)
<SEQUENCE>3
<FILENAME>d773514dex105a.htm
<DESCRIPTION>EX-10.5.(A)
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5.(a)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5(a) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020
INCENTIVE AWARD PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan&#146;s
purpose is to enhance the Company&#146;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following words and phrases have the meanings specified below, unless the context clearly indicates
otherwise: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 &#147;<B><I>Administrator</I></B>&#148; means the Board or a Committee to the extent that the Board&#146;s powers or
authority under the Plan have been delegated to such Committee. With reference to the Board&#146;s or a Committee&#146;s powers or authority under the Plan that have been delegated to one or more officers pursuant to Section&nbsp;4.2, the term
&#147;Administrator&#148; shall refer to such officer(s) unless and until such delegation has been revoked. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 &#147;<B><I>Applicable
Law</I></B>&#148; means any applicable law, including without limitation: (a)&nbsp;provisions of the Code, the Securities Act, the Exchange Act and any rules or regulations thereunder; (b)&nbsp;corporate, securities, tax or other laws, statutes,
rules, requirements or regulations, whether federal, state, local or foreign; and (c)&nbsp;rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or traded. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 &#147;<B><I>Award</I></B>&#148; means an Option, Stock Appreciation Right, Restricted Stock award, Restricted Stock Unit award, Performance
Bonus Award, Performance Stock Unit award, Dividend Equivalents award or Other Stock or Cash Based Award granted to a Participant under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 &#147;<B><I>Award Agreement</I></B>&#148; means an agreement evidencing an Award, which may be written or electronic, that contains such
terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5
&#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 &#147;<B><I>Change in Control</I></B>&#148; means any of
the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) A transaction or series of transactions (other than an offering of Common Stock to the general public through a
registration statement filed with the Securities and Exchange Commission) whereby any &#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) directly or
indirectly acquires beneficial ownership (within the meaning of Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> under the Exchange Act) of the Company&#146;s securities possessing more than 50%
of the total combined voting power of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s securities outstanding immediately after such acquisition; provided, however, that the following acquisitions shall not constitute a Change in Control: (i)&nbsp;any acquisition by
the Company or any of its Subsidiaries; (ii)&nbsp;any acquisition by an employee benefit plan maintained by the Company or any of its Subsidiaries, (iii)&nbsp;any acquisition which complies with Sections 2.6(c)(i), 2.6(c)(ii) and 2.6(c)(iii); or
(iv)&nbsp;in respect of an Award held by a particular Participant, any acquisition by the Participant or any group of persons including the Participant (or any entity controlled by the Participant or any group of persons including the Participant);
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Incumbent Directors cease for any reason to constitute a majority of the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more
intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination, (y)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related transactions
or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) which results in the
Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction,
controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#147;<B><I>Successor
Entity</I></B>&#148;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor
Entity; provided<I>, </I>however, that no person or group shall be treated for purposes of this Section&nbsp;2.6(c)(ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power
held in the Company prior to the consummation of the transaction; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) after which at least a majority of the members of the board
of directors (or the analogous governing body) of the Successor Entity were Board members at the time of the Board&#146;s approval of the execution of the initial agreement providing for such transaction; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The completion of a liquidation or dissolution of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Award (or any portion of an Award) that provides for the
deferral of compensation that is subject to Section&nbsp;409A, to the extent required to avoid the imposition of additional taxes under Section&nbsp;409A, the transaction or event described in subsection (a), (b), (c) or (d)&nbsp;of this
Section&nbsp;2.6 with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#147;change in control event,&#148; as defined in
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Administrator shall have full and final authority, which shall be exercised in its sole discretion, to
determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a
determination of whether a Change in Control is a &#147;change in control event&#148; as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> shall be consistent with such regulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 &#147;<B><I>Code</I></B>&#148; means the U.S. Internal Revenue Code of 1986, as amended, and all regulations, guidance, compliance programs
and other interpretative authority issued thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 &#147;<B><I>Committee</I></B>&#148; means one or more committees or
subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent permitted by Applicable Law. To the extent required to comply with the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT>
it is intended that each member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> a
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3;</FONT> however, a Committee member&#146;s failure to qualify as a
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> will not invalidate any Award granted by the Committee that is otherwise validly granted under the
Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 &#147;<B><I>Company</I></B>&#148; means Annexon, Inc., a Delaware corporation, or any successor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 &#147;<B><I>Consultant</I></B>&#148; means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render
services to such entity if the consultant or adviser: (i)&nbsp;renders bona fide services to the Company; (ii)&nbsp;renders services not in connection with the offer or sale of securities in a capital-raising transaction and does not directly or
indirectly promote or maintain a market for the Company&#146;s securities; and (iii)&nbsp;is a natural person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 &#147;<B><I>Designated
Beneficiary</I></B>&#148; means the beneficiary or beneficiaries the Participant designates, in a manner the Company determines, to receive amounts due or exercise the Participant&#146;s rights if the Participant dies. Without a Participant&#146;s
effective designation, &#147;Designated Beneficiary&#148; will mean the Participant&#146;s estate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13 &#147;<B><I>Director</I></B>&#148;
means a Board member. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.14 &#147;<B><I>Disability</I></B>&#148; means a permanent and total disability under Section&nbsp;22(e)(3) of the
Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.15 &#147;<B><I>Dividend Equivalents</I></B>&#148; means a right granted to a Participant to receive the equivalent value (in cash
or Shares) of dividends paid on a specified number of Shares. Such Dividend Equivalent shall be converted to cash or additional Shares, or a combination of cash and Shares, by such formula and at such time and subject to such limitations as may be
determined by the Administrator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.16 &#147;<B><I>DRO</I></B>&#148; means a &#147;domestic relations order&#148; as defined
by the Code or Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.17
&#147;<B><I>Effective Date</I></B>&#148; has the meaning set forth in Section&nbsp;11.3. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.18 &#147;<B><I>Employee</I></B>&#148; means any
employee of the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.19 &#147;<B><I>Equity Restructuring</I></B>&#148; means a nonreciprocal transaction
between the Company and its stockholders, such as a stock dividend, stock split (including a reverse stock split), <FONT STYLE="white-space:nowrap">spin-off</FONT> or recapitalization through a large, nonrecurring cash dividend, that affects the
number or kind of Shares (or other Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.20 &#147;<B><I>Exchange Act</I></B>&#148; means the U.S. Securities Exchange Act of 1934, as amended, and all regulations, guidance and other
interpretative authority issued thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.21 &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a Share
determined as follows: (i)&nbsp;if the Common Stock is listed on any established stock exchange, the value of a Share will be the closing sales price for a Share as quoted on such exchange for such date, or if no sale occurred on such date, the last
day preceding such date during which a sale occurred, as reported in <I>The Wall Street Journal</I> or another source the Administrator deems reliable; (ii)&nbsp;if the Common Stock is not listed on an established stock exchange but is quoted on a
national market or other quotation system, the value of a Share will be the closing sales price for a Share on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in
The Wall Street Journal or another source the Administrator deems reliable; or (iii)&nbsp;if the Common Stock is not listed on any established stock exchange or quoted on a national market or other quotation system, the value established by the
Administrator in its sole discretion. Notwithstanding the foregoing, with respect to any Award granted on or after the effectiveness of the Company&#146;s registration statement relating to its initial public offering and prior to the Public Trading
Date, the Fair Market Value means the initial public offering price of a Share as set forth in the Company&#146;s final prospectus relating to its initial public offering filed with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.22 &#147;<B><I>Greater Than 10% Stockholder</I></B>&#148; means an individual then owning (within the meaning of Section&nbsp;424(d) of the
Code) more than 10% of the total combined voting power of all classes of stock of the Company or any parent corporation or subsidiary corporation of the Company, as determined in accordance with in Section&nbsp;424(e) and (f)&nbsp;of the Code,
respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.23 &#147;<B><I>Incentive Stock Option</I></B>&#148; means an Option that meets the requirements to qualify as an
&#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.24 &#147;<B><I>Incumbent Directors&#148;</I></B> means,
for any period of 12 consecutive months, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company
to effect a transaction described in Section&nbsp;2.6(a) or 2.6(c)) whose election or nomination for election to the Board was approved by a vote of at least a majority (either by a specific vote or by approval of the proxy statement of the Company
in which such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
person is named as a nominee for Director without objection to such nomination) of the Directors then still in office who either were Directors at the beginning of the <FONT
STYLE="white-space:nowrap">12-month</FONT> period or whose election or nomination for election was previously so approved. No individual initially elected or nominated as a director of the Company as a result of an actual or threatened election
contest with respect to Directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be an Incumbent Director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.25 &#147;<B><I>Nonqualified Stock Option</I></B>&#148; means an Option that is not an Incentive Stock Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.26 &#147;<B><I>Option</I></B>&#148; means a right granted under Article VI to purchase a specified number of Shares at a specified price per
Share during a specified time period. An Option may be either an Incentive Stock Option or a Nonqualified Stock Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.27
&#147;<B><I>Other Stock or Cash Based Awards</I></B>&#148; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.28 &#147;<B><I>Overall Share Limit</I></B>&#148; means the sum of (i) [3,375,868] Shares; (ii)&nbsp;any Shares that are subject to Prior Plan
Awards that become available for issuance under the Plan pursuant to Article V; and (iii)&nbsp;an annual increase on the first day of each year beginning in 2021 and ending in 2030, equal to the lesser of (A) 4% of the Shares outstanding on the last
day of the immediately preceding fiscal year and (B)&nbsp;such smaller number of Shares as determined by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.29
&#147;<B><I>Participant</I></B>&#148; means a Service Provider who has been granted an Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.30 &#147;<B><I>Performance Bonus
Award</I></B>&#148; has the meaning set forth in Section&nbsp;8.3. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.31 &#147;<B><I>Performance Stock Unit</I></B>&#148; means a right
granted to a Participant pursuant to Section&nbsp;8.1 and subject to Section&nbsp;8.2, to receive Shares, the payment of which is contingent upon achieving certain performance goals or other performance-based targets established by the
Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.32 &#147;<B><I>Permitted Transferee</I></B>&#148; means, with respect to a Participant, any &#147;family member&#148; of
the Participant, as defined in the General Instructions to Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act (or any successor form thereto), or any other transferee specifically approved by the
Administrator after taking into account Applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.33 &#147;<B><I>Plan</I></B>&#148; means this 2019 Incentive Award Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.34 &#147;<B><I>Prior Plan</I></B>&#148; means the Company&#146;s 2011 Equity Incentive Plan, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.35 &#147;<B><I>Prior Plan Award</I></B>&#148; means an award outstanding under the Prior
Plan as of the Effective Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.36 &#147;<B><I>Public Trading Date</I></B>&#148; means the first date upon which Common Stock is listed
upon notice of issuance on any securities exchange or designated upon notice of issuance as a national market security on an interdealer quotation system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.37 &#147;<B><I>Restricted Stock</I></B>&#148; means Shares awarded to a Participant under Article VII, subject to certain vesting conditions
and other restrictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.38 &#147;<B><I>Restricted Stock Unit</I></B>&#148; means an unfunded, unsecured right to receive, on the
applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.39 &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
promulgated under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.40 &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148; means Section&nbsp;409A
of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.41 &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended, and all regulations, guidance and
other interpretative authority issued thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.42 &#147;<B><I>Service Provider</I></B>&#148; means an Employee, Consultant or
Director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.43 &#147;<B><I>Shares</I></B>&#148; means shares of Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.44 &#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148; means a right granted under Article VI to receive a
payment equal to the excess of the Fair Market Value of a specified number of Shares on the date the right is exercised over the exercise price set forth in the applicable Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.45 &#147;<B><I>Subsidiary</I></B>&#148; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of
entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of
all classes of securities or interests in one of the other entities in such chain. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.46 &#147;<B><I>Substitute Awards</I></B>&#148; means
Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company or other entity acquired by the Company or
any Subsidiary or with which the Company or any Subsidiary combines. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.47 &#147;<B><I>Termination of Service</I></B>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As to a Consultant, the time when the engagement of a Participant as a Consultant to the Company or a Subsidiary is terminated for any
reason, with or without cause, including, without limitation, by resignation, discharge, death or retirement, but excluding terminations where the Consultant simultaneously commences or remains in employment or service with the Company or any
Subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As to a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, the time when a
Participant who is a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director ceases to be a Director for any reason, including, without limitation, a termination by resignation, failure to be elected, death or retirement, but excluding
terminations where the Participant simultaneously commences or remains in employment or service with the Company or any Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As
to an Employee, the time when the employee-employer relationship between a Participant and the Company or any Subsidiary is terminated for any reason, including, without limitation, a termination by resignation, discharge, death, disability or
retirement; but excluding terminations where the Participant simultaneously commences or remains in employment or service with the Company or any Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, in its sole discretion, shall determine the effect of all matters and questions relating to any Termination of Service,
including, without limitation, whether a Termination of Service has occurred, whether a Termination of Service resulted from a discharge for &#147;cause&#148; and all questions of whether particular leaves of absence constitute a Termination of
Service. For purposes of the Plan, a Participant&#146;s employee-employer relationship or consultancy relationship shall be deemed to be terminated in the event that the Subsidiary employing or contracting with such Participant ceases to remain a
Subsidiary following any merger, sale of stock or other corporate transaction or event (including, without limitation, a <FONT STYLE="white-space:nowrap">spin-off),</FONT> even though the Participant may subsequently continue to perform services for
that entity. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Service
Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein. No Service Provider shall have any right to be granted an Award pursuant to the Plan and neither the Company nor the Administrator is obligated
to treat Service Providers, Participants or any other persons uniformly. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATION AND DELEGATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Administration</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The
Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable.
The Administrator may correct defects and ambiguities, supply omissions, reconcile inconsistencies in the Plan or any Award and make all other determinations that it deems necessary or appropriate to administer the Plan and any Awards. The
Administrator (and each member thereof) is entitled to, in good faith, rely or act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon any report or other information furnished to it, him or her by any officer or other employee of the Company or any Subsidiary, the Company&#146;s independent certified public accountants, or
any executive compensation consultant or other professional retained by the Company to assist in the administration of the Plan. The Administrator&#146;s determinations under the Plan are in its sole discretion and will be final, binding and
conclusive on all persons having or claiming any interest in the Plan or any Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the foregoing, the Administrator
has the exclusive power, authority and sole discretion to: (i)&nbsp;designate Participants; (ii)&nbsp;determine the type or types of Awards to be granted to each Participant; (iii)&nbsp;determine the number of Awards to be granted and the number of
Shares to which an Award will relate; (iv)&nbsp;subject to the limitations in the Plan, determine the terms and conditions of any Award and related Award Agreement, including, but not limited to, the exercise price, grant price, purchase price, any
performance criteria, any restrictions or limitations on the Award, any schedule for vesting, lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations, waivers or amendments thereof; (v)&nbsp;determine
whether, to what extent, and under what circumstances an Award may be settled in, or the exercise price of an Award may be paid in cash, Shares, or other property, or an Award may be canceled, forfeited, or surrendered; and (vi)&nbsp;make all other
decisions and determinations that may be required pursuant to the Plan or as the Administrator deems necessary or advisable to administer the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Delegation of Authority</U>. To the extent permitted by Applicable Law, the Board or any Committee may delegate any or all of its powers
under the Plan to one or more Committees or officers of the Company or any of its Subsidiaries; provided,<I> </I>however, that in no event shall an officer of the Company or any of its Subsidiaries be delegated the authority to grant Awards to, or
amend Awards held by, the following individuals: (a)&nbsp;individuals who are subject to Section&nbsp;16 of the Exchange Act, or (b)&nbsp;officers of the Company or any of its Subsidiaries or Directors to whom authority to grant or amend Awards has
been delegated hereunder. Any delegation hereunder shall be subject to the restrictions and limits that the Board or Committee specifies at the time of such delegation or that are otherwise included in the applicable organizational documents, and
the Board or Committee, as applicable, may at any time rescind the authority so delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section&nbsp;4.2<B> </B>shall serve in such capacity at the pleasure of the Board
or the Committee, as applicable, and the Board or the Committee may abolish any committee at any time and <FONT STYLE="white-space:nowrap">re-vest</FONT> in itself any previously delegated authority. Further, regardless of any delegation, the Board
or a Committee may, in its discretion, exercise any and all rights and duties as the Administrator under the Plan delegated thereby, except with respect to Awards that are required to be determined in the sole discretion of the Committee under the
rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or traded. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK AVAILABLE FOR AWARDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Number of Shares</U>. Subject to adjustment under Article IX and the terms of this Article&nbsp;V, Awards may be made under the Plan
covering up to the Overall Share Limit. As of the Effective Date, the Company will cease granting awards under the Prior Plan; however, Prior Plan Awards will remain subject to the terms of the Prior Plan. Shares issued or delivered under the Plan
may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Share Recycling</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If all or any part of an Award or Prior Plan Award expires, lapses or is terminated, converted into an award in respect of shares of
another entity in connection with a <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar event, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that
results in the Company acquiring Shares covered by the Award or Prior Plan Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the
Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Awards under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards
or Prior Plan Awards shall not count against the Overall Share Limit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In addition, the following Shares shall be available for future
grants of Awards: (i)&nbsp;Shares tendered by a Participant or withheld by the Company in payment of the exercise price of an Option or any stock option granted under the Prior Plan; (ii)&nbsp;Shares tendered by the Participant or withheld by the
Company to satisfy any tax withholding obligation with respect to an Award or any award granted under the Prior Plan; and (iii)&nbsp;Shares subject to a Stock Appreciation Right that are not issued in connection with the stock settlement of the
Stock Appreciation Right on exercise thereof. Notwithstanding the provisions of this Section&nbsp;5.2(b), no Shares may again be optioned, granted or awarded pursuant to an Incentive Stock Option if such action would cause such Option to fail to
qualify as an incentive stock option under Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Incentive Stock Option Limitations</U>. Notwithstanding
anything to the contrary herein, no more than [20,255,212] Shares (as adjusted to reflect any Equity Restructuring) may be issued pursuant to the exercise of Incentive Stock Options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Substitute Awards</U>. In connection with an entity&#146;s merger or consolidation with the Company or any Subsidiary or the
Company&#146;s or any Subsidiary&#146;s acquisition of an entity&#146;s property or stock, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted before such merger or consolidation by such
entity or its affiliate. Substitute Awards may be granted on such terms and conditions as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Overall Share Limit (nor
shall Shares subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of Shares
that may be issued pursuant to the exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any Subsidiary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or with which the Company or any Subsidiary combines has shares available under a <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan approved by stockholders and not adopted in
contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan (as appropriately adjusted to reflect the transaction) may be used for Awards
under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards may again become available for Awards under the Plan as provided under Section&nbsp;5.2 above); provided that Awards using such
available shares shall not be made after the date awards or grants could have been made under the terms of the <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan, absent the acquisition or combination, and shall only be made to individuals
who were not employees or directors of the Company or any of its Subsidiaries prior to such acquisition or combination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Award Limit</U>. Notwithstanding any provision to the contrary in the Plan or in any policy of the Company regarding <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation,
the sum of the grant date fair value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of all equity-based Awards and the maximum amount
that may become payable pursuant to all cash-based Awards that may be granted to a Service Provider as compensation for services as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director during any calendar year shall not exceed $1,000,000
for such Service Provider&#146;s first year of service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director and $700,000 for each year thereafter. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK
OPTIONS AND STOCK APPRECIATION RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>General</U>. The Administrator may grant Options or Stock Appreciation Rights to one or
more Service Providers, subject to such terms and conditions not inconsistent with the Plan as the Administrator shall determine. The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the exercise
price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the Participant (or other person entitled to
exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of
exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and
payable in cash, Shares valued at Fair Market Value on the date of exercise or a combination of the two as the Administrator may determine or provide in the Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Exercise Price</U>. The Administrator will establish each Option&#146;s and Stock Appreciation Right&#146;s exercise price and specify
the exercise price in the Award Agreement. Subject to Section&nbsp;6.6, the exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right. Notwithstanding the foregoing, in the case of
an Option or Stock Appreciation Right that is a Substitute Award, the exercise price per share of the Shares subject to such Option or Stock Appreciation Right, as applicable, may be less than the Fair Market Value per share on the date of grant;
provided that the exercise price of any Substitute Award shall be determined in accordance with the applicable requirements of Section&nbsp;424 and 409A of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Duration of Options</U>. Subject to Section&nbsp;6.6, each Option or Stock
Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten years; provided, further, that, unless otherwise determined by the
Administrator, (a)&nbsp;no portion of an Option or Stock Appreciation Right which is unexercisable at a Participant&#146;s Termination of Service shall thereafter become exercisable and (b)&nbsp;the portion of an Option or Stock Appreciation Right
that is unexercisable at a Participant&#146;s Termination of Service shall automatically expire on the date of such Termination of Service. Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock
Appreciation Right, commits an act of &#147;cause&#148; (as determined by the Administrator), or violates any <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or confidentiality
provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right to exercise the Option or Stock Appreciation Right, as applicable,
may be terminated by the Company and the Company may suspend the Participant&#146;s right to exercise the Option or Stock Appreciation Right when it reasonably believes that the Participant may have participated in any such act or violation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Exercise</U>. Options and Stock Appreciation Rights may be exercised by delivering to the Company (or such other person or entity
designated by the Administrator) a notice of exercise, in a form and manner the Company approves (which may be written, electronic or telephonic and may contain representations and warranties deemed advisable by the Administrator), signed or
authenticated by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full of (a)&nbsp;the exercise price for the number of Shares for which the Option is exercised in a manner specified
in Section&nbsp;6.5 and (b)&nbsp;all applicable taxes in a manner specified in Section&nbsp;10.5. The Administrator may, in its discretion, limit exercise with respect to fractional Shares and require that any partial exercise of an Option or Stock
Appreciation Right be with respect to a minimum number of Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Payment Upon Exercise</U>. The Administrator shall determine the
methods by which payment of the exercise price of an Option shall be made, including, without limitation: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Cash, check or wire transfer
of immediately available funds; provided that the Company may limit the use of one of the foregoing methods if one or more of the methods below is permitted; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A)&nbsp;delivery (including
electronically or telephonically to the extent permitted by the Company) of a notice that the Participant has placed a market sell order with a broker acceptable to the Company with respect to Shares then issuable upon exercise of the Option and
that the broker has been directed to deliver promptly to the Company funds sufficient to pay the exercise price, or (B)&nbsp;the Participant&#146;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker
acceptable to the Company to deliver promptly to the Company an amount sufficient to pay the exercise price by cash, wire transfer of immediately available funds or check; provided that such amount is paid to the Company at such time as may be
required by the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by the Administrator, delivery (either by actual delivery or
attestation) of Shares owned by the Participant valued at their Fair Market Value on the date of delivery; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the extent permitted by
the Administrator, surrendering Shares then issuable upon the Option&#146;s exercise valued at their Fair Market Value on the exercise date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the extent permitted by the Administrator, delivery of a promissory note or any other lawful consideration; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the extent permitted by the Administrator, any combination of the above payment forms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Additional Terms of Incentive Stock Options</U>. The Administrator may grant Incentive Stock Options only to employees of the Company,
any of its present or future parent or subsidiary corporations, as defined in Sections&nbsp;424(e) or (f)&nbsp;of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code.
If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not be less than 110% of the Fair Market Value on the Option&#146;s grant date, and the term of the Option will not exceed five years. All Incentive
Stock Options (and Award Agreements related thereto) will be subject to and construed consistently with Section&nbsp;422 of the Code. By accepting an Incentive Stock Option, the Participant agrees to give prompt notice to the Company of dispositions
or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (a)&nbsp;two years from the grant date of the Option or (b)&nbsp;one year after the transfer of such Shares to the Participant,
specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or other consideration, in such disposition or other transfer. Neither the Company nor the
Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code. Any Incentive Stock Option or portion thereof
that fails to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code for any reason, including becoming exercisable with respect to Shares having a fair market value exceeding the $100,000 limitation under Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.422-4,</FONT> will be a Nonqualified Stock Option. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK; RESTRICTED STOCK UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>General</U>. The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject
to forfeiture or the Company&#146;s right to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant if conditions the Administrator specifies in the Award Agreement are not satisfied before
the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the
applicable restriction period or periods, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
set forth in an Award Agreement, to Service Providers. The Administrator shall establish the purchase price, if any, and form of payment for Restricted Stock and Restricted Stock Units; provided,
however, that if a purchase price is charged, such purchase price shall be no less than the par value, if any, of the Shares to be purchased, unless otherwise permitted by Applicable Law. In all cases, legal consideration shall be required for each
issuance of Restricted Stock and Restricted Stock Units to the extent required by Applicable Law. The Award Agreement for each Restricted Stock and Restricted Stock Unit Award shall set forth the terms and conditions not inconsistent with the Plan
as the Administrator shall determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Restricted Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Stockholder Rights</I>. Unless otherwise determined by the Administrator, each Participant holding shares of Restricted Stock will be
entitled to all the rights of a stockholder with respect to such Shares, subject to the restrictions in the Plan and the applicable Award Agreement, including the right to receive all dividends and other distributions paid or made with respect to
the Shares to the extent such dividends and other distributions have a record date that is on or after the date on which such Participant becomes the record holder of such Shares; provided, however, that with respect to a share of Restricted Stock
subject to restrictions or vesting conditions as described in Section&nbsp;8.3, except in connection with a <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar event as otherwise permitted under Section&nbsp;9.2, dividends which are
paid to Company stockholders prior to the removal of restrictions and satisfaction of vesting conditions shall only be paid to the Participant to the extent that the restrictions are subsequently removed and the vesting conditions are subsequently
satisfied and the share of Restricted Stock vests. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Stock Certificates</I>. The Company may require that the Participant deposit in
escrow with the Company (or its designee) any stock certificates issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Section 83(b) Election</I>. If a Participant makes an election under Section&nbsp;83(b) of the Code to be taxed with respect to the
Restricted Stock as of the date of transfer of the Restricted Stock rather than as of the date or dates upon which such Participant would otherwise be taxable under Section&nbsp;83(a) of the Code, such Participant shall be required to deliver a copy
of such election to the Company promptly after filing such election with the Internal Revenue Service along with proof of the timely filing thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <U>Restricted Stock Units</U>. The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as
reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#146;s election, subject to compliance with Applicable Law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER
TYPES OF AWARDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>General</U>. The Administrator may grant Performance Stock Unit awards, Performance Bonus Awards, Dividend
Equivalents or Other Stock or Cash Based Awards, to one or more Service Providers, in such amounts and subject to such terms and conditions not inconsistent with the Plan as the Administrator shall determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U>Performance Stock Unit Awards</U>. Each Performance Stock Unit award shall be
denominated in a number of Shares or in unit equivalents of Shares or units of value (including a dollar value of Shares) and may be linked to any one or more of performance or other specific criteria, including service to the Company or
Subsidiaries, determined to be appropriate by the Administrator, in each case on a specified date or dates or over any period or periods determined by the Administrator. In making such determinations, the Administrator may consider (among such other
factors as it deems relevant in light of the specific type of award) the contributions, responsibilities and other compensation of the particular Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3 <U>Performance Bonus Awards</U>. Each right to receive a bonus granted under this Section&nbsp;8.3 shall be denominated in the form of cash
(but may be payable in cash, stock or a combination thereof) (a &#147;<B><I>Performance Bonus Award</I></B>&#148;) and shall be payable upon the attainment of performance goals that are established by the Administrator and relate to one or more of
performance or other specific criteria, including service to the Company or Subsidiaries, in each case on a specified date or dates or over any period or periods determined by the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4 <U>Dividend Equivalents</U>. If the Administrator provides, an Award (other than an Option or Stock Appreciation Right) may provide a
Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and
forfeitability as the Award with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement. Notwithstanding anything to the contrary herein, Dividend Equivalents with respect
to an Award subject to vesting shall either (i)&nbsp;to the extent permitted by Applicable Law, not be paid or credited or (ii)&nbsp;be accumulated and subject to vesting to the same extent as the related Award. All such Dividend Equivalents shall
be paid at such time as the Administrator shall specify in the applicable Award Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5 <U>Other Stock or Cash Based Awards</U>.
Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive cash or Shares to be delivered in the future and annual or other periodic or long-term cash bonus awards (whether based on specified
performance criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as
payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. Subject to the provisions of the Plan, the Administrator
will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal(s), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement. Except in
connection with a <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar event as otherwise permitted under Article IX, dividends that are paid prior to vesting of any Other Stock or Cash Based Award shall only be paid to the applicable
Participant to the extent that the vesting conditions are subsequently satisfied and the Other Stock or Cash Based Award vests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADJUSTMENTS FOR CHANGES IN COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND CERTAIN OTHER EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 <U>Equity Restructuring</U><U></U>. In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article
IX the Administrator will equitably adjust the terms of the Plan and each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include (i)&nbsp;adjusting the number and type of securities subject to each
outstanding Award or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article V hereof on the maximum number and kind of shares that may be issued); (ii)&nbsp;adjusting the
terms and conditions of (including the grant or exercise price), and the performance goals or other criteria included in, outstanding Awards; and (iii)&nbsp;granting new Awards or making cash payments to Participants. The adjustments provided under
this Section&nbsp;9.1 will be nondiscretionary and final and binding on all interested parties, including the affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 <U>Corporate Transactions</U>. In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other
securities, or other property), reorganization, merger, consolidation, split-up, spin off, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially
all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate
transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Law or accounting principles, the Administrator, on such terms and conditions as it deems
appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of
time after such change) and either automatically or upon the Participant&#146;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to
(x)&nbsp;prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y)&nbsp;to facilitate such transaction or
event or (z)&nbsp;give effect to such changes in Applicable Law or accounting principles: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To provide for the cancellation of any such
Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#146;s rights under
the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#146;s rights, in any case, is equal to
or less than zero, then the Award may be terminated without payment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To provide that such Award shall vest and, to the extent
applicable, be exercisable as to all Shares (or other property) covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To provide that such Award be assumed by the successor or survivor corporation or
entity, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation or entity, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of
shares and applicable exercise or purchase price, in all cases, as determined by the Administrator; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To make adjustments in the number
and type of shares of Common Stock (or other securities or property) subject to outstanding Awards or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article V hereof on
the maximum number and kind of shares which may be issued) or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To replace such Award with other rights or property selected by the Administrator; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <U>Change in Control</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any other provision of the Plan, in the event of a Change in Control, unless the Administrator elects to (i)&nbsp;terminate
an Award in exchange for cash, rights or property, or (ii)&nbsp;cause an Award to become fully exercisable and no longer subject to any forfeiture restrictions prior to the consummation of a Change in Control, pursuant to Section&nbsp;9.2, (A) such
Award (other than any portion subject to performance-based vesting) shall continue in effect or be assumed or an equivalent Award substituted by the successor corporation or a parent or subsidiary of the successor corporation and (B)&nbsp;the
portion of such Award subject to performance-based vesting shall be subject to the terms and conditions of the applicable Award Agreement and, in the absence of applicable terms and conditions, the Administrator&#146;s discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that the successor corporation in a Change in Control refuses to assume or substitute for an Award, the Administrator shall
cause such Award to become fully vested and, if applicable, exercisable immediately prior to the consummation of such transaction and all forfeiture restrictions on such Award to lapse and, to the extent unexercised upon the consummation of such
transaction, to terminate in exchange for cash, rights or other property. Unless otherwise set forth in an applicable award agreement, for purposes of this Section&nbsp;9.3(b), each award subject to performance-based vesting will be deemed earned at
the greater of (i)&nbsp;target or (ii)&nbsp;actual achievement measured as of the Change in Control (to the extent then measurable). The Administrator shall notify the Participant of any Award that becomes exercisable pursuant to the preceding
sentence that such Award shall be fully exercisable for a period of 15 days from the date of such notice, contingent upon the occurrence of the Change in Control, and such Award shall terminate upon the consummation of the Change in Control in
accordance with the preceding sentence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For the purposes of this Section&nbsp;9.3, an Award shall be considered assumed if,
following the Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Change in Control, the consideration (whether stock, cash, or other securities or property) received in
the Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding
Shares); provided, however, that if such consideration received in the Change in Control was not solely common stock of the successor corporation or its parent, the Administrator may, with the consent of the successor corporation, provide for the
consideration to be received upon the exercise of the Award, for each Share subject to an Award, to be solely common stock of the successor corporation or its parent equal in fair market value to the <FONT STYLE="white-space:nowrap">per-share</FONT>
consideration received by holders of Common Stock in the Change in Control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 <U>Administrative Stand Still</U>. In the event of any
pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the
Shares or the share price of Common Stock (including any Equity Restructuring or any securities offering or other similar transaction) or for reasons of administrative convenience or to facilitate compliance with any Applicable Law, the Company may
refuse to permit the exercise or settlement of one or more Awards for such period of time as the Company may determine to be reasonably appropriate under the circumstances. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 <U>General</U>. Except as expressly provided in the Plan or the Administrator&#146;s action under the Plan, no Participant will have any
rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as
expressly provided with respect to an Equity Restructuring under Section&nbsp;9.1 above or the Administrator&#146;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will
affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#146;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in
any way the Company&#146;s right or power to make or authorize (i)&nbsp;any adjustment, recapitalization, reorganization or other change in the Company&#146;s capital structure or its business, (ii)&nbsp;any merger, consolidation, spinoff,
dissolution or liquidation of the Company or sale of Company assets or (iii)&nbsp;any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROVISIONS
APPLICABLE TO AWARDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>Transferability</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Award may be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or
the laws of descent and distribution, or, subject to the Administrator&#146;s consent, pursuant to a domestic relations order, unless and until such Award has been exercised or the Shares underlying such Award have been issued, and all restrictions
applicable to such Shares have lapsed. During the life of a Participant, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Awards will be exercisable only by the Participant, unless it has been disposed of pursuant to a domestic relations order. After the death of a Participant, any exercisable portion of an Award
may, prior to the time when such portion becomes unexercisable under the Plan or the applicable Award Agreement, be exercised by the Participant&#146;s personal representative or by any person empowered to do so under the deceased Participant&#146;s
will or under the then-Applicable Law of descent and distribution. References to a Participant, to the extent relevant in the context, will include references to a transferee approved by the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding Section&nbsp;10.1(a), the Administrator, in its sole discretion, may determine to permit a Participant or a Permitted
Transferee of such Participant to transfer an Award other than an Incentive Stock Option (unless such Incentive Stock Option is intended to become a Nonqualified Stock Option) to any one or more Permitted Transferees of such Participant, subject to
the following terms and conditions: (i)&nbsp;an Award transferred to a Permitted Transferee shall not be assignable or transferable by the Permitted Transferee other than (A)&nbsp;to another Permitted Transferee of the applicable Participant or
(B)&nbsp;by will or the laws of descent and distribution or, subject to the consent of the Administrator, pursuant to a domestic relations order; (ii)&nbsp;an Award transferred to a Permitted Transferee shall continue to be subject to all the terms
and conditions of the Award as applicable to the original Participant (other than the ability to further transfer the Award to any Person other than another Permitted Transferee of the applicable Participant); (iii) the Participant (or transferring
Permitted Transferee) and the receiving Permitted Transferee shall execute any and all documents requested by the Administrator, including, without limitation documents to (A)&nbsp;confirm the status of the transferee as a Permitted Transferee,
(B)&nbsp;satisfy any requirements for an exemption for the transfer under Applicable Law and (C)&nbsp;evidence the transfer; and (iv)&nbsp;any transfer of an Award to a Permitted Transferee shall be without consideration, except as required by
Applicable Law. In addition, and further notwithstanding Section&nbsp;10.1(a), the Administrator, in its sole discretion, may determine to permit a Participant to transfer Incentive Stock Options to a trust that constitutes a Permitted Transferee
if, under Section&nbsp;671 of the Code and other Applicable Law, the Participant is considered the sole beneficial owner of the Incentive Stock Option while it is held in the trust. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding Section&nbsp;10.1(a), a Participant may, in the manner determined by the Administrator, designate a Designated Beneficiary.
A Designated Beneficiary, legal guardian, legal representative, or other person claiming any rights pursuant to the Plan is subject to all terms and conditions of the Plan and any Award Agreement applicable to the Participant and any additional
restrictions deemed necessary or appropriate by the Administrator. If the Participant is married or a domestic partner in a domestic partnership qualified under Applicable Law and resides in a community property state, a designation of a person
other than the Participant&#146;s spouse or domestic partner, as applicable, as the Participant&#146;s Designated Beneficiary with respect to more than 50% of the Participant&#146;s interest in the Award shall not be effective without the prior
written or electronic consent of the Participant&#146;s spouse or domestic partner. Subject to the foregoing, a beneficiary designation may be changed or revoked by a Participant at any time; provided that the change or revocation is delivered in
writing to the Administrator prior to the Participant&#146;s death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>Documentation</U>. Each Award will be evidenced in an Award Agreement in such form
as the Administrator determines in its discretion. Each Award may contain such terms and conditions as are determined by the Administrator in its sole discretion, to the extent not inconsistent with those set forth in the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Discretion</U>. Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award.
The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4 <U>Changes in Participant&#146;s Status</U>. The Administrator will determine how the disability, death, retirement, authorized leave of
absence or any other change or purported change in a Participant&#146;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#146;s legal representative, conservator,
guardian or Designated Beneficiary may exercise rights under the Award, if applicable. Except to the extent otherwise required by law or expressly authorized by the Company or by the Company&#146;s written policy on leaves of absence, no Service
credit shall be given for vesting purposes for any period the Participant is on a leave of absence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5 <U>Withholding</U>. Each
Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#146;s Awards by the date of the event creating the tax liability. The
Company may deduct an amount sufficient to satisfy such tax obligations from any payment of any kind otherwise due to a Participant. The amount deducted shall be determined by the Company and may be up to, but no greater than, the aggregate amount
of such obligations based on the maximum statutory withholding rates in the applicable Participant&#146;s jurisdiction for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such taxable income. Subject to
any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i)&nbsp;in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company; provided that the
Company may limit the use of one of the foregoing methods if one or more of the exercise methods below is permitted, (ii)&nbsp;to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares delivered by
attestation and Shares retained from the Award creating the tax obligation, valued at their Fair Market Value on the date of delivery, (iii)&nbsp;if there is a public market for Shares at the time the tax obligations are satisfied, unless the
Administrator otherwise determines, (A)&nbsp;delivery (including electronically or telephonically to the extent permitted by the Company) of a notice that the Participant has placed a market sell order with a broker acceptable to the Company with
respect to Shares then issuable upon exercise of the Option and that the broker has been directed to deliver promptly to the Company funds sufficient to satisfy the tax obligations, or (B)&nbsp;the Participant&#146;s delivery to the Company of a
copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company an amount sufficient to satisfy the tax withholding by cash, wire transfer of immediately available funds or check; provided
that such amount is paid to the Company at such time as may be required by the Company, (iv)&nbsp;to the extent permitted by the Administrator, delivery of a promissory note or any other lawful consideration or (v)&nbsp;to the extent permitted by
the Administrator, any combination of the foregoing payment forms. If any tax withholding obligation will be satisfied under clause (ii)&nbsp;of the immediately preceding sentence by the Company&#146;s retention of Shares from the Award creating the
tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#146;s behalf some or all of the Shares retained and to remit the
proceeds of the sale to the Company or its designee, and each Participant&#146;s acceptance of an Award under the Plan will constitute the Participant&#146;s authorization to the Company and instruction and authorization to such brokerage firm to
complete the transactions described in this sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6 <U>Amendment of Award; Repricing</U>. The Administrator may amend, modify or
terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a Nonqualified Stock Option. The Participant&#146;s
consent to such action will be required unless (i)&nbsp;the action, taking into account any related action, does not materially and adversely affect the Participant&#146;s rights under the Award, or (ii)&nbsp;the change is permitted under Article IX
or pursuant to Section&nbsp;11.6. In addition, the Administrator shall, without the approval of the stockholders of the Company, have the authority to (a)&nbsp;amend any outstanding Option or Stock Appreciation Right to reduce its exercise price per
Share, or (b)&nbsp;cancel any Option or Stock Appreciation Right in exchange for cash or another Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.7 <U>Conditions on Delivery of
Stock</U>. The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i)&nbsp;all Award conditions have been met or removed to the Company&#146;s satisfaction,
(ii)&nbsp;as determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and
(iii)&nbsp;the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy Applicable Law. The Company&#146;s inability to obtain authority from any
regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite
authority has not been obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.8 <U>Acceleration</U>. The Administrator may at any time provide that any Award will become
immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 <U>No
Right to Employment or Other Status</U>. No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continue employment or any other relationship with the
Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement or
other written agreement between the Participant and the Company or any Subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 <U>No Rights as Stockholder; Certificates</U>. Subject to the Award Agreement, no
Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the
Administrator otherwise determines or Applicable Law requires, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of
the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on any share certificate or book entry to reference restrictions applicable to the Shares (including, without limitation, restrictions
applicable to Restricted Stock). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 <U>Effective Date</U>. The Plan will become effective on the date immediately prior to the date the
Company&#146;s registration statement relating to its initial public offering becomes effective (the &#147;<B><I>Effective Date</I></B>&#148;). No Incentive Stock Option may be granted pursuant to the Plan after the tenth anniversary of the earlier
of (i)&nbsp;the date the Plan was approved by the Board and (ii)&nbsp;the date the Plan was approved by the Company&#146;s stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4 <U>Amendment of Plan</U>. The Board may amend, suspend or terminate the Plan at any time and from time to time; provided that (a)&nbsp;no
amendment requiring stockholder approval to comply with Applicable Law shall be effective unless approved by the Board, and (b)&nbsp;no amendment, other than an increase to the Overall Share Limit or pursuant to Article IX or Section&nbsp;11.6, may
materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#146;s consent. No Awards may be granted under the Plan during any suspension period or after Plan termination. Awards outstanding
at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent
necessary to comply with Applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5 <U>Provisions for Foreign Participants</U>. The Administrator may modify Awards granted to
Participants who are foreign nationals or employed outside the United States, establish subplans or procedures under the Plan or take any other necessary or appropriate action to address Applicable Law, including (a)&nbsp;differences in laws, rules,
regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters, (b)&nbsp;listing and other requirements of any foreign securities exchange, and (c)&nbsp;any necessary local
governmental or regulatory exemptions or approvals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6 <U>Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>General</I>. The Company intends that all Awards be structured to comply with, or be exempt from, Section&nbsp;409A, such that no
adverse tax consequences, interest, or penalties under Section&nbsp;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#146;s consent, amend this Plan or Awards,
adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to
(A)&nbsp;exempt this Plan or any Award from Section&nbsp;409A, or (B)&nbsp;comply with Section&nbsp;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#146;s grant date.
The Company makes no representations or warranties as to an Award&#146;s tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment under Section&nbsp;409A or otherwise. The Company will have no obligation under this Section&nbsp;11.6 or otherwise to avoid the taxes, penalties or interest under Section&nbsp;409A
with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#147;nonqualified deferred compensation&#148; subject
to taxes, penalties or interest under Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Separation from Service</I>. If an Award constitutes &#147;nonqualified
deferred compensation&#148; under Section&nbsp;409A, any payment or settlement of such Award upon a Participant&#146;s Termination of Service will, to the extent necessary to avoid taxes under Section&nbsp;409A, be made only upon the
Participant&#146;s &#147;separation from service&#148; (within the meaning of Section&nbsp;409A), whether such &#147;separation from service&#148; occurs upon or after the Participant&#146;s Termination of Service. For purposes of this Plan or any
Award Agreement relating to any such payments or benefits, references to a &#147;termination,&#148; &#147;termination of employment&#148; or like terms means a &#147;separation from service.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Payments to Specified Employees</I>. Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of
&#147;nonqualified deferred compensation&#148; required to be made under an Award to a &#147;specified employee&#148; (as defined under Section&nbsp;409A and as the Administrator determines) due to his or her &#147;separation from service&#148;
will, to the extent necessary to avoid taxes under Section&nbsp;409A(a)(2)(B)(i) of the Code, be delayed for the <FONT STYLE="white-space:nowrap">six-month</FONT> period immediately following such &#147;separation from service&#148; (or, if earlier,
until the specified employee&#146;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such <FONT STYLE="white-space:nowrap">six-month</FONT> period or as soon as administratively practicable
thereafter (without interest). Any payments of &#147;nonqualified deferred compensation&#148; under such Award payable more than six months following the Participant&#146;s &#147;separation from service&#148; will be paid at the time or times the
payments are otherwise scheduled to be made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.7 <U>Limitations on Liability</U>. Notwithstanding any other provisions of the Plan, no
individual acting as a director, officer or other employee of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in
connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer or other employee of
the Company or any Subsidiary. The Company will indemnify and hold harmless each director, officer or other employee of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#146;s
administration or interpretation, against any cost or expense (including attorneys&#146; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#146;s approval) arising from any act or omission concerning this
Plan unless arising from such person&#146;s own fraud or bad faith; provided that he or she gives the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own
behalf. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.8 <U>Data Privacy</U>. As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the
collection, use and transfer, in electronic or other form, of personal data as described in this Section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participation in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#146;s name, address and telephone
number; birthdate; social security, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the
Plan and Awards (the &#147;<B><I>Data</I></B>&#148;). The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#146;s participation in the Plan, and the
Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. These recipients may be located in the Participant&#146;s country, or elsewhere, and
the Participant&#146;s country may have different data privacy laws and protections than the recipients&#146; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in
electronic or other form, to implement, administer and manage the Participant&#146;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any
Shares. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#146;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding
such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this
Section&nbsp;11.8 in writing, without cost, by contacting the local human resources representative. The Company may cancel Participant&#146;s ability to participate in the Plan and, in the Administrator&#146;s sole discretion, the Participant may
forfeit any outstanding Awards if the Participant refuses or withdraws the consents in this Section&nbsp;11.8. For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources
representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.9 <U>Severability</U>. If any portion of the Plan or any action taken under it is held illegal or invalid for any
reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.10 <U>Governing Documents</U>. If any contradiction occurs between the Plan and any Award Agreement or other written agreement between
a Participant and the Company (or any Subsidiary), the Plan will govern, unless such Award Agreement or other written agreement was approved by the Administrator and expressly provides that a specific provision of the Plan will not apply. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.11 <U>Governing Law</U>. The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware,
without regard to the conflict of law rules thereof or of any other jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.12 <U>Clawback Provisions</U>. All Awards (including
the gross amount of any proceeds, gains or other economic benefit the Participant actually or constructively receives upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will be subject to recoupment by
the Company to the extent required to comply with Applicable Law or any policy of the Company providing for the reimbursement of incentive compensation, whether or not such policy was in place at the time of grant of an Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.13 <U>Titles and Headings</U>. The titles and headings in the Plan are for convenience of
reference only and, if any conflict, the Plan&#146;s text, rather than such titles or headings, will control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.14 <U>Conformity to
Applicable Law</U>. Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Law. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in a manner intended to
conform with Applicable Law. To the extent Applicable Law permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.15 <U>Relationship to Other Benefits</U>. No payment under the Plan will be taken into account in determining any benefits under any
pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary, except as expressly provided in writing in such other plan or an agreement thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.16 <U>Unfunded Status of Awards</U>. The Plan is intended to be an &#147;unfunded&#148; plan for incentive compensation. With respect to any
payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or Award Agreement shall give the Participant any rights that are greater than those of a general creditor of the Company or any Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.17 <U>Limitations Applicable to Section</U><U></U><U>&nbsp;16 Persons</U>. Notwithstanding any other provision of the Plan, the Plan and any
Award granted or awarded to any individual who is then subject to Section&nbsp;16 of the Exchange Act shall be subject to any additional limitations set forth in any applicable exemptive rule under Section&nbsp;16 of the Exchange Act (including Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act and any amendments thereto) that are requirements for the application of such exemptive rule. To the extent permitted by Applicable Law, the Plan and Awards granted or awarded
hereunder shall be deemed amended to the extent necessary to conform to such applicable exemptive rule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.18 <U>Prohibition on Executive
Officer Loans</U>. Notwithstanding any other provision of the Plan to the contrary, no Participant who is a Director or an &#147;executive officer&#148; of the Company within the meaning of Section&nbsp;13(k) of the Exchange Act shall be permitted
to make payment with respect to any Awards granted under the Plan, or continue any extension of credit with respect to such payment, with a loan from the Company or a loan arranged by the Company in violation of Section&nbsp;13(k) of the Exchange
Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.19 <U>Broker-Assisted Sales</U>. In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed
by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&nbsp;10.5: (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes
due, or as soon thereafter as practicable; (b)&nbsp;such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price; (c)&nbsp;the applicable Participant will be responsible for
all broker&#146;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d)&nbsp;to the extent the Company
or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (e)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and its designees are under no obligation to arrange for such sale at any particular price; and (f)&nbsp;in the event the proceeds of such sale are insufficient to satisfy the
Participant&#146;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#146;s obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* &nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp; * &nbsp;&nbsp;&nbsp;&nbsp;* &nbsp;&nbsp;&nbsp;&nbsp;* </B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby certify that the foregoing Plan was adopted by the Board of Directors of Annexon, Inc. on December
11, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby certify that the foregoing Plan was approved by the stockholders of Annexon, Inc. on July 16, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executed on _________, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Corporate Secretary</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>4
<FILENAME>d773514dex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYEE
STOCK PURCHASE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan&#146;s
purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qualify as an &#147;employee stock purchase plan&#148; under
Section&nbsp;423 of the Code, and to help such employees provide for their future security and to encourage them to remain in the employment of the Company and its Subsidiaries. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following words and phrases have the meanings specified below, unless the context clearly indicates
otherwise: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 &#147;<B><I>Administrator</I></B>&#148; means the Committee, or such individuals to which authority to administer the Plan
has been delegated under Section&nbsp;7.1 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 &#147;<B><I>Agent</I></B>&#148; means the brokerage firm, bank or other financial
institution, entity or person(s), if any, engaged, retained, appointed or authorized to act as the agent of the Company or an Employee with regard to the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3 &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4 &#147;<B><I>Code</I></B>&#148; means the U.S. Internal Revenue Code of 1986, as amended, and all regulations, guidance, compliance programs
and other interpretative authority issued thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.5 &#147;<B><I>Committee</I></B>&#148; means the Compensation Committee of the
Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.6 &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.7 &#147;<B><I>Company</I></B>&#148; means Annexon, Inc., a Delaware corporation, or any successor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.8 &#147;<B><I>Compensation</I></B>&#148; of an Employee means the regular earnings or base salary paid to the Employee from the Company on
each Payday as compensation for services to the Company or any Designated Subsidiary, before deduction for any salary deferral contributions made by the Employee to any <FONT STYLE="white-space:nowrap">tax-qualified</FONT> or nonqualified deferred
compensation plan, including, if applicable, overtime, shift differentials, vacation pay, salaried production schedule premiums, holiday pay, jury duty pay, funeral leave pay, paid time off, military pay, prior week adjustments and weekly bonus, but
excluding education or tuition reimbursements, imputed income arising under any group insurance or benefit program, travel expenses, business and moving reimbursements, including tax gross ups and taxable mileage allowance, income </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">received in connection with any stock options, restricted stock, restricted stock units or other
compensatory equity awards and all contributions made by the Company or any Designated Subsidiary for the Employee&#146;s benefit under any employee benefit plan now or hereafter established. Such Compensation shall be calculated before deduction of
any income or employment tax withholdings, but shall be withheld from the Employee&#146;s net income. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.9 &#147;<B><I>Designated
Subsidiary</I></B>&#148; means each Subsidiary that has been designated by the Board or Committee from time to time in its sole discretion as eligible to participate in the Plan, including any Subsidiary in existence on the Effective Date and any
Subsidiary formed or acquired following the Effective Date, in accordance with Section&nbsp;7.2 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.10 &#147;<B><I>Effective
Date</I></B>&#148; means the date immediately prior to the date the Company&#146;s registration statement relating to its initial public offering becomes effective, <I>provided</I> that the Board has adopted the Plan prior to or on such date,
subject to approval of the Plan by the Company&#146;s stockholders in accordance with Section&nbsp;7.7 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.11 &#147;<B><I>Eligible
Employee</I></B>&#148; means an Employee who: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) is customarily scheduled to work at least 20 hours per week; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) whose customary employment is more than five months in a calendar year; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) after the granting of the Option would not be deemed for purposes of Section&nbsp;423(b)(3) of the Code to possess 5% or more of the total
combined voting power or value of all classes of stock of the Company or any Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of clause (c), the rules of Section&nbsp;424(d) of
the Code with regard to the attribution of stock ownership shall apply in determining the stock ownership of an individual, and stock which an Employee may purchase under outstanding options shall be treated as stock owned by the Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Administrator may exclude from participation in the Plan as an Eligible Employee: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) any Employee that is a &#147;highly compensated employee&#148; of the Company or any Designated Subsidiary (within the meaning of
Section&nbsp;414(q) of the Code), or that is such a &#147;highly compensated employee&#148; (A) with compensation above a specified level, (B)&nbsp;who is an officer or (C)&nbsp;who is subject to the disclosure requirements of Section&nbsp;16(a) of
the Exchange Act; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(y) any Employee who is a citizen or resident of a foreign jurisdiction (without regard to whether they are also a
citizen of the United States or a resident alien (within the meaning of Section&nbsp;7701(b)(1)(A) of the Code)) if either (A)&nbsp;the grant of the Option is prohibited under the laws of the jurisdiction governing such Employee, or
(B)&nbsp;compliance with the laws of the foreign jurisdiction would cause the Plan or the Option to violate the requirements of Section&nbsp;423 of the Code; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that any exclusion in clauses (x)&nbsp;or (y) shall be applied in an identical manner under
each Offering Period to all Employees of the Company and all Designated Subsidiaries, in accordance with Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.423-2(e).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.12 &#147;<B><I>Employee</I></B>&#148; means any person who renders services to the Company or a Designated Subsidiary in the status of an
employee within the meaning of Section&nbsp;3401(c) of the Code. &#147;Employee&#148; shall not include any director of the Company or a Designated Subsidiary who does not render services to the Company or a Designated Subsidiary in the status of an
employee within the meaning of Section&nbsp;3401(c) of the Code. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on military leave, sick leave or other leave of absence approved by
the Company or a Designated Subsidiary and meeting the requirements of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(h)(2).</FONT> Where the period of leave exceeds three months, or such other period specified in Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(h)(2),</FONT> and the individual&#146;s right to reemployment is not guaranteed either by statute or by contract, the employment relationship shall be deemed to have terminated on the
first day immediately following such three-month period, or such other period specified in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(h)(2).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.13 &#147;<B><I>Enrollment Date</I></B>&#148; means the first date of each Offering Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.14 &#147;<B><I>Exercise Date</I></B>&#148; means the last day of each Offering Period, except as provided in Section&nbsp;5.2 hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.15 &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.16 &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of Common Stock determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If the Common Stock is (i)&nbsp;listed on any established securities exchange (such as the New York Stock Exchange, the NASDAQ Global
Market or the NASDAQ Global Select Market), (ii) listed on any national market system or (iii)&nbsp;listed, quoted or traded on any automated quotation system, its Fair Market Value shall be the closing sales price for a share of Common Stock as
quoted on such exchange or system for such date or, if there is no closing sales price for a share of Common Stock on the date in question, the closing sales price for a share of Stock on the last preceding date for which such quotation exists, as
reported in <I>The Wall Street Journal</I> or such other source as the Administrator deems reliable; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Common Stock is not listed
on an established securities exchange, national market system or automated quotation system, but the Common Stock is regularly quoted by a recognized securities dealer, its Fair Market Value shall be the mean of the high bid and low asked prices for
such date or, if there are no high bid and low asked prices for a share of Common Stock on such date, the high bid and low asked prices for a share of Common Stock on the last preceding date for which such information exists, as reported in <I>The
Wall Street Journal</I> or such other source as the Administrator deems reliable; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If the Common Stock is neither listed on an established securities exchange, national
market system or automated quotation system nor regularly quoted by a recognized securities dealer, its Fair Market Value shall be established by the Administrator in good faith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.17 &#147;<B><I>Grant Date</I></B>&#148; means the first day of an Offering Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.18 &#147;<B><I>New Exercise Date</I></B>&#148; has the meaning set forth in Section&nbsp;5.2(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.19 &#147;<B><I>Offering Period</I></B>&#148; means such period of time commencing on such date(s) as determined by the Board or Committee, in
its sole discretion, and with respect to which Options shall be granted to Participants. The duration and timing of Offering Periods may be established or changed by the Board or Committee at any time, in its sole discretion. Notwithstanding the
foregoing, in no event may an Offering Period exceed 27 months. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.20 &#147;<B><I>Option</I></B>&#148; means the right to purchase shares
of Common Stock pursuant to the Plan during each Offering Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.21 &#147;<B><I>Option Price</I></B>&#148; means the purchase price of
a share of Common Stock hereunder as provided in Section&nbsp;4.2 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.22 &#147;<B><I>Parent</I></B>&#148; means any entity that is a
parent corporation of the Company within the meaning of Section&nbsp;424 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.23 &#147;<B><I>Participant</I></B>&#148; means any
Eligible Employee who elects to participate in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.24 &#147;<B><I>Payday</I></B>&#148; means the regular and recurring established
day for payment of Compensation to an Employee of the Company or any Designated Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.25 &#147;<B><I>Plan</I></B>&#148; means this
Employee Stock Purchase Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.26 &#147;<B><I>Plan Account</I></B>&#148; means a bookkeeping account established and maintained by the
Company in the name of each Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.27 &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;423 Option</I></B>&#148; has the
meaning set forth in Section&nbsp;3.1(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.28 &#147;<B><I>Subsidiary</I></B>&#148; means any entity that is a subsidiary
corporation of the Company within the meaning of Section&nbsp;424 of the Code. In addition, with respect to any <FONT STYLE="white-space:nowrap">sub-plans</FONT> adopted under Section&nbsp;7.1(d) hereof which are designed to be outside the scope of
Section&nbsp;423 of the Code, Subsidiary shall include any corporate or noncorporate entity in which the Company has a direct or indirect equity interest or significant business relationship. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.29 &#147;<B><I>Withdrawal Election</I></B>&#148; has the meaning set forth in Section&nbsp;6.1(a) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PARTICIPATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1
<U>Eligibility</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Any Eligible Employee who is employed by the Company or a Designated Subsidiary on a given Enrollment Date for an
Offering Period shall be eligible to participate in the Plan during such Offering Period, subject to the requirements of Articles IV and V hereof, and the limitations imposed by Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No Eligible Employee shall be granted an Option under the Plan which permits the Participant&#146;s rights to purchase shares of Common
Stock under the Plan, and to purchase stock under all other employee stock purchase plans of the Company, any Parent or any Subsidiary subject to Section&nbsp;423 of the Code (any such Option or other option, a
&#147;<B>Section</B><B></B><B>&nbsp;423 Option</B>&#148;), to accrue at a rate which exceeds $25,000 of fair market value of such stock (determined at the time the Section&nbsp;423 Option is granted) for each calendar year in which any
Section&nbsp;423 Option granted to the Participant is outstanding at any time. The limitation under this Section&nbsp;3.1(b) shall be applied in accordance with Section&nbsp;423(b)(8) of the Code and the Treasury Regulations thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election to Participate; Payroll Deductions</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as provided in Section&nbsp;3.3 hereof, an Eligible Employee may become a Participant in the Plan only by means of payroll
deduction. Each individual who is an Eligible Employee as of an Offering Period&#146;s Enrollment Date may elect to participate in such Offering Period and the Plan by delivering to the Company a payroll deduction authorization no later than the
period of time prior to the applicable Enrollment Date that is determined by the Administrator, in its sole discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to
Section&nbsp;3.1(b) hereof, payroll deductions (i)&nbsp;shall be equal to at least 1% of the Participant&#146;s Compensation as of each Payday of the Offering Period following the Enrollment Date, but not more than 15%<B> </B>of the
Participant&#146;s Compensation as of each Payday of the Offering Period following the Enrollment Date; and (ii)&nbsp;may be expressed either as (A)&nbsp;a whole number percentage, or (B)&nbsp;a fixed dollar amount. Amounts deducted from a
Participant&#146;s Compensation with respect to an Offering Period pursuant to this Section&nbsp;3.2 shall be deducted each Payday through payroll deduction and credited to the Participant&#146;s Plan Account. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Following at least one payroll deduction, a Participant may decrease (to as low as zero) the amount deducted from such Participant&#146;s
Compensation only once during an Offering Period upon ten calendar days&#146; prior written notice to the Company. A Participant may not increase the amount deducted from such Participant&#146;s Compensation during an Offering Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding the foregoing, upon the termination of an Offering Period, each Participant in such Offering Period shall automatically
participate in the immediately following Offering Period at the same payroll deduction percentage or fixed amount as in effect at the termination of the prior Offering Period, unless such Participant delivers to the Company a different election with
respect to the successive Offering Period in accordance with Section&nbsp;3.2(a) hereof, or unless such Participant becomes ineligible for participation in the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <U>Leave of Absence</U>. During leaves of absence approved by the Company meeting the
requirements of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(h)(2),</FONT> a Participant may continue participation in the Plan by making cash payments to the Company on his or her normal payday equal to his or her
authorized payroll deduction. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE OF SHARES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1
<U>Grant of Option</U>. Each Participant shall be granted an Option with respect to an Offering Period on the applicable Grant Date. Subject to the limitations of Section&nbsp;3.1(b) hereof, the number of shares of Common Stock subject to a
Participant&#146;s Option shall be determined by dividing (a)&nbsp;such Participant&#146;s payroll deductions accumulated prior to an Exercise Date and retained in the Participant&#146;s Plan Account on such Exercise Date by (b)&nbsp;the applicable
Option Price; <I>provided</I> that in no event shall a Participant be permitted to purchase during each Offering Period more than 50,000 shares of Common Stock (subject to any adjustment pursuant to Section&nbsp;5.2 hereof). The Administrator may,
for future Offering Periods, increase or decrease, in its absolute discretion, the maximum number of shares of Common Stock that a Participant may purchase during such future Offering Periods. Each Option shall expire on the Exercise Date for the
applicable Offering Period immediately after the automatic exercise of the Option in accordance with Section&nbsp;4.3 hereof, unless such Option terminates earlier in accordance with Article 6 hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <U>Option Price</U>. The &#147;<B><I>Option Price</I></B>&#148; per share of Common Stock to be paid by a Participant upon exercise of the
Participant&#146;s Option on the applicable Exercise Date for an Offering Period shall be equal to 85% of the lesser of the Fair Market Value of a share of Common Stock on (a)&nbsp;the applicable Grant Date and (b)&nbsp;the applicable Exercise Date;
<I>provided</I> that in no event shall the Option Price per share of Common Stock be less than the par value per share of the Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <U>Purchase of Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) On the applicable Exercise Date for an Offering Period, each Participant shall automatically and without any action on such
Participant&#146;s part be deemed to have exercised his or her Option to purchase at the applicable per share Option Price the largest number of whole shares of Common Stock which can be purchased with the amount in the Participant&#146;s Plan
Account. Any balance less than the per share Option Price that is remaining in the Participant&#146;s Plan Account (after exercise of such Participant&#146;s Option) as of the Exercise Date shall be carried forward to the next Offering Period,
unless the Participant has elected to withdraw from the Plan pursuant to Section&nbsp;6.1 hereof or, pursuant to Section&nbsp;6.2 hereof, such Participant has ceased to be an Eligible Employee. Any balance not carried forward to the next Offering
Period in accordance with the prior sentence promptly shall be refunded to the applicable Participant. For the avoidance of doubt, in no event shall an amount greater than or equal to the per share Option Price as of an Exercise Date be carried
forward to the next Offering Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As soon as practicable following the applicable Exercise Date, the number of shares of Common
Stock purchased by such Participant pursuant to Section&nbsp;4.3(a) hereof shall be delivered (either in share certificate or book entry form), in the Company&#146;s sole discretion, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
either (i)&nbsp;the Participant or (ii)&nbsp;an account established in the Participant&#146;s name at a stock brokerage or other financial services firm designated by the Company. If the Company
is required to obtain from any commission or agency authority to issue any such shares of Common Stock, the Company shall seek to obtain such authority. Inability of the Company to obtain from any such commission or agency authority which counsel
for the Company deems necessary for the lawful issuance of any such shares shall relieve the Company from liability to any Participant except to refund to the Participant such Participant&#146;s Plan Account balance, without interest thereon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <U>Transferability of Rights</U>. An Option granted under the Plan shall not be transferable, other than by will or the applicable laws of
descent and distribution, and is exercisable during the Participant&#146;s lifetime only by the Participant. No option or interest or right to the Option shall be available to pay off any debts, contracts or engagements of the Participant or his or
her successors in interest or shall be subject to disposition by pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other
legal or equitable proceedings (including bankruptcy), and any attempt at disposition of the Option shall have no effect. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROVISIONS RELATING TO COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <U>Common Stock Reserved</U>. Subject to adjustment as provided in Section&nbsp;5.2 hereof, the maximum number of shares of Common Stock
that shall be made available for sale under the Plan shall be the sum of (a) [337,586] shares and (b)&nbsp;an annual increase on the first day of each year beginning in 2021 and ending in 2030 equal to the lesser of (i) 1% of the shares outstanding
(on an as converted basis) on the last day of the immediately preceding fiscal year and (ii)&nbsp;such number of shares as may be determined by the Board; <I>provided, however</I>, no more than [3,713,455] shares may be issued under the Plan. Shares
made available for sale under the Plan may be authorized but unissued shares, treasury shares of Common Stock, or reacquired shares reserved for issuance under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <U>Adjustments Upon Changes in Capitalization, Dissolution, Liquidation, Merger or Asset Sale</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Changes in Capitalization</U>. Subject to any required action by the stockholders of the Company, the number of shares of Common Stock
which have been authorized for issuance under the Plan but not yet placed under Option, as well as the price per share and the number of shares of Common Stock covered by each Option under the Plan which has not yet been exercised shall be
proportionately adjusted for any increase or decrease in the number of issued </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock, or any other increase or decrease in the number of
shares of Common Stock effected without receipt of consideration by the Company; <I>provided</I>, <I>however</I>, that conversion of any convertible securities of the Company shall not be deemed to have been &#147;effected without receipt of
consideration.&#148; Such adjustment shall be made by the Administrator, whose determination in that respect shall be final, binding and conclusive. Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or
securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock subject to an Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Dissolution or Liquidation</U>. In the event of the proposed dissolution or liquidation of the Company, the Offering Period then in
progress shall be shortened by setting a new Exercise Date (the &#147;<B><I>New Exercise Date</I></B>&#148;), and shall terminate immediately prior to the consummation of such proposed dissolution or liquidation, unless provided otherwise by the
Administrator. The New Exercise Date shall be before the date of the Company&#146;s proposed dissolution or liquidation. The Administrator shall notify each Participant in writing, at least ten&nbsp;business days prior to the New Exercise Date, that
the Exercise Date for the Participant&#146;s Option has been changed to the New Exercise Date and that the Participant&#146;s Option shall be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn
from the Offering Period as provided in Section&nbsp;6.1 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Merger or Asset Sale</U>. In the event of a proposed sale of all
or substantially all of the assets of the Company, or the merger of the Company with or into another corporation, each outstanding Option shall be assumed or an equivalent Option substituted by the successor corporation or a Parent or Subsidiary of
the successor corporation. In the event that the successor corporation refuses to assume or substitute for the Option, any Offering Periods then in progress shall be shortened by setting a New Exercise Date and any Offering Periods then in progress
shall end on the New Exercise Date. The New Exercise Date shall be before the date of the Company&#146;s proposed sale or merger. The Administrator shall notify each Participant in writing, at least ten business days prior to the New Exercise Date,
that the Exercise Date for the Participant&#146;s Option has been changed to the New Exercise Date and that the Participant&#146;s Option shall be exercised automatically on the New Exercise Date, unless prior to such date the Participant has
withdrawn from the Offering Period as provided in Section&nbsp;6.1 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <U>Insufficient Shares</U>. If the Administrator determines
that, on a given Exercise Date, the number of shares of Common Stock with respect to which Options are to be exercised may exceed the number of shares of Common Stock remaining available for sale under the Plan on such Exercise Date, the
Administrator shall make a pro rata allocation of the shares of Common Stock available for issuance on such Exercise Date in as uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all
Participants exercising Options to purchase Common Stock on such Exercise Date, and unless additional shares are authorized for issuance under the Plan, no further Offering Periods shall take place and the Plan shall terminate pursuant to
Section&nbsp;7.5 hereof. If an Offering Period is so terminated, then the balance of the amount credited to the Participant&#146;s Plan Account which has not been applied to the purchase of shares of Common Stock shall be paid to such Participant in
one lump sum in cash within 30 days after such Exercise Date, without any interest thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <U>Rights as Stockholders</U>. With respect to shares of Common Stock subject to an
Option, a Participant shall not be deemed to be a stockholder of the Company and shall not have any of the rights or privileges of a stockholder. A Participant shall have the rights and privileges of a stockholder of the Company when, but not until,
shares of Common Stock have been deposited in the designated brokerage account following exercise of his or her Option. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION OF PARTICIPATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <U>Cessation of Contributions; Voluntary Withdrawal</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A Participant may cease payroll deductions during an Offering Period and elect to withdraw from the Plan by delivering written notice of
such election to the Company in such form and at such time prior to the Exercise Date for such Offering Period as may be established by the Administrator (a &#147;<B><I>Withdrawal Election</I></B>&#148;). A Participant electing to withdraw from the
Plan may elect to either (i)&nbsp;withdraw all of the funds then credited to the Participant&#146;s Plan Account as of the date on which the Withdrawal Election is received by the Company, in which case amounts credited to such Plan Account shall be
returned to the Participant in one <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment in cash within 30 days after such election is received by the Company, without any interest thereon, and the Participant shall cease to participate in the
Plan and the Participant&#146;s Option for such Offering Period shall terminate; or (ii)&nbsp;exercise the Option for the maximum number of whole shares of Common Stock on the applicable Exercise Date with any remaining Plan Account balance returned
to the Participant in one <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment in cash within 30 days after such Exercise Date, without any interest thereon, and after such exercise cease to participate in the Plan.<B> </B>Upon receipt of a
Withdrawal Election, the Participant&#146;s payroll deduction authorization and his or her Option to purchase under the Plan shall terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) A participant&#146;s withdrawal from the Plan shall not have any effect upon his or her eligibility to participate in any similar plan
which may hereafter be adopted by the Company or in succeeding Offering Periods which commence after the termination of the Offering Period from which the Participant withdraws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) A Participant who ceases contributions to the Plan during any Offering Period shall not be permitted to resume contributions to the Plan
during that Offering Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <U>Termination of Eligibility</U>. Upon a Participant&#146;s ceasing to be an Eligible Employee, for any
reason, such Participant&#146;s Option for the applicable Offering Period shall automatically terminate, he or she shall be deemed to have elected to withdraw from the Plan, and such Participant&#146;s Plan Account shall be paid to such Participant
or, in the case of his or her death, to the person or persons entitled thereto pursuant to applicable law, within 30 days after such cessation of being an Eligible Employee, without any interest thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1
<U>Administration</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Plan shall be administered by the Committee, which shall be composed of members of the Board. The Committee
may delegate administrative tasks under the Plan to the services of an Agent or Employees to assist in the administration of the Plan, including establishing and maintaining an individual securities account under the Plan for each Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It shall be the duty of the Administrator to conduct the general administration of the Plan in accordance with the provisions of the Plan.
The Administrator shall have the power, subject to, and within the limitations of, the express provisions of the Plan: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) To establish and terminate Offering Periods; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) To determine when and how Options shall be granted and the provisions and terms of each Offering Period (which need not
be identical); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To select Designated Subsidiaries in accordance with Section&nbsp;7.2 hereof; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) To construe and interpret the Plan, the terms of any Offering Period and the terms of the Options and to adopt such rules
for the administration, interpretation, and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. The Administrator, in the exercise of this power, may correct any defect, omission or inconsistency in
the Plan, any Offering Period or any Option, in a manner and to the extent it shall deem necessary or expedient to administer the Plan, subject to Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Administrator may adopt rules or procedures relating to the operation and administration of the Plan to accommodate the specific
requirements of local laws and procedures. Without limiting the generality of the foregoing, the Administrator is specifically authorized to adopt rules and procedures regarding handling of participation elections, payroll deductions, payment of
interest, conversion of local currency, payroll tax, withholding procedures and handling of stock certificates which vary with local requirements. In its absolute discretion, the Board may at any time and from time to time exercise any and all
rights and duties of the Administrator under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Administrator may adopt <FONT STYLE="white-space:nowrap">sub-plans</FONT>
applicable to particular Designated Subsidiaries or locations, which <FONT STYLE="white-space:nowrap">sub-plans</FONT> may be designed to be outside the scope of Section&nbsp;423 of the Code. The rules of such
<FONT STYLE="white-space:nowrap">sub-plans</FONT> may take precedence over other provisions of this Plan, with the exception of Section&nbsp;5.1 hereof, but unless otherwise superseded by the terms of such sub-plan, the provisions of this Plan shall
govern the operation of such sub-plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All expenses and liabilities incurred by the Administrator in connection with the
administration of the Plan shall be borne by the Company. The Administrator may, with the approval of the Committee, employ attorneys, consultants, accountants, appraisers, brokers or other persons. The Administrator, the Company and its officers
and directors shall be entitled to rely upon the advice, opinions or valuations of any such persons. All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon all
Participants, the Company and all other interested persons. No member of the Board or Administrator shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or the options, and all
members of the Board or Administrator shall be fully protected by the Company in respect to any such action, determination, or interpretation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2 <U>Designation of Subsidiary Corporations</U>. The Board or Committee shall designate from among the Subsidiaries, as determined from time
to time, the Subsidiary or Subsidiaries that shall constitute Designated Subsidiaries. The Board or Committee may designate a Subsidiary, or terminate the designation of a Subsidiary, without the approval of the stockholders of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3 <U>Reports</U>. Individual accounts shall be maintained for each Participant in the Plan. Statements of Plan Accounts shall be given to
Participants at least annually, which statements shall set forth the amounts of payroll deductions, the Option Price, the number of shares purchased and the remaining cash balance, if any. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.4 <U>No Right to Employment</U>. Nothing in the Plan shall be construed to give any person (including any Participant) the right to remain in
the employ of the Company, a Parent or a Subsidiary or to affect the right of the Company, any Parent or any Subsidiary to terminate the employment of any person (including any Participant) at any time, with or without cause, which right is
expressly reserved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5 <U>Amendment and Termination of the Plan</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Board may, in its sole discretion, amend, suspend or terminate the Plan at any time and from time to time; <I>provided</I>,
<I>however</I>, that without approval of the Company&#146;s stockholders given within 12 months before or after action by the Board, the Plan may not be amended to increase the maximum number of shares of Common Stock subject to the Plan or change
the designation or class of Eligible Employees; and <I>provided</I>, <I>further</I> that without approval of the Company&#146;s stockholders, the Plan may not be amended in any manner that would cause the Plan to no longer be an &#147;employee stock
purchase plan&#148; within the meaning of Section&nbsp;423(b) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event the Administrator determines that the ongoing
operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, to the extent permitted under Section&nbsp;423 of the Code, in its discretion and, to the extent necessary or desirable, modify or amend the
Plan to reduce or eliminate such accounting consequence including, but not limited to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) altering the Option Price for
any Offering Period including an Offering Period underway at the time of the change in Option Price; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) shortening any Offering Period so that the Offering Period ends on a
new Exercise Date, including an Offering Period underway at the time of the Administrator action; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) allocating
shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such modifications or amendments shall not require stockholder approval or the consent of any Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Upon termination of the Plan, the balance in each Participant&#146;s Plan Account shall be refunded as soon as practicable after such
termination, without any interest thereon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.6 <U>Use of Funds; No Interest Paid</U>. All funds received by the Company by reason of
purchase of Common Stock under the Plan shall be included in the general funds of the Company free of any trust or other restriction and may be used for any corporate purpose. No interest shall be paid to any Participant or credited under the Plan.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.7 <U>Term; Approval by Stockholders</U>. No Option may be granted during any period of suspension of the Plan or after termination of
the Plan. The Plan shall be submitted for the approval of the Company&#146;s stockholders within 12 months after the date of the Board&#146;s initial adoption of the Plan. Options may be granted prior to such stockholder approval; <I>provided</I>,
<I>however</I>, that such Options shall not be exercisable prior to the time when the Plan is approved by the stockholders; <I>provided</I>, <I>further</I> that if such approval has not been obtained by the end of the
<FONT STYLE="white-space:nowrap">12-month</FONT> period, all Options previously granted under the Plan shall thereupon terminate and be canceled and become null and void without being exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.8 <U>Effect Upon Other Plans</U>. The adoption of the Plan shall not affect any other compensation or incentive plans in effect for the
Company, any Parent or any Subsidiary. Nothing in the Plan shall be construed to limit the right of the Company, any Parent or any Subsidiary (a)&nbsp;to establish any other forms of incentives or compensation for Employees of the Company or any
Parent or any Subsidiary, or (b)&nbsp;to grant or assume Options otherwise than under the Plan in connection with any proper corporate purpose, including, but not by way of limitation, the grant or assumption of options in connection with the
acquisition, by purchase, lease, merger, consolidation or otherwise, of the business, stock or assets of any corporation, firm or association. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.9 <U>Conformity to Securities Laws</U>. Notwithstanding any other provision of the Plan, the Plan and the participation in the Plan by any
individual who is then subject to Section&nbsp;16 of the Exchange Act shall be subject to any additional limitations set forth in any applicable exemption rule under Section&nbsp;16 of the Exchange Act (including any amendment to Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, the Plan shall be deemed amended to the extent necessary to conform to such
applicable exemptive rule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.10 <U>Notice of Disposition of Shares</U>. Each Participant shall give the Company prompt notice of any
disposition or other transfer of any shares of Common Stock, acquired pursuant to the exercise of an Option, if such disposition or transfer is made (a)&nbsp;within two years after the applicable Grant Date or (b)&nbsp;within one year after the
transfer of such shares of Common Stock to such Participant upon exercise of such Option. The Company may direct that any certificates evidencing shares acquired pursuant to the Plan refer to such requirement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.11 <U>Tax Withholding</U>. The Company or any Parent or any Subsidiary shall be entitled
to require payment in cash or deduction from other compensation payable to each Participant of any sums required by federal, state or local tax law to be withheld with respect to any purchase of shares of Common Stock under the Plan or any sale of
such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.12 <U>Governing Law</U>. The Plan and all rights and obligations thereunder shall be construed and enforced in accordance
with the laws of the State of Delaware, without regard to the conflict of law rules thereof or of any other jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.13
<U>Notices</U>. All notices or other communications by a participant to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person,
designated by the Company for the receipt thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.14 <U>Conditions To Issuance of Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any certificates or make any book
entries evidencing shares of Common Stock pursuant to the exercise of an Option by a Participant, unless and until the Board or the Committee has determined, with advice of counsel, that the issuance of such shares of Common Stock is in compliance
with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any securities exchange or automated quotation system on which the shares of Common Stock are listed or traded, and the shares of Common Stock
are covered by an effective registration statement or applicable exemption from registration. In addition to the terms and conditions provided herein, the Board or the Committee may require that a Participant make such reasonable covenants,
agreements, and representations as the Board or the Committee, in its discretion, deems advisable in order to comply with any such laws, regulations, or requirements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All certificates for shares of Common Stock delivered pursuant to the Plan and all shares of Common Stock issued pursuant to book entry
procedures are subject to any stop-transfer orders and other restrictions as the Committee deems necessary or advisable to comply with federal, state, or foreign securities or other laws, rules and regulations and the rules of any securities
exchange or automated quotation system on which the shares of Common Stock are listed, quoted, or traded. The Committee may place legends on any certificate or book entry evidencing shares of Common Stock to reference restrictions applicable to the
shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Committee shall have the right to require any Participant to comply with any timing or other restrictions
with respect to the settlement, distribution or exercise of any Option, including a window-period limitation, as may be imposed in the sole discretion of the Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision of the Plan, unless otherwise determined by the
Committee or required by any applicable law, rule or regulation, the Company may, in lieu of delivering to any Participant certificates evidencing shares of Common Stock issued in connection with any Option, record the issuance of shares of Common
Stock in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.15 <U>Equal Rights and
Privileges</U>. Except with respect to <FONT STYLE="white-space:nowrap">sub-plans</FONT> designed to be outside the scope of Section&nbsp;423 of the Code, all Eligible Employees of the Company (or of any Designated Subsidiary) shall have equal
rights and privileges under this Plan to the extent required under Section&nbsp;423 of the Code so that this Plan qualifies as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code. Any provision of this Plan
that is inconsistent with Section&nbsp;423 of the Code shall, without further act or amendment by the Company or the Board, be reformed to comply with the equal rights and privileges requirement of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby certify that the foregoing Plan was adopted by the Board of Directors of Annexon, Inc. on December
11, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby certify that the foregoing Plan was approved by the stockholders of Annexon, Inc. on July 16, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executed on _______, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate Secretary</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>d773514dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon, Inc.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our report included herein and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ KPMG LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">San Francisco, California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">July 23, 2020</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g773514g02e84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g02e84.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ T %) P$1  (1 0,1 ?_$ !X
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MJ?Y'.EY;-&HJBX$(KFAZK^6;F+A><W%BU=L6O,I+BQ*[WMT'FH%ZW< 6]42
M5+MH9H;TL[^7+K?H%F\;U%OG;@&5@T1K))8YP$:" 8,@^FQ _'O(S\O?4U@R
M6HP,!XNJ1TVZ(E/:4 I@G)>IY"&SM).)Y*;:3T[8;)ESN7VCD4DD<"O-HH@
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M;9,DGU@"/@?Q2+_%]PS#WDP<AJ0RJTFD!M:K7<</65;LKA,7KN\L[YM^(5;
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MV2IO&I)AD]'FI 5&U",1)2 61(>4<Q'+IR1UZ>U V.N\@_7JI?Z5@72W1/\
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MROXJK&D9$&A9<2RX#B+2'_( P$QEDR"FL2@.X5$B4$V@0N(4>%,-F9$=-?\
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MNLZKDMCUF M0AM$9GK$MN8;+9EMS%;.&+1$M$)-7@LUNRU4;"Q9#=R:<%(Y
M-9)B=!(F-CJ.OX=%5WCQ]<;'OZ*'D178-:Q*R9E<,66ICIA_=)K\E24/K^PC
MQ_HTB5L]XXC*U@6-=>M##R4<K9FVB]2P1W6L5U<X/3&3MUWY_/Y_BAB.G>0
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M2J_^BI%)EQNNT% :ZDJBR8NL@KNDVSEZ^>9CKU^>GYU_,%<D@DR8T]K8S[,
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M,Y7; 5;R-#QX&'/9%($(PTC[<V:'"Y1*AI9X%D(]*41:).CAZ'(%0Q$,ZEC
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METU@E;RF5US6CVX9N*:-,QRN6,HC\)VD;]Z29#OH]ELG4T#Q\,)0=K'#Y11
MF_; QA'<*#D!K\>#(%QK46*^9P<0;5Z_4YW>;AUW2#B[I,&MD4:BL$AQKLO'
M$,.L2GC.L*9YZ"ADMLU(A+1I5)I6FF]9C',@::ORRS"//"MR[ZZ]--])@]C'
MOU,;21G79W3_ #38ET<.TY7_ $/1DYMV(_(M7#>5U7#K:@,FLB,+Q6"7:$E"
M$A@X60/I.%6C9E1,0>3)"VVX<GOHP(ZMW6VJ62EK7 .)! Y3K!CIU6R*^?\
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MWW@]NG17U\4)XBUW]_\ _B'X^_\ U$*:_P"&%X>*S?VO\I^Y6OOG_P LR/\
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>Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g773514g02r42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g02r42.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1^B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C$< @4
M,$UI8W)O<V]F="!7;W)D("T@06YN97AO;B M($)U<VEN97-S(%-E8W1I;VXN
M9&]C>  X0DE-!"4      !"8U\"Q),OTVXNV(I*0.S@F.$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #P     $  0/      0 !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    >#A"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8              ;D   -X          $
M     0             #>    ;D                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   &Y     %)G:'1L;VYG   #>     -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    $SA"24T$#      5 P    $   "@
M3P   >   )0@   4YP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 3P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M      ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+
M$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52
MP6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S
M1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  ("
M 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A
M<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1
M #\ ]57/_67!^L&5E8K^DW.II96]N2UMFS?ONP_Y3=ME5%>3=7=_QF-_VJ53
M)ZIU:C*R6.=:^MMUGI[&M<[8#[&UM&SZ#?W_ 'H-_7,MGIMNLR_<'!C*:2XO
M>-I9^EJ_D;W_ $?TNRQ/$"=D<21M/^,%[_??74S@E@I)W.LPF7.;OK?^JUT_
MM2WIN[]:]/[/^T?4O]BJY6/_ (R;<,8PL87V5O%ES'U5NW/QZX:WTF,?4[&Z
MCZOV>ZI_OJ_G_P#!V67F]9RJ?39O.5ZNT5@R+(BLO/MV;_;;OL_T?O2=UOJ%
MDAK78^U[6'VESBZ3NV>J=OI.V_SB7 4<7@]2DN1K^L/4K:P^K'M?[&N>QX:U
M[7.A^SU/4]!S65N_?]3UOT?IHV5E=:=T[!NQ\GT+B^T95+F@A[0?<WUBVQU?
MHQ]*I"4:%I!LTAZ_TWZV7]4R;>GV6&FRES<5[,@TUU-.-D4NJ=C,=7OS7=0L
MHR:<JRO(]G^%P_L_Z>1/^,$95VQE/V=U^W'#G5NV5>KCGU+7AM=EN/\ 9:<M
MOT?MF_*_X/U:PFSZP7NFS/=BL88=566O<!'ML]4M>Y_\IB&VWK5GIBSJ-S6@
MQ<X0PZ\-I_1._-_?_P",_P"#3+7\/BV-O^,$TUACVMM]!P>;?0/Z;;?ZCCZ+
M=N[[1]C_ &7L_0_8_M7[4_6O24J6?XP*\O%98^N[&&2UV18?1!^SDMKMK=6R
MNO\ P?Z>JREWJ>O^C?\ H?3]&G6SK#&VA_4[[P00QS7.#FP?;=['-;]!GT-G
M^D4Z7]<JO)^W6;-I 87>I#X#MX]8;WM<_<S:_P#F_P#!H_8KA\7M4ESO1LGK
MMV8ZK*RVV,]&QP_1-;%A=6VF-NUUM53=_P"YOW_\6M/#S;@<NK/?7NPB"_(:
M/3K+',%WJ.98^ST?3]V_]+_PG_!UI'#H?!OI+.J^L'2;&L<;G4ML;98TY%=E
M V5>GZMKOM5=/IU_K%.U[_YS?^C1;.L=*JLKKLRZ6NMK]9DO$&N6M%V_Z'IO
M=8STW_X3_!I(;B2IGK'20"3FXX W@GU6:>G_ #WYW^"G]+_HU%O6NE&Y]'VJ
MMME;A6]KG!L/)AC)='OL_P '^^DIO)*LSJ?3;*VVLRJ75/#BRQMC2TAA#;-K
M@[:[9N]ZK5_6/H=A>&YE<U@%X)V[1+F;G;H]K'L=ZCO\%_A$E.DDJCNK=+:Y
M@?ETM]5@LJ+GM >T[O=4\G;;]#\Q)O5>EO+ S,H<;=OI@6L.[>2VO9[O?ZCF
M.V)*?__0ZO(R,1F?DUOL#;&6/<]I($ E[FZ?];<[^PHML8^ICV/FNW:&.!(#
MMWT(_KKFNKXW4K.I9MN-3ZP?E75E]9W0]MA=4+GRZJM^QWI-J_G/TBJC!ZU;
M:SU&.;+0VL6M<'M+1]J=]G;^;D>FQ[G_ .C5D8@0/4%A>R!K#FLL<T6/^@TD
M2[][8WZ7]= .?@LL=4Z\"RNM]KB)T96=ECGO^A^B_P (Q<I]DZSDV?:1BV$.
M;'Z0>F W4SOEEOK>F+&5;F_I/\&B6].SF9%3L.BR\VUMR6TUDN:S>'FFEK[
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M]P.[Z1V[O\)9N_KKG,_ZT=3HZKU#&):64WY JW5AQ<6V'TZ]V^EK/T?LW?\
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MV[V8_P"DR/TMV;9_/VWIG8'U.J.^WJ;G>UUK?<R06A_Z5GIT_P"!_P"T+/\
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!
M$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M 0   +P   #H "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,3DZ,#DZ,3<@,C$Z,3,Z,3$ <G(U,#DQ-C$       .@
M 0 #     ?__  "@ @ $     0   WB@ P $     0   ;D         !@$#
M  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (
M  (!  0    !   !1@("  0    !              !(     0   $@    !
M.$))30/]       (          #_X0%(34T *@    @ " $2  ,    !
M  $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M    ?@$R  (    4    G $[  (    )    L(=I  0    !    O    .@
M  /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q.3HP.3HQ-R R,3HQ,SHQ,0!R<C4P.3$V,0       Z !  ,    !__\
M * "  0    !   #>* #  0    !   !N0         & 0,  P    $ !@
M 1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $
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M 1$  A$! Q$!_\0 'P   00" P$!              4&!P@$"0(#"@$+_\0
M-Q   04!  $$ @$"!@ $!@, ! $" P4&!P@ $1(3"105%B$*%R(C)#$8)3=Q
M,S1!47>X,L'1_\0 ' $!  (# 0$!              ,$ 0(%!@<(_\0 11$
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M/3#!Z88/3#!Z88/3#!Z88/3#!Z88X++&BJBR,14_[17M14_^O]T]_P#[?W]
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MR+21YC7(HDF,;L"T2GE2%([$\V*Q3F'2H6S*&"<3%;A"D^2-489&H>UC5O\
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M =DS/<<:=9IT5\S&LG[62\)]-BR+"2.\Q*%$K$KZ&)&DI2<$_P":[%U6Y$A
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MRT='46"A@5*5]0*M;%&C^6)5F_,/W*GKP(*C%\[$;4YF@%$=K([6VIQ"1R(
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MTD3V$_Z-7_:!UJ20R-D\@9!&4%Y8&M3ER=.J@2]FZ[D<7>/LL=?]JE__ (R
M=JX'QW^GMB9<1^$;P4YPR_BS%,2.W1V\%S8,M(\W>JPX:"8<=!77%09(-#"T
MDQT<+7?!LAQKT1%)>GK0>/>NB-(XHLKE]+:V:"%HFD/NY1@&4GML!QP<1R9'
M+R6'S$OS<O %7_U[][Q:F_\  OC.A\1^R^']?>76=YYVD30":>^S ^8"T ).
ME95ML[&N1M)+1_R4BU8[_P!BPJS7N>YWW?8C8T9Y_.];SV>ZI%U6< YN,(4.
MDZ:35IV))-77?8#MBY!%#!$%C-QWRS6"10^G;MC3&-_A7O#:'Z$'\C/)=$A7
MY-5+#E"J]5B;$]SE3G*2.^?P;(O^KY,>B+&K4_MZ[">..J1D:,KEU9>)/7=@
M5=>95_%?&U;;Z(R;L4=Z! _4=C_7R^:'_#%^$U6<XB^[5Y*:D?X111@VFFYX
M#&QB3#RSQM+JN>BV#(C$'CAG9"5&_P"E\\43XD(E5V7\=]?D6=#Y0::+R0^@
MZX075M4; AD;T:=0.ZDBO5C7R8 -@$!OOS[\\_UL<6)!_P /A^.,&EAI)<9L
M;,49I3!IK?;6QA T9=B-9K#"]'Q1)' 0' P7_;5\0Z20)(L4TJ/BG\;^(LQ$
M(O/C2-0%I( 2H%$!3R>!N;KMMC R\.L,;)#76H5=55$'WWVL_7?#\C_!?^.]
MHM:#!RUK8J>6PGK?:S,?*-+:-A0Z9TCB%<5.3]$2RDFJ21)[*BR^SE]X!XQ\
M1* O]H2!02P5D.D$T&8!C0+4-1&YK?$NF(L2%0L=B:4MMV)JS5G;M>(SU/\
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MGZZ_9ZOHN7Z<T0?J,CQ0E'TO&-3&4-Z%(VV;U<;[>W' SK YEE.NE'JT %N
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M=R1/EHK1+"(@9'YD4T> 6\"(DF;'">_Z(G$PCO2C.ZNSM$&3+L&55;:11OR
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M]18Y>*E>$W_H65_^=_*__P#:;L?JIDO[C_CYO_Y<^/5>,O\ OJ/_ -A\)_\
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ML[V8A&E D?I.6I&963+"V*=\ZMWZOT%\B88<A#F<U2/)F9 CR>6S1-Z&(!T
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M)^G9;-]2RY9$73EI\VLT>7":-<;Q0K/%(S/'*I(J=J>GJ<]4UE#0U@%-24H
ME545%6) !6U=8!!&*#7UX0S(QA @QHHQQAH(XX8(8V1QL:QJ(DP 4!5 50
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M?,NLYEL]X\Z"WER+(,OTV%T:BWF*);% FMC]WD#L!BQ#ICR]FD4:FOMN3O\
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MJVEI)*/5K-(^%A'SD9$BA#QC(V"2&"7Q'TX+(@S#E9 P<JA]5V/2:WJ^^PV
MV&V3I])UJ"I%J;O8[C8#W_CWPW*CP#\P3+66FEXS; N&F-L6W%IK,FE9]PQ+
M8(W.LUO'#RS&EL65JNKH)BA2762/8]7"R0+XHZ>B*JR:0&!!DC(/MR1O1 _
MWWQ('3?U#XV-_P!<_P KPZ+#P,\MZNGC(,XCIB7D2PK<"4VIP-\E@\44[YS1
M4X%Y0F5_R>D#0(6,LU<O['RD;)[*O2C\1])*K'+F 260R!:IU_R@6E'V^?O
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#8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g773514g09l31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g09l31.jpg
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M4U97<W6RTM48)CAB8W>2EJ&B&39T>+.VMQK_Q  = 0$  P$! 0$! 0
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MZJK &BT'2Y-FH9ZHQ5.FX$?#<@'Y<I6D!H/XGM&AZ#G/7LTWZKJ[-W'H8_\
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M;E8^"L*T5<J[()0,W+2YX"*B)E1I(JDC).3G4E(6.8/10=/99-2.;)*O"&1
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M,=(UME(57)99*=@)V*:$:0,047V]X\]VO2K?8:QK><;DM2-NR'#9!)992-L
MOVU$7J,V-@"LP,%8Y&6=$N=@B9!*;?08R[-E&0, 2'\:JP,K)D23<:(3?A;^
M-_FINT4+TN5V[5NX=/%D6S1LBJNZ<.5$T6Z#=%,RBZSA542I)(I)%,=510Q4
MR)E,8X@4!'1%6'@RE8I]P[T^%@9./F(#',]DW#-<D8Q\WD6CNJX1RG=,1U!T
MF]:J+).2NZM2X9V5R"AQ<D7*Y$ZG6 YBD[Z]OOU5I-%":(FB*M?#L;UO*\2%
MZ0'>,O/$I<2Q@_\ =+3,><.DZ&WO!RVW"]A+[7O"43DW2,F(E)X=GCK\U)F5
ME#'J"D24YTPLDQ 5QR)#BF8T9*R[1*<1!0/:(9S!%DVQ#EV,518@E$!VU9HS
M. Z2H.@)Z%QU4REYR@ %*W!)LD4H<I0 H#[I0V  'IG-R[;!SCY:Z1H&VV]8
MFW5P[-@LKYB>NV_ '2X]X/NW10-C'+VV2(4@?'VNW-]8FYQW^'8/(-2#L>+G
M'APX_%00-1T#LUOO\=.I>6X!N >2*(& .^PJGY $P@/81 RG8?F3( ]M1O;I
M<=^@#0V[O-U)TVV;8]-R=1_'H[5QET4'"*C9PDFNW50$BZ*I"J(N"K%Y3IK)
MG Q%4SE."9TS@)#$Y@$OM" K';K+1?>P\F_P4CPL3OQ%CT6TV.M]R55B_<-D
M>[!>2H4B6"=\IUSP<B*J\"L82\P),G!0.]A2B.P^Y),D@^](L6R?M)P6G4CV
M>OHZO=QU46;Q/K6.VUQ\_.ZH@^FUF:J[0XE!XBNLT.DFJW6Y%D%10<&26(H9
MLY30,4QP5;JJHKD*!T3G3.4XU5%C221/O3<!)TDE =.#E2.B#AX*G5!4AD%"
M%Y^N0RCA,Y#D-SE*(:(N?5,RD92CUK3KL9I*(<POFT/)'(93IB"9CN&Y#"W>
ME0-RD$QTUR(G$I3"41 !6/0K!Q%]M5+B?$=E-,A2!<53 4 *!E(> 4/V'S$Y
MX@3"/PW$1';XZ*<YZ!\?KTZK7IO,U\L22K>9M\LZ:K )%FB*A(YHLF8! R:[
M:,19HKIF =A37(H00[<NVB@O)%M//>M)"= .P*  !V  */;_ --%5:\1A6$[
M6YO2<-%$N3ROLZHZLQ6*032]:CY%]+L8)60Y/$&BVLI)OWZ+03]$CIVNL!><
MXCHIN;6X7OWJTV(,/2.3& 6-_-I1%:*]7:%38 BZFWYVBATG)0!7G:PR8+%
MJ2SM%\X<)\YR,$43MG:LVOU7TOU^>JRL VUS<G>VVG3U\>/1UJ]52IE<I$7Z
MKKD>1FB4Q%EUSF,N^D%>4$S.)!XL)EG:YBB4I14/TTDMT42)(@1,M@ ;?M7[
MK>=0I.A.P .VVCNSW[>^RVKL)#EWVY !0@_'8PE 2;AW[\Q1^;<![!N.\VO_
M -)[M;_!+V'_ ##JO86[N'8%[![ <H#ML5)=,0W#D,/)S 'Q#<IA^D2$$=]M
M5W .^I![]OAL5&Q(VXVTUTZNGH'#LLO4ML)^8-O;*0X[!L',8H"?MY![?-L
M;  ;!MVUHW8CH)&O0%4[]'UW_A>YZUBX94D?DUH9(PD+;:C))R)=Q$%Y"JR$
M6K%+<ONE4!I/SX+K; 98OA$U#"""!"\T@M;JTV]WG;Y[--Q<^?/Y'53/K)2F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(O ZJ:9DRG4(0RIC$2*<Y2F4,4AE3%3 1
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M+^IO+V0V -@ME;T?$_53F-MP>XZ^ 6C!.]A/U-@[% >8FP#L.P%#\'<-]Q
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MX+0$7RC?<A=H&LE*:(FB+Q.<B9#**'*FF0HF.<Y@(0A0#<3&,80*4H!W$1$
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MB9(P<XG.D='VBB043%.H)1#8G=?M'^R>CL^J+B'M0J" F4[%#E* &#8I $1
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MEI&X\_)2C2L@,F"*(=5,NQ2@'M!W -N_,/EY?'MOOJI:0=B>NQ4*=8_,"*1
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M)0H'343,4Y#D,&Y3$.41*8I@$! Q1$!#N ZA2O/1$T1?@B  (B(   (B(CL
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MQM8UCP2'-(L!9U^)/O14U6QTTRE333:) B@DF0O*1--+?V$R% "D*!2@4NP
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M1H3R)]!OM+H-N\^)152XF,2%M:@VBOMT261DF"3U .1$)EDF @F F'E(+]H
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MV7(BDZ.&Z3%J5,J;5(0W$ZYR% #*;!WVV#MN \H!L4+4W:PH(G,3W]A @^8
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M$P Q'*S4>H2;W+&6-C8 #8:DZ!N+L?;% Z"*NQ:M=)%BK7U=8!!/_.,$,38
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M%,#C<A.7-SW.]HW\/<%>P^7<KL(HHMTDD&Z2:""*9$D442%22223*!$TTDR
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M HP]R9;))*JNBIB#2;(W3V*DA+D25%4I"$11DVTDV;@+9%!17%PLX@;<.Q;
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MF(R#+1[!&VBL-XIG(2ZZ2*<9-1+!<%E@</731NE#O';B&11CTI$30+>L0,I
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M#CIMZ@VE7J:\FY0!JU?O'35BR1;N9C#7-#<N:,1$B]\@!:W>]R ;7-R18$D
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M\Z:92!;76X+3?A;4=O1[^,#&LK'8-487"]F=T[<3HZNI;*T,:6-B?2UU(8'
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MSDS5U*I/$L43"HQR4NM+R<(9@$DPBTHEPWE%9!TV2:)QRZ+TZH-E2*F[XB+
MW%LMKWTX+ XA0&%E4*ZC--,X0Q5 J83!+,93$(HY0_FWR&1KHPQKBXO:66S
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MK*+%=P:SE.)G)--7RN5/)JGY385)3.:UE;#GEP^H( =%/E%HW.WYB>PCF;J
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M]AOP?R@UV1\>[YKC.Q[#X(/O%^O[->A'Q[OFN23AW_)>G7JQ[M[/DN!^W?\
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4V@BX *[+M?,+YM-$31$T1-$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g773514g10j85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g10j85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Q84&AO=&]S:&]P(#,N,  X0DE-! 0
M    '#R^<B@X0DE-! 0      %0< 5H  QLE1QP"   "'_T< E  "')R,34Q
M,3@Q' (% #--:6-R;W-O9G0@4&]W97)0;VEN=" M(%)I9&5R<S(N<'!T>"!;
M4F5P86ER961=+G!P='@X0DE-!"4      !#M:Y7^YQC@H,=(3G[;DP*R.$))
M300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'-T
M4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I
M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0&I1'L         *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0    >.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/T
M       2 #4    ! "T    &       !.$))30/W       <  #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
M-@   ;L          0                         !              &[
M   !-@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !-@    !29VAT;&]N9P   ;L    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   38     4F=H=&QO
M;F<   &[     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    ".$))300,     !)4     0   *    !P   !X   T@   !(X !@
M ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !P * # 2(
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MHLM^F_:_V+DKOJ7U][<)E-M5-@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                            _^% $&AT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED
M/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN
M<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@
M-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @
M(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R
M96%T941A=&4^,C R,"TP-BTR,E0Q,CHP-SHQ-2LP-3HS,#PO>&UP.D-R96%T
M941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^4%-C<FEP=#4N9&QL
M(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM
M<#I-;V1I9GE$871E/C(P,C M,#8M,C)4,3(Z,3<Z-#@K,#4Z,S \+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(P+3 V
M+3(R5#$R.C$W.C0X*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O
M8F%T($1I<W1I;&QE<B Q,"XQ+C$V("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.G1I
M=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@4&]W97)0;VEN
M=" M(%)I9&5R<S(N<'!T>"!;4F5P86ER961=+G!P='@\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @
M(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^<G(Q-3$Q.#$\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @
M(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#HU-#8Y-4$T-C4T0C1%03$Q0C,P,D-&
M1$,Q,$1#-3,W03PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^>&UP+F1I9#HU,C8Y-4$T-C4T0C1%03$Q0C,P,D-&1$,Q
M,$1#-3,W03PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C4R-CDU030V-31"-$5!,3%",S R
M0T9$0S$P1$,U,S=!/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HU,C8Y-4$T-C4T0C1%03$Q0C,P,D-&1$,Q,$1#-3,W03PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,"TP-BTR,E0Q,CHQ-SHT,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4S-CDU030V
M-31"-$5!,3%",S R0T9$0S$P1$,U,S=!/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 V+3(R5#$R.C$W
M.C0X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HU-#8Y-4$T-C4T0C1%03$Q0C,P,D-&1$,Q,$1#-3,W03PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,"TP-BTR,E0Q,CHQ-SHT."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HU,S8Y-4$T-C4T0C1%
M03$Q0C,P,D-&1$,Q,$1#-3,W03PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HU,C8Y-4$T-C4T0C1%
M03$Q0C,P,D-&1$,Q,$1#-3,W03PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C4R-CDU
M030V-31"-$5!,3%",S R0T9$0S$P1$,U,S=!/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO
M=&]S:&]P.D-O;&]R36]D93XQ/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T
M(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( (T R@$!
M$0#_Q  >  $  P " P$!            " D*!@<!! 4" __$ %,0   & @$"
M @4(! <+"P4   $" P0%!@<(  D1$B$3%!4Q0187-SE187:U(G%W@2=8>9&7
MMM8*&!DC)"9GF*&X\"4R,S4V149(5E>FL<'1V.'_V@ ( 0$  #\ M%ZXV?<^
MX^V@J^-,>[D6K"U%LV!QO$I4L>OLWP\]3IS'<9FNU14]8IW$N.+6UA*_D&9A
MH1^^?/)H9^4KF(+-5X^J2<;,R#UOI[QBZ=O<;8]>O[(VN3YW1ZFZ>V]DGZ%G
M:G;B!CU7%D:(^$GHFTXL<\H@GX"^!)T0OA+V[!SCCCCCCCCCCCCCCCCCCCCC
MCCCF4+KJT*[W/9W'R%4TQ4RE*'Q7#O:YE\LAFQK!6Y.N?.U(V[$EMBL39/QR
MUN,@Y9.XBDT>GR!WLTZ<9DL$NW]8KL;/1KK45CA)TCCRAHOJTVICU*F5=)Y3
MV1R*,ZHZ3@V)7%::*)_XL[:"6 \6@<GZ!DFI!+Y"'.9\J5WYQIGN5VRZ:N2L
M97O-KK'T#M3$0>5<4T5$I,8M*>OC++CZ3R+DM6&B/;KQL$J6KUYL6Q3Q:?'*
M';F2BAF)$KKE"EKI?4#C;!N*6@P6V^0_EG+6:PY9O2E.V1Q/?L=4=QM[1G%D
MQ%B"(E<LVW&>2BVG ORID*K8L$UN$L\'6:^9%O(>OV=./&5OSO=4S4#IPYOV
MBQU<<>5_"V#[IL#<<6XGW$Q)F&Y; 3N 4LNOF^&V3ZU2.5:C8:V@%+?,TXIA
M?X.8M+:-1:*2+H2*MVK?414I1U.56LS3TJ)'LO7X:4=D;%.1N5U(1K9VX*@5
M0ZBA42JK'!(ISG.! *!CF$!$>0<<<<<<<<<<<<<<<<<<<QE_W09)1B6WCV,9
M,Z7=)^R:>1M/=,K=@"_YLE<+"YL>5KE'Y.QW-14_ 5['-QD8&FW%PD_CU59A
MTC2TY)X=$D,P*OH$I^PF<]:=.L-73.6)[;LK<7D&T]K.=4HN$=QL!14*_P"U
MZY:;8YS+DFH>A(C74&:-EFAL,F5><46=)@9DH9T7LW27>VC[SP%RM&/<:9+H
M\!3I)E$'EKU(8DE8^=D7171G32%?8HREDQIZS$@V)[2;RR\6NF#QF=NFX35,
M=.<?'*H>N9]4AOA^PV3_ #V"Y9;COZ/Z+^#JQ^2,><QXXXXXXXXXXXXXXXXX
MXYEWZQB2N2]MF^#[)BJN2./)/7&C3TG?6&A&>MR+A89%OE6R/FU+F)C#$_6'
M%"AJ^O#-)R'$[MX>2-,3K-THU9.EFDA:WU#X6-DNE=L5!/8:Y2,8MJ^]9G@\
M9U$["W+HI5ECZ)C7<>28+*$.44R$/09 1468E7K+I8AU#JEBGT:XK'\S9=E<
MOPF382YWV]L,.0%MK./M.,E:8XOJ4'1H:Q1]45CJ1D.+9GL]QETWTD:T6&.>
MO$VJ#.)B2IMVC5H9:]GCE4/7,^J0WP_8;)_GL%RRW'?T?T7\'5C\D8\YCQR(
M.'M]=1\^[!YMU8Q'FNLW3/6NRA$LN8^CD99&1K!O6DX]YZ-Z]CFL5-EB)-9&
M*G#P+^2)"RBR+"2%LY533-S0^W.L)-ARZEGSQB\NRYZ^6TEP@:VQ09%&!.S-
M(D?A7!7]<_2C2FDRMO#ZX,8'M$&_J79?DBN..............91.N+;L*Q>U
M%*<W#(^5<17"C8SQX\&XZB8CD7FW<I&V>S9,F25^#S2^RI4*E!4Z(K>.;S=Y
M6NO:9;G"$/ V&1$I#N6J839W!Q=?ZUT<LRR-YV^V R2K1J9:\UT'-U4OL5@;
M+-DQ:X]:L>.JADV]1T#(1D@6,JTM'LK?825=-]-C&)2*$9[6(0J_].BRXEYX
M^?[C:-F<:[,6::0QFT<3]"W@M&X;JOQ4>TLBD=%S+:9QIC*+QZ50[QTJT"/B
MWKR?.#H7[DA8QN0;WN.50]<SZI#?#]ALG^>P7++<=_1_1?P=6/R1CSF/.KLS
MY4985QO8\ER%-R-D!I6TFBJU3Q-3I&_7Z6!V^;,"D@:I%"#^540,Y!RZ(@/=
M!FBX<G_02-S,3:]S>GQBR];@WC4'5+:W7OJ&[3Q<ABZ5RLAJE=[#;HG-=WKL
MW.T49ND*STH,%(2TE#KW!S$L8&.5LBL(M,.64HNQY'SHDZ=,X[:NJ[4;^8QW
MBRWU*9FPW;V9L/D+!F6*/A2KU M&;UF!1M4_9V,&RD+4C76$U%LYF1BVS7T<
MW&PJ+5P[8H2)]I7'''''''''''''',\>\^VO3^BLZ/R[@=.7+UPR!7(:VXQK
M>3;Q2==(]O;<=K/)&+F'-)E+MGRL6"7I$RFZE",WJD2U5&-EY-KZ!H64D&JU
MEN[CNQS'3MSY)X4GJ?C"<>ZX3LM09N\R=7K%1J#4]3*_CPE9R5"3I]91917^
M1M9IWZ]!0;L&T@)EV;4#FK_Z*E>MU:LVU\0HPLU&QM'.,*)5G$.6<[X_V SC
M4;7)TI[8+?9+3:*2]EG,)2;VVEJ_,4"$FI=V5TS)(3D6UBVDB+,.ZNHAAO)U
MBVWZ8&6Z-8LU2L+4]MXF#NV/ZF]DSXF@ZFXQ5F)[)9$O4)"L !5T>6&N0"<W
M:)%6%C$1;-&#5J]DW"SG.F?$V])H3.*-?H>WC>Q)T^VI[]JF:Y<05RC+.>H=
M7I^%+C!RNY(G>'9=2&UY;D-B0[LP8^>,ZYW,X<LV/.X]EJ!U 8WHQ[FOZ]<:
MSCS3E*:V7DJ9B3/6-\A.\]J:X/\ -JSG$L?6YBR6)A+4:(+5E&(5J"N$"YE(
MN)*@11)%HLT;MMC6-_&&.Z$"HE,H%+JWI#% 2E$_L-CXQ*41$2E$W<0 1$0#
ML B//MV.:1KE?G;"X247;P4/)3"Z"/A!99&-9K/%$DA.)2>D4(B8A/$8"^(0
M\0@'<>4R?X;[!_B$OS39-[@(A_TM;^'O_P"]?@/W_P#XY0+>;QH%A#>2C[S8
M@Q=GYIF+.F[>.[_E1&U7.*EZNDP0IV4G<ZQIT(5V7U)U-S[YA)B,HZ?$CTFR
MK&*5CV:AVRE_7^&_P?Y_P39-\OM5K8?S]Y4/_OR76H/4 H&X5IMM5IU,ME9=
M5"OM+ \<V$\49!R@[D21Q$&X,'CE3TI5% 4,*A"D\ #V,)A .3ZXX]WOYX 0
M'W" _J$!_P#ISSQQQQQQQQQS&3UL)/"F0=MLK0F3=?=H:1DZ(P92:MC',1&.
MK[O&=[1BYW)*+EQ3PS;;(Y%C%/ZY>K55IN;:NU7D8\F(ZPO:NRF*;7WSO3)E
MRAX.R#H18J)L//'IV!9C7*/99)M,I<XYHZJ5.:TI@X>V)Q?&GI(@TC7TFR<F
M2Q-B.(UT^:$>I(.6JQ45(N=+."U,DU<Z9;P)MKD/<;)MQ>T:L9:R/EEXDSO4
M)!4N,E4\9U96G)4K'QH"!1BI24?0\FI6@&S>LN9!*3>))E(A;KQRJ'KF?5(;
MX?L-DO=[_P#KV"]W++<=_1_1?P=6/R1CSU,I_1ED3\#VO\B?\P#V6 8V>)D(
M*27EF[%^!"++PDU*5Z3(5-8BQ?5)B$=L)-F<3I@!SM721CI>)(XF24.4T+<Q
M5W4[%<C0V&9,CWNOR-@L!5Z(C.YES \5]M,B@Q]JM#(61T$9ZD$KZJ:7<&:H
M(%?&3,X*"A^21K&&JE5)EG/Q4QD9X[9E5%)*<RKD*R12A7"!T3&7B9NR/HMV
M'@4,9(7#53T:G@62 JA"'+H<Z&WTPYM'MV[XTA?CW_\ %#?]X!^O]W-+/'.B
M]G\>7?+FN&>,68SM/R'R)D7$60J31KEZ](QGR5MEFJLI#U^P^T8@!E6/LB4=
MMG_K<< O6_H/2M0%8I YGJU+D\E?W.QHEE/(?5AV7MFR3:\;#5]O4K72Y&_9
M8F(%E/U%G&,8$27Q9A)-&II&!E)!8C-069!<%4$!65. :#M7=CL=;=Z^8GV7
MQ(>84QMF6IM+G3CV"-&(FC0[U9P@B,C&&57%FY](V5 R(JJ=@\(^(>_.^^..
M......9(^J/@Z<VRW"N4)!:QY->9V8X7AX= "7G3*?:1&+XB]9IH%?R;#5G,
M5NC))-GD6L76Z FP9/TG$')JTZ=E6C*T55BB:Y+J%4O*$CTU[9AK&>MM[V>L
M%PQ+7\72F-('*-.Q[?6+!>M-F2MH+<)0CF ?3=<D6+-RNG#MY KZ0[.&;!_'
M%61-U'TIL([64?(&RV5]ML>Y2A;UDB+P_7(G(.9LD8&M-WM<!CZ.M#5G7T:=
MKG#QN/ZG 54DN4S>4<KNK%9Y*5D'+\K=%JW2"Z;CE4/7-^J0WP_8;)_GL%RR
MW'?T?T7\'5C\D8\]3*?T99$_ ]K_ ")_S!$8.QC@/EW,?S\_?XA'S^ _;YC[
MNX>8#SIW)^!<2YG?4Z2R92XVU/:)+>V*PN]4=I'8/3'05.0_JSA KYFNHT;J
MK1SP'#)8[=,RB)@ >_;_ )^8% H% /#V\@   .WD';L %#X!Y?9R\3H;C_##
MFWX?P:0HA[O=\J&_N_4/-+''.A<WPVS,NG7PUUO^%Z*J@=\-H-E[&%QR.213
M.5O[-+"%J63\<#%';F*Z%X9Z:5!T"J (E:BB<5JG-A,<[B;$9NINDNP#[I]Y
MBIEJPY=]BTS7K53*\Y7V$IC&^XZH;-A\FWVR2Q%G[@<F*2#>7!ZD+)./5; U
M6%[Z5"QO4G#6<L$5=IC6\SFM@8HJ->806,:/K]A:Y8F95%)LZ757;*$LF6<A
ML'$2**OA:L6#",40<&464=+%/Z()A<<<<<<<<<QC=:N!1CMS[[<<^9.UH>LV
M>&L=0&&XM#6//^2LWX]K%RM.1U_6%5<<Y/K,'89!B-9M-Q=(2KA]#JUNEOI=
M>FM$(R1<R>DW8VYW/&_3POEUPOE2C56Z5C7!G)8_S#=#P]<HS%ZWJ$>$5<I%
M>QMY6N5UBZ1$L@R<V)K)5^&7<-5YM!W&-G1%(F='*W[Q9!Q_D"X[6W)"VT)]
M\GV.''4AE#">8K1)'9R]R5G[.[O&"FY*HM$3-?=T=HBQ<O';GV[$ST@P0B8A
M\SCT[G^>.X?:'E[_ #Y5%US//I(;X=A#SP;)>?P\YV"\_P!7++<=_1_1?P=6
M/R1CSU,I_1ED3\#VO\B?\P1&'],P#Y=C#Y_$>PCY=O?^H.W<?W@'(C[,:W7#
M/,UBN6J^;;9B=#'T\I+RD?70<&1L::B[!<JAO5I&/!*29E9JMVBSHKYH"#U?
MQ-O,P*RT .Q2E$XG$I2E\9NPB<0\O$82@4/&;WB    (B)0#X7B]#?Z8LV_:
M.-(4?_E"'W!]WPYI8Y5YO#NEL7@[8;5K6#5[ N-\U9/V2KV:[6FME/+$MBJL
MUR&PRPJ+Z1*$C#T>[N7KZ23M'^(3.S;II^IB43F%7Q)\''-G6O\ AHKI-_KH
M7S]__EX_F_X[PMGLO=7<W4/Q=).-,]0D\D):;9P91583VVNJE;>4E?-. EYV
M==V,<%$=-)N/G&]?8,(8D0NW?L9*0>JR+52/2;.II?/9UK_XBFDW^NC??_UW
MY]_4G=G:C(6X64M-]L]=<489O-&P%1L_PDUB3,TUEB%F:]<[O:*0G&R!YK']
M&6CG[=[6'3D 13=$%$Q ,/<X>&USCCD5,(;GX"V%S5LO@'&-Q:SF2=3[=7*;
MEN'35;#ZC)V:NM9]FO&&2<*F?,&BJKRO2;D")^H62(E8I<A5FP"I*OCCCF>/
MJY5_0J4V2UWG,Z%*&1*>W-+[!.(7%F8<DND--YJOY+I4PG=97&,7)Q6*X=[8
M[-(H1>1[*>)>1T,2ZQT9+-V$A+)JS0ZE>?\ ^]WTP7L&.<@X4Q)0++2I.HPV
M3<@9"CZ'%5=H^H$BYQLGCWUZA9(A[%(3#UG&1J$>XK$HFRKZKR:;1TF:/!FI
M"#H)1F)*VIM'7J(VUZD;PZE<?7#)]\P5L[8=F'%XF;(C:!:R5TE0H]&QW5),
MGJ3L[:$HD4T()'"JDE',A!J9?14(]@$0\^P"/;[>8?\ (<_M=3[?M\AC+).Q
M6<BW:2L5GS[D6NU7;K&=PUDH']^5CUA:L40M3M]WG:.^&<PB]M;^MV?$=-K=
MLBJA3Y24B7#F+EP=GYQLR\ZB$QT9-SG=9L&,I'3!I-[+L*F[V/:YLDMFYO6]
MGFU5'$CZD3LN_1!W#J54&*=9D,DMG,TZC$4UW*R[)1B?FQ7&_C^;NA>E$HJ?
M(NK>D$G?P"?V&Q\8D\0B;P^+OX>XB/;MW$1YZ^4_HRR)^![7^1/^8(C=_&;O
MV]X@/Z^_E[O/OY_:'[O>/Y#[P#MV[_#N #V /N[=N_G]@>8![N?GO\>_F'?M
MV]X^?Q'M]GN[^0@(>0>?+Q>AOV^>+-W;_P!M88?N_P"U#?W?N[=Q^_X<TL<I
MLVH^N8Z5?[$M]/ZLXD_X_P"!Y/[8?/=SP>C6%*AK5F[8@U@4D2/4<-M:6Y4K
M!6)6ID5)WY7VVK%*21%P<K+U$7@B9JOZ8$0!,3U?2^RFR+_=.@;$(]-?<TM,
MJ^L65\-OV)V6&@FU+->,I8=ND2Z;M@RL*!XM*+H,PD[6,X(JFZ59D(B<JISD
MLLUYV-O>;I:QQMNU4S]KRW@H]F^9RV8VE$;1UB6=.5$%(^&-4;I:'!GC,A"N
M7(/$&J((J$%-4Y^Y.06IGU]>>/Y,K ?^\'F3ER?/COK%7XM?U:3G8:.<^ JG
MJ[Z39-%_1F[^$_HG"Z:G@-V'PF\/A'L/81[#R(N7X;8*U7!25P]N=B7$M--'
M,FZ=1G<)UW);\DBB"@/9 UF<97JJATG@F3%-C[) &H)B .%O'^C5KJ_B[-I-
MEMUFM$V+T[Q+<<9Y)IU+G\H4[2J@0]JR^C>\6T?,4E,6J499D8.GB[:?N#MD
MJ15])$<+,2OUE2.EE4R7.X;>6VIU5:,S/L#C[+]K/)N'*%H@*K"8O9I1:B:(
M-HTU>;W.VIJK-U"+*&?^TR"N58I!;)^B\1^\F$E'2B N8Q^RD6P',F+A@Z0=
MH H4 $R8JMU%$_&4#%$Q?%X@ 0$0#N'/=XYE^ZR\OBF-V(NB5YQSD>)GY+35
MHRITW2<A;"TR*W+L(Y1D!3U(M,?A.MSD98(>-@@L<@HE.NH^;1D;W%MV9AK+
MRR*)V&]3.VXKB^FU/T2ZR&.\(3>5<31E2Q)7,JP@2T!6KL6J-9!C3_2%IM[9
MP$Q"13=["Q]D5KKTD ]23DD$E#MBIFAIT#X]_%V;;^/89;:96H,=*4".J<L&
M39B^/9 $)?)+A&SC#OJ;36]-;3%5>5*,=12[9[*+V& G'0N0B%8I,-'_ #\@
M4H"80*4!-_SA  [F^'Z7EY^7V\JBZY@ '2/WP    #!LF   =@ /;L%Y  >[
MEEV.OH^HOX.K'Y(Q^WS_ )^>IE/Z,LB?@>U_D3_F"(XAXC!V^(^?8/M#[_>/
M</N#R[^X>?CO^CY>?\X>7D/P'WA\1_7]OGY'X!Y=A'OV[?  \_B/;R\O( 'O
MR\/H;_3%F[W>6-(4 ^X/E0W\ON^\/AS2QRFS:CZYCI5_L2WT_JSB3EC^SUVR
M+C77#.^0\0UDUSRK1\19"M>.*B2->S)[/=X"K2DG6($L1&G)(28RLRV9L@8L
MCD=.A6]"@8JIRB&7"MW3KN]7'II90BTX%?I^;?5/9^G-ZA(+DRCKB:>PY'4]
M.1L"A7[AM/S[\'D[*BT[-D2QJ_J HJG*LW_2TB:!XQS[A?377C%FTMY^<O82
MCX[CH/+%\^44G;?E1;$'3U1W*?*69:L929](@JW3]=>M$%S^C\)B=B@(PKIG
MU]>>/Y,K ?;_ %@\R?\ ]_V\N3Y3-E^@TR^;K9K+=JM!VIK%4C#A6"4['@^(
MQ]:0FU'GJB@IN#-@<((']*!$>P& KO\ QBC0B"\:\DFP[C2R)5I/23*.20]G
MQ;M6RXPQ%69^KBHYD&2+AH1])6R#<I/&X&=%=(@P,DU(5<$EG185,SVI'4.C
M6[&6U.]V2<I:^YYRUC[*M_@I&D8NC=;L=H26-/4JC75H0DB@WR\]7J;AC7GI
M*RM KI+'L;2(B;>=PU.]]5Y=QB['^%LG5QQ8UM8GF,C%F9B-2KN5,>1-=LAD
MV:(^A?$81DG/H*L%E5D!:K'>IG<%(<#I(E>&.C,CIR1D?"5O8R%B&;>.AXO9
M*W-(J-9D%)DP8EK51,BV:)"4@$1(4WZ(@DEZ01%4R29CB0+&^.8ONH-B& #J
M#9DPG>:_ICCUE(8J1S3A>\;#]0+:S RLM(90R5D)>T6%:)B)Z.K%CD(JU&!9
M[C: 78-86(!@$98$8Z4)&P>B7>6=E<9],/-UDB,EQ./YRDZP.EV.6ZZE,3D7
M6EV5/:-%[56GR:5CL:3$R'IEHFR()SDW%-EV\Z0DH]:>%>$O0M89.;U+,CF[
M[,XGS77S$I+"I4G'.V:>X4E26S22O3Q*R6?(:L7%240YM5>DZW#%AGB;D\D\
MITA9%UF[V5<Q[2_;CE4/7,^J0WP_8;)_GL%RRW'?T?T7\'5C\D8\]3*?T99$
M_ ]K_(G_ #! ?L!S^7?N8P>8]A#N(]OCY!V\O/L/V]O=SQY=^X>?;[  .X]A
M^/EY=@[C\!YX >_?N/;O[OY^_E^_[_@'?OVY>)T-OIAS;^S2&^(#V_SI0\O+
M[??]H?'X<TL\ILVH^N8Z5?[$M]?ZLXDY<GQQRFRF?7UYX_DRL!_[P>9/^/+E
MR?*E[H82[I9_,)"@4*1ACNN= 1*F)8VTJ]O63>@12%,B9G?8[U(4BM#/U"H-
M&+B4C>5$,;P@ H)%$B9 $GJ8I^B$DF_[E$ACI&0]7%L<@D62;&:^RS$7(Q-#
M2*5>AO@/2NLZ[YSV7S] Y1RQ<I_::=+:,@U*\O*Y(TZ(FH!5:/@EZA%QM<BY
M.%)%0A@KB34[UTFO'-&S=ZFH\CT09S4 PB8_^3I^;QZ ?Y$8WI/$BU* >0F!
M85!5*F4$_6!6]<(D0BYY%HC+<FZ? ^*-V9-V#]+9:V&[@  !P-5:<(*@("8J
M@*@(* L15=-<#^F3<NDU"N%;#..9>^LSKAE3.&QK"YU?$Z&4Z_6\0P&/\33]
M!8:@/@I&SLC:Y=_&0^UK[8J%D[ &'9*'EZRO P-;<^A65<SY0C3S,I$+'T9L
ML>Q%LP]#8TR[4*+:HN3H<'6;]2EZ_'2N.Y4Y(5FTFX9&MR;1:,<U@7:2R+&-
M=,C-RL"H)&0 I?"'R<1:Y:^Z_DFT\%8/Q+AI.RF9GL1,6X\J=").GC@7+'GF
M"U>)BPDC,2NG)6AG@+"W!PL"(D!4_B[GXY5#US?JD-\/V&R?Y[!<LMQW]']%
M_!U8_)&//4RG]&61/P/:_P B?\P1'["<P>X>X^?8.WO$1\O=]_V=_C]OX /?
MV\P[AW#XAV[^0A_L /N 0 1YY[]P[@(]Q[=@^'D(]@_?V'OY]O/O]G+P^AO]
M,6;1_P!&L/\ 9_ZI;_#W_  #]0_'FECE-FU'US'2K_8EOI_5G$G+D^..4V4S
MZ^O/'\F5@/\ W@\R<N3Y4I<%11W?SP<@*%4"D81[+%2,!"  RZI0.Z$&**/@
M623<B!YMH**;920.2/;,7%KK/)VSE0$FW8KHI2H1H%*+91(4O"_C"D*=,QVI
MD!;@W;$4(HVC3-/9[@BR$&:#?M<<>TLY4]3,40=>'T,E^AZNH)O)1$H!Z$3^
M+N4A2I^'U$#%$AD!2141/&1_D7!_$Z 2N1\3J4 P>K*#XRBS=@8"]B'],!RJ
MK$*!/: K&=)(D2?GDFS&W<MZ?)A.PV>./B$Q]GKH<QC!V$YSURHF.IXO&J54
M%3"*A5R.7R:X&!9.2DR*%?N;#..9Y<P]-;;Z3K.X.M5'+J-:\ ;IYKO68[+F
M[+;.]KYSQI(WV692:!2UZ/;+05XLF+3-DFF'IX;) ! -8V!0.@U]F@96_6F5
MXU1I]4JAI-]-FK%:@J\:9DU!6DI<T+%M8T9.06$1%5\_%L+MVH(B)W"JAA$1
M'OSDO'*RNKUD+*^,-&,A6K$-AME.E2W7#D-=;I12.0ME,Q%8<K5&%RW:(9ZS
M:NWL,O#T%]..5K"R1!W7F@.)ILNV58E<I4XLJAU,=\NG%L#K;A@<2Y1P%E#(
MFRF(L79]V-R1D!#+4UA*NY@D6N*+)%OF];DT\@P[FLQ;9M%76POQD; V2!VX
M<.TP2?.+/H"V=;*"@H6#2UXZ?ZR4-$QL4FLIG+,A5%4XYFBT(J<I*$)2G4*B
M!S%*(E PB "(=N?SLEGZV%DKL]7E]>NG^V1G8:3AU7"6<<R&403DV2[(ZR93
M4("F.D583E*80 PE !$ 'ORDDW1XZLXF\7L734/,1^E#(_Q^S_,C[/+S[\C5
ML-HQU+M;977Z&N=0U8DW&Q>>:EK[3SP&1<A.DHVVW",G92/DIXRU1;F:0:",
M Z*Z<H NLFJH@!43 <PA)3_ []6;R_Y$TU\O]*.2/YNPT@?M\OCV^/)DZ:Z=
M]8?3FUW"UUW&NCMQ<6^O-*\X:S.7\J,4F:+22)) X149T8YU%#G("8E/V*!1
M$0\^W+"/G!ZVO\73I^?=_#GF7^P7E_MY$W)>$>LODG;76C;)YB#1*-G=:Z=F
MZGP]2;9ERTK$V5#-<?58^0>23Y6B [:*PA*NDHS3:D,1R9VJ"XE!,@C++YP>
MMK_%TZ?G].>9?[!<C=*;O=7Z)VQI^H#C6#1X^0KGA&WYWCIE+,^7C59"K4RW
M5RG2,>[?#2RN232\C9F2[1L5H=%1HDX4,N0Q (:2/S@];7^+IT_/Z<\R_P!@
MN1-B<(]9>)W:NNZJ>(-$EK)=-=:/KPXI)\RY:+"LHFDWNW7IO8D9$**+Y20?
M.;8LP6:'3!LD@S25(<5%#@$LOG!ZVO\ %TZ?G].>9?[!<B_-8CZS<MEV[9>#
M#>AK>6ND/4H=Q%CF/+"C)BG46TH1HN@[+0DI,5'3E\@LN0CQ%-(C856H(RJ<
M9+1?OAC3K1% 2EPQH1X"@!4@',&5RB4J;ERNAX@2H*29!*7V<0P-4VI$_5E?
M4",$VU;2K4;L09:ZM>;<P[/X0K6 M*6%DU5NE2H5\?2^5<H(1,O)9"H<-DF*
M<UI5*E*E=LVD'.,F3P[AFV\$@DNDDB+--LDA)8,<]:+Q")L+:#B!UEE5 ^>#
M*GZ7IRHIJ% 38^-X^Q/6@ 7/K('%4A7!5T%9="8^K@FF=:+!K7(2$=A'0J=-
MD3(4ID20.\S3EYJ#"0E8R)CEV#4$:*H=9JF,4"R;AVHL]4%8PNUW*_C<*][_
M #@];7^+IT_/Z<\R_P!@N3FJDUM$O5JTO=*3B&/N*T!#JVQA 6JROH)C95(Y
ML>=9PKUY$MW;R);2AG2,:Z=((N7#,B*JZ2:IS$+GPSZVVQZ@>9,_:IP,;G96
M@:_9.LN3()6^QU<PY*3K:+F9>@+4FK9.1J-BH-C9/FME7MV'(?(-""34B(B+
MMR^2F3Z*3]+I?QA#K5[&V/X!PA86SB$I57B%V]MEVU@M2"L;",F:B5DG6:J[
M2:GDSHB67E6JRK>0?@X=HJ'35*8><\<_"B::R9TE4R*I*$,FHFH4ITU"' 2F
M(<A@$IR&*(@8I@$! 1 0$!Y^44$6R*3=NBDW01(5)%!%,B2*29  I$TDTP*1
M,A"@ %(4H%*     <_KQS^:JJ2"2BRRA$D42'5554,4B:::91,=10YA I"$*
M F,8P@!2@(B( '*%C=7BF6#;5C7:K6E-A-6)1G2WT?9ZKB:]-,H8=EGUFDL?
ML,XUN$FX19//&N5JMYT*ZOEK%93KXYF![RC9_7I9I*C?64P'*4Y>_A,4#!W
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$CCG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g773514g16w09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g16w09.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1KT4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "0< 5H  QLE1QP"   "   < @4 $$%N;F5X;VY?3&]G;U]035,X0DE-
M!"4      !!% DT3M\DA >LW8^)SCUT".$))300Z      $S    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    H $( <@!O '0 : !E '( ( !( $P +0 R #(
M-  P "  <P!E '( :0!E ', ( !  "  2 !A &( 90!E &( 82 9 ', ( !I
M $T 80!C       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/      0 ".$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              )D   'W
M          $                          0             !]P   )D
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   )D
M    4F=H=&QO;F<   'W    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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M6MT[ZM68O2\OI^5G6Y?VHRVX[FNK]K6L]/=;<[V6-]7Z:RO5_P 97^AH_P#
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M.-U!O4GY&76_*RFM%;/4-F/^C:P':WV.;_GK<^M;:JJ^B5M#:V-ZIBM8T0
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M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !?DU- "H
M   (  P!   #     041   ! 0 #     0&K   ! @ #     P   )X!!@ #
M     0 "   !$@ #     0 !   !%0 #     0 #   !&@ %     0   *0!
M&P %     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "    %
M -*':0 $     0   .@   $@  @ "  ( "W&P   )Q  +<;    G$$%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,3$Z,#<@,3$Z-3<Z,3D
M    !)    <    $,#(R,: !  ,    !__\  * "  0    !   !]Z #  0
M   !    F0         & 0,  P    $ !@   1H !0    $   %N 1L !0
M  $   %V 2@  P    $  @   @$ !     $   %^ @( !     $
M     $@    !    2     $X0DE- _T       @          /_A 8!-30 J
M    "  , 0   P    $%$0   0$  P    $!JP   0(  P    ,   "> 08
M P    $  @   1(  P    $      14  P    $  P   1H !0    $   "D
M 1L !0    $   "L 2@  P    $  @   3$  @   !X   "T 3(  @   !0
M  #2AVD !     $   #H   !(  (  @ "    \     !   #P     %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C$Q.C W(#$Q.C4W.C$Y
M      20   '    !# R,C&@ 0 #     ?__  "@ @ $     0   ?>@ P $
M     0   )D         !@$#  ,    !  8   $:  4    !   !;@$;  4
M   !   !=@$H  ,    !  (   (!  0    !   !?@("  0    !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #$
MH0,!$0 "$0$#$0'_Q  =   " P # 0$            &!P ("00%"@,"_\0
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MC1V(\=_!_NLA,M"MJ2PA+>&!Q6,:WZ^V.HM>ZE?UPU8#:ZU4(K>L%/%ZE0!
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M19$:Q8(^0;"?):99;(=&2VMYMIM#BE)0G&#6\?0R 1;]*I=6,EHUMUX; C+
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MZ?4L;2NE7J 5"K,$S58GY&IL0%7XXV3C4DJCFS5&2#$D[DE PONC,$H(*D#
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%3AWQ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g773514g18a54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g18a54.jpg
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MFO66S+&CE-W=;%7#++C%B0AP4%#K#%W/"H&SE1:-)H,4H:[69#F9 J\H)-P
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M]T]2I7OX1'")J4PZA0*4&KHE8B<W'6LUO&3U+,9--*OL%S$9 '/4N$81Z'J
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M60N<][W!K&- =<N<X@ #4D@)WW.G+LB.$25TY_2)?XJ7K^]UA<NV-?'(>R<
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M))H&/NSQW)->U8FI.M[ )!8]- 1>)3UA-(34@*!.0<MJ\\XFO8VK(@,3239
M0#6=@[&@6P%X+<&XC)O;(A^_V<%&SM"7:V\KK[C0G?JU\NZWWQHQ83'^HE<F
MV\R$3666=HK;%LNHV?J:0Q:.7).V@\K9L$C+JBPX"IT0\%E'KL73Q#1+=H3=
MC'<A(KD39HF4>D=N?)I?47'43>YU\J?OPJ4<(CA%'I;7VH'2#\('D*_<KQ_\
M*H=P[YS?4]('YS_[!Y#\4ZL_/E.9FY!OE"I>R\5]W"QCRM^!M3Z=0>V*IG<W
M:6J:4"H??)3/Q>K/]:!>6W&N\F-]CXG[E,KE@W?C"NTJ'WJ)='CGFBMYESD>
MS7]Q%X?%JQOUD;YZ5<+>#> ]CX9[E M&.(N_N+]HUOO,J0WE^5F5M?QU_9,%
M_BWO^Y%?<T<Y=_#^H[,P_P!4JVVY(_!&#TZL]4:9I\I0]Y/5/[DVA^>Q'FF_
M*E\9P?\ D5?M(%[&_H]N\/*9VOPY[EBBK-\Q4O153"^";[1BN/N):OZ+)<[O
MR>^$U/Z-5^Q*U-^&M\@F.]M<-?>].KV?-@5XLHX1'")NEV^\OI]^(N3?XD]I
M.%(V=YOQ"YX?G*^U9[??>>O?V:KGF'N)^_5;\^/W>%>EW(9\E/"'HV(_?6)*
M)[E@665<Z^2?_P!&=WOO10OY1:_,B\#_ +G$/GTWJG6F'PK_ (]P3Z)COML+
M5N[G>UJ,CA$<(CA%6$\H=X]R%+J'Q"XJB0ZX]0HA=]:C8QVLB772(]II'_"2
M1R@&+M"W=KD/:V#'.I,@B<<]H%V#61T&Z-;.QK-49.%]TFN=RK;:WC)W!-AU
MV%M";Z;$6NI1_)%9=90#HH\W/V+#<Z2I]3#&KSEC6X"K![.I( FD/L$28CEF
M&C$;"C+!'@(@3L>/R8ELZC8HS'DI'*(Z>BK$O'R!0T$FP!OK>PO;J-Q8_2E9
M\?=)MZ!ZW@:_3K6PJQ<MS!!V^%6G9\+MZ<&LIL1085(2\SKQ7,/714C@<(%$
MC@K08@-#A&#?<>DMA19<H)N>KZ+V^W\W3V^%":/W<LN_:LH9X;ZP1 --[P-S
M^J(7#PA]I'"@Y-E++'C0F:EM0$JMJB@TF+!H"M*24<C;NVH(@8D;<2T=R >/
MW>.$RD6OTMM=O,;=1W-AL5%+4/E:N^P;3I71EI )E49&5==*;LD6UIB5P*W9
MA8U\UIV5FYR5PT1F[K%"05I5TDHL;"%Z^V=VLVE"F)\4'6?ZHRCZ^2J+1KOI
M>W6+ @>(::[V'F3@@/85&^/)_P!2,HTOV%J'ZK=0N]^NV+XJM_6>9![;LGHM
MG&8MZ\_>^VM17L?.#>4OH_9VQ,/C?&_K^GS26LP[=TW8@]3_ !+T^<_^P>0_
M%.K/SY3F9N0;Y0J7LO%?=PL8<K?@;4^G4'MBJ9W-VEJFE J'WR4S\7JS_6@7
MEMQKO)C?8^)^Y3*Y8-WXPKM*A]ZB71XYYHK>9<Y'LU_<1>'Q:L;]9&^>E7"W
M@W@/8^&>Y0+1CB+O[B_:-;[S*D-Y?E9E;7\=?V3!?XM[_N17W-'.7?P_J.S,
M/]4JVVY(_!&#TZL]4:9I\I0]Y/5/[DVA^>Q'FF_*E\9P?^15^T@7L;^CV[P\
MIG:_#GN6**LWS%2]%5,+X)OM&*X^XEJ_HLESN_)[X34_HU7[$K4WX:WR"8[V
MUPU][TZO9\V!7BRCA$<(FZ7;[R^GWXBY-_B3VDX4C9WF_$+GA^<K[5GM]]YZ
M]_9JN>8>XG[]5OSX_=X5Z7<AGR4\(>C8C]]8DHGN6!995SKY)_\ T9W>^]%"
M_E%K\R+P/^YQ#Y]-ZIUIA\*_X]P3Z)COML+5N[G>UJ,CA$<(CA%$MWI\A<NZ
MQWK"Z/BYWHU7N)%4JUINISW>[3$>O4?-8S+WT2Q$X,S!5U/7A<N-PPP7+.BZ
M@AHX9DFZ(74BN--Y8E4&W!-G$W_A;?Z]1;R>8I>.UG5.&]RZLKO$RNJ9TQI&
M8U,3*\NHHO5KX62BUF5*<KBQQFA.W*OL,$]@A6$3$TU;GF<?"%T&#IJ2:DAF
M^_S<% .4[ ^0WT-_(0;I0^F3^&N*1%C8-V)L#LV$C91R 3L.T!4+!S9EJV&B
M7@R+E!$%JZGQ;5J.C[\,2!+NX4W)%P!@6=W*&6)1@17(=]@/(+V^TGUIUW"A
M)Y:52UE=T-?UY;L%C-BPDFZ&/WD:E@EJ7%[$0A!N6"E$47.F^6A4,5:-20DH
MTW0(#'[9!XQ<H.$M%-2D$@W&A2=@^I/5^,32NK%CG7^HP$YJ*(-(!5\I#0..
MC3$"A@Y@9%#8Y%G3-@CL(&BQ<CDHP4BTPGD8.DLD8L-V[60&$GI+G74Z[Z[^
M=-[MK[4#I!^$#R%?N5X_^%([AWSF^IZ0/SG_ -@\A^*=6?GRG,S<@WRA4O9>
M*^[A8QY6_ VI].H/;%4SN;M+5-*!4/ODIGXO5G^M O+;C7>3&^Q\3]RF5RP;
MOQA7:5#[U$NCQSS16\RYR/9K^XB\/BU8WZR-\]*N%O!O >Q\,]R@6C'$7?W%
M^T:WWF5(;R_*S*VOXZ_LF"_Q;W_<BON:.<N_A_4=F8?ZI5MMR1^",'IU9ZHT
MS3Y2A[R>J?W)M#\]B/--^5+XS@_\BK]I O8W]'MWAY3.U^'/<L459OF*EZ*J
M87P3?:,5Q]Q+5_19+G=^3WPFI_1JOV)6IOPUOD$QWMKAK[WIU>SYL"O%E'"(
MX1-TNWWE]/OQ%R;_ !)[2<*1L[S?B%SP_.5]JSV^^\]>_LU7/,/<3]^JWY\?
MN\*]+N0SY*>$/1L1^^L243W+ LLJYU\D_P#Z,[O?>BA?RBU^9%X'_<XA\^F]
M4ZTP^%?\>X)]$QWVV%JW=SO:U&1PB.$1PBAZ[G5CU=86$Q7[%^5:>]6I >U.
MR6-0>27=THKY/>-ES"GT;:,C+PHJ1R1S$@+YL[%AE4"+SZ';#MN1(D'NFRNA
M5"_4T'Z"5X^[TSAMO=>.O\RH:W*ULVJ@UCI"S782((3.VDXVR A78$M(0EK]
M6:WM(U "N%TG@N6/HPXII(MERXB?\9ZO]=U:&2 ;@@@D:7MZC:]_LWL;)TW0
MUW08>MS%;]<'$A-5I%#3@L)DCCKPI145<:2/;*F1(<F*JBHH-9I<<X8NMS$K
MBX$@4RV7%)3<N1DFRQ4J4&YU/7Y;^LD^:_T:)]?"A'"(X11Z6U]J!T@_"!Y"
MOW*\?_"J'<.^<WU/2!^<_P#L'D/Q3JS\^4YF;D&^4*E[+Q7W<+&/*WX&U/IU
M![8JF=S=I:II0*A]\E,_%ZL_UH%Y;<:[R8WV/B?N4RN6#=^,*[2H?>HET>.>
M:*WF7.1[-?W$7A\6K&_61OGI5PMX-X#V/AGN4"T8XB[^XOVC6^\RI#>7Y696
MU_'7]DP7^+>_[D5]S1SEW\/ZCLS#_5*MMN2/P1@].K/5&F:?*4/>3U3^Y-H?
MGL1YIORI?&<'_D5?M(%[&_H]N\/*9VOPY[EBBK-\Q4O153"^";[1BN/N):OZ
M+)<[OR>^$U/Z-5^Q*U-^&M\@F.]M<-?>].KV?-@5XLHX1'")NEV^\OI]^(N3
M?XD]I.%(V=YOQ"YX?G*^U9[??>>O?V:KGF'N)^_5;\^/W>%>EW(9\E/"'HV(
M_?6)*)[E@665<Z^2?_T9W>^]%"_E%K\R+P/^YQ#Y]-ZIUIA\*_X]P3Z)COML
M+5N[G>UJ,CA$<(CA%6X\B-E=7KP[$V+"QW9"V:\L.#586ZN]B(-_V7M^=P@S
M2%3!^[E;9] SC:J7(*NYD;9E7K@?/!!&91:9!F\9?J #*<8$N]2Y&M=:X /6
M.DT?6+Z@>+356!JIBT3AE<0F.0AHNUC Z, TA.SX;D27?-O9C7Z,H?9*#Q3G
M20D],:O3N[T<R?J%%G6[ULBYRHGJ7&=S^&WT)0>$1PB.$1PBCTMK[4#I!^$#
MR%?N5X_^%4.X=\YOJ>D#\Y_]@\A^*=6?GRG,S<@WRA4O9>*^[A8QY6_ VI].
MH/;%4SN;M+5-*!4/ODIGXO5G^M O+;C7>3&^Q\3]RF5RP;OQA7:5#[U$NCQS
MS16\RYR/9K^XB\/BU8WZR-\]*N%O!O >Q\,]R@6C'$7?W%^T:WWF5(;R_*S*
MVOXZ_LF"_P 6]_W(K[FCG+OX?U'9F'^J5;;<D?@C!Z=6>J-,T^4H>\GJG]R;
M0_/8CS3?E2^,X/\ R*OVD"]C?T>W>'E,[7X<]RQ15F^8J7HJIA?!-]HQ7'W$
MM7]%DN=WY/?":G]&J_8E:F_#6^03'>VN&OO>G5[/FP*\64<(CA$W2[?>7T^_
M$7)O\2>TG"D;.\WXA<\/SE?:L]OOO/7O[-5SS#W$_?JM^?'[O"O2[D,^2GA#
MT;$?OK$E$]RP++*N=?)/_P"C.[WWHH7\HM?F1>!_W.(?/IO5.M,/A7_'N"?1
M,=]MA:MW<[VM1D<(CA$<(J^MS^0H14RODF.G+KZF]?\ N=6LW&P#KI54]KUN
MZNJU*LJ0>.FM81HJ(Q+0%F7P)[%$9?,V-=JU\U6&U:K8KU<$T+R5L<;KER!I
M-M'$6))Z@3UC2PMI>^IMU:*>:&EBY^(14Z?!+Q<\:C8,L;C3E7"SF.ER(QJ\
M) G"V--,*KB'BRP]57&FF%%&^V^--?3Z,%QK9.$1PB.$1PBCTMK[4#I!^$#R
M%?N5X_\ A5#N'?.;ZGI _.?_ &#R'XIU9^?*<S-R#?*%2]EXK[N%C'E;\#:G
MTZ@]L53.YNTM4TH%0^^2F?B]6?ZT"\MN-=Y,;['Q/W*97+!N_&%=I4/O42Z/
M'/-%;S+G(]FO[B+P^+5C?K(WSTJX6\&\!['PSW*!:,<1=_<7[1K?>94AO+\K
M,K:_CK^R8+_%O?\ <BON:.<N_A_4=F8?ZI5MMR1^",'IU9ZHTS3Y2A[R>J?W
M)M#\]B/--^5+XS@_\BK]I O8W]'MWAY3.U^'/<L459OF*EZ*J87P3?:,5Q]Q
M+5_19+G=^3WPFI_1JOV)6IOPUOD$QWMKAK[WIU>SYL"O%E'"(X1-TNWWE]/O
MQ%R;_$GM)PI&SO-^(7/#\Y7VK/;[[SU[^S5<\P]Q/WZK?GQ^[PKTNY#/DIX0
M]&Q'[ZQ)1/<L"RRKG7R3_P#HSN]]Z*%_*+7YD7@?]SB'SZ;U3K3#X5_Q[@GT
M3'?;86K=W.]K49'"(X1'"+7"$.B)<X*DQ6*QPG) .NVH.0D 8QZ<#:[[;;;Z
MBBSEJJ_':[[;[[;89N$<;;;;9SC.=L^DBV/A$<(CA$<(H0[Q[H]@81Y(05-1
MF8-58,-LKK55['K>VC\#V-7#%;OI7L_8T[MII(SS9O.&1*!2.I8Z(!NPLI!U
MX,8QV6-YJ.(NC#8F$C6_D_\ [_@JP 6WVWUUW%M/,0?/?7;0Y";6;W0DW<'K
MQV(9^+[L\A%*@HSM!5QX,YNWH)B0DC-XRWK+((V_$))=O51NXP4UI*1(F]WA
M%F[3<% N&#5\GN^492EAE(SMU(.S^H._L^4)-?(N8[P]Q>M12E8#XQ^R,:D+
MZ90V1IE)?=_0M$-HTCA+9Z[0WW"]MS#[UE=/;&C?&K+9+._I^E43U_GSOW)M
MQ70\%\40XYB%/5U5-'1UE,8J)L+IR^IB#&. GEACRM.KKR VV!74.-N':GB?
M 9<*HZFE@FDJ*:825//B(-A>7.!,4,C[G8=&WC(5="T.B/D1IF*HS6RNDL]C
M<8<2^NH$B3S<_5(O\^66Q8,8JNOQ/J8&^RA#7V_/9E&P.'VS34:+R2]IFG@X
M,T?D&NP?](CA3_8W$/\ W6&_\Q6&!R)\0';%L$V)[O$-@+G_ *AX@EI@WC7\
MHT7GD"E3WH'8B[**3B(RAZW:WUTUV=.&<?/CRSINUPKV021RY60:*)M\+*I)
M95VTPHJGIG;?7Y,0^$!PO5X?B%''@^/MDJZ&LI8W/CPX,:^HIY(F.>6X@YV5
MKG@NRM)M>P)T7UT'(YCM)7455)BN#.935=/4/:QU>7N;#,R1S6AU"T9B&D"Y
M N=2 K6/^U]VM_\ I4]N?_S5X]O_ .R^:DK8K*/Z[?J?_P"555+<\;?E$L*T
M;$G0OH%8K(;,)M*I,P:/[YZ::OFS,\>(%6R#S5OV170U<HHN]$U\(KK)85UW
MPFJIIZ-L[9X/R_\ "^'85AM!+@^/22T5!24LCXX\/YMSZ>GCA>YF:O:XL<YA
M+<S6FQ%P#HM=,4Y&\>KL1KJR/%<%9'5551.QKWU^=K997R-#LM"YN8!P!L2+
MWL2-4WFMN@'D5MX3(#M=]*9U(146L*QZJ/.OXS]4Q/J$^J2;'*ZL(#] <OL:
MX=?5Z91PT&R49HN Q7++V@$(DA;AJ^7N7](SA3_8O$/_ '>&_P#,%\'^A#B'
M_:^!_P#'B/7_ .X*=6A7O=/JCT(-T=9OCA[";%$)TRD3F5 [GZ0$8T@W*3R&
MN6+;9/7M/I(%'*ZS'#+_ +D(JBFX=(**JZ-=7#A'7?E(XKHN,^)I<;P^GJJ6
MGDHZ6G$58(6S!\ >'.(@EFCRG,,MGWT-P%FW@?AZJX8P.+"ZRHI:B=E1/,7T
MIG,1;*&V ,L$3\PRF_0MM8E)-Y9:*\AW?N64N?J_QPW=$6M;1Z8""Z,]O3H\
MV7?+R(B#>-%!N(]VE/I[(HIBUM7&72C;?&ZB6$]%-<[[:X&XQX5K>(YJ&2DJ
M*6$4L<['BH,P+C*Z-P+>:BD%@&&][;BRWO\ @P?"(X3Y#L-XNHN(\(Q_%9.(
M*["JJE=@D5!(R%E!3UD4K:@U]=0N#GNJ&EG-MD%FNS%IL#"6;\;?DCCEE0&H
M#/2^7L[%M"/3^5P6._QJZLN,G %7*PU"=O\ VLUO-<&,]A*V!$=,M3!,>\)^
MU\9#MR&K$GEGTS_1CC/_ &[#/^.J_P#U5M/_ $_>2[_T2X[_ /E\ _YYY%)=
MXXNE?DLZ;=J8I>]@>/.V)+&@,;F89R)AU[]*ESJSB2 '8EHJ@F;[,AA^44%W
M&JCG*C[3?"6NV4M%-_1IGL/"_!&(X'B\6(5-512Q1Q3QED#IS(3+&6@CG((V
MV!(O=VVWB6%/A _"RX&Y6^37$N"\#P#BG#L0K<0PFKCJL6APIE&UF'UT55*U
M[J/$ZN?.]C"V/+"X%Q&8M%RIXKX[*=[)S2]HPZJ?&IVV@ME2:#2,)!9DI>_0
M4=I%Y21&N&P8YL_%=PGA)GJ.>J).<N&+1PZ2PG\]%%3?&-<Y!Q&&IJ*"L@HY
MOU:KFIY8Z>?,YO,S.81')F8'/;D<0;M!(MH"M+.!L2X?P3C+AC&.*<-&.<-X
M;C>'5N.8.V"*H=B>%T]3')64(@JG0TTQJ(6OBYN>6.)V:SWM;<JM!>M%^<]C
M!9W:M]TA=1B&UY7LID4UD\K[!]4)B\"5Y% Y:1R51-%&]34A=LAXI,N0P)"M
M7;UPKNXT',7#YSJFKB^?@KB^JN:G'Z:H)88RZ6:JD=DUNP%](YP;=SB&@Z%Q
M(U)7H3@WPKO@P\/!K, Y'.(<&C;5-K!%A>'8#00FK;S8;4/AIN(8HGS9886F
M1['.+8V-)+6- VNNNOGGZ$"V<HK"D+SC8Z7"!11$E%>R'4B+*F [QOH1%*.T
MV=^#7FZ>4'>%T6S]+15MLMOC=%)7*FN*X>#>,J<N-/Q#3P%P <89ZJ,N U <
M64C20";@$K@Q/X4GP6<<;"S&^1;'<7CIW.? S$\+P#$&P.D#1(Z%M7Q#*V-S
MVM:'%@:7!K0XD 6GD+]E^X8G7I (GOC<[4OIO#K$0;&"3FZ.B9!:PIDPZDW[
M'Y!J)?)=ME?HWKS9V:F&[^3[ V;@8&((9=_6!X)#D<I4L<L5+315$G.SQT\,
M<TMR[G)61M;))=P#CG>'.NX F]R 5YU\0U6&XAC^/5^#TPP_"*[%\3J\+P\Q
MMC-#AU3733T-&8X<\4?ZM3/B@+(GOC8696.<T FN1Y%/%KY4.X?="\^R<"Z$
MSR-Q&T3$7(A0DOOOIRC(V"0.!16*.="B0;L88&:**O0+EPAAH2=:Y:K(94VT
M6RHDGTS%^%JW$,0J*N*HI61S.:6MD=+G&6-C#?+$YN["="="MGN3KE_X5X.X
M+P/AJOPK':FKPN&JCFGHXJ%U-(9Z^KJVF(S5L,I 94-:[/&PYVNL"+$QT1CP
MZ>4*93BS*WC?4,P2FE.OHJ-L<-_&SK,S^KCV;1EI,8PC[1?W2U%%_:<<?-2/
MT@)\329_2^J$%&C_ $4:Z6W_ #)Q'_M5%_Q3_P#X%W;^E)P5H?\ (?$VNW['
M#.K_ .)*QGX5^OWD1\:@'L,)M[QR79-U[>,5J1 J5O>G1]TD.2A;&:-2.A?,
MG[21O?11UO)6>S+#/5YKMJ@Y^GV0SA+"O:>'<&J,'95,GEAE,[HBTPEY YOG
M;YL[&;YQ:U]C>VE\!<M/*;@O*54\/S811XC0MPB#$HIQB3*=ID-9)1OC,/ZK
M/4@AHIGA^<L(+FY<US:27M=VL\MQ2  T.E?C.G\6LW28,UI$_P"PUJ=*C$/7
M@F IW1^T$MH-W)V*IR7>0;QM9JNY_P"7ZBT"Z:G_ !*C7EXK17&)HP]U,R;.
M,QJFR.C,>5UPT1=+/FR6)TRAW798TX6?PC%7S.XRBQNIPTT;Q3LX?DI8JP5W
M/0&-\KJYHB-,*<5(<&GG.==$1T0Y0IV]??RF:$FH82G/7\)!M[5M8-7<.% K
M8IA80:G<Q;&G0*&MV@WM&;]@C'28U^X0?.5A YAD<@@Z-MTEO5W=D=2<3.<7
M?KN'-NXN(:ZK#=;]$#*;-%]+6.@UM>^5(.(.0B&(1?YL\9398FQB2=N OE!;
ME'.EXD;GE(!#B\.:<[B69LI:\:@KQ^4LPN8P%A<71>&S6IFLR$O+'R*L_K:_
ML\A"]R3=21L(J9D'<1(4B:R+U<H@LD]<,&[O9++G/T7S\\^JEBX@CDC%1/AL
MD D:9<HJG3&.XSACG@-S6OES: ^3:PX[B'(U64=<_",)XVI,5=1RLP[GI<%C
MPV.L$;A3R545/FE,(D+3,(NFY@(;JIAL=ONUF<XQGQ5=N-<9SC&=LW3X]\XQ
MC.?YYSC'<K.?1C_SSZ,9S_TQG/+ZL291_7;]3_\ RJ0KA4HX1'"(X1'"+6W,
M-B#V4C9P\BD;=S4,-=A@\P<@A:\I%!W^^5'PD;(%6NY9B->J9RH[8M7:35SO
MG.RR6^W\^$6R<(CA%$99W<.F;]G+OKE;5 WP(J 3W=K3KVPO]N6JY.N'':>F
M)M [ZJZ,O1H.RWEP"09^:Q6(#V)Y_6NL8*DW;>-%B0Y,ILMH50!&H([DZ:WL
M;M/5;:YW^W1/1ZK]L8!VZC]HRFN8_/P 2L+B/TXZVL:)$X*:/$0,5A<NUDP^
M*GTVDG$QXT)G IP&3E(@"?7;ZY=/ K)-9OC<H(M;;47T3HN%"C=GODEAU<7I
M:552.B[IWKJEK>H>CK1['#%JI=U="9]V/CE9'*RT-@'%ELK<VC;M];<*C1F3
MB*Y+"P9@E](_43%(."*)5938&XU!<!K>P)OU6ZB=]AX]$WF$=]Z:ZUF;#HN.
M=5>U0.RII=YNS856$GS4;246Y(^V-L=B9\1E8IV?MYB)JT*8D%57#+1$8N4E
M7<@TAK:/>PPI!R50&-R921>XM;Q[6 T\IU&U]T\2;75!NQ_1R/7Y6;E\Z@-P
M12G["B:A5I@>63#2B7PLHU:%V&JSG1B78:N,L2K--RZ2;$&[E%)RX3TU6W*6
MBS['<$@_1=/$EDB:Q"+266/D7#EE%X^9D3QNTPGETX:A1SDDX1;86421RX51
M;;IHX5523RIMKC=337T[8*A1"P?OC0%S3.K>R5G=>^S-06!!>GTL[%]>1A05
M$K)?7!UQ["&Z5$2(M!HK04YM1\4EGUC;4R+=1*8,8K)8M];A;]TS2$/33\25
M9:1<7!Z5C:^A%][@:;F^N@4GW7^X@78>B*6OZ+C"P6-7?4]>6['@Y_5GH=$A
M+'B(B8"AIG4<Z?#]2K%B80;$-6+UXTP[26PV=+H_,5W*DBQ(/42/J2N<*%#5
MIY%JL[5TY(J\GG5+M6$A':/KOV&=U&,&-JID\@[)PR',<P:TX35Z%<VQ)CD7
MLG8;*$G8(99(^!H.!JCLVB73;AB6S4JK6ZQH;=>G7UCR$><;;7^T<\M]!PP?
M%H&[I:]XPE7QG2L+AT(JU"79=>VT=O&+]519B8'Q%L$6%AAGEJ2 .(4>4RO9
M!$6-;F2<D'!W@Q44J3(?&-@1OKI?33J&][#Q74@EV^\OI]^(N3?XD]I.% V=
MYOQ"^/:GL@,ZM5>/L=_ YA9KP]9U25#%X-!7,38R.13>Z;%CM80H>V?SF1Q*
M*#VZTFE S1\0-2 :Q9--EG*[C5-+;." 7-O(3KY 2?L"8;%N\O6VL#%DW*]I
M[L1"[NO'M[2W5&]*I,QX;*#%;7 V3IJI(D4ETC@\DEU0Q>O4(A;E72)G+65@
MNV$T;R@6QCB9.7NEX^U*K*=K@@ N!ZB+$FUP"=B-M"/$I@^%0D [2=A '56A
M;!OR3QJ23$+7S0(NYB\0R%UDAM>02<)$QS$5O(RP(&FNH3/,]MU29<>U2;ZK
M*;N-<ZXQL4@7('C\:CQNKNC7$]B90I9G43M5I:'2J\8M:M@4TP?TDV,U6I$Z
M>EUP1NXI;9+*Z5*.>5.2@/U@;"-\6;L5.SC5&%9 MS*>^J138^,6/7KXQI:U
M][;!+K2WDQI:\[RCE+Q:%6H(:3K$H&5Y9<I%Q(5$9E.('5U:W+/:^; 4YB[L
ML%((M +6C1-9[*H($CA1VPDP\0:>*BV>Y8H+2!?S?;>Q\75XU(QPH1PB.$1P
MB.$1PB.$1PB.$4;HSQNQ1O=)2S#5Z7%(:^?=IW/<UOU]<,JK'UNA?^ S(.#D
M[V0CJZ0M@J)BVPY@;!Q9>PT@/UB'#B9-D1U:>K*%5FL+6&UKZWL3>V]OLNG:
M4U14=I4K>)8 7-%5[WNX]>LC3,;,=D@\B/PV"0IR(">I,VF^H5$? !KI#5_L
M\?>N/'V5'FZ&6Z2)03>WD%DMW"A1N3WQN1.Q[QM:T)%>EPIUO=UO4)>%I]=1
M;*JVU;S6=];X]5X:M-2\E=UT_M9&-($*@A4D.1P)/0[,X3'[MGF^1#ET.7*K
M-I:PT!:#K>QO?KM_$>I)4CXF1Z\1O:*2GM/:5CXOVU US2TG:5-]2['<JSD*
M84?,5"^LQH0SM,H\)#Y:Q>'1>7K& U= Q 1K7[>-ICL:+$SG2P L+"V8?3H=
MSUGK3DYI2D(ZW]&X[0=;I$4H)3\3I^O8MDP[T?F7 B,2^%BV[XR^30:)/3)'
MU?9^6=HM&B#@@Y<K(-&R6^B"92TW?<]=_44\661UK+XK)HF^7<-F4HCYF.O'
M+7Z/#INU-CG(UPNVRMHJEAPDDYW41^E343^DUU^?IOKZ=<E0F%]9/'7&.NR\
M>(F;QMZ[C-?]91G3^I'EALJM"M*JH0=]6U%XQ&QU:UY"-"Y<XZAD,7D$KFJ\
MH/$-8D"03=M$DG^"!5%Q-] +DN-K[GSDIW'7^G077BB*6H&+DRQN-4A4]=U%
M'C)[9GL<+!*XB(B'BB1G8<U8L-BKYB'0=$,L631IEVJKELV01^8EJ4$W))ZR
M3]:5SA0HCH1XF0\)APB)MNW/95UO7-3V_4/7@TW1IF-D^NP>]B YS9,K@+Z)
MU6#+&;"(#1J8 %+9X6E3B)#'3]:.-AY=UDGJ_/Y_/4JLWD&]SOK]OEZK+%[>
M'*I34'ZX5M/[<E]@0KK:436C(HI3_5H(^(@&<WA-B,8ZVDT4HL)*(3N^D\(1
MQ.)5 C$=F5E!I'*F,X/&7Q- LR?G\^= X@D]9\_JZ_)?8V(V3^KM]Y?3[\1<
MF_Q)[2<*!L[S?B%\.U77 =VDJ\=7+V>2RLWH"T*BM^,3>%,XL0/@)K2EC1RT
M(8]0'30#)HP1:IR6+C,OV!<(_9O&>%FRJ.VBFW" V-_(1KY00?L*1(5X]X$V
MJ>55U(K0M"<RBQNTM2]OK3MZ2_45M.)_;-/6+4$\C:;T;%89&H,!BFK"CX'
MDH_&(H(181 >IAHO@^X<G%BG,;WL!H6@:V ((.YOUD[[I_\ PJ4W_M-U[!=J
M:$L&@Y+)I%#@]@-0B#B41/0,I(@J\?E 26#GHM*0C#(55;0D!::J)$A;ULHW
MW6TW1SG;&<%(-B#XO&F)V5XH1UJ1F6L97VV[!DIS:%O5[;ESV&_C?7M]FV]J
MAC2$9J>M9?6JE,)T^]J.#:-]3R,$<0)TPDLJ45.S):0N,-]&Y3F\@T%AOI?<
M[WN?/YDL4(\=M=QKMT/[G2>=2"PK9#Q98,+=%H#2$5<X/EJYB58265FI77=8
M1&<RG8A'HLZ4!1:1R8E$(4\F<STC 9B-=1X=&B9M+=5[[GRV%KVZ_5],A7"I
M1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB3^T8$A9T'+PER25$(EG 1?<@@VT
M=JH9"GQ9[375!15#3?#C<9JVVSE77Z/1;93&-LZ8TV*0;&Z4#A0CA$<(CA$<
M(CA$G\S@*$PD=32%4DJQ4JJP"4^:M4VVB^AE<C5=F5?L-75V53V9I)-K(<&,
M.4]%]]EQ2+3*6J;K==$GC\O]X/X)0.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.
M$35NW%RV#3$*KEW5X^&OYE95\5%2XU6>H&W<9$XLZ2Z1Y0V^:1XB**N_9?TF
MKC1LW?(?2^C;3;;^>/1ST\;)'/YPN#6122');,<@N!T@1KM?J7%,]S&M+<N9
MTC&#-<@9W!M]"#I>^Z;#'^\5T/%Z>!%J@A>2!/N?-.H-U34/+7BD+$&(>H?P
MQ,5P%>I)2HJXES(:W(_0&\)CH:LR.A")(X128;N><TL0$A$CM*9M1&PMZ1#L
MNCSW(#;VN-77:0 ";<39Y"6 L;K,Z&1P<<HRAQ!:#TCF &^C3F%S87=_+^RD
M+AEQQFE"0_=:2RK8'JQ>8L6A ^J63SIPT:^F&RJX8];)3YBC??.<1RN3>S[T
M_1!L%'*:Z"7SM@<Z-TH/1;>XR3';^TV,QC_VGBW79<QE:UX9UFW\48W_ +)>
M'GZ&F_5=)',>P=L1F:7$8;-*[>U535VTS3Y>,KAI*WL,ZUM2-4<4>RD/,4Y2
MO'M" ,A<^FHR'+0%3:1)Q_49B3"WAE-XPY&PL<V,=/G)8Y) ;C(.;,HREN7-
M8B/5V?HW)RD!<;I7ATE@TMC?&PBQS'.(S<.O;3/H,NMK7UT\@?R&4<1WD2K\
M;+P@>+M1A,O)E'%>26--0AR'7',@A9<O K ES=KJ4;T9-P20IWE \UE*L; D
M!31X?:8P-'+T;927$@-Z8=<.B!%G,;MSK7$BXRAQOT2@J8S<D.  N7=$M (D
M()+7&U^;<+;YK"VH2X6):\SBA3K^D(@C? 6V)V/BLT<2DTF./0)$I%BIU@P;
MA Z9AH<D:S\?NP>XT.(!!2# DYU(DUE!C5YQ,C:X37?K&S,S*+A]G $DFQ#;
M&XTN21H-;<CGN'-V;HYP#KFQ:"--!>YOIO8:Z[+0;C[(2>OK(0A43@BDWT'/
M:2'G!S!8>E(BSN[97/@@]K'%CD@C$=8*Q<56Y0L65/$M&;U.0BLMG+;<0^;$
M*XH&O87N?ETD()O8<V(R<U@XG,9 !87&4Z&XM2^4M=E:W-;)<"UR9"X"UR +
M923<]?DU1V6>2>LF8&:*0N"V#(Y5%8-*3+@6Z;PYDT!SR.U>=L]2O9:GK-]S
M;1RQ'B&XXW* @LU VY0L-'CI>1<+J^K\C:)Y+<SV-:YS1>[B2PR"/.WHV(N;
MAI(?87+!I>@U+0'6:XEK7$CHZ.:PO+7=(D$"P) +;D#,2MK;=XA<>C4:6FM9
MV:5/&S#.NA9&+@J[%!9_<;2=PZJY5!(>'(74?>@78.PI8X#*.9>>;Q99&+2=
MX'FL@8-@I _!I27.ROC#0,Y#B\ED98^1KG$1-#@6-OT07=(7:-0V14  $L<2
M2&@@- =)F:PM SN(LYUKN-M'$$@ E4*<[9P*ZK!DM;QV.340;C&)XF]>'$8F
MN)4(5A.&=<3P3NO%Y;)70DB%F+SV8Q3D3(*A+&C,B<ACB0@A[LBEQ20/C8'D
MM(=DL!FO:1I>P])K006B^A);<!UB0%6R9KW.: [HWU-K7:[*X:$D$':X&;4M
MN 2FJ./(:8.C[P2J^-UU/I?#[)J$34$39S5)):?02=]EQ'6@W[??I.%TH[*M
MS2#V9 'RB.@%G$K,I]V7;+J+'M%?H_5 TQ<X7L:YDAD<6'H/9"9A8$7+;$-=
MUES) W8+A_621)D#7%KF"-M]7-=*(C?70DW<#8#*^,F]RLK+?(7J"B<IMD!&
M@$HK(+<K2F&(MT35A\X]LR7KO5EMAB<BP=<;-(\WKV9R>8QN^V+T7H_JV#@C
MM@FDVS:KY@-+PVDNYL;G%KS'SA(&9MFS/C(;;<O8&NB-[/>0P=VT@ZIL"\-!
M:)!& ='7,;'W=?8,<2)+CH-!<;!KEG)9V[M:$.E=2D>KTPW+3XA048T&MI(/
M61M\2T@K)2:2!1P9(X3JXG)9%)/F@VS=*0!8\%CS]23F74I<-X[#:>-PT<\$
M,YYU\I_9DO.5HL.F&ANO<DN.@#075.F>W<--W<V+!PZ?1&8Z]P23IN &ZDNT
MVT9>][&YA6D0$;5.Z,$K<L"M9\)S$9CKNXC%/R,C_$"V(^7TL#=., UHLO"P
MXR.$A$S7$VG-0L8?R$D#5<2%E28H@U[CSEA&Q[#F;HZ1HR1N&2[CFS$N!9=C
M2X &P,B20N8T9+E[F.%G'1A.9X.891EM8$.(<X DBY6=N?N.)J:9I!OJ-*RL
M,B,TD48M^P4&P!8+&W #J[8'9C:-1\;B6-9@7F#B.@H4LDMB)+1%1M*<B\2#
M0_INU91%3&1M\S0YS0Z-ES<WG9#F<<I:&W+OXLUVWRVWE\X8ZV5Q:TD/?H0"
M(G2Y0+YBZP;U6UM>Z^[WNQ"0TM 0>45Q9\0DA.Q]*M.(R96K!P6%RQV.JHX&
M8')?_$]6'%7TCCMQQ&01P!"C\LE1IBVDC)@ 6D )P$4"F<6N>U['-#.<&7G"
M7-!D!(;DS -,;@YSVM:#8YLIS)SX#FM<US279#<MLTD-(N[-E.8/! :238@
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MF5/GA/*'AY<7&^HN1<<YSQ!+2TB\A+K@@@[$(8F%I:&AHZB #8Y!&#8@@V8
MVQ!! L0L)3O5J%T\[!$F!N0R,F$>62;]:.;L,Z/93:A"..)+)G"#5FC_ ,T:
MBXNPC@9WE7=_H)?2!8V_.F9 2++3).Z0$$!H.06%]HP[*-3M=Q<>J]@  T!0
MR(,(-R;%YUL-7FY)  N=  =]R2224YSG N5'"(X1'"(X1'"(X1'"(X1'")A?
MD."R,[4-;-@L?M24 6O9&C"5G!*<;3Y[-7M3,9;JM8":+.LE49HZ&Y!X5P10
M"J8<*)9UUU_W\Z<^JC+6R/)=&UW,RB,R9,HD+>AW8+;WVNN"I!,;;!Y'.1EP
M9F+BP.&:V7I;7O91L*QZ\-%*!BCB&=X@8QUV4L&3UA.UE;_EBU#=7QEVQB30
M\%8P$ ^,/Y!9MAC A&!1II>1,HVK2CI :5FVF%4D(F?^W-%^V=FI7'F&->RT
M3>=G,1:XL<0 UC"0\F(#/*T!FG2'R6DO&,M0 97.:[]H>;B$C7-#P#<O?8M'
M.$Y8R2[^JYR7CJAG:6,'^T;*?K6CF/:Q2O04,D%P+6,*)3>]1!6YT;'LEF+L
M[66( =).)=5.YD#FO6DEIQ9R@R1@JLC2$&<*<-8Z!P@+!'FS/<]L8C(;$1$8
MX[QY2<IYP#.1+_7RD@+EIFS-=*'%V7*T-+\]W2 R9WV>#:X++Y2YFG1)U3E9
M['>S7^R'VH$3YZZDEEE*AL]K7*%='])1)57SFO3+<8R ;PVG:=*)R%P;W2U$
M-AXDP65>;M\L"":^R3;7A8Z 5$!8 &"1A>7BS>Z&X<^06 WO86W"Y7"7F)0Z
MY>6.RAI!/<]65C-2=@ 3XCK9-^DQZX8.0G#WJ]%+_C]1RC:LQ$<0D,(M#0D,
ML(/&+],603#1&VJHMZ?0B(2#YM @,E%J@3@YN3,3;=L4B;TL8G"_*UL;@SGW
M1.D;G+K.CL6%T(8"Z.2-KW#]L;<YG#2W1P :N,E[2[FA(&.R 7:ZX< \N(#V
M/<UI_9B^3*77L1TG)QO7.U[\GEGD8793%N+80RLX?8$J5U"-1;AR8N6+PHA$
MH4JWVRJ\"F*XE$:OP3*@3Q-N;3![5,5)NG"AIYAQPS1Q,C#F$DND<QNM](BX
M.?Y6O:Z$M.V;G - N2-\CGD.%@UK7'2UR]K;-\A8X2!PWMDWN4T;0=)C[ Y-
M(]&.R8R(L[*@K8S2EAQ'M\Q+3:/@8E?PE6QI](V,->2-U)IU,9=$I:1&U !G
M@D'M6=/CYPZ MC*Q>N_HNT$,<Z NR/+96.IR&.+H3D:"[+E8UKF@R%CG9Y,F
M:UG\5G&[P),N9H,;VRW< )!F=T2;N+@ZS X#*P.M>[5?M6<WI4'7BDC4W-/V
M=DU_TEO"?R8V[22+^UNV-8]>XR\!#CC/4@LPD^KAHYO"8J '1-X.*D(B@2]9
M66%-7Z/'&R*2:4- +'U,3&B]K4[YG7(T!%B(FYK C-:VME4]TC(XRXG,V"1S
MCO>9L0(!%['_ *1UC?5M_*O@\M3MJD5-H \6Z8B[ F[_ (%G#%!^SSMU%]<5
MCZS&KY&[UX$5IN&L#Q:P0 F6+1^H]BD;&(2O$C(:!,+2QS=/87YL.('.@37$
M0Z>L1S'G'$!A(S26<<N47Z+/,">[+03S9,=G2'H:2#+^S;<N ):PD &YL<V*
MCDV[B2"<0?8XTLY5&*7QE1=)2,&('7DK%R"D^SC!K%)D[1H+221ZOP5@!ZF:
MF"[!A=</C#B7@)&,NVRRNC7>%26T[6OMS?2B_K![VD20',W]ME<\M,EA>)SL
MK@8F"^<'3ES;YC:370M8062Z']G<-#@P$_M&C,"'N/<N.E]=W%+K@ O_ *X3
M* [2[KE8(20[Q60DY36M:SAG/**>BFL2=9!5_N_-F!^)]ZI)CHH?)R@]-[E)
M!B)$MPC/A:^)L1&5KRV=A;F :][,DH.;5]F@Y+M!+;VW))/(6O+P;EMXG V<
M2QKLS+ :-U(S:V!(OX@%X+B'W#6=6Q"+1R86"5T,3"TEI[85>UV3L:=CV4D&
M67,H6*&Q @E91-N$WE[Z+PXB923?9%"&[=JP<PMD12.1:8S&^1SBU@LUF1CW
MAC+M+&N)<.;%\H<X#2YU.8BSC\[&- +C=S\SF-+G"^9S0&G.;9K-)UL-LH.C
M90]A=T04'"AV+.S6LL$142'D  O3A,M&8I"!,&@6PB>QZ?(P.4&Y?:QXXN28
MR@ DG;16.JE)"_TI$Z[K_(66<Q93%Y)+"TDD$2@.<\O?=I;F:&Q@6+3^S!LW
M]J ^[>+-,&VZ68  C(2&M#6D.#LCBYY-P0,]KDY"6V.V0&U.Y<GLBM DSA1T
M1 "S,&-D",DB9O1G*8TJ0L87.I3*RC"A0H^-F?98>.F(HTD<MZ^%56+P4L9I
M;4K*%8C'J7QTS6/+7@O!);E<.B;,+6M!E)(U<'$-F%P0)+-S.EKYBY@<UP:0
M 06FQ%WASB1& #8 @%T1VZ%W90]CK&9/2#K]49F2.WI,D0A(=9$P3557*GPN
M$LIQF2%UE\Y74,22-Z"3I;=;YJV2)!S]+HGO\Y/7YIP!-(!8 .-P-@?XFCR-
M=<#S:$[KGB),;"3>[18G<C^$G;4BQ*77G$N1'"(X1'"(X1'"(X1'"(X1'"(X
M1'"(X1'"(X1'"(X1'"+', XD6L3<#!8X<X-O\E3*[!BV:+%BF6C1ADD35;I)
M[OW^6+!BRR\=;*N,M&;1M])]"W1TTDDFUR386%SL+DV'B%R3;QDJ+ 7L +FY
M\I\9\9T"R/(4K'$PXDVVRS,BQQ=IG#C&6I-BV?MLX=,G0YUC*#M)5+.'(]\]
M8.,?-]"S)XZ:J?.0<*I[R"1J"0?(;;&X^H@'SA00#N ?/JLCR%*.$1PB.$1P
MB^+AN@[07:ND$7+5RBHW<MG">BR#A!;39-9!=%379-5%5/;9-1-37;133;;7
M;7.N<XXVV1?1-/1+31)+31--/35---/7&FB>FF,:Z::::XQKKIKKC&NNNN,8
8UQC&,8QC'"+]<(CA$<(CA$<(CA$<(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g773514g20t78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g20t78.jpg
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M8FQA8VL@<G5L97,@8VAA;F=E9"!T;R!O=F5R<')I;G0N)B-X03LF(WA!.^*
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ B $@ P$1  (1 0,1 ?_$ !\
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MNUPD@A7%)/Z,%^@Y&/R-RFVC\E $B1)?&/=\8ZES;&;-]5#I9<&VD3B9X_\
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M&2TIJUL_)-EJ@/8.3S.S)(C]ZV?**TJ^;L<PZX(-A!)-9V21:R0QLXZFD;B
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M?6"N'6'_ (NN^N=&S=9Q*9EM2ZRHU*JZC4%M!H\".QU'C18AB&+%?#+7"(
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M$=3+S%F.4+N'T<?JLBF0!=I#FFS+3-PEU&6(QT2OOK#!TAL[$-944[2B\TQ
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M,*VK"U8[#K+BYMWVGD6>R;[!#IK%YV)37&+V,@\["K.EQ76'96(+7S;H\H=
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?R;KNWKM=%LV1565PPR*S6N#FDM< ' DD&0$\3<O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g773514g21m00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g21m00.jpg
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MT]88,U-C<W22)S27H='2UQDU.$526&)G<G>1ML?_Q  = 0$  @,! 0$!
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MP:'77$]39&#KGHD)E^_@94DF]50&",WCT7,J-9=B4EY'@D@!0K[#D#VCR.S
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MO3U8M1Z@TM2=?BY^.,C6'\JLPA6)[ U&)&S$E6;A JN!8;M&)%W4,G$<.0!
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MZIDS-(2&Y#D-_:X("205)8A=V)!(W;<YKF")5(52 2.W)R !W 4%B% (!V4
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M6R;9@VZA</5SK'(5)J@ AZ5<X@DGU@!C (AF51W("(S%F"J%4DECY*-AW8_
M>9R995!+$  %B20-@/,G]P^)S4&[A\!\LPOF/F/OF<AE^,@;O'Q'SQC/YC(O
M[I^GW&<%V1LR@Z@ILSL'9MKAZ73H!N+B4G9MT5LU2Z^L$6S=, .YD)%XH (1
M\7'H.I*1=&3:L&KARHFD;8JU;-V=*U2&2>>0[)'&N['\2?@JJ.[.Q"(N[,P
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MIID "D(4 *4H 4H   &>")))))))W)/<DGS)/Q)S]! !0%4!54 *H    V
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MF$]T?7[G,#=P^ ^6,K_I_P"=^>0QA_>/T^PR:GY?/Z8R.0/W!X_0<8R)NX?
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M6B**C%A >IS,_6(B"T9B::4U8VCDA15]B.$2.&*"-6DE#AF+*%B!)Y,_)(^
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MC&0/WAX?4<8S#&,DM\ ^(9)/>'U^QQFDR[,-Y'Y'[9$_Q#\O(,9A/='U^YS
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M [9HVP67U>3D@!90 67ER ! ).YX-LNW+V3V[9KBW6(#"9.+$@$G8$CCOW(
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MR"D8)VZ9&(1XT3D&IVX.VHJD41]8:G.5PB59)5 ZB92K)*)&.0UU>9J\\4Z
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MDLLQDC]X>'U'*7]X_3[#&:-R\:-""=TZ;MB?#VG"Z2)>T8!$"]I0Q0ZQ !$
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MSG_\O*6UK1D]_5M,7_*OU5^\HSAKSG?PH8@(K\M>.1P H&$&>Y=?R ]1C]@
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M'TI*R*[9A'LT" )UG3M=)!(H=HYRA[\O +$*H+,3L  22?P '<GY9%R K$D
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M,W9 PCZKL6LOO<4>H>H&4@X$PC_<@7K$X>\H&#WY<O2W4C>6A:J/A[5*=/\
MKHN:K^E#T<IY]<=+M_\ 5ZU0E^.W^]3/W_ >9\QVSB[[I!>%C+W+\C]:&$#@
M4?5999\'6)1-U@+)HX 2]7N$X") -U%$W:$ RY>C^IV\M%O#MO[4:I_UV7O^
M[SS7;TL>C=//K'16[[?J[#2_#?\ WI'[?O\ +X;[YQ%WTFO!5D BMR'K!P*4
MIA]5@KN_'J,;L   QJ[@3&Z_>)2@)BE_&8 )^++5Z)ZI;RT><?#VI:J?#?\
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M_P ??I%KGK-ZCQ$03#M]8'=[U46$2]7O 4T=0( 4P&_,%3AU!U=GK'K#6_\
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M0? 8H%,#R_VMT E W; H@O+' 2@?\0 /N[7XNKK]^?5!4JJ=UK5P?Q$,8/\
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MTY)@ZE8[6M!N%^?Q;%1%)[),J?7I&PNF#-5P(()NGB$<HW;J+""1%5"&4$"
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M+?OYYPU_O?H<HSM!)<!]I,0* ]L'G'A5MV0*7MF[?I[D3J "_B'K[B^\>H!
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M6"/*X%$TJU!;Y!UY!*FJQSL#X,M>-8V[\08]PZ[^6^_?;S^/EMGWWT:V(9-
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MW_O$O]3'M=H.Q[P %/QY8O66OCSM1-_E5:X_ZL:_/_W=LH;T5=%$[KIUB/\
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M-FQ;MV?G@]Z$?I&VO:]!IB DNH3]7J6V=5I]KL!UE$OM&W,.H%>XG:[(@/\
MS@)A[\]F.J=%/G:<?.O8_*(Y\F;H3J=?*A&_G[MRF/\ K3KY_#^.V<3>]#?T
MD3$1!7C8[5 !*':9[/TL] 1,7M!U UV,J80#W@8W9[)3?A,("( ,QU-H9_\
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M*=JHL4Y51!-T2J*?1DU'1.LH%K7XEIZJB<8I%($A;_DTK']=$3NQJR[LH+%
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M&K*,CNW;J(E)V.LD@-8:-R!'IN:^R7D7ZC>6'/J<;,%1W]F:2)RP7SC1I-T
M_$*1W/[_ -V8]9=4+.B]XHI$"ECMXCA &W )V)!.WPW'X'/9>L.2>U_N'W_M
M7>6II&M2NC4KY-1Z3*LVFAM]I5&HT)K>6TS U6\*R5FK3IVJ>0K#AC).I=()
M&,&09O7+9X5LWUY(4$L21OR$A4'<ABC%^.Q91Q/P/;\>^7)*Q21I$*F/E\".
M2A0VX!W(^(V/X;_'/.,_S7Y(UC7O'9W)U/3,[?\ E._C9>@$UU$[0O\ &4NE
MN=7R&RW;:STZ)=)6>WV<$VB$/#N:W,Q,5+)FF9M5O&LZ^JWD+D@CYR[&0+""
M&Y\%+'Q @*L?9 [[G?<@[#OR&U;3R*(_90M*?9X\FV' N=QV)/EML0"-SVV[
M^/.26]]X6?[Q+79FEYTA<'G"WB=.S>N6EBL,26HW%SS^D*;8)&/:@NQ<L%K#
M",_0E<+H(RZU8?-HB556(15,=B-(QP XR#QI@'V!Y*(%8?CY'OY[;]QE$DDA
M9R>2'U>$E=R-F-AE) [>8'GYE=AGTTYO\HKCQUBH,NN34>5M[RF[/ORM2LE.
MVG=IB7KVLXN(DI%PP::V:ILJO H^TO5[!>+G-Q\3 J.(H&L7.F<O0C=.&%97
M;GR"\D7DK(H#-Y \MR3^"J"3W[C;-N>4Q@<2I;BS<2&)(4 D[+Y#X%CV&X\^
M^?-_>_+[F;*UCEM=]=W/7]*HU9XM<7MTUJ&5922]RHC3;\1/2KQ6GS+=FBWD
M;0H[:KLYYQ9$WL&5@SASPS".<*R/IMJ*& & ,K%FFEC)[;-P('M#X+W[!=CN
M>Y.P&:DL\X$Y5E4+!%(!MW7GRW(.W<G8;[]MAV&>MMP\V=MZ:V12:0_;ZBNR
MT;9M"U'=<32ZIN1TK77N[[2G7V$HUOSIL37]/ [5<):KU>Q/;!.V1FR<J+JP
MY73$%*Q725&/MKVD:,EDV/AJ3L5'M'\"0% )[;Y>\[QL%(1MC$KA0_8RMQ&S
M'V1^(!))'?MOG2&].46\=K<.=H;L0+2Z7KQSM2G0VMX2A3UN0WVS3U]S.UQK
M252M @X:PKC[5QK24,_CH<\6:)1F86%>&F4)QRX9SBACCE6/VF;@Q8N%\/VZ
M[-V[;[*2.YW\CY$=ZY97>NSCBJF10H4GG[-A$.YWV[C??;RW .^^?2'B9NN;
MY$Z6AMPS3*N0Y;A-VE:%K,"M(N7]1@HN>>PS"KW=>1,4QMB1!HY="Z(,V<?'
M1\R*T8Q;+(L@D7U$T8B<H"3Q"[D^1) )*[?T3O[/Q([G\,VH9#+&'.PW)[#?
MV0#MLV_](?TO+8]OWGT9E66XQD'\A\_R.2/WAX?4<83R/S_(9AC(/[Q^GV&8
MG^$?EYAC">\/K]CD<9:WD?D?MC&48QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC/I1GG\[&1/\0_+R#&,@?O#P^HXQF&,9);X!\0R2>\/K]CC-)E
MV8;R/R/VR)_B'Y>08S">Z/K]SF!NX? ?+&5_T_\ ._/(8P_O'Z?89-3\OG],
M9'('[@\?H.,9$W</@/EC&0QC-/FQC(G^(?EY!F!Y?5ON<9,_PC\O,,SC/%?*
M;^VWP,_TL)7_ &7.2.<O4/\ ;.D?\X-_V"[GO^C/]P_27_T(A_[Z=(Y[)/WA
MX?4<Z8\V^?Y#/ 9,W</@/EF<9#&,@;O'Q'SQC('^(?EY!C&8XQF!^X/'Z#C&
M2QC-$I\9O'+D]T?7[G&3-W#X#Y8?W3]/N,9#*<8QC)J?E\_IC(-YI\_S&1/\
M(_+S#&3R!NX? ?+,KYCYC[XR&7XR!N\?$?/&,_F,B_NGZ?<8QE.1/\0_+R#&
M,P-W#X#Y8QD,8SI]+2NE*Z_;VAOKFB0[^"FMAW5O.!!QC1:*GMFHJ?>=9"O3
M)$]5?7)L!PM4@)R&DT ,#TYTRCU7"1MF+N>(5023V"H#MO\ #91Y;^6(X>;H
MD<7.1W(C1%+.TDK;;*H!+/(S;; $L3L//.)QO'WC/;*97THW4VLIJC/M6-:!
M7$4JQ%KPR^H9A_$6]K5&*)FWH_LD_DXZ&GR1@$!JH]:,WAD_3)%,$189]I8Y
M2RR%)D<,2&+)NL@/Q)5NQ_ Y.S2>I//3M5_ L59):D\#J%>&2&0QS0.OP,<B
M%6'P93MG+932NHYJ1GI>6UQ3I&4M%II5VL<@\@F"[N;MVN$8]O0K')+G1$[N
M7J"$3&HP#U83+1J3)NFV,0J8!EW-AL.1V 90-SV5M^0'[FW.X^.YRDHA))52
M258[@'=DVXD_O78;'S&V<*0XH\:&-QG]B,]$:K:WNTOI^1L5N0I4$E8)=[:X
M68KUH</9,C,'2IK'#3\XQG"^D DJ27DE'Q5UWKA53#RR\ OB/Q!  Y'8<3R&
MPWV&Q (V\MAF/!BY%O#7DVY+  $[CB=S\=P2#^/SRMATWQRB8AJSM6NM7-(*
M1I-3X\LVD]7X+V8]H*LTW9TO4R+=^W,V<0)K \:(P%: AD/:J[?U-#UD4Q"A
M[+1[,\Q3E*I#,_'>:0B--CN-Y'9@B_%B=AW.;-:A-<:2*K4DLM#4L6)4AB:4
MQTJ<+V+,SJH/&"O!')-*Y]F.-&=B "<Y)KO3&J-15>0I&L]>U.E5*6?O9*7@
M(&&:,XZ7D)!DTC'SZ71!,WM1TZC(]A&++OQ<*'C6+-@)O5&J"*>7EDD8,[LS
M#8 D]QL=QMMY=^_;X]_/*%1$!55 !)) 'F2-B3^.X '?X9U@CPRXGM*9):^:
M<=]1-*9*V5M<7M>:TB$;L#VEF@JT8SR (M2*LY-@R<.6,>Y9*MSL&#IVQ9B@
MT=.$5+EGF9^1E<L%*@\COMN-Q^\'X[^9[^>0\"$*5$:!20Q 4#=AY'YCR!^
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M":+2UK:MI5EX9(:NFZ3'4AJPU+G5#0)::T\:VY)(=8HFHL=>!*%*K!3:"*:
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M)=,6TLE*-J\]8,7ZB-QU3:80M%&NU86F<SG9T\-Y&-7]3QLJ@4<V#QD<MPI
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MPH5_U=NLW2F5R1V5#5)&BBF%,\+4D<=(&=0\[2%B#(O#]0HC4REMY?9[;;[
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MCL2_[,3JD\UF]I0;J"OL(PV)L2-U_9$WM(^[9U+/=;QUI:T4+*I0^NKIV1&
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M6A3UMU=5V0,(&YR5=4DV+QZY<Q@L@;18,J8-*@CGEL2[RRO:>P@YR+$@&RP
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M:=V!MJ=X:^'/9W*NO4JZ9Z_,"3P5V"2#-*/Z*I<)(PD@21Q)Q%B?:-Q)XO*
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g773514g21m47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g21m47.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1KP4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "0< 5H  QLE1QP"   "   < @4 $$%N;F5X;VY?3&]G;U]035,X0DE-
M!"4      !!% DT3M\DA >LW8^)SCUT".$))300Z      $S    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    H $( <@!O '0 : !E '( ( !( $P +0 R #(
M-  P "  <P!E '( :0!E ', ( !  "  2 !A &( 90!E &( 82 9 ', ( !I
M $T 80!C       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/      0 ".$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              5D   1P
M          $                          0             $<    5D
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   5D
M    4F=H=&QO;F<   1P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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MXK@T%Q_1;O3^DC_7[K&?AG&Q,2U]#;6/MM?6=KW;2QK*VV-]U;??[]JI9O\
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MP'BS8/8G_M?W_P"Z\Y]?NGV>AC]:QCLOP7M#WCLPN#J;?^L9.S^Q;:LOZI9
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M=?7^FQ_^,9PS_KK-]/\ UQ>?8F<[,ZET4ODNQGXN-N/YS67[Z3_6;5;Z3_\
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M_9[PUQ<=K/?Z6W:[]]RRL!G1\Z_J63F]9KZF]V$:<AU3!2VO&ES['G8;??\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T *@    @
M# $   ,    !!1$   $!  ,    ! :L   $"  ,    #    G@$&  ,    !
M  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !    I $;  4
M   !    K $H  ,    !  (   $Q  (    >    M $R  (    4    TH=I
M  0    !    Z    2  "  (  @ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HQ,3HP-R Q,CHP,3HU.0     $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   1PH , !     $
M  %9          8! P #     0 &   !&@ %     0   6X!&P %     0
M 78!*  #     0 "   " 0 $     0   7X" @ $     0
M2     $   !(     3A"24T#_0      "           _^$!@$U- "H    (
M  P!   #     041   ! 0 #     0&K   ! @ #     P   )X!!@ #
M 0 "   !$@ #     0     !%0 #     0 #   !&@ %     0   *0!&P %
M     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "    %    -*'
M:0 $     0   .@   $@  @ "  (   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,3$Z,#<@,3(Z,#$Z-3D
M!)    <    $,#(R,: !  ,    !__\  * "  0    !   $<* #  0    !
M   !60         & 0,  P    $ !@   1H !0    $   %N 1L !0    $
M  %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M<X65EI>RU-;A\?_$ !X!  $$ P$! 0             $!0@) P8' @H!_\0
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M,IE,K"X0B0P$C1Y1 J$&0\D7UJB*<VL;:6Z+6:RXKWF0U0D'(HP&;*W+8^7
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M2A/TU_+4O0W5FO1'I>1.(BU0%:@EJ/'F:-WK%Q#7?\5 XIRZYGR(2??CH/\
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M#M+\8A]I([BM3?5GP61VXI\X YP&1>,&1*^Z]U,(5MBEU19)T"F5M*Z3-<=
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MLT5!"38B/ :<IE,"Q>Y2\],J*@+6UQ >8W9],4IRF*8 ,4Q1*8I@ Q3%$.!
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M_N^7X!'^$.1<5?=T7U5#_<OG\&+&/U/BWDW%:_\ I\EV_H\T>KY1^@KCQQY
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M@<>GT^?/EJ*Y]R=O>\O9R^9Q?[V>'=>_(;]H[[VO?LMVX? Z9B2:.P[;.1,
M HX^\4> X#Q%YZ975'CZ154.(_6(ZDYDT 98HUN7D@/_ &G'";^-SOXXHFZ2
MJE*XZ\2BHW(S 4W/\%$&&A(]02D > &)U:V;'#<&C!A&;JQ)D3Z@^XTI>.!F
MJ.H/T=RF+**HH \^GQSCSY<"/D&HU9Y &;*S]\B?' BGY21[,7B=$\D]'[AT
M>WR.N)/;[G-5=2FPO8^@$^KV'%@GN?10X94W&) (^&?'U+4,'IR=*QRA2"(?
M4"JG'W1X^?6T\*C^SZP+;>2Q2?6'7+?E?%B/WZH"E)ROPZ40-2:_6PGMV53H
MI5O_ -5(\;#NVGGUV_D70'W]*1_-B^:VCB=]CC7X4B?U4G'!^@O]NB;^(U<_
MM.@X6!V?_*QVQ /[O^'Q#CGYL@5_CG[OY/JUQF@_7RC_ (4@?G36+.^,'VJ.
M)WXA9MV/>:%./S[_ !MAS;J-;92;I]JU_HT<Q]LO-;0'(&-_# OM![C5V;U5
MO%(";RYLL6XE*R/<()D-+)N##RW()9"9MHPKE$E14)"I3(\JA;"_E+*5%*!?
MEUR"MGG8=9?L!%-71VXEGA;Q3H%=D/%JAU%SS!F2Y5U8HU3=92Y*6$D$BFRF
MXE3L I2A$+8!#A!2JV\YFLNW+...LQ5X'!93']H923R-!0S4\K$=YF-DKK@P
M\"DE-P;B2B' F 12!T)^.](O$=J347:34H=19!*XKR'"BY3UC?N7F3VCK6E+
M;-^6K>UL72<0\FTWB-D7,63ZAU?DV8*6_'9DE(<$.9I#U.J"!?TE09R(\I "
MK+ZH G2LWZ"M&N=>R+3*I?:F_)*5FYUZ'L\!()^17<3.,$))@L)1\TSG;.$_
M%2-\=)3O2. '(8 E3&D-2X[$IA06S(9;?:6.2FW4!:#[4D;<P=CCY_JW1ZAE
MZL56@U5A4:IT:H3*7/CJYM2X,AR-(1>PU)#K:M*ALM-E)N"#CG89%_9 O7UW
M"S@/'KY3;T?R!SY#ZZB9*_=4K^<O_P!:O'T/9=VH%#\*13/4/V&R.T]]A?>W
MKPYST</VO?"_GS_NKE+_ &IW'\_F_'J0W#_[%*=]W._/I.*:.F+_ )06=/2M
M^QLL<R1_FO2/Y0Q8U=;;"T&G6N]61R#.O4RMS=JG78B4 ;1%?C7,K)+_ !A*
M7]*9M%C@ B'(AQSYZVV0^W%COR7E:6H[+C[JOX+;2"M9]B4G$=J-2IM>J]*H
M=-:ZZH5FHPJ5!:'[Y,J$EN)&1?LUO.H3>QM>^.=GDZ_365<BWO)EC4%2>OUN
ML-PEAY,<I'UAE74JL@F(AR5NV,Z\!L0."I()IIE*!2@4(FRY+LV7*F/&[LJ0
M](<WOZ3SBG"!L-DZM([@!CZ',L4"%E7+M!RS3@$P*#2*?1XFVDEBGQ6HB7%"
M]BMP-ZW%&ZEK*EJ)4HJ.5X^W#YZQ-"N*[B_,V3\>0#N16F'<-2KQ9*S%NI5P
MW:M%Y)=A#R3-LJ_6:L6395THD9<Z#5ND8XD13*7-%JU2@MJ9AU*;$:4LN*:C
MRWF$%9"4E90TM *BE*021<A(PU9AX>9"S9-14<T9,RQF"H-1T0VIM9HE-J4I
MN*VXZZW&0_,CNN)CH=?>6AI*@A*G'%:;J).=?9K[PO\ G1;@./7]ER]!Y_\
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MXX)^J#_N;A;W==FSLM[R@V^>W@+<KUMW.W^(W/;><F8:DP;)N[/ +JU>1<D
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MRX$^,AYHE"@04NL/ J0M-[**%CW0+RO3HW5-]VFV6H760>(K9"JY0I&4&I!
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M18OB#3JLX[P,B?WZG$ ?.V:Q3)O8.#FT#%#N =:[D:B>>*VTMU&J'3=$R1J
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M]2XEY\R_DFG!:%U2>EN?+0C6*=2HQ+M5J"@?1_8D-MY;2%E(>D=3&!"WDC"
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MY.*2<P5VJ9HKE6S%6I*IE6K=0E5*H25[=9)ENJ=<T)W#;22K0RTGT&6DH:;
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MU[B_NEC[ZGX;_P!^/$K]S/6_T:ODQ7)[G_\ DWYJ^_D?_9_3=*ZI]4:^]?\
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M^F%ON=9;>PON1RNI6Y'A;VX8#?L2KQ+R-;@FW*M'.&*!2D J*!5&QT$@ A
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M!@H4CE1@\O&1K0>-,L15Y'0TYD->.0@CN@+\5X:.EFZ"P$64BG?:)#>C4FD
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?[$V  )  '(#?X3VF^'-EE+#8;1R%R3VDGF3\^6/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g773514g22x55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g22x55.jpg
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M_\0 'P !  $$ P$! 0            D%!P@* P8+! (!_\0 6A    8#  $
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+!!G9N=#G9LY34\47:*L5>GFJ&GH:9PR<2HJ6"DS9X3S(G*<G*>,CMF<0O#
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M85>R\;SZ2(JJ?C6$4/9[>ELHYYLZ.R"<,RQND:E.ZPIR 2&-/S,S/KM(7-D
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MU"$!@1>N(S?L\$2>/;&7.==!VGRB82A4!ONN?8N<>@,L0#V^EA]U1NT5A[?
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MS9? OT1J#^K:/8)>+VOG) <$# +4,_\ [\K$_FHIG]+[YSZU-O%9WI:VNIV
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MXH%\A+O72QM>4YZ)54'EW\B0A@#OIB6^@0@AWZ&2#_N[UK_-3++W)-SI)O\
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M7S;?._\ #MGZ[;'S0;=D^D;*'99/N6SC8;(K@S9OWOKM9)%K!_$*;_R0DO\
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M*7HXCS#'K\*K_P",#_LSTXHODH/)1JN\7M?.4O+A P#>"\!(@ZX0.](@Z_\
M3-,_N[U_FQ \TCW?.'4/H6I]:M SKN=[P1>?T_15<FT]<'_S!_XM?_O,)G>S
M^^G7^/7_ -]8!_< 8 P!@'3;%@S)9]?3JM)-[JW&[#ALG@T@TA."G6[9):R+
MF!U]QJ!EG (5>X'!1[G.$4:$HWU!B+'H.P[ C!B_BQ/;Z O.A9=T:^RM%TC'
M"XC;4J15G&XXZKH_#>=J_P"=:4!&$6GIX11MSK=GK6/3-Y7C]]D\]ERI\TK;
MV)@7(V5M=NV@JSK\,,.6?\M%TM*F7+AGBZYC<(JX$=15S576ME2*T;3N"26)
M951Q@I."76V\H7*1)89%5I\FU#HT2A9(XTI6<+\\*#2V0A8O<UBLX8PI#.>B
M[#!ZOYW^LKP?$[XS !" '!_*X0AUK00ZI>$:UK6ON:UKWI^+6OW-9$EJ7(1G
M/6^5@7B=\9@P["/@[E80=_="*EX0(._C]/QZVT;UOX_C_P!N2E)S5S6E7,3>
MM\K.+[4KXQ?WA'*/]"<%_N?*L^/QHOVG^8F];Y68U,_AVX<*["L65+N+^4SZ
M,7<V4U'8O#?L<04X#;;+/9][.<]DOP.]Z]^]HWF'/U:M@I+[(.WD+&6V;&+3
M$$(8SHYSSHL$L7/23G.2O>+_  ,E?M2OC%_>$<H_T)P7^Y\G/C\:+]I_F1-Z
MWRLY@^)WQF!UH(>#^5PAUKT:"&EX1K6M?XM:TT^C6O\ 9E+2;FU-O%N]B;UO
ME8WXGO&:+6PBX/Y7$'>MZWK=+PC>MZW]W6];:?1O6_W=;R))7I),9SUOE9P_
M:E?&+^\(Y1_H3@O]SY7GQ>-%RO\ ,3>M\K,9'[P^\*[ZU@4]2<;<FI.>HYSW
M<<)GT='7L"3-YEVRBRN>WJKG-=&1-FDZAR00=FLI$C>3]!4MI$DT@)UL$B#Z
M[.BG/.BGA.;PY2<YR=[G-2O>$G/\#)O[4KXQ?WA'*/\ 0G!?[GQGQ^-%^T_S
M(F];Y6<H?$YXS !T$'!W*P Z^X$-+P@(=>G?IWZ-::-:^/?Q_P"W*6IWN]\=
MXSGK?*S]?:G_ !G?O$.6/Z&(1_=.1):ER";UOE9P?:E?&+^\(Y1_H3@O]SY7
MGQ>-%RO\Q-ZWRLQFM;P]<,.=\<U26&<9<GM-5UZYVRXW^SZKN!M*9S9'ZKG=
MKKX;NR>]@2WI,WS/1#FG]UZT6V#3#<RQ:V0(6F=%XT5WZS_,E1.3O<W*5YDL
M7XF?&":6 TK@ODXPHP 3"S"Z5@8RS"QZT( P#"T;", P[T((@[WH6MZWK>];
MQGQ^-%^T_P R)O6^5GT \3GC++UZH.#N5@!^[Z 4M!PZ]/\ C]&FC6OW-92[
M[W>];OYQ-ZWRL_7VI_QG?O$.6/Z&(3_=.1):ER(3>M\K,EOU-//O^AJN/^4V
MC_NV2)O6^5E[\$# & , 8 P!@# & , B43T#/M^5EEZ C7-BB#1)N@MK1FU;
MU5OM8*&&VVV70FH28,_,[@Q2 B\ULV:GN!IJ^5U98<:4T_#HM%%\\B:A/+Y0
MD7.;MV[:"J?>RGIPU8\4KYZ',EKP4C & , UK;N\>5TML$O",L5#2SH"L7/R
M16A?'V)I39,.G$KNJO+ \;3;0\4L=T?+EL1.A=U,1ZE<B)2I:9S)&MZ8RXL9
M+8TRA(CT3(/%S.5TW?FRFE*34<[I?JW36N_23W\[1&:5_P _47 ['=O?ZPX3
M3E91&>OONPUP]^II&X4R,TH=O? []F7>^+XB7+/=AO[*I]M[8S]</>"V\67C
MP!@# -?/J7@2\'R0=U+JVBM@R>$W;?G =P/#>9-H%8,QN*$U=.WV1] 0J',G
M0#^^UWL$4:EK6""U;:K<VTXX-T>980FC[E&='-!PN*)=[A-)K"4M6$GZU?QD
MKG#$'L2M.1J$@%K15F@TZB,#1L3M$&)-&42*.)$*Q:5'FE0@A"A5!6YZ21K3
M07)&V"'C@K=(M.B*&:!&2&HL H>+,L,$# & , 8 P!@# & , 8 P!@# & 6L
MIZ[JCZ"AOV0J3L.+6="??Q_C7PGB#H2[-.GZ+N9[._M>U)._5TJ;7%.:0<#>
MM:&'V2@D1J8\@XP&FL5+:73P#J*V>0]OG$?K58_H"9Y*HY)Y@P1;UC#'9PBT
M,7QEJE$@ 046/1#2S.DSBK<J6JAD$>[WYM2%#,4* EX!V[ & 6HDUZ4Y#G\J
M*26RH>U2<V4U["=QTY[1FO::5VRH=$E:,:]K3&'K6U=.3V1W!&@N!"8#H%N6
M&)AC*(&/02>HNO@'48+/(?9L5;)M W]!)XL\"7EM[PW",V0:H:7-8RNZ(TLX
MLE2D<&AY;G!G=FY80G7M;J@6-R].G6)3R0 =NP!@# & , 8 P!@# & , 8 P
M!@# & 8Z];L-VRSFJZ(?SBJ9VV[IG!'>%UZ_/SF8T-D3=Y>$N-GS8Q:42H-]
MTP=K=%\N;499(QN3DRI&T/J[5^L$2I34\-)KM3_@;HS@>HY!!BY1%KQY$6W1
MQI:;[!*^@MMT\@DBNMF!31UF51-(A49?0<E9X5.HG%*,M*2V:LVHB3Q/H6]I
MI\U-:22JGD\5MJ-X7WXR>+GIS;\4M.K44;F3A7O"S&?C^XCW:<1Z(-2]^<6I
MD>[IFT'FE&^X/(9>MT.4S+)M2M7^;3-EM[GN25Y&T>G:/,LRF\28D4#L%%&8
MQ(#')GA<?'SD-I)J[DN<X5J:DTYO2IZY(D8[PYPN>Z^C[1C=?A=$)MU\8T?#
MJZEA#X^Q-MCCM1';319E[,FYPPZ"JB;_ #>M)]#5+&02K0N4F+@SF%M&:7'G
M$]ODA-*3TIO5@U=<U?Z[N(QP?_%;UE'S;+WSU8)50.TM%Y'XC&Y"5<UBC3L-
M576Y05YY1@Z(@"AT515@BZ]KF0]_!='I?5[E)G.4QTE<^+3A'Q?S_P B<Y:5
M/P="5Z4GJY,&RN1'QFW_ "R71K4XB+55?,I]RV1,=\E-71]A6(U5Y%W'CAQJ
M1!KX:>S8%#^7.^@](++<(6WF?!UAT45)U)BN1.T@1%R0VM$V\V4Y:<Z>U=[=
MKT8%J8/XDNC5$EKLVW8M$9<K>$'BK>+NLLRYI$ID#XX\GQ'4/Z,C"X&R4ST^
MJY88E;WIODA+@3\(TB4Q(J.3JW1Q!D;,;N1/_P#2K.5\KO"24M$3FN)2PN]1
MV-N\;7<\4G?(K[&7!G< T;+WUN,',+Q=)+ (Q5Z+N.W;:BB(B+;C#19S#(&O
MFZ6PZ(MK[7UM+4LSVP,=26A"=0.(I'=UDB:OPOXM,M>I.]W:+F2R^/2+2)@J
M>WGUY;'-A9+0[!Z]MFNV!W1J6U8WUS.[\FSG&G3WL5%DGMR6>:TLLY F,*+-
M]PS9.<H**4G'% %+_!<RU<G.9XX(& , 8 P!@# & , 8 P!@# & , 8 P!@#
3 & , 8 P!@# & , 8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g773514g23r02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g23r02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5L<:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<R,W(P,CPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S(S<C R+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,CDS-S0Y)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" R,BU*=6XM,C R," Q,SHU,SHQ-B8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" R,BU*=6XM,C R," P-#HR,SHQ-B8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"U"
M;VQD)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@
M(" @(" @(" @0TU92R8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @
M(" @1W)A9&EE;G0F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @
M(" @(" @(" @9S(S<C R+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @
M(')R,3$V,#$T)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R,BU*=6XM
M,C R," R,#HQ,3HS-28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" R,BU*
M=6XM,C R," R,SHQ,3HS-28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @
M,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R
M87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@
M<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA
M;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@
M9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0V%L:6)R:2U";VQD)B-X03L@(" @
M(" @(" @0V%L:6)R:28C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A
M<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0TU9
M2R8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @1W)A9&EE;G0F
M(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM<#I-
M971A9&%T841A=&4^,C R,"TP-BTR,E0R,#HQ,3HT-2TP-SHP,#PO>&UP.DUE
M=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#8M
M,C)4,C Z,3$Z-#4M,#<Z,# \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \
M>&UP.D-R96%T941A=&4^,C R,"TP-BTR,E0R,#HQ,3HT-"TP-SHP,#PO>&UP
M.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@
M(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X
M;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG
M:'0^.38\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP
M1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%
M<T%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"
M3$%!04%!14$F(WA!.T%117-!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!
M068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF
M(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(
M>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9B\X04%%46=!64%%04%W15(F(WA!.T%!25)!44U2068O14%A
M24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)
M1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-
M1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H
M0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N
M:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F
M(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP
M-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR
M96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)1
M14%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T96
M2FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:
M1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)8
M1C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E)
M;4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V
M>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T9867$W1EA9<3<F
M(WA!.T970RMF9DQ8-6=A;G)&;F5E5V191VXR.$UC850R-WEY;W)S3&A:1UEO
M<6Q4.$,Y97!&5C9(2E))-F]+04=I+VYC,$-%-B]A<$YY2$HF(WA!.T]%1$QX
M06Q*-4@V;TYY,W!$8G181&-6,U)M9S9**V%8*TIB4S@X=V%R8GHV5F%G9C90
M8G-53&QR6C0S3'%K56%V*SE+=#A85#EM;4HF(WA!.TEP9#)E-4),<U9D:7)S
M5F1I<DAF4&UM*UIT4S!%,F9L-BM45&)U4U)43F9/-U)M3TI&6C9Q>4MX<5A6
M068X;75'3F151C4O<%9V.$$F(WA!.VTO3G!S4S98-7$P=59*2F)L66HV.&0V
M>E-&1$MS66U-2C5"1#(S660O:#)%>E-.,#5V=$4O3S%B<4I,2'I"879A3E!)
M2EI*;S1"2TDF(WA!.U!726I)0S)V2&PV255N<CA28C)W6$9/-TI023)N96-,
M2S!V4#A56'$S=#5037-S8E)U1VI13D5N3D58,#1Y:6E4;%%64#!D>$MU:6@F
M(WA!.VMU4E,W1EA9<3=&5D,X=G)+>&=-.3=C4E=S04E5>7I/<V%663!!-4U1
M3CA64TQZ:4QV569,4FTP83A12DA01%!036PR,6]J,C!%=V$F(WA!.S54-C%&
M57@Q4D=5<T]M16,P1F=T:'!0-7A75VAT4%HK861/=6)%4DY0*VM:<%)/;3!P
M6FXY85=*:'A%4S=K=%1Q97!Q2C)%8F\U8D@F(WA!.S@Y6C0W=6$R,7)42'0U
M=WHV9$MO:F-C1VM2,%I324],5FDU0E,Q4E$W-S!)2'!4=3E',#(V5S1T57)0
M1&-815%63' T1T1)2G5#<W<F(WA!.S(V9F%Q065X1U%3:7-69&ER<U9D:7%H
M95@Q;EIW;6$W;E-#2E%36&M92TM$<C%W9TE*<$E0*U9M*U%F531F<#(P<C0X
M.79V-EI0=UHF(WA!.SEX85!Z5TLV-&@X,"MS.5%S8C)&6G)394]E2F=#1U)G
M4E$Y36=1,V=G<2]*9D59174U3#1J1EAC,"]M2#,T<6QF;693,S%J47)V5%DF
M(WA!.V)K5S!T=V]#>6UP6#171$980VQ3569J>&-!+UI*=VA71S9D-44X,C9B
M<3%N8U=M<W=1-EET.&QZ9#988F5V1D59=E%H:&16-7E3:V<F(WA!.V96+VA2
M:5(X4G!42E=%26%,.')F33EN85(R5VUE8G!B2S)7,DE0<$MY36)T;DQM63A*
M1D1$96YX5DY/<'<X6&MT2U5N-5<K8T<Q0V8F(WA!.U5"-7=K*W1Y4FU*2GHY
M635!1UAK4U S.45Q9T=Y8U(T8F18:4AC:6UC959.23%,4TQ3-F<Q3%8S,6%3
M835A94=A56YL2$<P84PV434F(WA!.TTK=V176690249+9"MR2"]!1&HW>&=3
M-S%9=C4Q*SA9,')V5FDO;E@W>&I3=3E73"MD9G9'3DLW,5EV-3$K.%EQ.'@X
M>B]K='!E<#8F(WA!.V$P5VTV<DQ9,W%R-F-%<F-41W%.8WIZ>4)L5&=4>BMS
M;&1J,%9C<T4R2D-#,&XX:').2WEA>#5H=6)M9#5(859B67)$1$EJ5$I+038F
M(WA!.T]:83$T56)T4VXX=%-M83 Y2#AS84Y:*U@Y0G,Y2&=U6'5)<DY/0WI4
M37!D<7-72DY!3S5Y0C-3;6YQ>&9Z<CDT=TID-G-8.#8O94TF(WA!.U9D-G-8
M.#8O94U69#9S6#@V+V5-5E-J>DIO5G)R;'1B4G1D1S)L<S5X8S(X>4Q&3%(O
M5&5*9S!C>7E2<T1(2W<S6%DP4&)#3FM-470F(WA!.V9Y9W-,85=53')->C(Q
M>' Q-W!T>$5Y>&HT8C%M8FQ'1D-Q;D0Q1RM';%!B<FMU2F%1,7@K4BMJ,V)8
M83-7=%A2:'5N85IL:CE'4#DF(WA!.S=,2$MS-V-1;G!Q2&%52&EQ9T%+3RLK
M2&I+2U9*+WE2,$=5<W@Q<2LY5#$R;FI03T5Q1DM"1FE:3TA&;S9+=DI4.7%M
M*T1J2V%7,FXF(WA!.S5&95=,5U$K;'%T-DQF;$E286@T4D=!-CA!04%N.&UZ
M2#EQ9W(P=SA:4E0P3%(W2S,P>E-B3%19-7I.2%DR.%9S:S!R07E/255#0FXF
M(WA!.TEP5FIX<6-G5U-,.5=,*V1F=D="6&5R2"]/4'9'2W-C."LK9'),>6YO
M>EAK<2MR9%-N,#=3,T)P>FM)3DMN<U!(,GEZ1FE--55(2#$F(WA!.U=P:FAG
M6E-F3T]T95DY6#$K.6$X,5<T8652:E9)*VM394%23V=P-#EC,VU,0D=!,F5-
M,5=U>5IJ=61U-5%2=&=E,U1,;D1P361',6XF(WA!.U9.1G9&=3E.;F$S;$)$
M374O<'8O04LV9$=Q3G$Y9D$U6&QW4GE$9'ED4')C=4$S13=D>C,W>4PU>'0O
M32ML97%"-E8Y0E)B<41W8G@F(WA!.U4W5D(O=T$V9$TP96)#8V-Q3#)E:C%5
M8SA"2TQ)>FQ4;$QC2W-F=E!/*V<R6&UM,SAT6&-J=V%H9'A#5S-K:UAJ0S5:
M:7%X:'EF='0F(WA!.WA.3G%%+T18;'1L9WA%>#1H>6-E97%H2$E-6E!Q2W1O
M6&UV4F1D=4Y19S!Y67IN5'!"1DY)069467-$4F\R-DUV2E=7=FE00VA-6E$F
M(WA!.TUA=&YJ>E)N9&1%,GE,83%I:')&5VIH5G)&5W-68V-68V-656YU8F1(
M16)Y;W)N;VA906UV5%DT,&DQ5$9,<U9D:7)S5F1I<F5+<V0F(WA!.VXO34AY
M;F(V,DY%;G9F4S%&<#%T56E:2DM.32]$:6ET>'!5*W%U1VET<V=M;&EH:65A
M5GA(1D=P95(R3D965D934U0R07=+;&-(;78F(WA!.U)*641/,'HR.%9&2T<U
M:&QT+U5%9TI4,'965E!5-4)A,%-P.&-00U9T9D0U;#!A5UI)=E=A2C5$>&HY
M94M704UX-DM';%9&3$AS2S$F(WA!.W@T56YB;6QE<&9M6#5+,'I7-4Y%=CE2
M1G9Q55)66&AA3U4W=6E32T%Y<5902EI"5&9(:$M,46(O04IX9FQY;'ET=3)S
M24A03&U42$LF(WA!.T%H53!+=E9!465V8DAH2TQ$25!,,VU842]-5FDQ.6\Q
M,$QU,%-1=W1+<75T2%5":71(0VYO=W=%56Q.52LR=GI'2UAZ>BMD,G90<4@F
M(WA!.VYI4S(U9G5D3U0P15AW66UR+V9T;7HP16%I4SAX,C5L2FU)9$%(9FPY
M8RM9:'!7;VY43DMS9%)T24=%.3,Y8S1%:&=H5TUQ<G5V3&@F(WA!.WEA;7@S
M8C5:6G%/1WA:25!K,&1N;DM)4S1)>&M/="]J.%=Z,C8P+SAW<'1*:7,W=E%D
M26(V<TA4:3-%=D=S<4UP;7)Y.4U!.&$O1'8F(WA!.W-.<WAO>7A#5FE5;F%4
M:'%*44%-368T-G-E."M79FU76%,T=%(Q5%,W2%19;S)I:D17,W!L-4]59$EW
M0W9*;%9%44-H4#E":V%A54(F(WA!.TMG4UA8.7!9.'!H>%1J1TY6>39O2#AQ
M.5AK,"]Z:F%+0V93=DMW4TM/:#)*0E X07$W-&1F0S18,TYF665B9WIC4%-1
M*S4Y1'9'1S,F(WA!.TA83DLY96AY0T11.6-K:&HO;DQY=D(U9S!X8F8P;T1E
M4GEX3F(S339";6E15'AV3G=A:%E&-#!);TMC=6@R>65/9D-7;DYI17AY1B\F
M(WA!.VDR4$I(<&5H*U@Q.'!A;F)#>'1P8DM+2SDQ1W=02#%*6F\T-V8Q07%)
M2D=K:VTU1#=,8D%&=&E12W-M<')*6F(Y4#)D94%2:GIQ:E<F(WA!.S(Y8FTO
M='-S8S S469-53)P>"M2-VIZ0DPK:#E'63-1=EDT+U1K:U-"8E-625)*-F@T
M:4PV,7E3<&)J46)%8U%U9$MC830V,U W6%4F(WA!.UDX37A)66I,,'@S*UA$
M42LS.$(V46YM+WER2D],9$Y8<S)L6G5#<7,X6G$O.&])3D]8=#%Z1SA/6&,W
M1'@T13%X1#5P=&M',5I)-F\F(WA!.W!D>4964E9M2F]!0C-*>$I!1FQ)0DIO
M26(Y2S9:+WDR468X04EX4#8U4BMB=R]Z-"]-3C,U8DHO3FPX:38R,4MW=7!(
M:G0W:4]74U F(WA!.S=A<7=*2#EN=FAX86Y(:TI%6D%K27EA9DI!07E"04M*
M3UAT2VYC97(V16YP9C-V12MN+W)5,C8K*TML-7IO,7@U9"]2,7%L-6]S1G@F
M(WA!.T=)44Y8,4\U:FI,0S5!0S-)=4AC2&DT8VXW4BM76E5G8C)0=61D0U5A
M1GAV=DHK,C)8*U1O<#1V3'1Q:WAK24141S,Y879Q9E9J334F(WA!.W1G,60V
M:41H,7EJ2CE4;#1!4D%8-2]+.79S5'))3GIS5E5:<G4P9TE%.#!C4D\T1'-&
M2BLX-5903D-(,5-!.35B25EP>2MK17%-;7,F(WA!.S941VY.-WE(:4M6;S9N
M<6%D051L571B:&E,330O3G-J<$UP3D--=FMI-#5)-55%:V)",%E65C%)24DY
M:4UY27E%:%E.:&]L16<P9&DF(WA!.V=.6G-42EI813%P8GA386Q';VQT4S92
M='EL:4EK:E5L*WI-9T9A9VIS46%%37)R8FUZ>&-014],-F5Q4C8S<E=L,T=M
M2%)0359Q8FDF(WA!.SEU65),9F%D83@U15)#.55$>4%O0G5"6#1V=WEZ1D-2
M1FQP>C5C8UI%4DYP5')/;S-T+W%D>$1!6'1B<E,Y3FQU=G)+05!&=UDQ5U F
M(WA!.S U16%J3T5"-3@V9D13:$E)04XX46I8<%!8.41B:DUE07DT=E=/;G8U
M2')S='1,5U,V-5A(<G908GHX,TYT23-+2FQK4'=O4WEU3TDF(WA!.TA49U!M
M85EY;V)*9TI3,RMZ.&9O6D0U8EE->C9B9DEK,'-+0U<Q;&LO94\P5%92:TQS
M3U1'4%IE4C9Q5G)V6$5M.7=W351(67 R9$PF(WA!.S!X:DM7=$E36FA366U.
M4&I'*WIB8CE4,7=)5F)A,71B5TI98F%&24E6;T9J:E5);T%&0E%+04]G>%97
M5#=A+TU9<&9-+W=#8W5N4S(F(WA!.U!N+U5*2$)P9454<3-9,2M';C!"4FUZ
M,%5V4E1Z2&)/2W-T.312+VQE>"],>E9*<E148E=,5V)J5DQO4E)Y47AE:44U
M8U4Y5F=E4S F(WA!.U5-2#-B86A&8VQK;FMJ=65';4]N>&%A6D512FU26DA.
M-5<X<TI02C9M:F5:;'0T>59,<7%-0S!D1FQQ9FI"*TE-,5%A9E)L67I4-S0F
M(WA!.T]24%-9<BMN2VPQ-UDK4TY0=F\T9%=G,7DR:&Q66E5J;5=.6&]#-FUG
M8C=1,D9'*V584FQK23E00S1U6$AP-%-Q67E$,V]0.'0W3G(F(WA!.S-Z;EE*
M1#EM2GI+465V069$,C=J;%A$<EI6:G)V875X.&9&<4Q(2TXO<6938D]&1R]W
M0C)A4C=&1'-X63%/4U%X3'I0-6XX,3969G4F(WA!.VUN95=P9%AS;&I6>$Y$
M37%U>D5/6%5+469S.%8Y>EAB0T%%1D]&,%<R;'5P-W9566)A-W58-5)1>2MG
M07E7,6%R0U,W4T9T>5-X,D(F(WA!.SA";%A!0V)/-V8T>$%!:5-"-RMV96AV
M3F1H4&,K5G11<V)'33@R='EK8T58=T9K02M+3DMD3U-!<4UV>&M!:'AC-$UO
M;G)B1G)Z>F(F(WA!.T)Q161X<%5D=&)83VY854Q15SEJ1WEM-%ES0VYP=F)K
M:5-*;&%L95,P6'52,7DT638S-G5*3$YX6$=G66YP,2M43DY'=&)I,#!I>'0F
M(WA!.V)L+U9U3&4S:6EM:TIQ5V1%0W,Q9F-J2TI'>5A-:$5I24(W:U1):75P
M4G='5FA2;$EQ0T0R27E*04EO<W=31%E1,S9+,'HO;&IG+S4F(WA!.T9P+U1+
M4'EM2"M:2#5"=2]--5 U,'9M6%<R;6%F87EV3F(R.&-5<VXR;E911#152&=0
M65DT=$QI>'E-;WA!2E)K,4=364%L26M"16XF(WA!.TUH<%ER-6\X=RMA3DAK
M=DQL3$,P8E)O658Y0S=K;DMS8FE6;%9F5D)#:$51:&=D-DAK:$QO;V1L<FY)
M:C-/6F=W-#4P3%!'5'ER<"LF(WA!.VXY:#)*;TAE579,9'5D3'1T4C%I0T\Y
M,65E='@Y8G591CED1FM02D9Q-BMQ:#0P2E)M8F=X2W%E25=K.&-P0TY7-"MQ
M:&I/4WA%8F(F(WA!.V9G+W V."MA465A9DIU<3)(;4$V>&]/;S9L13-M2SAT
M8DQ726)9*W(V5G4T8U14:#-757@X1D,K;3(S<&(P3D-!=$UO14=X,61H9S$F
M(WA!.V-:431*>&EE045I*R]O3VYX-S)7*U1F2S%T-5@X=C(K:C(X.'1Y<TY7
M:VUL66YL235Q-5)#4TDQ<C!29G!Q>$I.:TDX27!W.59Q1&TF(WA!.VU::U8K
M4'14=DIU3V]Z5V1P3W=A94-/5F=+075Q<U%0<$=65'=W;6)L14@S:'-H;&Y(
M-E-2.%9'6%)T2FQ1>'9:=SA44W1%5E1S83DF(WA!.U%!8W%N;W--:%)H2#5.
M:V18;&EB16HX,%9&1D9&1TDT:U=/3E)2555!040R07I):$%21D%51VU5:DDR
M5%I8-4II=W988DQ53$Q8<FTF(WA!.SEG=#5*66(S,#5"8S(X8E-Y4E!(1TEY
M:DMO3#A70T)L6E%D-C%P=%<K16A7-VE:67E%<D1C=FQA.#%F56TQ4U<W:W0W
M=7ET5W,W4C0F(WA!.WI*0WI34TM83'EL4%1F:6I33%)197@X8V]Y46I):GEC
M>E0U<'=%:'0V<35I*UAV.39395I03%AM3S<X;U@Q;'!R:%IR,$9V,&Q:>FTF
M(WA!.S1)9C%!6E,O1DE8*U!I55!P27@V-UE-:T])8D9Y9$YN:D-136AS;V9L
M3G!7;S9..54P*S@Q1F12=FME-3E:07IU64QD,5$X4TI1<VDF(WA!.S!M:EA9
M<4XR>4],2$M)24Q:<C@K4$Q)1T=Z,5A*=4,W1E9Y9F)8-6I&3$(O>FTO3#5V
M365L3'%&:VY,57))17%",5I/<$909G8Y2&@F(WA!.U$R64UV069*>$YB<%)M
M:%A58VYZ<&)85W-A2'%83T-387<Q0T-Q.#!9>'E,>49$46IX535T9UEZ2&5(
M;$I#94=E,7AK13)4>C4U>$LF(WA!.T9',7$X2TYY-4M:,V]E6G$Y9"\R=2M%
M65ED=U%D8FXO04IX86TQ8E=D874T=G)D>%!F,UA(,#1V55IP2#0Q3&-25W4Q
M4U1L9T591'4F(WA!.T122U=83DE!,TM4,V(X<&9*56UJ5THQ2RM3;#=C0W%)
M97%J8V9Q3W@Y>C)P;6XQ5V9X2F)C9SED,F)O=D%H=CE2-7914U-D>FU--T(F
M(WA!.U)N37=G:TU#<3 T5FI%<FMQ<&5N=VAI06%#=498;4=S95EF>F1S66QT
M3'%B>3-P.7DV0FQU-6)P,%!'36=-,W!Y,'%*1'-+1&(U-4TF(WA!.T%-9#%.
M9E!N;F%Z<WEL>G%0;&UE-%%W4FE:<G V1C5&-'E'6#!Q<6Q*4V]&86)6*V5.
M0F)5>C5Z+TU8:&-P*VLO2W9Q4VAJ069R,C@F(WA!.UA+=D1I4#)G0590>&1C
M84,W=6XX."MD6C)+5U8Y-5EG=D970C5W,3!E4DIJ5U(T>5-X56AE4BM*4S(S
M:&I15E<P4'I6*UEU<4PV9&XF(WA!.V8K6'(V-&A+.$9H;6-E=4913$]'549N
M55)U>%!)2TLW9'5Q449E:U=V,7(V<D0Y8C1F5W946#9X-E9E2'%52%!H5W T
M.'5L8VEL5G@F(WA!.U9R1EA(1E5R.'DS=7!7;6Q02G R;&Y6-3)D16%Y1'!(
M>6I9+W9#5VM)6%I+-V1Z:E,S5$=B6'I6-3!G<T=33'E.2D5L=7-+,FQR1F0F
M(WA!.S(V2C942U%&06]V2#!G04-!3G9L,4Y"5$EK,F5A1DAN9CAZ94XU6'E.
M2GE"27-F.4MH;T)2=4IL*TPT='AV>"]P53!/.49L:S-L5%<F(WA!.W1F,5,R
M;&)79$5K,&%A17%O5C55;$5P,S5-;D%N:6]O3W9J9TE3;G5"6%EQ-T97.%99
M>#5N.'AE8G1-,4=+2%-03%0V,5I00T=K;FHF(WA!.W59-$-K<&-J:%)W86II
M2S1106A!2C4Q.#AM4D9F>4YD24=:5DPO6$Q99V-H5W!P,D(O>G)T:&]D-C)K
M1W,V:#4Q,4=A2S9K.&=Y+W F(WA!.V%#2F]H9GAA9TE'35IQ5VI$=U-24T)3
M,41X3$@U9#A26&5Q86IZ5#4T=$Y#:&DP<GE02D1.1T)"1&%V8WAC27A(5F1W
M3TY6*TA9.'4F(WA!.S1/*TY$=E-Q>65D4'I!5S95>"M3-7!R3U-*1U5#-6E3
M5EI$4EI%9FY19D$T86Q+.&A2<V%(971S;CAU87!Q;7!A96)N53E,:S!I-3DF
M(WA!.U)K1G!,26MR8U)3:CAK,C-R:U-Q85EQ=50W82]-67!42$E*66(U>2],
M+WE4<7E'-#%623=6="\S=TMP56LQ4&=D>G5E2D9C<VAK;$@F(WA!.VM7;DQG
M:&M&4T9V368K5F5F;&-.43E%95DT9V$O=T)X4U1L6"M8<E@X835K+VUC=&9S
M8T4Y;&%E+W="<C!V>6HU03AK86%N<C9A23<F(WA!.W1I3C-*1$1X,T)Q,UAE
M:D4K,EDK5$Q+6$UU8F<P,E!%4%%+6FQX:CAF>'EP=F1W:3AF>'A6<FA$-&HW
M.$MP5')(;$AY;G)5<5,V=G F(WA!.W1R9GEX3'=J931J4U)L5W9+9TQ!,#-W
M9VQ&0D-,*UA8-69R2$Q'3D1S46LY4%=8,%DV4'A.4GDR,V]4:GA&84-J+WEQ
M+W=$3&%O4"LF(WA!.T@Y4#)R+W5M4'8X05)J>$9A0S<O04I6<"M86$I7+U%6
M:'E504LS<$I554%!;V%D<6)9.%)79VET33AK95,Y3'90<G5N859A5VPS.%@F
M(WA!.RMK4E)O<VYX+V$K24-U*U!%5F]*>#96<B]-4"M#=U=683E+,2]M2"]!
M05=.;%AE;&$O>D0O9W-B2W4Y1S O;4@O0EDR5F0V3G O35 F(WA!.RM#>'-Q
M-S!B5"M99CA&:EI6,V\R;CAW+S1,1WER=E)T4#5H+W=73FQ896IA9GI$+T%)
M3$=Y<G92=% U:"]W049J6E8S;S)N.'<O-$PF(WA!.T=Y<G92=% U:"]W5TYL
M6&5L869Z1"]G<V)+=3E+,2]M2"]"63)69#96<B]-4"M#>'-Q-S!R6"M99CA&
M:EI6,W!7=CA!35 X06=S8DLF(WA!.W4Y2S$O;4@O04%73FQ896QA+WI$+V=S
M8DMT:4LQ0G)Y1S,K5FIU<DAV>D0X.39F-4\P2U153&=H<#-Q;')$6&0S24Y.
M=2\X06XR0D\F(WA!.U-X-'I-,$='5$E)4G-V:R]Z5C4Y.'AE6C<R5S0Q0S9F
M,&Y.1G1L66A!=EE%0VY,+T%$;T(P>F-9<T5993DP;6)65&XU0DDQ8DPS1EHF
M(WA!.T(U63@V95E03'0S2%!P,3 V<6AQ64=*35I(9C14,"MJ2W-U0TTK9DYY
M34]P;FI/>#)F568U965E-TQZ9F]O=31X-F0S1E)B<41R>&(F(WA!.S4O-2]J
M;6YY-&I#5D8S;4Q+2GAS37!Y='-7-%97;D96<V-K8W%"-#-$;V5J2U%186)D
M4F="56EN659A>%$Q:7)2=W$Q:7)72W5/2W4F(WA!.WA6<D9867$W1EA9<3=&
M6%EQ,VER<U913W$V=F(V9$A(>E9P<#5I5F=T;S9C,TDS62]%5D%693=%,"MK
M9UE116IU635E95ID46]:3&TF(WA!.SEI,#)!8VE406]K0S!:56\X.'%M3W9*
M>'1W52]/:'AV=419369E5D]4>E)C5U8X;&MD671:-RM58V]T3W9':%-A5#)J
M.4PP,D9F2&<F(WA!.S-Y>4AI4C9T:# P<7--<G1.4W1P.5!T<C%M14UD>D5K
M>7))44-!-FAQ2#5C<VU24F-92S@Q>&)W.%!7;%-0,4A%8V9.9W9*,C9+=&4F
M(WA!.W!0:&=686)Y,$-23UHT=VLU0W=T>5=J;'5G53$K2W9T:7%R:7(U:"\U
M>4DX>7EA;#4W97=6>6)F5$5%451T-FA*-61/=CA+;DTO4G@F(WA!.W%.=7,Q
M.#=):6=,96(X;7!O5FMM='194UI6+V525V=J5TYA2CA*6G!P3&AM67-0:5EC
M5C8P555!>3,Y-S5.9%E$,$M9>&%B*U9!,#(F(WA!.T=75W@X=U-J:TEF<G-#
M24EP8G8P=S!K45IX,%4X841I1V]4,3)X-'-L.#1S=D1W,7EK:&\T4'EP6%1:
M-VAR5%A43$=S:6AJ-E!O<$PF(WA!.TDP;C%:6%E!2#=!0DHX4C!Y5C5,-7A9
M8T=%0S9K:F9Y3SAW+V\S>CE"8DE81G!Q4$M(,'E19#9%<5=.0C!7=5$Q<TQH
M9F-N45I+;5DF(WA!.SE#*W!N:G!U3VYH;7%D=W!95EEF<$]J969.4#%J-C%Q
M9FU+2R]W0D9$>E-4,GI7-GAY0D-P.5!I-F<P-'1V5#9/=W=K:6Q!2UAE6'8F
M(WA!.U!M;G)Q-F58-$19=WAY>E,O54E79C9K-E%#5E%I3$-W8WE/=V1I;D%+
M1%-N66Y-8D1+4C5$,'5D<7-C23!:4SE:03(R3B]S,C@R638F(WA!.VYR1VLV
M5D%T>'%L-V(R1G5Z0TY:<G%6255,:T5H47IL4E=I:S!Z2D%*-4]"2U%(3EAT
M-VDS=6)E3S1T-55M=#5L5U-'84YG-D]J:7$F(WA!.W-R0V])24Y14FI3,V$O
M07)2=W$Q:7)72W1->7%P6FE!;S-*3W=!1TMR175)2DAE3T]26&5+9VM65%5Q
M5%A9,"M73DMG3DTX>&%6<6,F(WA!.WI25V)Y4%)E85-V0DY&1DML865P0DQ)
M:5)Z<'5$>6I::%%G,6]2:$U31TU:03AL4%5V3D=I-F)E+U4W=5=22FQJ5V5:
M:V=N:VEH:&0F(WA!.VU66EHU;S!A2T9+>'8X56I+049*-D1#26MR2UE(3DU:
M3&TS:DE%:VEQ4W=106M6-4U105!P3&HW.&I42E9X5C)+=7A6=D952')-9#<F
M(WA!.TIO.3E(64U6=FYT-59T5U=G26Q+14E14U9&959/<'A6-2]Q1B]P*VUQ
M;'<V6%9Q<3)L=4QY,'0W96$V=4QE5U5'6C1:<GAQ=U)Z3S F(WA!.W$X:DDS
M26=Q86)Q,D]746I'>4QB9$Y!>FYW06=%.39R<3)K,U=H-E=T-V-V>G,Q:VI#
M3%E+.7A.3E!D4V]S6F%-:%9K261G=%A9;"LF(WA!.S-&>4M#539&,5HO2$IN
M:FIX4S1B-%(S;F(U+V0W,DTO.'$X6'I0-6QH.#%,8EA59#E!.%%U8E9M4T)%
M;F=65U%3<DYW=5EF:#1-45DF(WA!.W%L4T-T45%40U=N2$9D+VHW;DMW.7%'
M3TUW078X9FIO>D,R.'%A1G(K;W9A86Y454(U9F=I<W)A*W1P2EE1<G9%575,
M9"]48T%Y4FTF(WA!.TY8.%8U9V12;'A,<DM8,VXU3&528G4V1GA01&-M9U W
M;UA-<7@X>4%054%"1D=O=EDP.7-E27)33'1V>6XX;%<K;S)/;U(R<W8Q;E0F
M(WA!.VY34S%:<FE:9W)X0D95:TUX0B]U>&<T:6UM6#1&9DI0-3@V8DY99FUD
M<6IY5G!E;$QL1%$P-'-/24@S2FUW,'-V439V6%)Q9"M362LF(WA!.U4W:GDU
M;RML0T-X."MF;R\Y37)A:E=R8S9F2DHV9$E*5VM8;%)U66IA47@O1%1K5%AP
M5$1/>60T.'9.3TQH:4YP5F9.;71H*UDQ;$HF(WA!.TQ+='@K63=226]&>%IZ
M9F]H059U6G!:1FQ,2T5K<49H3%5(269A0C=5>6\T:B]-*S%V1V-F>B]S4V)Z
M=G)6:'%/:W<V5G%0;G1.4V<F(WA!.U-.3&=145=%4D-Y4G=X*VUG:VEB97%Y
M3W4W8DUT1&QU2TI"<U(K,7!Z>6I+3D=F,DUA+TIV5#5R+W=$351356DS.4(R
M;FLO,495<50F(WA!.R]W04U-=#%C<7AL>#E$1SAG4&,K=U-10E4U<&YE25IY
M<&%O1D)K:U!0+S!Z*V%)3EID4$M21&52>' Q<S56935#<')K:FUG-TMR2'<F
M(WA!.T)Y-F]F:B]P1F]%<#DS,F8X95%U<U<K;6Y4*U1A9U1P1C=(8UA&,W%5
M=%9U43A%9BML5%1,>%9V<DU2:4A"9E1(;W-G4E589T%U:S$F(WA!.U5S=S%E
M34%I:GE(5"MK1'8V<C9F9W4R,#!C2C P>5%D=5HV*U(X<38O9TI86EA7<4IR
M0UAD>F(S32MS4F%O<S%V<%@Q:4))-4HS9V$F(WA!.T<W4T-/4G9I161T2DTV
M<UI!2W%&<C0W;V99-GE843EB4FHV-35Y:4XO1C5B<T5/<S@O6'4Y165&<&)A
M1U=8.30S2S1E83!G9VPK364F(WA!.V]Q4WEE<CA->4EV3U$T44(Q-69J.&99
M,6MK9E1Z-W9X*T]R3%!+,34U<750<E@V9G1V<2](,"]Q,S=I1T1L6&QZ+W5R
M+U5U5DM,,30F(WA!.V8W3'1#64A4.&991V-$23@O=T%F854W;3E8,&XY3&HV
M=$1W-3$T.'%B5G!V5$LU6%(T96)D1W)&.&MT+S4R9B]!2F-V*U-U65@K1B\F
M(WA!.S=8+W-N3"]W8BMN+T%,1G944C5G*W149G!!=V96-B]U:$A8;# W93-Z
M,W@P,S5N:E!I.%!$,'(X8W9F=6I594)W:G<K3&DV,G!E8F(F(WA!.V)6<G)Y
M-68R*VM%9G!'5TER04,P84%M;S5+5$Q&8THX4S%&0VTO4W$O84=X9U%#3&-$
M24-9;75B>'HX<TY/.'A,8V$P9&%T-WDW,'0F(WA!.W%X,S%S0WIT2DEK9TUP
M351$;DUQ9C=T:59U5&<X945L94]:,G!-849C,T$P<UIG;FES:CAF:CEB2DE4
M3F571W!2>B\V5F982E=E,&0F(WA!.V)*<G!7;F5#9%!R9TU5:VM,2F-7:3A2
M=S)5<T\U,S$P3$),<S5K1VHK4'@K3W%D95A(3FI(239L64QQ1WAG8E=:3#=N
M6E!"84(U1$$F(WA!.SAA;%I91E-0+U-J>$Y.-F-I0FQN4#5T6DE"*T@T+U,X
M,3@K858U:UAZ2G W-DYB,W1J65-X;V)'2FPY1E4T3E5S:U-T2SAC9$M&234F
M(WA!.U%(:E=I8T965EA--T)+4$-B-75U,45*.%DT8D%E-C9"1G$P5VLR-F%T
M2C9M;T%.-C=M4DIA,6-L9FIJ9W1%3D9O3F]H.5 R:G(U5F4F(WA!.WIS;UA7
M+U X9356=F8P='I8-FPY6#15*TPQ=61A*S-(35A0-#$O=2M'=C96+V]C<D0T
M5F5V:79Y<CE+0W5V.$%&;F].-E Q35-B8V4F(WA!.U!/=E56*S-T,'I%>2]N
M94@P*TAF>"]3-4=0.$%+,W9X,3A0,$IP8F979E%4-GIW33E0,VYP,316.7$W
M-7--6$AW:FIR:38Q>6-,2G<F(WA!.SA2-&(T9DYH=')P9C5M2F-W=F-A9UAT
M,61436DS=&]X2T$O14%V-D9H<E5D=6$O-G<V-6MK>"](.7)I:4TW,U T+S!Q
M2'4T3%=7=W4F(WA!.S19>%!&<'%7.&M%=&LP2WI81G1,47DS<TUY0C)K=4I,
M<%!T<WI.>DQQ-DTT9FM(<7E&57E86'A#;6Q+=#1S5%-02F)-:WA6,&A/;T,F
M(WA!.S1H5WI,:4YM;$-M-31B9D5+1#1J5')#4%!:;DMQ,U-N57AQ.35F>DQP
M879$<C!A:4<U=6)/849B84-/<&MJ:'5:-VDS;35L:U!Q27$F(WA!.S)R=D=7
M3S9P3'EA46]$9FMX;'5D=68T+TA*53AN84PU=# V-VU/<E12=F)42SAK:7A4
M5S=H<FPR571+631D3C Y<70X5E=-<F4T4%4F(WA!.T-::C O2#)L64-13R]W
M0U!S1$Q-9S)/>%8R2W9/4'HK+TLK9GI8<$5E<397;E!73DY5.%EH,6QI3S=)
M3S%F;BM'5UE-=D%F2G Q1T@F(WA!.VIJ-79M3%%.5VTX=2M926(R9E0T3'5E
M>&0Q;# W54EI.%)9<3!:5U=).%16959F66I.:V953V)Q66MW;%I(2FQT="MB
M;#-&6D-Z6'DF(WA!.R]O=VDU>'9)5G1E3%-,2% V-%)Y1RM)9$8S-T1)94)V
M>DQD*V)08T5K,2]Z0DPU:C%/,VUJ,'DP<UIV5%<R:G1.3F@Y2DI'36I-<#DF
M(WA!.TY3,5A04&E+9&=-=6A%44A0-75.:VUC:W1H.&XP4BM1+W=#5S!V;"]4
M;C%Z5EDK1W S;W!(17<S:6HS1DXK-3A2*T]X>E<V;DYX;6@F(WA!.WE$=#E*
M9SA/3R]-=E8S8W-F8G=Z1V-L2W1F,6HY1#944'%0,5,T=G912U9T8E)056YB
M;DEQ9D%N9FIY<69B0T%R15EF>F1S-3E2;',F(WA!.V]V3'5T1F\Q4U1K8E5!
M;$=B9WI53&I:4WDY3W9B2F-+3%-R52]-+VQU.#%+-FYV4$LR=6TU=')L9E=I
M:FIU:W1R:C!*;S123SA-36<F(WA!.V=U1T96*S!J17%O56UG07<W*U1':&0W
M<3)Q969T2#%A:5AV;'98;$=M>FEE1U-+2S1G:U8K1%%/>5-7>G%3,S<U:S1H
M<45'=&9!9T4F(WA!.TM10VE)4'I*,&)3575.3W0O3#)S<$9:4W9(1S1S-6Y%
M:$Q-5VQE4G%U5VMK-4UZ3E9M4'A'<D4T0T-5:6=V:B]!1&8P<&I)<F%(<F$F
M(WA!.W1$551(-FDO1E=643-%:VM%13%&2V=93T9B6DHU6CAY>"M93$]A-VIS
M3'EW4TM8,&A(9G=M0U(V27)C;%%K+T0X9%!M34)&2E1F1E<F(WA!.W-68V-6
M4W989%5I,$A28FI563='83A%3$)J85=38S5N86%52WA63G$W=GEB,G)H-6]9
M6EDK9F9+3G!C,T=O5V9L3%4W5SAU5TEU-VDF(WA!.TQ3;&IN:V0V>4@Q1U$X
M,S5-<$I/*R]82D=Z,5%!0GE$5C4K64=H>3-S9#5C*U1D575:2W%K5C4K:F<X
M<6E!:5=/=D]J<G=L87$W,$(F(WA!.RM)63!E.5-",TUR.'1E63=(>D9(2F51
M,D8U84YB17=G,S%U64A)96I(:'E*<5!H5W523WE5.'=*9&ER<U9B>%9I3W0O
M;4YA-E!R1GHF(WA!.W!K*VIA<F-'05)M3S5T3%9P-'!/86AI1EE%9EIR=FA!
M4F%56$AN;GEX93--3W%V-5 Q2S4Q4T9*9G%D>%!P:2MU=C%:4%<T<DLS2C F
M(WA!.RLS.$Y/-7E7+TLP54QU=#-A;"M:96I4,CAL=DXU5#%7.5=35E!R545L
M:'EJ6FMD4GHK4#=:4FM7;3%D:#!W065A4W$R6#5P84)A<VPF(WA!.VY&;T=Q
M5TU-:VA%35ES5$-P:VM,4U!69FA8:S=&;2M%:W1U975*0E5+>B]M+V]I0D=B
M4TY:-'4O<&\S,48V32]-<'A(>&1F:$\R4$,F(WA!.VTR46579DY6<C5G4S1E
M,W-R,GI&<W=2>&97-U<U66UV,D$S5VY(9G=W155T<#%G5C)+<&YK1U1"=D]N
M-4TK4U!.:W!U8C(Q*W(S>$(F(WA!.T%U<EDK;7A*-W14-U@P-5I$3$M02G)Y
M66]Z-6AG2"]1<4]I:6)B6$QR,&9$:$AY*RML378O3U,W;D<O27<X,F5E5"]Y
M5SAK95=*1G4F(WA!.TQA,DXQ96AA1S5U1'I046<X46%H83$S03)Y;65A575:
M8VI(:&I$:T=D1TUE2GEP=&$Y2F9%-'$Q-D-E2G<R<G915'A/3G$W-G5N:6,F
M(WA!.V)25%@Q85!X3TYP9#E6:CA4*T=.;W!R-G)(-&XX4#99,G1/*W%2*THO
M1"MM3G)46#%/3'AB.% V63)T3RMP>&5,9F@O5$<Q<#,Q3TPF(WA!.WAB.% V
M63)T3RMP>&5,9F@O5$<Q<#,Q2TQX8CA0-EDR=$\K<%)E3&9H+U1',7 S,4M,
M>&(X4#99,G1/*W!294QF:"]41S%P,S%+3'@F(WA!.V(X4#99,G1/*W!294QF
M:"]41S%P,S%/3'AB.% V63)T3RMP>&5,9F@O5$<Q<#,Q3TQX8CA0-EDR=$\K
M<'AE3&9H+U1',7 S,4],>&(F(WA!.SA0-EDR=$\K<'AE3&9H+U1',7 S,4],
M>&(X4#99,G1/*W!X94QF:"]41S%P,S%/3'AB.% V63)T4"\O6CPO>&UP1TEM
M9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @
M(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,3%%,#1#1D5&14(T14$Q,4)#
M0T9&0S4U-D5#,D8P0S<\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX
M;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,3%%,#1#1D5&14(T14$Q,4)#0T9&
M0S4U-D5#,D8P0S<\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T
M03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T
M86YC94E$/GAM<"YI:60Z,3!%,#1#1D5&14(T14$Q,4)#0T9&0S4U-D5#,D8P
M0S<\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U
M;65N=$E$/GAM<"YD:60Z,3!%,#1#1D5&14(T14$Q,4)#0T9&0S4U-D5#,D8P
M0S<\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$
M,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET
M:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @
M(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HR.$4S0C0T034T0C1%03$Q03=",40S135$-3A#-D1%-CPO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,"TP-BTR,E0Q,SHP-SHP-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,3%%,#1#
M1D5&14(T14$Q,4)#0T9&0S4U-D5#,D8P0S<\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#8M,C)4,C Z
M,3$Z-#4M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S
M=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R
M;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM
M;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @
M(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&86QS93PO>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L951R
M86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G
M.DY086=E<SX*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP
M,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P
M,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO
M<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @
M(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D-A;&EB<FDM
M0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT
M1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@
M5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-BXR,CPO<W1&;G0Z=F5R<VEO;E-T
M<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS
M93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9I;&5.86UE/F-A;&EB<FEB+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT3F%M93Y#86QI8G)I/"]S=$9N=#IF;VYT3F%M93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^0V%L:6)R:3PO
M<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R
M<VEO;B V+C(R/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^8V%L:6)R
M:2YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!4
M4&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @
M(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$
M969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!0
M1$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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MW[%@=)R<9R[ P%$91B:JTMJ"3F3 62Y0G9GI;1&4L!N&2P&-N>G;D]E5FX(
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M#N<.-^C\/>S+7M:"37"C3;9L,#,A>X9<]O)!7E@COE964D9C(KYYX_\ [2G
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MKRKIUO\ $(R0&D$>[J 6"9Z[:]%]GMD)^&+.^BM!-);G6!+>1P<QX+23B&]
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M+IM*WT><0N&TZB!'UK7PBXQ,JU7HZ;O0L4+RB-ZJ+T=$H&&*!(,"%'EN/E9
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M7_A<UI_UXK7_ &GPWM=]E1! ]I7 ?_K;H/C_ /?Z?Z-O:'_P%XO_ /5S5_\
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M:)K)CYE_+UMJ;&*KI%?9%FYQ&9A<)HH\)56QY!LX4'-.8%W>1*PLHY(FOKA
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M<9S_ +68SUY_]:V/_MGC_P '#V)_\ M/_P"<-;_]Z5/^G+VK?\,+S_T+2/\
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MQ*=QVNB"-B<G;B,)RU)Z=%8*.@7'2MM:<?2*\4=YI\36ZE%WPRR--&JX ?\
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MHZ?1ZAL6I:-I8:IT9%.(B=F#Z->I<5G5>K.I81LFFZR*FYMR("L:UKF])%9
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MIDV86=S"J4FTW]^*4V9H\H55EN$$-P[6B45K(Y]W*CU?LC[,1Q9+Q(2_V?\
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MYUMQQ>7$V=SPZIH^C7-C,PZ[#%9VEA<V\;'H?=[M&4'(W8P< .L[I^LFU:1
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M$-X4M;BL(2E&%..*RMQ:L)QC&5N+SE:U9_&4K.5*SG.<YY:))[23T ZG/0#
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M&!8=<$U:'6U4[I160-18,%)UD+6%W6E5V3/V#8]<3"=?A0@-;QL._5ENJ&L
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M9EHAPB!XM&08L141$GB?&1M4J<>PV9V/)+B8Y!\3'$Y(1WB#*LW851Y )#A
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M0<9/PD_&!]Y"RC[V:^+>,?95Q5PC+(;RPDN+$$A-0M%:>TD'4!N8JCE,V/\
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MYEN9YKB0_P <TCRM]-SEB!\ATKTBQT^PTR$6VFV-II]N.R&SMXK://9DK$B
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M:>0!G\BO[9W^EQS9/O>2^E-B^'F?6GD 9_(K^V=_I<<V3[WDOI38OAYGUIY
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M<=_USU]/*F:@"]F=Q_\ F7_UKSQS9/O>2^E-B_,_4^F*>: +V9S])?\ Y_\
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M*FD2$Z4X]*FSILEUV3+ER777Y#[CCKKBG%*SGZ4M88;>%(H45$154*H   &
M !T  Z#'=^(KY*N[F:ZGDFN7>1Y79F=R6;<Q))).26)ZDGJ>WKUJ-*NSW?#_
M +OZ^_+5L=O8>SY?UWC\?K@R1XZCZ]._YCY^(_H]A*NS\N,_U[<<NUC,O>/Q
M'^8^?B._ZXKLH7V=GI]'S9^C\F?R?#U9]'JJ!QT/9^G\O$?B.HJP1CNR#VCQ
M^8^?]=HKM)5V>G'_ $D_3_QD_E^/JS^6Z#G^OZR#W'_.K3+CJ.H/G_,>?8?E
MVD+[?3CT]O\ I_9GX?EQGTU@XZ'IW@]XS^H/>.^K3+WCL[QX?,>&/+Z9%=Q"
M\9QV9[,ISCL]/J[,^O&<?1\/=V=E?1@00".\=H/S'B#WCZ]_;0"5((/T/K_7
MS'<:W,=R@Z_#FA=@U70VP+)XOK*QG<L:KLYF=EF)J6^')F',5XB0?7A$/4NR
M"KWB=AC25I&4FVSH>Q(BQT)R^LV/QSVC<%I<PR:WIL6+R%2US'&.MU"HR6P!
M\4L:C*G[3H#&=V(\>_>R;VA/97$7#NKSEK"Y?9:32M_Y'.Y^$;B>D$C'XQG:
MCGF_!F8O]UVN[G%OE6A'X[3L:1W[T$L/D(RS,%&(+JXQ$;.CJQA<>7$E-.L/
M,KQA2'&UISC&4YQCP-6S]>\5]/2 @8QV'H>XCN/?Y]OZ5LKU9]V?ARJK52.*
M5"OY.?J^..*5)XI7"O5GW9^')7M'U'ZTKH<OTIQ2NK&FPIBI*8DN+*5"DKAS
M$QI#3ZHDQM#;CD63AI:LL24-NM+6P[A#J4.-J4C"5ISF RMN"LK%3M8 @[6Z
M':V.PX(.#UZBKDD,L0C,L4D8FC$L1D1D$L3%E66,L!OC9E90ZY4E6 .0<=KD
MU;KH*]>??GX\4KCBE2E^O'N_7GE ^VWT]*J_@_WO\JF*]6?=GX<KJANP_0_I
M4M7J1[OU8XHO8/H/TJ#BIIQ2G%*ZRO5GW9^')7M'U'ZTJ1R_2G%*<4IS'I3B
ME.*5)7\K/U?#'%*FI]6/=CX<4J6OUX]WZ\\4J#BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*5RGUX]^/CQ2N5_*S]7PQQ2HT>K/O\ U8XI7"OEI^KXYXI4SBE.*4Y4
MGVA^/Z&E.5?^;_K[U*Q'ZI>IS.DXH"A:]!QMA=1&S&Y;.L-=N//M#8L2*XU'
M+;&V).B=K]>UI4LOH?+3^^:G'9N&*W7L.DY:WX.RTW3XKA)KZ_F-II-E@WET
M #([L"8[*S1B!->W&"(T&5B7,TVV-?BTNIZE<0SVNDZ3;#4-?U+<+"R)9888
MD(6;4M1E4$VVFVFX&:0X>9]MM;AII!MPS'=-<:YG!U\ZE[<8ZD]DQ7L3X6;L
MVVWJRF3UISE;6MM/QL^9==CQL=XW'+DX)RV.^ 1*F6%Q]:^S$NN*+QU>RT2%
M=%L7RG+LB3?W*#OO=1.+F8D EXXVAM@"0(=HS72Z;[/])M3'J?$]PW$NJ1;9
M#/J84:592D]FF:.";*W4,56.69+F]9E5O>-[8J\#MW!)+U:NUV6+-R#$\G%?
MC!I<>;@.% 1C<4F5D)@+=:AP1UB$,U9YQ_P;#1N0D/VXGIRPGG&@E F:8/&T
M84GF @O([(0@W=69HW,HQG*#?]DY/=I=0/R%MWCF24NH,+*RI'$LBLQV9"JD
ML8@;. LIY9PXVU2U(WM0K_=;%0P<YM!VOJ-9;8FF:BB<<CUDO& V0@)K$2RS
M+NP*"E9PR,^6/U8&-GLF I$+**"RXZ=)R)],NK>V2Z=<Q/RMQ5)L1F=&DA5Y
M6B6!FD1'.R*:5D*.DH1T91@VNNV%Y?RZ=$^+B/W@H&DMMTPM94AN6C@2=[M$
MBDDC',N+>!)ED26W::)UD/M;7W+JK1E5=N^X+_5M=55N2W"28M)6,,8ESWD.
M.,CAK3JO&BI-YIEYUD:-8ESG6F7G6XZFV7%)U<DL<*[Y75%\6.,GP'>3\AD_
M*NFT_3-0U:X%IIMG<7MPP+<JWC:1E4$ NY VQH"0"[E4!(!;)%6OJ&U^ECK5
MH=JK=.N>O]VTV3&\G6ROQI*),R U*[_$220"36X9X([EUI;X0RJ'"=;F1<RA
M,U,J'X5J_IFK/;W,=[IEX8[FV<.DL#[9$/@Z]I1QE61U*2*61@RDBJ.*>#+R
M&T?2^*]!E2RU&-XS%?0;K:X4 $\F==T1FB)5U>&436[[)%,;A&K*GN?]SL]F
MZ??->Z&Y]GL^E=E[1T20M!5]4DK9!^L;B2"U,T4DN=KTHI,I6:WDI-D*7)($
M$R9\A>7I2^SN-?2'WV*[MXTAAU.PL-46!!M2%[ZVCEN(D Z*B7)F"*.BIM4=
M!7@?#3SI97>G7,TES-H>KZMH1N93NEN(M,O98+2:5NUI9+,6YD8]7?<[=6-9
MIN2HS3:G79##;2%+2MQQYM#:%-)4MU*EJ5A*5-I0M2\9SC*$H5E79A.<XTE=
M#4QMQMYMMYEQ#K3J$.-.MK2MMQM:<*0XVM.<I6A:<X4A:<Y2I.<9QG.,XSQ2
MI4N9$@,*E3I4>'&0II"Y$M]J.PA;SJ&&4J>>4AM*G7W&V6DY5C+CKB&T8RM:
M<94J3DH,Q&BS<D8.(<YR(S"EYEQ\1ICT]Q#,%J*_ESP4AR:ZXVU$;96M4AQQ
M"&<+4I.,L'P\?+M_+OI7>SG&,9SG/9C'ISG/JQCZ<\4KSQA<4:CXF!R8\M$S
MX+LE#)L:?'SX>+'FL=C\5UUK^[0I<66U^-_=(LF/(1VM/-K5)!':"/K]<?J"
M/J*@$'L(/T^F?T(/T->AR*FG%*I'J^VB,UMJLN\4.8K0V2--$K)8\=BLUBC5
M@*0LU[M&6\]OA$5RHB#1E;6<=CR866L9QE>,XPHHGGDCAC4M),ZQ(H[6>1@J
MJ/J2!5V6:.WBEN)F"0V\;S2N>Q4C4NS'Y *37YAW47OZQ=3V]-B[TL;+HY=V
M-Y\V*XI]4B/2Z &CM!*#1X3F<Y2J-5:E $B%R4XPLG,C2RTS+L\A*>=^G^'=
M,BTC2[6SC RD2\QP .9*WQ2.>_XG+,,_9#!.X5\>\5ZO-KNKW=]*QQ)*PC4G
M(CB7X8HQ@GX50*,C&2-QRQZUIKWIFOM^U$>W>L_K:BZ\$V Q30A;9-\#4U^_
M7BOUN+;3E+H4(@I3YPV* D0TN>Y(P.#1GSP$:X723+P(CNPDU>"UO8['9<SW
M#QI,Z6UO),+>"24PI-<,HQ'&\BN  6<B.1PFU&-:B#0[F[L)=1,MG:VL<LEO
M&]Y<QVYN[B&%9Y;>U5LF25(GC8D[(P98D,F^1%/6;Z6.I_)&GA\=..]U%=A!
MG;%0AB=17]1"ZU]CR?E\[4H>*_F18@[&"XE3Q(0W+AM(*#5N/)3.BY>S%UG2
M2LSG4]/"6SB*Y8WML%@D._$<K&3$3DQOA7()V-T^%@,/]A:T'MX3H^J%KR,R
MVB#3[O?<1C9F2W7DYF1>9'N:,,HYB$D;P#Z$CI.ZJ(!P#6)W35OZ)8[3@_FL
MU^5IW8;!NPXJA*,&M.08IVNIGEL5LO,AC#_B##^!!"7&B$/%Y$AIM=::UI!C
MDE75=-:&'E\V47UJ8XN<IDBYC\W:G-16>,,1O569-P!-6I>'M<26*%M&U833
M\WDPG3KP2S\AUCG,49AWN89&5)MH/+=E5\,0#5<CHSZCF0E#F#]772PVR_7#
M<=(BZEKU,NQ7;M=-:,;H3E[\[*(S6L$@[$7\(@5#'>JE2FG(I1):**\#$S-A
M=>THR7*M>6\4-M!8W#7LMQ;QV4L>H^\^[<FY,VQRWNLA/V0<IL+Y;;$G#.LB
M*U=+"YFN+NYU&U&GPVUS)J,,NEBT-V9[00;XPOOD6.K'X7YBQE5+>'5NE+JE
MN@V*8IW39ORUB)I1X)"*UO3^PC8Z49C%C(&2)C31M>DQGR,8[7+ %DPFG5R8
MY8&7&O-(EC9C+.1)K>D6[F.?5=-A=4$A66^M8W5&2.0.5>52$:.6*0$@ I(C
M@X92<*+A[7KE!+;:)J]S$[F,/!IMY+&\BR20LB.D+*9%EAFB9 =PDBD0@/&P
M'D#NG[?A03$L(K2.W20(A=XVM(1B!K>Y2Q4[8TPJ@#$H4(A'#.1)-UE''&PL
M>K,NK-OEG$#6X*YBTLJR6U73$=HGU&Q25+<W;QM=P!UM%CYK7)4R!A;B(&0S
M$",1_&6"@FL0:+J[HDT6E:E)#)=+8I(EC=-&]ZTG)6S5UB*F[,N(EMP>:TG[
MO9NZ"X*>CKJK9K6R[=/Z?=M!0>GJK6+SLAZQ4<]7)E9IMQ?F,URSR1)R% +2
M09!L:4GY)P(4N)$#B2QJ:]'$#)TUBRO$&BF:S@75;%Y+Z>:WLQ%<1S"6X@"F
M:%7C9XQ(I=%,;LK,[I&H,CJIO-POQ +>_NFT;48H--MX+N_Y]I- ]O;7+.L%
MP8ID25H7"2/S$1D2*.25R(D=AC@M*'V5LN8PIMQ.4YQG';Z,X[.S/]?]'-NZ
M+*CQL 0P(([0<],CJ.AZY^?S[=)%(T,B2H2&1@P(Z=A!Q_+Z=V*^YKN(W6%.
MWCIJI1;@461MXQR3J+8[LM[PLHE<:.*%R*A=9??J4XI^_P"N)H-)$@\M<H[>
MJAL R\YEV2K&/DWCC0_V'K]S%&NVVNB;NVP,*JR,>9&O< D@8J!]F-HQ7W![
M.>(_[R<+VD\K[[RRQ979)RS&-1RI6SU/,C*AG)^.59#WUOYGCU1\*<:[5LYQ
MG.?G4W^17TI^A7U*]/ISRBMGH>W]?YUVS+CJ.S]/Y5XW*ZHJ%?R<_5\<<4J3
MQ2J8NUGC4FF6ZYS8<XC#J-8/6>6/%LXD$YT8 *EE7X8YA2D)?G2FHBV(C.5I
MPY(6VC*DX5VXJ0;G51C)91U[.I Z_+QJ&.U2QR0 20.I.!GH.\^%8(M];L^M
M5S75WV=3M=C:7=-5[4V^8+:SV[-V7/K=<UOK(3M9(R.)?UQ4$'C<VNSIK4MN
M,1B1V7HPJ0,668-NH#YW(RS*A8D.D8WILR78IU^-MH##OSGKG!'6SSB K,J@
M,K/\+[CA4#]FU0203V''8<G/3*O2VX0F[Z8_<@8.PUIN#:;=3"@.T.5=\N,L
M%(/SJT?B/2Z79KC6)K3)4=);CS ]B)1)+24NH>_&[W%J1#&P4D'*JP(S@AAD
M'X@K#H>\"KJL'!(!&"RD'&05)!SM+#M'<35G- :;TUTL779.L=? QU-C[DML
M_=@G$TZ3)&+C8BD**-V#!:G68J5-G)U;("X=CEX3,<9@"[N/B1(C$8>^ZK26
M%M::9<W%I$JQ>]N+N'?(S/,=@2>)3*[/(T+()FP>BW*@#X6->D\6:[Q!QSHV
MC\0:C++?MP[;?W=U+W>TAAMM/CY[W.DWLT5E!!:VB:G#/)I\1,:F6;1)"TA,
MD,:Y>\W%><5T%>O/OS\>*5QQ2I2_7CW?KSR@?;;Z>E5?P?[W^53%>K/NS\.5
MU0W8?H?TJ6KU(]WZL<47L'T'Z5!Q4TXI3BE=97JS[L_#DKVCZC]:5(Y?I3BE
M.*4YCTIQ2G%*DK^5GZOACBE34^K'NQ\.*5+7Z\>[]>>*5!Q2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*Y3Z\>_'QXI7*_E9^KX8XI4:/5GW_JQQ2N%?+3]7QSQ2IG
M%*<4IRI/M#\?T-*P]U,2VKU"3!>YI^P9VN]/M68P[KO5%)'AO+-S"5FPD0<2
MP;ENAL<7)^#LKHMPQ&U[0VJ@@ /D1AEILMKF*G0X.1($B0IMW. -SL3@%L$A
M%! ^'.-[[LX)55Z&K*%Y,.6VID[47&2 < NQR>N"=JA< @$DYK"+3=M"70CO
MCK,NQ4<-';-M]AA5&P&Y;$2#5NGG4I$A4*'&1*EKPR)'GG11[8Q1++R(\TA;
M$R'L.N,LN9RN)A.+C3.&;1'E;3K>$2P0JS-<:QJ")<W3;5&Z22)9(;),@LBV
M[ 8#,*N< +:IIVM<;:A+# NLW5RT%W<ND:6G#FD22V=@A=SMABF:*YU&4A@L
MC7:,V2BFK1;KNFVMIZ(D;<,:KA4SHY+V+7T,G9[0:E0]S6&AV>X!1,;;P>C)
M%$*^#UO#E$!I(D'NTAT[9Z(\2(^3:_'D1IK6ST[AVTLKEK4:D\_$L=O=R16U
MM$K:=#=06\DATZ6Z+K+->2*CQI);!88+H(F^<@J=%K/'5YJULEU^QTM>"I[S
M3X;C4+V9H]8GLKF\AB36+>QY4EO;Z=%(\<TD5Z7N+JP,DG+M=RLM[#K]SU?)
MU+H_3V -DVMO>]7QR!<]IO9@T\4]#&']GWRSGA]0C"I!%4> S*CUJG5U ER=
M^(N67CMP21.1S^EV-MJ[ZA?ZB\MOI^E6ELTL%B US('DBLK6&%K@R)&"Q#3W
M$PD"8PL;%T5>QXBU>]X8M])TO1XH;[5]?U&]6"YU,LMC$ZQSZG?75S%9B%Y2
M$W):V5L8#)G+3J(I'?S]-'(56V;9=;;/I@;6N^#<.5;(RZO8CQG4>Z*M-EY*
M$=E:/?*RLBDPBQ*6HK=P,.!"M(\Q(\>L_E?+C9EZYK>FNME!J.G7;ZEH3&.-
M9GCB6\L90FV&TU+E EBL0"V=QO:VEB^&#EG,0M<+:Y%+JMYHVN:8FA<7PF=Y
MK,27)LM1B$F;N]T9;HCE;I\MJ=ERX[V"?XKSG8$YT@=W\U5MH_=]([*9A&BN
ME0-,*5MUR&S)EAJG?YEADS24XQAG"F1CMJ"+K<(?,E>#;FKK<B*VYX1C#:_+
M.(N>AAE 8PA&4D#*I(6R2QQA=R[0I.,[3WC!^UO8))I$R:KI\DD$>KO=1W"Q
MR,BS7=BL"HB0!B&E%M-SWE5<E!.CD8)(QT[BQJ_:<SJVKM_J0\Q$UW4J];XF
MS#R&9#(&4-,5J?##5F5,RE$2<2EVAVOF(HG#JI+;8=PNEG+(U:L:O0%N9=06
M5 W)C63GOU";60A$\"Q?8P7.=JE\8%>C^W"YT.PX#N=.OI+<ZM?7-BVC6FY3
M<K+#=Q27%XD8)DCACLUN8'G*A"TZV^[=, ?K)[GG:JO$U>9(DK '&3^H;J5Z
MHK[K 3/GQHA*X5X'L(F&5* Q7UMN%%M@Z\P<=:AX>=\DO9)H2N"V[(1[WK\;
M136%J5._3]#T:UN.AQ'/[C%+(A/7&UYBASC# K@'I7Y8\.2I<IK6H(1R=5XI
MXDO;4Y_Q;;]J3V\,B@]TD5NL@QT*MN&5()M08[FY?)UV/V&%M@%%KA'=&W>H
M(;55C2RFH.WMI[1O)!R\*FI7A6"(?24^E:W@Q66,,LSV[H0\*\P5@>+ZX7:[
M0I0Y$<<1;IG9&BC;]#(&?.<XVCIBMR;=BQ.\8YC2;>OVV9OBSXB,A1CL.[K@
MU<B#TA]220),*_U(6,43C ]EQ:U; 6R-PL)R:L=2>":MDD*$W8(%/#A]127V
M8L<, 0F%<D"X]KL;"[-,=3%H,\6X$1 C*%E9$/0-E_CP6)D [3U7)4' R:A#
M)C!D/0-@AG&25PF5!V@(>X=#C)ZU9V=TG]81W:L&LVF\VTUJ!0!F;%G2=YV\
M_1*F41MJY;$CUTP#M1N?>MPS@5>D52D!K+<:] E]L2!8<'X+%9A5B17SH!&2
MJJ'SC'+ =ARU3(( 6,$@L0K'J2,'<6J@Q3%@"Q*8_P#I&*J=Y;!#99\#"@L
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M.1I7JTZX  V['Y%,70]<$*WTGWZ?'F5@;:-F6 Z&L9:X:LMLR2%'[5??'U;
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MH::;1E;CCBDH;;0E/?*6M:LX2E*<8SE2E9QC&,9SG.,< $G &2>@ [2?"H)
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M;GJ;MVOJ-Z$*]IHEK?6MZUR"K4FJ]1Y6CU[7=1WM7;?!EWCH#.ZOH([<IHJ
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M &3T.OU-TCL+IY);N!%B)::Q0O=Q@$?% JQS$OX_NVPNXG !(^:+^V+Z=?\
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M8%BMIPDK3EYF5'M9[W]]%*5EMWN6:1$YC$W&HO3)W1G9UA;MT _L%JP.Z5V
M>#W:Q[R1'EEM<:]A5J1<M=1+9YWS'!Q&!%N]6\HZX.SP[@^-8QLH\/&CIB)2
MJ)=5X<M8N2T=N8Q>VZ/!%8Y5+F=I!#<-%R0&5C!+LN45]QB949V7!F+1.*KV
M43QRW0E.GW4D=S-J.&>TM5B:XM!/SVVLJW$.ZTD="@E5I41&W&L(FJ>Z(Z&O
MMP-Z[+;5ML'1=VK^X[60DS9Q"G3=HC*'5]]V [(U]>"#\+9MDI04M!MML*P
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MC2A)!'+/)=74V[V'TR:6&[.+;F%58B(VB>2XV;N8NZ7F"3+LN-893%*L,61
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M+#ENOUJL06@A-Q^6I2D8-]-;6UFFEV<RW.9A<WUV@(BFG52D4,&[#-! K/\
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MDI*K<X65O8[07F<"/DVZ-@@MS"QW["%&+2%]GHSZOA^7'TX_KZ^W'.B5@?\
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M+L1\C)M6*MX0M9%ODXKP*^;M2,&$'JH.6&601I&<D( '(7HP4!<]!TZXYMF
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M)'GY8Q4E)S,)-$%Y;JQ3F._14)&=FSO7)PKJ>P /D D "IHY-V]"N_EJG5F
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M6FP^(\_2H%4<IG..R3 [.SYW)';Z\_-XMGX\<]/!OR'K38?$>?I7'F,4^:5
M^TD8_P#ZV>.>G@WY#UIL/B//TIYBE/:H'Y\C]VXYZ>#?D/6FP^(\_2N/,8K[
M2/\ M)/[KQST\&_(>M-A\1Y^E/,8K[2/^TD_NO'/3P;\AZTV'Q'GZ4\QBOM(
M_P"TD_NO'/3P;\AZTV'Q'GZ4\QBOM(_[23^Z\<]/!OR'K38?$>?I3S&*^TC_
M +23^Z\<]/!OR'K38?$>?I3S&*^TC_M)/[KQST\&_(>M-A\1Y^E/,8K[2/\
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8Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g773514g25h63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g25h63.jpg
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MUC1YEK+4U2,E)C)!5)29TMA10E5AL?#_Q  = 0$  @(# 0$
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M33HH9K+& I:P[2 +,"L@5LU>%R792!WI& 2<Y2%U%[,5"(OUQ4&X$E 6<'<
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MB(Q$8B,1&(C$3C#04/) Q:.R(4-/1\^,?A3H,PR;$Q!D.5:JL28HJ.>)+,R
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M19P,9MG!55(@=.$>5R*KE?9 T7?=*;=$WJR\/999@V.[XZ;F+8Y <LDXY #
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MQHA$C$--<-CJ.N8[, 1)RUF+43H8Y.J_9NUGB;KC[;:,^/YB:5]:,68[V?\
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M[L_T9ZW]F@G7K7T]4,1IN44A&81#*8D=9 8XU9RJB(7-3KMXG+:IFY-T0?2
MN^==K:)HH\<*:2X;<ZYUO$GECH#S/7/ACT$>F;7_ *A>8_YP7W]_O"HG_P#7
M7$9'H'R_EC^H7F/^<%]_?[PJ)_\ UUQ&1Z!\OY8_J%YC_G!??W^\*B?_ -=<
M1D>@?+^6/ZA>8_YP7W]_O"HG_P#77$9'H'R_EG 2SQ5.0L6DIEG\@GOG;L2
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MJUEKM>I:W958L.JXWH]9Q#A6MT>@U1T6KU%6RG4AG7NVWJS O6#8BVHK5,Z
MNBN64%@!-?\ @VC;G\Z^:XA5E]V=Q:]AAB!]T[D*!8[(&0T62)*N14;'GY.U
M8'S#(0WZ^A%R28L]MMN.QK-OP-8LM]=AV\XYP;M%VDUG%> \+/">'W5Z=$T[
M54:=[+:J@ENILT^E>S3TO<P\Y*K'#;>]=C98\XW9KAW$.%<(T^BXGK/9VKK:
MTM:'LM5$=R4J2VX+;8J+T9U4C.Q5"*LF/GCIWT8B,1&(D 'WYTV+_H 3S^<5
M7&)/@?='S-)_XD1B(Q$8B,1&(C$1B(Q$IR^3"\IY2MW^47-;^@YQ2YB21NZ
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MJ]2TLBD6$%@!+CC?77/U78<ZR'%QZOT\[^E!^Q;+ZY^KUM/7/7.]YU8, PR
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M^:0]ZP)R><6&.'/I@BRG_$6</XYV0@3P$3,R.-)(7()\? >H D_(.7P_#7L
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MZH^IT^U_:K[\X3]!KIJ;RD?9G"/O;7?2Z6=;'/I":XC$1B)WM_A;_-J^<_\
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MUWOC:G>NE.^^^NWTW'>*Z.BO3:?4K734&"(=-I7(#,SGS[*'<Y9B?.8XS@8
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M8V=W9-C4\\W^YWLD5M2\;9L\"U(LYGXY=++06%SR8R&(58/>NC+SI>/UN&C
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M)E%@Q"5U?&K7MVE3L-LB25XD+4%3"B:]EI)FJ$D(=(A.61*RX*K&5>&SDV)
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M ,\XR/2/C$8/H/Q&/UQ[X\O\O+QC^^BH_P#YYQD>D?&(P?0?B,E7$)C$;!C
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g773514g26o17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g26o17.jpg
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M ?_$ !X  0$  @,  P$            )!P@%!@H! @0#_\0 4!   00" @$
M PD*"P4&!P  !0,$!@<""  !"1,4%1$2%A<9-UBWUB$X.5EX>9.7F-4*&!HU
M5%=V=Y6SMC$V=;*U)C)15I32(B5!4F&A\/_$ !@! 0$! 0$
M   " 0,$_\0 -1$  @(! 00) P0" P #      $"$2$Q$D%1<0,B88&1H;'1
M\!-2P3)"<I)BX8*B\3/"TO_:  P# 0 "$0,1 #\ ]_' ' ' ' ' ' ' ' '
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M%LMY345++65B\)6EG#;SP5GHZX.8X X X X X X X X X X X X X X X X
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MH>/668LET&JRB.0RW56ZNZW6:!>9WYA-8?SCNAOU^1W@J&LOX3]&5[X(' '
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MB*XS!E>PY(:,(*HK++M.ET7+5TY(#,^T<NNQ'AY\/GD1'I9J+BJ:EV)ON_\
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M2&6./2G8YM5O3Y7^4C;3@P< < D)YG?F$UA_..Z&_7Y'>"X:R_A/T97O@@<
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MDE&33BFDHI--WGL[/E(Z?Y*?YOT[_+:I7_(DW-EH^3]"(ZKFO4]*W.!W' '
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M_@_'SC;^_P#%-??^2[.<^DW=_P"#IT>_N_)Z7N<SH. 1:\+?^Z.\7Y>]U_\
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M.GT6RF<N26?%C8L(0)-Q::3%-P_R?*N6;+2)-5%+*BFKSEMMO5+'#!6C@D<
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M:>J;7@9*X,' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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,!P!P!P!P!P!P#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g773514g28x11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g28x11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2>J4&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
MEP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='
M!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F
M=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;V
MP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $
M)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M      1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $
M)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M   %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M!09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M          5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%
MD            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F
M]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%
M)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30
M/M       0 2P    !  (!+     $  CA"24T$)@      #@
M _@   .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M    D           $ .$))32<0       *  $          CA"24T#]0
M  2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0
M!:    !@       0 U     0 M    !@       3A"24T#^       <   __
M___________________________P/H     /________________________
M____\#Z     #_____________________________ ^@     __________
M___________________P/H   X0DE-! @      !     !   "0    D
M  .$))300>       $     #A"24T$&@     #-0    8              B
M,   6R          $                          0             %L@
M   B,                      0                         0     0
M       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M   B,     4F=H=&QO;F<   6R    !G-L:6-E<U9L3',    !3V)J8P
M$       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P24
M1L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=7
M1O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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MT$*       #     (_\        #A"24T$$0       0$ .$))3004
M $    !3A"24T$#      =(     $   "@    /    >   '"    =!  8
M'_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:(
M?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="               !
M#VU@ !     -,M2% @(
M                      $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'
M0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&
M)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
M  AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@
M0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'
M0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86
MYY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G
M-21T(@245#-C$Y-C8M,BXQ
M                            !865H@        \U$  0    $6S%A96B
M                      6%E:(        &^B   X]0   Y!865H@
M  8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         624
M5#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W
M<N:65C+F-H
M           &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T
M(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C
M$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M            !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:7
M1I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97
M=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M              =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X
M !6%E:(       3 E6 %    !7'^=M96%S          $
M         "CP    )S:6<@     $-25"!C=7)V        !      %  H #P
M 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ (
M$ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \
M#V /L! 0$' 0T!$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8
M,!BP&2 9H!H0&I ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\".
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M:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQJ=:AFY[Z TBL/K;UQZ\8[).S^N]5\_K>$6#_E8:+E&"KDE<D(FIM6'(;)D
M$*F'$=PR7/(]VQ5AL.7(ERP W[7J]0:ONQ%&.M*5(*_VJS/HHI'QH&K0U#UO
MK ?]1??![EL3HF6S%#JOL:;5$V,3%9E1.5CQUWR:/CE2(WC^*6=T 1!)AVJ(
MH:,6CAY)20F2DES9WVU(LWV=G,2MP"K.4@!R6!##Z7O[DQ2?[8OU;_=CA_=E
MM3/<U[S^L]+0SRN'TWIATT.O3=A]CVG:<CC,..3S-B<;270P&JHME?RO-IEH
M+5JL45FJ6X5UX7!RRLF=*K-'D24E*LF=:2/-N',HM9W*@X($6,5,5Y*#AU ^
M2H3IZPH9C+0Y,DW_ .8]V2P2034/U9[7KGO%Z=.U_J"CK]G]YT@RQX9C$DJO
M2L)H9:HNNFP\"4VM8:NT\'1<J%6$3D(A$ )2=M,O"E>4H2D@V4X)RT(8&]B6
M(8Z7$6Y4V>JJPV9+A@Z05520X!8,S%Z:@Q$'5/W(]=]=WS/XW&=0=L7BW%5N
M8RJFS2$ZM6]56^LE*AK/L&?>T%-GAJ@."[>.R9]9:<)AV"A(078@$D[WKTH_
M\6U3YH405EWJ U*D,&%:CX$1&>3]UGN(; IPO4W:F"@)L6FMO4N:J@FQY8>U
M=0C,0D4KD3[")IR"Y*(B?6;)P.%F(<X:50D42H*8 N]:E]:[7O2F?,J533\B
M">3  /?4MS,8V%]UWN,R@W3/JEMU9(5IK#Y/A<ILG1.TB])_&*9@Y0]4@3($
M6$B3YDXGU6>'X/.D##R@&4]#5@X-R=[-TBE<^<&:87Y;5]CI77?:[SVTYS/;
M+T&Z79[:,T_8M@R>KU;.6SEGQR_)VR=8$[395_3DC@1CD/QF(B8^O7*8I*48
MB:E "4I4P L P[^\;&0HKDRU*+E202=R8CKJ+DB':\S6@"X5; R/MB B(K5Y
M[>>9@SG@BB9XF/N)CCB?6*3>K\N@=CU;^"'B^ _>Y ^I@0]]Z8:)U!IY>EG,
M36M!E*KU9(!"0>XVQ*S9YQ_.>V9"16(E,%'='T//JKY]][=(H).@I4WI75W<
M-IKR#17#O7Z66HY:OEJ&C;_G=+^9'=B59'&KV/&U'F2G'%A+[==T)L$$PP5M
M!C*\D'<)3$^D2#N"*"^CV^.C/S:(J1^D?L%!)BWW"WF';0X;=;%Z)25C28A/
M=$ F[G;4HF6R4)"([A&09W3/UZ0!V&I?E7ZF_P!XV>#?U6]G.1H])WQFMXQ%
MZD):[EQQ:D!),<,0JS?6%@%"IR28\V@Z4C(<*8$=GI#<#3X\JFG=8.-6R?NV
MLZEDZU5.0VBN"R9CKV2;*DN*.;;R<NJ(->J>%B<+ 6P,&4#/WZ0&Q:UN7WML
M/>L%7H749NSXQ=*^24YJI,)MUX,8B9);5BY<\QWJX$)_&/J8GF(Y^X(ZFY;?
MDVOO7G$@LPU-'M6[\K=&AF;-U4PNG[MBM:S06U6MH<BKC6UJSGK$O$,1PP1G
ML5#B@3^I.2*)[9CB9?'OI3\<H@Z_ACKJ3SO:_LX+F9IXV_2<R_V4#D'6KJR$
MQMN>3(6HE?;5D(B?<1+"!G@2F"F(]3$:Z:4#O[EPX=]+ESK&_OTM5V=!IN8I
M%NK,Q'DD((O*7X"R9D2F!\93$S \C,P7(\00PQ&K^P_BO-VY1+@L E@P+@[O
MM;\ZV>)L=J%[5LU 4G.3B3NPE;ZA@=1&/812JE8-CV/.!@94!&,E#!&(B B.
M WK70]_Q$:7?0]2=W% ^EMZ1/][7:N;JJ9(L6:P)9@#HE=N;"Y4PIKG$A(RK
M^F1S!'WESQ_F8!V#L2#6M'T;70"FE-*B-22*4:QL1R<:^[O%3O45'6?I5[G'
M'7U+9,CTUSZL0>H5=;!=W$5\Y52NLT,K_4KU:E-S7,>];8$X\0DNM)LEAS0L
M?A @V-#KRZ;_ $(BR;3MKVJYCJ?[L%8LA5KC&14@_B%5L]L3*6I6$R12,!VS
MQ$1Q/$SSSZ;L?OM]OS!ZV%-#]7'O>[;"'S*J6R9&G=[P5DJLSY@\YKB8)?':
M9!$P\I#CAG$S']L]LQZAR"S&U&'QU.XO_E0@'WK\B.W^SKQ7SZ=,\<-Q[5@M
ML"3)B9A?=!DONG[D?PCMF?N8B.?\QZ.6VU-/<BK O6H(TZQ.SZ\_PY#=(V J
MI&1G91$L2"NR9.2"2B8CF8YXGF9Y^HG_ /YZEM;4%+5&Y'P:HZPWU^?U_P Q
MN(S"_$M3;"ZW=,04UR'F1 H[!(2[9^X$1XG^?Y_B>/3K[G;G6W2OO>(C2WK0
M?N FQC7JA1&+&C^'$1!0KN&9$>>V8CCB/O[GU2JX)-&MJ344'O%0J"&J3?0"
MAJ?:&[D,DN40^'-'O[R@8@.T?&0QV1$3SVSW1S_W+G_')B;L=".NMZ6#4^#T
M.PH"+,>E]*W+UY6$:2YEG%/E!9QXT\N@6^.?!S/=V\1,$4SQ/;S]1_/U_%3>
M]:/7I7EW6]&9W;9F!9P2'-#]G&@$,[?\!A>H>NV,&UD+-)0^LX8;%ZG9#\(<
MEB6I<(A)C+&+=$=G\<_7, ,36YH-M3<_3Z.TD@@, "!KJY T&FNVNYCC6&;K
MJ.RA@;50,]KTCRG)TC?8MU&"0"A%Y;WDQ214M9^00+NGNF3GF.ZJ(%+4K]!I
MSIK6AB:&9&SX;+60==M5LBD8=W]PP'=! N>(@)B>/OGB?\3S]0VFX+EN@N-_
MMRA4W%K5TJ]![&NI]XQJ>?DC>KEHR(IF2.1B)B6*.&<1/T/?/CCZ_NB8GZ^O
M1K<OHUNEOA $UUV)Z[G4:FM-R3&'MJ:KZ-<29907EFP5FKP4@<E+))T2P(!8
M_<<S,_41QQ''H'J^_9YO[-:! HQ!)!Z'J-6/4,7UCT3N6+QM:&V[)E6KH4HC
M\<F,R[Q$#. F3YF8F)F(D)F/Q*>)X$7YW^GTMS@DD,[L'9PS-;XZVLUR\233
MV?%64(R5;*.FOX!(&&95TQ',1(_<<27/UP4#/\_YY]1;4T/5]VN=7J]M!6)!
M%:[O[?3\1DVLZ@AK()ZR7)$Q(>9<,Y@R,>X"*"F.#@9'[F)'B8XF/0U&O07N
MW?QNS2+Z5W._/O;E#AQ6=3\+ML<UUFBU)<=I*\D00B4<%)#^'/,<<<_Q_'/J
M7WH>]=?:(AW4LF@I: 6 E;&!"^V#G@6<&+1A8$?:7$BSD?HXXYX]2XWA!,C_
M !'_ &C_ ,>D(_?2$+TA"](0O2$+TA"](0O2$<TOO%'R>YWJY#3.%+VA+8[8
M[CGMP^,$U@N.V#[PDH[S+MB>V(F2B/75\-!5A)0! RDCKJ1R?<M'R;XX0E7B
M[C^8M_QJ&_\ \LE_@SZ7WO *JB_%!-6<F;1GXX)B1GQ,$?)!*#DV,.(+[#M_
MYP,%(^L\H%'(%6:PIK>K,P^!8VYA"&4"*D6&I!+<Q04L*%XE7I?D+5?;DA\>
M)2^L]C96Z6-FJW@(<$!!1$L@(XC^I'<11V<!'-J>'E3FO+DJF5!;TE6E&MI2
M[\]GPZ8H8Z5120N9D(!']P2"0KD#V:0: =9M,_\ 5+7];&P Y#5<'A:VQ&9
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M6+L'%2$?'M6IBXJJ#F]K)DFKY*2/@BB9B8D5YW^=@1J&]C</$M[KU.RFV8O
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MF(GO>#/?L=WW^4'KT1]\O2_J7LF/Z<[3E:> W>^@K^.2YX'C,F"Y"Q9IKO\
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ML7C57 P8R0'R&1',?<Q'Y?4S,>C,*::=U^ON8A_=^MJ"Q)MK9NM[&Q^Q&?\
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M&/M.N#OENYLNQ7#-UE]BY+[=)59KB.;$JQI0%:A5GQKK )^*""!'U3P_&8?
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MZ>:EE2%^6HA)#*0X9R2SZN=0U:P.^NY6[D^M'5+'9&N59^*UC2\3D:;Q(&U
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M]",;(1B)F%\T#SR"@ASF&9('I3D-"3MJ:\1Q_P /S.%3/TDXI$]"EYI"S_4
M2P4%!0!<.U4L'+!J0]-!ZJ87!W[L9]MW;*+4/O47)M%8"V!G*T5K0F)_)53K
MO5!5+P":4C7BOWB)D/I'#^+HD3!E,Q2%D*))<)!% 0:$,SDI>S%X\\Q_#?-1
M,\HIEJY_M%G-&(+@@D,')?+2#GZ2^X_3=.VZC9TM+[FL9-TXC,8G)U$X/"88
MAM2JT@ZEEKJ0 =BXNPN:H5"*9\DA)6/OI9>(1C F8!8E%@A+ @L 7!KR%=-8
MT2L),EI\N:4E8.=Y:BHJ21R >VI+,.D%!O>'V7%[-BMHZ0U+ZHZBY2CA\NO&
M4B3AZKW/8B+=U55U@876HU1.;X,";*;*2[9%8Q%V8HH7*(_N6$K%FJ 5*Y<]
M00='BA.3(M*_[0%!B[!Z@$@;LVF4OJ8!;KO=?AKF#QENLY;KN-8VDJNA'<)^
M2PY9!7$Q"RI D#2KA+$%46<M&.[B-\E>8H(;U LU=B6/L"U^1I&NFA($TG<
MMR =Z4O1ZO[B!CFU;Q\B&/8"UU4VH\U$VK-[R&+3_)1?-ARU2J#-P^;EQOMJ
MY\9,YRDT-F8,%:FNFSAWY$VC7$.* \Q0@5%Z"U.IT:D"5[MZ+-HTGIEAJ3%3
MD<IULTC,5\7E:;1Q1GIV;C8&TK<S9$WJ>K'&NL#!84^871'>OM9;XRE$[#2D
M'U!:P6%6*0 7ZI-1N#4@1G\-=,V:I0%)) +5)4*>]A=@=V:.NSV.VK%WVD]!
MK=O$U,%9L:'1<[#T7V+53'&=JY,U$V;2TV7BJ)B":]2V&?<1#$SZYA24I44H
M#)%@Y+#J:_&,IWUS<V ?V!(^<"_UZR34=7MG@IF15?K @N('L+]NHD(A]<R8
MD93!Q]QW3$3_ (]4P]G[M$.SDJRR,.^3)Q+4*RF.T1(^X9EI_D1"OR=H#(P
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MA,R9BL9C4A:YZE)43AY  .0I2K)FS%V20Q<F,GQ!AUXE4_BRI_\ 47FPDJ0
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M> W'+/$D&\L,8"2](#X]GF=7^D'EBZT]F-R5>^A])U3N7*K"S3:!TP2F+8/
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MU">6BN3+N@X+B>X?YXDN8F9@8F/^L>H"2#?Y"K58MON3[&*R01;V<TV:HML
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MWE74"%,YD6J9//* -!I\0/I2F_2 >R/Z8/MGZ<YJC6JXC8-TR^VVQ7;?O/4
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MOJ>(SF3!U-6\:K6RL+O7>]H75YI+,&U=&2[/ 'QF&AW>D9XEHRB8,3 _I_\
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MN&ELM5ZXLOTE6J_EFXRJ?P$ 3!K^*S;?/"F][%B0S_Q%Q/\ ,3Z1+=+@WY[
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M;2M4OVQE]\JJ4U<]BX*(FD!2#&"\"!K!9!>D1OWMKH:T=OA6)1#7:&<"QE,
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M-=^8=K/4?%[[U>)JZ;]<=&ZVZU4S.IYBLQEE2S5CVO6%H;-4P)ZE)(Q^6M+
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M5Y&L[-JZTZABN17;-*0KRNL7<H&&P(YE7,]2)$R3AL(A *,9ADRD8@%T(5*
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MI#PVW&;_ *MB=P#6*PXG$9,15G#;7AA7#LDEKK-!C_\ 9EUVH-TSS+B>UL+
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M95+OB*3:N+417\S;1R8H43BY"(F<Q*%+1AL00%RO,*@[^I2" 0!IFT!8!G8
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M4!DD FYJ"U7<#2DK>W?'-NIPUNI(57555K-4S;("Q E!C"V1#"GN(4( 6?<
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MLP-8%([9:%Z($28 <Q@B%RE*/JS+(%6 #.#5G<T>]6!H\,?)6B8A,L$%" 2
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MPC,3/'',?Q$SZ4NY!^/N[C6((-J$?#Y5&T>RM*J*$@[*Y@;3;(L$F#!',SP
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MI.&"9G',<2(3V\P'$?427,3,S$_Q'JF)8UJ>7=G?V(9]8Q;^B?-2]$NKP#0
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M#5R7>+*.D>MY?3^FNG:SG_#&9P^'55R45[$VDQ:\K6,A5B8B7!'DB(/B.?\
G[>N=QDU,_%3IR'RS%Y@X8LP%M+1T&'2M$B6B8V=*64Q<.YL=8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g773514g28y21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g28y21.jpg
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M ?_$ !X  0 " P$  P$            '" 4&"00! PH"_\0 -Q   00# 0
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M-[3(@)+W-+>?^O8URY.PA57 -VV$:*@9!_KD.V'X>OT8&W<-GC##YB\6U?\
M2D-O>]A74>:!%COOY>_NM^@OQL>8RJHM_.55XY%[+M [&Z3-AG# MH>J^,N*
MD@AFTY9J3( U4&R5W6!(H$G'(*VG$CP)AI26;BLAA,F=@BCH)X\K/ON:]-O/
MY[A>*Q/CE\A1N,'9G%SNQ"*5Y;];P^SI!(?I-&+"KIM,+ A1&THJUC3J3F26
MP\S7!UN-A<B%Q>;$]7$??YCB(B5Q@B7)T.\N;^8%UY<?>Q5P8/\ $'HV<]'1
MOE5 ;.(W<4EKR/V0A'Y:VA@A=F*D<&S8;-BH+3F[R3EU&D<U43+R2*QZ0UX)
MD2*\0?35&5(*A]"BC5]OO[\_T7Q">I;0.]N37E@_5L)1B8*N9)8K:90RR7TP
MEL,$##T&!0)2ZHUB&"XU!'=[?N&;EZOC;*9G)5@)54C*%Q/V#[5V+)6UWWJB
M/G6_ _3E.B.X8#7O,\GZ!H205ET2D'M&N:;:Z0:>ZS./I3B=VO"*O*#'&:F%
MV1+Y))H1B98/O:M@45DUGRA4>E%HU&W!TPQUP4AI)H[;$[[;43WKRY.W<FE!
MU*_%&A,K#0LU=,='5:VL/G^G+MBVP,XZF:&[^>R"VHA-X.^4_%!WS,K CU6)
MKNM2HH,800EK0!(8^!E4<D U$G2=ZWHD=NW!Y[_975KQ554!7#W+(2ZM^@AE
M4-&UGYF!VQ47F91.5X</LJ4"7(.2V:'JIS)UJI"6;(1+X@R.6*'A3&:EDR)+
M9^=<*D7NZY39JNW' N@;J^:OM?[+ ./A[<>JP\-!&---(S&X_.[&L@2A!9E8
MM?%&LHMYR[<6AC>20>7QZ2NXS/4WFXV401X7<08L :BHVZCF\?"AQC$EGGGW
M /IW[^O*]T^X)Y.LT$XC4PJG+H.\G-IV*]0#3NRXBY>R>[Q!&/V]]Z2B$R!$
MWD<L8&6(!Y9"'+Q6$EQJ^&3F/;-T4$TB D?MP#QN.?+L>>W"W>N^3N?*HFS6
MQJ_KEG'ILS9V"P;G]#LJ(N=&EJ*56K/T]D2YT@S5VDBE)5=NY56;*+-=HFWR
M.49_D3/Y$EDBKVV^EU^Y47%_AS<7GCUER,Q2 U^]MN/VM&IHP7EUAYB_X^]6
MJK.Z'41A6LNUAU;2&U4'#K]_RZMP43E<J6>/7)DT[<O72RQ.H^?%?3CY=E]U
ME?#OX\MTA(2T]J'<D2EIF;G)4\%6':D27DCNR(E5<'G#,[O#YP!_*Q^1QRD*
ME;OXJ^PO&,$8!') W$(R%G^5W)9&U^7TLC]S\UAKC^'CSO:,!G,5"QEM 9-,
M!UT-FL[::OI2] D.@[PA_1]NE&P.3E'HA1U,;F@<7FN[UKH-/Q,@,06K8]!7
MC=B]9DZCY^7T%#Y#9:C0'PQN>:5#0IP:3D=A67$)S.K"6LC:63V%+R,S.[7<
MW*N'E4=C,U383^%QV<J,S48C-M.K)U8F6&),]?$92_*&GI27$^7 '%[  ;7=
M';>J5HI!S%14IM!O<YZOV1&S6IN!R-O*MR\C1<IFJQC%KPR"OL,&QA$1MO'X
MS>%J"D4MA^S=VG+G*Y%%X['AG XHLU5[;_6K^=!:Z?XXYNDM)5ESP3K?1.J*
M6;1%M4(@-*YQ&Y)66\#!JQF)$H)8\<DPJRXL>#1UP\!)20-+V9]P(($Q[TDY
M:DWZ3DEFR;W-WZWS?FHA*?#!X?+!HZ 6ILBQ%QN-S:(MTX_;MWQ9T=CEE2A2
M:V(+GI*-60))V:E.98JJ?EJMBO)2YD))11<JNZSOMC).H_WX';]%OK+@SDD;
M:8NXQU."Q\R#$A!T:R82.:LZY;28!!$:P!S'_1IM)4J?6G(>O&[:&C)PO!59
M<QC[9L.;&DT&R&J9.HU5[<?I=UYK[Y1PMRK-+;UN^3U4D5G^7]?EG.RDQL%O
M"B9:J5]'=:E3=5,Y8WJL\4@KY-(E%B)J&/W@4HB@48KHD$$7.A+-5]_/E9"L
M^*^9J>M$G<E=5GJ GQ+]\_;O%)?/3<<BW^ITB:RVQ\UU 9#*2L J[,\DK)J:
MF&:XC$6S(R".%R^7>VV_ZB62*_L+/N>3Z632P<)XAHR+%X&=,QMI-"U+W9T!
M=U!$SB;I%[4!GI4U)Y'9@<-AD_28&1:YB;RW0*F:'N$@8AV#8CVJ3V,C2OB6
M=_4 'U JOV6/COP\N.X>"IZ,0VG$(8 H;$@1K(7#9O9,3:C!<JL!G:TAC4BU
MCTQ&[V%#"UD#A\T=0BQ-Y7$,R!BS(:!-%6R.="=1-V2;YO?M5[]ZVM9 7P/R
M4(3?M6]1H.Q3^>@+)3C9R9V))(B$E,8/RB5!-8C#I#+BD6A,7:R2:RLXK H>
M'!P-\3/$'A"-.EE<;:DL_+_\_;;VV7LAO#'+T!FM96#%ZY(M9)3008!K#!&R
M;5D,=AS<+ GE5B"8N%2.;EH7M*AE:/W<"8S9W'W,Q;1!;,?2.ZB]4VVI.H\7
MSSYG>]SR=]ZOG?L%GJ\Y Y_JFYK&Z @,2D *U+;*%CEC&LVA:Y4'*31I,0W>
MEWT"-S<E7R!--B!#"AKYC%FCD(%&M @95@)2PR\0DD $[#CT6_6C1E57+ WM
M:6#$6Y*(/38&3ZLPQ(W"RHN518\.E$9ED;E,))QV5Q26Q^1"1ID+*(R;$GQA
M!FBY9D45-<YR4*O\3X#YUBLG=DTX8.(1-A65:U- *_>I.W(* Q>NSMG2M=XT
M(/B#XZ?E4UE%KR0M,I.>(NB1O=F$W>[KD6Q H3*22?F3^IJ_V5V?%"PLDDD>
MAT?-RR6G!,9B\:%/SDAD1X@T$A 886V4>$BI8H^509#QS!HBJY=O'2R3=N@G
MNJJIKIKG."+U"2PP\*&' K]J4#F1[(L))L5TW+$B,(MDWC!^S<I;;).&KQJL
MDX;KI[;)JHJ:*:;9UVQGQ%D/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$
M3Q$\1/$3Q%'MLUP!M^LYW5\F;,G(2=1<Q&W>2 MD9;L]R3-5%D6T&D-=VCEX
M%?Y;%QWU?TY1(,6KA)5%9)-70I!HWY*A=C4<%I"T^"S,2FMPZ'B%Y1:G):EF
M\;JTKJ61"+\?WJU09O*05L-U30])V0KZ+R%9,;"&ZF) .P:V<*%G#U^Z*;OJ
MXXO@?\AWY^OHNFWBJGB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(J
M<A>]>99%<^:$"RJ9OK 2F1>OW:N:;N1E!6,N$&)[&OQ3JT",#9US](Q+:IM6
M%1HNA*%P<DF]93R&AB;R31HB+2*:-7[=QW].?XL7R%/ENVO$Z3@12Q)IL4V"
MCB45 MV0,:L8.G)-.Y:#@4(C ,8AG39X:E<TDT?C0A%55LUR1*MMGKMFSU7=
M(D LU][;D_H%2RU[KK&Z3/PV9M7<M&&A,\Z8CT\ ,MUM&$B_;<FXZZ<-#')2
M,O=D3@9S]B39_>L2;%L[8.%?MG:22^,Z>)5=0\A7_L%T=\4)XB>(GB*);5OJ
ME:-;B75QVI ZR0/:FMP>TUDPJ/[&-8Z+5,F_QB9!R@J^R-')?6<ZMM%=M5%F
MC77&SM\R07]72]"UG6W2MTC2\[4G0&$3C"QI<@0_B)1#!XIC:X1^)(>EI<0*
M#W&F,>YN7)S<3##3EY,..']?1XTC8^KPVE[^GJ(OI:+->8') /OAMSU'8@*2
MRB!V; YA&8:2*")9(HY*@I<''"(1JF^+M319D]68#MQS%5-Z[W<N$TT6>^KK
M;?"&?J>IF:/JVGSXV-G:;G8>3F1Q38F/D8LT4^1'.XLA=#$]@DD$CP6,#6DE
MXZ0.K96AR\7(9))!D0RQQ.<R62.1CV1N8+>'N!+6](W-F@-^%D8Y9]=2^OV=
MK1F<Q4W6CX&XDK:>,#@Y:)[ &:2ZSXLH<PXP/;L1VC9U^26<+I:CMVKI-[]!
M1LMHGRR--U#$SWZ7DX65#J4<[<9V!)!(W+$[RT,B$'3XCGR%S?#:UI,@>TLZ
M@YI-H\B"6 9,<T3\=S#()VO:8N@7;NN^D!M'J)(Z2"'405CZJN.J;RB_[UIZ
MPHE944P0="5#T.-LC@] HRU2W=#72S)53[1\@FNW6W:.=4E\-W#9QA/*#A%3
M?KJFCZKHF5^"U?3\O3<KPVRB#,@?!(Z)]ALC0\#K8XM< ]MMZFN;?4T@5QLK
M&S(_&Q9XLB+J+>N)X>T.%6TD$TX6"0:-$'@A;%-9M$*WBAZ=3Z2A8?#HP/6*
MR"2R$@W%AQ ]#].-W+U\ZW312USOOHBEIG;*CAPJDW0T47533VSX6%EZCE08
M.!C39>9E2-BQ\;'C=+--([AK&-!)- DGAK07.(:"1TFFBQXGS3R,BBC:7222
M.#6,:.[G&@/(=R2 +)"S8PF--#AY@.09%A!9DU)"R@UT@^'$ASY#1TR?L'K5
M15L\9/&RJ3AJZ;JJ(.$%-%4M]T]]=L\)(Y(9)(9HWQ2Q/?'+%(QS)(Y&.+7Q
MR,< YCV.!:]C@'-<"" 00KM<U[6O8X.:X!S7-(<US7"PYI%@@@@@@D$&PO;Z
MBE>$H4& QA$T:(L1 <0Q=DRI4F[08#1@U@@HZ?$"#YTHDV9LF;9)5PZ=.%4T
M&Z">ZJN^B>FVV+Q12321PPQOEFE>R***)CI))9)'!K(XV-!<][W$-8QH+G.(
M !) 57.:QKGO<UC&M+G.<0UK6M%N<YQH!H )))  %G986%3:(V/% ,Z@4D#2
M^'2@<B6CTECQ!N4#EQ[C&?IN63UKNHBKKC;7=)73]6%$%TU6Z^B:Z2B>O?-P
MLO3LJ?!S\:;$S,61T61C9$;HIH9&\M>QP!!H@@\.:0YI+2":PS19$3)H)&2Q
M2M#XY&.#FO:>""/KW!L&B"M&>7C!U'CH1#=B]J2!HX68N U8#\2I%B3;J;:+
MB9!+M7#.O8643QHJI]E.9A&5E-$ML(X44V234RKK7Z>_KW\S^EKS?IO.7_\
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MF2-XMKA8(\B"" 6N!#FN <T@@%;)'X^"B8(-%XP'&Q^.1X8Q"@00=F@.$AQ
MQLFS'C!K!KHDV9L635%)NV;()Z)(HIZ)Z:XUUQCV?(R)\N>;*R9I,C(R)7S3
MSS/=)+--*XODDD>XESWO>2YSG$DDDDJ[&,B8R.-C8XXVAC&, :UC6BFM:T4
MT    4 M)DEPU[&2R\;<'=C4N;:)*.(3#19:<S5HBX3PHW>$8I$&)HX(%K8W
M2UP;,,AX1+9=#[DBCJLGMMQ5Z^_OV*TF1)6A;($U%7-;0N%PF2BWP0ZA<WV=
MBE"PM\V49E!!&KX*<TBKL*99N-V^CUW<'W:2>5M2$3WQMJEGMCY$^)/#E8LT
MF/DX\L<\$\+W1RPS1.#XY8WM(<Q['M#FN:000"%62..5CXY6MDCD:6/8X!S7
ML<"'-<""""#1!!!W6O5GR#4-;02-UOJT)RN#Q(?J+ PB0.&K>NF+#"BCK9NM
M6D<9 H'(E\DEW17,@FH"53-P3<;D24H($,8=^T:EJ6?K&=DZEJ>5+FYV7(9<
MC)F=U/D=0 X :QC&AK(XV-;'%&UL<;6L:UHYX^/#B01XV-$R&")O3'&P4&CD
M[FW$N)+G.))<XESB2259MFR9CFC4>/:-F#!DW1:,F3-!)JT:-6Z>J3=LU;(:
M:(MVZ"6FJ:**6FB:2>NNFFNNN,8QA79>GQ%%L0I&I(!.[$LZ%U[%XU/[9=C7
MUC2P2,2;&)8Z$ML-62I-SK\__3K^MPX3;:H)OB"S@H^T<DG+AVIZF7K6K9^#
MI^F9FH963@:4R1FG8LLI=#BME=UO$;3Z_E:7%Q9&&Q,+8FM8,T6'BP33Y$4$
M<<^46NGE:T!\I:*;U'ZD"K<2XVXDJ4O>6M*>(GB+DB]Z^Z:5^(V YD(1>#5K
M1SM<B_16E\AIY*X+ U%BBZ8[>NAKJ\D"DDK>1MV",T*O([6D@LZ'KXS%SH$.
MS<NS<?B]ZK]=OYOZ*U#I)Y.WG0^G/:N.=U?6]>AX)14:D+THY:2FP!\ F=B1
M6E@4EA["T[&!P-FB[DKB&1Z42 #^0'@]'3120G-UTP\=:N-'99VW3V3U5E0
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MGL@D?$O0QPN!@,^C\]D3R1HL2)QV-;.VS!Z(56"E-64C,LT&1<H4U_JKL/\
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M.1,'Z(7\2.6/Z6_#<#M*T+4S\0:+&[6M4FTV7"EGD;D:2V-\;/QNH@1N,6*
M_P 29X;4<+\=[#-XLC8.9U!XRLW'&!F.&'C,R&S-8TQY3G!Q,,%N'5)^4-:+
MMS@\$,Z6E\FT#:KZ[Z;KVV"5>3"J7TYCS8XY@$\:Z-)/'5%MU4LMWR6N$]MV
MSGZ7WPETX;#W;X.Z8/78L6X<*,&_FZ]I;-%UC4-*CU#$U1F#D/@;GX+B_&R
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M:CK6\0@VR+!J13CVR/Y\!HJHHNID<]=H87PB4?I7S_N2K7^(GB)XBQ)]H6(
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M-L2;0%"%W;F$0<19%NSNRH[64)<O@D9<.(95<?EPNMXHOM&(RFM'XL.4;QL
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g773514g32p90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g32p90.jpg
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M+$6[U!&(S&&]UNV'+E0""22V!GPX>\"3H"6$+V[2!>[<N7#[1YNW>/-R2"
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M";M8A1%0*&M)U-PK( ;8 S99<*&("X.<,6R,!<D^&:J6XB80L&)$Y(CY'+$
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MWZ=I[IW@'^8@_P!J6Y?O"Q[*''/X;'S;I/ZA3VLG8C[RC^<G%OT[3W3O /\
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M4Q2HY;ZA5[_6)VEW6 BK34[-&N8B?KTVS1D(J6C79!(NT>-%RG353,'0Q1Z
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M?]P<#HN)B=5[2VEQ'CH.&]GD@]<W^[Z<:144,:V.QBRQ50L<FFT8BP9KJ,V
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M,@NPEH288*>KS%:LT*\(E(U^S0;L#,Y>%DD$';18"G[5&RS==;(6]Q#=1+-
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MMYM$SLX:N'P2!OU2././@L9,'&?3SY GK43>>+2Y+W ST.@GTZ]IG.RE%^H
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M],C(JW$MXIG.%;O!#<K=@0P& 2M-<ZNZ@42@'0#N:6Z5+_QBF(H4X&,(@;H
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MYBLHYF$A[%'.8B>BX^9BGA!3=1THT0?,G!/F!5LY342/VCYE$2]Q# !BB!@
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MC'_(/R5NH_\ WJB;L(X#;J=9]/\ [QCZ_DM=4_A5<4C_ )1MB_LN38/FZ?\
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MU*/KC:0BI-U1$*V+D[4M G'L,R7L51])['G%/3'D$%CK&-G+:!:/J,>J&XU
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M=\.W<@W3Z5I%[HG$>FP.>L5GJFIQ:%?M".BO=64DN.;!C6N+F)P/\8KF2W+
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ME#Q\RSAC\,?Y-5\*M_)^#SX9DMW>M\/-5)]_=U]G$L</T[Q P]GLB?8^CZ"
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M:@^;?9$J"VE:6,;G<G>5)#L[%CD@Y.1R.,#&34MF,3[Y&<W$:QN0JIC:& *
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M7M*'@XIW+M20C>1!Z\-/2#-%<U7UR;9CN4WFV-JS[G&8RI4$)NV*W0DX.2/
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M[1K;4VT^RX<F=H["^AU-]1: JKW=J2;1((;F/+QPR,97::$*\BQ;%9%+/)V
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M62/8.2UI\5>-)673YTHZ:(4S6K*JO$DNP6\,TID" CO20&4*Q)C)&%)\[KN
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M( 3A1@%B.N0I.#@G'0\ZR@AN5/'FP6_3M!A=K5B1N/('7BFV--0+91Z9Y?\
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'*8I3%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g773514g33c68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g33c68.jpg
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MG5.:9V9)SMAA;9X\AUNSB.V'/H&I!MQ"$&D(.L]4CH9B6(D0;PL%/+KN0AE
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M Z-5^:R\//C0(\5;"6:I4!S))@F8(X$^L=RP]^.CXY^@.:^B.2K2NBF0!U[
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MJR4*0X F,HB,AZ(F08XDP2) .8)T*M9[2I;I8@=^.VS*=KO3H25\H7 7FMD
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M=!.9&-9%Z(K$H>U;ZWI!F8<@8=+S0>XFJ8?2/QI\O8)?2>LV;1[^_O\ 8K.
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M_P"BO7OBDZ-[/M*L'\4)XBKX^*'^#?XT_45#_P"3J^*7:GM/M5@_BA/$3Q%
M%(T2C3,GZ2DJ4F5D.W1%_NKV79J"=!>L36<U!3]3YC**^I%_DTEHE4R1W\6W
M2%[[*'5!WX=C4=J]>E,Z=0CUD_:I_P#%">(GB)XB>(GB)XB>(GB)XB>(L*/D
M="1Z1\+]/@Y7,@\ CI*JCC<M*CX&2RP,P:_:-=\M2,/ARR$GFK<TIIH"VA 7
M*SV9;$M8QHS?ZEMV3@I;J,ISTF/7P5<WQ 1:T15A]$G6+'FVH(";D<7VMGEZ
M \9W?QU.*QG;*O #*!G0E:3NRS$5$1Z?19+\HC,E:QLV\FSW&K;$E:+1A8**
M*SN SD<=X.!SST&6><3D,XSE7X>*B>(N)L_8Z94QN]::91=(L5<;.4=<I/G.
MB"C=FIC.^/J.E]'3;=%OM]"RNCA#;33;"R>=B+^\O&FN[E/9TVUW9I:+N],K
MI8W:H*:J;)K.=<[?2@EOJDKMHHKC73;5)3.N<XTVS@B^J:B:R::J2FBJ2NFJ
MB2J>VNZ:B>^N-M%$]]<YUWTWUSC;7;7.==M<XSC.<9QGQ%7[\5G\'_S;_BQ)
M/YP)=XK/](]WL"L%\55\=6S?1PJ[T01U=+I(-UW.J6FKA9!KNX4;(JK8UPHH
MDWW=NMT$]]LZ);N7&R>NN5E,[$7V\1/$3Q%XFP)W7%?1_<O:<RA,(BK]QJ#4
M*6!(04:C[UT0;N=M1&[V1/&0YRX>M&[S;4?LKNHY;H.<X1W325SK\ZE6E1;O
MU:E.DV0-ZH]K&R9($N($D P)G(KEV6'W^)5C;X=97=_7#'530LK:M=5A3:6M
M=4-.@RH\,:Y[0YY;N@N:"9(GN8S*(S- 0Z40V1 I9&2Z.S@1(HR7'G011NFL
MHWW6'%A3AT/>HZ.$5D-E&SA7359)1+.V-T]M<68]E1H?3>U['9M>QP<TB8D.
M:2#F",CJOG<VUS9UZEM>6]>UN:)#:MO<TJE"O2<0'!M2E5:VHPEK@X!S02"#
MH0N]]9?!/$3Q$\1/$3Q$\10Y?^+-4J.9-ZBC%53*:/1^C!..W9.)17-:$ #Y
MRBTENLDF$-@]BR$2FC&%BR[/+*)O]'3]-LT=N!K1=8DU*1$YS'&-?7"H_P#B
M!;0PO?4VE "2TF_2$4"%A40CU7=0]+7&DTCP!:JX27E\>AU]<P4.R=")L-K.
MM74LM&-2>:M9&4'10TP;-6TZ=G#Q6?&@G7.0!GGK!.8SR/V+N/DP#R@+TW']
M=8O=H*F']*#SK ]S/S5\?=DE2=N/+%L1U8VUAR?L82_)Z(_DZI!R@AC"F^B"
M9 A)2TE=+NBS#[,C8C, F<@=_JTW<NV5L L<XRR9YUSOG7+5OG&5-4=%,XRC
MI]&5-&_T-]-\X_\ FU0Q]CKM].$OZ#&OBHL$K;^1BA*:Z.WYHD[65O)4'K[%
MESN3"7->XCM>QI:-6#,&BQ<":GP6TI5MF.5I(BIEQ5]<SX;#6;R,.9P_C;:3
M"UEBG=,3PF!D<].J./-2/R9U[!^NXS+SD6A=C5J:@AJ*BI1 [581-C+QK2?U
ME![DK\_MB#S&=QM8/,:WL2+'V&$)$H4&.'! !(AH8^')#6Y"(Z]<Q,9&.("B
MCF']-?Y-/UD\P_Z*]>^(=&]GVE6#^*$\15\?%#_!O\:?J*A_\G5\4NU/:?:K
M!_%"A_H8X7C% WE)8^0<"3T>IZS#@0HTVQH[&EQ,+-OQI!MOG&V-'#-XW1<(
M[9UVQJHGKG.,_1]'N)?O?3L;VI3<6OIVEP]CAJU[*+W-<.L$ CK"R38VTMK_
M &OV5L;RBRXM+S:3 [2ZMZ@FG7MKC%+6C7HU!(EE6D]S'"1+7$2OSH%_EX^2
M)-=9/7K>U_JIJJ::_271SGZNF^VN/IS]UQ].?HQ^[^YCVE6X[C9:"<6OLP#_
M *1O$?F+]4:_DB\E%*O6IM\G.RF[3JU&-FRKDPQ[FB2+H"8&< 9\%\O_ &O?
MR2?VV]K?_=D?_+>G[N8W_*]]_P#49_TU\O\ %+Y*?_AQLG_4:_\ >UL^?L>#
MK+HOJ@!U6]Z"MF66DXAI*F4(OO)WFCO\#2.H6IL8U88T22^S_$=@XO+KZ<[?
M7RQ0^CZOU<_3G.Q5_?7IQ07MW6NNA^)=$:S@XLZ076_NP&QO;C9_-"\F?"JV
M-V3V4I^3^KLOL[A>SYQ-NU0OVX91?1;=?$GX +4U0^I4+C1%S7#,Q'2ORS6R
M1[.UY"3Q$\1/$3Q$\1/$3Q$\1/$6/G5VM#*<XW&GT^[:,*"4@Y5.T'SIR?9[
MLXXIA/39T-=Q/Z)8VD"#[9FK&7$3_P#BE&0ZBU(Y_OUJQ\4B9$:SEVK''X\F
MW*N8M:)GFJ97[9Q(]+@SJU;-Z7:=%+6K*3+*.MA469NY%T?&(Q)"X".1IDB-
M!L8VUWC@?79WOMIH8)DG#PI=/&!R B.X#FK$?%5>?EGY4XBTES!M0.TUQ'S/
MY'ZRI0@E%]I3^'.?R?UDBHE)<JF!R6^Z8,*#$%B&@_+C9DDHYPGIL1:E4N^-
MSY"U:VOB,6Q2 "_R<WOGIN="UHM<<:EB\FOJ_?C^JFFX'U9KFUFM3,(C$JPO
MB,EW8%86T83ZIW4AD/YNJ[0AT%AQZ2.U?7>;EG$ "2-(<3&4S(,<CE)S,238
M_P =W9IFP[](IT\]E)8@2LXW;UF:RJL$T^X:NE?3G"=GP.CV>I.:,SQ%:+T3
M1M^U7N)M\=#HD!VD^L:%%%HW/";[SW_A]BB6P.Z)G+)T]DD@Y:G,B5<!R95O
M4M(<+0N P:%UG$+=9V!<<BC-8W,>?HQ&L:EGU_6=/:YK-Z1J368-FY.N:HDL
M.A[(/&').+A5PVP$826#C&;A0JF)XQ TU)C,Y\SFN\^)[+[/QX\PY)ZM-268
M:<R0U8;+;L=7WY=2O[WJRW<:)N-VF''VF&^R^FBVR/U,JZ:[YVQ@C_2/=[ I
MGZP[+HGBZ'QV:WH>*BALLD6L9C[("#>2 P1?ZME'SU9-BT^KA-@+9)Y<D':Z
MR6B>%&[9#5P]=-6JV5;)[&8[MI>7-E@5"C5J6EL;JX?<5V6]&G3+@RFTO?,U
M*KSNTV-:9ASG%K&/>WH\;V@PS9ZA1N,2JOILKU>AI-I4G57O=NESCNMT:QHE
MSB1$@"7. ,?]F];R2A.25.EJ+KM2]-BB,))1MJS3,9$:Q2:Z(/&DW+(#&FQK
M<"B/<L]LI(ILUL.";'+M=FAJX4T[#8S9&VQ_:T;-8YB(P+HC?4[ESS1Z8W=D
M7,?8T75']!\8-1K\R7M+*53<:]Q:#Q=H,=K87@9Q?#;7[I;XMWT6M%3H^AN(
M<VY>&-Z0T@PM) #3+V[Q: XB=>9K5E%X4%55M36 $:NE,]B3$^:@A7+G[V!=
M.-UD\:X^^MF;W#(BBDD6&:O6J+S0:_::NM/M\*9ST6TV%6N!X_BN$V6(4\4M
M;"[J6]&_I;NY78T Y[CGLWZ9)HU2QSF&K3>6'=A=E@][6Q+#+*^N+5]E6N:#
M:M2V?.]2<9$><UKMUX >P.:'!CFAPF5.GNB79)XBK]^2?@@+\C//@R@CUDE*
ML9#;*CEC:R41&VDI=*KQT-)PZ8K(UX7"HZ(NM9*HONZP[VW2V::)ZH;X6VW3
MZS%L,;BMJVV?5=1 K,J[[6AYEC7MW8):(._,SP6?>3C;NMY/-H*F/T,.I8H^
MIAUSA_Q:M<OM6!MQ6MJIJ](RE6)+?BP:&;@!WR=X1!FCC;FL?Q_S+4?-@N6/
M)R/J@"^!-I80%( WAK1Z?+GMG*XIL](H,MD]RV[;":;UQC;1#53.^,[YTU^]
MA:"QLZ%HUYJ"@TM#RT-+I<YTEH) ]*-3HNFVPVDJ;7;2XMM)5M&6-3%:[*[K
M2G5=791+*%&ANMJN93<\$4@Z2QL%T1E)R:]S%C2>(GB)XB>(GB)XB\W,F2Y.
M(2H<U',R[DA&SC)N)(-]'; HN[&.D$1SYJJ_%I.6;U135LY;J$QVBR*NZ>[]
MIKMEPF14M_$OS1*Z6-$S]I\C]0T=9[JHP( K+[LZ3J^\JI"NM$((,E%;4(&B
MEUV;.8Q%"&\(B3AJ\L!H2D3B+5[$ AV<%G@1GHZ*[CR+3F= 0>T^: >Y>P^2
M?XOZA[*FOYV9S;=95K+OS:Q*H8T3MZHX); *+I:$[E [%8HVELHB#P1))(CT
M&6U'_A9MM]6TH11,WT3(%*W&""1&O+<LXF3!(D<N^/">:N.8MLLF3-GE=1SE
MHU;MLN5M4=%G&4$=$LKJZ-DD&^BBOU/M%-4$44==MLX223TQKI@J*O"_/C-I
M+HF\R5SS643YBPF JO65HUD"WB"$4LHA4@6UH_6AHH=?1-_84==1\3<LQ9$F
M4-F$?%2ANB ;G63EL/?HERMO&(Y:=4ZY:<!K^Z)-Y:XJA?,4$LB':3ZQ+8*6
MRYC>DWG4[>  TK( H/4$(H>"Q]DK6@&"CPS>-5E7L='IE1+%F>?GU#,H=$_Q
M(GK]T*"9C(". TU)XSS\("Q[X&J2$4AT_P#)#75=MI$TBHBT><G3%"4SN=V0
M:U6+<S00D]RXEMDR66RU^GL[<K;-T'YQR@Q0SHS8IMF:**":(_\ )/M0\.S[
M2K4/%">(J^/BA_@W^-/U%0_^3J^*7:GM/M5@_BA03U)^C+T7^HFW?YOY#[A8
ME^#K_P"A77U%199L%\^MB_TLV<_;%FORE7?]-NO[X6_SFWM!,]!OYK?8%^QE
MW\KNOI%;ZQRX_K+CK<8_8K_]2G:/^&*#_DUS>V%L!Z6,?J_V7J\8?#)^3^3#
MLVT^LV86VA[8R\/)XB>(GB)XB>(GB)XB>(GB+$CM2"6/;-&2ZHH%6HZQ6=D@
M)''Y1JK>;F@SP!!$,Y*1Q]%9DVJ>VU&IA_*F(@5@LD$;.XF@Z4E+#8B^%MQK
M@I&1U([,_M'#]RC?@"LNC:RAL^']&,IXR-$9&+<QK2>=C%>QGJ@I 5E!UNRE
M!6AJ'6B*'WOZ,+!=14@P05_WQW)M]\9;9(8R@D]K0/83/>L__%">(GB)XB>(
MJ^OBL_@_^;?\6))_.!+O%9_I'N]@4O\ 6%94;:D)CX&]Z(.7U'6DG0*" 4>B
M9*4$@9ELR=8T+_6#OAI$:T5;;K,'6VCS#5_JXU9/$'".^-,93LGB>.85>W%Q
M@..T,!N7VSJ5:O<7=*UIUZ+GM)HQ6IU:=1X<&U&RS>IEI>QS2)71XW9X;?6]
M*EB>&U,3I-K!].E2H/K/IU&M=Y_F.8YC2"6N\[=>#NN!!A=/'>IH.W<O8%&*
M1O\ :*P$='F#J,BJ8)-$(R*>C]_R:9),D'"35FRW&L=M![9MC"2+9MA/31/7
M377WUN-E[YS67]UC> /%_4N*C+FKC-)[KFJRH/C+R]S2][Q4>#4<[SG.=)))
ME4I8S;@NMJ.'8FTVK*37466#FBBQS/O+0T$-:W<;#0W( 1 64<;.:R0$,.ZB
MC8/4FUU=8$R0:H'.L,;;;:_=R8Q7;=1DZU^K].R.^^V<:YUS]/T9]C%S0-M7
MJT#5H5S2<6]+;5!6H5(_&I56P'M/ @!=S2J=+394W*E/?;O;E5AIU&]3V'-K
MNI=W[X+Z)XB>(GB)XB>(GB)XB>(GB)XBZ.3O7HV-R$B-7$M2+ &6>L')Y55
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MO1(%R[T#9+(@QV'FH]N5"9/<!X ">^)41?&+,+'CWQZ<\M!U2RBP'HF%R))
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M[[T7_DZX/_.?$O\ AUK_ 'E:V_QCXC_)-E_6Z_\ =T_]XPM[^UBK?_*')_\
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MKO\ IMU_?"W^<V]H)GH-_-;[ OV,N_E=U](K?6.7']9<=;C'[%?_ *E.T?\
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MWX])G'DH?#B\?E$G:S)]LVAY,&"/@R),6=>-&YD5LK]_;E+=1[_O]],UA/\
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M][W#_A5LQ_./ ?\ C&'_ -X6D/N/BW\EXC_4KG_I)^<2O_\ EU#O_P G"?\
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MMC.,9\23S/BI+\4)XB>(GB)XB>(GB)XB>(O+S*$Q&Q(Z]B,ZC8>6Q<DN,<D
M!]B@2%/5PI5B=$JN63G3=!;8>8&CR37.^FWV3QF@MK_1)ZYP1>2JZBZ6I%*0
MHT[4U=5=K+2JYV5[0*&@(JM)S+A\2)*$Y"X"L&;@V]U>F"JZ#@DJZ4;??W2;
M;9))7;3Q223J2>U2KXH3Q$\11[:U50"[J^DM6VC'4I3!9:V:MC@51\5$JJY'
MD69@6^'F03X6=!&@ID<.- CX(F--@C0]@7$$&1%DV<I%()!D:A=%":"INO:M
MC]*1FO@&M7QC#C85$CZ3B9-<O'Q9\?)&"SZ8N#Q:0R$N?*%#YJ2R @4/FCI(
M@9*DGA-ZZ=*DDS/'JR]FG8%]?S!43^_^96I?I_5Q#OZ^<_\ $W]?.<_].<_U
M_$D\SXI^8&B?WOS*U)]'T?1]'YN(=^]]'T?1_P#1OWOH_<_Z/W/WO$D\SRUX
M<E$<3XDYYB=O6];[>NH62(V^*K,21C1*"P=:,1E.LF$D'LG$89:1Y-=DY/ZR
M19>0;KN'.KM<>/V1U0PCMC<DGF<NOLR[,E+GY@J)_?\ S*U+]/ZN(=_7SG_B
M;^OG.?\ ISG^OXDGF?%/S T3^]^96I/H^CZ/H_-Q#OWOH^CZ/_HW[WT?N?\
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KGB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g773514g34v86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g34v86.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M5)#VL0%.)>Q/UZ#MZXWPR'5@=>'C8L*R5B[,A)0EB2D>29?;1R.,CPTD1(-
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ML[XXN+[@E,NG,ZI5LYFLXF44L&02Z-SFS(!)MIE"X*YK((?"G(!,XP3BKQ:
M.E(E(M8LY#-YD%3:-)@B=U8,<MRH<X;'ICW9S^NJ]YO\>O'C.=/+'9TXV:2I
M]/J@M-PHTFMCM@.;'H=@+%U7-48:A,$X<UD<<&A [%T4:@47,G:BV*,MW.IM
MDM=2F3H,[ @>0.ZXMQ\;7$RPRW!;>BQ@;6\[I$]%625B\PL6)2@G=P$T[D8.
MR $QC$P$2R!2(,<(DR8M6OS47;,'18ONU;)8+$<.B<QTUV&-=1CPQL?>O7:?
M&EQ(P'5Z*'TDD.95:RN<9#-1U@VJP<-!'0IAY(;C"&GS.<HOI@!FQ]^X-NP<
MQ<GQ(PM] @"9BW;-HJ@5YG>/A\A@? +]1^-'A]O.8#8J%#"49-6@RHQ<7U3E
MUBZQE72A C*.4J4EL%Q,/V/8DGJX(-&CH1,+!CLHE<?0',,L#22C)JHD4YCM
MGQ^>^#N <G(&AZJ5(%Q[S?6!.IC,$K%A'R5&:7>G5+I$[*WFT0TZ/EC:<W5J
MV3)'GB)']]2IHW+N\F4R61*B>&T>R(9;;MMB9.HSOC/NT'P"X9#AWE=M,2]@
M(5(.3EYTK?9LL:Q(IGLJ\*=/#8:(O9WLUVD>S!/:P!M?0]J\30:I(A]0J>\;
M3#*NWZCLG,=L^'RV^"[>GRS0B48YTAFE>,M8SR60BA7GD7^LR7*=;/X/ 2U7
M15PR<9-9>&\B(&<*Q]/24N#B3A)WE\]T<DT6[U(F3KKOOYZY70;BX+Y0OVR4
MK<M>J]I+/,#X(,?$FL\LN+BI UJ^5N9Q6^TOB41F0&(31Y Y6]>F8D2EH$T1
M .'CI(8Z;-7"J&Y X@8!TU\.HP?<1N-CIX!<>C\>O'2,TD<^S2HQU()9;DAO
M8\B2E,]*Q=[;$OA\X@4PE^D%)RIW!V+F7Q:R)N/EHT?'6H23N#[@L=&/S+9@
M0:DYB>O3'N&,#Y!>K!?CMY#K@/'X]%ZT/_H$0G]66=# DDN*[YP(A,OI-X6?
MU4O"!LWL>0LX<!A;DX3V%PR,HBX9NDNFV>@';9HS1;E2XG7.NO0==#TW/4[E
M>4U\>''AY]&"KZG\-RL.L*[+2CI4+/K0C91C-.C3.LANY\J2CLU%O2 JQ#:;
M<D:BA-=Y$TW3(=N.!L<#F.K<IS'QZ :ZZ#;X?SXE3#0_-U-\T@I+'Z=BY "V
MFDK<3B9E9!,YU8\PE\L<B1 #8[*IY9DEF$WD3Y $!"A6.QB0O4QHD6Q&CTVK
M-LFCJ0DGZV]/!3EXHGB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(G
MB)XB>(GB)XB>(GB)XB>(HLO/>SDJ5MQ:DUQK:XT*TG#BJ53([4N'Q8Z$:)K0
MK0L+W6;X?C%9'H-2?M/N$-EVNZJ>JR>V<;ZD&XSMU7S9\^_-#T]T];]-U]$8
M=%@,8Z_F_-0;G<NYB!)=^RC=61-M*/DTW/)N'B2#MU"'[(_$H.YRHDD(7T;/
M-LD<JIJZ%Y"P#.^@/-MH3^7X[G3H<::B@+>_;J/<LS2)G^AHO7]0V3\!E@6?
M"N84AY) /*I8V(]'1^3,*W>2^S"YXC.([F.)V/*92T9R,_M 4VD2)LF0,,E)
M,ELC#QIM(->O^7&?+TQYY7T!<;7GT<98=O<]WM.81/BG.E)<]S"!3V 0,A6"
MR(F]N?I%+EHJZ$+3&8JN/V.7BZC<'(]S&3)1H\PY*9PZ33U2+Q. P" 1G.F<
M['T"IQR5\IE?5[S3\/ DEU#29:$22"N*\[>FDNLF.2<]6,M%<FSV>UL!L>3N
M)*X>U_.)=9$'4&M&$OQH<E;@<4",&RS[1;"95S3S/T.Y(TZ<V/AJJK;?-7V-
MO6\;F;JX.<8M/V?)G(O0$;H>0U:LO.>JK*MV[; K><5%66VE@B"(?98()"N<
MM0$<E4D&$-AY!'88#0D2ZI:# >A_,X9!T& ".A\_495NC/RW75M9#ZDH[9/-
M8JZ0O4WRO5G((E93EI&!,&K#EZF+TGO+<LMQU^O-GT!A9DM"H<3DT\)[#6<M
MB;62O ZZ*3,D[8%"P:;ZAG0ZDXYL::XSL.NBYVQ.N[&Z$^#_ +-M0C8TDS;T
M ;SBKI=+XNSA\&7 S:+F80A(V4!FU)V-/X+-HRTW.+H1VRH)+-&ID6XP.(L&
M)\4;1V(&CG:,:'!\=]L@@? _,%4-)]P]C<9V]T-5$N)26=W)PEQ[':51FL]<
MO"T*L&MI[V?2L>J3KR2C2TGC,9,20/0%D(?ODS()6,;HS>$2;][RL6!5,NF[
M._DJ TX)P YQ.FG^4DM&F@YM -< C=3O-/E5ZYC JJP$SZ@X_I ?,Q?>A =?
M$D1IJWQLN8\\1OGR;4R&*)4WT%)*DB-M29S8<N@DBB@R<'LD62 XH%BB<C-Q
MYEJ^O'ZU4Y=S@DY:,#/4.\1G<#XXU72:?[!Z\$7M;77S A (&PM>;_"*'Z&H
M605P9+$3SOK&FZUALJ9Q67/9HP>UGI!]YJ_, V;B.2,F](:-6TA=808.&9$A
M#< :G ?@Z:AN2,C'7'B-_CWAUT?V3>@[D2WI;8]9Z2:X[5^3F%4/^SJFDPJ0
M43GG.BNOX4TD&';"U$6-ERN;%*Z"._I%0(X?'6:6$ S50R[W,($( YL9TQG7
M?)SX:>"BVG^T>AF->T79L)OWGJY+[(_$53,L?7A:$OC\3^QD1_JNJXK.ZED\
MCFEPMJD*73%PQ>11YJ1LDC%B<KNQL-Q,G01D0?1K+Y[[*EH!.A YR !X ''A
MI^@SCKGZ'>&NQ*UZEIZK" FR\2ZS9#3D<MH^#.1477\ZUB$AE$LA@B6G(,"D
MDQCXED7D,*D0UF^C<K.QHVH+5-1U\J!)#-]B\9&"?4CRR-\'W[;C.J^;WAZ3
M=2T-R@C\B1ZP)[55*,*&GT-FTGEMLRWJHET-<T]ZR!P>M+%'\^V)9T%K2IOX
M=!_U:&?NLW9\#%M]R[<Y+4EH0P/JKEY#@DMT!R,:   -.=0,ZG&=#G'HK<<\
M?(5W9U++N=Z/A%OTY!#L\OKOVKY9<Q6H(?:*Q:&\KAN?YM S Z,UE=Y&JW$H
M-M;+,Q(^2AMEGX.['K:R $LY>-&>5BA:!G.N #ID;Z'<9^0_7-.ZX[LZ(K*C
M.8+N/6-%.R.@:VK'YCSRS8VTD.\\JR2TFG -@M>6,SCUD$7A13#79"=EV,M$
M#I&PK(E'(_&-0S-BTDY@K@9(U )9X:@G&1IM]95VYC\KDPI!HUW.=N<J=!1&
M3<7=AV1!+DA\/CT,B\BZKK('0INJJ-%:CK(F J43-KK8YEPO" SUK)#@DS'A
M9 &@>#D'Q(LAN<Z.!!:"/(YR=NF!Y!5<3[]LBGYMUY/QEG,Z[MSHJ?<?21N^
MQ7E8'XT0,LOBFIRW)0P4.W?>M(5=6X7[M%1[C1\?E$NDJ2>L6@L9?G'>Q!D6
MBT<K1X!VNO\ 7C7#3DGW>_9?ST-VCUMVAPOVL6D4QK"#U)"/BTY6OF>P"/UL
M1=R>;V%UI3DU./VD>GCR:Z[PB*1"5PU4ZV9K Y24)LG#6/J$FJ2;HDX*M:&N
M;UR]PUV]D[XQKGY?IJ!1';/4<S^0@EP/)A\<3?4S.+RMVUY>VAKIHP.\<E8%
M7#[DU(&35?;#4IV:GEN[QB7O67W2Z^M*RM39BQV+*Y:E@M'+S9\ !USUZ;=1
MY$=53/J3F^M O6ORBLF#VW/TF#?%.>Z-BL?>]$=!E(N*N&R5.K0\SE&L6*6>
M\CKQD6&  [-&($!;N$ATF"&0<<&[_GVWAV/H51^5IP,\^,X&<8:=\9_==)@_
MR!]C<WU[7//TUMRC&P,I _BP3!])&JE=QV)<MU3U;$[;#RTG8 DI9;D-,6\-
M<4W&HY&IK+9+%A2TFGFA*4-]1OVPAK52T'49UY],YR6G3H/'7'0=-Q(T(^5K
MI964\WJ3RTZ5,4P9Z<LKGTE8U0QF %K$Z7'BNG U+TU;\.I267"'DV:-LX/B
M1 3,\H+:TWD7G Y]*DA+V$C?TQR4+-\9T:'8UTRWF()QTW&=P,;JP_Q2_(1U
M/V5;#_6W%*?9P>0558TU*UL,DM,C;:HZQ(?<(B%C(%_#Z*W3.+F=Q1",EW@Z
M;2*XZW@!8;/ HW+)-H.E8\,D67  9&=]/#&-\X WZ#.AWTUHK%NY>OH;65I@
M.=I)3-3B*DH'Y7NTY"WDE82>S]Y>1Y:[CGD290H<X-6@/=QO$_&/4=) <5<F
MVPG;)%2/1YANX'?I):Y02!J2>[ UP/:;DYTZ:8\NN5<[Y'2-E] V'\0\?A\/
MVFJE^;7M+913&>E;?Y;ALQV;\P(6"U9R"VJ;%GIP.;0U[JL?!)( ">I4B-0#
M/?LF)=^]1*  <^3MC!P"=\;$@?-4AD/9L\XF']RQNO)ZUJVQ9%WCT4\C0<I'
MH-:8)[_ SA7CH^YC92UN@;PI 0S$,7)!FRWRDWFER6EESKF%Q5,LS-JY>[/P
M_<A7ER&Z;-U/AE[NFOQV'7HIID'RB=T.*DZXZ3CY*H&4'H.I^ " BM$:L7*/
M&TF[7H[FZ=SJQI!.C5GQMBPA%$N['F$K%""FC1@6';[HSJ9 X^"W+Z$Y6^R-
M<D..<^!<  ,'4XQUUQCSU\^-^]KDO^E)M)KI.UE+2L:N>80N&S"M)A3\MQ**
M^9 XB> $9YI1-G6Y6L9L-HZD14(<CH*8*:Y'B@Q_<8,U/)H>+!&#[O/]]?K"
MT$\43Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$
M3Q$\1/$3Q$\1<,VCD>9;L%&8$,TW%;$-A>[86Q0W&[%M\J%-F&R2&F6>Q+?.
M=R&6^4\O-\YV<Y4SG.?$7JJPZ(KZ,DUXK&UDQK!\*':*@QBF@\643U1)#66N
M[7;5JP(HZZI/F:&$V[M/771PFIKC&/$7+(C1S=9TY;L&2#AZFW1>KHM4$EG:
M3-/=%HDZ5T3UW<)M4M]TF^BNV^J">^^B6-==LXR1<"E!(.@WRT0AL41:Y?,2
M>6R4=$)M\DA:FRPTAE'1GA/+X<KMLJQ=YU^X:*;;;MU$]LYSDBC -S/3(&ZY
M=T"/A[/%DS2'UO"";]QG[D4Q"U00G9*%J1\&MKL-CY5@YL>587+"D&SYVB]3
M165SHCKC)7)QCH"3[SC/Z!2WM%(ON]?$MXV W(D]\*DG^P<=L](*:CEP^JCY
MUEME=WO@0Y<B\;KJ*;8'.%V.,_;*J);%%Y6L:CC$+I&V0 *SCJ2.S=, U%,6
MX5-#=39;9#04DAHQT1V6VV5V3U0QIE3;;?.N=LYSXB]EP($NU73AT+'.5WP_
M82]6<,FRRKP5MLKOL,=**);;N!^VRZVVS-7;=MG997;*?XJ;YR107(.5Z*DU
MF59:Q6!"-I'341LJ$0,<V;H-(@. 6R0@Y69(NH>@EI'R#AR0KN+NV#MTQW6&
M.&JZS39-5RIOXKD@$ Z'?W9_DJ<5@85PHX57#BUU7;@>\=*K#VBBCEV)V3W%
M.G&^Z.VRS@9NDEN/74SLJRV23V;;)YTUS@HB(0*V^Q^W$"T/TQ=ZZ&_1'M$O
MT]T1^X_4'+'\B.OVB[_[MW]ZLA]-1U]TX^OMO]93\Q%Q'[#@V1[@3F&13]*=
M-G#)T,_;HC]/<LWC_)1VT<,OL_MEFSHGMDBX043V27?YR\5TV<9RIXBZ_%J=
MK2%3R>V=&(DP%3RS1\+#S21IKOW#PF#KH4Z#0B/-$7CMPS QR-LWY18='H\V
M%!="IDZ<48*&SA8@\)GIT'U]>@\%W;8"#V$*Q_8,*V N&R[-<)L.9Y$+-'7U
M/NFJHW*.6:C9S]57ZZ&Z.R2WU%/J:[?GV_$B\3&-QT9LTV&@ H_9AA;5CLQ%
ML6FS/5PW:M'&K3*"">6^%VK%DV6PC^3"K=FU1W_,FW2UT(OY:QB-,7*KUC'@
M;-XX>$2*[MJ)8-W*Q QH@F7?JKHM]%5'A1-JUT(NM]]EWVC9#5SNKJBGC4B]
M)*#0E!D-&H0^+(C@SET\$#TH^)39"G;W1PF]=#6NC3"#%R[3=NDW2[5-)5QH
MY<:*[;ZK*8V(O8<1&)N]-4W48CSE/1Z-)Z:. HU;30D&03:AR&NJC;;75Z*;
M(I-QKO&,+L4$DT6JB2>FNN"+S:1F-IM7+'2/@]&3U@T%O&>@EAJU=C!Z:B+
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M-6G'1HP!\0,^NJF_Y;:VI"9\GDY3<5&\\72^KR6Q I7VW3TS1JVG8-(SDD%
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M^0GF[IZ;1:OZR(V$WD<]HD7TI7R4\JJ?5XQG],D2@8&M,H<1EP(4U-,A1J1
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M/1QUU)"8Q86\9/"H;G V)<6Y)&.FF-\_+9=[9=Y1]M?BPR;3=*!5S'/C^/\
M74\J21T-;;2TH^QCEACPY:S&T[U37CAZ'MPF[\&TK.-1LY/7Q=-(UASHW6:B
MG!3ET'4DXSD8\O\ LE1%VK\EW[-Y:Z,G?-9']N7OS;,^1V-BU_<-;F-"H6'=
M26G7T5B9; Y0L,'?A)XA+BQR/%FY$]H,*1PD D0%D7;NVK$@;DC.QSMY#]CY
M>GBM+;AO:!TCI 4)>H7=GK4FV:ZK:)QP9N7DDUF2<2E4]=! S3ZK9IA=I#81
M*SZJA!\Q062#Y&LE71PB(%D"@&?W\M0,GWD*ES?Y1:9?7'*:\8PRW=XC ^1
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M,.G:\:9Q=64L:WVVG>8H_)L)>E#U&AQ^ 9H.D\9*8.,]#_.,^F=,^*Z-;WR
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MQK?K1#\[I1Z;@E&)@V<8EF@YFDUW9(X,3PZ=?N5QJ,!9Z((%'!&\O^;/D!@
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M[=ZSIZWZ7Z<N.O;,H2:=%.ZW5KEH+DR-#I#)E"=T8]*0EX0.2Q=Z(F$>4BY
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M!>5E^#<8<6UG"SZ)S+2VOIJT/8V?[TZ%S*EAR8',;33#VXW-?$>8%Y$H#?\
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M:?7%)LPJ(Q*$D:DEQ:+1U_M*WT>%/E)6>8I,4B1,B[^@TCA'?8KRZX!SOG?
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M6Y%24P0<NVX<<VVEDAAT2A#H"%4+RDHY8-R*3$7&A@C9H=R_*N& !S GP!R
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M\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\18+_)[_O\
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MMYJJXU45-&<$MC#SF6>0#7NJ>(/GE(_+%&\]%^:LJHJ&EGJYCB."-TCM<%Q
M]EC<_P":1Q:QOBYP"B;B#J8%V1S57=Z"6[,85.LEA,YCC);=9*+SX$IAC)PN
MGUMU'.C+9UA,L$^[WV=+1TJ'=K[94<9SGVW&O#$_!_$EQL<KGRQ02"6BJ'M#
M354$XYZ:8X :7\A,4W( P5$4S6Z-7YK3<676@@K& -<\%LT8.>ZF9I(S77&<
M.9G4L<TG=6S]Q1>R3Q%T^P(2!L:&2.#R;5;8')!BP]_LV6U0=-],YU61>-5M
M]%4TG3%RDB\;;K)+(ZKH)Y6152_.GMQGC+A6T<;\+WSA._-E=:;Y02T58Z"1
ML,\+26RQ5-/*]KV1U%)/'%4P.DCDB$L3#+')'S,=[OAN_7'A>^VR_P!J,8N%
MKJF5-,)6&2*1P#F/AFC:YCGQ3Q/DAE:Q['F.1W(]C^5PSN&Q^GN&8?(K=BAY
M>XY)(23>O!>&Y<.@/'Y=?7.N!SMR'T)Z--L)@L.B"ZNB[A=5DQ:-6;'5=POG
MXIH;-V9_9*X9O?:3P]=YNTZ^7JN@X+H!!<K9#149J#+=Y:*IJ+8RN;2GDM(J
M*V:5LTTTE)24]/34C99I3],55RXV^T#>[9P7>+?%P1:[92R\359DHJV2IJ1%
MW=OCJH8JUU*Z<$W#N:6-CHXHV5%1---4&.*,0G<?;]KSV%14U7;(Q6;!J5(C
M)@^%*:$TUSJ:;)T'9HGE!Z6S5FX'JKN4V.Z+1P[73>)*9>-F.BN_57:;]J_M
M%XQX6X=NO!%)=.!*.GN%=0<35=N>RX1S7=C*6HME+%=WT4;J>EFHY)IV4CXJ
M>:IF;4QO-5!2-D?SW@?L"X.X=OUXH.)ZBAXJJ):.EJ[)3UC74CH[<]T\-=/)
M;FU+Q-/%4LCB=4-DFB@C= ]O<2U!8V\U9]018%7%8(] S$7$K/E(7[QV-(,7
MK9RHR4*OV0,X918,%&4=T."F[,GLH3V&,]MG"RR&J+?7.B7UKP%V_</VG@?@
M&+MEXFM_#?'_ !!:OO-305M)503R4LEPK*6TW:YQ4=&^DLC;O;X:6X%]<;?2
MDSR21-B@ 9'\_<5]DMWN'%'%K^S>R5EZX2M%?W,-733P2Q,G;1T\]?;Z&2HJ
M&SW1UOJY9Z0-I!5U $3&2&24\S[BZ;Z*Z:*)[ZJ)J:Z[IJ:;8WTWTWQC;3?3
M;7.==M=M<XVUVUSG&V,XSC.<9]]-,>R1K7L<U['M:]CV.#FO8X M<UP)#FN!
M!:X$@@@@X72+FN8YS'M+7-):YK@6N:YIP6N!P000000"",%?U[2B_,XQG&<9
MQC.,XSC.,X_'&<9_JSC.,_U9QG']N/$VV6'G+_QL22GOD5N*WS! XYHB(L\2
MVA1CLR_=#%I#9N"B+T1EDJY6;[-ZI;H2$2U:N]-E\:%(4=25^X3W_)UC8^#)
MK=Q?<;A(^4VNG;]XM3'2/<PS5H>'1\I);RT $T;6N]K#Z:4'(*_H)VN?:JM7
M''V7^!^"*&FM\7:)>IS9>T:KAH::&K9;.$S2/IZT3LBCE$O&4LELK9IH'"(N
MH[_;GL[IPYMQ/=G+^?:>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)X
MB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(LM?ET#PLYS/$V<RV[B=Y0N
MR(EHM&?CRQNGTI+96#BL\,LQP-]^=%L*C@ 8Q+SZ1$GKIFDV2AS;#5?)-1@@
ML6F:'_+M_FV^BH ^%MZ!*LNC"D>%_)8T8NE:8W2)?)O,!4NM$NT>@9F=&+UT
MX9D2+YM7&XLVS(M-EUE!;\D5=O1"ZJJA-)N5?N/R?^@P/#PUV\U>OH+]TWW-
MI#R=&!UKUK]G HG:FW6U=%:WUUIV5NI%)$8<'#!)PSD"QR<$E(<2V<LT(@68
M!XJ6T+NC$:,OHL\7+(TUT/3!SKIKMC3W@^'51MR]S9_N_P#6_03HA?-Z3Y&;
M5O G%85O9#V,N:_AU=,I1+2Y]O7JX-D.=N-8Y8LJ.--8Z_',6=;Q:4Q8%'_K
MQ\R,9AR'8:#0G4;G;?X:;=3ODK2?Q1/$3Q$\1=1FT @UE!$XW8<.C$ZCR)J/
MR-('+@0R1"$I!$S;&21<VF.+-G;30M'9"+&G A#5+#H678,R#)5%VV15T("1
ML<>B[=XBRU^'/_DGT_ZI.[O^]>_/%IVX_P!+/]C5J5XLJL/8X;G\CSI9!?I^
M.M)73,&"KS^3@7S\HR;DE8JDJ_%---!1(6L1(.B7VS4*,67W1=G%QN-$-W>C
M7=/DW!\U_CXAMT/#-0^EO%=,V@IIV1Q/=&*HB.5Y,L<HCC;'S.FE:T.; V3+
M@PN!]?=&43J&=UP8)*6%AGD8YS@'=T"YH]ES2YQ=@,;DY>6X!.%A18/<U \I
M_&O75I<+0@#3=G=1REC^:$"29B2-83+:_6'-[>)OF!]^]PNF.28C8>S>?;C'
M)H7*8R<W;[(-T=$.\+?P1?N*>T>XVOCBNGO%MX8I9!]^FBBIG5M+7MD=:(V2
M0,9RND,DE8]G/*V&6EJ8 [)<7<0GN]';K#!46>%E+47"0?X+7.D$,L/**ISF
MO<<\O*V('#2]LD;\8QC?SF&_(OT_0M8WI$?RHC+ C+0F[&?5PLM'Y"WV4'RB
M,N]_PQG9U'9"T)"%5<ZZZN/M-726,H+I;;=#<36&JX9OMSL=7[4M!4OB9+C#
M:BG=B2EJ6#^BHIWQS ;MY^4X<T@<SM];'<**GK(]&SQAQ;G)CD'LR1GSC>'-
M)ZXR-"IY]Z)?L44WE#9%8523R%Q,HD'D$B!+,!SU?95-OOME9%5P/<*H[840
M0+LTG E=SKA7#9)]NOL@XT3V04Z^[5N&+QQGV<\8<+6"N;;KQ>[+445#4R2/
MAB,CRQ[Z2>:,.?%3W"%DE!42M:_NX:F1Y8\ L=R_@&^6[AKC+AV^W:E=66ZV
M7*&IJH6,;)(&-#FMGBC>0U\M)(YE7$PN;SR0-:'-)#A@Y9'.?05,UVM(I0H-
MA\8,38%'Y#&5F(*:.90Q2%24DQ>M"; PY:0E8<69LL-Y#HF\,NF#TM'4&S!J
M<<OM?Y67+LI[0.QC@#BV\]H'"=NFMW$U3:^%*"SUES9<8::Z&6INU-Q>7\.W
M(BFGM=-;:VUVUTE=!+++?IV3PRT1J*2L^\J+CWA'M)XMX?MW"-_K(ZVR0UU_
MJ[E3T3Z.2>A$<-!-PZ&WBC!GBKYJVFKJYK*66.-EJB?%(RJ;#44W!P1MTX\K
MLIK!'LL(U>E.,X;AZ\BS@>2%2/(@6LXWDA^-+*'98FYSNV4$[%6VC:/X109Z
M++*N6>=/5V^Y]J=\[+;'0=G'"]]M7#MDXBN5-Q#5< LOTL]^XAGI[94T-POI
MIJBLN4L\%)R00M$OX93R"'NH*626DB'[ZRBX#MG'5SJ^,[Y:J^\W*ST4UH@X
MM=:F0VFT135T-526D3PT]%'%+4<TTI+/OTS72<\D[&3R&WC+@V^;;0$V'9UJ
M#&\FE* S),5(HL0UDD1!"0PL"'8DWC<VZTF!]5L,V+OW#Q.(N4-R*8<AAX2'
MO3A'OZ7[)7:+VGT?"7&?%W%S+5Q-=K/0P<84M_I*JLN]*VW.?;[5.PQ2 5-P
MDX=I[5^(4E=)23LNC*J2IJWS3RMBZD9]H+@[@>IX@X;X>X>=7V.WW"JEX=GM
M%1!3VZ=U8&UE?$X2,S!1MO$U?]TGI&5$1H70,@IVQ11N?K77\=(0^!PF)%S"
M$A+1>(QN.DS[48H$;'" 0,R&/3#<,J3-*B$";ELJ]1&*&2RC!-?5KN3?[)9=
M*_T7LMK@L=FM-DI7RR4UGME!:Z>2=P?-)!;Z6*DA?,\ !TKHX6ND<  YY)P,
MX7QQ<Z^6Z7*X7.=L;)KC75=?,R)O+$R6LGDJ)&QMR>6-KY"&-R<- &5V[WLU
M^%5PN?KSFSG<Z*C-V6[&*X.'!/ZX(82'!-+<B*^\<L-GC59L/<ME=4W;1=%9
M/5;ZR.V--E4]-%D=E/3W+B"S6B6."Y7""CEEC[V-DW."^/F<SF:0PM.'-((S
MD:9 !&>TN!.Q/M5[3K=67;@'@F[\4V^WUOX?6U-L^Z/;2UG<15(@F9+4Q2L+
MH)HY&.,?=R N#'N='(&\_(>E*&B-:12Y);:<1BU73C47M$IS)"&00 [@X/<E
M@WV+LJFT_-DJ+9NB([531/9XR1W<M\*(XQOGRS7FUT]%!<:BNIX*&IY/N]5.
M_NHI>]8Z2/E=(&Y[QC7/9D#F:.89&J];;.RKM%O?%=YX&LO!]ZO'%_#YK!>N
M'K52_B-RMQMU5%15_P!X@HW38%%63PTM46EP@J)&Q2%K_978*JNNI;S"/Y+3
MUAQ6R8^+*;A")J(%FQH8S,)M&KY48L\:;;H:ODF;YFZ5;?GRJF@[;*[ZZZ+I
MYV\U#<J"YQ/FM]7!6PL>8GRT\C96-D#6N+"YI(Y@US7%N<@.:3N%ZWC'@+C3
ML]N%-:N..&;SPK<ZRC;<*:@OE%+05<]"^::G95QP3ALAIWST]1"R7EY'R02L
M:2Z-X$H>_:N(IXB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(G
MB)XB>(GB)XB>(GB)XB>(GB)XB>(GB+Y_?D/[0F6;SD/'DC^-OJ;HT%&)-7%H
MU+8E#V<6J-[+%V$/#2!ZXBY8:0CDD/+QLX_F41F;>+E"0+<$IN)D#=)=RY3V
M+;6Z9YFC?1VN!H,[$#?3Y*4/B#CX,3)^OC0SB.]^(7\UE%8RLC"K[FIJ7%#:
M!!*QM&*->LG:FP"'U5%542(R+12/Z_3#O'9IEMNB';QX8,*.SIEP=X<OSR<#
M)\=SXJ>>U*H^1D;-&]T_'):%"-9 9CHJ,VI173<>/O:YERD<=E5HY/X?*H;]
M"3QJ<MF!EQ'3PQT]1C4E!CHXLHX&D8]C!@C>37F!\BW&?@=/KX<UP]2';0F0
MRZ_?D(M2IIK>4EC(Z 0FN*!!EQ%-TS7S<JK(CC800DB*,GE,QGAS 1S+BIC+
MELP:P^.B@KQTT27<*D<6_P"4$#SU)_CW?L%H_P"+*>(GB)XBS ^1* 7)(]ZH
M+<^]"6Y7G02UDU0,I>MX7*<!JQ+C1EE@RM^3*[H@DW5;6%7H:GG!=>0?NY3<
M+'G J,AXBW3G,X9CY46FX!.0",'.?V\\X_Z4K7EUA?-66"^B%>_'[TCT/%VP
MX2^9VA64SYQ$Q$LJ29)NW+%DSL:YH;*-5Q2JF6;M5R"1:K+Z;*,EW3?.BVQ0
M '_,!Y'F_9I'S4"?">4?&^!H^9)@2,6)%NB^V29"-%UA[@K'GK_LB]';L&37
M$O" M8@(<+*#GJHU^]8*.FRN[)VY;;)+J%7Z.QO[+-1M^4+63Q95&EC/)OR3
M51;=<&%7%@UE7UN%Z^L,.VE4CAS=U**V?H/V[Y0G#Y %($XDNOLT.!7:C[(8
MHHS2>8247%Z[H<W;#Q5V<W6TW&$-H+G7VF&X6^9U+3UCFTMRC=&Y@CK*>:.*
MK:T/@F8&=]$'EF0V7#O4%UMOU-4P//?T\-2Z"=@DDB!DIW!P)=$]CC'G#V'F
MY78!W;IW3DWGSE[FVKMU.7F+<!4UDJBK%;O$K!ETSC)K<T('MQLE$/IE)3Z3
M1,R(3$I[+#5FJ1%) ?\ <:JJ((9T_%Q7Q!Q-Q'<P.)WNGNMN;+;G,-OI*.IA
M$,TCI*:9E'34Y>89C*0)&N,9=)RD!SL^6VT5OH*?-O 933ELX/?RRQOYVM#9
M&F61X'.WE&6D<P#<YP%%W:'R!UGQE/.;83-,M7"UWV+H#D2ZKKZ&(+7":&XP
MC8+[.N=OIMALJ+1G3*3E/Z;X(WE:K/;9X*UUQ[/@[@&Y<8T/$=;1<S6V2W&>
MG ;S??KB7"6.WLSC+I*6*I.6G,<QI0\!DN5^>ZWJGM4U!#+@FKGY'DG'<P8Y
M73N\ V1T8U&',$N-6K0'&<9QC.,XSC.,9QG&?QQG&?Z\9QG']6<9Q_7C./[?
M<"VW7NE^^(NDV(]K]A$"[BT%(TG"?I)IF-9:FQ7"+:[K:?;HN&Q#15!RLHYP
MEAHAJDJNHYPEAMILMC3W%>-:O@VCX:N4W'S[$SA7NV,N8XC922VF1KY&"&*:
M"L9)#/(^?NQ3PB.25\_=B%AEY5[[AF#B2HO5%'PDVZNOW.YU";*ZHCN#"&.[
MV2*6F<V2)C8B_OI"]D;8N<RN$?,J&WGUQ&Z.C$ %\X@:[*@)"F7?:OF;+?6*
MCDQ[ILBY&MQ4?=A=]#BZ[G[@E]VN@X:);ME5VKA0@FLA\@]K7VD+'V36'@ZW
M]B%GX)N-FO3+E5MJZ6E<WAZB915$$510PV^S5%K<V[2S3]]7?>9H9J:-\$DM
M/,^M9+%]$=G_ &,73M NW$E7VGW'B:CN5L=14[J>>=IO%2ZJAE?#525ERAKF
MNM\<<7=TO<QR13O;*R.:)M,YDE5+5M#J2WI% [$A@NS <?D08;M#1D&VD*@9
M,N-<K!Y#MMN*UPW6<N9(/)N$OU?\[G !89HXVW9_EWV^>>T/C_[0/:5>^#^-
M>%J#CRT66]VNA=PQ0<)NO3[7'<Z&:6V7MSGVX""6:>^45?/'^)<TXLTM V9S
MZ7#G=O\ !_"79'P7;.(N&;[5\*7"Y6RNJA?*OB!MM;7.H:J)E;;&AM83*R**
MUU-+$_[EB/\ $F59C#9\M&W$9_6_VW'_ -S?1_<?Z()_<'VWY/M_UO[!O^J_
M;_3_ .']'[_[CZ7T_P#T?3_+^7_T_A[^K-A_%OP.S?CPB%\_"K=^,B#D[@7;
M[G#^(B'NR8^Z^^=]W?(2SDQRGEPO@FZ_</Q2Y?A7>?A?W^L_#>]YN]^X?>)/
MN?><WM=Y]W[OGYO:YLYU72;M@1JT:DL*OXU-))7,EE,7)C8U.XB;*QV01219
M1RN!-LBH1RS)I)L2R+-4@V;.4L$AN'@Q?.S9XMIMY[G225U!5TD-3-1S3P/9
M#54\LD,M/-C,4K9(G-> R0-+VM(YV<S#EKB%R#@'B.@X1XTX9XENMAM7%%JM
M%WI*JZ\.WJ@H[G;;S:Q)W=QM\]'7Q3TCWU%%).RFFEB?]TJS!5QXE@8X?/)0
MGQ=WGUU2XJ7=L6U;A.QHY?Z+$ #LN;RV5+A:?A4@=QBW (O!H@^V#$[+)L'*
MHTL@@HE]&%1$JU6W%FG6RG4=JX(NG$%MCJ.)+A<'UD-V#(HJVIJ)S';Z69T%
MPB9WKWF-];(UQ9(!C%-3O:3'*[/]->T;[7?9[V*<>5ME[ N"^"J3A>Z]FSZB
MXW'A2P6:SQU_'%_MD-WX*N57]PIJ=M?2<)TE3$RKHI)&OY[_ 'NCF8*N@A#9
MTD/4(OOV16M\7I#E Y6A@0"E8$E)74R%/HY3KVKM=-8E,6S!A%&;AR#9REK%
MAP5$:HU2-C3;-DFND*)+*Z^SEOC.+)J[@B2PRT4D<51$^=U2Q\-N=0C_ .O4
MAC:=KG1-G; R,,+1*R5K00QY*Z\MG9'6?9MM?!OVNJ7MEM_%=#6W&S7*DM,5
MCK*>Z\<0<7EQO5CFJ*F\3Q17">T37BIKWU;9GV^JH)ZAT;ZRDC88ADGPB?I%
MB<2BXL]=+0)F%0&=</V!1V@V(GXUAQ-")T=ILLF\PWL%RY(5TPV12T_0AX^,
MKJI;*[.E<^OF[,^[K.&F0.<:1L89?W-D< ^6'FJ7RLU#@VK)=1M+0.Z:R!Q&
M2]RYO:_M_P#WWA?M^J[O!%'Q'/7R5?8K35%'!)+2VV[&*PTMOJG!CH#+PS%%
M3<45#9'N_$:FINT;'AHA8/I0;MT&B"#5JBDV;-D4V[=N@GHD@@@CIJFBBBDG
MC71)))/771-/3773337&NN,8QC'NY@ T!K0 T       8  &@ &@ T 7\JI)
M))I))99'RRRO=)++(YSY))'N+GR2/<2Y[WN)<YSB7.<22222O-ZK">(GB)XB
M>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB
M)XB>(GB+!;O:Z_D$M^\+#Y%YZIB 5C0<61AS:9]<VI05L]6;FS)^)1Z;.1]3
M4U"ZSDT&WDT*_< U!56QW9 $[=I**MWHM\E]NB6VAN,DDG7V00/$:DG]E=#X
MZ(H;J>!R.CY-??6/24@A#"'R0G9_5-=E*W?.%)FK+&6H*N@LHAD9F6L2%;0]
M5;+8\:G* E4@@+$R/5!LN.9EEQR3H!Y#;]2O9^1B=]HU95H"QN2IIR##!<8E
M,?=7 6Z\-'H%#0T,P?%;K&\V8SD;4"!";YTS'Y0+)1Y8T^$G%7D1D Z1L![
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M=W_>O?GBT[<?Z6?[&K1NP(R0FD&E\0%2@M"2,HC9F/M)@ T:J'HPJ88+L,'
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MEV!S.A'99@D)5T<M4AZ#+=)EJF\RNZ^<?M#\<]L7"?:59+%V<5%YL7!-/:K
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M;X:9V2V0<9;#!DF:ZYU?#L_DZULEYXMJN*ZVR5XHA16OO):J>.D?&Z:"0?\
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M&SM):*[:,L:HY7V*OZ:L._Y!CPWT'N]ZWR\6$\1?FVV-==MML_AKKC.VV?\
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M!P27/B8P@M<['KKK35-;03TM)*R"2=O=NEDYL-B=_P#E #027/9EG3 <3G(
M,3_&]S%=G'W/VM#W!8,/L=A&)*5?UT5BNAU+<-&#N^";^,D$S;)IOLDRD:Q4
MH-60W5_!$RLQVT008-<;^U[1>);+Q=?S?;105=N?54T3+A%5& B:I@'=,J8S
M ]XR^G;%'(' >U"'Y<Z1V/SV*WU=LHA1U4\=0(Y'&!T8>.2-_M&-P>!^5Y<Y
MI!V=RX :,_WU)\:?,'8T^&61>8Z=GI"$CC2*ADA,\,@0XH,T>OB.$60D?G1J
MDX<OB+IR]>9QLZ=;[(Z*J[(M6R:+ACM(XFX0H);=9)*""GGJ'U4QFH(9YI9G
ML9'E\LF7%K61M:QGY6#F(&7N)EQL%NND[9ZQLSY&QB-H;,]C&L!+L-:W0$EQ
M).Y.^@&+S1\.E'0(2/H/"1% &(&AT2!EZH1+ODAC-%DF\*D%<85?DG.B&JSY
MZIC"CIUNJOOC&RF?<'J)C43S3N9'&Z>628QPL$<,9D>YY9%&-(XVEW*Q@T:T
M!HT"]PQH8QC 7.#&M:"X\SB&@#+G'4N.,D]3DKE_>):3_P#'B+'*E6/7R?4K
M525ZV)JRQ)'^TY<E\FOV$M&_SN?N=6"CG.(\LSW1_+B+)C<[?37PTRQTTT16
M_)_,CLLI/M+,^T#3R<1MXV%(+Y5GBV>Y&Z?_  ^2QYG$[:-\^;+)3.BY18(Z
M#)CD%.:1K&1R%GV]QW4=BCNR*5EF/#)J#:Z<</PT7W#_ .1QW0B+NC4MB'XF
MR</R;NZJ YX^^$[BY\>=C??TW7Q"GB)XB9QC.,XS_9G'X9__ !GQ%AYR_P A
M].P7Y%;B+S^Z[XD7-59L\3&IADGM6P34:F*]F:DT8W''K$J?<LC;>LVS>2,S
M";M-53!D3%22Z&6Q5+\_65CX?O=+QA<9*NY76:RT3?O% R>NJY(*@UO.(87-
MDE+)11-$[9 X$]Y' \MY9!G^@?:YVV=DG$/V8.!Z'AK@'LZM?:MQ7/\ @?&E
M9:.#N&J"ZV*/A,T;[K=*>HH[;%46^7BR62U3T+H7-;]PK;S2QR=]1OY=P_=F
MK^?B>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB
M>(GB)XB>(GB)XB>(GB)XB>(LL_EL?I-J#J<;I/R].%9ATM7->!;S9K4IM':0
M5L.-3^%G[)L$/?BB$%E$&'PLY* A*-M73&7D29X-M#W[(Z@T=)%IN^=\#.#G
M!QT./WTSC.B\OQI5)#:W;W,9W[R1^06[9BI6J5HVR.=5^TC\9BT3%28/5<%C
MD*K(L>BD'&#T5)B3W')F'1,F_)O"[[1%-TTRJ1QR?RAOD,_NO4^42^^:AM+S
M?G"Q>EN6*OM:8QV,3 74_25W%*@C=EPQM+OJ+QV7DH1)8[98J"SC,8/QI<W&
MU'355VT<,C0F3QW0_&"I&AQU )QU S@_#&GUA5/^&"S)K9TDE^LNOGBB3,*E
MYOH.@X31_%EFD[A8 (55:TE%@K*N*:.E%AZ<N+HNMX[%!@_=+&0+(ELNV35:
M[;J%IX Z.R222X8SGH/3KGKX+Z O%XT\1/$66$*^+N+UBWBR-9W-+8.YHNLN
MF:TX_+#HG%293G%#JB<,YY-Y#KI(4RX2QC,5<"0T/KW4P$#,1-?L51!]M)Y$
M]5ENI:YO$9R03YX&!Z;G/RPK%NN799,;$B4EN:\"=N0BLK3C5U55"2M<P>,%
MX?84:KHM 6V[N:1-N+_<$8P\D<BG+46O&V,A:RD@V:+2][#V/[6<E,[Z;Z?/
M/7Z]^JN)XHLM?AS_ .2?3_JD[N_[U[\\6G;C_2S_ &-6I7BRJ]V;T]4E27!1
M='3,_J/GO0A.2C(&Q_X66^%(R(R145+K;*ZY8)F'RC*/1[&Z>VQ@Z]T8-,;[
MHN/I^_MO#-VNUHOE[HZ<R4%@BII:^37FQ4RB,")H![PPL#ZBHP1W,##(_ (S
M^&HN%-355'1ROY9JUTC86Z8_PVEQ+SGV0YV(V=7/< -CC(N+=Q=,L/DSM)]-
M*,Z+&<8KQ,E504RM2]G[QP0XK3!H^,MO3.D:^@JG,) I)A2;U/1+=Q&)%%LD
M-MM8\CG3MBJX)X;?V;6ME%?.'I>,15QW2>$7FV"HE;<C#!):CFIRTT=.*:5S
M"2&U-/5=WCOSGC4=WN#;_4F6CKVVHQNIV.-)4<C33A[VU(_P\8F?WC<X&8WQ
M<Q_P\KO/Q9=KW]?UP=,0OH*NK+AK:3RTC;E*K3&'24,+CT-W481QW5R)0H-:
M#L*Q\6VC)86V14^X+.W,U+;Z_CKMC'XNT_@NPV"T<-5E@N-MK'4U)':;R*.K
MIII9ZP"2I9<W112/D(GD=4Q2O<.6)C*.('9>7AV[UM;55\5=!/$))'5-(98I
M&-CB]F,TX<YH;[#1&YHSEQ,KEM_[I5<N3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$
M3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\
M1/$3Q$\1/$3Q%D#\JKVW2R-$5Z+^-*OOD3IP_8NQ:01F771"8-^BS89 [&9
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M,?K\7&I4&C$0@=:[.&D91JX(-&P<L@ =HR8,1>%3#IT^OKZ]5IQY7$8&&D@
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&XB>(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g773514g35y96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g35y96.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2GT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *=B^$'$CA"24T$!       6!P!6@ #&R5'' %:  ,;)4<< @   H  '
M)0 "!0871T:7EA9V4@4V]N86QI(%-E=W=A;F1I($%R:7EA<AP"!0 74&]W97
M)0;VEN="!0<F5S96YT871I;VXX0DE-!"4      !!!["38D[B0^B<<P,FA]K
MGX.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M  4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<F
MEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0
M!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E
M!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G
M!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V
M]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M!,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F
M]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6
M) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M          0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M              4G-L=%5N=$8C4'AL0'#@           *=F5C=&]R1&%T86
M)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B
M-2;'0               !4;W @56YT1B-2;'0               !38VP@56
MYT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W
M)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M    UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M     X0DE- ^T      ! !#@    $  0$.     0 !.$))300F       .
M           #^    X0DE- _(       H  /_______P  .$))300-
M $    >#A"24T$&0      !    !XX0DE- _,       D           $ .$
M))32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M   0 M    !@       3A"24T#^       <   ______________________
M_______P/H     /____________________________\#Z     #_______
M______________________ ^@     _____________________________P
M/H   X0DE-! @      !     !   "0    D      .$))300>       $
M   #A"24T$&@     #-0    8              R@   .%          $
M                       0             #A0   R@
M       0                         0     0       &YU;&P    "
M  !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M       $QE9G1L;VYG          !"=&]M;&]N9P   R@     4F=H=&QO;F
M<   .%    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !
M(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<F
MEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %
M1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M   0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M          0G1O;6QO;F<   ,H     %)G:'1L;VYG   #A0    -U<FQ415
MA4     0       &YU;&Q415A4     0       $US9V5415A4     0
M  !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0
MAC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V
M5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&
MEC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !
M%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M      "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M        MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M       #A"24T$$0       0$ .$))3004       $    !#A"24T$#
M ?,     $   "@    CP   >   0P@   ?%  8  '_V/_M  Q!9&]B95]#30
M "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!
M,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"P
ML-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,#
MP,# P,# P,# P,# P,# P,_\  $0@ CP"@ P$B  (1 0,1 ?_=  0 "O_$ 3
M\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M   0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R
M)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#
M87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V
M=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9
M$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&
M7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ
M>WQ__:  P# 0 "$0,1 #\ ]525!UEFYWO=R>Y\4WJ6?ON^\H6OX/%T$ED5=2
MKNS,G!98_[1B!AM:9 BP;V/K=^>W\UZ/ZEG[[OO*5JX/%T%Q6+T3Z[83Z+\?
M-+G9.679U-EAM:REMEKZ7-^UNO:[U:;-F5]C^QO]F%Z-7Z&^VWI?4L_?=]Y3
ME]HY<X?,I6K@\7DCA_XP!DUXOK/><FD6Y-Q<QM>\4X5616^VJG=4[U?M]>)7
MA/Q7[_ $LRRS]':K%?3_\ &'668[<T''92*VVN]%UL[F![[G.I]^1L?^KV?S
M?IX]GVG]/;ZJZ3U+/WW?>4O4L_?=]Y2M7 7 9@_76Z_J9R[#Z+L;.IZ<T7,:
M0^TXXPB7XU6+_H;7U7V5^OC>JJM?3?\8^(;*J,MMC V\5W.<QY>6XU-&!9<,
MH6.KL=;7[_ $?T?VW[5D9'K49"ZGU+/WW?>4O4L_?=]Y2M7 >[B78?UZIR W
M'S!DX[,@5UN?Z+'&F1>W)R_P!"[U:V^M=A9-&-]DR+?LN+=CVT_I_4;I]7U\
M^UX3LUS?19=LRZ]]6UU3*:*G96^JGU=]^2S*R*<=E?^&].W[.MA]]PL:QKIE
MI<Z7D. ^BW:T-=N;N_EIC;F;9TDM_TCXWS]'=Z?\WM_/\ _ DK5P>+SM6']<
M<+,<RI][1GYHK<]UOVL-H=]HLR,QK[V''Q&8U/V9N'7Z.)ZUGZM=CY'Z"VV)
MP/\8Q%5[<@LO+!7:#;46P+['^L<7T78[+WUVT[O2ML_4\:ZG^?NHKJZ0V9>Z
M!S+=H+W201[_\ !_\ ;?\ I/\ @TO5R9&HB2#^D=.W\UWT/I_O,_\ !$K5P%
MH]'Q_KC7U1MG4\D78+O4WU?H@&SM=1Z7HTU7>WZ'Z2VSV+HUDBW,/ANVDD"Q
M_TNS?YOZ&W\_\ \#2-N7!B)TB;'C7\^?T?YOYG[_\ P:5JX/%UDEE>KD[N?;
MNYWNG9^]&S^<_X/_P5,+<N!,3!D>H_G\P#]']%WY_[G_")6K@\76262;<N#$
M3 C]([Z7Y[?YOZ'[K_ /H*7KY#7MW.&PV,:";'?1<0WC9_.;S_ #?_ ((E:N
M#Q?__0]%,&P@Z#<9/S63B?6#$.';;U*VK"R,2Q]&747</8=H-+/==;7:SWU^
MU:KOI.^)_*L'ZR8F)37]NHQ&V]7R[&8F+:07;;+ 6MO].?2]6JIGLMV?Z--9
M38%A$.I],R/K'T_,Z?D-M.2VS"RZP"UT;?7Q;'UV-:[VV-V?\ ;:Z)<]U/$P
M^DYG0KFPS'QK!C76G0%K&S3=:?Z_KV/L_EKHB"-"D51ZN1G=<NZ7?E#/J:S'
M-;K.FY# 7"Q[&[OLF3]+T\C?[V_P""?4B_5W#NPNC4#)<?6O+LBYSSKON]^W
M<_\[9L]3_A%G_6NZRZ_ Z7C5#(O<_[0:#(#P)JKK>1]&I[?M#[W_Z&M6:OJS
MB7$Y'6C^U,ZS6RRPN%3?\ @L6AI8UE3?Y2/1&M]Z=G:8W<CQ&H3*EA="Z3@7
MG(PL446EI87-<\B'<C8][J_P U&;GX;@\BP#TYW!P+20":]U;7AOJM]1OI[Z
M_ST*[)L#<@)TD,96*3#;JW$[H#7-<3LULVM:?=Z?YR9N9AO8U[;Z]KP'-)>T
M2''8TZG]_]'_QB5'LGB'<+N/Z<-D3Z9.V-?I?2W_N_\&L3J?2\_(ZSOQ.K#
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M6,^JJG^;
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MOE/-."KN[D)>89./:]/BT((QX)TQ?Q\++-IJ-??[\Z5L8L_:O3%:R+DG!WZ
MFDIG.L;[\);2J)18S)IG+7(&+\[T8,NU/<625+1P<1D.UQ)#7^T2E7:14TV2
ME*4Y@4K8H+LS]HI438[MN\IYEV];SKCB/#N#ZAEO!.W;*V5ZMBZP[BG#K/E!
MEZ%-!$2#?.6WV^8;QI+0KJM5PSR_NCT2=R=27SJ.C*,XMS:3LC9PW4K$J_\
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M(R37EL@TL:E*3BCJPIQ[4MD/6[971E%$Q=?J'AS.14KQ0&PB^73M=)#?'?\
M'5)QKB/#.WE#"F&6U7R5*62S9:NAC62%B\OV6N-*_7V&/G%'QA>KUCB&CS24
M[-I)S2;QE,@W()45*N^$['+;X6X7VZY+S3NPW!2]QP?F';S!&SMEN#NKC&.,
MLY(BTOL=1[ SH,%<)*37C@3BXF:R;9<BOXJ/120;JB)1.92L>->PNVYL"8N/
M&[F-^<+)4#'50Q%<9ZM[CD:G/;@,8XZN\C=<;4K.,I5:+"KS$7CLDD-.IKNB
M?H^FH:C,8R!3E5#,4GNE*SK8^RBVZV:P6FQOKCFA%[;=]>+NT&D46MEIGAD,
MS8DK3&K5NLLO%X]=N@QD\CF"*TY$/'3RVNWIE5FEVCTS%0*I_>I2;:-K6/MJ
MT9F.)Q[+W&8;YNW#Y:W+VL]RD(617C[WF67:S5HBJ\:$K]>3:5)BZ:)IP+"1
M3EIAJW$Y)">E%!*J5]_II4E-*4TI32E-*4TI32E-*4TI32E-*5@*=O-F93,J
MS;/R$;M7[I!$@LV9Q*DDL<A"B8Z!C&X* !U&$3#ZB(CK72W$JL^EL!6( TJ=
M@V/+/UUUUKPJQEMK>1X27>&-V/>2C+,@). X R3R  JE?I#MGUBG]Q8_E]0^
MES_G#]E?\5/\3\/^0/[V;[=/TAVSZQ3^XL?R^GI<_P"</V5_Q3XGX?\ ('][
M-]NGZ0[9]8I_<6/Y?3TN?\X?LK_BGQ/P_P"0/[V;[=/TAVSZQ3^XL?R^GI<_
MYP_97_%/B?A_R!_>S?;I^D.V?6*?W%C^7T]+G_.'[*_XI\3\/^0/[V;[=/TA
MVSZQ3^XL?R^GI<_YP_97_%/B?A_R!_>S?;I^D.V?6*?W%C^7T]+G_.'[*_XI
M\3\/^0/[V;[=/TAVSZQ3^XL?R^GI<_YP_97_ !3XGX?\@?WLWVZ?I#MGUBG]
MQ8_E]/2Y_P X?LK_ (I\3\/^0/[V;[=/TAVSZQ3^XL?R^GI<_P"</V5_Q3XG
MX?\ ('][-]NGZ0[9]8I_<6/Y?3TN?\X?LK_BGQ/P_P"0/[V;[=/TAVSZQ3^X
ML?R^GI<_YP_97_%/B?A_R!_>S?;I^D.V?6*?W%C^7T]+G_.'[*_XI\3\/^0/
M[V;[=/TAVSZQ3^XL?R^GI<_YP_97_%/B?A_R!_>S?;I^D.V?6*?W%C^7T]+G
M_.'[*_XI\3\/^0/[V;[=/TAVSZQ3^XL?R^GI<_YP_97_ !3XGX?\@?WLWVZ?
MI#MGUBG]Q8_E]/2Y_P X?LK_ (I\3\/^0/[V;[=/TAVSZQ3^XL?R^GI<_P"<
M/V5_Q3XGX?\ ('][-]NGZ0[9]8I_<6/Y?3TN?\X?LK_BGQ/P_P"0/[V;[=/T
MAVSZQ3^XL?R^JK=3D@:A^ROE[JH>#\/ /X \C_\ ;-]NJ&?)MU345)[7*8"J
MJ\":.BQ$"]X82D 2,R@)2%X(41 3"4H"<QS")AD](F_/_P#Q7[-!P?AY _ '
MD/\ [9OMU^?TH77ZV3__ !T;^4T](F_/_P#Q7[-5^)^'_('][-]NOP;)UW,)
M!"9 @%-U&*6-BA!0.DP=!^MB<0+R(&Y3%,_44H=?3U%-47$H_*!]ZKM] 'UU
M0\&X><8B88/263?V'+';W8/MKI')-Z$2"%A5 "G,8P!&07"@&-U F?F*$0(0
M/@**8IG$H\G.8_!P>DR^:\O+Z_?]7LJWXEL=O#)S^4._L/L]V#[:!DF] 8QA
ML2H@83"!!BX'I( @<  HA$@<0*)BF+UF.(BF3J$Q14*>OI,O_;]'_-/B6QR3
MIDZ[=X<#.<>W;IDGD,YWS^0R1>P(<HV1<QC&*)5!BZ_UI@'/)2 6(*F)3<AU
M"H0YO(.DQ?/D;F4G/A'L V/OR2?H(J@X)8X(TRG)!R9#D<]A@ 8/7()V&"-\
M_H<DWH2I%]XU0%,1$YPBX'J7 3<]*H#$B0H 'PAW!43=(^8B;@VGI,N_J[C8
M8Y>T;YSUW)&>F-JK\26.!X9-N9[PY/OVQ[-@/IK\FR/>S"?BRKDZS 8H%BZ^
M()  G'H)UPYQ$H@8H"*@J'X3)P<!%05'I,NWJ[<]N?OW_ABAX)8[^&0;YVD.
MWLW!V]^3[:[BY,O %. SHF$Q"E QHV' R9@)TBH3ICBE$YC?K# <ITP/Y%(5
M/X-4-S+MN!@]%&_L.<[>[!]M5^)K#?\ !N<C _"OL<<Q@C?KOD9Z8VKI/D>]
MF-R%E7('2 =)(NO"7D"@'5R>'.;J$0ZQ^+IZA$ *!>"A7TF7_M/S?X(JT\$L
M2=A*.6PD.-O>"=^9W]V!0V1[V82B%E7)TE H@6+KP@<0 0$YNN'.(&,(\B!!
M(3D Z2%#D!>DR[^KUZ<L_/TZ9S[<T/!+$X\,HQY2'?WY!^K%?LN2KT!>D;"H
M8>[,3K-&00&ZC&Z@5X+%E)WA ^ H='="7S.F8_Q:IZ3+YKSSC'U>>.O/.>N-
MJK\2V'YDAV(_W&Y^>W4=.GF#0,E7H%N\&P*"3S_LXQD'W/F'''4$6"_D/Q!^
MOYY'S$2\%!Z3+CF/?@9_Q[.7UT^);#.=$A'YO>-CECIAO;SY^S:OTCDN\I 8
M#SQG F,(@9:,ABB0/_B7P\:@42A\A.4YOI,.AN93C! QT"C?WYR?H(JJ\%L!
MG,;MG\Z5QCW:2OUYY>_/3^D>^=V8GO,XZC& P+>RZ]WA  ! 2%#V/W(E$?,1
M.D<_(>1P#D!KZ3+G/AQY8V_CGZZM^)+'\V7GG/>'Z.6,?-GVUW?I+O/(#[>-
MP'3R7V9"\&Z4S$'G_P!-ZOC,(*FZ3!PH4H$Z$A,F:GI,OF/V1YY_X]WMWJOQ
M+8?F2=/_ +&WVQ]9\1QC?E@;41R7>4@,!YXSD1$! RT9"E$H  !TE\/&H ("
M/F/4!C<B/ @'  -Q*>3 >Y1_<&JKP:P&<QNWZ4KC'[)7Z\UW?I0NOULG_P#C
MHW\IJGI$WY__ .*_9J[XGX?\@?WLWVZJ4)D:X/9N':.)4IF[F39-W"0,(TH*
MHKN$TE""<K0%"<E./!DCIG >!ZOEJY9Y2Z MD%T!&E>18 \AY&H;CA5C';SR
M)"0R0RNI[V4X949E."Y!P1R.QZ@UXK1^\<Y]JOOQ"FH)_6E_3;^>L^Q_$[7]
M7A_IK5"UC5E4TI32E:WNT'W@9'VB?H2FJ958.Q5^WVF>;7<TRB^.L,1!,HQV
M,/#.6CYFE'2LHT=23EN^<IORD-% 4K-0G?E/E6T:.<L>N,>?+;YS]^=:OB=W
M)9B%T4L'.ECT&Y&Y^G?ISZ5/VG6N%O52K%UKCPC^ MT#$62$>$]',5-Q[>38
M*B "/2<[5PF90G/)#<D-P8I@""12K'((R3C/EDUL8I%DC1U8'4 <@[9P"1_'
M_'G<FK*OII2FE*:4KCD!^8?Y_P"_Z_1Y<^H:K@@ XV/(^ZG4C;(YC(S]&:YU
M2E-*4TI32E-*4TI32E-*4TI7CD5D6T<_<..]\.BR<JN.X.9-?N$D3J*BB<AT
MSD5 A3=V8BA#%/P)3E, &"^/U@.IV^__ #5K$!6)SC!SCGC&^#T]_2L$8ZHV
M-4:HA,4V"=LH6_5>+<KEDI29>R+Z$E8T'35*16?RL@L5Z9I('!VNDZ%<ZZBA
MS.53@5360[.3ACDJ3R  SG?D!Y5CV\, B#1(0LT2%M3,6967(U$LV^&WP>?4
MU6F.+*%&UR5J3* *A7IM=-S*1P2,NH#I9(S<R9Q<JOSO$>DS1N/2@X2(/=_$
M40,?JH78L&)W'(X'^,5>MM"L;1!,1N<LNIMSMU+9'(<B*Y7Q;0W-794M> (I
M68YZ>09QGM&6*5%X<[M0RP.BOROCB)WSH>A1R=,.]$ ( $3 C6VK5GQ'K@>[
MEC%#;0&,0F,=VIU!<ML<DYSG/Y1YGK[JYFL6T.Q1D##S,"1[&UEL+.#;#(2R
M ,6QDFR I@JV?HKN.4F;8G4Z47/^JZNKJ,<3 [*20<$\^1S](H]M"ZHC("L8
MP@U,-(P!S# G8#F3RKUR^/*=/3T19Y:&*[G(+P7LI\+V21%I[.=F?,N&[=XB
MU6[AT<RH>(05ZQ'H4ZT^":!F *@X!YC;J,?PJK01.Z2,F7CTZ&RVVDZEV! .
M#ON#GK0,>TX+:-Z"&*%J$>1EO&R75R+'V;SX3QG@/_9?J/\ VOI\?_%^/34V
MG3GP^6WGGW\Z=Q%WO?:/POYVIO+3RSIY;8Q]=<1&.J; SLM9HF%*TFYT'Q95
M\#Z36%V$D[(_? +=P]6:H]^[3(L/AT$N[$O0ET)B)!%F("DY Y#;H,?PHL$2
M.\BIAY-6MLMOJ.IMB2!D[[ 8Z5Y(;%M#K\9/0\1 $9QMG;%:3C8)"66!\W*D
MY1*F*KA^LNW $WCDO4T40/\ K.>KJ*02B[$@DY*\C@?XW^>J);0HKHJ +(,.
M-3'4,$;DL2-B>1'.B&+:&VJ[RF(P!"5I^\)(.XSVA+&!9VF=LH1879GYGQ.#
MLVQNA-R1,>[X$@@<X&:VU:L^(=<#W<L8H+: 1F(1CNV()74V"000<ZL\P.1H
M_P 6T.3KD54WT 1>OPBYW$7'#(RR8-5E!<"<X.4GY'BO(NW'PKN%2AWGD4.D
MG2#L&+ [GF<#_&.E&MH6C6)D!C0Y5=3;'?KJSU/,GG79-XQHUC+!EF8(KT*V
MV39P@#(2J'@6R0( FD'AGR/?](-D/B==^<>CXC#U&Z@=AG!QGGL/[C;YJJ]O
M#)HUIJ[L83Q,-(&/)AY#<Y->F1Q]3Y6S,;C(0Q7%DC?#>"DA>R29D/!G4.VX
M:HO$V2G=&4.(=ZV/U=7!^H   !F"Z0?#Y;?Q.]5:")I%E9 9%QI;+;8Y; XV
MSY5RVQ]4&=J<W9M#E2L[L%0<2@/9$QE 60(V5_LAWAF!>I$A"? U+QQU%X.(
MF$68J%SX1R&W\>=!!$)3,$Q(<Y;+;Y&#MG'(>5=$)C6DUUW-/8:#*R=6%!PW
MF%0?RB_C$72AUER"1R^630[Q0YS=38B)B\\$,4H  "[-C)SCEL/\;_/5$MX8
MRY1 ID!#G+;@[GF3CGTQ71&XLH<1!3%9CH C:#GQ(:78A(RRH/!3 H$$7"S]
M1TCP!"A_9UT0'CSYY'D78D$G<<C@#^ JBVT"(\:Q@(_KKJ;?'M+9'S$4-BVA
MGJZ=+- $&LI/1D"1GM"6 I7@G.H*WBP?@^$>M0X] NA3^+CHX  !K;5JSXN6
M<#^&,?53T:'N^YT#NP=6G4V,YSG.K//VXI*8LH<U"0M=DX CJ&KQ3EAV0R,L
MD#,IR@0X N@_2<K\E  Y<K+"'J @/GH'8$L#@GGL-\G/+&*-;0NB1L@*1^HN
MIMNG,,"=O,FO3-8XI=AD8:6F(4KR0KZ;5*'<"^DT!9ILEP<MB@FV>HHK]TN
M*<N4UC'_ &3B8OPZ!F (!P#S&!OT\JJ]O#(R,Z:F0 (<L, '(Y$#8^>?;7Z9
M0=%C,T8TL;N-?%NMCLH0\5)M7TD5LH9C!OGCE*39%D$XX[8L/'N2H=XQ<"#T
MK94"D6*5PG?&6R@!\(DC)&W611[^?]^A(.+?)"J2R,I[YX+A$8%L;6TK$,-6
MG&D'&0?%@\]ZSU:/WCG/M5]^(4U'/ZTOZ;?SU-8_B=K^KP_TUJA>H@'S'T_W
M_P OI'RUC 9( ZG'TUE9W .PW)8\AC?<\_=L:M*GWVE9!C74Q1;5 6Z*92<A
M#/)"NRK.6:-I:+7%M(1RZS-94B3QHL %504$J@ =-0 %)5,YKG1DYC/+E[??
MC_%6I)'(':-U<(2#@YW&Q^@\\X]F:NW5M75"OM ,$#G_ &QWVO1S0KFVU%!/
M(E(X(*BREBJ:+IV:.0  $14G8926@2$ .@5I%(Q^>D #(@8*<G.,]/F^^>8Z
M5@\1@%Q:RC U11ZUSD9W.<8!R<=-MMP3R$>NR!RXI?\ :Z:CR#@RTMA^W2M8
M3344%5<E9FA&R5]14YC&-T(KOYF':)B(E29PZ)" !2<!6X0AM6P&!Y<CC'+G
ML>>^^=ZQ."S&2W[MLZXR<^S8CSR.7EC/TG:SK&K<T'R 1^C2E8=O&X'#6-;W
M3<:7O(,!6+MD @'J4)*K+(*2H'=^ 0 7?<F8,1>/NIDP"1=- ?NR*-V8K+)G
M($BQ,RZAC'EOG^']]^F:@>YACE2)W4.^,#/+/+/ESQ[ZR%:[-%TRL6.VSBQ6
MT/5X.6L$JN82@5*/AF"\B\4YZ@ 1*W;J"7@1Y$/(!]!HJ%F5>6HX&?[^6^U7
MO*L:N[ A4YG;##S7?<'IN#6B+LVLAYBW#[Q,J9HM5KL;N!)0I)S-02LDZ-68
M?WNL+53']1BXOK%BW0BJ]&N7[<R1 <=:"JJYU%W#I=QG7,02!1L2AY@;')&<
M''^/9G-:'A<DMW>3SN[8BSX?R6# H.ISC(/L/GTW^ZUU=%32E-*4TI32E-*4
MTI32E-*53Y95!"+DEG2 N6R3!XHX;AQRN@FV5.LCR(@ =ZF!B<B(!\7KJY/6
M7?&^,^VK7SH?"E@%8D#'+!R3DC;I\]8]HCZ)E*139. C1AH*1JM>?0L0(E$8
MJ)=Q#-Q&QHB0QR"+%FHBU$2G.7]5\)C!P(SMD,P)R<G)\SGG5D!5H865=*F*
M,JOYJE 0OS# J!/:R7V\8TV17ZWXZN%GHEK99!P"Q9V6GSLG7)YJRF\\XXAI
MAHWEHART?HMI6(?OHN1037*F]CWCIFX*HW753-?$ 9 " 00VQ_0;[^^L?B#N
MEJ[(S(P>(!E8JP!E0$9!!W!(/F"16OA+M/\ ?C/7EA6JEBW::>)R1D7?KC?%
M4A8)/+K)_#K[(9-U+REFR TCG<BA(-K946+B!CZ_77+!=2TBC87,[#PJAZ^E
M?W<>,EGR%C)  WUCD/<3G?IM[:PO3[LN%6.W(=[M$+&0$>BG)9P"<ZEV 7'B
M\1('AK!=+[5+<JRM^<MS3 <4RV*E<5]G+DRX;?\ (.2[J:WQ+;/%$C(RT06U
MVN)+#!-)1>Q3[F:F7TNT5)8%F$0U<,%9%55ZC<8EPJ[ZLR , ,>$Y!8_XY;^
MRHDXA.'FG'=F/19.T,DCZAWT8#+;KG .HDL2/%MS.37EW%=K-G?(=/W9XQJ\
M]C"+@D]O^0<KX=S-MOD,\UJQ5DN.=Q-"QD#$F1KW TF-R$>:AYY=5Y;L61L?
M7HZ21D8))[*)D56U585!0D')<*RMIZH6Y DCEL#N1@U2;B,SK<(IC [IY(I8
M>^4C1/&F-;A0^58Y:,:<[ G!J1>2>U[S!0,\Y(QO PVW_(5&A:7O /3G]989
MT7G*_<]K.)I.^HM\A7BS0E.QS<W,U,P4C 72G8K<2+JD.3IMG-U>N2D4<V+"
M"JDE@24SG3@AVQL 21MN"P&1TW%3R<2E29T A= MSI*B74KV\9?QLP2-\E2K
M+&24) +=3^ENU8W;5)5CC[(N+]M3+*N66FR26PU9HFP9&:XAH\1O%=WEBDXS
M>YF#EG7 T1>BNB++U9S$M9UY*QL:V5;*'!TL[I3D@MI4N&&!J.@ [8VWSUY8
MZT^,+A<)(D DD%JT;!G$:BY+C\+DY\.@CPD DCIO5KW?MCMSU5O4/C&!PS@7
M*MTQ[40M.; PU8\AY2K60%S9GM6+?=[#-FJ;5Y%X]DVT?4W$K**987E4XJTR
MK"B.TBO4'4KJHA4C)9E!.%U  CPY)8'GSVQS&_LJU^)W"N(UBAD=%U2]V7D5
M_P *T>F)ER$.%R>\SACI]M51#??N,SYNXVD)-YK'.,,'R&_O/^#&^-*9D*XL
M\ZST7A+'65:_(IY\J .$:S*5F?GHYE;6,,DU21J3M&I [">=2S.48T**J/S+
M:$.2HT^)E/A//8'!/7)Y<JKZ7--<6V"D<1NY8A&KL)6$2.#WRYTE20& _).G
MGD&OHLU!6ZII2FE*:4II2FE*:4II2FE*HI9&%:9)P\SD8L7TG*W5=M7W_P '
M_HSUO79A^]=CU& W]JB6S^-_5E./+SX@ O)@DC!U*0=@\61Y_A%Q]>]85^R"
M!PRZF:*Y"-^8PMIF)^=0R_/67[1^\<Y]JOOQ"FK)_6E_3;^>K['\3M?U>'^F
MM4 Q>K_(0X^GD.//S#_F'\PUC@X(/E640&!!Y$$'IS&*^?S%^2V'9];_ /+^
M'KN[& P'FR41MD#)O1.2)K#JP*JR5;FA4-R5&)9/7,S19E< *5,K5A).U2-(
MDPCL !+;%@,N"?#OON=L]-MQ[3C>N<61>'WTL/B[F3203G;4JL<$#!\1(W\_
M94Y=P/:C;8\(HJ,8.PES!;1)RE X\=-)",;#TF$#2]L$YH1HGY#U),5)1^GP
M('9%#@^L=+9G8*3C/4C&WGSY??EN,^?BUM 2N[MY*1CZ?9]_.HU4/ML,32KM
M)GDG$ETIR#LW"4A7):(NK<B1UC)%,[9G) /TQX*;K30;NEN1#I1,'2!LEK)X
MR K @@-DGJ1Y#ECW_P!C6*O&X=^_CPN_J G*] 2<;\\XY=!SK'798VZIFW>;
ML8+&1WXXLN[!Q?*>G(1Z\6LE%1MU73B$?!.@*LCX%K;GD:'4414*U QC")
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MBRJD]+"[CE _X*[H&(QBYQ\CLWCA+U4U)%ZZ[X\2?/\ A$V_O\U8'$6*P.H
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M"]\=$IS*%2,IQUF2*<YS F)A(!C&,!>3"(WF1F&">N?K^^*IA=6K0I;I(?7
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M4 YK>#D5@2?>,,25MW$Q49G.=9N5\@/6KMW#8!MPUVVN73,M4<D;.I1)1N$
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MU/\  5FKPGB3\K24=?&%3^=E^CG5N1/:\]G!,NR,F>Z>FHK''I*>6KV08%H
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MH$C4#FYYU.7;AVMNUS.,\CCB^.+#MES859%BYQ7GIB-/=.))40(#6!M#TK>
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M/D<^1'E_CECJ;7A=O:LKZ=;C?++D98;[D>6<;@X.?*IWE "  % "@    4
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MI,NWNSGW9K.-H_>.<^U7WXA34<_K2_IM_/4]C^)VOZO#_36J%K&K*II2N!$
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M'/CV1PLJGUEE8L3U!Y-[C@UM^T:,TG#[A 3!-80I$0#I5HRVN/\ 2&M21SW
MYC;*FP# 5+WW9PW";N<W5&)R)A6MN)C;MMUJ5MC4I6JOXEDB9*_WYM%ODS(+
MN)$'B;>(EB)BHU<3<V@10DC L%6,8 N)7D89C7P("-L8P3R'/)/,\]CM6=*S
M\(L;2P@<Q7,@6[O70X<2-@QQ%AT3 !&<'0IW#G.",YX4F>S>L%IQ+D2+M%_[
M.+-+YRUI5[(F[G)/;M/6%T90]2LS@A'#E"(;R*A)"#DCIF.]400F(P'=A2L4
M<XC($2R0S M;2@@'F4)Y8VVP=_80&'(YR8I'O9;?BG#W6WX[8,LC1[*EZD8Q
MD;C)9,QNIP-+&-B$*,,^;:_THT6.<5"WRU:N>$X.KEG<9YK93S(R<A6.\;GC
M(F3(#A5/N&4,J=VG)F429-&;0B#=[(MA24:S6@N(LPR:7@52T,X8;KD81A[%
M).3C & 6&,8/:.3@_$>[XC8K/:<7N)^[XEPEH6T)-I8R7$3X _"2  H,L[.6
M*1$$-83W>3ES,-IM=:V([=IC<U'8X;NW=^R6K+(57&K-5BV.Z6@ZW.2BC!K9
M)I=$A_ -FL@1Y+"05:_&3C$Y'HW/=DDB"/O-/K,3A=C@@>>W7KT!Q44/ HTB
M1^*78L3-CNH O>3$$C#2*,F,>8*G3^64(*U*[;;G*&W'88I>7H6.6A4[,T=I
MR4$Y7!RO!SL0_=1$W%'<@DAXE-K(LE_"N100.Y9G;N%&[=10R*>3%()8U<#&
M1N/(CF*T?$;)^'WDUH[!S$PTN!@.C*&1L9."5(R,G!R,G%95M]RJM K,O<KM
M/Q56J\"T4?2\Y-/$F4>Q;)^74JNL8H&44.)4F[=,#N'3A1-NV257533-<S*@
M+,0J@9)-6PQ23O'%$C22/A51!EB2/+R',D[ 9)( )J -5F-UO:52CVL[8$YG
M;OM10?.(ZU[H[-&.V5LOS5!8S1[%8AACF:/>%P*XZY!LNT6: D0DO/UMZ(U^
M2P&FEN,K""D6<-(1XB,#D#CSZ'/GMD5TT=A9\)"RW^B[O<!DL4(,4)(R#<-N
M&(VV(*[G2L@PXW7[5]G&WK9-05JWB:N-8MP[23<7?)5F7:O;U=GJ9A44DK=:
M5TFYCH N=19K$M"L(&-.JJ9A&MU5W"BUZI% A.54#=G<@<SS+$X SCR'+K6)
M<7-WQ*=5(>1B=,%M"C,JYV"11+J).!SP6.-R0!B5OBVO#4?$M^'Q@(R'OD^'
MAQ04= 5J/5PX,+9%5P!4NL10246 .[(8P2:T\/B7QG">(>,X+87?Q'2"VV=@
M3R!K$[N3\)^#?\",R^!OP0UK'F3;P#O&6/+8\;*OK$ ^C5U64TI32E-*4TI3
M2E6BX*W-F';\98Q@6)?9L6A0ZN#K#0;250#<%$.DK85S?$)0ZBE\Q'@HS0YU
M<NJ9/E^%C_O6NXEI[G<G/=W>D>9]"N,Y^;)Z;UG.T?O'.?:K[\0IJ*?UI?TV
M_GJ>Q_$[7]7A_IK5"UC5E5P( 8#%, "4P"4Q1 ! P#Y" @/D("'D(#ZAY>FJ
M@D;@D'S!Q0'&<=>>PWZ;^>VWNVY4X#Z _P M4))YDGW[TSL%Z+L!T \A7.E*
MU9,&B6Z;M#9::6 LCBO91#$@8M,_*D=)YPM(&5E'!"B'=K*U@C/PSDG'4QFJ
MO'J@82N0ZL_ CA12!J<DDXW&Q8;]/+WXS@[#5!?3>(R'/X.V TY]5V/A.-B"
M1EB>9_M"S*N1W6RSM3+9?AZD,:928U&1R"S(!RIEJ]X1CXF<LW=D 056@+W#
MK6%0Y"F67!1S'I<"^4 MZ@26RZAK89YY8CESYG&0.73/LK FGDL>)E@6,;L
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M%QG)]8X.-7OV[1VY9#M*?1D_<UE>P-U _7Q%&;0.*8A4I@ #MU/=QHXFU6_
M  ">9!0W'(B B(C$./V-H<6/!K5AT>_ N91Y$.F@ ]3C'E0]B>-<233VA[8\
M6OT)&NULREC:R '*ZQ&HFRK8(Q)@D;@@D5>M'VMX&Q\\"5@<<PCF>ZP5/9;,
M#BWV4ZX<=2_MRSKRCY%4X\G.9LHAR;T H>6L*Y[2\9N04-X]M#N!%: 1* >7
M/)VZ9S6YX;V#[+\+<30<.CEN-BUS> 7ER6&=X[B?7) IV)CC(75EN>]9](0"
M 4I0*!2  %*4I0 I2@ %  X^$ #RZ0\M:1I&<DN3(Q)S)(2SDGFQ.=.HG<X
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M!5'=;+L H \(&GD,C[DF_P!/OP9<*[F&WX+>1\.AB$,$$7$[U!$J "-5595
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MII2FE*M%PL=/,&W],J8'*XOLVDH;I$>[*6A6E<# 8/(@BHD0G)N0$#"4.#"
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M3MTT)T+*FU1>@M64B%3=/6Q[PL>!LNZC(P,[<_G]OMQS%222S+)*8]1"7!T
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M  B')?H'Z=,_? ^_W]@I_P [>_[_ .:Y . X 1]>>>?/G_\ 7R#T_AI3.*X
MO ^H^?F("(\"/''5Q](\CR/J(B(Z4IT^H<FX$.!#J'T__0^8!Z<^?'KRJN?X
M8ITAQQR/J(B//F/(]7GY<#Y^?IYB(B/(B.GW^_\ 'W\JIY>S[_?%.G^)O0P<
M<^0 ;]H #TX'Y_3IG^WU4KGCZ!,'EQP!S<>8" CZ^H_/GZ ^7D*G+YQCK]_O
MO7.E*:4K@P=91(/ E-SU<ASR AQP(<#R'TA]'/\ 2]& SGK[,^=490ZE#R.?
MKQ_BOFZWY;:/_*WDE?*M18J)X%RI,+GDF3%N<S3&M^=@9RX:I(I%Z6U=LADW
M#J-33*5)FX*XC4R)H-&!%]A;7&V@G W]@'/IY'^)VZXY3BO#NZ;TB( Q[J6R
M/6S@C<ZLYZ@8V.^*U%W>[2MKE"MG)5$H1R1,8Z);J^(4[EUU U?.6[1P0KB4
M A@<)LW2B1"',DF*8IG.8^802#ML1@>_RYY\L[8'4UIAC=3UY^7A(.QP,<CG
MW>W?Z--@N^>'L4C3=L5QHQL8IQ-'@H/#4I*3YI=W<6U7C$XYQ$3SA1LT096Y
MVU;$E6S1L5)NL'BV"2":I(\'N!);%U!QXB2,;;CIG<@; 'F#[JZGAO%T:2*U
MD4$L!&AQG5IP!DGETW.W+-;AOX?/UU@$$<Q6].Q/OIJE4II2FE*:4KQ20NBQ
MS\6//C@9.O!< 01\7W!_#< IRF(]]T< H'0(_M_#SJHYCWC^-5!QG?!;PK^D
MQ"J/G8@9Y#.^!O7SY]K5<<L5S'&VDB3IRSM\S5YA&\%;(M/:99DT;3O:XI>
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M^_$*:EG]:7]-OYZI8_B=K^KP_P!-:H6L:LJFE*:4II2FE*>?R\QXYX^GC^?
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MDYS@9]4==_,<OFKZ/2B42E$IBF 2E$I@$.# ( (&#S]# ("'T@(#\PUJR-.
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M2FE*LK(M KV4Z-9L=VQ)TO6K?%N(>:19.CL7:C)UT]Z#=VF J-U!$I>#DX$
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M;.[3C,<2_P#5>CSN\SJ6 +"$Z2N@Y)9D793I8 5Z-P?M3V?M!;\(XG8/V1N
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M*66"Z9%+NMM*54<S@9V'OZ\]AC>LFSBCFN[1)%616NK=6AD;1&R&5 S.P/A
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M(K':+S'L1.%8)%>I(J,DDG:<C)F35=.4156(V1;]\LJ)2\LK1K'P\2-J6))
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MJ#0;,^M$XU6?!+S28.W,M*-&+=O%D6CE%V;Y\P$RAY4A0%@< $Q5 '7:</\
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M(XI&@>6[BCDN4!+) SC4H !+%F((&^XR 36IJ1D;'/+/G-@@G3B/L*+"9"K
M6GRKXZDM%M(]6,QI,Q<Q%]XE4'[<UDL4C*M7Q'"4H9&(< V3321\;F9[G69
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MU95-*4TI32E-*4TI32E-*4TI32E-*5;TK5*]-JD7EHAB^53_ .&HN@ G+^T
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M\L/W4WV*J<+4;&VF(IPNP B*$BR65/XID;I33<)G.;I(X,<W!0$0 H"(CY
M^FKXX6$D9T$8=#DLNP# GDQZ>RH+KB=K);7$:R@L\,J*!'*,ED8 9* #)/,D
$8K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g773514g36c17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g36c17.jpg
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M$<-Y: .HCC*^  >T1JLKP.@)Z5!V/D:^),T2;@Y(B_,JBB'-W@E .\+T'EV
M0V'<VQ1]0 (B(]..&I2BB6X)Y3MXS^:\MZZ]:E9/]O*HC5,R 9.LZ\N1'\Z2
MU$R%#F =]Q'8IO6 #T'<-M^@@/J$!_HXD*)(&XYF#T^_KT%72HF 0.7+J==
M>M)#G,8PF$=S> F'J([#TWWW]6W%_P \JJ0 2!L":\ H]=P]7ATW_-[/G_JX
M58 @D0)CG&W7?>E*)$3IK H)^\3)N3E$NW-N&_-N CL >H! ?;Q51(*=!!]>
M8^OT-09E*1$ PJ=3!U,$: SH/G7J:1#E$!$W38.FP?W#O_5Q"E%,1&M642.[
M CEU@;<_"JS)P#R$!@=V9L8DC'MW[<6SE%8>1?F^*H0@F%,P<H;E/L<O@8OQ
MB\84OMO!81G!;=6VH*0I(E,:@F H:[C0\MJXS5PV_P!JE 4.R=4A69!29$:@
MF!!\!!B08%4-1,! 3==P#?U '0/7T]@>WC(E6PTCY_DUF\*2\9:4O33 =AW'
MPW]7LV]GR\8E*.HTB?H:DJ) F-.?/UIV6@\PEUQZ,B[; .J[3N ;]1ZY>J'L
MZ>WB$>\D]% GRD5*/?3_ ')^HKKA\L[D%V3[LR4D'2K<'KS6&W533,8H.$CH
M:8$SIJ"7;<G=J'*(&$2F X@)1WW+S2E*HS)"H(4)Y*&H4/$&"*YZ4(4M&9*5
M%*TE)4-4D&0I)Y$$ #K/A7)KI/QI5,I94=0UO;FEH^!H=[NS&I)NW3%:]3=2
MK[J6BZ@FY8*H2*:<BND+E\6-61D%8UB]1:.&RRA7*.F<>8S?X'@2+G#UBW=N
ML4PO#7;]3:'4X7;7]VAA_$%(=2IDEI*NS:+R5,I>=:4XA:04*Z+C3%KW!\&2
M_8K[!VYQ'#K!R]*$.)PYB\N4M/7I0XE31+:3D;+J5-I=<;4M*P,BK6J-Q@WU
M@@GUDQ[C[S%K9T74K./8"SDJ[&!7.V:J,YRNTQZS/(Q\+W_G+,69$IA\X= C
M-.ILHL"->;B&'735I=-6>+XL75V2D,6K=W9&^=NDA:PY;7F(M.!EVYRY'.T)
MMVDMYK9%L>V+G*OK"Y;MKANTQ3$^T7:*0S;MW-F;QVY2%+2Y;W5^VL-./Y"A
MP+)8;2@J81;GM%*RM:,"PEFU690QA6'<75*7"J7ZZQIX)RXM:#2CUZJO[\Q8
MP?P@O&N9.3>0B35DBT>.D!8/7"J3IRJDP445Z.QXJN;+@7!,;O6W[_$;D85A
MKPNDHL%+Q.[OVL*==N>R2\AEANY4MQ3C;:NU;0E2$)+H">GM.([BSX-PC%[M
M#U[?W PZP=%RA-FI>(7-XWASCEQV:74,M(?*W%.(0>U0E)0E*G0$XSUBTJL5
MA:@LZ-$>8M;/IVPU<'B:38S5Q*S]HJC.3EY=PP3=OT&+V4<J"Z<L&+A1BT5.
M9!G^ (41Y_!.(7^(6>.*Q%\O.V?%G$6'-2OM$L6ME?J9M[=#I;:6ZVP@9$.N
MH#KB0%N=XD#E\+7M[>V.,JOWNU<M>),<L6R5YTM6UG?*:980X4-J<;:0,B''
M$AQ:0%.=XFF5Q3YP0(.$.\5375? B\9K!YL@V$PI@@Z,LH  !RC\40, =2#L
M(["/&W+@9W"B802E0U)B21E$SL=M=^8KM7$I_P!Q[(%!+84%H&91 G,F "9Y
MZ:P:JTS&(JI6Q.5G"K/HM^GYHW2,1RR=F.NJ198'B7,D0O(7;<#& X !@#F-
MN-&UG_QBVR0TZWF65'(I! D)*")!.Q&D1K)%4:6?_$4U;D-N-2LJE*D #N@I
M5!\,IV@S2Z.IQ581XC'@0'*[4BXR#AP5, W O>HHEYBFW..X$Y W$"B([@&P
M4<?"7053$D9$I)C>"2-( UY#Y5B7>974!Q6@6I/9)!5WB("U$ Q Z[R>43L7
MT$+Y2TD.Y_45-XBL5OQK/UZ5IAGT< L7ZHRRC54%H=1US'<I%,T*!S(E$#$,
MIR&Y@$P>?\<,X7Q4RQP^UBS-IB%O=V^(97#G:1^G4%)[9(D)))*050 8!UT/
MEWM!<P?BTL<*VF/6%GC;+KK_ .G?4M;10NTN+9UMU;)'8O)9N5.A.;. $E3>
M54G9#<3U[69B9)?%,B$ZY9(*I73%MX,52UUWO0/^%C".0!;O4!,0B+DIE$C\
MQ0 P'.)0TEE=UPOB*D8@VBW"E)598G:)RVMQ &CI2<J2H@]TP% *&P(KPC"+
M2X]E_$17C[3[2'!_X>,X4#^AN2%]T.! "7K938S.-Y4OLK&939;(<K55GSL[
M,HZ?J"XS.9LE+5%*2;-RQ[H"F>1;1PD*8GE$$P,* H+;H"N(& 2=V.Y=RAQZ
M)@?'N%XWB)P4.)1>AG.HMJ4$*4",I1*8(4G4A*B<QRQ!BOH'A3VJ83Q7=L88
M&;BS=N4W"6+E02FUNW[:2MNV7G*U+4VDN@+;25A+A2#E)'7#Y%<<#X-UYB42
MB4<PX@,4I"F*0@'IUO.!"%-N(%+S<H=? H<;^1$"9@"">D5ZT1$"9@#4[GG)
M\:Z!^W(_);:H/T*?M$8DXBI1[P^/T-.F[/?^0/H?_F@Z:O[&*5PHOWU?W*^I
MIWW"JT<*4<*4<*4<*4<*4<*4<*4<*4<*5C;,Q^ZP_E90 W%/&UZ. " " \E7
ME#;" ]!WV\!Z>WB%"01U!'J(JJQ*5#JDCU!KXE,J]-*/W,BH"::CD16.F0"D
M*7<? I" !"]1\"A\OAQPVD=DA+0S%*= 22=AN223.G/RFNN:1V3:&TDP@  R
M9T$?AWJE\^YA$3#L&VP==O#KTXRUDT@]=(_FHS%YA Q  W0 'H  /R[#MU\.
M* Q.;0S(W.GGK35.X!D<]=*A,/AT,/4/#^\1Z;?)Q>LI(! Y[;:P?I^:5X;8
M/7L/7P]?S[?YZ\*JJ(UT,DB.<'2?'QY34OF-_P"8?Z1X5CDG<S48@=02[&,?
MD+RE$P_BEW_%+S#\4O@/*'3B"0!T!/SZZ<_&I,#8S.I\3U_/6E90'8 'J(].
MO7Q'C"2))&W*-**B3&W^*A.D([;$#IT\ #QV /'Q_-Q=*HG,>D;G[U*2D3,<
MHD3UI<06Y&HD.B87/.!@7YOBE)L("F)/6(]/C!OU#Y=PJH&2H&$GEU.A!^NA
MCRK%)*]%#* 93&L]9CEZ>%.HT&"!M<>C,H?&$-5NG<=A_P![M0'Q';U>P=^)
M0#F28T*A_P#T!]365)[Z/%21\ZZQ?+4EDFTAV7CA<Y4D$)+6&HJJ;H5,@):7
M $QAZ[!N(!^?CFUV"3"DD[!0/SKBIBKRTAY)C*0EE4BI=@X3=QLE%OG+"19.
MD3 =%RR>M3).6SA$P =-9!4BJ9@ Q3 (;\8GV&;EERWN66KAAY"FWF'VT.LN
MMJ$*0XVX%(6A0T4E22DC0@UG>3;7#3C%PAI]EU)0ZR\A+K3B%:%#C:TJ0M)&
MA2H$$;B*O ,\W!O).9 F5;4A*2$<_AWCI.T3*3E[%S"K9:4C7*B;HIG#*4<L
MVCB0:JB9%ZZ:MW+DBJZ"2A>O.!8*IIMA6$X:IEIYFX:;596ZD-OVZ5H8>0"V
M0AUA#BT,K3"FT+6A!2E2@> <*P4M)95AV'EIMUI]"%6C!2AY@+#+J 6SE<:2
MM:6UB%(0M:$D)4H&AQ&2'L584[5"7.2C;2@[</4K%'3#YG.IOG1%@=NBRR"R
M;X'+I-9P5RKW_>."++%5,<JIP-RW[&SN+15C<6=L_8J0AE5FZPTY;%""DMMF
MW4@M94%"2A.2$%"2D I$<IZWL'[4V;]O;/6:D);5:N,MN6Q;;RE""RI);RH*
M4E"<L)*4E,$"L_X*OP6[/^*)3)MG5N;!O+1E?47NLVXG4&\0DT<,8R-54EG+
MI1*(CU'*0I,DQ*@V3YNY33$=^.BQ>PM;' ,58PFT9L.T0[<J186S=MG?6M#C
MSQ2RA"5/NP<[JI4HZJ48K2./+9-IP-Q-;X T+"\<LG[IE.%L"V?7<AQMYYQO
ML$(FZ=0VH%9E:U$!15M5>UA:1#5FZV'(=/1/'4X\R"4[%B4$U:RJJY[SS](I
M$^16#=BL46"Y"@4J1RE,)A*(CU_#7$ ?M6;.Z)<N>R 8=W#P2/\ UJG9Y,$*
M$Z[&"8K3/9K[0T8OAEAA.*.!S%OT256[R5 HQ!#8/<5J3^L:"5"Y:5"LX*T]
MT@!EJ]<:E;3,LLV D-'+HL3+MP.NTD'2)A.8Q%@)R'77*F94$]^82AT#H;C:
MA<$J;:!!><27"A4!:4';N[Y083/7S$^IBX45,L!69UY)<R*(#C:#M+<R$I)"
M9B-MB:<#I-PNIFC(*UFG >Q&,J@JW?SZY5#IH.1YA*TA42"!DSK/CARFY>82
M$[PP=0*8.FXCQ0899]@U"[^Z!0R"=4""%O*G;+_3R)Y&"*TSV@<4CA?!TVMG
MDN<<Q(+8PY@B59DI/;7"\L*+;"2#(,9RE)D*KI8RNO6J[CJ(QJ^1BVJ<+'1J
M\<RCS^;1<8FHD"D<=HD)AYET&[@G>=\!@.(J'V IRAQX)@S;ESB%QBK1<(N'
M'6W''DR\X6E]FX%DZ!"G$*R!)T$ \Y^*,/../XRFX+UR\HK=<>67.V6^;U*;
MAS-D0DYUA<+5HH&$!7=K6M:7,]2]4&.UJ2D>%=3#D&D].0!"M1F*^NV25D73
MTI"@FLJT31.JB(D,GS 7<H^/&^LH9N\%OD782ZAI*%L,O=X(>[0@!,R E4D+
MV.@)((T]MPQ-IBGLUQO_ %5U5XBT0ZY:6MZHK_17S94FU:87/:)#BG$))SS"
MU#,!(IS.N;+S]73;F^K3C0J$ \K=12ITDN[_  TV_";3.X<BB8P""ZC-(QW)
M$RE()DS"!0 P#QKO".",M\08/>,D&X1<77ZM*4C_ &VUM$]E($Y6W(R%0)@Q
M( K3O9+9N.<5\,KM[EQYQN[OW,2LPA9;L$VMDXTR[F45IS/J?<0I0(DEN=@3
MMR\BJV' NNPP!MSY>P\;;;H&],MO0/:']^_7V?0_3Y^IV_/\?<2A$?V@_+?E
MOO701VY'Y+;5!^A3]HC$G$5*/>'Q^AITW9[_ ,@?0_\ S0=-7]C%*X47[ZO[
ME?4U46NIAS?<M94Q!@FBM\D2F"'T#!9CN-@MY:+CZLW6Q0#*V,\90<TSK=UF
M+7D9A596"L5BC&]=CZO6V%B@V<O<6T\Z<0S-41 !//8=1KKZBLF4',49:*%$
MW:[0<AA9S+6RVTP*ED^4K,7/-)VKW>QTI-B=S&3<I7I)Q/*UU28@Q@)N89RD
M4^9NHQZ_;JD<**CYUD26M%9@3]W.6*"AC_P'XDM+Q\<?_2;T(V-^*\<(C_I"
M1$&#'I_"WH@U0[Q?\'PI7J=GK2HS8)6&#4&M+%;6,$Y9@<:^X,@FZ*WFP*X$
M8I8S55)R5)_W"@H*)K 44SE,*E-\U+ZFH?3_ (/M>:X6$9948TRX4NGSL) 6
MR-CU&3ZV9!K./797,D1I,I-WM<D+0S>RD2JU!]YNBLER)+"0!5($F.M.&7L5
M?;3;*LN)V&;V.2:.'\=7UY-DE-OV#01!T]912BY7[IHV$!!PY0;J(HB @H<H
M@/"HI$-UII5W#8UMK(.6L;*3+IN,]% NVB(-^M%S4JX2%WWB,;#R;9Q'2CY0
MI6L>_069NU47"1TRJ5$\N50CH:.L4A:JVQK\N9@2)G7DY&-8:4/*E*:+)'2:
M[HC)Z:2*8IF!6RZHO"F*+<% $!X4J?(6BLQ+I-C*6*"C7JSJ)9(LY"7CV;I5
MY/+/&\&T3;N7":QW4RO'2"$2W*059%9B\39D6.U7*12K4JN7L:7BZY"QW4KG
M 6"Y8I?Q43D.!BY%L[?527F(AG/,XJ6124,=O(!#2<3(NFP@)VC>7C0<=VJZ
M(F"E2LU=,-Y:'V8ROG_*LKQ!V,=*@Z GH#7Q&=Q$HCMMT';^OY?[@_/Q@KBF
M"%&!MH8\/7Y#XU*X5BJ:542AL !_3Q4I!,F:DF8\ !Z5X"A@]1?S@ _\=^+4
M)DSS^E>D 5#% W0-]MP^7Y^()@$]!34ZZF/E-3S-BAM\8>N_J#U?X\4[0\Q_
M'WJ*C!$$PW 1$1Z#N'^?9X>K?BI43IIO-)TC3>9Y_P#532E 0 1\?9T]0\5I
M7IMP_%* ^WU?-X!U_NXD0=S'P)IISGTG^11LH.X&+RE]>VX" _+O\X=!#IU]
M?A940-9B!L0/#KK$Z3Z:S "1L2223K ]-=M/CUT%/$[/:!E)G7/I ^"FJKPS
M'5!@!^[!,IC=PT:Y8J*RZZ@E#XI$TRB81'8/4/&);[;!:[580%N(;1.ZEK6
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MF $@D2K72NEQ[B+">&L.<Q3%KI-K:(*4YB%*<<4LP$-M("G75G_XVT*5 )(
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MDRBZU.2.&$K8"+!R2>J<G*7#"+^%@&PS;>M/&$0[D8V%5I#]2#C73SU\H/\
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MGYS3N\U_ZF\M?[LKY_RK*\*J=CY&OB."DJGNFHF<AP*41*<HE-LH F(.P["
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M#%;D.R PG=:+F>[R5U8+Q]=CJ>^;.GB) ,51T^,V,FDHOML )I$7$ W_ !A
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M'@&XAZIS!)@2J1!,$ 3S._3Z_&BEQH-28V,:$[[;;1$Z[Q%2!65.<PE >7<
M  WV\.N^VVW7QW^;U#P.D$'7?[>O*?/G4P( /PG?X;[>!TZTH,<Z9 YOC"(;
M &VVWJ /7S;AZA]?KZAPUF==]_'?ES\.55$*.43 .V\^6\:]-Y](#'$P" %#
M?8!';Y-^OR;_ -WMXBK !//GTYF8])\^IC2H2& G*(E PE'<>HAO^?Q\/Z.)
MG2(Y$3/C/3Y&?"*%,SKN0=O"/R(\9Y1E(==4_*40#NQ..VX[<FW0?8 @(]1\
M-MNN_ D91)V, =9_S4:(&^Y_/X_-*FJJF%L5$!Y#&Y3FVZ["'B&W3Q$?'??I
MX>OB( 5FW$1&T^/AY40D9LQURD@#TY_FU.HT(ME$=:NBUX<Y#D7U9Z>4BE P
M"H42Y?IH&$Q0W$  3!L([;AOMX<60I*G0D @C*3TWG0D]!ZZ59"PI[($D92E
M1YB#!T/,[UU;>6TMB*P_9O.#*I$,V<ZO0(F<I1.KWQ-,!3"F(E,)1(!=QY=A
MZE$1Z (<Z=0(WW,"!_//EX]*YY5!2F-%3KII$1KRG;3>N$"LM'<S*-H,[E0S
M3O3*J)F.<2I(MMS+J$+^* BD4Q!\0Y1,(!Z^*.J#25J $C0; DDP!/B3K6-Y
M26FUNP,P$#D5$Z)'C)($:GTK=O@QW#S<91\>4D'3BI5]TXE925CRD6>1DHJ@
M!E4U3<J7=(N^3?E$#)%(0QA,7J(^48JBX2^_=7@#=RX4A*%:)6VD$)RD$@!,
M!(US$GF8KYYXP:5ARL;Q_$E,C$;ZW;L+>U?[K%Q;AQ,*2@DJ<=:S$E04"= !
MKKMTP>*>/<>Y>GFK<'9O@1X\9(M%6YQ?K(1JZ1R@H41 Q@.4ISE-T(83 7<>
M@^9\2,G$<1P*W)*$B\0ITE*@6P%)6(!Y*B!K]AX ]B(O,1:8?>+;CUBWAR.U
MSI2VF\O&V\RDJF4M(65@)UA,17.#D=TL\M#]YYJ<#R;Q42)[]XMW[A<2[*#N
M814!0W7?K_2 <>[88$IM$)*Q#:9*N64 $$3_ $Y=>L ^%?9^$M):LF&DK3E8
M:2F0 E.1"![HB ,H@1,>$4_*2@8G&B&E,'K@6]]*[2$#NQ.*4>-C= FV>(@0
M! CB/%%!9$3 !A4#8"=0XT]+KE\K'@@!5H0I:DI@%26B%%"I/NJSJ2H#2!K,
M5XW:WUQQ"Y[35,HS8*&RVCL0$N/*P^V(>;4HD9DOA2T*.G<5HK4BL#]L2SGT
M=0%,0GGWPF<,<PITG)VP-T0%0[H%SH)CL "LJ03* 4NP& =Q -N.U]EJ[5S
MKE5HT&4&_N$Y<V90*5$ $R><@3.AZ36V^P%.7A?$@XD)?5C:ENK4I2EJ0NSM
M%LA94 80PM#<D:Y2H222=T>E.(85?L\L%1A8Y_.S;R$GK1%L8\#%5._>3TFY
M3!9=,HD132*=,#&5,7=(O( ".P!XUC3ES<^T[B.X#C=O:LFRL'UO1WDIMT+A
ML$@DDJ.HD9E22*\;]K%U9W6/7;3[@MWG\:NB'M"TS;,,VN'/+=24DJS-,RE*
M05E13!"9(LW+>;*IIXQ"PSKDN/2L]QE':D*A"M'(@+.846.Z;LGP (E31;ID
M(L8FW*(B $ -RFXV##\-N\;Q5W L/*K*T80V\I]:1E=9*"%J:49U)S)G4@C7
M4UJ7#'!USQ?CRL P:]::PM*7[E:W0OM$,L+9:-TM$)4X;A3@[)(6$J3.=9"5
M)+!+5VK&,LM8VL]5R1#SJ)GT/-QL?5HU%J:N.%I%N<K5Z[56YG0J,5BE,V)S
M?@S'%4.I0 -MM/9O<83B#-YAR[;M"XTIV\6I9N0EH^Z(B N97">]'6)]C8]B
MG$V#XMA#^$XXP[96%W;WG:W!<;?MPA[-<,V]NTD,D/H)25*,A$MB$*,Z)9>6
M7=M [Q8J[9<[L6P*'2,X2*4YDT2F. =Z;E2Y2_'$X& NQ!*40#CV()"=0(41
M"H@)TZ 0-=S U.O,U].I2@1&BTA(7$A,QN!MK!)\29U-=_\ Y%$ A@77< ]/
MXWL._P!=,MP_\.)K)70CVY'Y+;5!^A3]HC$G"K(]X?'Z&LT:3KB_QWV6NFG(
M$57GEME*+H#PW<8VJ1W/\(69_6-.U<FV=>8]TDNKYY-.&*<:V[M%8_?N2<B2
MAMB"HOWU?W'ZFM5%\U,WJMV+2EK;C<HH9YNTQV..O;4%!5I*'IJ5,B;LBYT3
M7J49U6)HL'%6YU4FTJ#F*6K-@GK5:F<30'+#X<<6@UDDWRI T4G;OI&NX]\:
M^7A6?LGZB-2E9HJ^0<<ZT<57RDWG-/9W1F/Y&J_>LR_.5.I9]U-4W#.3U;=-
MPF%\6U%UCO(E1M/PU1D#Q,3?8JP5^X*1-V4AD4F5;4 !TC7*N=]PDD<]P=^6
MVG,QM-3NJ'%>H^1TF7[,$[?L>R^N'%>#875K.4G%4)>:M6\H:2KEJ$:XDG&E
M2H4#A]QD%;)%>HV/("PGQPS,M4\JQA'$8:W+P$EPI (F(A,QK!.8"=YUDF)W
M'2O)S5-K-@8W+T,U5M>58#3WJ.U'4"PV7%#7"$-J6R/@FCX\P[<(;+M&I&0J
MFCA[)4C@FTY7E,;9:J55CJ)(6ZP5R"6KH%DT;)39E2$Z'J!H9@&2""09&@D?
M/2L<ZO\ 4CE>X8<[0F.J6>[:.-8_LQ='VH[&$]"URH4N<C'V;Y_4C#7R41=*
M5%.RQD;?ZKC6K.I*(G7CF3JP/)1"!>P!US]U!T!/0&I '=D?U*!'7* 1]>59
MNU4:P,VZ9[[JY2K61762J=B/0WIRR]7!L5<Q^^+2[?D#4=F/"^3\L2[FCU.K
M*S,)2*A2V5_L%?>JA"-#U.PI()1#%VLBTFH ! TU*B(ZZ3'T'Q%4#5AJ/U3X
M+LNH>@X^S9*6:O5?&>AO,=$RY/4K$TM*TV5SOJQ>8 NN+[(A!4>!J-GJEWID
M.ZO%/>HQ$-<X:12L96UG5AO@%O'*  Q/4@_ 3.\_QY<WOZ2K]E%_FC6_A7(V
M2YO+,=@;,^-HS']MM<#08&VMZODS3SBO*+VLS!<:U"B5>39P%ILM@)7Y$:RW
MF_@5VT834E,N6!9!94$: [3.GD?$FF?P^K?4-:JEC+-T#;GQ)R9[3*U:,\EZ
M85*U2%8NJXU1U W?"*:Z+[[E@R,SR;2,70M9U-2<R\N#RMR$4I9BN*S]Q;V%
M""4CE_Q"IU/*?+P/3Q.]$TP:C=3<W<=#$Y?\]360H/43GGM!L&7BDR=#Q%!5
M\(;3W9]1SO&5NBG]0H4#;&MTC6.&XBORYR60*E,0TBY46J*4\B,ZX4@'-&D)
M!ZZG*"/*23UY36WS,XB7#V6#!XEQK>Q#;QW"KRHAQ"MCY'Z516Q\C]*^*58+
M=8;(LW^'9B1E 9-$F+0T@X46%!H@79)LEWHFY4D@Z$* [!ON''5,6K-ND]BR
MAO.HJ7D3&99W48ZZ]!X":Z2TL+2S#@M;9E@N.+>=#*$HSNK,K<4$ $J7,J4K
M57/G5KF #&'8 'V=-_5UVXSR1S(KF5,1$2*E _Q2"41#<=@'V;]  /5TWV]O
M$Z99W,ZSOL?'Y\_A4*$C\D>/I,1K2I1P<"@3FW)OOR^( (^(AUZ#T^3Y^*B
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M6!F W3KMSZ<^6HD:::U@<"BM.Y2!/AFY'3GMH==329\F)%$S J!@%(H[%$!
M-_ ! .FX"(@(#UW#?QWXL#(5W>9 )\YW.\_F@%7;,A0(@@G?<ZQ/E_CQET.A
M!/FUOZ,CBH&W[K#3J I\P;[CE^H=>41#KL&^_4? ?6'%VS"DC+N=X.TCG!_/
M*LS:H6!!U($QIN.?X/E75QY;>IRQG9K)\@&%1YJ_'<1VY032TP"(;<H[\P#U
MZAMMZ_5S*YL:@SM.G7_JN$!LWE&J1IIJ)D$2F!(5"*$!3^% '>$*("(]2G$
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M$4J[:[CO']0F+%8JG1:=5[!;UFCBVSE=K$)"S%H<,$ :L%[%)QK%L]FUF38
M;M%9)=R=L@ (HF(F'+PI2!'$V*V]UD,DH8TQ^AD662!"5OR--KB=UDT"QP0Y
M49"TDC2SKQ(L04L6";E^H0(XH,0#S8 2X4D]:H\1@7!D M6G$#A?$\(XIDO+
M6"GKQ&.J?&K52>GM_AR;K2K.'1/!2\SS&^%I*+,U>R/,/GBRVX\*4LS2(EPY
MED0ZB&,[X(![1"K2HAQ!V,]*@[&>AKXD[@JZJA%%MBG6*4XDY1 2\VW]/RB
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MJT)[J@#H"&@5W)%R12FHY@Y<%8OX:<9O2&.<>^;2#9079%-]RCSCN8VX&V$
MV$.@\;/<X;9)++JNZL/,92(B4*2E( Z<M-=.M>FWF#8:\JV=N66UN6]U:/LJ
M(3W'6'!V:DG<%.PUU$B#)ITN3U[QIFP5I2M] 54:&G$I*<6(DD10CR3DE&9C
M-'2( ;OVKA!0Q024V[P!_!A\4W'08;^CX@QGB*TN^^;<ALF2"A"4R% Z04"-
M0"$QK7F^!L89QOQ9[1<.QQA+S3)M;-C,J(M+95RRIUI4@MN-W#15G$%) )TB
MG(Y?IELS/BVJM;+5OAY]8G<+.N4V#=5J_AD7YRIOA%(R)0 6[<R@F$0Y!3*!
M!'<!#CIK"Z:PR]=<MGPSV(6T"LA:%Y4G)J5&<QC,="DZ^->?\*XK@_"7$V+?
MHL2_0VE@S>6+:KEUMQF\<MX+$.),2M8E $J,D[+K.&'.S?PHGD:,L50LCETK
M72-C*03AB":YGK1PV6<JN045 5"%4+W(<R8D*)MP 3 !AUS'O:'BEEAC@Q"W
M4EMY1AY+B5( 4%!L9DI!$P%!,28W(D# [[5.,.*+*XP!-O9LNW[3JA>)+H4;
M1:"A0MVQF25(S@Y^WS* DI$Z:@^UCOQ)S4I*T0@HK)8Z1+"&=)J)J%,<[)N[
M\W 0ZD\T%8C<Y-QY%$S%$0WV#T_V;VY'#MO?P4?ZDA%P$*!!C,OO&8U6HJ.P
MT@^?MGL,P X-P>'G%E;F(7MZZJ9 /Z=]VT0I,F2EP6X<0K8I6 )$$];GD4I@
M' VN[8=P#+^'NGJ ?N,MP"(#Z]]@$1_X\>@5[-70=VY'Y+;5!^A3]HC$G"K(
M]X?'Z&D&(=05\P1H4[)2*H>/JK?7^>Z!I1P4<]IO4I2FM7=3NEMY=8Z>WBZ3
M<5)5GST)Q'228 Q<L$7J;YFVFE2#'BJ5"5+\"H^A-7!1NT$OE[:UW&S3%]=8
MZC9*W:TJE*0S!_=+CC9$-%.8:OARUST.[@:HE<W\?>I[(./7D0V?P44K6HJ7
MLCR0<R[RKL(BV*@ICR[OGWAF'QBJM1=8&K3)V9Z_A6,TM8ZQ7:2:<L#:ALD1
M67<W3!YRB-<H7W*./+O1TF=#Q=8XJ>LM+F,92+VMK(SC2$N4.LW<RDI2Y!U\
M%-%"!$@SJ1MTB.?CKTY3O22K=HL[7T]2F=;WCV(KC[#>.M4-SU6X\B+"^F9G
M$5BTTV.5I;_'<7(.8F+3E9VWVN&DTJC)6%A6(FR5F*E;9'*$8M4FSE2-8!WB
M)$3//<Q\_&*=%@W+N;KQD#(-1RAA12F52$KM,LU$RE%O)9*N6UU83S3:V4!Q
M7[=%P%M9V''SF-BW/W3)Q9JU=(2RQS]FE799C*UYLJ-(&NNLCI_W_%,]I^MO
M+D):]0T+D&)J4^Z<=H2[T?:?HNMM+*<L45KITIF9%#61JSC7\K,HL*K%7FSG
M^#_X?9[FZ"LMQJ5?=L9.&4C:.DF2.I'AX::FJE):SM8(67"6)V6E''M9R[F6
M8U/U^('*68[)4Z4Z+@-A'351O;1.OXLN=M8T;+5:F(V9;-)>)1NE.EC.:K*U
MQ\W0&W"J8&\Z:;"=]QK&T>1ZU1&O:!Z@74K7U T_XE) S.NC)NA11$,W6Q27
M2N=7:W8M4O9')L,HL_N0>R5,(G96YF9IYDSG%58F,D%J^FE95,HUUV$[<H!Z
M^)]/'0-JYFLB)::PR;@BB2%RC.THONE";=162;.:"H61L:U#-80N7*$DI3F#
MVV,9^K0,@P6K]I-!?<XYM*^WW2&BT'2BD1.O](/G)&GAU^'C59Q%K^R]>;K@
M!G<\(X_K%&SIJ=UBZ3V[VM95GK3:8+(.EEYJ/<-K"+&5QO4HA]4+9$Z;+*R.
M=2082[27G8EV9BC'H.$3J$1S_I2=NH!C?E/Q\*P+F?6;:,]:9];6)KC1H2IR
MRG9?9'U/0TW0+G+S\?6):3K>3H!]0&.0(QBVJ.27M L%<AW+/+^);-)T>S20
MRS"/:LTX1)Y,*D)U3.Q6$Q'(G?\ P16SL#G4T<@H<QE%#Z9^<QSB)SG.;%O,
M8QC&W,8QC"(B(B(F$1$=Q'B%;'R/TJB]<_\ ]OYKXOBITER.573DZ;I$J16Y
M0)OSCSAS$./B7E+N("(<W@&X!UXX*0H$94@@DDR8V&X\>6FW28KJP"DH2A(4
MA1.8SX:'H9V\MJI8B/.8^^YAW+OOO\4!W  WW  ]FW&8 %(!'B8$:^,1\ZY*
M4C*/'Q/7SKP@\XCS==MP#Y@$-O#Y_7Q57=&FDG\^E8SH3!(U/.E1#;"(F$-A
MZCN.P"/3V_)Z@XQ@GEO'(<JJ0"(_)I:W3.[72;(GY3+F*F00VZ<W0/;TWZ>S
MB%*RRI0F-2#I,==OSK5%0A!40#E!)^$^L#K\JJ!VHMCF34.)@2 2'$IO'E_&
MW#YPW$=OE  XKGS00 "?=TTWZ@:Z'?UK$E6>(TDR 1S(,1OXCUFDHKHCT36[
MH1Z J'@'KV$3=-_;T#PZ>OBX'(C,=="#IIX<M?'3>K0Y_4E)2#,:=-AR^',B
M8I>A'E023?+_ ,+;',<#B50"F-R]!V$!]6WB(>(=>,1<,Y4]U1',3(/4<N0$
M>=44Z5J*$]Q0@A)!T_F8VY>%4EX_154[I%,R($.!DS[F^()=A P'Z (@(AT\
M.@=.,B$$#,85(@B-^7G\9V\HK,VVI*2200=%")T/+41$]-=>51S=CEIX[=65
M>JOEV;9%DW67-WBA&S<O(DD [?BE*&P;@(_*(\&;5EC,&FTMI6M2U)2(!6K4
MDZ_;TTJK%LQ;)4EA*6PM:G%)2(!6HRI1TW//E3C]!AA-KGT8"([C^ZPTZ>P/
M]K].]G'(2 " .H^M<A'OI_N3]176YY:Y896&BNS>:Q[M1!O(O-7*CQL!]D'8
ML":8S-N_3$0*IW)G*HD$>I.\/RB FXRJ;;6I*UH2I: H(40"I 7&<))$C-E3
M,$3 GE7)<9:<4A:T)4MO-V:R!F1G@+RG<9@D QO Z5P7UB;6A;/&SY2@JNUD
M$GJB9!*',8%@64+N<1*!>@B'-N " ; ;UU>:#K+C),!QM3<] I)3\IJ'V4O,
M.,G1*VU(YZ I(Y:[?&NJ729FBX:H:B$M)K,("F8\9D,LR4EP^$IM!!LF4[!<
MI>Z238!R"0%G &Y"*& H% 0X^?>(\.M.&KLMH;4]>8DZ&PZAHEMEQ<P]&I"@
M()"8S&$R8,?#WM$X/LN#[I5M;//7U]>,O/M%YM"&+-H7$Q:J.9;ERM;PRMHT
M&6>82:;0;75LKZA(FQ5-:02I.+;2\<SLR8NS2QV4B*Q6[5(J0=V+:/;@*"/+
M\4W*!R@!3[\9L1M;JSP-ZW?2W^JOK/(PC3,RVX @JDDF5$E941.H&@BIN[.\
MX,X/['&4-NXIQ"S9JMK%,*=L,+:N6W7E+*S_ .VY< SB0$E4%4I($O4X[J>6
M<E!-'ADVJD.9FUAC2!1*9R\,51PK+>:B;8HE1("21Q 1,D4AMQ -AKPU9W6$
MX6W:*N2M2@L.%![H0HB&@01(!!)&G>)D$1/.X5Q._P ,M+ZXMY;8Q);MY=LL
M %3+:$H82PI[W<[KJ\Y2DP,Q UU.MN$0FJOJILS634;2#"[5]W#0;A4_.T42
M% G<M5N<P@4Q^Y6)UZ$$"E @"(".^.%I_AYCLNZY97.9Y)]Z5%0S@].^@S)Y
MR8%>SW:[?$_9]87#27K=6&/V]]=(:$/M*:="G5)B,V4$&# (US<ZN"-H<+5:
MG>+?+M6;Q)6Q1%9BFY5"F;&<RTH1)RD0! HBFDS(Y$^W*(% .GLX2KMZ\>M;
M9*W$EMAQY2M9/8M%>:9(G1(2>LG2JW.,W-YBN$85:J<0HV-WB5R5(/:I988(
M9*MP%*N%-Z]Z2(C63O&SU$X()"X=92T.P7K]'9PEPAJTSC@4+_HUJ@=DR;BJ
M!4DD'*Y4R*]Z(E4( \P;AU\;X7/$BU\1+6ZXFXN[J[M!=N.#1!4M':%+<D]F
M@G*D 3I.E?.PQ*_;Q-*\ ?=+N*86FRQMU3RVU*<OU)=NE.NKEQ;RAVJ^T25*
M;#DIU,4U>X:I)Z"SG3XZO4J&64R)%#*3,?/J=TUK=59(G B46N3NT <*H-E%
MQ* "!U5 #DV$ XW&UX::<P5UM^]?_P# <0VV^R27;FZ6HE2G0)40F3,R($ D
MZUV>'\%6.)</<0XS=W@81A5V[;V;6'VZ'F+J]>4E&5QAR7 T@K0TA0*'$I!6
M%I.:;UR7G9Q1K $Q 2"L)&MH4]EFI-CR_AFX,U' MU3 F  .Y2)@)MRG$"FW
MVWYL5G@K5[;"VO&$W16X66VG4A0!2O(% $[J)$ [208.VN<)\+7%\QF+CHOU
M7HPZR;0\XPZTM;R$E:%(6A61(*E*2)[LC4S'*#EZ\261,DW*Y2SM9^^L$[(2
M!W;DX'553=K'53.H;P$PIG(&X;% I2@&VP[_ $#86C=C96MHVA*$6[#;:4(T
M2DA F!TS$F*^^\'P]G"<+L<-8;#;=G;,L)2F8 ;0$G0R221)),DR3J37?/Y%
M&42X%UW (;#]][#OK ?^YEN]@CQRZ[&NA#MR/R6VJ#]"G[1&).%61[P^/T-9
M TJ8,J&:-#'9BREL?6-HZPKA+2MF*D? $BUCTTKU"Z>XNLQS^6(O'O?A1BA!
MVNQL#1"Y@CG!991RY;K/6<8Y8JE1(4N.94/A-7+.=F[@&;9Q:B5@S/6;E7LT
MY9SU5<IT7*,O1,GU2]YYDUIC-#:$M-3;Q!B4W);]<ZMFHS]F_JYP28%CHR/"
M(A_,%5S'X0 1R,:"?ON.45G.B:7L;8XRTOF6KN[BG:G.(JIA!PWE;,XG8MW0
MZ78K-<(0))291>SLU:#VZ[7*SS5VFYR2MMDF;1++V"8DTC-$6JDZ1XSZ_*E#
M72M@9LKJ4,ICV(?-M73D5M0$:_%=Q%WYNICF,Q8ZBWC#O"(-(N0J<<J21:L2
MM_/I:9GYIPHI(R[I<RDG3PV]9I!ISTM4'3+!K05-M67KHB5A'0$,^S+EBYY9
ME:I3H4#EA*15'UPDGYX.LQ93@0$6Q?A26*WC?NAE)D8:&&/4)GI\ !] *QGD
M#L]].N2$<P)SB&2(Y7,F6*IGM^]JV4KK5Y"@YRID'6*_"9=Q,]AI5JXQ]>R1
MU.KR3N7B#\CQ)J]8K-ABIR?CY10*(CP!&TB"2=09'.KP@='>,X"VX3O:=FRK
M-7'!2E]=URRVR_/[=/6B5R?$1U?O4QD29L;>2E+>_F8&'B(1D1V\1852'B(F
M+IC&NL8QBW04G?;7Y>7YUZFJ$AH9Q"V+&%2G<C[1.J&8UB-.:Q10B&=)Y265
ME)Y0?N=W/!N#STT(5+<*ZB$BH5&/3*W8@U4D^HCX?@H:Z&L0M'4*\3G<CBO
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MD:  ; #D!5,\3B'38P[FV .H[>L0Z^KC/M5R9I0DB0X["'41V#XVWJWZB(@
M?GXHI1!$=/O45$=,$P 2= 'IL/40'J/RAL.WMX A6AUY^'+X\ZL(.A,1,:@?
MQ_-)Q*7Q$-_F$=Q^;B]7*!&F_(R:4'3;F-NF!BEV+T$=QYMNOB/AOX;]>@\8
MRI28F//[Z[]>72L(! &;<S]3^<J2&* >'A[/7Z_\.,E74-CX)_G[5!PJM30
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M!F$Z@Z$@\M^5\FR^3K;*V:5,H O)!PLU:"J8Z#!H<Y^Z9-2F,8J:"(;%)R@
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M/$BP+29WRJAC>8*EYA-S)E,?G,( '( >.V_'F6-VT7UT^BV<:"2G.HH(: (
M#B2 1"U:C_D=A,5X!Q[P^DW=_CEI9/"]92A+TD(MQ;MI.9[6-0 ( .X%.59U
MU[INDY[*5V>EAXYPQD!@UCAWCMV=PF!P0:F6$#; )0#<AN@G$"^/7H$*1B^2
MRM@'E!24+0DF <V:5Z  ^)&PDZ UHEYBC/M#L\/X9P=E=Q<(?MEW^:$,6Z&I
M0I;A03F25$[IY!(&;;0AF*YRF5,C62X2(+/GD[,NED!%0ZAP;J*[HD^*82D[
MM+NP -@ W/N.XE$ ]BPZS;P^RM[5( #+: 0- 21F6= (U/P&@T KZIP7"[;
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8DFW?^;>;-N^=K((*JLEI8()3\QT\Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g773514g36m63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g36m63.jpg
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MZ;J"6P*K:0'/8I1W3VC"T9?(9P 2(V6O;"L8GT)G</A,CG+9_%@L:+46CUG
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MW"(.$D]'*[Q9R4R=#W:#DH3)?&)Q&9 /HZ7J L41,&),;D!TC<=YO9W*UIE
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M&#68NG<A!R 083B[]5D4WC#UAA ^FENP5<MTE-]LD52WQ,\1]/<I7)8\GMN
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M:/>PUG_LFU_PZB_X:)>36WO[=;:?S9M'_C%:J(.06]G$N=Z,$)+Q@+6;[EF
MMA,F%NB*EF#+!=A4&RCI,:^&N(ID"/$[H/F"ZRKEWL83U2<LEF.V^NOF1VH/
MV=I]N-KJIS+C5[0P]H=WDJK?41P-V?J+)%4ND$;IXIF7'TR>H#HIFM#(A2N+
MF2,E )]$^S5FT$^Q>R=,UUOI;!+V?V>.FKX))W7Z"]24K&&1L$L+[>:.&G+)
M8G/+Y34MW7QNB)"LB^)Q.XX)VCT%&HB*#W0NSY'YS836;V18?\/3^[X3).F7
M,:(Z,(U5\K''EY5)TF84UMIK'<1D6Z5D">LF=-=A+SM_]&FLI[CL5?JZEMU+
M::>JVSNLT-MHG3NI**-]OM!;3P.J))IC&P: OD/7=#6X8WJ+])*CGH-L[%15
M5PJKK44NQMJAFN-8V!M56R,N%W#JB=M/'#"V1YU(9&!RWBYV7NJ;^2-P=+?(
M'W0ZL6',6,A(MZ&5F<"BIU>;,&Y%UR546QN+ 9&["0UQ)T<*[N!C FN CFY/
M\4U]AX[ZOTT\C[8%PN5K+)&PO#,LF><,B<)VELCCAV&L.'$X. .1Y+H)VJ.D
M;M%LZZ&H923-@:Z*JE=N1TT@KLLGD<&OW61. D>=Q^&M)W7<C'?$SJ1!.K.!
M'=55^Q>2(=<C!2%UK-I(ZKYGLY1HZU_M\9D,F9QZ?.XSNBGC#1T]TCLBW;.$
M\ZJ-UL9W5UV^RQ>=H*TR3,J)#3U1?/&[>CF=Z1!O2,=AN6O/VFD- (.@ 6T[
M-73/VWN[ZBJBKIW4%R,U9 X/AJI#7T6_41.W(PZ.4Y>PAC 6D8:!@*Z/YR"]
MFD[HXC2L&#1&(#V&O3J41>QBQ",Y<21HYA?/KLZZ,,7]?0C6+[BI L]"CFR#
MR1Y-,&:9M=4-N[P)1V/;/^Q;_P"*4'_.7I]]"+]^$/\ *FT'_1*@R:2DA(ZL
MZ:9OB,+?)1@#8X%@E%"CP@_8-$80Z<:LY>BZ12T'2/3=??9PT:;*MM4-D?R[
M_GQO^/7VU4$-%M!L+)%#<XG5U99*N9UP@CAAFE==8V&2W.C<XS41# &22!KR
M\.R,$ >BNUFT-;?.SSM^I:NMV6JX[!9=N;/11[.UU75UM'31;)5,PI]I8JF*
M-E'>@^5QD@I3)3B(LW7ES7$]XW+\GZ"=U?S\PDM/UF$AJ\&:LB\E$WB<D!P=
M% \(C.:VD#&*.*3 -2AB<K*OM)/&E92+;P!)HW69R*<;O=T&G=I>%VGCX:?G
MI\5N5XHGB*$^EFS-YSE?[0C%9!.A[JD[4;/H3$TQZTIF+->"GDG46C2)8:9%
MJR"0(;[B0R9(.58*$7;;5X-?M\J-51T!5',:XUY]WBN>SX'[GM^6W%8]13(C
M>>836W.<"?1B.6E: BRQ<7%ESXYI7['1<;QYSB['&2%?CV<B%*EI/(UBL3.,
M%M!"9%N<P#GM)]>/D AZ:#V9^?R73_ZJ)XBHHZFX?ZKM#Y0Z/Z0@;<=_#"*2
M#F0PVM56P$!I.GH74CZ^7?0-7,X&NIJ4+H=&,)Y!1*[J/MW0UW@/G26*,FHM
MDKEY/CS5'(_#UY'+NTYK79W0/81OYM;I!Q7OL]"96[X&ATT'3A#FNCI N*K
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M8YLUG]=NVS*4,AVAR)L-C0ENX=H:L9"*P["%=,[*#GSG1/?;4BES^MI\FO\
M='J_Y\N>?]B\11/K\C_>^UYJ\Z8^)PU_%%&IT+KW'?UTJ4P#Q 7$P<05)[B5
M?M3]N[%<R)JLAF/8)9-:L]=26S'#'?5?)%+'];3Y-?[H]7_/ESS_ +%XBB.W
M/DC[UH]&NG%@_$Z<9)VI;,'I.'9$=H4K(]G4_L1VZ91=D1U!Q-_L%$N%V:^'
MTB*X:!!6FNJA%\VT4TVV)S4N?UM/DU_NCU?\^7//^Q>(L:FG</R-P&'2R=R3
MXE7R$=A4:.RT^NR[EH4F\1"QP6Z,%56@T?''#\@Y38LU]T&+)NN[=JXT;MD5
M5E---B+RZQ[Y^0VWJX@5K0CXF";N&V3#XY.HHZ)]NT6"(N8[*Q#0X&7?A3$9
M9EA+Q4>];[N1I)HV?LEMMV[M!)=/=/4BSG^MI\FO]T>K_GRYY_V+Q%$E9?)%
MWK;INVH]"?B<-NR=)60[JBP$R?:-*@D&4S8@04E<-1+HO%&;>1#M14C%*:&P
MBCX2HX47::.]G+1RDD1;)5MTO\@<GGT1CUA_&6I5\&,GAX^56'GLNCYKB&A'
M*^J;^0YB8(.B9D.!R.=E_M0U5-X[_+])'?&^<9\16->(GB)XB>(GB)XB>(OX
M553034664T111TW5555WU33233USNHHHIOG&NFFFN,[;[[9QKKKC.<YQC&<^
M(JQ^[_DRA'&!J"PL3&(C:<_F RSY"^"GKO@U,1Z,!*EBXN72 66F<K:EQR-C
MR40624K:OWK0<XF6S$NMDN(8C5GF7GSY^]7'7SKG'W+?:G[*%7-4]8V\"%2
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B,:ZZZZX_#&NN,?AC&,8QC&,8QC&,8_#'B+Y\1/$3Q%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g773514g37x35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g37x35.jpg
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M#_OI HTP'BCALKWN_<W5M-Y.)9WSR6>2-:K/\S\SKG*YY)U1E='(1$6>_K"
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M*AF%>R9%MLO)TVE0'4/(M9>U ^1CS)6++'+->RZGILRAN!]; %(WAEFNA,W
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M3U^DYM?QN^0I2&UK'ER*3XJVKA8!413K:6?M^]#)LYW(LJYFDD;.O9>GMX*
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M4>NZ M(W/V4EMG5N#!ULB>;B/%8QL-L#5-1+2<64#K*)O\&4=L5>2 %VRRK
M@X:L?M,U62^?>0)7=NAOT)O]1MMP4' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' (8_/-1=I[$>/\M7505;);CE>=T4K(7,#B@I V7)QR/S!%_(5<!C
MI9!NZ;MA^*F;E)53K#)/OO'+\O7??.WV?J:"BQW!ZS%9"JL,I<3H:C$*:*3+
MJ89]%*J9<=3)=/-:E3E,DPQP.5,:@F7W8G9LXU;+GS:.KE4LQR:F933Y=/-4
M<4IRYT<J.&7&ID'NH'#&T]Z'.'59E,O^ZTV^_P LZ\O_ (9BO_\ J\V2^^)V
M#_[&4W_*6"__ && ?Z"VU_KN9_B];^Z6P/HZ^MERZSZX['QNY*1E]#.Y9LPM
M+(E$)D :1M\[C7Z'*I *%V@QBNX;)LESX4TWZS3S_P#(X;KYY=?7[R[[U^VT
MQ#!,4VFQ2OV=HX:#!JB*E=%204LFBADJ714TJ>E2T[<F5OU,N=,M VHG'OOW
M431G.%2*RFPZDD8A/=362X)BGSG-CGN-Q5$Z."\V8E''NRHH(<]+;JR2-A=S
MH?*H'OC0^V4LUILC;2@(YJY=-&8PJJ8("MJ7U-<,VGM?RQG/TJV.DQRCD98,
M(C):NB,I!)NE@G2#=E(E1P$MFX5Q<[%.\+ANE=IY\=>/1KGKGQM?12^XANL)
MAM9#*GUPVSU6A.&C9GK5K7/2.PA[B*4KO:5LF7% XC98I%EXF *5_P!19]6Q
M%\UGXXC3 ;%Q:8=[@2.-V))Z+ENYW:?NLV\[PKX/CSOFG:UK79D_.IO(@^NQ
MY9,JFVTB99EY$]8H6ZBT+L6<#Z*7U5E.M5:B=E)''X"W((QMU TK0<RMVSDK
MP>N[A4A#=DXFH *O#KHJ*>YMPSA?CNHFUGSVMI:^G08.T*U6W C>.KE39.]T
MJ:AU,PC>.2S\+*K%M")5I*-BPFQ=:237X3(7:9I5.54]+8H^)&^QP1? !-DN
MK,05S=MSLK1+"K:S>3;W4LEINQ)NV6:RUSO9F&I#4'D;M/6ZSH 5AV\DO*'=
M6*N;[31?94LK*P\HW;$;34A('#_4\8H9*,FE>CH2(MPD0[JE(;4>,)3@^.3+
M.6(+*)/;V]K?25]RGE;6\/1"T\GTZ:W>I;]X/D0F^8+)5J<U$(UU/]LX[LTW
MEENMJ+@^F4"JJ86O/&+V&!NK/='B-MH)1F/5G$@" MS)^WY9$80,%XLNY$%B
MHH"Z#"Z%ZY*UL][>LN;\'._-K^DVF\8]CNK-UD^]S5O7Y;DS!V7/X98?]IV#
MPBN[OK.>14@V%R&IYQ%JZ'L(DT=Q59-)VQ=BU"2),6:9D,"CE)REBB$2L]$N
M*LVU;G5VWGTY^+0D,X+2O/LEXT+*/._+D!UZIZ(PZ-[2T'J0[JKV(Q$8\+M^
MZ*RM&];7N4.?[P)YEAIR8/9*!$%99.V8\467ER7?1AR-%E,Q@^BB5H+MNSBO
MJ[)VM:_BT1@V0Z>;JY2XSN"QU7E)@K.]M-X;'ZU,SL:CFUE16#[,:4PG6& S
M"0%G5DX4[F63FD!S+3P6$L0R2$PB:YO6*1PJQ+",*?Y^VMO3] O#I=9)*]G9
MVB<3RM?.]N%[9V,Q[0Z?V!2GC[T783+8"XFQK70CXGJ0FM)Q>00A;7V:2N(;
M6Z[Q8Q)3; C7KR?DR0\D2_\ HA 58 $<HA$HBJN%RQ0*H%:A-.*/)6?=&GQS
MAB]K,L3\'S*@_EH\H>_&NN^]FT905YB*[K.(5]4)T:#<5'6,S=9%9E'WY$RY
M5,RN.D2N6*CEIADDADZR11QRRQ2PPQ_Z<E_L7]C6BV^D8Q.J\3JL/>&3J*7!
M#3294U35505,43C<V);KA[@DDM=YWX&+;2;0S<"BHX95+*J/NE3XHG,F1P;O
M<G*224"SOW1WOS(CH_OI?*[^UB$_T[T7_P /Y*G^KG@W]I,3_,Z7]\QG[X%5
M_5M-_?3OV%K#PO[.W=MQI&+MS826LYO9/5N7'"WDB8QF/Q%%Z(A4T> PO602
M,,!HANLFQ;X8K*(M<5%L^^\U<\\O^[FLFT.&08+CV-8/*FQSY>%XK7X?+G3(
M5#'-@HZJ;3PS(X8;PPQ1PRU%$H79-M+(D:BJ'5T5%5N!2XJJDIZB*"%MPPQ3
MI4,QPIO-I.*R;SLLR5_G3G)' ' ' ' *:?DY\K'D)HKR%;.412-]AX!5=6NZ
M>9Q2.K4[5<N<M_SOH6LI\=5<'9/&WYEWDYD<G+.4\7+M;%LBLFU0^S;HI)83
M1V,NQ=0[>89B-?5XK5X?'15\-)#+IY$F;#'#%3RYV_$YD2:BO&X;+*ROJ8GM
M'M)-P.?2R95)*J%/D13HHIDR.!PM38Y:A2A5K6AO=\6:.?WTOE=_:Q"?Z=Z+
M_P"'\DO_ %<\&_M)B?YG2_OF.?? JOZMIO[Z=^PMP^('8FWMK?'Q2-Z7O)6D
MPM.6&[N%R61L8^$BS8FG!;]M"  5, 4<9#PS#-&.1<0V6Z9M$NEUD5'2W:CA
M997/5S%J.'#L5Q/#X(XID%#B%91P3(TE%,AI:F9(ACB2R442@432R3;2R))I
MISJ*:GJ'"H'/IY$YPIMJ%S94$QPIO-I.*R;)+N=>?8< < < < I1;\^6SR-5
M/O-M=3U2;"!8/6E46B/A\-CBE+5-)UV0Q6MX%)U^W!R11EZ8?*JDY&_S^N\=
M+98)_9IX9])X8XXSAV-.Q1A^W6!5>+U6+UE!,I\5GX=#)IY$F;!%!*I*&I4Q
MQ3(E$HG%510M+*T$+U;,/VCVGG8)6R:251RIZF4DNI<<R9'"U%'.GR]U*%6L
ME*3OK=OF-3?[Z7RN_M8A/].]%_\ #^2'_JYX-_:3$_S.E_?.@^^!5?U;3?WT
M[]A<4\7%ZV;LQH)K5>ER'&LELVQ(:5*R\ZR#"H\U)$64RDP5)PD%!M60D?U[
M",:89(LFJ*7>>&2G>/>>>>7>J=5)5/55,A1.)2)\Z2HFK.)2ID4"B:62;4-V
MD2;!%OP01VMOP01VO>V]"HK7XVN;]\^!<84O_8NE-6:Y=VWL!8(BLZZ8EA )
MU*3;<HZ9)%S[KIB'8?8!V!)]FN_=]]((=)M,\?K]_P#?EAU_UY2**&&%Q11*
M&&%-Q11-*&%+-MMV226;;R1]),F=439<BGE3)\^='#+DR9,N*;-FS(VH8)<N
M7 HHXXXXFE#!#"XHFTDFS17^^\\5G[8\ _\ ;MD?\)YQ_NVC_P#-TW]_*_?.
MZ_DKM/\ V<Q[_!\0_AS<K6O;;7/<"*'YQK7:8*V(I%I*I#Y 8!-#;)$5)DA(
MLYF(<HG18EWTYQ$FA;[ZR;?-'M%ZE]57O/Z^./W@C@F0J.7'#'!%>T4$2BA=
MFT[10MIV::=GJFCJ*FEJJ*?'35E-/I*F7N]TIZF3,D3Y>]"HX=^5-A@F0;T$
M4,4.]"KPQ*)733/AVMV_U^TFK4=;FR,Z3@$#+36/5\/+Y"BQE1Q)Y-B_<,&F
M# *S?/?L&XT27-%7O:'LHL*))$WJJ35HKGU<?%)MV1_:1[<T#$MCH=J?(ITW
M%WC854'[H@\5<#R/3:50:,/GC(TL$.XML@KXTS3&E"GYNI/NS*X,43,H,U![
M!TND%G:]LD[7Z6:YOO+'HV%A@>P)+:S^)1.4:W,]K845E$)EX5.>U$].LHQ@
MI!DW8?%24SE&1E009S68C%Q/47<BC^?<?[:F&3E45W8KM6T=GID^GFT>>G29
M&0\A6KF5[QO6U_+I0"M>2)Q5ET-D%:V$(C,>FLVKE[;L7JB96 [C>$#B-O&:
MT&$IDSK8[(V4I5#L5<L6';E1JW<"EG:_#75:7M>VMKY7YS'\:\KND$MKBWK7
M"V;)<X72P6%RN3O'U26P*)2*#V3+7L#KFP*P $X8T.6O!I[,QA&-122UZ/D0
MXN69YM45.LEV?;D5W7=*VK:U6JU3YFN-[6-@J]VPK"S(@(F\=!74R#&_;_8V
MTOU\NR#2)+[M*/1#C[PBTO@@61"_KNF"ZC3[Q&-O;6.;8BT^V8NVSA44:L[9
M?,TUZ5=$8GDW7FMG2ROQL4UFWI97#3%CR]"A;YU)M&@()/G8,]6<->V,2CP^
MT96HSDU:R+ YA#): ,Q=4AB=@GWEC@/'XC"! 70ZZP9K2*]M>A:\?$^EHVQ\
M645"P[6-^'95S>5=RK.W[+*VK_:6L" V9>\YM4T2:%)C8%F2BMC!>+9R ZX=
M-FG0QMB)7$CQ3%BJ&9)I(Y+"D6KS3YMW2W,O%[7U)(>"T< < C=\K7ZI0K\7
M7CW^?37#@NAU?Q8_J1$D7!:4%/.1ZJ=\>ZC7;^43/-JNUQ]Y;5^583ZFO(T[
M(/?,*^)6?6IB*KFRQ'1=F^CH^F\Q_$5LC\3"G/.K;OPVVN^4N-_:523_ (/R
M/A'FRAZM+)VN8H=B. . . . >>CYB/5GWB_?&O'RH4CS;KM=?!W'_/4OJ,@B
M[L@>_<.\BCZS-([>;#& %Z;Z/SZ3VN/\7;0?-G>//-O:?PEVA\^8MU^H-A,.
MY.P_R&CZO+)FN=&<P< < < < \Y'R8^I?OO[_!GP5J/FY':\^!>)_*:L^R\'
M(GV^Y8I/-<CK5::6\G@P<OS^#[TI]-/=](?B1-N>9F)<HU_EM5Z^8;&2>\R?
MQ,KU<)*SSA'T(Q/+EJ1<.ZFH2],46I!\+!0MNIK 9)V'("D7C+D? I2B=)-'
M!D/')6^:N7+='[)KW@%<X=JY?^3O#'K\O?7XK0_Z4PS$,-<WN'W=1U%)W;<[
MIW+N\J*5W3N>_+W]S>WMW?@WK6WEJ9GV.MKGL#M[L;MPJ!8J]D=IL%VC6&NI
M^XU7O!\0D5ZHW5]PJG3*H<A2G/5-/<I1;ZDS-W<=;C^XG\HO_P"!U#_U"6+_
M $\<B'[S4']HHO\ "5_^B>E_^U$J/_123_\ (,?_ $83Y>&+1O8#1FG[ZBVQ
M/=:X2RU;Y[LP.TK"6FYF%91].JZW@J:+TL=A\*==$E",.(.<VZ0I1%-LNV[Z
M=*9Y9XX2IL[@ZP#!J+"%4.J5&IZ^Z'*[BYG=JF=4=Z4R;N;KG;G?(K[N]E>R
M\\NS;V3HNS)V3]I^R1%@RV>BVDCPN-X/#7O%(:/_ $;@N&X,DJ]T= ZCNRPY
M5#;HY/<W.<JT:E]TCY3R!:"W;OA?%5L,[2CE2ZW532MS-,G&</!6C()S;M]!
M'U02=@3@4JQ;1]B C5'$I4R R[H@H<9G)Z6Q&L6JC1(GAW/[/;+0BR&+=3LL
MVUGS)._CU2?S&DKGQ.[=VD.J.06O.($"V U@TE%TMK]?0"0/RQ9AL+2%_&9%
M2UA%F+@*FX4BME4LB-B]TL'W9!1ZE,9R#S8E^NVA)6J]O;V\;+M]9JSLXKM<
M+/5>-/1\,F=>E7B:W3LFB-#*P>':-@)SQJ4# 9Q2+UXFSL)G:F[$9+QE]A'Y
MYF4B?;H'KP.C\.P!O5 ZJ!X_)9,UD[L2Y0A 9HL&^DX\G:-N_.H7?1<^?/;A
MQRS7+O'1M5;&S;P[*Q590VDK6VOI#>VQ)8,L@D<L*OIW7.GI#7J2T, C&,)8
M,I:S>SM4>?!6-W)0@]*%8D6[N/8&LT6*C]13>5E9NZ3A67"^]>]\GFU97\9B
M&L/%?M2TK$P'NRH]:;05JC4;3O2^ 4^2N6SQT'V'B6K.PTENXQ9TDE\0C$3.
MU6=D*1"/9U['B+*<B6<M#+XSUF[C;E5-T*N)-Y75XHHF[++>X<[MSY:Z:&QU
M&^.[>J)UVW%,MP3.N(=S+[/D<9H&#'3]L1.F(=,;/F,OAE9A;#DG8 K)FT+B
MAP. 4=]AV(YLY8KCPB601F/54%&X;_@WTS;LWEJTLL_&^EMYF&_)7IW9-Q;,
M#-@Q6H6P4]?00@?A$?*UQY/XOJO%9K#EJMBY5S8:0 N@H3@15HZ1E<3-"8H2
MCQ(^)KOJ3S#(P!=#L&H0M)6;23S=X%$TT],^#7HS5N+D8\4M?AH#J>V^Y:3<
M4@E,['G,[?#'NTXG<LA.RAQPP;/;*(WR#?$1LF>2#(;B.59HNL\QG0/!%Q^5
M?-3/(4CUUODOYN[;HLB2C@M' ' (W?*U^J4*_%UX]_GTUPX+H=7\6/ZD1)%P
M6E!3SD>JG?'NHUV_E$SS:KM<?>6U?E6$^IKR-.R#WS"OB5GUJ8BJYLL1T79O
MHZ/IO,?Q%;(_$PISSJV[\-MKOE+C?VE4D_X/R/A'FRAZM+)VN8H=B. . . .
M >>CYB/5GWB_?&O'RH4CS;KM=?!W'_/4OJ,@B[L@>_<.\BCZS-([>;#& %Z;
MZ/SZ3VN/\7;0?-G>//-O:?PEVA\^8MU^H-A,.Y.P_P AH^KRR9KG1G,' ' '
M ' /.1\F/J7[[^_P9\%:CYN1VO/@7B?RFK/LO!R)]ON6*3S7(ZU6FEO)X,'+
M\_@^]*?33W?2'XD3;GF9B7*-?Y;5>OF&QDGO,G\3*]7"2L\X1]!P!P!P!P!P
M!P!P!P!P"OOY^:]CYZL*/F\IV;I_6^/LU[FHXR1M4=94A,/X[LG#@D)GD@IB
M(53'Y;*9;<("L1,ZBH4*K'L@:T6LB89&#@)OUTLXH_FZ;E\#U23>C_)SSX6O
M:]^9&X7B(@%90O5$J<I:<5!,Z@M>\[@M*LF5#I%VM7P&#F3Z(".0$,//LQ9D
M4>$C8P@3L000"A5A=EFY@RZ'XI(IN7-2D3;>=[I).^OMS=%B4;@M' ' (W?*
MU^J4*_%UX]_GTUPX+H=7\6/ZD1)%P6E!3SD>JG?'NHUV_E$SS:KM<?>6U?E6
M$^IKR-.R#WS"OB5GUJ8BJYLL1T79OHZ/IO,?Q%;(_$PISSJV[\-MKOE+C?VE
M4D_X/R/A'FRAZM+)VN8H=B. . . . >>CYB/5GWB_?&O'RH4CS;KM=?!W'_/
M4OJ,@B[L@>_<.\BCZS-([>;#& %Z;Z/SZ3VN/\7;0?-G>//-O:?PEVA\^8MU
M^H-A,.Y.P_R&CZO+)FN=&<P< < < < \Y'R8^I?OO[_!GP5J/FY':\^!>)_*
M:L^R\'(GV^Y8I/-<CK5::6\G@P<OS^#[TI]-/=](?B1-N>9F)<HU_EM5Z^8;
M&2>\R?Q,KU<)*SSA'T' ' ' ' ' ' ' ' ' (2O,/,&%,&-0=BX5<XFN=GZM
MF=M@:!KTW0E@;*LKI'V/!1XRUH[C6=5*-K!8.(X #!9 G8 -ZS0CB6"X$BKD
ME,4D\A? KW365KMW4-K:9O+-NUGK\UUF[Q#H05]JH=L*)W,PO*57-?ET6Y=T
MH%UL:ID> O.727#J?U^VJ&38XRBN\82H/'!5 TE^N:*K(JRYTHKC)4E,A2.^
M]FK6223=\DLL^/Z.;(E'X+1P!P"-WRM?JE"OQ=>/?Y]-<."Z'5_%C^I$21<%
MI04\Y'JIWQ[J-=OY1,\VJ[7'WEM7Y5A/J:\C3L@]\PKXE9]:F(JN;+$=%V;Z
M.CZ;S'\16R/Q,*<\ZMN_#;:[Y2XW]I5)/^#\CX1YLH>K2R=KF*'8C@#@#@#@
M'GH^8CU9]XOWQKQ\J%(\VZ[77P=Q_P ]2^HR"+NR![]P[R*/K,TCMYL,8 7I
MOH_/I/:X_P 7;0?-G>//-O:?PEVA\^8MU^H-A,.Y.P_R&CZO+)FN=&<P< <
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M1-N>9F)<HU_EM5Z^8;&2>\R?Q,KU<)*SSA'T' ' ' ' ' ' ' ' ' (2/,+
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MTI]-/=](?B1-N>9F)<HU_EM5Z^8;&2>\R?Q,KU<)*SSA'T' ' ' ' ' ' '
M' ' *\V[EK3&VK?NC2ZNYU/;=AMR21"I)-6MGU.E#:VB]N#Z[$W/U6E#;;I5
M_*X&E*U(B#0ESZIMC*GMZKYF1=D((3L.(""+J.)B]9)-KGXW;3NLU=/7*Z:>
M=\S?OQ@4_&*5H291D-%+GA,H*W'(Y%:D:NJIJEI<@-L=Q#H"(?)0>&:^1B,:
M]JU]E&0L6S'22E,#<,D\A[DQE_(24X=2_%N+7KJGEP=_TY^DD>X*#@'&EC(<
M"S[('"PT*PZ6;MNWQ9\U',^G#M;!NU0[<O%44>EG+A1-!NE]?ZZRV>"2>.6>
M6./8$=_E:_5*%?BZ\>_SZ:X<%T.K^+']2(DBX+2@IYR/53OCW4:[?RB9YM5V
MN/O+:ORK"?4UY&G9![YA7Q*SZU,15<V6(Z+LWT='TWF/XBMD?B84YYU;=^&V
MUWREQO[2J2?\'Y'PCS90]6ED[7,4.Q' ' ' ' //1\Q'JS[Q?OC7CY4*1YMU
MVNO@[C_GJ7U&01=V0/?N'>11]9FD=O-AC "]-]'Y])[7'^+MH/FSO'GFWM/X
M2[0^?,6Z_4&PF'<G8?Y#1]7EDS7.C.8. . . . ><CY,?4OWW]_@SX*U'S<C
MM>? O$_E-6?9>#D3[?<L4GFN1UJM-+>3P8.7Y_!]Z4^FGN^D/Q(FW/,S$N4:
M_P MJO7S#8R3WF3^)E>KA(P=JO/#LU26TNP]$5_KM1,DB])V8XKQC(IC/K $
MGCG;:-QL^H0=CPD=(CVW67YP8H88(N>__L=]Y8]?EZ[RCG:3;W#-F*^7A]92
M5\^;,I9=6HZ:&G<M03)DZ4H6YL^5%OJ*3$W:%JSALV[I;>=@OM.]ONSYL=5[
M:[,;2;(81AU'C];L],I<>GXU+K8JNAHL-KIDZ"'#\'KY#IXY6)R8('%.AF.9
M+FJ*7#"H(H\$?XBG<[]EW6'_ .3[6_X=S'_OOX#_ %;B_P"11?QA,W^S-[,/
M]N.QK^=[4?\ 3)97T/V.-[=:@T-LG)(R*AQVW83A*"D8!O79(2&==E20[-HP
M?/TT7CEOUTPQ4Q4<)8*=]J=]=X]===<E:7&IDN"8DTID$,:3U2BA423M=7L\
M[-GG564T=%655',BABF4E3/IHXH+[D4<B;%*BB@WE#%NN*!N&\*=FKI/(VWY
M><8< < < < < < P5UJ_K?U>'>S'5#U%UL-V/^Z^[N_1[%OTI=L?NC\WOLNY
MO]U_G#]?\WO_ $][1[?[3^;_ %T$^V^Z^O9."MW:UW;FN[<^FFN9G7@H. .
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ML[AF,5$NIJU5*9+D0T\/<9\$$/<X(YDQ744F-N+>FQ7=TK65LL\;?X8BW_\
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&#@#@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g773514g43r37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g43r37.jpg
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M P # 0$            '"04&" ($"@,!_\0 -1   00# 0 ! @0%! (!!0$
M!0,$!@<  0(("1$2$Q05%ADA.'BX%U>8UR(Q)0H8(R0U0O_$ !<! 0$! 0
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MR:6A%9^4THC4$=U=$%LGS]6EJM;'FW%EQ<K>&WUI';"*-:['P.8Q%",(0O\
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M.U4L2.0=L)V@)UV*&5XZ?%BL/9C^44(L[?/W8)%DX=K]J"'/;(W\?L*KPC:
M8+YP 0*8<><Y+(2\<@$/;J%^;&ET<'>7SLL!A([L]]2LR)QWJKR4B%)]"2B?
M!$6L.V)=.F8OQ-Q=N]OK_NY-Q[S1YQE3(R-E'G^DI(.D<S6L>0L#U4P0PR/6
M&X0TU7GAEJ0 N$"DS7;<\MUI0^37.*(<Z1[?=)ZUS@2]V;"C2M-MYUJT&]2U
MFA9FML-ZL1&!Q9*=:V*!$(N,WJ6\"N3^MCHR6*QUA_\ (?\ Z8(F0$-_PQ[U
MRW4$E[D7S:?^2H"]YDDP(4\/*K63,"2AE,,!,%D+>@5/'"$T(D'@8<1?L+&C
MM(QPTR*O7_;>2HPAG^WMJ],7+0:X"/?UCZF=J2J/,?$1B,TI:I*:"Q"4KB[C
MAY:$UE$XNT?DY3%G+898;!%@ &+MI$6A\E?C_P!=40;G.@ALB+<+<MGSQLH*
MYUTL8RU(GY1K"M'[NUZ\IL!53L?5]+$V9NMHT^BKL 9L$;$ZFK5Z#0C[UJYB
MR=C3IBSB\=68=Q\(9D2Y!%N/Y</7F@NW;-WY7;_)@%:B\P^DJ"F<(@P>+,ZL
ML*L[+\R/3M5@Q$,*"Z\1+R2O9]7D5*-@;=>/"!9]E(QO ]@UX&,RK=4D.0VM
MIN\V$M/Q3WOE/8W(K2'FF$!6<RD%2U.U95/4;R LY@<@<<+FHI2X"-/&!.'H
MR!Z)?'DX6E&/U%H0CZ3I0>]8.'R#AFXY=K\*A+W>9\=^IGZU@%$)+-KEJFO:
MR%$K'AL7ZXL:(0>.@)!+8+^DC%X@T?'V A@;( 6H9$3H,,(K]-A[-LR00:M^
M6R2:87Q-ESL0?*)'\?=;W 2I67.O)T,O/TRFVU(JW,,ZK#6)>"9IZ[:C>9>
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M:+CL<T'BX@&[IXC'G/U?D0=\3$7 0CR?)87%1J(:+Q#V+\@D7C8AOVNH@*
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MR;1AH6N?X(CAZ;&0]._U+AXP&;?"T&B;#IN07547X1&39< 8 P!@# & , 8
MP!@# & , 8 P!@%$%^!)S7'R-5VVAC/TD: SJ:45*"H3JW?=)Z+6<G.+8/B+
M'W'U(7)W'ERNZU\RQ5HE8$TJZV!KH7,8>3=140*C;0N#<'AM?M;MJL4RK*.;
MEVMB&[PXO<333133223X222XY3223YYX333XYUSPFGQSK7/'''.M<\\\ZUSS
MSK6M:UK6M8,'G@# *[?C#_IWLG^^3Y'/\\O1&#565\M'V4EB6#(P!@# & ,
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M->5W\/'0O@0>2,@D'CH[/"<Z2D*;\4%$:C99F[6+AP^OX*__ !N&2JV>^R/
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M776][WO> 5W_ !A_T[V3_?)\CG^>7HC!JK*^6C[*2Q+!D8 P!@# & , UB6
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M_#AY3\I7Y7-<Y7='C[U[&_=/ENC/:%:KR^!5S)QDWD,LKAW&6LJDY%Y$5I=
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M-[B] #N"LD/O^NWQP^0Y;:=F##SOIV3(K.7KCKI9?O>Q:\_\:/M19A@R, 8
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MKG6N>=:USK6M:UK6M:UK6OIK6M:_EK6M?RUK7\M:P9/[@# & , 8 P!@# &
M, 8 P"B7P[X#\J7E6EQ699L DIV:'_<'R$)%28ZY+NB31PF']O7X%':2 PVQ
MH_'F>T1P]HBITQ%-NG2B?3IWTN[6774&ZJFFDG_&C1?TI.ROX5'A?_:F9?\
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ML3K@@P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MH\<*OG6]N'7:JN]]X*\4]/RSG/YG^NH'\:_K*;P?>X9,]B:R?;ET4WN.R?\
M/#;4@;$<\_7Q'Y,K^:8,E56;)Q^;_&:M55&Z'::7?7&QK]-)UTIJ5.&1?\.R
M2;F&QLPY3X<%GOA'Q 1>E%^.52+LA*9?ZUE<G?.GRFNG+AY(Y02(R0\Y55[6
E+GR#TP0[<$72[E02K_VJ_!=G@R, 8 P!@# & , 8 P!@# /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g773514g45j64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g45j64.jpg
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M 0( " D3%9?7$1(45Q96%R$8(S%!42(E)X&A_\0 ' $!  (# 0$!
M      $$ @,%!@<(_\0 11$  @(! P$$!@8) P($!P   0(  Q$$$B$Q!1-!
M408B4I*3TQ0R87&1T@<C4X&AL='B\!5"U&+!)#-RX18E0X*BM/'_V@ , P$
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M\QKL-<4=$3J6C9DT#0V.Q6QK9CP&5)2TXB[L=L4BS:(C)*#D#/.S!.3@-U\
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M;55!&QD,Y !+ !W9PNXA2Q&[!.!F;@,%K!;$5T0<+CQ89IY?X[]].'(=TO\
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MX]B@HZ>OGKI?;1%LT:-DE%W+A;?1)%%/=13;737.<2%9F555F9B%55!+,Q.
MH Y))X \20!R9!( ))  !))Z #DD_8!-)41VBZ_]FV$C)T-:D6LQG$B28F2;
M1YTMNL(>+_D99_EM':#5WJT(ZM76XPCJAN/)IMG&[!TXU05SIU.U>P^V.PK:
M:>V>S-;V9;J*A?17K=/90UU1P.\K#@;@"0&QRC':X4\2MI=;I-:KOI-15J%1
MMCFIPP5O(XZ9P2#T(Y!(F^^<J6HXB.(CB(XB.(FFYY+;F"']V4"J$/.8]H$
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MUB#^&T_SEH]=NO\ 6E=^[YWX?Y.*O;L^$OSHR_LK[Q_)'KMU_K2N_=\[\/\
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MT6ZNGQ56K2B37;5D8[!V#:HR"176W;%>QN41.&NF'7MA "$>K6Q34?(7&+M
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M=()FFP8NH)R\P+?_ (]A.SNT+%M9-%JF%%WT:[%-F:]0'2LTL-N>\6RVI'4
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MA6WA>?\ :64E/ ' Q*LT:I,FK9FA]_DM&Z+5'S5-UE/*;IZI)^8JIMLHKO\
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MBW0PY?/'65G*O&U6H^DVBP(*U6G3T5H&+%:]-17IZ]SD#>Y2I2[;5!8G"J,
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M/6AS9RN\C($=*2R3J4+L-B*"(])=-MK-FBL1-ZLCX%Q=0R A:;-C,HWDN/\
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MU'J9V-W?=8RIY%5=M8#88<,MUA<C!+'((,T#1TC=C>-PL!.[G]8Z.2..JFM
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7Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g773514g52p85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g52p85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1FL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &9"^940X0DE-! 0      $\< 5H  QLE1QP"   "_N$< E  "')R,CDS
M-S0Y' (% "Y-:6-R;W-O9G0@4&]W97)0;VEN=" M(%)I9&5R<S(N<'!T>"!;
M4F5P86ER961= #A"24T$)0      $*3$TJ 789<-5/.C_G@/.D(X0DE-!#H
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M/X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          (X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      S4    &              *
M   #T@         !                          $              ](
M  *                       $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  *      %)G:'1L;VYG   #T@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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MM&JME-;*JFAE=;0QC!P&M&UK4L6.0UE>U43_ "_P4YLD#I$1W
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M (6ND))GKS%8%](\]"3 GY_"NDU1J!LBB ]S'_(/UUQF+8]3[@/F?K3E6'K
MZ)]\Y>6OD*X"HU>:*'H=3\PP]6.>9^'XY^5/61_R3YD?,#X5VA40\VY/0Y@O
MOU+I]<8&W(_RN7-,??IWK)-PD].4"<^^N6N0F.]9))]$?WD3 '4IRB&X!_G
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MC2)Z^)!'*=,O(^%:%K S,2!I/[(\HDYY#++J9A;=O0( _>#YB-M+!?4+WO\
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M3%@E,1U/UT'NY>^8BS', 99'+3P\1S!)Y&:57;GP@81&]Q$!MI;IZB';F(7
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M+E7$P:+IR.B?%!RR3%=PY122=1[S#G&W'5,A"FP\&TM-K*W&PX3P@M)DC>R
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M\Q[HF*LV3 D#7X9GEKR&LQG-.K$XCX>EA ;]0N';I;4/(,5CH/M>(.G*1/\
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MB$!4<G!+"+$ZA';LSDJ"Z2) /K]>3Z\Y<[BBTZDMN-DC>4VIL((G,?M)!'(
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M!<?V-'\[)0_]78_VDJC^ZW#[;PC]Y6/];M_[2GZ/8U^[[G^@N/[&C^=DH?\
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M_O"*2P(.402<(^T(4_LETK#[-9/Q>!5/Q&\!RF+<;7P_1*T5GP$R8GV=/A5
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M\';6RZHW+2'.'9,-J?4RP5;RF[=I2%.'V3 5PTN%"PFTG\G,;_\ #1_^T/\
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MR20D37PK;':2[VNQVXQNZ;+#C[&&VS=OQW;A%NSAV&VF'-H:6Z I+:DVH>W
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M]<YR[ZYF.G]1/[G+;&UPRVLP\M.2$:P!FE$Z]DYC3+W4WRRR.G&50IJ'2<
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MTO(PZ[-TZ*LR<IPC@X(N ;OFH>S*\;)E61.KH8Q)EY3Z2DMFU=+2RN "$+"
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M7[VN_P"8P?\ Z=2#M@SRPYJ._%_TNM<_R)<;_P#5C(_V29?WPX?HJK][7?\
M1L?Z%/TQ:_=S7_C?Z5'\B7&__5C(_P!DF7]\.//T4/[UNOZ-C^SI^F+7[N:_
M\;_2H_D2XW_ZL9'^R3+^^'#]%%#3%;H?_ML?V=/TQ:_=S7_C?Z5?)\C^-U0A
MR'ROD#$.4Q#%-2+$2F*8! Q1 <X! 0$!$! 0&X<L>_HHJ9^UKN>O#8D>!X9I
M^F#)R.'-$'(C];F.?^56^N'OAJXM99*%+6$=2M!1^7E%R%#1"68$&[?.*D2E
MT&T$J^0:4Q73Y4#H4M#H)+O'BT<7VU1R#!)J_P#=U7A);VSH=-RI.(W;*KBY
M;N);2R>'N*<66D!2"-Q3BTJ,@D<) D^U-/\ ;J0FV1ZC;NIMF7&(<+HX@4$(
M0XHA<[Z6TJ&7L[SBB!D!6C7'#?QMT>NK2B%$_M&TILXPC&H8FGVTA'ST?&_[
MTCYENY7S0B'!OB;))N]52<1;!PV775;+-DU$3!C0_LQQ7G74XE<MI<<6X&PA
ME26PM15N)*D%12B=U)))( G.K.WVL0S;L-.6+3BVFFVE+_62LMH2C?.ZH %<
M;Q   )TB*1B<)O%"2M%,QR</L.2OU8\(E2M"Y:4\%4'C0(5(&1IP,U_B1F_L
M2E0\ N?_ &<I6]_8E @:?T3,[WVK=3UX;']GUSSY^569](=T;$8:6W3AX<XP
MLC<79M0[)/$X'%X6]O$JG<_:)5J2:<_Y$N-_^K&1_LDR_OAQ[^BBOWK=?T;'
MA_Q?3*H/Z8,_NYK_ ,7_ $JZE\B^-AT@LV<Y5O'#=PD=%=!>C8Y9%=%4HD51
M625S?.FJDH0QB*)G*8AR&$I@$!$,/T45^];K^C8_LZ]3MDVE04G#VPI)!207
M@009!!"P00<P000:Z6.0?&C&-$(^-RE6CV#5,$FK)C1,6S9MD@N()-VK;-U)
M!%,!$1 B:92@(C8-</T45^];K^C8_LZR<VT2ZM3KE@AQQ9E;BU/K6LG4J6M:
ME*)@9DG05E#DCQOB A_)A(#?D-),;#V'_P!, _ACW]%53)Q6[_HV)_\ ZZP_
M3%GGAS49_P#&G4=-X5:3[/\ X;<]:&JR&D<WH%U35(95Q%:-Z$C)5G&-'[NH
MJW?,FZLBV^'5/4:BS%E MYQ8_OR<:HT?5<Y8-U)5!L*[;IF;8-...E:G%N)2
ME15  W9D@ 9;TB1F/9!F29Y*YNP^VTRA ;;94LI$$$I5D@$DDG= )T$%1&8B
MO8;$FH=&%*,*5AO" 9/:X[>@:VTU'<?U?'H,$&O#R^,_#SF(_A20_2'Q&TN'
M+KI<!U\]^W;$YE1D#G/F!I[A(/\ "H;R93E)()\->43J/CSS%(DDCX3B-MQ$
M!\NW+;KT'O:R95 $QEUZC3X>=53B=8Y&.Y'EX>'G%);](;&ZZA8>MM-QY".@
M@&]N>+-M72,LP?NRUTZSY:07DSG!/RYZ]<O/P%),BCN( /\ A_';L W'%JPK
MO\N6GD1YGPJJ>2<Y\>H!Y1$Q/36/$4D/T+E, <K^@^@:V] Z;8M$$$#P_'ER
MRC/O'("H*TF9CMS[B8CEU[128]0 0-I<>6GTUO>X;#V -+C>8TOO&@/B-#\_
M/WU7OH/3*?'V3I&@R!S/+D-*2WS;40\.XZ;6Z]+@.O+MB>VOQRU^[G!_CVJN
M6,S/3EK.FHR [G/6.4)[YIJ:P7#4;=[:AMSOS#S  #6Q9<&6?+//6.HU,Z'O
MEG4)ULZCOD,SKG!$Y2<LA\J5732X"'AZZ= Y /ST$-N>F+%M<00=<\]1K]'6
M8YU =:"P2)WID=9Z#J-2<\O*EYPR, B(!?I^K7\QVZVVQ+2L$#EEY>\9?49U
M$4B#NE.4Y&!KESD#IR&FA.=(->9>4UF/2<_0]81PRE-5(Q-'RS$%W+0ZR J)
MKD%)TT51<MUT'"*+E!=%8BB2Z*9RFN40Q$Q/#[3&,/NL,Q%GCV5XV6KALK6C
M?02%"%H4A:5)6E*D*20I*T@@];C9K:'%]D,?PO:79^\]0QG![D7=A=<)IX-.
MI0MHA;-PA;+K;K+CC+K3C:D.-.+0I)2<HFCLHJ$HC+YAE= TZT+0L?&/(@D#
M) >8;.V,BNY<R2,B,F9T>0^(N'KQ9Y[V*I%CN%0$H)B"9=6'X/AF&82S@5G:
M-C"V&7+<6CLW+:FGE+4^E[U@N%T/*<<4Z'"LJ*R#[) $W']L-I=I-K+K;;%<
M6?5M1>7MO?KQ6S4G#WV+FT;89LG+062;=-KZFS;6[5MP A3:66U!17*B]0%,
MQ-/1C"#@(IA"PT6W(TC8J*9H1\:P:I )4V[1FU32;-T2A^ZFDF0E[F\.HB,M
MAFWM&&[:V9:MK=E"6V6&$(:::0,DH;:;"4-I')*0 )$0=*2_OK_%KZYQ+$[R
M\Q+$;UY=Q>7]_</7=Y=/N&5O7%P^I;SSJCFI;BU*(U4D@0WM67AW"X[V_CTO
MIMOKRQBMV=-(]WF=3X_C6"&2<SG'/I.HY'+EF8ZD:LK-J(B ;[7T#81"^X7[
M6U]1TQ =<$9&2 =!IIWUU(Z934YMN2 !D-22?KGF?RIP8MK>'3H%K6]+6ZZ:
MW\PQ6NKDG.!&>FG3J?PZ\IR$A("1(\.AU)YZ?#K,TZ1[>P%T +:Z7T'37O>^
MFN@CUUQ <5K!S/4<CE^6LFIK2,P3,9= !T!\3!B-.<&*<HY#4#6'EH.@;!ZA
MT"_SQ"6K4^?N'WQW\ZM$(R .>?3*,YSU[ ]1XPZQZ-Q+;F//;3KZCKH.UP"^
M*]]>OGTYYGMI\=:F-)DD]-.DYZ'RY'28IY8); (:7N CR#7<--PL7Z:XJ752
M2=8GQ^!T'PSJT:1F.>GA[QRG/WTXL4A$2V#72]^7SZWQ6NJ@:C(>Z>N?;RZ5
M8H ,#O\  <H]VNHRUU?&"7A NG*^MM>WR\@UWWO5.JC7Q,=_AK[HJRMTYB-3
M$ZG(Z\N8R^I+Q%I_NWUM;7R#7EK<0$.GD.*]TR1F=-,O 2=2>IR[958IRY1.
M8[CWF(GZS-3V-=9T84HPI1A2C"E&%*,*484HPI1A2C"E&%*,*484HPI1A2OA
M0/$0P6OI?Y:X4I/D4@ 1&PAJ(:"([AOS#>P>HXDM*(CE&4SRR!/;E[N]:5IF
M=3EO:021R&70R<CGG$Z),FA<#" ?2P#VT_(+]PQ8M*F->AF=1F).NDZ1[]*E
MU,$^8Y>1\Q\.QI(>HWO<!U&PZ:!;;GY"-]]=-0Q:-*R';OJGSS^&507!D0=8
M[2.L1,?*(.E)SY"]]!L/+J.N_K>_*^M^>+%E921RCOU)S\N_+QJM=3KD,L_E
MV/0=9TBDM\@(";0=^?Z\[7T#4?*V:7($0.?X\N4^?E5<XD3&@.G;[IC/+,'*
M.J<^;"43"%[:CML.X7#]6T[XFI41X<Q]<_HU$<;WA Y:D]-<^^?0QD9$Y*;Y
MH!O$.X\KAOT'M8=^7Y3&W#E.9ZZ @^?73RJL=;(.6D'(9$ZR-(D?72E)VSOX
MON];AU\O\/34;8FMKTSRY'I![C2>O2HBD\E9\@>PY=I)UG*.F=+#IB("-@&^
MH[:[_P  ]- TUQ.0]$9Y\L_#0YB.U1%M1F.>@B.4_+.?&H1=GJ(6WON&E[[6
MZZ:>'GB6AV><>!^8/+O\*CK;!/M#SZ^\>'N%:ISBHRLJRRQK:F,O:H_8BM)N
M#<,J=JH!<D&(?G.D8%?;M"*O&8.$2*LA?LTU'D<5P+YFD=RW1*-?C;-_?81?
MV>%WWV=?W%NINUO?:!8=)!G>3^L0%)!;XK8+K6_Q6Y6@"NEV&Q'9_ ML-G\8
MVGP8;0X!AV(M76*8,0VH7ULD+3N<)\BW?+3BD7 M;E2+:Z+(MGU)9=<(P,D*
M%KBA\JZ,I3,JK/V\KF%C%6M056*KM?XJX4?NW+< <OTTGSTK!BNUC"OWJ*3Q
M^5D#QRF1=8Y0PV?M\2PW!</LL7O_ +3Q"W9*;F]*E*XRRXM:3O.;KC@;;4EG
MBK2''>'Q%C>416_T@XILYM%MGM!C6R>!)V;V=Q"\2]A>"I0TT+-I-NRTX>!;
MK<MK8W-PAZ\5;6SB[>U-P;=A2FFD*.WTF0W"P '8 $.7(1^6P<M^5JIT<SVZ
M3S'3OR/X\@&P(@=9TC+L/QT&9Y5+-F(C:Q;!MY?7O8=^O7$9;TZ&/R\=3]1)
MK>ALJCD.6GN\@>DQ3(T9V + '6P\^O\ CKUW&]X+CF](/3K/+GWZ>6DFIB4!
M, 3IH(D^><#G[CS)+2Q: -KA:VVFP;Z@%]_\0Q#<6.N7/N?'Y<N^524()[DQ
MKH>4:C+/,_D*;FC4;E* <P\N6@\NE];WOTUA.*/7.?,#I] ?C9,MQ!CGF8R*
MC\<O'\G!DW OA"P!L'2V_G_"]_6(XN 8Y?PZZ9]NN<BIJ4Z1J<N>7/N1WSY4
MZ,&]K:#KO_MZAKIWT ,5;SDS&<3/S/O^7C4]E&FAY^[4:#G[_FYLD1 "@ #J
M%K[?X[]^7;%6XKJ>YUU^7/*K-E,"?*/?Y1'S\)<8UO<Q1UML'D%^XV[#;UYX
MK7ESEF))F/>>>?3S.M36TYY\\I&I \AJ1/STFGEDGJ73OMR#8+::WL'/0;=,
M5CJC.O4ZZ :>[4QS$@\ZM640,]9'O/+0Z#N)GGH'5BGX2WUM:W+?3_:/?;3$
M)1DGQ/S^C4P:1$1'7[_X]<\JD,>5[1A2C"E&%*,*484HPI1A2C"E&%*,*484
MHPI1A2C"E&%*,*5!R2 #<;?O7Y=0'MU^H!WQFA4&.OU]> K%0,9&(S'D(($?
MGK%);U"_B 0M?3R'6PVZ7#3ZXL&ESE//*.4?E!_"H#[>I&D#E.OX=)($:]4A
M^V$IC!8 O\KZ]M.@VZ=[C9LK^&1 ^?0]CSG.#G58X())U)S\1W[^_*E%ZW_>
MTU\O2X]MO6UK\Y[:AEV/;2<P.<ZSYR>50G6^DD::Q!.A![$9]M>M)[YK^\-A
M$1ZAKVOZ:A;F-KZXLV7>_/+J._AU'XYUCK>49 Q,SEVT\P9B.>E*#QI>X" >
M?3<;W_+?KUQ9(<D1TZ\NWX==/"$I,Y$0>OW]QKV\.2JZ:"41 0TU$!M?M\_2
M]]]L24+B!XYSI]'W5%<;WID Z&#SZ$3\LN^E+;IC>^EM]^VH?CM?D&@AKB6A
MS/E.GCGGYY15>XUSUUT[C,0#.?@>Y')<<,!"X"6]AU$ Z6W ;;>@_7$I#F@^
M!F.>GU&?;*.I!&6L<CJ.I![^[/PJ(6C_ !?YM[]0_7IR //7>'NI/GG\=?KQ
MK2I ,@C/GUT/,=H]_:JIY?Y><2D3Q YKU37^8E-3F14ZQ*EEM13!)4)FGW9'
M<:9FHZ(:!8)M0;,$I9M(J$FY3XL[=M78I) B5-MSN&L[3-;08M=XAB5M<X%<
M-I&&6#8A^V6%-[I4> @)A >2X2\Z7%K0N$A( ^H;28KZ,+OT<[(81L[LSB=A
MM_87!7M1CS[B398DPIJZXR&MW$'U/<2Y79.VH-A9^ILL/6Y6X5[[EG CN@!L
M%[<^O.^O3]!T_&/.1TE5?*^ !R.9CF!'F1\_*LI*.L(:7O;6P:#TUY>=QVQ@
M7O?&>I)R]WA\XK,-I3(Z9Y]>P'7S$=JK/Q'Y'YV9JRN3[S*#.9WE,RHJLPFZ
MU:MCR*85+$F4CC)![.. 4I9>/2:R#=*!FA3@Y%.65.^6)[L0BW(;2X;C.*/8
M0O"L97A2+*]#]ZVDKB[8!0=T[@/$* E:0P]^H<XJBLRD _7?1CM?L/LG:;96
M^V&Q+.US^.8)ZC@3KJ;90PN\ N-]4W/M6:+E;UNXK$+$*Q"U59I2PDAU2D7,
M;1XB-_"'4 U$ "]]!'4;::C\[XZ!;@ZQYP3]9_0KY:EK.(,DP8R/7E&Z/'XT
MQM6EA H (CRMO>_D%[;!J-@#ESB+<,]^G(=^Y^NU3V6M,M,IZC(0GMEGI\)I
MH9-+>$1 +\Q[#;IN'YA;IB,I02.NOPZYBIB$C(P F>FN0G0YCJ/$<X&ACYI<
M2C-XY2;<([J39HNEDV[UMGGEXF=XU36.5%R#1=FF=$5TRD5!NHJ!T_&"1CW*
M(XLU6& +0E1VH0VHI22A6#7\(4I()3OA9!W2=W> @Q(@$5\W5M7Z2VGG4I]$
M3EPPAQ:6GFMN]G IYM*B$.AI;*5-AQ("PA:@I.\$DR":RWW$WF71<1)5!7_"
M1G'#04'&O9:9E*<GLMJS1CHR-;JO)!\NFRJE@L5HT:(*N%UA3 $TDSG, % P
MXBC9_#[QUMBQVHPIYYYQ#33=PQB%HI;KB@EM *K9:2I2E!(2DDE4 22*]?\
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M^Z5_X40= V62;XXY[&<;1M,C"TX03@Q9"U8I[<!19*RLN3P0$N_J. 0721Q
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ML(W[:"(WWMH([ .W73&:%01G ^7UE]36*AE //3\.>6>G*0,J47;??2_33N
M6'GYAK;?GB8TN#EI$3,R#KRT'++W5$=;F9$:^$F,NL'S\I)I1?LAU,4->P7\
MP#Z!K<! +VOH,]IP"!R.A^733\>PJM<01/W91U3/\ >F5*CEMH;3GJ%@"PZ_
M6U[CM;2P@.+!MR3(R,3]9:$Z>&HR-15H!D$>?3L3I()Z]\CHN.F@#>X7]+!K
MIH([7&]^6FF]QF(<B/QS$=.6AT[P>E07&2"<CV(SGR^_+OTI:=L=Q -0Y;[<
M^MMN5^8[7"<V]U/G,>Z?E\JAK:G*([]>G7KF0<M,Z7W#(0O<.O+D&E]O,?\
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M<RU39>*YN4['-ZP@5GLYE6@#<5<QXENF_,J_H=,';8QJH:E5A0*NF;WRQ@'
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M,_\ ^!Q3_I>S_FCLA_W9<?\ WU=A_)%?#3TN>EP>&T>&?_X,<N<FO@W!?.F
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M<KIMFQ74E)N&S-N*[E9)NB"JR8JKJII$ 5#E*.#MRVTDK<6AI(B5N+2A*9(
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M=S;-Z5G&%9J"V<NZ&[Q*]:Q"UM&;);MN\$EVZ&]#1*BE1D#='" "U)5[2@J
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M5&=.@'+W16L) $:SK,5G%3(2WA*&G/<?F/Y8QK*M%<4W_)DXBO\ L+S:_P#
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M>5U7[J!B%:RI:NJ+J5"F8A>ISQ]*1\I3>95:QQXNFF\5&M_C(.6C5!W&Q*[
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M^+IA*)CH<SENZB&S)W&1:[+2+*V"=S<44 J*4*<=4E!4E2"&TE9#:=U:@$H
M2F04@$ BS&U^T*;D7J+YMJ\(9#MTU88<U<7)M[FVNVW+UU%HE=Z[Q[1A;CUV
M7G7MU:7EN(>>2OK><)62,C.0=3R,16;^I*<BSQ,54#S-O-MQ-D0%"NVK5T[E
M5:W,]DYB(;9FUTWI^>D5G4W3:-0N4X%_&E;L0:C96Y4E92XI:$[B5E]\KB'
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MT)]A"$H 36U:9X3N&2CE$5Z;R"RDC'+<2BB\)0=.N'Y#%$#%4!^\8.'@J%,
M&*J9<5 $ $#7Q6W.U&TEV"+C'<6=2K5!O[E*".FXAQ*([!,5T>'>C#T<X24+
MP_8;96W<;(*'DX%ARWPH&0KCNVZWBH$ A165 @0<A6_TTTT2%32(5-,A2E(0
MA0*0A2@!2E*4  "E*4  I0        Q0DDDDF2<R3J3U-=R $@)2 $@
M "  !D !D ,@*^\*]HPI1A2C"E&%*,*484HPI1A2C"E&%*,*484HPI1A2C"E
'&%*,*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g773514g54i19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g54i19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &**^8P8X0DE-! 0      #X< 5H  QLE1QP"   " ?\< E   T1-1QP"
M!0 B06YN97AO;B!04%0@=&5M<&QA=&5?,39X.5]);G1E<FYA;#A"24T$)0
M    $*0_5W#,]8V!H;UJ6&Y!L=@X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              (K   &X          !
M                  $             !N    (K
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   (K     %)G:'1L;VYG   &
MX     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "*P    !29VAT;&]N9P  !N     #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     8X0DE-! P     #E(
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MM-FW/82W;<X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@9$70J$DL<$84E>6T=7P,S5RX?$9)28G-#8W.$-'8H.S1$53561XDJ*W_\0
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M^V/^)'1HUC6ZE./I6HGV2 2/U.2./Y9Z-8OBP"?I7^2!_778.)(SR/T((/\
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MWKS7]/GW.J3D8\74#Y<9!(->6GOSSTWZ^N@C4;43&1?MYC!S_P#.BN>V//\
MM^/]/Z];%F/\S?K_ +WK58X5%"&/O?"**_\ TZ6(VIVH"D[57U>'MC_X45S/
M\A_M_P#N\\'QGIHW7R0S6/0'_;]\=]2V.<>@&ABHCOY:D]N ;''Z:R2]2-0
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ME71RC*0+!3M=@@V>_8GTUQS!WZ#;-QVR=\/;LN) ),C'R<9)(FZF8&.3@'\
M!KJL6"*)O2FWJ9J-4)<I46Z;Q5#V.+;0BZZVR5MH!*G4*7/ *D#ZMO.<<@](
MUY$$*S9,AE8J)"39#'L#T@'GD'GCY=]2R@;QEYTF)LD382Q231PQ%(3Y48ZW
M=6) 9HQ3=//5W*D4-%*Y>FJ%83"J$:^KM2A*6XN!=-::4GTTG:' F<A*EX2
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M=6/1U+85E)]F 'XB*^59^S"?*V2/';Q.B,R--"\,!ZXF58R().D@4+J^."+
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M_ R$^6%,:E>18'%\\=J ).E]P\61[GB[)BM!/BG:89H99(Y'"3S-))+]X=;
MZ@&\OJXXKN!KZ[?9\ GM*[70%!>.W71(%8&-Y&FEL#=C)QN&#C)QXSU.)?2M
MBN.WMJOL;9C=V2;/<V2;/UU8OK;6-#HT:^?#^UZ,J/>UVV.@$@=K$)LX&?\
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MT43D,A&J_*',LJ?$5ZUDDEDLCI# TINEKI("\&U+$?%RIKH4]%,B4>M3&*?
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M6ZR2A L=*!NE>3P!8%:2ZFE%%@0@ [GZ"C7MSZ?TT1<:2ZX25')62H))X2>
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M2'W$H6C< K84C() .,D@$GKRMO@QAO.ZC#9'Q!N&6,9XR6C:%<B14=&/Q,K
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MT--S^A UL[_M?/\ ]<CM@_\ [9WO_P#J5[=5C2GH/J?\?[:U,8\%V2T"G:D
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M7;GCD_8*[.__ *I':V/&WMTT13_;3.V/;VZY](O1-,A[I*ZD>U&O\=O32_\
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M('JW;D<^@8;E(E09+C90\U(:4ZP\TH*:<0\VHI6EQ*Q_#6VI*@4J .04@9(
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MOVOFB:YX]_2O;2G:[=.E580ZK($>(\XXVJ2D))CJ43M4M*LIV[@$DJ/"59/
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M'VQG[G^WZ'K6)C(> .#^['/?_IHTXW)#[C+#*W5+1&06F$*_*TVMQ3JTHQR
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M": ^G?W]Q]-/44<T-N539P;5(4VER.\RH*0 HI*5DD)6$[<@X0<$@8(Y%H3
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MF%3DA+C*RM07NW@@C)Y! 4%'SA2<@8&,8S2LK W';'!RL?(Q9&/4/.1X_0.
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M$!!.2!GS_?&//&/?K;J-%;X/[_KHTX(#C<8M(4<(<1N!4>=RB?Y<<'R./O\
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ML#U $L17H+TJ>E:%]@ !Z@>E#CGY<^_?2BMQ,5<=M<EI]LJ0DI&XEO&-P/(
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MY&G@4$V2>3P"+ [=OG_N?IHN[55J>?(4IU*TH;#KREK=0TC"@A))  ) XVG
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MT?-E5)8ED:9H$$8:Y*\U4C5773[:OO"+YI5XXS"D:)*?A9U9@2@)\P*5/!8
MT*-]]58EJCTUZ0Q$2IV.H[F]^ KTR5@ I&-IX/N<Y(R "3Y@W-,/!SLN#;Y&
MR,-7)QY9*ZWB8<=0"K3*;!M0"0#TBN+&A+*&84W/ OCY=^?]_F-=[;5"EU>'
M$J3PBPW7%,JD.DEN(I[^&T^X$G*PV5)>4D920VH <J)6\-1[;E[SA8N[2B#
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M=!'KKV!Q!4=R3MR21R1C&,$<>.MB!$J-P6-6I//;V]*(H?TK1I7@U-D[ XX
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M^<\_?&?&>H5,J92HL'@$FZYKMWH<<&A\M*&O8#Z CBJ!YXK\O32I'=]0**5
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M('#@^^5+"L @*/4W]I&/E;W'%XRRLN/%FGQL*+&VX1@,N*O269'LEI%FD+$
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MDTTN-X#\!Q2U15LN#*7 EH $I42E86#A61UXV\9>&\_PWO&5CYF,8(<F:>?
M?I/1+BO)(T"JQ !>.,!71;Z75OKJZXN1%D1*T;AF4!9*(-, +'N.;[_7L=,I
MJFO2D)6A10<^_&[S@D\9P..22 3[9Q35B,S*JUU,RA0:^(DTM?/D 7V_KI<N
M 0"0!ZV2!?I\K_3@:,&DU*&4N3FI2(RE-Y>*'BWZ9)*EH5P"4IPH 9!( P1C
MJ1GVC<L$1R;EAYV+BNT8;(DQY>@1L;9T=@J,RJ.I5ZOC-#MSK D0\(RDUP P
MOMQV/Y?+4[VJJBW+)H-H6_(<BR*G*;1/JU<CLSDQX]/;^9;3#:"5/-MNK86Z
MN*#ATK2RHEI2^NX[#F[#OT>T>#O#4DZ39;UGYV]8T>5TXNWQG*C3#5FZD,TT
M7F/CEA%T.RE1'QJ(RO.QUGRIAUK&#T)"65F+_">KGI- @ UQRPYUZ$T6;4X]
M*A1Y,&W9#T9D1ER&5SFFGQ'4IE#R&D-*2R'&T)66$DADDM#&S'7H\G*CZ4>/
M'9T1$+)*8D;I11U+'Y+>6& L(&8+?2&8"S55AB<%U?+ 9F:BL;$6Q)!8R L0
M;%D6>YYUZ=?M?0QWC]KYR.>VA\8]^-4;V\_8=?.;71?0?4_XUJ6PW$H400<Y
MW9R,8 Q@\^^?M]_ZZD?$#?I5?J?WV[:QZ?I_G]_EIPQ:6Y/;4MM"5'! "<D
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M!KM9-<:66,\<BK!].WH#QS]=+] 33'IC":HZ6X2BL+=200A11E"E$'.W=C(
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M*62HL[5N'Z@O:LEM)2-H&U*B H9QDIX'DS.V^)_N>4 2#%./XET/CY/'-!5
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MP0-;>5')(LI ,D)(#<V#0')^8L'Y?72"XWZ$5?K("T J#84$[OJ_*D9Y//C
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MA[:4*W+2H%16  DYR1CKGF9XKAEB;$Q9X%W21Y8UC,R Q"/\3R*3:\50(/)
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MTD!RR.32GX".JM^;MPAO4[M]T-ITD!,BGZ/Z907TI_*EZ+9-#8<2D> D+0K
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M6J%2O"#/N5WMPHM"IU'L:V*A%8H.EEH1:1<[KE?IM)JDQBMW.Q(K<AN%+F3
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MW9I46:6=#'PX<'@_%TIP!1!8USV/%7J7P?$NZ>+MQQ-NV9\<%V7,:7K!$V+
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M"S[?U'OSIHP,DO0H8@CDD4%'M?[XH]NRA&J<20TRI+[2"I 6MM6W@\Y6L^,
MDE/!W+(& !D)LA!(Y-51[\?OZ<#MI)H'0M:L3="CW7B@O/J0+^AH^ZA)D4F)
M3W)[\M ?86VB+!0!ZDI3J0I;A&0 E"#D*/G.XE.,=)5,95B$?\-PQ:4GA.G@
M 7ZMR;' KUO2")D23K"D9Z)+,LI/"!3\*K8/XJ%WVYX/!TBTC4*+2WY,IV$'
M5K :82"%*0WDK4IQ2LI"ED!1(20-J<$@$';(P?/14,A0 V>GUXKBJ(X)_4\=
MCI;*VMLF-(Q-Y84VU@D,:H4!7 %T+NO;@Z;MT7]4KC4$$)BQD[/X; VEP(4%
M)2\>"XE*DA0!P I*2!QTIBX,.(/X?4QNPSGJ()JR/07_ )TXP=MAP1\):1[L
ML_:_7I7^7U'![&M)42X"A4=,A)5$8"PIM) =<44DI42 "!O5E6W&1]NGJ,T3
M&2,A7]#0-<4?S()%_/3J6!6#E/A=JICS7Y=O<_711ZI++SA:7M;5CZ2H<))*
MO3.02I.3SR,@ 8XYRS%CU$DD@=P!7O5 <7SI3H%"Z) %D#N0 +YOVX]OKSI.
M5.D%Q;@7M<7D*6G )3P!M/..!CCC''CCK76U+0!%T;Y)[_\ 3OS?/Z:*DK=7
ME2BI9SRHY)P.!G_3[#HUD#V'Z:L;:>G<:QC9EWZKT&4JUKJI\FIT2 ZF4RU5
MX;[#D:'4'94&0S(8BLR5F46V7D2G4Q4H4TAN2A2H#*W*3.3.P]ER%^^84BQY
M,HZ 8) P9X5$BLK2,H"'J7I7S.J[6M5G.W27<UW+;?#V9&NX[<\,>5,?+9L.
M1WZF00R!NN1D1HT9T,/4Y(+&-P&4BAQKIN.5"H--<^4]38TXRMT-,DO+2'%^
MHIQ9*D':&PHJ& ,K4,JD#D'%Q5DRI@9.GJ<M5NW2+Y "D@@FP*-DT 0-2<V9
M]PQ!-F2CS5!9@Y!+4J_#Q0L$$EJKGF@*U;.T-#+2C4YE58ARJQ.*0M\2Y3Z6
M4+)40VW&0X@J&U)/\12R#P/\F:IE^(\^1G2"7R(+I%51UT"/B+,#ZGTH#V/8
M<9W_ .T'>?O#0X,\.) &94\N-'=A\)+-(P8 =1XZ5 (!!HA@%BX](+0C4Y=1
MH=)9I-5A*;EP)$:1)8>8=865,N@%Y25[70@[2%[BD$D<%37'WK-\P)/,\\,A
M\N5'"D-&PIE! %?#?-CZ<UIMLGC?>I\U<3/RCDXDR/%,C012*X>@R'X5 !!:
MR.DCL+U5^JW1=U.NB1.JTV34Y1?]:0_,98DNK=<BICJ><<6A2BXXP "LJ*BI
M2EY]5Q;G5JBPL&?#6*&%4B8? (W90%$A< ?$. W-&_8#I &NP8N'MTNWQ0XL
M:00B-5C2$^4BJK]81$6@H5[H#@4!V^'3YHE\W7%>:K5(IJ2^PAI3<U5)3.4S
M.15FJJN;#*HKHB2U/IC>JZR$.OM1@SZP9<<9<L/A[9_"30Y\7B%D=W41XD$^
M7D8L04P?=SYCXS>;*(8VDE6)[3X6<#K53J'SL#:Y ^#FY15) P>(9?DAXG@.
M,(YP''G1!68K'+<8<ARI=48)W<7<]@7C)I%7MRWYU!N&5'<=O5<UI+**Q<[E
M4J3LJJTZ,AMEJG0I,"33]\)IIAI,MB2MN.TV4),6FVIMF[[QC;=G'.\.+FM_
MY<D9B\D6U>7$(H9I7 >=XI!*/.:F=>DGD'2_@[ W/;,63"S<U,[&QR(=O=&5
MFCPT5%ABD('4SQ]+(&=I&\L)<C7TI5U^&MEL.[T+02E)VGZDE2=P"@,X'V.2
M#T\L$U]?4=Q\N_O^FKGHGUG1H=&C0Z-&AT:-#HT:'1HT.C1H=&C3VI'_ )NC
M_P#YW_Z[O1HUNR?M+%NP+D[ONW./.?;CF)V^29<8K_,7V]1;L#8;.1]:/SI.
M>-A//7I_[ ,2#+VG>3.O4<;=XY(T!Z6#_<<6GL&P8V/4"!PU7QJN^(<B3&6)
MHQU&0,K&K !?GCC@@ &S5'CG@ZN-RTJCMTUY*U,R)$6H.,H*P%'8X^I;B@"<
M!3JB7%XQN4<D9)/78MUP-LAPY'41/DKEE'>EZSU,Q/77XFY-L:%WS=Z8XV1E
M/*@/4L30*PY+*"5!H"JH D@?+T'&HNNRF4E"8"J<AGYA2P7FV4@(45*"E%:!
MP4@I&4$8/N/.:AO&'@E<80*O7U"21(Z520X<AE'!0D#J4BCR*X&I&%W)<.;
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MR,C@X!ZB,7)R,F;(#1NF'(&DCE HEE8*RAO1F'<]QTFB#>IG+$&+#'(>AYH
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MA8,K(%2(O4JT?<$"N.?7D=^_.BU]08=I_@\BWGVWY4]D(GAC\R/42$@N<G(
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M18OL..?RT5D2Y#Z\/.%02<A!.Y(/@G'OGS]LDX ST"@!7 ]/U_S_ -M;4+L
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M !/'W+*Q/ABD(0DL4JXQ?HJF^D6>RC3/9_%+[6RPQ2A8S8=0 2>D>BLQ)(%
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MGQ_3/'GJ7AC\H)$ !$L811W%"OB]R;Y)[\\WSJ+E:23*E9P0I)HD=B6KN>2
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M,/(GI#-/*D99(V2RQ-=+61T\ $\FSW [Z<1XDV5B0I*&C46#U*1P.W!!X[@
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MGN57_P#:/W^[,^]1NMM#HT:^?)^UWR5,][O;BV,_Q>U2G*R, _1JYJD,9()
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M%*5OXWJ 4GA*U#&T@#I,OT]1 )_M^G'KR?6K];.D)C(JO1/O=6"/B)L*O1=
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MMPS]K=I/ONW[GMNV9$(5 2^Z1H\62O5(.K&B#U.X^*,C\!M26U TKU"J4_\
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M+JE.N+D!:E/%PY()4DA0!VDJY\ ],E\/)X*DQ\K:E#1R=4,RJM N%HV#U"J
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M<=Q&5!/*K?<WZ_/U OV%2D6O)9O)J8IQG\.<JZ&VDN.866G]R$^FVH@+ 4H
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M0;9#X;"G.'"@J5ARGBGP^55SF-&'LJ)5X85YC=%,P^%?B-<  4#P=3,/VJ^
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M*FW93:T.;4!#</ &0V%-!A[MD21J[+MV)D1XZI@Q9>^;?N^:XR!$[SLK8KF
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M9;%\@@]J-B]2I6+Y9CVU*H,Z(F)4F6TDN*2AD+<*U*4I+:4)0C<L'Z4 (2%
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M'AS:F(Z8"ET (Y'"@=ATAB0#V-\?/WUL?LY\'GE=J6+@BHI9E517\J"3I!L
M\ =OF=1K;]UZOW(Q)03;<PRZ<JH?(3HC+B%,(+0]-*4G_P"4*3EQJ,V7G"AI
M6<N*P>P[1_X>,O=,%9_O:8>:<9<G&@69V)C9EM<F6)7 F96)580_X2+#4#%3
M>#O"V(\4D?WZ#RI0J2PY#BF(;DL2:4V0232DKV'9OW-K/=5DS12:A;=@3WV2
MV93?X:U-2'%-I<2PO>$*9*&TH*VL;VU*4'%)6I24\Y\4?9P/"^\3[/E[F9LB
M!(W8X&09(XO-!=8Y#)&KK.JTSHRCI5E'T4@\#;;G!Y(]W\11EUM'3<IL>AR+
M"HO39YINQ %"@-,J?W$MU*1\P_IKIRRX /JCT+:5$)P227-H!(*@D# *E!("
M2!U KX?1%Z5W/=*]+G%"S[ 7]?ROL=/,?P(,:/RE\4^*94))_B;JY %V!Q%U
M'VLD]O<DZ-TK7RA1B\[)TOLF25$_4BFELI)'*<+6\"V 3M4-JTY&%#8,:2[!
M*P'1NV>!V(>0M8].S)W)^A-\:QE^",S)55B\5^(8%0BS][62P*]?+1K[$@VI
MY+"R3H^GN-*W%HBZ>:?Q&G%@J!H0<*4J=*RD%<I0*5*&'!LRH>., :_^74H%
MMPW!F[WYRU=4#^$FSZ <^FD__L^%=4WB3Q1,R@ $[K(@/P]/9(A3 ?\ NJ_0
MDDGB3K7(E*:<39MDM^FM*V5L4-L%"DE2@>7SD;5;<*24$@$C=DG(V)4NL_<!
M8/4/. !!H&Z6S9')/?MZUK>+P5'"K [WO[AU97$VZRL2K5V_A_#R.&0J1U$<
M"J.-:[U0!"'K9L):&'!(#;EN, K6"HY>4RMM:]Q&T_7M(2$E(QUH=@@)M<O/
M!*U8F7MVH6O'>Z([WWH4@_@+"^+R]U\1H[IY/4N\Y!"I0!"!PR@ =OAZK)Y]
M!(<'N7I58^08K6G5E-*B!3?K0_Q*%&+26TEIM$6/)+$,.+05.*CH0IUQPK6<
MA:7(^;PQ)%UF#<,IPX!"2",M^(W;&NHK?'58 X %@BO3_9CD8PGEPO%&^MYS
M!F6?[MD2%C:NS3R1]<Q"4%$I/0$ 4G^7'/[C((HS,:F67:\%V#M2J6I^H/DK
M;4%)?1NFH"-VQ!6TVVAM8)0 %8=ZS'X:)D9ILS(=6YZ>B,<572QH]O<EOKZ:
MQ!]F<HS7FR]^W;(CF'4L*C'B95;EE8B @D%F",260 &ND= ;C/=QJ;)?7&I%
M>8H0<CM0W!;U)I=("HC)1Z;1<C1D/+&Y*=[[KBI*P$%;J@ $N?\ RIME RPM
M/3%@N1([@,1R0"0H)%\ !;O@79E1]D_A%$Z\G ?.<,TG5GYN9ELSNQ))21_*
M%W?2%Z+_ )/>.[BUYU52\H+OVYG\K2XE;U4E%6[TD[2%AP;$I2 AI*=J4I V
M <'J1AV': JG[A IHCX5^'O['GOR;[\\]JL.#X)\*HH\O8-JC'3T](Q(@.YN
MP$HL6'+'GN+O462]4K]J<MR9,NZNA]:5 NIJDY*U)6O<I*EI?WJW$Y4.$DI!
M(R!U()@8<2A$Q80M\ 1H:-5?(]K%W\O4DSD.P;)"GEIM6 L8(/3]T@<=0['I
M9:)%=_3\^<(U(O9L@)O.Y<!8=PFM5)*2Z  '"D/X]0  ;QA6/IS@8ZW^YXO/
M_IH1?IY2?KVK^_I\]*?Z'L?_ /2-L;BK;;\4D@\D'X#QSV[:EFV.Z+N,MF+^
M$V[JM>4:&XLE-/5679K*L*)(#<HR%Y"R5>F.2K*L<$ICIO"6P[AD*\NRX,N2
MP*JPA3S1=*5"K\?41_*%L@$U0)U7\[[/?!&X,[Y/AS;%,E>8<>$X8DZ:Z?,^
MZM%UU7'6I/T])#C]X7<Y*J$.GR-3J\M(<2ZXMI]I#C>584HOI2@@)4 LI2H(
M)&\-[@I733/\ [!MTLD,^TXBS*ELH_B!2>J@.DNA(]P3W(NN-0LGV5_9_&C3
MC8,8L!2=4V6]=)##I5I31L"N.J_4\5)([R=;849467>]7E%U28ZI\]A$ECTV
MV@PX'LL+7+>:4@[%$DA85N2M*U8A/_).RLRR1X<$82V\M%"MU,;!5N.@'U'J
M..*YK\GV0>"\J1I?])1"1UO##E3*['J)0 >=TJI5R*'9:Z2I!M*5WB:IR(TV
M/(O2YI+3ZFU)IYEJ1"4MMU#NWTV%A6T..2'&D@ !0!7Y"@K_ .3=M#JR8N.C
M532JB^811 Y*]^%#=[' NM.!]DGAB,0A-JPUB1CYA9LAI6%/TN59C"3U=-L1
MU LS+5_$W;A[IM9KBD,.L7G5$/L'T(C W251F?1#.QM9"O4/IMMHWA 63N.3
MR2[QO">S8JL&Q8R#\3LH$:NUV250+0LDBR:OTT\POLM\%8D1679,>52!YDDD
MCAGZ6)4D&0%0MFD!Z%%*  *"W2^]?N-@-B&J]9DV6R\AWUI5,@N5$+CH<"R9
M4B(N0I*&U.J!6HAH*60$@J46\O@CPY(>L88C5@P94D81GKZ> @/222!=?BKD
MDUI&;['_ +/YIADKM!CX)18LW*$5L .KI$] @ !2".U\GG5B[>^(/W 7*RNC
M5&H:>0:?;]/_ !RL56M6HQ-6J%O;+;)C-.-F7(<4M*0W$0QM"L ?E*+!X"_\
M/?A+Q7G[KEY6Z9FR8&V8)S<[)AFD>00AVC=H8@3RO2200W(  -@&"R?L<\+B
M"-'DW;)5IW3%QQ)A4DA!( E;",JQKR*DD;X1TDD :9%R_$PU"0_'B0Z/I]=5
M-892%-UBQTTQII:2I*FH[;-4D)5&VY""XTAT)4$DDI20U\2?9']G&WY,:^$O
M$/BS.#H[9>5G.D ,MT##2QRT:+$.@ - $BQI1?L$\,RK&QR=SV^5 0K09.,Q
M*VQ%].'&O5;'W%@&R0*BF3WFHN"M,5E_MVT>DS6WT2$I;IMPIBJ=R-SGR2*R
MF"-P*4N(^6#;@1DIVG8F)C\%F'':!?$>]]%%2S20%PI Y+^7UV.3=DCT^<A'
M]D:XF/)CQ>/?%N-CN K*F3@ A  :#OB^<.W4 )5 )(4KWT^H_<KI95T*J=9[
M1M.7*I.?E29RX%>K]*AJ?=DO*48]-90\S#:QC:PTXIM/.S"2$@C\.;M"BQ0^
M+-U$4:A(^I(';I7@=3D6Q]R>3Z\ZDL?P!O>-#'!B_:9ORX\8*PK/BPY$JI9(
M5YFS 7*W5D6  #VULQ?M,/;EW'ZV=TG;_/T7T3U?U-H5.T&>IM:K.GFF]XWG
M2Z;4E:@W9)%-G5"W:/4(42>(CT:28;\AJ48[[+WH^BM"SZ=^R[=,/!VS<L?+
MW3"P#D;BD@3+RX<9F48D,9*B61 U&/\ E)-DBJ4G72<I03&W06H-VLD&U/IV
MOM7K^>M9^E_#Q[[9-2D13VB]T$!GZ@I]W0W5%EES:0 0Z;7"3NP3MYQG!/'7
M0L/==FGRYX1XAVB%":+ON^$L9(')#F>N?50!7OQRTD!52WENU&Z"EC?]SW'-
M<>E\DHTOL([[J162]![.NZMY<5Y+C,EGM\U9=0O;A0*5)M-8(/C )Q]\^(7-
M\08&!N8FP=VV^?RCU"1,Z!XG(H$EDDD92.*I#VY(UL(RZ'KC;XA14]^>_MZ^
MO?\ RZY_9'\0&Z$P'I79_P!T;#\0AM'JZ!:K,8VG<"0[:K9 RM7U#*3X!XZL
MF1XPPMW7%DR=^VB&9 %"ON&*G2HLU4DD+$V3\93N*[C2,>,D 98X^D.>H@ ]
MSQVY[@#CGU[D\*%P]AG?8U%CJF]H7<Y4Y@*%H,'075&2VWA:3A1;MA9)(R,;
M4CR>!Y7W'Q%LR1QC(\0;-DS?B'D;GA.!1!Y*SGGCVXY[5K:*)@34,J+V/4K+
M9J@38/MQ7H*UVJ'8]WQ7/(H351[->Z:/#;+2)2/^3[J<$H]/Z=RU/6BDG<D#
M/Y4I'&"1UG-\5^'MWDVZ/-WG:! HB1XVS=O(J.U#-YCT37/I55V!O1,9X%E:
M-7+,2P[\DV0#1X%W_0"O1=E]@'>*Q4YR(G:!W-& F""SMT!U,<"EA)PA ;M?
M;N\ A&<'@<8Z<S[EX'3-R(X-X\/- (;0#*VQB6 [!?,Y/T]N .VM$&4T2%D<
M26+KJH>_<61Z@^U"^^E&@=CG=K"I'JR.R_NB,[USN;>[>-4G%%"<C(!M/.TD
MY'D8'G[OML\1?9[C8/F39>Q/E&4_#)-@.17J"7%*0>>#S57I&>'/>4!&98N@
M\J2&L_V(]S_<C2O&[*.ZZ=(GKE=EO<]'VL/*CK/;KJBE)>P2C;FTT@X5C !)
M../;#R/Q-]G63)E-+D>'HJC<QGS-O_%5@J%<#KNJ% 7QU6"=)-C;A&L*I([4
MZ=?4QLI8!!)OFOS%]_>*GNPKOBK,T(=[-NYUFFMS20%]OVJ$=:F<XSDVLC(*
M1D#G'!\8)IS[OX7RIP'W+P_'C+D&KR=M3J2QV/F"Z [<]QZZDNF5$X#=="S9
M(L#T^G?OSS7MIPW%V'=WM/K5&8I79=W2.P0RS\\XQH%JF^RE2E_6"M%I+05$
M$J.Y0*<X()'4ENF\> L;/P8\/.V-\?RD,\B9>WLG<E@26:ST\D]7#<4!IOCK
MF-'(9K#]3!.XH=@2#1NSZ4/7WIWWIV']V<Z#$BT7LX[FT+7!!?4= -2_X;R0
M"1N1:XPHCZ0,I(&2$X!S+;YOGV?S8\4.%N?AI&:%BQ7)VU: Z2H9O-4EQ1!L
M^O59YTUPH]P5G.078=?P_$Q%&[H=^GC@<GO=5>D/_D$]V-,MF.4=F/='(JH2
MDN-MZ ZHO+W$E6X$6HXHYXRDC _+[9Z:#=?L[Q]HC<9^Q2Y9 +=.7@/_ #&[
M(<BJ'/S[^HTMT[@V2P_#"!Q^*_3T^M\_0FM-6X?AY=[5;CFKT_M![F8Z4H"1
M37=!M3&I2UYP%^B;8"DC R?H/L ??J#W6?PIN>-]]Q-]\/8R+T@1+G[8DS'D
M E!*"%%?%0YL=[TZC$J-Y4B2D\GK 8K7H"2.+OCGWX&FQ'^'_P!^5(<A33V:
M]S\I#+GJ_+-Z#:GO+!&,AQO]U%?20  "G \\'S$X^X['@MC3ONVPY:HU^6,S
M;&E!X]/-Y7V4T>2:/;2K*[6.F0 BKI@>;Y!_S?!^0&B=?[$._&K253U]E?=,
MRVL) 89[?=4U%./?TVK2W*)SR=F1[XP<1WB#>=GSR,K'W'9HD!),>-/@2.QO
M@A(7ZF /?CBR2:YUM'&Z *5<D<"R?J>#?I\[[ :1'.P_OO<;;95V6=UNQKA)
M_P"3KJ[D@9\__!'')]^,<>PZJ[^*(IO)QR^"D<3CJG"1_P 1%/X:$0(OW+-Z
MV"=*^4WNU^B\BB:]>KD<=N_;MSK.Y\/WOM<;2^>R_NG   V#M\U9WX&W *#:
M2E#CS]''/.>IN?,VW(B@R6W#9@JLC-C'(P5+*I'#_P 13;"NI64%3P5X.DZD
M!/PM[>U>A-7_ +&ASS>I '9CW^56F4ZWE=F/=##:;+;0DJ[?]5&$(:1M"=ZE
MVFWZ81[G<<^<#)ZO0\<[?EXF'M,FZ[/C(E*C'<<%%500 "WFK07GFJ_PV&($
MD><(Y=N3W8$^_2;Y( H >GRUL@?LTW:[W#:"=X/<#6=7M&=7-/*%6>WG\)IM
M?U TZO.T*1/JR-1[)D&E0:I<=%IT&;4#$BR)8B1I#SYBL.N["TTI8YM]JLV
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M;EI  ^/\PYQQ[]5C \58L:?=YL_:1&P #'<\($F^]F3GB^W/SYTX:%K!Z&)
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MD\=-<]OA]/;6#W7YA;^=GF]9L#T_'_@' _L./Y=!)\DFS?E*;LW9!LW[GWT
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:AT:-#HT:'1HT.C1H=&C0Z-&AT:-#HT:__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g773514g54u14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g54u14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2<,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )O"^F6@X0DE-! 0      #X< 5H  QLE1QP"   "_[P< E   T1-1QP"
M!0 B06YN97AO;B!04%0@=&5M<&QA=&5?,39X.5]);G1E<FYA;#A"24T$)0
M    $(:EM 4U8[@(GB!8(B@V/W8X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q ;9LK
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              &*   !J@         !
M                  $              :H   &*
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   &*     %)G:'1L;VYG   !
MJ@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !B@    !29VAT;&]N9P   :H    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     '*
M   !    H    )0   '@  $5@   '(0 &  !_]C_[0 ,061O8F5?0TT  O_N
M  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43
M$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-
M$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,
M# P,# P,# P,# P,#/_  !$( )0 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !
M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M*4DDDDI22222E+$^LWUFKZ!70YU!R#D%T>X,: P!SO>X/_2>[]'6MM1?778
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MMJ_,24\_U3ZF='Q_JO><ZFO/S<#!R&TY3VD;0!?DU54LWO\ 2HQGV[,:O?\
MHJMBZ'ZOF>@]-)_[B4?^>V+GNJ?7#IMWU7O9F6!N9FX606-QZLFVK_#XH_3N
MQ:O2<VRES;F9#*?1?_VXNA^K^G0>FC_NI1_Y[8DIT$DDDE*22224I))))2DD
MDDE+.W;3M@.C2>)7$?\ -?ZT]7K<SK.;Z7HV[Z=VVUI<[2VZMM+J?3:SV_9F
M/_\  5M_6/ZT#H=V-4<5V1]IW'<'!@]I:W97[7^K=[_YKV*CU'ZYY5;&GI^
MZPMM].XN=7: ?]#'3KLMS+K/S/5_L>LK&&.6(!A$>OY9'A_1[+)<)NS\NX\V
M'U,R^AW9^97T_#LHN:P3=8_>7,#MGN9/ZL]U@]1U+?\ T6NN7G^-UKKOU??D
M9O5*775Y;P-K[*FM%NMA]1]'K.Q[/0^A2ZO_ ,]KNL/(&5B4908ZL7ULL%;O
MI-WM#]C_ .4W<AS,")<6\3H#Q<>RH'2NH\*3)))*!>__TK_U_P"H'IWUGHO;
MD6T;L#9^JY./B7&;7NBVS,9=ZU/M_1^S]%9ZGI_SEB[WIKS9T[%L+G/+Z:W%
MSW-<XRUIW/LJ#:GO_>?6W8N3^NF5DMZLS"N_:PZ;DX9:[]EL98'V
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&4X()I;,9S E8:1);N;%U\RT<?>O5-:9K,Z.,LCSEG"(:KY*8I*(@\XXJ=A
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MV4N)RG")J6I]=\]7V[/Z_HVPX5PL0_8FQM4'/RZ-,D@]8O\ J>N0;3>Z]9[
MR/\ P4$\'%$&$MS"$YD<2)MS0XR9+*#I\2,B;WKMGK5O&-FZG80=H#/.OL-%
MZZ6@&QCK\9S+,EEN>-D28JW8[J5-/MI=RMIQ.4.82K&<>(G>>(CQ$>(CQ$PV
MJZYU[19EA(4BB4RG3[:2R8M<ZJU<)7IEF+Y^?N5L,D1!AO&B6?JN^\XDN3*S
M]1?N[^[5[HD(M$_QD/J$?U-<&_Y3I[R/,^X?-I/D/>?DLK*LOH16(GT,,Z6K
M&YPE&V!/]2#875FSOR\BQQX6SM!V+9,79>O*,=:4SF,C:^H#C9E^F6)$%8UC
M%OLD)\D["<AH8F1]?7_$UC4/0&V8S3PM O%MY6S7*E6=$ZR*O4+6EL 3^GZE
MK;JO7G0%RV3U(V3>*L6?;%BJ]'FTH:TERQ0LS+?:YA"RI%%4"X2)MFT>@A1#
MNR[+;(U5YBBU8MOSKK8XRMYU;"0@=K;=O+54TII?7.(S%:Q!:&:?V& D[ '
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M?63IG9W/?:#6Y$[FK,"U6()N[HW7>J-6\^6-:8,0\%%D=&Z[U/7FC'X3,>G
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M?1.S+%K8#>]-;,VA;2FJ>)+=W3M5)"J6^FUD*@KK@#<:/&J>NYK-@((3<(Q
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MA.,J?4M6<8Q[8^2U_):E>V/U4I65*S^JLYSG.?.$)W)/=WG?N  [_0#8 ?D
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@CNR/MXH]B2T(A.RI,LG-ACV)Q>7+*R9DAU$DYXB?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g773514g75k69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g75k69.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'W*^@% X0DE-! 0      %P< 5H  QLE1QP!6@ #&R5'' (   +_[QP"
M4  (<G(Q-3$Q.#$< @4 ,TUI8W)O<V]F="!0;W=E<E!O:6YT("T@4FED97)S
M,BYP<'1X(%M297!A:7)E9%TN<'!T>#A"24T$)0      $&"G4V#3T^#)AG7I
MA4TJJ*\X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q :AA1X         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8
M  X             /X   #A"24T#\@      "@  ________   X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             !]0   =8
M 0                         !              '6   !]0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !]0    !29VAT
M;&]N9P   =8    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M       !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H # ,!  (1 Q$ /P#U5))))2DDDDE*22224I))))2DDDDE/,=0
M9UE^=U$.LSJ21_DR[%:VS';5Z3/4]3':^M]N7]H^T?S_ +_YG[&B=$IZ^_*L
MRLYME%+,>ME&,^US_?M]Y^E^EW.][WY7ZPS^;71I)*>'?C_7JS"94]]PM912
M18UU;7/>,?J&1MM]-[/3OJZ@>G8>1_.497I47?S%V30NOZ?D/R,5EEE=M+XA
MS;FACY&A<6M+F^Y65CW_ %C93U?(Z7]AS+'8V,<GUZZMU;P 7^C2[=[[G?0K
M9^?;[$E.PDN?H^M]=U'2+ATW.:.L6&IH-7\SM_PF3[O94[^<K?\ ]Q_5O_P:
MO='ZTSJKLMK<7(Q?L=[J"<AFP/+21ZE.IWUZ)*=)))))2DDDDE/_T/54DDDE
M*27%YG5/K.UW6_2LR6^C5>>GAF(7D6LM97B5M;]G._[2T_H=E_4_7H_7;_V7
MZ7V52S.K_61W4,@XGVH8Q+88,0EM>&]F([]H8[K*6VW=1:^W,_4'^M_-[/L'
MZ#]*E/2==<]G0^HO8XL>W%N+7-)!!%;X<US?HN1>FESNG8KG$N<::R23))VM
MU)*P<N_K5WU0RK'!MEAKS&V/RPZFQV,TY#,6]U-5+-F3;C-HM?7Z-'_%U?S:
MW>F1^S<2./1K_P"I:DIM))*KE=1HQ'M9:R]Q<-P--%UPCCW/QJK6-=_624G?
M=2Q[&/>UK[##&D@%QC=#!^=[6J!S,0->\WUAM9VO<7MAKOW7F?:Y8O4!]7NI
M9F'G9F)EVY'3G^IBO^R9@VNT=]%M :[WL8_W?N*E9T7ZFV8^7C.Z?EFG/N&1
MDM^S9WNL;):^?2W-]SWI*>I%]!L](6--L!VP.&[:>';?I;41<YCT?5K&ZI^U
MJ<++;G>BW'%OV7-/Z-@#&LV&G9]!K%K4]7Q;[6U,KR0YY@%^+D5MXGWVVT,K
M9_;>DIM6BPUO%3@RPM(8]PW .CVN<S<S?M_=WJC]FZ]_W/QO_85W_O8M%))3
MG?9NO?\ <_&_]A7?^]BJ7YN5C6FG(ZWT^FUL;J[*MKA.K98_.#EN(3\7&>_U
M'U,<_P#>+03I_*A)35Q^L]+<*J7=1Q;LAVUGZ.Q@WO/M_1U>I8[WN^A7N>KZ
MP_JCBXQ^K?2[#37O&/60[:V9 YF%N)*4DDDDI__1]522224I))))3G_6#_D'
MJ7_A2_\ \]O1NE_\FXG_ !%?_4-0?K!_R#U+_P *7_\ GMZ-TO\ Y-Q/^(K_
M .H:DIM))))*4DDDDI2YWJ;/K'@T5W#JK+/4R,?'VG%:(&1=5BEW\[_@VW;U
MT2R?K)_0<?\ \/X'_MWC)*;&!B]5IM<[-SFY=9;#6"EM4&?I;FO?N5Y)))3"
MUQ94]XY:TD3Y!>;8_P!;?K/915:[.9-C&O(]"N)< Y>D7_S%G]1WY%X]ALO^
MQX\70/29IL;^ZU6.6A&1EQ1XJK^7Z+'ED0!1IV,+KO7L+%IP\;-#**&BNMII
MK)#1H)<N[^K>=D]0Z#@YN40[(OI:ZUS1M!=W=L_-7F0KOW#]/W_<:O1?J9_X
MENF=_P! U'F81CP\,>&[_E\TD8I$W9O9VDDDE697_]+T3-ZW1B7&C[-EY#VP
M7FC&ML8 1N_GFL]%_P#4J?98KF+DU9=#<@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$0'_Q  >  $  @$% 0$             " D' 0(%!@H$ __$ %<0   & P
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M M" (.]>>A!$'>]"UO7OUO6]ZWKX8!NP!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# ..=VAJD#6X,;ZV-[RRNZ-2W.K0ZHTSBV.;>L)&G5H7! L+.2+4:
MH@PPA2E4E&D'E#&6: 0!;UL"-X>)./@,9D9#S'1>H\8Z%/8V3581#37MU(2G
M(25OR+V3\GT<6B4*$0/(O0-)#S4V@>I,$#8&=(W H1#53FMB41C495O25A1.
MRA@9&UH-<D46:P,<92+1MZ9/M0EC[,46TLJ<WTBFQN+ B1@)3AT7H#B'VHJM
MD[=.V>1UW"GYIM U"?9#:\1AF<D$\/;&UL9VXZ7I%B(XB0FH&IE:&Y&8Z@5#
M3(VM G)V I(0$L#JTMYKY[GJ-2W3:DZMEB!9+QV J1R&"QIV3*)R:Q%Q<R8'
M%+6TX(Y*9&RBF QZ%K;B-G+"VB4;2:]3@&5(['6&(L+/%HLSML>C<?;DC0Q,
M3.C3MS4T-2 D"9"W-R!*64F1HDB<L!*=.06 HHH 0 #H.M:P#F< 8 P!@# &
M , 8 P!@# & , ?# -@# &A](L81A](0=["((M:$ 6P##O8=[UH0!!V$0?/S
M"+6P[UK>MZP#?@# & , 8 P!@# & , T%Y^6_+XX!4S3$S\4M?WE=3!;L'KQ
MOXL1M*G=6R!N:6PN0G^I>+.!$U.Q%3E0,+J[(TL;U,]Z7R/>FXF#JPQ6O'"2
M2Y(Q =*Y6G?C".J+L SI*NZG:W=G1/1_+R9I9VG2%TF((O&C&AG<B]V@VE"B
M(EIAQAJ<;\[D:D:F7(0VVH:V9C+4 8\BU@^-6;X>W0L@E=>5JF[1;7B5$TFU
MM34UGEKHD!VD@5CCHI2_$$.$I:TI8 5RE<H0WHW!.DB6WAKF/M9[<P@6N\M.
M?0+Q1<&<.I&6,1Z]3R7?4Z:(86 N,)%!3\YDM.F<>GV0F*4AS$6V* +E:M"X
M+]F[6.,=BRX]1'&L"06 , 8 P!@# & , 8 P!@$!O#</.4<\2XP\XT\S76O<
MQ6AG&#-'HHCL:[R22]"'L6]%E$@ 44#6_1++ $ -:"'6M"+8NA$^<%& , 8
MP!@# & , 8!BFU$5WK$;1JDY%5<>< *E.WTRTX;+IDA4HME TC+:4T2G<$/1
M*BU&C!J3EBIP*-*$ LL@D8=F" PO[#[V\O+YR^0?+\/_ "&7-[_A\?[X;W_#
M7]& /87>WXR^0?T&7-_6'P![#[V_&7R#^@RYOZPV /8?>VM>6K,Y"U^:C;F_
MI^D/\?Y< DA!")XFBK639CG$GB; "J]MN,&9'F.Q90+:Q0)'MK9W^02AW1A+
M;]I2E.E;ZOV:L H/*$20:4F) [=@# & , 8!H+?EK>_CY8!">*^(!SU+[6-J
M=L5S@E::_P!PQ)CFCA!'Y+7<LEW/X#S+DB\9D_J#/E[M PHG/3CZ]"C0.)C2
MY%,*YV-2B!L#YFGQ"^<WVJ'6WFE18REE1W:9SJS1915LV:;,F5P;$AVAAT5K
M=[:6V7JEKHD7ENJ0QS:VHA.R)W![=3&UJ;EJL@#K:WQ,N:"6!G=6PJV90^K4
M]L+I!7$5J29OEFUTV44^((U<+I9$-2M^U\21P)^=&QL7[6",4/BEQ1:AY$D
MI*&(":\:GT.E\/B\^CLC:G*'31B9Y+%I"6K 4W/;'(&XAW9G%$:H]3L9*]M4
MDJR B" S90];$ .]"T$"%OAIF%F\Y2PTH8#"S.M>Z#"S"Q:& P!G9%X# , @
M[WH0!!%K81:WY"#O0M>[>MX(LDEN2+ <%& , T%OR"+?U:WO_P"F 52M\#\3
M@'B+.$P761"!\&C;@!2PW3HVCD^D.D+V62A 6&%%!"ZDR0U$Y+$NV\MY-8]H
M"M7$K)1+(JJ Z[SE7WBKLM_=0NM_6?!'NE7MEEA=!-3,],FG5JD:IEC1<!6*
M% ZS4(M(V@HER1/)R6*PQ&DDH7=S=HG:29T;G%M Z[S57'B^LM(]0ME[6U6#
MI=CX^.)G-CVF<6P4<CRH4]DJM<XR(A37,H.,C*]B.9369*26F*'%@(XRVP"K
MY"A6R%<!*KPY8MVG#^=&IG[MEK),+H+<$XRE[(N2K_DD;U'(^0G;G@TA!ZW<
M@3O)+V-Z4*95.].:\TYV02%$TKF^+QX">N , 8 P!@&@M;$$0="V'>];UH0?
M+T@[WKR](/I:$'SU\=>8=Z\]>_6]>[ (/F<=V",PP8>^>VB@F#&/11;SS9ZL
MO0Q;WHLOUG-!AF@ UO00:$,8M!UKS$+?GO8MUN7;XD6>/*;NV]*<7SR9=[=C
MIWE-=724 +*9'#G-*A]AU1T)9E8QD8BEG.:\[:XV.1)K-=#M*-$J'(:L],F1
MIS"DA LK)[%LB^7EBGOYRT*K8&Z5Q$4D7>+,L*VUR56O4CFEGGQ-3+E@%JD:
M@I&K-A,2A# )*W!'I*@T1'R#PI@!TI/4G>9VQB9%P!@# & ;1^?H[\O/>_=\
M/SZ_/\/P^[ *7J6\-6UZFZ^5=2?=W6)TJ53WH273.P6M'.TL]O6*VZD/(@U3
MV)$%3@?64)C];'M]?FFRV!MYTEDOS;,Y@R&L]]D@EP'ZMG!W51B![D#U.:"0
MV*P]UZ[MK#3,AL9QB"F3/4;=X/,ZSG0%X&]U)CRR(/2XIADS)\J<VY\.*<53
M.M3(](5:WB#CF+PY.D*\F4HNVNK<IHZZ;MCW3,=O1'+8;,QUN@^^%G$8F;*\
M5DG:7P$@]=5A<72L>FN2'A(L$@\YQ7+XJJ] K0%@\<X]HT/.]+<VV; (;=<$
MI*%06)QU-:$1896D/606)$P]#)O9;RC7H4;PH;@J]"/3E^F06X*DQ1NRC!:$
M!A3PNF)EB_+;Q&XVTMS#'H_U)VRQL3&T(D[<TL[,T=>W4VM34V-Z0LE*A;VY
M E3HT2-,460F2D%$$@ 66$.@3;2;VM+N+$\ 8!T"RDUGJXP:34+S V&9[6(Q
M)G&QXS(9;& ( FZVX%'LT8ED*=359I'F%&>6^E$IS=>F<F5 _P#1X!'KV%X@
M'XTN._T"W5_60P97A\67RE\P>PO$ _&EQW^@6ZOZR&!>'Q9?*7S!["\0#\:7
M'?Z!;J_K(8%X?%E\I?,'L+Q /QI<=_H%NK^LA@7A\67RE\P>PO$ _&EQW^@6
MZOZR&!>'Q9?*7S#]"6/OG1Q.U5H<@C3:.+VH"GHBYRCQ$:'K9P23#.C#2RSA
M%^D$HPPHT!8]Z&,L80[#L1VY$UTM/N2)>%^?H^_?GO\ #O6O+6]^6O/>M;]^
MO?\ @W@A^GGK?PWYX P!@# -//7UZ_IU@$!/#5WK7,[OY[UK^^A[>_#_ -LF
M],&4MJ_%A_4B3[\]?7K^G6#$UP!@# & , 8 P!@# ( ^&O\ 1VE_VN.Z_P!\
MJ\<$CL70NXG]@HP!@# & , 8!UZ6,JZ11E_86N2O<-<GEG<6M!+HT6R'2&,J
MUR0U,G?F,J2L\ACQCJU&F 6H /C"\M(E))>G!K6IMF)Q@5J7WSMT-6%&W-9;
M%XD'8RQ[KNI[%G+.D=(QQ::V*G6)1!WD#<G<BTG(R-48@/5MQ):P"56D4#3B
M,"0I(-V P(M^9=OB??37-O0=AT_5<^>/$A[)2NTXK>#R]T3-\9XL+0)W*31A
MK>EQ*$"KD14I D*5+C2TP%"E2<$D( FGG#T(P3SY\H77Q5VOUED$7:%L?C;"
MQN4B>9<X,[.W-BZ52(MF*?Y*K0HR4RA]>RHZTL+ 6ZNQI0US@!D9&AJ"J/-"
MWMB%)HI*4(<[@# *//&TOR]:0B7,":C[;EU1*9[:TS:)6[0LJ-"=G5J9:U?'
MU W#/DL?D2<A,!T2DJ3=)DQ)INRPA$;Z.M:U[/@#H# \)>$F'T5I&5>.%JX;
M&59/#5(TJVO1HNI3U9RIU(I:R]\G%W7/8^%PDTEB-$Z(KX["QI2KTZE"$%6B
MYPM5J*$KQC*#;46VL\MMBB'[]'NS\MOH/_YE4_[K<WS^POP0^/IC\X4_H9KC
MZO\ 3GW/1_\ 1*WT@Z9 ^C^N:P838O NO+XC3 ?(9=*S6Q$HK0T@<BGDI>)M
M+G38UM:JCM'ODJ?WAZ5 T;H@M2O- E*(3!*(+?L+<$%]OIC\X4LN;]QE?L@:
M=>V&C]EOW)6^D$_O#BZ[ZZF7>=!UI8_3EJ6; )RU6Z"1Q*:%P$YK5CCE=N;\
MS*2S&*#,+BF4HG1*2> PE>'0PA$48 98QAWK3V3. FA."6!T7B=%/&NIB\76
MH5GBL13KQU(474CJ*-"E)/6M=N3RRM9'J^"7"/2&G,1C:6-CAHQP]"G.GQ%&
M=)ZTJFJ]9RJS35GLM?8[V/6J'X:_-K]F:>/<&N , 8 P!@# & , @#X:_P!'
M:7_:X[K_ 'RKQP2.Q="[B?V"C & , 8 P!@# (Y]A?1(ZE^SG=W^C.3X!R_+
MOT9^=_YC*E_S!8, SK@# & ><S^Z''4UFAW&BXEF>'XPNZ;$#IN8B41[@9ZR
MH9"7L99:]>VI]@*T+UANQ*@BT6$6P!&+6@[V'[%N)GA.&&#K0PF*QK6$QZXC
M!QHSKR3PTE>,:];#T]6.V3=5-96C*^7F>%U%5]!8FFZ]##KC<-/C<1*I&BM6
MM'WLI4Z=6:<K^]M!JZS:Y?-W\X[E^*NS_P#PZ*?^<,_4?N_B/P;X1?D-&_WH
M:@]SJ7WWT1^6QGT$?..Y?BKL_P#\.BG_ )PQ[OXC\&^$7Y#1O]Z#W.I???1'
MY;&?02>'A3RE6_>)CRX2?#Y?'/4-5ZC"?(4C*00?Z52OFMED;;GQT,&8#6O2
M%H990=:WK6A"WYZS3?LR:1J8W1FAH3T7I/ *GCZ\M?'T\)"$[X9+5IO#XO$R
M<E\)J<8JSNI-Y'N^ >%AA\5I*4<;@\5KX:BM7"SQ$Y0M57OI<;AZ,=5[$U*3
MOEJK:>X;7PU^#W:]WU9^?391K@# & , 8 P!@# ( ^&O]':7_:X[K_?*O'!(
M[%T+N)_8*, 8 P!@# & , CGV%]$CJ7[.=W?Z,Y/@'+\N_1GYW_F,J7_ #!8
M, SK@# & >>3^Z /_=[B_P##_P L]D?Z'I'^#S]_^SSS9WL0_P".^"W^TM(\
MO)[6E?+EY#R?#9VX/8G/+C\)=76:XY<G+G9VSZ#SX^?Y_P"C?^S/US9;EU(T
ME?IZGX#S\OK_ *-[_9K%EN74A>V_J;[D30\,;RWXE?*G\C=?'X-ZWY_-&][^
MKZM?A_R?AS1OLYV6B=!+9]D<1E_PQL/V.\\9I3^2T;7>Q<<LK-W6;;V<Y[6
M_#7YM?LS\U&UC7 (Z7-TDQTZ[-,9*JZ^K:F#TVB>4,;IBHI-,RRVL"DU&)4\
MS=46R5;%S!*23"T[=*9XRNJT(=G($"H@(C= =3K?KIMG$V9Z^E//_4U*R*1#
M5E1\^U*:6#B#FH0HU#@H2G6163Q95<1]5M$D/.2IY9+& UQ$7M,VA6*_)/@$
MMM[\M>> 0^6=R46Q66_5?.-6-6+FRPZU)^BDMFU?-H-!9;$*1&UAM=^ATJ?F
M=(B?&^&$O38O5*  (*>&=80^1@;XS&!7; Q\B\3'F!2W.1BPVV&"3D"J\4;K
M.24Q8K':5C)+L5OJ*I7*MH*X,1+U+F^<*8O)0I#T)(1,1; [J)@7'$Z!2:6!
MO7^)?S E8&5X0*+3DCPY)[67/-?16GK"D%F0%MHI\01JY'2QX0WL9KS#$->/
MSHVM;L8[%%G.JM>C+BA$ATI)V,";T0EL<GL5C<WA[LD?XG,&%HE$9?4 A#0O
M+ _("'1H=$8Q! ,29>@4D*2=C  ?JS0^D (O,.@(1^&O]':7_:X[K_?*O'!(
M[%T+N)_8*, 8 P!@# & , CGV%]$CJ7[.=W?Z,Y/@'+\N_1GYW_F,J7_ #!8
M, SK@# & 1HZ6Y"Y_P"O&6)Q^_H2JF3=!WU7)(MM!,)O"E[.\+FM2RK%*=U@
MLCC3F8!4V*CTAZ50K.2F%C\Q$^F$(M=G"XS&8"M'$8'%XG!8B*E&-?"5ZN'K
M*,TXSBJM&4)J,D[22DE)9.ZR..K1HUZ;I5Z5*O2DTW3K4X58-Q=XMPJ1E%N+
MS3:R>9$?_@7?#L_$W,?UANC_ />SO]F_S9]3ZJ.$WX1:=_.^D/I!U/<K17WJ
MT9^;\'^A(@\.^%5Q%;E&.4OL"M9H_P A(OOJF'%. [ZZ 0[!'*\Z9MB!0]MT
M0V6>C3;"SQ2.,S2!0(G:I4!$%2N/4K#3U!KZJ.$WX1:=_.^D/I!7HG12=O<O
M1FQ/][\'RI/[CSEB=(^&/Q?SM9S#<53U6[LEB1A&](8^_O-K6_-0M)$B;C6A
MYVC:IM.Y"SEGKFT\Y&8HV@$> DP7JC"Q;T+73QNE]+:2A"GI'2FD<?3IR<Z<
M,;C<3BH4YM:KG"->K4C"3CDY12;63=CFH8/!X5REA<)A<-*:49O#X:C0<XIW
M49.E"#DD\TG=7SM<GSKW:UKZM:SYQV#7 *LO%<A\'9.:YIT*Z-;\[3BL4<.8
M(J2GMGH2%QXHJ=V?#HBM5*X)1%HUJ[68_H2)&H71B&HER>4S1\3MD*87="J>
MB!! ZMX6\),AY]T"%/WV<!<R:\WH+S1/=E+Z;/DPIIOS3C[1OR[2Y'M7\HWH
MX%= C9C3\E+%*]NP7&/!;0+=!:\P[U^SW_A_M_LW@%,-K^&G9%^WK9EDS.3U
M?5[78-']*45)Y#5BVU)',+2BEVQ]%'(>3+8K/G@R$0-/7)C8TRQ<3!U"Y5+I
M.TI0;<&)E4*F\P#B)!X=G3D^LVMNEYI9E&)K]H0KG5IJ>-QMCGFJID++2H;9
M33 V?N2\[<H;7*ST5OO06LIB:G1-6QS&T& -G'RA?L0'ZL/AT]*5S,Y7=]>6
ME2BVYKOCG3T<N]LE\=FI=;LX^A9W%YHPO-9;:59LA5CJPB+I6)2T20* NR0*
M#G-2YPI1Z!&@)_L7*Q##SC2G.L<N2X*_;J5A<#A:";5@^,D7EDB0P:($Q(DM
MX.=F"4(M-[D D#HJ0$)0#+7$I?5*]%$" :!ASPMFD;#RR[,ACN\/YC/U%VPU
M#?) I(6/SR-NZ\NI$-U>E:9,B3JG9R$1M:Y*"$:4D]:>>:4F( ,)00O>SLE=
M+);%D6+8 P!@# & , 8!0/T@P++.[^Z&C,DGUR(8S!J>YM51:.0B\+?K1A:U
MDK';ALA6A:*[FT7;U2UU&S-FU*M:G4*-Z1E!":$.MAWZ?@[H["8_VU[:I*HZ
M3I:CUJD;*6MK+WDXWNXK;LW&O.'>G=*:&>BUHW$^UEB%C'6^LT*NNZ4J$8/Z
M]2J6LI/98Z@[<Q5X_-3FQO<KZ&=V9Y;UK2[-3CU=TXM;G-L<4QB->WKT2FVS
M4ZQ$M2G&IE28\L9)Y!AA1H! &(._2_4[HK^+?\VM^E-??5QPH^^?_28'Z,;F
MWF6OV9N0,[1+NB&QI:D25M;&U!U?T\D0MS>A( E1(424BW"R4R1(F**(3$$@
M+*))+ 66 ( AUJ/@[HJS_:W)]UKYY?ZPCX<<*+/[)\C_ ()@=W\FR,Z<%-B^
M#=L6]7K9-K3>X8=RQ6LUTP6#;EFVBB22A7;EDL2IX;/G'EDI.:E2EJ;4*)1[
M.-3%GE)R_6%B'KT\\CI_!8;!8FC##4^+A.AKRCK2E>7&32=YN362V7MS&S^
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M\9VG:T;;-7+EY7F6E8(, 8 P!@# & , 8 P!@# & , TWK6_C_;SP!K6M?#
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MV-$952N:JT+<W#\B$^U<E<E!NO,9AFO<'4.2^RRLDK=KW$K\$& , 8 P!@#
M& , 8 P!@# & , 8 P!@&WT]>>]>6_=^;\WUX ]+7N^/O_R_V\OY// -V 0!
M\-?Z.TO^UQW7^^5>."1V+H7<3^P4VB%H.O/?UZU_3^?RP"O?Q A!V9P_K0M;
M\O$(YS%OWZ^ 4L[WO\/N_DP5*]^97+!_6 \]!\];WOX>6];_ -?]O\NL$-^
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M98RC.,9PE&<)).,HM2C)/8XR3::?(T[,_;(9# & , 8 P!@# & , 8 P!@#
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M 'LE5_Q3 NMR[?$W?,5V/^7:9^K)57\4P+K<NWQ-NJ,[%W_CW&?JR57_ !3
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MGY2VH94I60\9K>>TN.F(1ZA4W(GGSGY[BOGLR2?3=KU-/LYR?. , 8 P!@#
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..)'X P!@# & , 8!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g773514g82q36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g82q36.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!! (P P$1  (1 0,1 ?_$ !\
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M:B3GMVR>^1[\_,C&<9/3&ZIU'^5L XFSPV N3Z>VDIQ%N1O%W^%4&OY)@RI
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M'&GK0P:5Z3FK1!R#M2F,TIXKN)O6^@5H2$E58;MIP@PP*%(UVY:3((*':#N
M4@;CMZT-9S%9@7C9IK982S94A@TA+85,'(DZD!<D$[1N\V=+/T=3L<\8^R#3
MJGB./Q2?#%,IN0<50MPOF(V56S'1<W1&?8K-]-4QA4F89"DY.ZQ<8-GA[ OC
MAU8U*E4Y"1GSI(N(E&E;P<F1&,G,YKLDA1)"T;Q&(Q-S&\P*I\TJ'QN; !P3
M8UJ>8C*$V[%#)N9 KK().8@1?.)8 L#MSM&3C(J$&O1?[AH:JQ->JF7H6O*T
M%%=KA)[)WN1O#G&E<D:I4:Y-X>N"M@PFFUW ;?7R:5LC8O'V2XPMLK%=C:I'
MPV2T@D9I-E:;Z$L6:(MNZR ((P[!F82*%E_8S#S<NAV$EB8R<9@+24+M#@;?
M\F=Y;8"J@QMNCQ+'T; <;@ H#]21NGN:VJ9)RON)H.9Z,XQRK%PFV;<E@2?C
MKI*3T1*-I'+Y*<[JU@A31%1L[>3:,GE:?1LRW>N85>,9RPRT<,VJDM"NM:"X
M2.%XGWY,\$P*@$$1;PRG++C(?((SG&"!W%\L#O,DJ[<+#-$0Q(.9"A4C"G(!
M4@]L9R,XP=+['T;EHQK@W:@K7*+B)W8]LFW3/T!N 88V/;8:VY]MUDV;S.WJ
M$<U&2J6-T[99+',J)LU ?R:+"T,4#-X^")+R2;8RFR+U9);C<\@$\T1BW[2L
M*K<B8[@S[0!UZ#*GJ3@51Y(8XH0%0M##(LNS(:5C 8AM(7<2<#!/7U9-:@Q>
M",]15=ISI+:7="97:Y-V^R\S<E<PG7QW+UV@[.\L[<6;6/DFFUM*!I<E6H"
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M]HQCF35 H"99PZ=.4FZ"9?OE%E4RAY@'V]>35<DL<8'L.?;GW'K_ 'UC>/\
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M9?8L@5<'Y,K-@O\ 0:OD4[^)E;.@$0\M<=#!6EY%R^B+-(U*9=0,^]9^3U&
MOW#DG"XMT633K7ZRU30;Y9-ODD=S=175BD"SK,JS&6:%X%:+F2<B5X)7CGE
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ML\VB_O=L$K'U6%FJKLLZ-S'$YN%,6_*UZ E]MF9Y:Z721PG:GF-&:=LNZL-
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MYU&R3516"O#J/8R1XLHIH1#QN"4-XA'+NF"X7UPI!#+T$ &44@>39Y)P1Z2
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MTJHZFY8K<ZRZC-BJ[)%1QW"X1C!F18Y!^?:YQ'K/$=P+G6+Z6[=-W*C;"6\
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MW$4B*J\VUF4H^W W/!,C'FMW9TN8XR<8A!))Z;+<!B8Y(V4DD)*C94GP61&
MV#H &C9_7(>@K^:K?AG13$M@:0]\R!7]M<9&A)O8K"&/ZLXO4R_2F5DE7KR%
MJ=QEIFL4)G- U2.HC$UF JRSX'#MPJ[?K++G]CH6CWW$K 6G#MUJVSS?K34;
MLV%K$00,SW-M'#)<L@ R@NYKD( % 4#'EM8U2UT8 W6J1:>&&19VT'E-P^2<
MF&&5I5B4D^EY.D.?2.3D\QX[,LK>7I9S&NSS,&24NN59I=)!S]SE)V/;PLJE
MA^DUB!7,J(=<Q'DU*F'@0 X@ B/LI>&[;34\GU?CS0=+D"E9-.AC;5^62#T
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ME)5EU-8=/^./V*=4W1;)MP^,LQL4BLI"NP<.D:'E99( 267CD+H:JSL:S=K
M*K=IXM/^ 24(0DI) !7"G;?Z+#=L9]$XGT.^TYCN6:6X*2QQGKB00+<1EU'1
MCNCR>I1/1'-3COR=1%JN@ZO:7JC#116XDC=NV8VE:%]K'JOFN,$8=QYQQ:3W
M(=+1TCKE2N[<\2/=B. 7_#66S!DD7[/(,K'K#PLO6W\A$1LT85V_(M/N?UE/
MQ1XF9NZR&T!0!+<FC\!<'J)M9U!.*]63SH]-L-IL8F&2!<E)'C8 ^EY1*2RD
M$6;"JSJ'%O$9Y>FV3</:>W1[Z]!\L=?$P1LJLI(]$QQ@9'2Z6O#?H>\.;<XV
M4RO=[+,YWR2F:(!2Y9&3\MR-MO<S)(^-R,9772[]G"-&:2GAFJTN^MUI<NV+
MQ8LLT1<-P)YKB'Z0M>UB(VEFZ:)I"KRX]/TS,.Z/L$EG14D==I*F.,0P. 0T
M).">KIG!VE::_E4X?4]0)#O>WYYS&3IEXXG+(A&,J[<R8>$O3KL".$+$G:;%
M4$^J#ZHT5.VS($2Y(@X-6F4P2#0 @^#.X,_?(Q*0@?JG!)=TF!DTQ)KY]L;)
M'B%W-[.F<>_P^_M7J=N20/ ??TR/5W/]];.X7P;6)2@4.[*B[BK@F[=S /T#
MBY:2#$)9XBA&RT6Z$[5U'O(H@(."-O$G"J+M1,[E0@ 0=F*+*HX)1@<@@]SG
MIT!R.@\"/;[,=/F#\O41@@^WX>.,9RZ-W9#GPKM>\[?J0PFW0J*'M-#9GQY9
M#.5 'EVYD:<>'+*K@(]8/+:$FB8W:=$_ E'V.E\8\3:05%GJ]V(EP!;W#^5P
M8'[HBN1*J#'3]GL(ZX;QKA7_  WH>I9-UIUN7.<RQ)Y/-D^)E@,;L?YY8>RN
M=TAT.N4<+O5YO8YO=S!AL4U3.FU&N+YY+U9VOUA4*@^>5I>)CU68'^]\'+4:
MPF,01\,98W6$_K5^D2RU)>5Q1POIFJ;O-:[ME%M=@?Q*761]_CF.X@'JQ7GS
MP;=6)WZ#K]_IX&2+:=O*+;/<+L!10O;_ "D4Q]><]-P+"VW$0VV;;]@;<S<J
M=?<\Y4RD^G+M8**R%I"O\>XODEG4-X9LG#UU(SUQ-SM7%=XE Q#5RZ@7Z2#-
MPJW5?&^7\43Z1<:K*=#M[FTTW$;0V]TXDFC<QIS06YDIVF0,R!I'8*P\X=A[
MG0HM0BL8_K6:"XO1O$LUNA2-@';EE5VIUV8#D(@+ X7QKNKB>!) 5&-9E+U1
M(U:AW<=I6Z91X#T<A^'G7G:Z?<D^/C\,_G4FZ4HTI1I2C2E&E*-*4:4HTI1I
M2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*
M4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*5263!9)1(
M>T#E$H^_2E<8MUK:1V]Y]Q7N1BV[Q:-IUD61N31FBHH:0HMA;FA+>S*@01\9
M<)0CYW(1R!P.4)=C'K!P=$ABX_1]WV'/NJ:G*E2#G/3M]WJ'K\<9KL'#J1TK
M'L):*>-I&*DV;61C)!FJ1=H_CWJ";ED]:KIB9-=NZ;*)+H*D,8BB1B'*(E,
MZSFJ\8_$GXD_'K[!U]F*OI2E*'!0XTK/Z_7Z]U>M*4:4HTI7X(@4.1'C2E(.
M'A2 ( /'?[^SV^CX^K60">U*UTI>Y'%F2FK:4J]C(K 2B:*M>LSY/R?6K25>
M8G($C>NSCE0K!_+EE*[+HNZV95&S1R*#5[)PK-C*13A[V+C1;ZS8I/%B9"PF
MA4[YH,1Q2YFB W(ACFC*S8,#DLB2LZ.J\^'4[2Y :&3*-CE2L-L4V7DCQ&Y.
MUFWQ,&CR)5&&9 K(6R0,C4AX+HK.YU5V9DS5D78-K#$+BTCT#-R+/G().S^
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M_6U+^5_@7_VC==?_ ';>_P!37@?S05T8H=^6KQ^\]D;^0M8_DSXN_P RM_\
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M8/T=<5#_ -3@QZ_+;7^LS6?Y6N"?\_NO]G7?]57G^F'^BX_QO7K]YK)/G_\
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M>TJVI-5UXETY>Q[U"0KDS/0\EXCB+AV+4X2,;)4W-#*!EE8XZ'MN1L ,N1G
M/1E!'TCA+BV?1[@9.^!]BSPE\*R GJ 0<,N24;IM/0ED=A7TUMIN\W N^/!]
M:S]MVN;>V4J?*#238+@BSM5%LZ*"*LM1[] %677KELAC+IE=,EE%F;YJLUF8
M-_+0$G&2KWXK=65Q9W#VURACD3./%7&<*Z'LRMW!'7]T@,"!^B;&_M=0MDNK
M6021..O;<C8!9'7)VNH.2.H(PREE()GQP\YYY-Z?/W=X]GX_YA#18P/=ZO7\
M0?4/D>O45>S9[?W^\?=]O@:L:[OGGM_'V^GT_;S (".K<8[5"K.N[[^!]'I_
MG^?X-*59EW7?R/I^WX/Q>D.[(!/W?'P\?C[,]/$"G]OZ_7WU:%W7?R/ >?U^
ML _#ZO-VAQJQ5_'KZCGX'Y>Y3G,20.W?/A^)[>H=?6.W>K.NZ[^!^WM^WJ[!
MU.HD^OV]/CZNGX>TAE&;,NZXY[??Z/C\^P [PU(+GO\ 9Z\=/U]Y&0:B3^/;
MKGU9'Q]G7) !S5F7==H]O;V_;[>KGD.W5H 'X?E^O>>O6HY_M_/]>WP.*MIU
M#''M'L]'V^W=K-*\:4HTI1I2K78[%5:-59^_7^QQU-H=4:@]L=HES'!HR2,8
M$V[-HW2*=W+SDFN8C*$@8Q%S*S$@L@R8ME5E2AJJ658ADY+'T5'=C^0\3X>T
MX%25"YZ= .Y/8?KU?AUKEG8++==[N08^3=Q\K3, T20*OC7'SLA2O9-ZH51%
MUD&^'1<';OK?+-1%%HU3%:.J40H:%B#*K.)F5F=>.-Y',K]SV]2@$X5?$>W(
MSXGJ>MCNL:[%Z^KUD^OMU.>GN..PS71&JUYI78Q%DU3 A$R$*'WO \$*!0'C
MD?CK=[?K]?KI6D6)[Y[D_K]?CG+]*RO[W\T_A3&E1IC5"]Q[Q\ZLC\?A^-5B
M?5#W_$=9?TC\/D*LK-Z(DQ7M\$E) F9H=[P8JO IG7!%4S1,X&^],51X"!!*
M;DIP-U3 ("(:7&X0R;>^!]F1G[LU./&]<]L_W=_;5FWM.\Q-9K9P7#I<BF.Z
MW=5%ME#Z#M<A.8(N)38QRPI,FR:>A(+@TH@7%*B \=3O@8XLB,>D*P)+.B'T
M+41%;GF[.ELQCWE,\WF1XV;R,MMW]!X9]0JVX,F8.7NZSJ'VAB.7LDSNV]EW
M;>IZ9Q6B."MQV^S&^.L0U:<Q!DZ\R=GN%H6MD]D[$.X:V72/:RW2'$QH_0=2
MKE\Q6@:[6=I5J;9'IBL[&)-2Q=9;S:B\W&$E8\NW-#:222LLL:*J+M"20JI(
MLN9T'7+-<J48 YRVT '%:L<URB1J8W<EFW%XY2P!N@G<D$!8&WKD=E!.1D5D
MM5W8=(%=)[%#2WX;F<?UZ1R)AU:[R4#MDSDQ$E1N%7WC-KI799O.S<Y*-4*W
M;,1X">/)^(7AG4,GER%2F>I$OVBDK%K>S02%90YV2! 9HCYRM:E&& !YRR38
M4@YY9QU!Q(373,@,94;XRQ$4@&UEN P.6)\UHXB2"".8N>AZX=2]Z>_''^+Z
M<YM6 'S&"J6 ("7M<KDK#NYXTI#VJ-V)7_-\O)7O(LW.6B;>M(C<!1H+$UH%
MY!S5L<N;DE#.))>\BT4DY/:VCR/MF!9IF"A)(,%3=I$H1 %'6%S(N"%PN<;<
MXBMQ<JB%HB (@6+QS95A;/*2[%F; E4(Q(+98#.[OEM0WI;Q[K=BV.K52NWO
M'X13B +'4C$F0W436G4AN9Q?4Y&QY)=(V"9=Q60J)MSLSC+ZV.D+ T)-0JYU
MXH%R/TUHV+6MLJ89V23(.6D3+?L)&"H-HRCSKRM^#@XSVZR%Q.S950R^C@(V
M!F9 6<Y)#)$=^W(R#[>DB43=+OCO.0Z%3KSMX>4FAW*<QA4+A+1N(<U,)F$A
MLBT#<X^L5_C[\2SC"5!"K3^,,,.W4=*1CB1I9<OLJG9IIE9TXZ4/!X+1$=DG
MWNJR,HYD6"4D@"IL*Y;<KR=0<-RRRJ5R*FDUPS(K1;5;8"0C] RRDMNSA<%$
M.#U7F!2=V,SACJV9[80>X3"UOK]XD(+#F)R0N(,R(1]W?7/+ 1M<GJP,Q,6=
M\^;6F7R^K-UE66D6]<JZS:1"7@[-7+?8BSS<J%3+"6@E5ES+)F6/*A(\LK8"
M@;1'M8 ;FR,%65<58C2 21L&(C3". Q9\ C).=QD)7/1>N003D5S]HMTWW5V
MM[8)<E<W$VBJN,+='Z&X6.R) 9W/<(_<-(9>KZ.:Y)D@B:,R*2+C,8$G93-+
M(R$SB!$S&&8SM>>/):R,G6XZVC/.-T"GFW@A*&'881$W*SW3)DVB(]'ZDAN@
M(U4:Y"0$B4YCM>:&63=S2PYG;#8"Y,@(*# R.IK8)EO)WV 5PC8-LK.O.:]B
M:\W*:>ABG.EHBKE=*8TFD'E2Q7]#4YY\].NY0K5DJD?D-''D]?(^?D*6W95R
MS5>3DE*/)K3IB<MND10-\2E4?!W2;L ?O!BF\(0&\Y2!5HGN.S1 $1LS'9(0
MS*#D)MR?40'"EL[1A@:LZ^^#?F$#9IJ'VA2MC4C&>=4(&';XKRS V*0EJ;"9
M'L>*'DO!VF1A2EK=OBZ_68]Z[ITG<9N0NBI*BUK\ &0:E-Q&?);3*@W(4'D[
MB9(R '*+(%*@Y9"6.&"*%&[<VQ@<&YN,$B'..9C".#YH=DR&*]&"CJ"3N."%
MW CJ7A>RW.X8YA+)?FL(SL4H\LBP)5^&OE=CSU\EHF4*<Y5@<EP%8ND1,/*@
ME!NK"PE8=!!M/K2:<.YD(0(Z0=:,JJKE4SM 7TBC'.T;NJ%E(W9Q@]L9P<@;
MD99D!;&3GL&'FY.TD,%8$KC<".ASCIBI2U74Z-*4:4HTI1I2C2E&E*-*535X
MZ@\^;CCV^;[>C2A]OL^?3[ZH$[A]OR#2E?*0/]4?=\0U^\*_F\>Z^_\  U*6
M(<]9;P')V*8Q#<7%)E;77W=2L,BPBX)Z]E*L_.4\G7%W$O%R*I8.6,F@,Q%(
MF292_BK()-!T#)H"/-U+2K#58XH]0MQ<I;RK/"CO*JI.O1)@L;H#)'D\MV!:
M/<VPKN;/4TO6=3T:2>73+IK26Y@:UGD2.%WDMI"#) S2QN1#*0O-C&%DVIS
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M]/5GODCO@D9K?6I5&.JS!-DR0*DFF4A0   !'J!P'( '8!>W@.?.//.MS 4
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M<MGRHFEYH8 D*%1CNP(F!8J6$>]9"R[\$E"IP>TH[GF2"/E[3@%MS 8ZR*0
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M\:HKMZ&DX:1,<JL95L^:*H3I%$VZGE43M6HHP7A?0U=7%F^Y-5?6U)O;]O\
M?67 DO"&NB&=P,,C Q$$CE^<V;VXPXB<21-?1F-]%BX>8#3]-4_4T)S%8!EL
MPRQQEB5=2)@=IYF57$DATE>Y>]7-HYSCD%O:Z39,EX0R!EE"'Q)AQE:;BZP=
M(1IJO+GEHVJUB3<VUG"1R4(2=4L4?)2$8@RAY246AF:#)/GG@_1K6V<:;:M!
M<P6>HVE@9+_4&AMUU)6,T?+>>9! TCF3EB%D1BTB()6+GI#CK7KNY4ZM>K<6
MD]_I5YJ*Q:;I:7%TVDO'Y/*98[:WD:Y2*,1"4SH[QA8I)#$JJ&-UO2+92RQG
M&U7;#=KFL?XS_HC6^Y_']:-1L;U2PQ&58XS)6NVBY/JJRD%,@S]1%H1A REQ
MF;"1-B0_@V+,'KQL>G1>%+*QTZ"VOX([J\^J3HUU,+F[FBDLG#"6&W6=D%K'
M.&W2I;QQ$MW9MJM4^(>-M0U'5KB[TRXEL[#Z[77[. VEC;S1:C'M,%Q=/;JY
MO9K;:$ADNI9@$'1$W,M0C8]_.Z^?:VYJODYI$I7C,,%G^P*5/'>+J6^-F.LO
MT92$O\1*U*EPLM7)UG*D5E5%*Z^BT'\K(34I)(/)">FG+_?BX8T2)H&%FSFV
ML)-+B$]W>W"BPE4I):ND]Q)'+$4(0"57*HD:(52*-5YTG%_$,_E"-?K&+O4X
MM8F-O9:?:N=3@8217D<EM:Q203+(#(3 \8>1Y9'#/-*SPWG'<'E#<9;G%[RO
M(5>5M;YT[D9:7KF.<=8]5GYF2\7&5L-E1Q[5:NVLEDEE&J*TG8)U&0EWBH&,
MJ\$#&*.Y8:79Z3;>36*3) H54CFN[NZ$4:$[(H3=33&&% Q"11E8U'9:T-8U
M>^UF<W>H/!)<.[/)+#965D9I7P9)IQ96]NLTTA4-)-*KR,>[8Z5)-DWW[I+;
M*SDO:,BQL\%FH%!Q?98)]CC%P4ZQ4?%<RUL&-H><H[6EMJA*K4:79MG=9F7L
M(M.19$S,6\D6/6<-%>>G#FCP*D<-JT?)N;F\AD6ZO.?%<7D9CNWCN3<&X07*
M,RS1K((WSN*;@&'1GXLUZXDDDGO4E%Q:6>GSQ/96!MIK33Y!/8QRV@M1;2&T
ME16@E>(RH 5#["RFPRV];<Q-2]FL\SD@9:X7!ID>/GKS(U2DN[VXCLN,G$7D
M2-:W5:N&L\9%V*&=.H08N,E&D=#PSIU&0#6*:.5TE))H&DQI%%':[((&M&CM
MUGN%M@UBP>U9K<2\EWB=5DWNC/)(JO*SLH(J?BC7)9KB:6]YEQ<)>I+=O;VK
M7A344Y=[&MV83<1QS1LT7+CD5(XV:.)8U)!CO*&XG+67H<E<N]@C%J_]/;;E
M)>#KM/IM(AWN1;RWBV=HN$A&TN @&3Z:DF,)%LBKN4%$V+5LHG')-!?2)G=U
MKI=E8NTMO&XE\DALQ)+//<2+:VYD:&!7N)966-&=VP""S'+%MJ[=:]UG4=1C
MY%U,C0^5W&H-%#;6UK&][=A$N+ETM885>5TAC3+ A%4A N]]TRSO2+[N[/19
M;&]AR-7IFHS^)J)A"P,I+$.&7;^Q8UQC))2V/X&Q3Z^/SS\^M4'R0K0,S,2;
MV;C3N'JC:036?O%%^7'PSHL-PEU%:R1S1WEQJ$3+>WRK%=7:%+F2*(7/*C$Z
MG$D:(L;@*"A"J!TGXTXCN+66RGO89;>73K/2IE?3M,9Y[&Q?F6<4\ILS-,UN
MPS%+([2H2Q5P78E&Y=(GO%OJ^675FR\FXD,XR^*)[*,O&8ZQ36YRSS># CRX
MBEPG:U1HB8@Y.@A%1_D!]7'T0Y0%L0RJBQC*"=;\,Z);K9"*R(6PCNX[1'N;
MR6.*/4-WEJ<N6X='2XWMS%D5P<G '2LW'&7$EWY>T^HAGU5]/FOY$LM/@EN)
M=+"#3Y.;!:QR1/:<M.4T+1L-HR36-Y?WV[GLYTJZ8\R5>J]+T_(>0&66+Q$Q
M6*,0U)2T9/81R423(4M*U&B04RO<'<>D9K*SQ9%-_+MW#MO)K.F[I=(\K3A[
M2=/GM[FUMY4GMH#9V[O>7DW*M&8OY,B37$B"$-U2,J50A2@4@&L7W%>N:K;W
M-G>W4,EO=W2ZA=)'I^G6YGOD18Q>226]K%(;ED!624.'D#,KEE8BK%0-[6YK
M%54P_2\?Y(1K=<P-E)WF?%3-I1\=K.ZSDJ0;KM)&QJS;RIN)ZP>46*YXZ0B+
M-)S,&\C4VL>XC%&;)F@ABZT/2[N>^GN+8RRZA:BRNV,]R!+:JP98@BS"./:P
MW*\2I(&)8-EF)G8\2ZU8PZ?:VEX(8-*O6U*Q5;:T+0WK@J\QD:W,LV]"4>.=
MY(F3"E"JJ I/;S=PEB&U*/;56F3RYU.Z4&>E*[B[%=3EU*+D29>SUUIL?*U>
MF0[^%K%@?R,@1U"0[AC'H1S^1B6"#2+E))H[B-$TZ-8ML4K+!-!<1I)=W<R"
MXMU6."=DEG</+&JKAW#,6578EE4B<O$6K3<\M/"K7%O<VDKPV-C;R&UNY'EN
M;9'@MHVC@E=WW11E456>- J.ZMC.*MU6;\+X^R#B>D6:$5QAE%U$2-UQ[>,?
MX[RC39.;@C",+96M<R95;;$PMHBP$I6EDA&L?,E(DV3.].1HT*A*]TJQO;JW
MNYXI!=6J.L%Q!<7-K,B.#OB,EK-"[Q/^]%(60Y/F]3F5CK>I:=:W=C;31FSO
M3&US:W-K:7MN\D7^3F6&\@GCCG3LLT2I*  -WFKBY#O)W*%HJN.ONGR*E?6Q
ME+854>+P];<6\<.3UM)>9G%1;ZO#*7<F/I*TI^4G54)/EB%$57<0#8(1\]C7
M%'U+IG/%QY*HD%RM[M#RB'RQ(C EWY.'$'E"Q':LO+W@X?.]586#B'6!;&T\
MM8Q&RDTXL8X3<?5\L_E,EB+HQFY%J\WGM )=F"T8 C9D:07_ $DV\R0>6UX\
MRO$*.+Q1,:XSM1T\184:^5:+A^2-,8UKP@SQTW!BA4I$4W,<\C/$I(YFD<1V
M]<)1<<1KH+P[HZB("U<"">YN8O\ &[T[)[Q=ES)DW!+&9<A@V5\YL %VST?\
M+N('YS->QEKFVM+.<BPTY=]M8.7LXO-M!L$#8*,FU_-3<QY:;<<IN_K=7CR9
MK<Q1\C1M62J[/)T<RK$+CC&#+'TE'YI"%)E>/L^-DJ:%!MD=?4JW7$9Z/LE<
ME&2B-=@4VC=J6&C0;63:#I=PDB3V[2\TVS-*]S=-<*UGO\E:*X,W/B: RR&-
MHY%.9),D[VS"WXGUJTDBDMKM(1"MX@ACM+-;5TU#E^6I-:"W\FG2Y$,0D66)
MUQ%&%"\M,9QMLZ0/+&)<G5EW=;"V?X1<9YQ)G+(>-(#$&')2("<Q'*,',+(8
MJILK P=3Q190@6)ZBPFL=*TE6+AG1 +XRG&L68:VIZ#:W5LX@C*WOD5U8P7,
MEW=JY2[5@ZW4R.\MU'S")62XYP9P>VYC6WH_%-]97D)N)5;3FU*QU"ZM(K&P
M=!)8NAC:R@>.*&REY:<A9+4V_+C;(#;%6LHR3TG.=8W-V>;CMTN;FH8NR;N_
MMF\JD5B_8PQ%;YZ@97L,B_7CK9"KVJ!OY:U;8B%?EJSJ8K$RU).1+!+QQNDB
MY5CTJ8.&[(V-E%J$(ENK;28M(FE@N;N*.>UC"AHG$3P<R)W!E"2(2CL<$D!C
MN77%VHIJ&I3Z5.8+.[UR?7K>&YL[&>2VO968I/&9HKGE3QQMR2\,@$B*-P 8
MH-=YC?7N?GL>6O%E@OT-8:5;[];<I.(^?QCBF:?UG(%],L>Z6G&D_)4AS/XF
MD[.JY<.)93&,G4DUG3AT[332=.W2RVTNBZ:D\5RD#QS1016P9+FZ02008Y,5
MPBS".Z6/ "^4K*< *20 !S6XCUA[6>SDN8Y8)[F:\*RVEG(T-S<9\HFM)'MS
M)9/,22YM'ARQ9@ S,3<Y_I$MWUFC;?#364(=U&WK!M6VTVANEB3"S$9'!](5
M=K5.@)+Q^.VKF+802SPZK*2B5F,\4[>.,I*J#$Q8LZTT'2HVB=;9PT%Y)J$9
M-U>-MO)L<V<AK@AF?'G*X9#EO-\]L[+\3:W-',DEVC+<Z=!I<P%E8+OL+?)A
MM@4M5*+&6RK1E9.B9<[$V_LOTCF\B7R3B_,SK+J269,0I0J52R]'X]Q?%Y2?
M(UZ$>5B);WW($=2VUKRFT0K3YW7W#')DK;&4E$N%V<HW>IKK>$K^H=)C@N+1
M;3_%+K>9;5I[EK8&1Q(W)@:8Q6Q,BB0&V6)E?SE*D#$GXHUR2ZM+]KT"^LA&
M(;U;:S2[81QM$@N;E+<37@$3&(K=O,K(2KALG.(-]\6XB/N@7R)F<=0-A:W2
MK9&@QKN",%UZ'J5XI"]@?U:RTFN0N.6-?IDE&R=HG)A=2M1L82;F7QI:Q$EY
M!)!PG)M(L3%R66=T,+P.9+V\D>2&98Q+'-(\[/*K+&B#F,Q1!MC*KD56O$&I
MK<"X1[6.07$-TG*T[3XDAN(#(T4L$4=LL4#J\TCDQ(@DD;?*'8 C4:0?O91Z
M^DY)VX?R,BZ<OW[YXLHX=O7KM4[AT[=.%3&57<.5U%%EUE#&455.8YS"8PB/
M8VJJ;5 557:J@ !5 P  .@  P .@%<8LSOO8EF9MS,Q)9F8Y))/4DDDDGJ3U
MJVZIJ;]A[_P-)J>;W_+2ITLIW^[YCI6!W;W_ ("D%DR& P"4![?.'/GX\_9_
M#JED#[0>N<DY ]6?8<?'I@5?'(RAL=, =L^ /MJP/89FZ+PHF40'GMZH#P(\
M<]X#Q[^>X.[C6G/91R=& )\,]1[_  ]6,>'A6_;:A-%U1BO7IU('Q&?;6S."
M=[.]W:RFV9[>-U^<\8033^P4V(ODQ(8]#JB42"KCJ>6EJ*Z$H<E 75?5$I!,
MF40(<Y3<&[X9L+DEI+>-F.?/V+O]8.]=KC_2'XUZJRXRU:R4+%=2A!^YS'*'
MMC*-NC/^CVKII0/S2/TI-+(W1N$CMUSD9(I05=Y.P1#P[UT!1XY7<X6E\1B8
MYB@ "H4A#"/WP\FZPCPY>"[;KR9;F(>I)F('N$PE&?$^'4X\*]+!])%^JCG1
M6TQ'3+18SC'?DF+]?;6XV*/S3GNANM\H-%L6S[;,[=W.XU>IF>UN9S/7@2/8
M9ME#^,-V3^^64.LF9Z55-([A0!$O4,<W6ZP<^ZX1D@@FECO9VY44DN&CA8>8
MA?!8(#CH03@'U"NQ8?2(+NZM[:2Q@7GSPP%E>9,&614R 7<=-V<$^ROZ+F&Z
M+<E) ;Q;;_B&-4X^\-(N\G2:93!S]9-.V18'[>J(@!R]G(<]H<>("7)Z&4^'
M9$!/;ME?7GY>.:^I%H5P=HZ]L,6^[Q^_UXJSS&9-\<\8488N&L= 8!!-W5,3
M#+/D>>>J<JF1[!?&IE2?>CUC,P()O^3 H]73D3-Z4KX_G8'?Q"XQZO'J?96!
M+$.H5<^&.O\ ?GPQ@_*L7DL0[B<K-SMLP;@LHVB-7#JN*\C+A5ZHX W6ZY5J
ME4T(*LJE$!$I0/$F!,AC%3ZI3&*.5M5'7NPSU[GWGQZ9Z9Z5%K@=@.GCCI]F
M/?W)ZXQZC6>T/:1CRF@F+6*1ZQ *'6,W0((=3K<<\)]O?VCV<]@>K6PL2#KT
M'4>H^'J'LZ=NY\#DU29F./#U@>/;]>/>MG(BM1<.D5)HV33*4"@ %*4H<%YX
MY H!V]O?SW>C4\X/3K[?R&?GG\*J))[_ *S60  !V '&L$YZFE?NE*-*DGI#
MX_(U7+W![ ^&E8;N?>?G3.E97][^:?PIC2HTQJA>X]X^=61^/P_&JQ/JA[_B
M.LOZ1^'R%65<&ZRK==%=!0Z*R*A5454S"11-1,>N10ABB E.0P 8I@$! 0 0
MU8X!5@1D'H0>Q&>QI4J-\M6PB1$U1C'1DR@7PSAD/A3\AU1$_@5D4^3!];JI
ME >WD-:1MHB<X(]@/3[\G[ZMYS^L>_'6F2Y7LH@'+:%_<*OI'_I6@M8CGTN@
M)[C\JQS6]2_Z(JL.3["L51)5K"J)JD.10AV!S$4(<.J<BA3.1*<ARB('*8!
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MRDO%NCA+HQL1-SB;52&C'SQM-H+O"87+.2I3"AT<2M%M8,>Y=2 1T)('<@5
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M20[Y(UF61K>0VS0A?.\0?59NX7TD!+>2W+R6XV.;68W-R.09XV*72K"(6AN
MD4C6[0K=1"[2=FTD/W![?D.NJG8^_P# 5Q4[GW?B*4/]8?=\ T;T#[S_ -JK
M:I_H3?MOB.JSW^"_(54?3^*_A2!NX?8/PUBK:5/W![?D.L>(]Q^:TI93S>_Y
M:HK8I4_UA]WP#2E*Z5)/2'Q^1JFIYO?\M4>!]X^35=4X;6/[J';A_IZP]_W@
MUW6I??\  KS_ *+<?]R]=#2?^-=,_P"L++_Q,5?4$U\1K]04:4JFJJDW2577
M531013.JLLJ<J:22291.HJJH<2D333(43G.<0*4H"8P@ ".L$@ DD  $DDX
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MX]DYD7K5BS2,NZ=K$002+P G44'JE#DP@4I0[S',(%(4!,80* B%LA"HQ)P
M,D^P&JP"2 .YK/K/48*ALX-S=;S#0*]FG6-6KT?XH]D)&PV>10=.FE>K<8S
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MPU#EW;V:+C2PJ*1R]=:3<"]GZ]88CRRD",4[EZO\+M,*QLD5Y+S_ "4VX2.
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ML\#[\!E>-5ZCT>**S;+SFTYOQE+R>&\@X:QS.U6F2%T 36W(^X6W81E:W8K
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MW0!5VPB"1Z2T@91RF[09G)&)=VRM[RWBAAN+J&=8(5A5H[5H'E**$627=<3
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MADB1C,6$)B"HL.>5&%7EHA52+3Q#K!FNI_*P);YX);MEMK11<36TQN(9Y46
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M#;GSO;X!Q]H=CH/T@?1OI/"/$<_%O#[:=HFH<)ZI"9FO)-(U;BS6;VPLYX5
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M))R:N:?G]WSUANZ>_P#$5#Q3W'Y"F2=P^WY!K#>FOP^9J7B?</FU,D^J'O\
MB.HOZ1^'R%9JZ,FKAZ[;LVB1UW+E4B"") Y,HJH/5(4.> #DPAR(B!0#D3"
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M0=?>0<?.S#*.,(.W,9#O[+7F4F^11,V9.IR)0<*)JOVI58\X;2VU]H906P,
MD,0"<XR0&('J!K.WJ%RN2"0,]2 0"<8[ D ^\5=&5"7?-DW3&:B7K17K^"=-
M%3N6ZO@U#IJ>#61 Z9^HJ0Z9^J<>J<AB#P8H@$3,HZ%6!]1 'X^JBQD #(/M
M^-57-#7CFCI\^EXYJS9-UG;MRMX8B+=LW2,LNNL<Q0*1)%(AE%#B/!2%$1X
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M -*4KI4D](?'Y&J:GF]_RU1X'WCY-5U4"@<5B D4QE!.0$RD 3',?D.H4I0
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M[#*Y)ISL])IJ3W'%C9V",9L*Q,67*:%S?XT2MU0O#V@4]^]68+*$GS(7A?\
M9\N385!,(8N=CC>V'4J<L%C*!]K('8#.:B4E61?.W)N#8$A 0;E\U<J0P 4E
M]Q3*N57V9?2]D^X2B);;!:YQKSY?&YL936<YM_F'-5DF,CSU1N<,E=D8B-LA
M+%#)0%WQ%#(UIS$Q<74'$A*%5C;$I/P[T%V<6N(V,W[!QO#K$HBC4(&0[22
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M%LS2)JRW+-<W,)O+JVFM SVUU%-.Z"&%_(;O?;"98R\]JBQ[^4,).*+>\O\
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M+VB,54?["V]@'7,^Y1(NXM*@#)Y48SD !A^QQ(2#V&[ 4]*6FO"CD1;7V-M
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M 1WJ$H3<-O\ [(%*O5_P]E&.D3R^UVTO,<5["^<X>%K*<KM@RO/9D2\%6)Z
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M>"%G0LD&>T0.Q0 J@(JJNQ]<ZJ6N%74+N)+EXIKI(;B:)+FXA4*ES.B.$DN
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M/ ^\?)JNJ<-K']U#MP_T]8>_[P:[K4OO^!7G_1;C_N7KH:3_ ,:Z9_UA9?\
MB8J^H)KXC7Z@HTI1I2J22"* '!%%)$%55%U023(F"BRH]958_4 .NJH;[Y10
MW)SCVF$1U@ #. !DDG QDGN3[3XGQJ;R/)M,CNY1%C7>Q;:B#"(NXG:BCHJC
M 4=  *JZS4*-*4:4HTI7LG>/L^8:58WH+\/D:KD^L'O^ Z5@>@WO_*FD_/[O
MGJ#=T]_XBI>*>X_(54:H(MD2(-T4FZ"0=5-%%,B229>_JD33 I"%Y$1X* !V
M]VHD!2BJ H      &3T '0#W5:\DDLCR2N\DCX+R2,SNQZ]69B68^TDFGB?5
M#W_$=8?TC\/D*C3A!$# (#P(=H"'> \=^K']$_#YBE9NUO5P02*BE//Q33 "
MD\(9-8P '< J+)J*&X#@ ZQQX#@ [-:IAC)SL&2?5W/N'3QJ?,<?O&GBWVXB
M ",X\_ZC?T_YC4A#%D@QKG!P,=<TYC_Q&FBWJWB/ S;ON_2-_P AJ/(BP?,'
M<>)[=<^/NIS'_B-,$N]M$!YF70CS^D0_(^W6.1%_ /O_ #IS'_B-,_36U#W3
M#H?VB'Y'3DP_P#[3^=25W)P6/;(\/UXU5"Y6D0 ?*[KN_2(_D=1$,>XC8,8Z
M=_9XY]]3#'L6.<GIGKWZ?=5O:/%&D[)6AJVCFMEF63".E[$WB(I"=EH^+,N:
M+8R4NDR)(/V<<9TY,P:NG"J#07"XMR)BLH)H\L;0I4X!RJG.!D'<0.W7 R0/
M53/4D'KV)'?IG ./ =<#PZUD1;;8Q .95QS_ )*/I_S6H\M/X116; ))S_;5
M8EJL8@/,HX$>?.5+N[/V+65CCR,J,?V5DLQ\3\OE39+//B/;)+\<?I4N/_QZ
MQRT_A%-Q_B/VTT2R3H\<R*W(CV_>I!Y_\WZ-.6G\(IN/\1^VF26&:$1YD%A[
M/TJ7J_8].6G\(IN/K/VTR6>F! /ZN5$1Y_0I^D?UFG+C_A%8+-@X)S@XZFFR
M3<J//+Q4>[O!/U_K-5,B84XZD9/4^SPS[ZSN;UG[::)+R0]7EVH/(=O83T?Y
M.L,JY(P.A/LIN8>)^?SIHDI("':Y./;Z">K];K&Q?5]Y_.L[F[Y_7N[4V21>
MB(\N#CV>@OI#];IL7U?>?SIN8^/X?*F2/70]7E8P\CV]A?3_ ).H8&&..S8'
MNR*SN.<9_=S_ /+GYTT1RN//*IAXX]'K]6HD8/P'R&:D"3MZ]]V?AVIDJASB
M43&$W9SV]W/'?QW?BUBLGMU_B'_:Z?=3).X?;\@TJ5?*0/\ 5'W?$-?O"OYO
M'NOO_ TD;O'VC\=1?T3\/F*S2YN\?:/QU4>_P7Y"LKW'O'SJ@?ZP^[X!K%6#
MTV]WY50/WA[/F.H-V;WCY+4Z34[C>WYZK/?X+\A2DEOJ_;TAK%23TA\?D:5U
M%_1/P^8J;]A[_P #2I_JC[OB&JW](_#Y"I'NOO\ P-+'[@]OR'4:B/3;W?E2
MI^\/9\QU$_O?S1_YJEXGW#YM2FJ:A'X_#\:H&[Q]H_'6%[#W#Y5->P]P^5+'
M_1?MOGK#?N_SA^-6)W/N_$4H?N#V_(=5-W/O/SK83N?=^(JEJ#^B?A\Q5M+#
MW>\OQ#46]+^B?DU;%4S]X>SYCJNE+'^L/N^ :UZN3T1\?F:\Z5*EC=P^P?AJ
M+?N_SA^-97N/>/G2Q_JC[OB&C^B?A\Q5]*J>;W_+5-*4-WC[1^.E7KV'N'RJ
MB?O#V?,=1_?_ */XUFD3]P>WY#K"=C[_ ,!4T[GW?B*4/]8?=\ T;T#[S_VJ
MMJG^A-^V^(ZK/?X+\A51]/XK^%(&[A]@_#6*MI4_<'M^0ZQXCW'YK2EE/-[_
M ):HK8I4_P!8?=\ TI2NE23TA\?D:IJ>;W_+5'@?>/DU75.&UC^ZAVX?Z>L/
M?]X-=UJ7W_ KS_HMQ_W+UT-)_P"-=,_ZPLO_ !,5?4$U\1K]04:4HTI1I2C2
ME&E*-*4:4KV3O'V?,-*L;T%^'R-5R?6#W_ =*P/0;W_E32?G]WSU!NZ>_P#$
M5+Q3W'Y"F2=P^WY!K#>FOP^9J7B?</FU,D^J'O\ B.HOZ1^'R%9K,Z3&LY>U
M0T>_X%HX<F%8@B)05!%!9<J B @( X.D5 >J(&X4'JB!N!TG8K"[+W &/9D@
M9^'?X5) &8 ]C^7ZQ5JZ0C)60-O^V"]YFQ=>FU"D<>1\(FUCCUZI245,/[-D
M"AUMJ=^:R1DB1NUB8A_8018QB;-9Z_D6;I=Z"$4+)[H6B+/<+'(I??N).YL@
M*CGP()R0O4]@,8Z]+KEFBA9T8(4 P,+@Y91X@],9Z#'OZ5$-WWYS^$[/F6EV
M*K5>^0>$K[0Z"]R58LJQE,L=ML6:ZY"Y"QG#M:37L3NX1,K2OSLC7):8;2S8
MJB]22L!XI)C-2AZW8EH)5B9693*CN$6,L%$3%)#N,@.<C<!CLV,Y S!K@QF1
M2 PC95W%P"QD 9!@)@#!()S^[D]"2(>F^F0K47 2\^UPJW<D8XJD\L,(Q[EI
MA'2TG#--DM0WF,F@-4Z-( BJ_;65]BX[M%1ZU;V*#5DT3/4W"T5'V+IK,RKS
M2,R",D1D@$W36QZ[QVVB3'3*MCIW-37X52W+R ADQS "5%N)^VT^O9WQN'?P
M&9L^E8BF]QEZ?;<5U>LJ1\]=*RUF29E\HQ+R9I.XC;_@=X@J=?&42Z;IR:.X
M:N6V(\7;/WCA6OV&OK,FZ9&,^ZC]7DH'61B"%8CE8(#033>#D9')93D@#<IS
MW%2\M&XJR '+#/,R/-EBC/78._.5@!D]"" /.J*HGI6YZ[GJ=O9TI&MTB6E=
MJ4HRIU9L419,H3D;F?$.6LB7. 6CI6J.&<Z@QG*>PJ$4%9/6YES)1R2H3,>X
MF'4+'S-@$#+OW,!< LRD(IBEB12"&R,ABQ+;@ ?1. :B+QFVMLVJ3#A007/,
MCD<CJN#U4*,8)([]<5L#GC>5>3["B;H\:NZA19R;ONV9I5'%?N%4RE$/ZEE[
M+F%ZW/-WCZ6K+"/83:=4R#8V;J-<Q*3Z!DXA*7%RLQ#J*50VR&[Y#AG 2<ME
M6C(:*.5AT!)QN1>N<$'&,U9+<,+83)M4L\ &&##;)+&K=2  =KL.HZ$9/2HM
MQMTD616%4EHZY4>HWFQ4*@;OLNY N$W>4L4QC*B;9L\2.-5F$*,90KA6K\^/
M!/JZJA?*Z]KM)M"\?87S%M#F;IQRLWLD+ HSJKO;1HH7F$O/$'!.74H,[AL;
M<ZY4$GO45NG"G<JL56=V8ML 6&0K@85@QP1YP(5L,1CH*21Z5<)6\F=P-&0?
MP;90M!&H+Y$@V4*^LTEO;QQM5C;P2=+C1[:D&A8R_P 9=RL%00;#$&E(EQ#>
M46C*P+Y\@\SSFP<%]VPDA1:O<% -X4G*%?7G!!QE:P;SS@0N1G9MWC&XW*0!
ML[,X\[=[LC&<&IANF\^UVW!>QS--%=L\7?T0FZ_%V)KI7E7M<MS<:Q,S]YK=
MQA(Z>FZZV\8 \A5"GC)]E#PLF1HH115DS75.V2K6U59;J)@9.3;R2(V&4[@$
M925#''1NJDD9\34GG+1V\BX7FS(C [6\TE@PR1ZU[@"HYJ'2;S>7DJ@C!8Y)
M1'KW*FT-@KY(R+$6]*;J.XS*V:<8JQL@I+XN;FCE8R7PM(FF$8EKX^K"V&+>
M1%EBI-%=F:;6(CWDOO CN>Z%<-!'%)D8<YR)1C)QE3D$5!;H28 15.^#.&#
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M3>1X#I[*J%=(B4"^3(GJE414*4&"/5*HW6*X04 .X#H. !=$P??)K "I!*<
M-IL'K;[?[*;O8OV?VU=RS#L1[2H]WZ0WJ_7ZQL'K/W?E6=[>P?KVYI@DHY-Q
MR5+M'S%-Z>/T^H[1ACUZ''WBL[CVZ=L__+FF2OEC<\@GV<?H1]?Z[43T^P?>
M :R&)V]NN<_"JOACJ=4#"''?P < (\>?OUBLGJ/Z0^YL57)W#[?D&E2KY2!_
MJC[OB&OWA7\WCW7W_@:2-WC[1^.HOZ)^'S%9I<W>/M'XZJ/?X+\A65[CWCYU
M0/\ 6'W? -8JP>FWN_*J!^\/9\QU!NS>\?):G2:G<;V_/59[_!?D*4DM]7[>
MD-8J2>D/C\C2NHOZ)^'S%3?L/?\ @:5/]4?=\0U6_I'X?(5(]U]_X&EC]P>W
MY#J-1'IM[ORI4_>'L^8ZB?WOYH_\U2\3[A\VI35-0C\?A^-4#=X^T?CK"]A[
MA\JFO8>X?*EC_HOVWSUAOW?YP_&K$[GW?B*4/W![?D.JF[GWGYUL)W/N_$52
MU!_1/P^8JVEA[O>7XAJ+>E_1/R:MBJ9^\/9\QU72EC_6'W? -:]7)Z(^/S->
M=*E2QNX?8/PU%OW?YP_&LKW'O'SI8_U1]WQ#1_1/P^8J^E5/-[_EJFE*&[Q]
MH_'2KU[#W#Y51/WA[/F.H_O_ -'\:S2)^X/;\AUA.Q]_X"IIW/N_$4H?ZP^[
MX!K+>B?UW.:L'7[3]Q(JG^A-^V^(ZJ/?X+\A59]/XK^%(&[A]@_#6*MI4_<'
MM^0ZQXCW'YK2EE/-[_EJBMBE3_6'W? -*4KI4D](?'Y&J:GF]_RU1X'WCY-5
MU3AM8_NH=N'^GK#W_>#7=:E]_P "O/\ HMQ_W+UT-)_XUTS_ *PLO_$Q5]03
M7Q&OU!1I2C2E&E*-*4:4HTI1I2O9.\?9\PTJQO07X?(U7)]8/?\  =*P/0;W
M_E32?G]WSU!NZ>_\14O%/<?D*9)W#[?D&L-Z:_#YFI>)]P^;4R3ZH>_XCJ+^
MD?A\A6:<)]8/?\!U8_HGX?,4II/S^[YZII31/JA[_B.I+^]_-/X4ITG>/L^8
M:QX'WCY-2FB=P^WY!K%*;TJ:=S[OQ%5R]P>P/AJ ]-O=^56#M\6^9IPG>/L^
M8:K\#[Q\FK--D^J'O^(ZQ44]$?'YFJY.X?;\@U)/2'Q^1J5/$[Q]GS#4:4XG
MW%]OSTI3A.\?9\PTI39/JA[_ (CI6&['W'Y4\GY_=\]5-V3W?@*S3J?>7V?+
M46[GWGYTIPG</M^0:Q2GB=X^SYAI2G$^XOM^>JSZ+_SC\Q4O'^C_ .2G4_/[
COGJ![_!?D*DO[G]*G4^\OL^6L5+P_I?^>G"=P^WY!I4J_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g773514g88d44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g88d44.jpg
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MNCDH*2]I4;^$N0\T#%G0$J8808._7-B(;H'FTD<+ GCYDW57A X02=PDG V
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MP#3R@&L@<-: TFS6:B6FV6 V2))ZE60ST&-G28_&&V%,DG))SC&<G./#V5)
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MVQ\\UE&0\1/9V9TO)XY8," R"<Q_Q]=BZTI[XZSARJ,:[72CN/<-S5#)QSA
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MBX*T];J0L%*D9<F28/LJ0])I%C\'KW9I*M11<*A#$W3QLW9?#*[*@JRI)SD
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MSD<L]>6<>%<;#O)754Z2A9P!5MS;UY)Y+4T"D5F/FM8#XO5]BV_5L7N4)"[
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M,]B,\F:E*9<CDX]W,[2%8]$R6G5PD9>S)E-W09-B)E8331:KQ>TMD[ ^U?\
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M-TDUT]'$8!.=5AC7.K6Z^_;H3TE#R'W([2G4R @/!92.(N!#$9(4H^M@1F,
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MK3B6ZR[$T9<BR[.L[3ADK,,_;P2C#0P@TF0?=/7VMTCL*)Y8RP$MIKZ[;H&
MS);7&,YVTQC&?3T8-YM5R)3!GQI#J<\;"7 F2WCF'8J^&0T1U#C22.HK"]6]
MF':%H5#;^K-'WVS07^$Q;L_!<>L4Y*CA*[=?HGI%FN+:CLER#.D(4=@HY%3/
MSTJP2N$S:598DOT,S8T$Q,/B\,/HIF7Q_$E^/VSC&K+Y%DA\T^+SG.,8;?"^
M^SG.,8T^WG4]/@]_Z-Z9$])XN#T?TAGO^,\D]UQ]YQ?V>'/E61#2&K#:OMT:
M7U$;'W!D_;(LER-J]&'.1]H^C>B=P,'+O?=V,?>KN^=NL=IQ2G%*<4IQ2G%*
M<4IQ2G%*<4K/0G_"NPK^KTL_^TC47%6_@_O?E6A?%5IQ2O$D,C#102X.'WNH
M\4TV0T<.]D7+C">SE=-NCCW31%POM[:RJ>F/82VQKG;VMO9UQG./,N]XMMA@
M/72[21$@1RTEZ06WG@@O.H9;'=QVW75<3BT)]5LXSE6$@D*J8=[PU4%L9G -
M1\A(HNR -AF5-6R*89#4SAIG=TJU=*(&=D1WQ6<.M$QVZRF4%/A4U\;)YWT#
M=/VG]!VW6,?228EXF-R)EKB&_,,MHMK0N0CDOK8?6U<BW#]((?2B&IQ?=+[A
M#N4<2K2Q2:QB;M'+Z+E-2K5FYPT<JZM7S7W3C*6BV$\Z/FS53;\6IIM[6FFV
MGV^GM>UC.,;TL.I;)J>.]+L<Y,^/'>]'><2Q)8X'N!+G 4RF6%GU%I5Q)24[
MXXL@@*SYM[O65JGM"VI\OK60F.:6;UOJIA!SQ TC>-I:]CSHB)-;?K9JFY0"
M:UA6LRDHF,2;WP4]DD0!3=%U(X@^&QP;*/=JP3D9&>1)/08!./:<>7OJ5;&[
MQQ*O[7)T^SIF^+#D0R<1FK_FL$"5OM&7UFS6L%[>B,'9DIE:,.<X(&X6R).U
M3KT>SA<9<,,IS241IN1!NBKZ^O\ .HQMG(&V>OCCH/'ZYXYB)^1VE9NM!GD:
MAEP$(1,CM60LC9N\;BK&$UW8MO5R MJ+UY86'\W:RP2?9U[*HU(9&7$14]!@
MOS\0'6EZA\@V%**GAY[C;/OQX;>50I2GE+B<BS;@ZWP"@B4UZ#$6]]$Z\#D#
M!Z+T#+Z"I.YH3(;"&%2^KQ&72.27&TJ". P*+DE,9V-?Z X^D& RXK'XSS\C
MCY _G3AY8Z_#F1MY8&:M X[G1QO2?9JVR=76;##?5MT< SJK9^C#A\L>3)C5
M4&MJ/QT.6A<OGT+)(2T%94)9"C@R2D!J1,LNV=[);CG6-9J,;C<8/7WD=<>%
M<WCO1%XU+'];SN V*I(8F=/U=*+'CX6'C:?/7I!^MZO:"75]#%Y)92,S;:NJ
ML&'I''S\I CH*EL+<1PS/FLA1^&64QU]_789QD^_VUR4R[KRZ6TW-;3Z^P=)
M)K5RCHE8&T\!O[;-;!4(X7)"QT'K3K!*;%EDH-2*0-A(%T[<$0Z,-#/"DT<"
MI,R"+B5U  3@_B!\SL*GBANQ#BW968C),2#&JNJ5Z_=A8<ZC9UI* SZOKV"2
MADD-^DXYPX#R8M'9S6TV]Y(([[N/%8@<@A!AKNN[>K*J$8^)'P_R(]^:M+Q4
M4XI3BE9D^6DGH0Z=SZJ6K678/6EM&&X8L+CEV?0ADC#+'@,MD0RR+7I.K[3+
M4H&D4:8%1;2:DA@3?.^SQ&/R,(=1:%6"K)Y@^!!Z9]P)&3Y5XGB=6&.:9L!R
M*+P$NV7L/USO >_ML^01JT52CPILLR,SJX!(:25N8;+HJH.JY29IH-<I9*N=
M$B#]TBFHKGUY=4A'R&WOK0VU;4AE+P<I8<^=&VT<%.P8U1.,Q"7S^2D2TG/#
M8Q'0L>A,!!2:9R<T:/F!HL<(CH$H0<.7>F=6_NM%54U0!DX'Z?,[56 5Y).E
M1L[7H ==S%5>SX.+L*+EEH;8K*(MX^=C]@RL$UF4X?1!M#JWEQR.U-9Y8/ +
M$.1:=D6T E6&L<46$N$L*<)\/K\_:*@/L3?=#]QNGY&?4[,98?!P+LIU22>)
M[L+>IDVPDBMVT/* S.6PJ4#Z^DQB-2&!6'&YJ!&RP"1A<K!2"*S$8V)ZI@R;
M94@$'?J%>!Z'\QBK9=[X']:/2+N#7&J/OUIQUAOB+M$\:^UM@@:J^4,1RJ>/
MM_'(/UFZZ.?3/HLGIGTSZ<5">8]H_&NSZK3SZT^L'7"SO??$_6-0U03O+CVO
M;]_F75]'I!E;.W^=E3)#V\[?QYSZ\4.Q(\#[?F.=4YZ23.P9GVK\AI@O3_T/
M@KJZ8\"$SU&0#"C$])*OA0.LB0)OJT:H;OW.S&/M9656;*K-XT6.OHN2VW+M
MEU-\(TS)ER;[JYQRW^CQ3<F6FY0>0XEUZ#&:A+:'"D<1X64R'"DD,N/+96>\
M!)^M^WZPZ:L/8Y^S)"A:W^W-1-:#N=QFZ<<MLN)(MMJU=?KAJR)<'"\\XF,T
M)%R>L\-MU*'+K#MT>\1 (+S:4Z@<S>OD>OA<MF[QNNT=MT735RDH@Y;.4DUV
M[A!77.BJ*Z*NNR:J2FFV=%$U-=M-]<YUVQG&<XY"DI4"E0"DJ!"DJ ((.Q!!
MV((V(.QKD:==8<;>9<<9>:6EQIUI:FW&W$*"D.-N((4A:% *2I)"DJ (((K.
MCLAXQ>OEY1Y\R@J#[K=*BL@CQHS*Z1UVB#:1HAC#0FX9RB&!G8J)2!TMLVT>
MBCK\;L:!R-H).(O'23-V+)8?>=$VBZ,J3%"K,^MUIQQ^V#T=+P;<2M27XS:F
MV'E'A"FW5H+C3R6W0I02IM?U!V6?M:]I?9]<X\C42X_:I9X=MN<"!9NT B]O
M6MR?!>B-/VB^SF9EZMC*$NJCS+=&E"!<+4_-MZV&5OLS(DCH]?NT4.220K?N
MS)SC!DGIHR$=A*>KFTL;Z):ZXT0>R: Z4K+GGO,:^PH_?ER+[\+*JFZZOM9W
M[@M-\C@"'J5]U"0.%N[V^'.V'13\46V0K/52W%KZDDUBR^TKLBOBUN:I[ K1
M;Y+ZE*?F]F>N-4:/X5+)*G&+3J0Z^LK'#G*(T:%%C;!"4MHP!\GTI[]P_P##
M-5+UJNIEK^#LM7=HSFGY#OZ?;E5&,S^&ST!MG;&/35NK8K?&-\^FSG777VMG
M?ZLCY+MOLMS3XPYTJW/'S#,N/+:WZ S!YJVWK]D?LWWO"8&M.U;0;YW"-3Z1
MT]K>V#/)"[MIN^Z;N2<'<N(TN[ZHR&B3PA]UY)8W^*M?J)VI@2B7VNR<;A$<
MO*-I)X^W+A%]1LNGQ]5OIKC*BFSF+,E4]/MW1UVQOKI/]('F=I^G[[$(^\MF
M*S=&0/$+M<B6Z1C<E3"2!S Y4_V)VFZY7HWMK['M1H7LS$NNH+IV>W5:CL&G
M(_:%9=-VU#JCA*0U>)"%*.$N$%)5[0#OCU!/$$PZE\PF('%<XU3C]I*$Z=D.
MZF<XQ[G4#:PZ&E]E_:S[/N-6>5<[?@XTSGG(UJG3SJ^[-UC1W3R:G%RW/'R#
M4]$9S/EPUT+E^SKVVVZ,J<GLYO\ >[>C/%<]'HB:XMB4@$\9N6C95]@AO SW
MA?",;\53K#+<JVQ3$HC\!L.&S0U"MQ&DL&1>1BCCN/Y/,,$PNQ-(<Z<9;)%&
M.<N&*VWXIQA-;1/?91!?1/U8UP@S''VHDN-)<C%L2$,/-NJ9[U'&WQA"CPA:
M-TD['!P<@@:\ONBM7Z7@VBY:DTQ?;# OR9JK-+N]KF6]FY"W23$GB(N4RT'5
MPY #4A ]=HJ;4I(0XVI4A\[=8Q3BE.*4XI3BE.*4XI3BE.*4XI5/>^O^2Q8'
M^\%1?\Z*\XJ1S]ROP-7"XJ*<4IQ2L>;3HKJ"EW!M.Q^S7<RM3X*5AFC(WU+N
MZT8BC&XVZ>0Z%,06R\4F%AY"C XA,$C8<%2&US'96&F$G(R]I-GFA#"*JK G
M& #UW&<_+ZY>%1?Y?*M*6+T'K.O^OE8">P\":N"TL"2-_$Y+VX/" =?=?;9F
MM9%(9A6:K2^6%;.DXB,5'K8>Q^:/L1^PW[=<1)\R#77#YU*=E;['VA.^1S]G
M/&WRWL]T<ZVUI,>M\*G5[=2Z1CEMRU<UF3:D^OT8@YD_'H037JNGI:<KL[F4
M/ZP-2>B8#5Y8G5VQERG7+IPI#<)MMPJC=-4*Y\\X]^,[D9ZX)._7G5'FUH=_
MH]W3VHP1V/[-WE!ZKN2GXM<,D7I_QH55!51TU&0*PB8QH/E<FA]['XDA!9JS
M8%I97D.>%7!-O(@\)4+28'LGA4[8SA R#C[Y.VW0E.?;CS&#7Z&<_;C./7./
M7'[^/3UQ_MQZXSCUQ_MQG'^G&>*I6'QKQ3WJ<E4TN)YVLKS6^'MPU;;,1.CN
MN;X'6)"05O5]]TL3G5LUF)N9OI*[<L:MK]?AY=+H8>KP)JI7%;:-(ID:(5'[
MJMQ#EC;&#OOS!QG'(8Y<]R<\L??IKPVQVHK)K/&;@UEO7FO L4(N:L*0=\/F
M\ILN.]$V?CX?&']F"YVBW'0B04VU5DSN+#8>D<93YVHY'R]$*D@-T5)63G;<
M]?+BX^7M]G3SS1+Q<4NK1_FY[]148O)4:_UIV=IUK'3@V=-QL5B;.]( @S#Q
MLQ-2Q?$C%(XSKZ%0R^K)3;&N-\;;YQMQ]?7U^="<I3@8W.>6Y\<#V=?=MS_4
M_P 52L"%"[J>^4J^OB]5=8!"1 C4P8+R]ZS#>XJ^"L',=:8;O<[,ML#+GG)A
M=@(34TPL38YV:?"MV!+5Y\\WA]=P[39<1Q*DVJV-)N<Z3)N+C4;_ '* ^FW-
M\+N6B6;X\'68V0%.I!9+:&GP[N3MD*+?V&]@^C5-I0VQ(O7:G?77)2FVDR]8
M3];6FR-.%P!*EBV:+T].:8S@A]GNBE#;A7ME&);'T*]CQM%_L6&-0@=LX<1M
MF_E.Z*Z0QK[Y/=M&VI5WC+?'IESGW'LMM<XV7RGKG&<[GC7>!%L42>IUV3%:
MBQ4.+ML67=EH4EA'&"Q:V)C^&^;J@UPM#=PI&]:9L$=5V:A1X+T)Q:X[24J>
MN$"&QQI:1ELRILF/&#F2 ELNAQ1.$I)VKVD%8M8T:4U<BM#L8,H>Z6'2B,OF
MS,HT5335URL&DXQKN\8KIJ:;I*J,E&J^,^J6^_L[>G9BRK7J.V]ZF.N7;9B,
M%JYVN7%;DM+2E:5&'=HD=QZ.XA:5(<+"F70?44K!QV[O9UPWG[9=&83Z@"B1
M'1*M]TCY"E(6T\N&_+C%Q*D*2XRM?>(('&A.1F'\T86A&?BJ)GQ.OD4\YWUK
M^1).9U5#C&/POAFL=(D&QZ')*;8QIIB#R4$-;8VW4V"/,XPGGP?Z*2+5^\TG
M=W[,E)XA9YJ5W;3R^O=MPGGFY=M0HX %JG1&&P2KT5S[IQ$V%Z#ZU@N#MN W
M%NDI7<+0K&_ B,XZB1"2>0$"5':1DJ[A9V-= MB74-[;Q> 6K&PL. 20&_)B
MBXFUK+,1.2$6J#C=%K'QKTF) 8./B#%SA*+%0++#<)HZ6T9D5DFSA[A<6\ZH
M8[1(%HU!"BVR)-BO/QY$?4%\DV^<\VA92B&P[(CQ/2GGFEA-OD1&N[BAQ8:>
M4&UNXVQ<KXUK"';KO&8A1Y3#CK3S-VNCT22ZA*B$1FEO,Q^_<=;5PQ'HZ.!C
MC(0ZH)6YHMS=%;)IQ2HDLVA:6N=%!.TZNA$Y69XUR.)GX\/='@ZFFV=DUP4B
MPCH> NDMLYV2=AR+%TEG.<IK:^N?7SIUIMES $^!%E%/W''F4*>;/0M/8#S2
MAT4VM"AT-9II/M&UYH1;BM'ZNU!IYM_/I42VW.2S;IR5#"F[C:^\5;KBRL !
M;$Z+(96  I! %0Q]R]-8/^,H3LQ;U?MTOL;0NRWB78BN-$M?M2:X:66Y5M >
MT2SC&B+:/6V";HH>J*:.NF$\:>;]A2HN]IO=QAI'W8LU0O$+',)X9JC.0D<@
MEFX-)"?5  QC._\ :Y8=0>IVC=E&B=2NKW=OVE&%=F.J5+.RG2]I-I&D9+R]
MU+>N>BKBZMS]XM945%527]]=V*F[@LV-RT1&I]2@ZG]L2BT>OX>6EB#44XD6
MRVDU:5^[+R68+;C#&C4*>KT.SDIIJ.5<2H8:*CVV6VV/+NVI[?J-"+G:F)EL
M1;CW\^T-2'%I;4_GTI,13K\@EMS@;>AMI?=2CBD-N+0"FMT1NSCL#UGV(2).
MA>T6ZZ<U_*UNG[)TAVE3K+"C/2VK6$&P/:E9AVJQMIEPE/3[;J><_:(#TI#=
MFEP(<ET.IT\KFT*\MV,MIC64RC\WC3I11#4K'R*#Y)N\1],.1I%'3;#H279;
MY]T0#E$&90<OC9N^:-U]-D\9S"G0[BPF3!DLRF%$CO&5A82H?>0L#UFW$\EM
MN!+B#LM(.U?)6J-(ZGT3=GK%JRQ7+3]U92EPP[G%<CK=8<SW,N*XH=S-@R$C
MCBSHCC\.4V0['?=;4E1[SG;K':<4IQ2G%*<4IQ2G%*<4IQ2L]"?\*["OZO2S
M_P"TC47%6_@_O?E6A?%5IQ2G%*C8G3]8F9@WGY6% WTS:.QC]M(UVVVQ)%X&
MPWP+<:*X4QC"C'#5OA#/L9]GW.GKC/IS#)W9WHBY:B9U9/TU:Y6I(\B%*9O#
MK*E36Y-M#0@O)<"P N*&&>Z/#ZO=IYXIGI^0_'G4D\S.E0)*>N->S*SP]I2%
MY.'ST.3BTB3A>TZDFM8OI?!LO<PJ9$H!\=D"ZD474?9>#%\(),5"P^/'R(]_
M((I%R@=4Y^OKZZ<J^R]ZZU<0G*]BN11'>4.;5C5SJNM3+_1OF>Q*JW-,A7^&
M>JN&^K)"!NEF"PW&GP;AYM@DJGL[UPIQ3)^6/=G/XUG]+_%;')%+PT;#S5>&
M=<&KR(EC<$BQZU!4OD3Z&4PXI84H;=)V*I RTH^1I@TTK,=0W20LXU' <6V$
MO2H",3< J>+GX^[KG/3Y<MR:LO<?1"E[,8V66$@F "R)XA+EF\F>+2=4*U?2
MFCH90RP4J%B<IA1EW7N\7K.M"SJ(@93&5F\R@44GD=,Q^<1X'(1S\Z@$CV;?
M(Y^.YW\STKE:PZ/.1E"]J*CMJQBLP+]M9/)9-,I,R)RDT3B*Y>E:TI(/L D=
M@G9-(#!6/BZN"2L>2)*,F#$^YR.$ !8 4-9:J$Y(VY=/>3T '6IQ"]8Z_65
M22;BFAV=(VBO?,I<,UR6D3,7&>Z[$^LTO*-HZ2=/M,1(I6AXV):Q4@H\9(;N
MD2"_OR2.7&RF3\L>[.?QKT9UUCJR:,@R MJ>J@@!)/B0Z0TB>>5.?_PJ'>1\
MPP?/HAA@F4'$Q#Y9NHW)MW>P]XD/.A%1<B#B"[!45]>G>NL8IN92>01E$>+C
MVE84C0U7P\0W<HBX!2M$")+M#XSIN]<O'+TI])K!G"[LI[Y/5Q'4X<+715>
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M"8\+0C&Z!=/9H^-SY6.AHUO(A6S*N4&,6V !S?T%9X;Z2YG!-YVBE(<J9/\
MGUYY_'?Q\ZFBBJJ94?3M;U*Q*+GM8'$A(%[(G2&C5W)C3=OJK()0\:)J*HM'
MDE.K$3KMH@ILW:N""J#?T033QA4'<D^-2QQ2G%*RR\HMW=U>O\&A=@=2H6VF
M 1$'<@JSMUEJBU4C$@+0=!C2<JV96M/J]^;CP,[77)D@\9*O'I-)HFS(#'K)
M;#995D\/7RQSWWW&W4_7G*?0B1]BC8&ZQ]WV*4NV(1BV, Z+O:21*J(/);7@
MZ<)BCJ2&5P%*NMH$O&Q%B.94 A\B:BHZ4.B!_MDQ"F6K<R7?7MJ#C; QMOSY
MY/CN/95^N*BN"(6K5XF>B*J*V1 AEH2 *\DH&MR$PCS*>FXX.^*^8'Q$/<D4
MY"2"L?@GOQA5F.68MOA'7OU]/AU?84P>>-O&J2=T9Q#KGZG)2^F[@BTKB0_L
M+UG3)R"M3D,GT=D?R?LW58XQ#79QCL=8LMVQ)RT<D=A+MD=8/!B+/=P@@N\;
MKJL-B01O@\_83^%:,<56OS&57U/L7N3W$\@5%]BB<P@-,1>]&5Y&8E6IN)!&
MA&SYBTB4>K20&4U6\C,$]9=U]@;;.F^CCY<,?)[E5DF$D4]RIJ!NU7G5M]U!
M;=0OS&;/;9@7&9BKC--)?)95#1G@>6X'+8OOE#B(;<?[U?"ZL _I_/[1NRO]
MF?L?[%->]A]GTK<^U'7FE'8E]NNHH=]N-Q?M+;5TC:FE\!E6Z'!<A:_8%N:4
M&6USHEI^SV#)MD9QQ/Z8 HAE'PXD"-PYU'!!C 0PU>/GQ1YAD-:I,VN'9,FX
M=DB+G""*>%WQ!VZ?.U?;<.W"ZZBBNVW&FTM-MM(XN!I"&T<:UN*X4)"4\3CB
ME+6K &5K4I:CE2E$DFOS+GS9%RG3+C*+1E3Y<B;)+$>/$8,B4\M]XLQ(C3$2
M*T7'%%N/&99CL(PVRTVVE*!Z?+UU*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2JL
M]KJJE,XA@*P*J2;ZWQ1![-G4^JLIAND=),F2[*55D4=:YT4UCEKQ)<I"BNF5
M4T&SQ^'.;Y]^#:[:>%?H#\J,U+@!/VK:G?3;<2<!U:4E+\)Q6Q#,]@KC.;@)
M4IMTG+0K;_8YK"T:?OMQTUK%;A[.NT2W#26N$-I[U=NB/R&W[/JR&R>))NNC
M;TW#O\-00MQUB-.MR1W=Q>"I<IVU8M=]8PNU8:JOM'YH%0*MVSU/W!,0]UW4
M:&8\::Y_"9'HV9;$ !UCO^&Q+CGK7?\ "1SGGH6Z>Q<X,:?&)[J2T' E0PMM
M6Z7&74_PNLN!;3J?X7$*3TK"]<:.N^@-6W[1U]0V+E89[D-UUA7>1)K!2E^#
M<X#W*1;KK =C7*W2$^K(@RF'DX"P*DKG=K%*<4JO_:?L%&^K'7VTKZD[)T8:
MU]&E7H:,#L;;&)Q-"KIL @%? 4]-%=UI!/YN5C\.!(ZI[^V5-M,;8]CV]L*D
M#)QXU''1'K[).N_7D&&LEZU-WS9I^1WIV3E#7.NZ,CORV7V)-8&[1711310#
M%EUF-?0W5/.J3:#PZ-,DTT]&V-,*$Y.W+I[/G[_.OE[Z_P"2Q8'^\%1?\Z*\
MXH.?N5^!JS1.;PL+(P,/,2^+B9;*M'BD7BQ,^)82.2)CD\K$% (1T[2)F-&"
M.,JO-A[5QJU3QG=?.FN/7BHK_8[-X9,%SS6)2Z,2AS%BZT?D[>.GQ1M>.'FV
M/5P$/(C';I007;X^U8:0U;O$L?\ :(Z\4KI^*5^7'N I%7?E5U=R"O*W.3<%
MV Z="(#U_FH_MU(+%[/QHVA46Q_LA6[V/6\.ZSQ:-==G3@JJL/,5#)@R!FC9
M8;L8J%?G@KWD?7^GN'(?G5Q]WKR.X( &YV.V=]ML]?;6ROD!E]%@H-5T3MKJ
M>'[M36S[2TA]!]=B,%JV:NY59C6$S&5DC#5S<BK6!0<=%J\CDS,R2=&2#%(.
M!0>M4]W2Y))BZFH2"<[XP,D[\MO#SQCSJFXOS$]*NHX]I0/:"K#7COL2"-FS
M<=UQ(1V%'8Z-AQ!ND3 R:NS5"/9+6Y*#F%79!DV4%K"W360")$-?!VJK+"[I
M3A)W!XO//7P.<?Z8KTCO9'QF7C==9'25I]G9VK9<AHR;",LYEWJ0ZGQF7')B
M,&=>!=J0]D8'==*T+SFP(<)=0Z%6-&PC>4R= >9+B'#B1L7A=3"@#L-LY'JD
M\LG;GL#G(Y<\C&VU_%5K/OR852C='60I 7%!2CL%J6/82;!H<.K"42"ORKN*
M2T4%M-C7ER'H]7-C[Q8L29M$XW(7CG08Y,MILS'KOHDW7:JE)P>>//?\1N/=
MOTZUDOUTZ4]VH_VRI&=RZJLUE8H*(U\[.=DD3D7LZ(P&KQ?C %]=G'7=58K/
M][$GVL8[GH9M1S"GRKN,R;=FI8:\T=%W>Q955U*20<;@D[<CDJSQ<L?=PG\M
MJ]GQYWKVAL_S-=MJQ[+3&$3[?KKUWG585Y+X="A$!4/1MO?-?+."9R."I;+L
MCW[MVGHIJT=O4EFR?JGC53'KOA4''"G&=R2<GJ-MMA]>%:Y^2"9!X3TH[!/B
MP_4EN>@)F"A4=FR3G#>13]JI#@Y#VEDU-&ORUT:P^^+QC7='X?T2435WTVQ@
M/:=-B6_15YD2X3<])0Q&9:<0RON9$V0W#;FH[_U4N0 ^J6A3?[_+/"Q^]4FL
MZ[+WK5"[0-)7>^3F[?9[!?K7J"Y/K0MYQR+9)T>XKB18[0+LF7-5'3$8:;'J
MJ>[YPH8:=<1];H.<KNV.G55J#(J/W"-Q[@$>%F!+=VU)RJ.$569LXN@^043>
MK%2;?8O\2IHIE)=QE!-3;#73;F+=CMLLUR[*-/6R;IZW)80A]FYVZ6Q$N,6;
M<XDYX2+J\EQ#K3[MP?;%QXGDEYA;P:5PJ9&*]I,J-<-7W*YP;FU=8-R;A2X+
MR&U,+B1/0V8[%I?C+2E<9VSML"VALI"7&8S,EDJ8?:4J;84T:57816MT&K<?
M#YXH4F]>:-T4F[0>;T]VK.X:BFCIHDEIJINE+0;?777'P+TZT;ZZM0:>FG?T
MS&CZ$U=/T:RPS$T[JI<[4^D$LM-LQX=S3P+U3IQM#82AM*5*:U!:V4I ,63=
MF&@F/:T)3@GU]>VI\YMBE5^L>/&H-(][M@ UR3>ILVS&U86-T]IQ/H@/QMA
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M)2L%*DA23S2H @]=P<@[[U! 4"% *!Y@@$'KN#MSWKGEX9$W1L;(W$<#+'1
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M)W!'K=1Y?7T:MA=.N7G<?I&QQ]N& SL_*LZ_O^S\N@,2C&%/]GL_33*?K_\
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M_P OJC_\JM>9[*OZOM!_QM.?]"GL=GOY30W_  5A?_/XX>U_^N[-O_E]4?\
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M'(AS4I6GO&'"DAZ),9BW"(XVX@"3%:;D)D0G)421;4)..X,<#"(\%Z=U*/#
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MS[$T:&\R!D!8O Z2'7_&BZ7N3KIJ9T=).$403HF\132?-6;IOY%[L=OU!"]
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:BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g773514g89g55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g89g55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1NX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &YR^<&@X0DE-! 0      #X< 5H  QLE1QP"   "6  < E   T1-1QP"
M!0 B06YN97AO;B!04%0@=&5M<&QA=&5?,39X.5]);G1E<FYA;#A"24T$)0
M    $+[>;>-O^/36K_T5/8%L(O0X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              'D   #'@         !
M                  $              QX   'D
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   'D     %)G:'1L;VYG   #
M'@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !Y     !29VAT;&]N9P   QX    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     <X0DE-! P     $4P
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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ML^S[_3L_PBP>K4X]OUQQL1V#4+[;*[SGFZQUWHM99^CI;Z;/L7ZQ1]'$RO\
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M:ROJ^QK*\[:QC)S\EQV6"V2;#[WPYWI6._/H_P $M5)2DE@]8PNOY.::<?J
MQ.G95?I,])GZ>NX!]GJ!_M=Z6VO_ $^__P ^+9QJGTX]55ECKGUL:UUKH#GD
M#:ZQVWV[G_23C$  \0-] B_!*DDDFI4DDDDI220
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X  0 " @(# 0             ("08'! 4" PH!_\0 .A
M 00" @$$ 0,!!P$'!0  ! (#!08!!P ("1$2$Q05%A<A(ADC)#%9F-88"B4R
M.4)XM3-!5Y;3_\0 ' $!  (" P$               $&! 4" P<(_\0 /1$
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M+U$+KO3>X[W5-:7(':5:O?4[LOJS0O9BB[.'K6P*$>TR-O"F/465U],4B]&
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MVVY&  @[E9B)/-QI3 \$7B<$4HS ;#?SQWQ_ 5G+B\8PB7KW&H5^^UJ6J-I
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M<[)9DR $E6]CR$&:(EZ8>%8)CC"&'6QTK]_ORO&$28']L/&?Z;OE>_V>$?\
M.^(C^V'C/]-WRO?[/"/^=\1/05YD(4(8@POQQ^5D<41AXDDA_I^ZTRP.PVIU
MYYYU=\PAMIIM"EN.+SA*$)RI6<8QG/$3&*%YQ-=;1IM=V#KSH+Y/[I2;9&M2
M]:M56ZICS]>G8Q_*DLGQ$S%;#*CI$-W*%X;)#(>97E*L)7GTSQ$R[^V'C/\
M3=\KW^SPC_G?$3\5YA8M:5)7XW/*ZI*L92I*NG;ZDJ3G'IG"L9O><9QG'\9Q
MG'IG'^?((!!! (((((W!!\$$'P01ZB2"0002""""#L01Y!!'D$'T,XQ'F,@8
M\-\@CQP>5<0$(9UY]QSIZXP,,(.TIQUQQ2KVEIIAEE"E+4KVH0VG.<^B<9Y
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M3[LY4KT2F]83CU5G*L^F/YSG.<_SGDJJH J*JJ-]E4!0-SN=@-@-R23^)W@
M ;  #[AX$_5^82*<2I"_&WY7%H6G*5H7TZ?4E258]%)4G-ZSA2<XSG&<9QG&
M<9],XY) (((!!&Q!\@@^H(^8,Y E2&4D,""""000=P01Y!!\@CR#.L+\OU3"
M#**,\:GE,'!%"]Y;Q'35+0S $>E1&/G6Y>,-MBAI0IY/OSAH?"5+Q[/3.><.
MU5MMVZ]BJJ1P78JIW5?3[*GRH] ?(VG=[UD[@^\7[AWL![MFXLM'&QP>6X>P
M>';[3CPQ(F-4'S;:KVE4*[L;7GCY\FEVIEL%;L%:MU5ZE@V" G1GL+';EXB<
MBM@%1\BVXEM;*3@R7DJPA3>'<X3G')[=>^_!-^7/?BN_/;CSWVWY<?'+UV\;
M[3C[Q?QX]ZWCV^SQ[C\>T&Y"K;EMV^7Q<-N/+SMOYF:L^8"&&;2R/XV/*RPT
MGW92TSTX=:;3E2LJ5E*$7I*<>Y6<J5Z8QZJSG.?YSGG)551Q50H'H%  &_KX
M&PG%['L8O8[V.=MW=B['8 #=F))V  &Y\  #Q-L:5\FH&Z=FUK6;71KR*ZQ<
MLOYGVWC;W61ZEZ[A/PU?E;!G]0V95ND,1GY),5F(B?4-[[DY(1D?CX\EX=1,
MX2S?B(XB.(CB(XB.(FJ=Y;LUQUQU'?\ >>W9M^MZSUC7BK3<YT:(EYY^+A U
MM-D%-0T #)3,BM"WF\8&C@"B5^[^AI7IGT1--Z$[T]8^R 5Z*UW?S8HW64Y%
M5Z_UO:U*O&D+A5).>@56B!3+5';]=I-B:$G*ZV_,1$DW'.Q\@"*8\,4Y@0GX
MD3?%LEJA9*;?XA=SK@ +4/,UJR3&9:+?&JA$I&NA*S-^IS#(#XR#&W\B'DA.
M.)RA.5MX<2OB)#'QJ#:6U#TLT+H_7NZH[:-?TZ]<^ND=?9>O$:R*O%ZTY>;-
M1KN+$U"P21IN70+1"2X#*(V2FPY <1$G&2!T<4.2M('C^O\ ,F3O1;JHX7-@
M-V>O+.K+."+(&B:C5%U\=32GDOS8Z2<O13*F4J=PZ>@=&6DJ<PKVXSG"3.TC
MI*.F 192)/"E(PYE!(4C'%,&@F#N8]6WQ2QG'1R&7,?RAUEQ:%8_E*LXXB==
M:8;%DK-BKBB?I8L$%+PGW,,_8R+B5CR <D_!\C/S?!]CY?A^9KY/;[/E;]WN
MPB1ZZ4];6^GW5/176%NY*V"C2E"CJ0FZ+@,5=5CQ'O$N_DU5_$Q8,1.7?L>W
MZF)J2]GL]?LK]WHE$WCL6_U;5.O[OL^\R*XBE:ZJ5BO-NE6PC9)R-K54B"YR
M</1'QHY<B<L2,!)?2("*283EO#(S#KRT(4B09UKY6^D6UB8Z-K&R+<!.RUOT
MQ3(RLW?2^YM=6:0/["&RD=IV9CX&]T.O2,A3;L;"R;$?=P6":J,H7UD98-#X
MJGT??^'ZWDTK%9J+9*5=6D7RIC0R0)BKSMA1/0Y,97#SQ'(YQF6(Q(-""&"N
M%M96"86(\I:FVE9;4XG/$2-75/6M"Z#].M2]?)[;$7=@>N>D229"VHBV828L
ME-IXTC,RMQ#HH$U:)1L%L/#V<,QQTUA:VDM,$O/.H;XB2#UUO/4VU=75S<])
MO4#(ZVM%6K=RC[(6:W#L"05LA(VQ0;L\-+Y",K9I,1,1I3T5/#QTF'DIMDP1
MA[.6\(FTAR1S!V"Q'V2A2F6R!B1W4/CD,/(PXR^P\TI3;K+K:DK;<;4I"T*P
MI*LISC/$2-79'L?H32K- USN'9T/1K1V4MHND=203@YDQ9+==+JIN #;B:[%
M-$23T9&E2H*IN=(;$K\)@L'$S+1_WQ,O(D/?&%LOK%JW6]0\;^J]Y'[BV9U(
MI5GIMBL!NJ+WK:)N*-;;"+H^P)>GGV (RGV@>E7V2:IEK32KK;F(.=RT(:6A
M;R<81+7>(CB)#GM9W%ZU=;TP% WML0VBR6W8J5C80L.B7RYQT)%G2L#17+9=
M)*GUV9B:+4Q[5=ZM YLMVD:[ N2\T" F32XMU3*)'?QI7SK=J#75.\;VL=UR
M.YMC]0Z1,T.U6W]J+W1:M93=>6INNWI->L4H')T";EJ79[!'5ZW0-3OUJ-KD
MJ^D214T\V2@=$M.XB.(D'NY7=SK9U4A/TWV"LVP:<+L"MGA1]DK6B]T[1K<<
MF=-:IP.)JPZVHMFKT)(F3DN"#%0T[+Q4C,%$C,@,N_8;7E(_(G^7^I$T?XS[
M[UZU-KJI^.+6.TKEN+8/3FFRFNKW=W]$;4U]2"Y>C3H,=8@FKC-0I^M,V./D
MK0 *15(;8EAF$);,(0VZQ'R"Q$G]?+_]_G^4M1XB.(CB(XB.(CB(XB.(D0N_
M77:R]MNFO8GK93IR#K5HW'KB4I<)/654BF"BSCWQ'6RY-42(?))%0D=6%*"#
M(?PI2<H;SZ9SA$@]>_#/U]E)[K>JN5>'ME;J'947?79E78.W[$WS;-XLU_KQ
MM#3U'BS)_:TE?#IA-,G+A6I.NP,V<#68>)ASE CH/=^$Q!_E_#>5Z:V\!6^=
M>5Z^!E[8T)L(Y%YTK:(F!N\+;'Z)V8!U-ONU;A+"[60<37(YEY-E#LGTW?D$
MW#/,V)!L@5<#JX^!6(M$\I#P'[V+U_ 4S%UZF$.GTG=NMWG3Z/L!Z*ZQ-[/[
M8VGL5#;@ZA@(PEZN[+@J]8PJ*W&RQ4!@!%5K/U[N?% E@GHF07/P2]@;/=^\
M4I"[KTO2ZUV>B+M^*4#7)>QV"R35A[(ZSWZ()=I2U524NU)K%@$H\]4MI5R)
MVAL^CV\JWNSL/KVKQ<2'45(ES7CEZIVOIKUFC=,W.<K,O.YO^R[V^#2%R"J1
M56K_ '"2LK57J>#XBM-HC /NJ**_$T^E0+LV?+$0E/KT:\/',HDZU?QE.?3.
M?3U_RQZ_YXXB,?RKU],X_I]/YQZ?_?B)I+LSJ^7W?URWWIF D(Z(G=LZ:V9K
M:&E9C[/XF-E;O39FMQY\G])@HS\>(5)-/F?5&((^NVY\+#KGM0I$JK_L<*K2
M].:+A]13@PO8"H[*ZBW3;FX-MWS;6XG+)"=:&Y E--I_Z[G9\^"I0DU,S,A4
M*#$8J589:.6,4B.P@90J3OZ_B-O\Q_M(":F\#/9O7L+-E3]KZ=WLYS8?6'99
M&F[#5)UKKIMB:T?1^Q&OK7';,H]0U92(2&B+ C<\!?:BS!4V<37Y^EQT%-,6
M%T-J[%I$V4GP8[TQO^"VRK:F@ 8EG5E/K^0:?5KG34:UF:GU6LG7A>KM10[C
M5GG0='RTI,_J/Z$SM',>'&2]H&DM:V.?)BIZ.1.BH?@IWO5:/"L&2_37,C1E
M=,!/V'BJ5?6>L_99OJO6]NP<_<.SL8_&8DI78&R3=L#3A,F+6;2&/+:ZK)<N
MU-_=RU#(EZ'0GK7/]1.J&JNOUHM$1;9VCM6TD\VM!2$93H95PO5FN[-+HD=+
MDF2H-"H0]C:I=*&DB%&-UJ"C?E9#]< C(G6]RNK!794?0)E=73(>UZ<[-:(W
M&39;''N+E7*)K+8,3=;;4(*5!CC9$8BR9AHY3 #CHL.7(@ /R;S?U&'FT2%W
M2GQH;5ZR=Y=\]H;1>M8RM<V@WOU#I=28NR=B;3?W-O6-V]5Y#:<1/K70:43J
M"&"+H\0QJI@8:[)D7+#9\-'L-CJ1+I.(CB)5YY,>GW8CNC3Z9JO5MXTO4M>?
MFH6QV63V#$;#5?\ 7E_J-NKMBI&W=6GTR<'@;1,U<$.Q MZYV%$MU.3E9"(G
M3)C"HA(#J)IKI'XP]F=2NYFX=YYV/1GM3W66[)38495,WMG8>T"NP6X:_MJO
M#;MC9HQZ@,8T&H.UUS7\I3!_R,VQ=)F1D_PV2CXX]'Z_K+J.(CB)$3LKUXL^
M_MD]2#')R!8U!H_>A&\=ITR4P>H^_3-1U];H_3(8#3 9$:2-3MJSD!L8H>6?
M%:1(U&#."4Z<"PCB)#WK-X\=EZ6[Z[4[3GG:&IE%MC&_4NQ>D(W9T-==ZR&Z
M]H5C84#8>Q4?<[!8*JJQZG&A)F.A)*GEO,S<G;IN3$!I\0M-8RB6^\1'$1Q$
M<1'$1Q$<1'$1Q$<1'$1Q$<1/202.(RL@I]D9AOV_(^0ZAEE'N5A"?>XXI*$^
MY:DI3[E8]5*PG'KG.,<1&21\/H%R0S@EQM3S8^76\/N,HRE*W4-95\BVT*4E
M*G$IRE.5)QG.,YQQ$X[,I&$Y4D>1!(4AE1"TLECNY2.AQ32WU8;<5E+*74+;
M4[GT0EQ"D95A2<XPB>;4@ _D?#!HCV2VUO"X:)9<R2RWG&''1\(7G+S;><XP
MM;?N2G.<85G'KQ$\_N"9^SZ%#9^GG"2_[]K_  JLHPYA)/\ 5_<9RVK"\8=]
MN<HSA7_ASC/$3\0:&XPX2V6,L9G"\ND(?:4PUAM/O<RXZE>6T80C.%KRI6,)
M3GW*],?SQ$\ Y "02M8!P9R&U82XL,EDE*%9QZX2M3*UX2K./YQA6<9SC^?3
MB)S.(CB)Z'RA1LL)))8'44^D49+[S;6225H6X@=C#BDY>?4VTXM++?N<4AM:
ML)RE"LX1/?Q$<1.$')1TAE[ !X1V1UJ;?P&4P3EEQ#CK*FWOA<7\:TO,/-*2
MOVJPXRZWG&%-KQA$]I18H([A9I(X8K.,9>)*>;'':PI6$)RX\ZI#:,*6I*<9
M4K&,J5A./YSC'$3D<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$^=
M?SP2&PNQ;O7[QO:BUOLW;YFXG;'V![!4W4,K38&Y,Z*U IF-J+>9C8=CJ-.#
M G]VSE3D59.L Q3F*$2,&P202P.^_7Z_F)/%N(;8\22H;8\2RA2P!]"5#*2!
MY 92?42I*.W)W [$;?Z([FUF/8!N\_CNZ=]D(C=^I)AM63-J;%ZQ[NU7K'<^
MFK04P\\,1*;<T]:C[1%D1SQ[+EOF(+$<]AYMLX9(D4WG[+L3H_T:QU&K>ZBN
MUXO7?NU:.X)&GI "'L+?CALG9W<95FHES?EQ21I"ZV&=?,+T]'!9*FHXYN=D
M&8XE,K7B6I)).[$DG;R=R3X\>3Y]-MOPG9:UKN7N:QK&"L6M+%V#*I1B6)8@
MH5*DD@J5(.VTE18I34\[WCU7(]6QIEBWD;F\2F/&</#"6P9$7T<$UG:A>R,9
M6FTI^H#2HZ;1=0>P@<XO!:+0P6U9<+,:>SB)UR-VL(3-FUAOBM.7Z\:FN=DZ
M+[=@/*ALJ2UWM;9AM7W[+>1>,8KTGN*GU_+$Q+7A6JG;8&)(QSS;T#JLLN9>
M)'K48<XTB7:]*78%OPW^3VK4&G:S%UM32.Y]5UKMO3-.NM$U]V7K<9HB*%'W
M1 U2\6^]R0CIY+3M,,)AK+(5DTBG>L0M;K1SKK]?K[_SDDDA0=OA&PV50=N1
M;XB "QW8_$Q+<=EWXJH%8&B]EU31\%UGW7X>=?JN6ZM9>,+;,YY"Z_1:U?RM
M;RVSXO4NNE:N5L&&*:"K5IVU#;D7<+"J)J;KMGF8V,E!7W%13V%<2)(VW>3_
M +KQ6H-PO:;[JP/8+556M'4E8W<FP:6J&CBAK7M>%OIFZ.MT%<B=+7/K_2IN
M%)@ZA-1FPMOZ\57=:@SQM'O5H>MDG5G4(FO+!YC?(B;$=73:WL ^FN6#0M<N
M%4+VKJ'6U>9[<;<<[+W#55G@).+JM8V&9;:TBFP$(S!!]:2*58I)NSB[<>:C
MJP\S!1:)<GY+M@W> [?]6LC%.08FJ^F/D@[0ZQRX*+*QA/9;6.GJK6Z7(/1L
MF.5%2\GKZI7ZYRT.*='DLJ_-'.O"O-8REM$JCD^]OE#INMYO:9W<D^SJJ72[
MQS=VWJL9UWT;'Q\_8.V&T8;7MSTZ87%4D60%UY$P3TE)+(C'1+N_8%@F"66%
MCQBHPY(!WWV^1V_6_P#S,NNOEV[/ZD[/'.[-[('0S-:[@=Q:7M;IL7H6H1$/
M0>N&@]3;1N6E9V+VF?2EVN4D-L,U6/L+LLFYGO7!QUO](,PT/ SHDHD_K]??
M(_=1+)V7Z)]X875ID_*ZNTI=V/&K7.[.](ZMU&U3T;N'9/7[9%RA:&<W=@9N
M-JE-W)OVT6>#ONSFH(R2K+CT.P%,U\Z9P:\@_KSM_F)M36?>WL'VLN5-ZY]F
M^QKUBA.R&C_)$+W0ZIS77JJ4"+ZM3FIZ%;%:_H,%?"*:';)-$#$,@VO*BK;.
MV9@R-"G)B:=#GHX9*)]+GC<O]_VKX_>ENR-ID&G;$N_6+2MDM\I)97F1FYJ4
MH$$238)!3G]2SK![TS9B\X3A9![BTI2G.$X1)K<1'$1Q$<1'$1Q$<1'$1Q$<
M1'$1Q$<1'$1Q$<1'$3Q^-'O^7V(^3V?'\GMQ[_9Z^[V>_P!/=[/=_5[?7T]?
MY]/7B)X)890O+B&6DN*RK*EI;0E:LKRG*\Y5C&%9RO*4Y5G.?ZLI3Z^OICB)
M^('':]<M,,MYRGVYRAI"/5/KG/MS[4X]4^N<Y],_QZYSGT]<\1/Q(PR%-K0.
MPE;*5H:6EIM*FD.9PIQ#:L)QE"5JQC*TISC"LXQG.,YQQ$\DCL)R]E++2<D9
M]Q&4MHQE]7MPCU>SA/\ >Y]F,(]5^[/MQA/^6/3B(0RRVUAAMEIMA*/C2RAM
M"6DH]/3V8;3C",(],YQ[<)]/3/IZ<1/UIEEC&4LM-,ISGUREIM+>,Y]/3USA
M&,8SGTQC'KG^?3'$3U_4%PRL; P^!W,JRXQ\+?PKRO/N7E;7M]BLK5_4K*DY
M]V?YSZYXB>61AU99RIAE61L^H^<M(SEC/M]GJSG*?[K/L_I]4>W/M_I_R_CB
M)H3<NK:'<[QUXOUD@&S[EJ/:IDOKRPM'RL;(5TJW4&W4VT,)7%G!(DXF?KDH
M5'RT#--R,&<MN//(CER,3%%A(F_,CL9QG&6&<XRA#><9;1Z9;;SZMHSCV^GL
M1G^4)_\ "G/\IQC/$2L6A]"NJM<[JV;<$9K>55<X67M>X8$>4VCMV?H==VEM
M:/\ PNP[[6]33U\DM4UZSVF+EI$(^4A:6"0ADQ[ BAE9PK$?,?P/^G^\2SI3
M#*O?[F6E?)[,K]S:,^_+?_T\K]<9]WQ_^CU]?;_Z?3DQ*6(_QL=-*Y-=D516
MKK"VSBDWO6L-'&[JWO+0M(HV]3V_W=KFKX*6V:=#:F#OC", 3;FLP*F4N)4[
M#C$#Q3SP:T2YF%AHFN0\37H"-"AH*!C (:%B(T=H..BHF+%:!CHT 1A*&10@
?0V&111V4(:88:;:;2E"<8PB=GQ$<1'$1Q$<1'$3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g773514g90w00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g90w00.jpg
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MJT%45*>9+D55*-31-1?,DE\2>.F&;!Y9%8< < < < < < < < < < < < <
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M>6Y4' ' ' ' ' ' ' ' ' ' ' ' ' *A/,N)KLCU[K-S/?FGKX;>,;5KN+"
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MS/U47^\F'\8W_F< ?51?[R8?QC?^9P!]5%_O)A_&-_YG 'U47^\F'\8W_F<
M?51?[R8?QC?^9P"M.^^OM;S;ME4[HY-+(^#:X>P",A9A[AF8$<!<U<)JYQ']
M8.@%.L<09N77'(*2]M'MV*4NW^/DUJZRNM[^@\!X_>679?BT*-OPS/"JO#H6
M]2KPRSKSK1XE6XG&NKV5:E4]\=-3DK1UU-VRPJ37*L82\LJ5;B-NYU+C^$0K
MRFHW%6"BZ$;?E[I1DN[YFDZG)CGUYL\SS97]5%XQZ?4F'VQ_QQO^7_><Y\9L
M\]28W?;730@RWWWVQKIIJ[0VVVVVSZ:ZZZX4SG;;;.<8QC&,YSG/IC'KP#[>
M . . . . . . . . . . . . 0V[W7:AU^Z[RZQQKBKT;!&ZHHUFC;.\;UC3
MN2+;94*ZIIRJ?58(=/6,,1DY?5DXL6&)/4!RS9P>9-E%=L@>WH-;!^\>J%86
MI*/P1D]+7=B."2E<BHT$ACA8=:,U"ZN@XV'V7<<;1R[1&IN22HRSIDF\+*OW
MJY7YIPNU;@21L>" K1KV=UG*,.MHU8D-D\%D6K%?#5[L"EH1\ +:LW.=%<-W
M6S @XPW7RFIA%7.BGLW]OMR!U\_(_P".NC:A\8<U!S#1]=TOC=\4M-F=C3MN
MQ%G$CEFWQUYJB4[,1D12" QS9_60,/$%T4F2FRK=JL1]^A%XJM@"3*7AVZ&;
MIH9=^.JF67Q$V>SS=*WIV[RRRKK#<O\ *>OL0^;^0R6F^4ONA\[^#1>,?+_B
M_7("'HFUX'J*3E%/9R2?HV='Y*EJVU9HN%8(-SI\NFINX5D)A+7./@I;?$4]
M[KVI^[?;?7/KMZ:^W&WKG&V,8X;3[2\=<(M\1N&^6+?Q4T\XRV_@QKZ9W>>I
M^E5S[(/9I"XKQCV.X6HPJU(I9N%RI2:BO]8VZ+799U/E&TE5Z'S(O2*LRK\?
MG95U\U)B&[]'5[E\Y8Z.M&N[?1'135)LDVSE#&WP%<[[95V;;[+>O\I..Z?Y
MQKZX6.:":\W^CUSIX/YEO'V1>S1? ^R7"Y26<\SN.;$FVLXKXVPECIZ,[./B
MQ\:'46Z^IHJ<3_I96MIR!6?SH5F72*S)@&)N60XV4;),MQ[/XJ"2(A)L*0;;
MXWWV=:$W&VWPLC<X>=,[)WES?<)C7NZTJ]9W-U#O)XYN6%3$8_"DL13PMGC!
M\?>W3@'!NS7;RIPS@7#Z'#+!<&X1<*VM^?N^^N+=RJU/TDIRYJDDI27-C.<>
M+YSNIX"HQ;): K]6.N%'48.",CJ$P:.+7GCC,D=/_P /K"7F,_27_P +Z2HF
M<99TUSIE1/.CGTSEQJ@CV[L%QCL+PNCQ.':_A-3B5:M5MI6,X65.[5&G"%95
MX-SN:'(YRG2>,2SRIY6#@?$Z7%IUJ,N'3@J2I5(UH3JJEFHYP<)+]%5YL14E
MIRXR\YRBM\]_1\KYC]@5]7#@12N"%C,)H1':HV/-%&.=(,T!O'V7SK>/ZKME
M-$SJ6&FK=-75QOA?"N=-=$=E.JVG:;V03X5Q>O1[.5X6E"KPV-Y2_>NC%U95
MJERK5QIJ_:FH2A4RW*')S:<V7C"U*?:%75K&3HNI*-PZ?\*322C3Y\MVVF4X
MI83R]\:,E;UT_H[<T@5Q1&7W;5=%V=68-.1NI% 4K5G:.TG7WB9YO'QVSC()
MMAJEM)E@RB[SXF_R:6F[KY=WA'9LKI?:CM'[*[S@'$+7@' *UIQ>M3HJRN9<
M,HT%2J1N:$ZC=:%[5E#FH1JPSR23YL/">2_MJ/'_ 'JV=S.FK:-1RKJ-PJCG
M#NJL5!1[B#_TDH2TDL<N>A<G$/%!TN@LPC$UBGCYIT')(;*PLFC9YM;TT7="
M"L=DB;\*=0:NFJ[99TPU8L#B;)RFLANZSD8ME71/9PKQ4V0N$_+@#@#@#@#@
M#@#@#@#@#@#@#@#@$3>\]C2.H^I]TV/$)!B*RF,1MBX R/+2,.] Q)](@PIN
M_4S-$G,4'I);/\_&.2!B5%QY+;<Z["FDQV13P#5_CG[5Z]IJ6)%2IX3*)U"I
M:>!S2019@.90DDX)&BQ@/I$<LWZY!R-!C%DXFX?R@-#I0;)1YW)WD0%"SX9=
M^!8%P"KOS+?ZO2V/[RNJG^;:C> 6?./][K_]"K_Z-N1+9^C_ "/4/UX_SH_F
MC^9F2$X.QE41E;1OA^-00^/NU1>ZI9]B6^-\M7'^PK>F=<>FN_IC&?3;&<;8
MQG'SA3:5."UUIT]OYB\T?K??)2N+R#>.>M56<*6/CET>CZ:/0^QDR=MR!%=7
M8?EHNB.39X;L_@/L9:HJIN/GW&-\Z.=,[[:Y9Z:)IZMD\[IXQGU]V??-EI+;
MF71=-.GWZ8UH)MRZ<OP8^'$LK.<O+36NB26#NB^#C_@&1[^].V/_ '+SK_8G
M_8K_ .NO?_:CX0_=(_[RZO\ V#@7_P C+@>;<<$(HVHN@EVJZJ[*K))ZZ1GL
M1KOG=333&FRP6NM$L;YVVQC7*F^VNNF,^F=]LXQKZYSC'-FX9&3[-=I\1;S7
MX!C">N+CB&<>..N-NICZ[2XA8:_\*]^7PV[U^A*[FLF0' ' ' ' ' ' ' '
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M ' ' ' ' ' ' ' ' ' ' *N_,M_J]+8_O*ZJ?YMJ-X!:'M^6?V?;/WQ^?Y<
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=-$DDM-4T]==-<8P!D/ ' ' ' ' ' ' ' ' /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g773514g91c19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g91c19.jpg
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M !<! 0$! 0                 ! @/_Q  S$0 " 0,# @0%! (# 0$!
M 1$"(3$205%A<8&1H? #$R*QT3)RDL%"X2-28O&"LO_:  P# 0 "$0,1 #\
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M5XVSA^IK2G/HKW)=I;C7FJ1=.UU0TMG%J?0"(6GUB0IVO7RME8XXE[8#$HN
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MB2N3H\!A]&3@01*/S7G[@209K. XX,\R6;O?D=/EU:-=HS&\<^__ )4QV?\
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M3 <D@FS<OAJ)4JW: BH4V53M-H;2>]]GGMTP;9-\)=+7O\ZN7^=[;ZCGM==
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M!6P;DLI4\ZL*B:-:&X_K/+(7FV;-@QS25-C\Z5960@)CKIHPVB);]N<Y;,'
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MI^9R \2ELD(I1@*W82 T3"MF6C<8EML,U9?XT^EXC8FOX0> I"^_W_8_!/\
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MD3KZ4%F0K=^\>G9*2;LF;P_(3AEZ3/2$RJP&C!FI(V3?O$10L8*063'#F39
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MAZ%Q-Y&:B6,R,S(9$=*$A]<C=T7QE= 0F+%M!@Y@+0W]2VTUN.L>9Z</#F/
M/ / / / / / / 0Y[WXMKSZ!\MV-RU9AV116/3O]@?M)5%-VO[Y&Y%%#X^2Q
M\NW:OTUAY-LD2&HH$Q3U/"9 6X>-T'(Y]NT)LQJFITM5*)4YQ=0:]^9OSNK7
MYD<U:\ZUK+Y1/T2<ZD%ES"9RM%DQ?2"92(: !.G+(,.RHS B6H&*Q\:R%I.G
M^^N62SUR^=.WJZF0KJ=;E]DN$6$>&1X"E/ZG?$:C?J?/J<LFP;4L:JI/58AU
M#WZ\*: BS>70)X9W/;A=FIY)1$$=8D7)+<5)&^CY!),HY2* C&J _P#1#='Q
M*J)B+\[/DN$A$/!UY"XA (P@LUC4'BX"'QYJX<JO%VP.,BF@42@N[7VW7=+(
ML&3=-5RMMLJOOKLJIMG?;;.1@RCP#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P#P
M#P#P#P#P%(7W^_['X)_YE\B_^WA'ANC-7[*_LR[WPP/ / / / / / / / /
M/ / / / / / / / / / / / / / / / / / / / / / / / / 1HZ1ZZHSD]
MG!'-SG):Q<V;(B46@8&!U7:=PRV2F@P A*2Z(Z'5%#9O*-VHH +>DR1)00F-
M8MT<9<NTME4M=Q52ZL?=+[M%8OWA,LI%P)5D@&X>8''>M^-3+#!$:0#D,,B=
MI@GK7#\07:LBHIYA!=/#H:39-"#%?\;5ZU;N4E4M!JC-7[*_LR]'PP/ / /
M/ / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
M/ 4==O?/#H"X1"*K$M'.T32Q>]MX&OTA9)7GPYRJ[MJ(-@,-D-*2#G6OQXR4
MB($6:-7IEA:,;E<\<,1XMQ#)H%+Z%<EAM5);193;5JB<R[3TMFQK+Z4?&R?=
MFTESYH/O*RI)T3547YKK.;E#5Q2F$U-/(_69Q4E9=HO8:P$GD5K>/+%CI8))
M7.NS])Y^SH*NDOVY-?(M->ENRAS"A.[5N+<Q!M3_  &.9O\ 4]]&/]YM@?\
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*X!X!X!X!X#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g773514g93e09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g93e09.jpg
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M<G5YE[&X(2(C)%23)41256.4EM+3U-77)S$V0U%BAO_$ !T! 0 " @,! 0
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M?3G$[F\U.>[+=EFIY=+/ECA0A&:;JY"B1R_-1-9RR ([&GD=D)8]V[!:Q+X
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MG$Y)SQU\C343O\VDF/#[Q&4HN3F1C'6Q=4*0.3M2R:5=,W-:N4-;2R0V;SW
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M,$L+S;4TT6UXL<*Q.]7&RM[6FCN*;2UHL*:[2FCN554U3E!>3GZSK0X X X
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MCA&&X1;W"QKQ'%L/IL;6]WVWL+>OGX3?KC:6G.LZ*$J;6JTIIYLTTIMMZO\
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MGO8WP@38\L:;ZE$?:<>[WG9'VT<>FCTW8M?5Y]J@XA1.KF7.>70MT$K?!B.
M1[4O\99OK\W#Q_?M_=/@R?O:?][M)">#$< \W/S=_&>[2?G '_5P'\I':/O]
MBOTBS]$NYZP<B'S.\G7B6_\ WBQLBCYPI:!R(_?4ORF'ZW7(JT?4^P^EC\+9
M>$H_61ZFFA?P&]-/FJZ]_5*)<O7 ^\N#^*\/]$L3R,Y6OG4Y2_K_ +8_>'$3
M+#G*%?#@#@#@#@#@#@&-.W)EB'4(?XK@!-8$>7CI(!23> I&0V2B!IH5B9 P
M3*K$H4>EHPSMJLF3[W'&F@*#H3!(0QTMU'^X&D(M,S\*]N)*UUCRQ]NY]9%E
MXM&( #7/;;T CNBM>ZX"MQXC=:_^+ZT?'?K;6+.G&ULSC&?,L[B>HY'-C&#Z
MPNQ-?H1D9^?9H,1-O("S*#9RI%&/;V_'>95>7)O6I5-O?FDN&\G85?L4'3=D
MN]:(O7>"JC5HJY13=.4T,T4UE&[?//I5;!%1PA@KFGAEBGFNCCGWUVKAUD,#
M#S<G5E'95G0,G$1%?]GM'[/:Z7+!EIHRSRE!X+K>]JRLNTX@-F&D'-R47/F0
ML 8Q#5LAU&1\T^2C8^<EHZ+R7>("4XGI37G32\TD;9GXU]IW5Q'=EU[*U$(B
MT5L#![*#54*[ ['3X!L7:4'N&*;(1I=98V<B9S"ZR$T<#Q9: YN:<8V9 S)2
M9?9*H/1 \,CPLT?Q)364MZ-/)9+-1KGN><9KRG5VEJ1;^N&NWCI$R/8XC=P]
M8;:Z&C1S20F,5JXIPD.Y[<* )I8EC2XBK;"\$6L%(E2$..-F9L-PKN&%(-=\
M),UWTRS="93;RUYS3SE9/+6(CH\IL#<& X!B!;52')7N%I];L)&-W(+40CL_
M%'4FI),&[B,?69 5@P#TF\:NO@_DNI!R-3&*ZC!NNFPQ;89O<D<7"':@G<^M
M?O\ Q,O^"!P#5D]E(?@1U:^4>P/H^-\K[;[X'"O#WG]E0;I^XX^/<HWBC9_U
MG>32RY7!NZ. ;N/L7KX,NP_RRPWT11Y96P/Q7$_IEEZ-9FB_NQ>_NP/U;Q+U
MW>39WYWXTW' ' ' -=G;TLN+K>V5GQ,S,>XX-LO4R#KLD$K4U8BM5:T&9HC#
M$;M&]S!,VFVUPN;$+(Z;E<:R2AX69E9=B05JSK-Y!$;24<*#-)-;IAO?SF\X
MB,HX]3G1$G6VFN!>:FE?;(4]LVTU0MZI T\KIW8!/7PM:M:D54V5,!$\1BIT
M&%1&&)X9M2NOP^;&B6',QV0BGK=\R=>^T?+*L\!BGNB4W,=.>GG\I6&EE-CU
M-U:2(Q]VX;&F-D6B9VQ;UT(X"K%J<6F7>]B,TYCAX*7<C0A#0\)$C@[ BL<Z
M>=Q$'#QV#Q_(OE',@Z!N=T0DE[=+S?69><$$?-$?&(^07Y+]'?V+L%P3N76^
MRDD&X(*7*'9JT0:9!8^+3[G-53I\D4&$L((-T.L.NTE&CB)!S=1XKFIZ6*B*
MS9A@EAUUGBNKEEVGC^JZT7*NJM7V\7J[TI+F.ZW.RO=554YJNFUOUR5"2S52
MJM&WDZ5J?&VJO%*I_(65C:N7SE;6]=@DMSI=%WO#J<ZIJF-9>ABZ"PQHG<]\
M6A TS6,?8TYC5U36%..+^/G#0@BJS%WQ^"],(I2BU8^-QB4;W(FCAPT:-'<B
MNIE[NR<I,X_/#E;?#\$L+*Y6M6)XI4K[=J[U0E@MTFBFB^7NYNFN<>CG.NZ5
MUJ)7-KISF4OQV=ZQ"UKM[-72YK\WME953?[:'5586%O-,8;IS;:E9P^<JLHA
MO,5#)?)!')TFDBYR23R<)(+9N4$E^\.NU4T7"B#51=+!3TL4ULVK;-7#KK/)
M!'++M/'@:N:JJE2VZ9?-=5*IJ=,Y.JE55*EM0W2JJDGDJGJ^14PI23A2DY2>
M])M)M)Z-I3K"T.7D$GFY^;OXSW:3\X _ZN _E([1]_L5^D6?HEW/6#D0^9WD
MZ\2W_P"\6-D4?.%+0.1'[ZE^4P_6ZY%6CZGV'TL?A;+PE'ZR/4TT+^ WII\U
M77OZI1+EZX'WEP?Q7A_HEB>1G*U\ZG*7]?\ ;'[PXB98<Y0KX< < < < < <
M M;>1F7UQ2MO6%7H*]L\]!*P/3$)K6-S6PD;!+1D5E9H<"6.;9%RYQ=E,PR9
MP;?MLV<N>E7V'N=LX6]!',2LVE,2]>'21_\ C-W5N_;]M:^-JAT"E%5SFQCH
MVSA&H+PI,5+"AS:M[C;X;C1&]^W!&JK&U>$4W8[APPE9+WLPMM" (TX<BC'<
M2V$U)+3?NE.,D]5U\%H1R^0NI W#R6@!M;EL/Z "+5=42#05KV)K@3'<9-3H
MF;!)O"5506QP397O13LU+&01#RB<';P!"QT.>.)D[''AHYDV,?$B:9AQGQI3
MZ&I:B6ET/+H-FS@P' (^?(U^#K6S^L&T#_Q3UIP2M?)5V,D&X(.!TATZ;.&N
M2JZ'3E!9#M9JMFW<H]+)Y)]JMUT^^LT%T^LO316P[ZS34ZQSQ[Z[QZYE35S*
MJ:HIJYM2JYM:55+AIQ52\JJ7$-/)J4R&N<FI:E-2G#4J)36C6Y[F8TF@ M#D
ME1QT?8MLHM"NPI* G$\K!FU>W46VJBSBA%##-53/-MEC-#<0Z[6;Y)+98-LV
M^6?;===-3LERO]-M=L6M+3#L)==UP^SO%@_Y/L5S+6K%<,NKJ:22J3L;S;4\
MVJ:9J54<ZFEKBKQ=W1:W*FF\WQ4VUZKL[1?G-H^=0KG>[9*6Y7\Y94.5#RB8
M;3OP,#"(NT<-$9DEF\7#CW1VN3SKZ?=H]^KP2]2W</L\U$6_M8>GZG#OK#UF
M6>?M>EEWS@KS>7>JZ:W8W:QYM/-YMVL*+"AYMS530DJJLXYSSA);CD;*R5E2
MZ57:URYFUM*K2I9)0G4VTLM%E,LJ7GYCZFK)[*0_ CJU\H]@?1\;Y7VWWP.%
M>'O/[*@W3]QQ\>Y1O%&S_K.\FEERN#=T< W<?8O7P9=A_EEAOHBCRRM@?BN)
M_3++T:S-%_=B]_=@?JWB7KN\FSOSOQIN. . . :OVR^N@T">2QX8UWI[6_1G
M-7-K>:UM!L_'JE< KL2H6%(^OL#<YEMIE#24!KB;54NZ)2'M1O,@R[.8%H>Q
M)V*L*0-_0Q'T3?-CG.(>7/CJ7->JTT7'-$H'E5@LK*H#JI6P <F$DH25];S)
M:,U.)]O:[<Y5-;E<R&0<<51!E@8P+LBG*6P[Z%9F9[0<BL87DR+3-45Z<M1C
M2X<]:B>:\T]_M]I7WC3BI*&UN[9RM:#-4.OM@%*OV*B>F<GHG$]I9MH7K"3^
MT;+&Y^[[=/.\<L%C+W^Z2(.FZ:&#%M[UY9+!4Y>_RU<Y^>$2!\&)'S1'QB/D
M%^2_1W]B[!<$[EUOLI,J;^MEO0](6Q=+N$6)&M6 !2>.!]N^PC%YE(8B'4MG
M&HR*K5ZFR4>8MNT,'6;1SBCEGUGV@IUCZ/?+X!A-6/8WA."T6]-VJQ7$+K<*
M;Q59NUIL7>;:FR5J[-54.M4.KG.E5TNJ(YRU/PXE?5AV'WV_U6;M5<[M;7EV
M2J5#M%8V=5HZ%4U4J75S8ETN)F&:_G7LCP6[ZZ[ZU()O:[Z]OK_XQ0__ ,N_
M_P" Y?W_ )<[U_\ 5MV__3VW_P#0*\_\2J7_ *DM/^OL_P#XQ1XS[(3&A^:L
M.6SU4(W6)P8,BE)#&VXA+*.3:  ,%=LU%.P13ISGFJ'J2'2^.*..*;_!OZOO
M)ODLK^R\^Y]O-XL</LEM5=Z7<;G7=74\(M7^4==_OU]YZ7Y^N:DKXK/FMU9V
M;JF*N:OA9<HBLK2]5_R-:/\ .+>FV2_/K-<Q4W:[W?FM_FSF78.J<LJHC*7E
M[J1YN![:O8JM=?6FNDZ#N['=$;5 I=V5&SS:*R'@TB,,\E8IN'QBKOITD/9L
M<>L7S?U2CK!?OM3%+M+/J&UO(G>-E=G<2V@KVBL+]3AU%VKJNM&&VEWJM5>+
M[=KFDK6J^6JHYCO"M'-G5*I=.4RN8PC;JG%<3NF&O"[2[N]U6M--L[W1:JAV
M5A:V^="L*&^<K)T^^43.<0YT^4:=_/-S\W?QGNTGYP!_U<!_*1VC[_8K](L_
M1+N>L'(A\SO)UXEO_P!XL;(H^<*6@<B/WU+\IA^MUR*M'U/L/I8_"V7A*/UD
M>IIH7\!O33YJNO?U2B7+UP/O+@_BO#_1+$\C.5KYU.4OZ_[8_>'$3+#G*%?#
M@#@#@#@#@#@&%GD+HT(OW4&\A<VE\A;(<K:Q#L..\I*PV36N#P>KLN2&K#D&
M%82+ J)HX.6D5YIV*MD)I.;3;=ML8&5>],V_!-+::C?E]I&IX250*6+MK9^N
MNJZ#8C[&M;Q>7IP"MW:N],H">'/MV*K6?+GNU%=UM.1V=HM)=!BP"1>+DVD0
MT \9J=DLIDB4R<#*K=FWKFTEPX-E";?1NRD)Y)I"VJ2I0"*E1Z0UQ .BN$UE
MC-B+D]Z3/*/>OGF-B2UDYK:YBJ<7%V'$D9$T!X,;$EX^NBLJZ(DK#3D8P2H=
M,2][><4Y=$=TUN4]'0]CG@^8X!'SY&OP=:V?U@V@?^*>M."5KY*NQD@W!!K6
M;N>:J_\ 6/:FX*%#:HIX@&ZYE1V/C9DFQ->YM]A,A0T3KYONXHE8L/22=3:[
M=+W.T1Z]SHH^GUDIZ>>6R.Q/(M@.TVRV$8[?,6Q>[WG$;&\6EI8W;\R_(6;L
M;[>;M2J/RMWKM(=%A34^=4^Z;B%"588YMOB>&8O?\/N]TN-I972TLJ**[;\X
M_*5?E+O8VS=7,M::<G:-*$LDIS,,IWS\[-S\H%RKFF*(16"25T3L$T,; ]4[
M=NPXL#,V[SUA9GG[GQ8ESUUCZG))7W6V:^WGVCZU)3N5AR![-6%E?;*G&L<J
M5]NU%UK=7YA-%%%\NE\55$75+G.NZ44.97-JJRF&N&M-O\7M*["MW+#4[O:N
MVI25ZBJJJPMK!JJ;9Y<VWJ>4/G*G.)3J/+V1%M-CCEEW2% =]8X]Y=]=8V+[
M?M==>W_+#GYU[GG9AM+^7,>S<?ZO_P#B'T?*+C*3?YCAF2;TO6[_ /,;5%$G
MTE:M'TW:,PS91TO9%55X?2L?&>OZC6$D8",.0OF<?TZ6<.NF35U(JH-/=*ZZ
M_J,$_7+**>EGEJSCMPL\*QO&<+L:Z[2QPW%<0N%E:6O-_*6EG<[W;7>BNTYJ
MIIY]5-FJJ^;333SFX24(MC#KS7?,/N-[KIIIKO5SNUYKIHGFTUV]C1:U4TRV
M^:G4U3+;A*6V:W/LI#\".K7RCV!]'QOE4[?? X5X>\_LJ#=_W''Q[E&\4;/^
ML[R:67*X-W1P#=Q]B]?!EV'^66&^B*/+*V!^*XG],LO1K,T7]V+W]V!^K>)>
MN[R;._._&FXX X X!JQ7#,$,9Y*57.TK'3\E-):R]>F\%TC?7D>>Q.O4,YD8
MB%KV#>30%KBSUH B:QUDVAG !%KE0]T0G)"XRDB.0&B:!]R1GP7G_@?10Z<E
MQ7]&6XEZ]TUU=I-/O[:=MT;52]HUU<437:#?"+"HL63UH=['&IQ9YJ>!$>%-
M!.$2O2DF'664.B80+N*EYN.BNE2)F9R99"1H2\C""3&F)S4^6,H<[GT/R=)V
MGC^N\IOFCI(I.+0:6L7PI],#<Y,-J&=ZZ*0_78^+%$'"N@!Q;%U-W/;D7*(,
MJCRB,/7\=.PA/%9ILV*[=RCV(<3DH362F?MR,XN""/FB/C$?(+\E^CO[%V"X
M)W+K?925_P"0WX">WGS>+7^ATKSN/)[\NMD?K#A7IED<%M-\G<;\5WWT>T//
M,P_B8_S<?[NN>@YKU3HNI=A^N"22+Q!_&1ZO?TQ9?U)V5RM^5[YN-I_ X9Z[
MPP[!LG\I\&\->O5][-];FAYL >;GYN_C/=I/S@#_ *N _E([1]_L5^D6?HEW
M/6#D0^9WDZ\2W_[Q8V11\X4M Y$?OJ7Y3#];KD5:/J?8?2Q^%LO"4?K(]330
MOX#>FGS5=>_JE$N7K@?>7!_%>'^B6)Y&<K7SJ<I?U_VQ^\.(F6'.4*^' ' '
M ' ' ' ,-=_KE**+U-N8U!1Z3*CE0%,H<0A1ZTZ[IXORF7 81O\ *<#C*SU?
ML90GPV,C)$VZ;X,"":QBAR4D886*'T<G 2 FF.<ITG@W]BS?D,&/$]*29E9&
MS%@S#NTR:2D0;7L56-KMW/U?VKL1RW'IF^)=L*(P>J4M+!%<!$"N5/Y6!?$?
M;$I,)TE+D>VZD>,HJ8#*K1+<IC)KAQUT]I,7]]M=[9M/RS:Q$(:(-)]BS5&Y
M2/Q(F-3ZU9.(^OTXF?/),&VE C//;FYLAF(?,79)3*]</ZD99.&K-_/MLW:R
M/ I?<M2_-SET9/)+-YS,DIGD!K^V3"+U=GJJ*;A:9 NZ>I,T: E7=XXPQD!*
M[&57B<R]G^]D&\*78," S<JF95@VGH8/Q8NW\T;LIE"#B%(D12UG,9TU:[GS
M7$=,P0GSP/NSE9MSKD(ON6]K_.]%G>YB<*TV$>,[%JK+R9J3U=):T,1U523,
MH*,T6]",+XG5]N[F,*^[2!2%HJ7X90/0R[G+33+1Y\Q3/75QTURC/(PD>;G0
MFIOC'#[CK.'6%<-F_'VXL"Q;/N$P2V.'B'';<;R"Q(EJ63JN80()1J%I 34N
M*">ZHHL1GGA%A-#KF6AU,Y@1W,U9P^ZA)9-0]\Y<=(-BG@P-!SRV?&.;2?G*
M#?5( <WTY)OFZV7^BWWUMB!K]M7\IL:\/=O0+J1U<L0X XUOO2OY//\ 5[Y-
M.JZUVF-?O*OT:NQGHV:;_!#U6^;?1WU8B_/.G;'Y7;4_6/'/6=Z-CL#[RX/X
MKP_T2Q-?3V4A^!'5KY1[ ^CXWRF]OO@<*\/>?V5!O/[CCX]RC>*-G_6=Y-++
ME<&[HX!NX^Q>O@R[#_++#?1%'EE; _%<3^F67HUF:+^[%[^[ _5O$O7=Y-G?
MG?C3<< < < UZ3>1\6&\-P'DY"^4<YJLPL@OI9F846&;*UM2D81V97F(YC6:
M?586*#]S)6>L)2'&V,HU04GY!,BAHH0G&S=X/L1^-&?=4I33QAM;GKGP_'+)
MF5'D1J Q5ULJNGE;N&9BLITAJNB"F%OO61SMG8EV6":G(2+U:3+34)?&MS05
M)!XAP6+R$K:XXN4ET,R*#6AI*%9L9(12U+;3G-J&E$2WK347'\68B.UAKT:T
MO YB.+NC[_MBJRAD'44ZH!@R)!]Y$NU7#D7?7+?3TE5)8B4AS2+/']CR$F0#
M!,/MY>)'I:+?0K(*M=^:34N=?(O-'V&2A1MU0(9>@UKB1F4FPM8L6@6,4PP
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MEE%XJ8R*=5Y?Z2IW<7DOWZ%K/$5!2PKJE)"SL(Q#1\=N2QH\#>_P:3+4M6P
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M7WLWUN:'FP!YN?F[^,]VD_. /^K@/Y2.T??[%?I%GZ)=SU@Y$/F=Y.O$M_\
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M>*-G_6=Y-++E<&[HX!NX^Q>O@R[#_++#?1%'EE; _%<3^F67HUF:+^[%[^[
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M_18HS]Q.!+XOSLNM4FJ&K5 S<D2T3K50-*D<S%]P<O/U)3E=UQ-RL)D[;/\
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MND8H*8TG-[BVI%JNR 0ES2M8XDV+*YW2S6-Z^$2B?9/1&IJ<N$XF'\4)R<^
M#Q>" \#$3\E$0T7D]$.K6'JDM^>2EY[Y7F;W$VW!B. . . . . . . . . .
M . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g773514g93s80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g93s80.jpg
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M 1$  A$! Q$!_\0 'P !  (#  ,! 0$           @)!@<* 0,%! (+_\0
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MHUNDEFUVX0MWDMOU9-YF_6+*TD[32B,.+63)%DYE4DD+3)H^F:ET?4.913<
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MXB;/C(L!\^<8SG&,Y[.S&<XQZ>>V5^0]C:]LM+\+F]AY['T%;0$<4 (QC-+
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MM*U9 W2%#8.L(4KVSR6QY3(F5R) ^7.UO1(5;2Z(C\D.C<B7IQBR0I2DF@$
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M'.X6"2V4F*F[PTV,KD212_\ C%(2RRCCB#"+674/  O?OHJ%EA" LO9G8,
M Q@(  #K#,@A" ..S 0A#C&,8QC&,8QC&.SNX17*\(G"+D,W9]WEN1\Y%:^;
M'[VRD.WXL^?'GSCLSWX[^[/F[V7!?::FR!_2BGY:BJK+=?#.W805[Z_0O_\
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M5-I?!&O8(;!IM%%TA8).F$;I=SI71B4;_1EQ;O9V6"?LWA$F*>.'P2NK0XR
MFKJ_!VSNIC2&J91]-X*RJ\%)@\(9")>C)\JYNONIJ"K-%5T$IA"T+4E;5V;"
M1,$:+=W XA0FKUP0.T:;GU6L.5+WYN*=&MN7N*=R5'Y=U"0'JF8I+,4%G?)K
M:AU1-5.<#43B7?D+6W!G:YDCF  -C):]P&Z!NWNVUA:NW!,/9AU%A+(WMP^@
M-'T%,)7EI;0/CEIHYGN+I)V-EBCDD;(]W3.:.E+P7!WBFZ#K:A4DJ0UPV.+>
MGF4B]<CSAS>W-['A44WI6I"A0F.2@\2)H:FU$F1-K>1G!9!(,Y&(TT8S!*JM
MGK3&Z=S28H^C9NL:P6+BYQ.Z!=SG.+G.-R3RT3"<$P_!&5+,/CDC;5S^$2])
M-+,=X1LB8QAD<XLBCC8UD;&V#0,[DDK<_+1997(=-OW#FN?^)*G\Y'WG=J'W
ME1_O6G_(L7@3'?AS&?X5Q'^>3*<'+I8I.$3A$X1.$5$I/5*V2>5DB.CU#4?A
MD;9I/8PUC>;7GA+JI10V:O\ $B5K@G15FI2)E2\+)Y::F3J5!*<1_B0*#L P
M8+5JS:B"CJ9Z9U+,]T+S&7->P!Q'$ YVZEU7!?8JQ'&L*H<5BQ6BACKH&SLB
MDAG<]C7$C=<6^22+:C)?IQU--JL^:B-?/]+=C]_=V_N6?E^/EM[<:;C1S_AQ
MCYUD_P"XOBO[=8?_ !%3\RLDTMV$D>SU"M=KRV)LD)D1TYMB$.C!''Q=(F4I
M16-GRVNLKF]V<VEC7'D.P8R%TP4H;$XTHE>4O:=@K!P]JI*AM7305+6EC9XV
MR!KB"6APN 2,B1U+D^+8>_"<3K\,DD;+)054M*^5@+62.B=NES0[R@TZ@'/F
MM3[X[%W_ *U0UYL^NF>E$E;02OGN5/[U;2^3KGFRK*&\M#/76O-91B%N*!\1
MS*R#U2U&URTY%+BRGU3'F1L@T@4N"T:"ORT[\N_H6/[]^_R7G='W%8[L+([.
M+2J87!T:&UQ7,2T99JQE6+41*E4TJS"?Z48J;CS1HU ROZ6,TD8@?L<XY*+Z
M_"+EGZC?]L$=,KYOZR_2U>7,_1? U?\ ?O\ R<2Q%7\(T78/QW+J8Y@%ETX1
M.$3A$X14V=1/W?W17_";V%_DQS+A%<GPB<(N2S<6F5M@;T[DO::U)]"0$V;6
M[?EIB[?6RIO-$1K31BC*XTR7P&4.6%1OE."AA*7EI,%D%9*3%FB.,.Y1MOA6
M&5V+Q2UE$RHE;0Q,#W3U<9W!-4$-W8*B%E@2XW+;G>S) %O5'L*8QCM!LG50
M89C%1A].[&ZJ1T$5'A<[72FEH6NDWZZ@J9=XM:QNZV41@-&ZP$N+M"YU@=<X
M]T+</OY_K-1O;[W?G-.]_;GLSW>?Y?-IOM>P(:87&?\ 2\2TY#ZMX9V^-=?]
MLVUQR]L]9S^#=GR>O]9_/F;9*%>QTL)H"SZWJO-OVK('V<-8),Y*GAZUX@K8
MR1;,O8X4 Y*YO-(*&I<^*'-[,/2M[LXQQI\C:EF%<@2*E#>G4Y2BV+P2LIYZ
MCQ:QK(7;C0R;$YG.D,;Y2'-;7;S6 , +F"1UW"S'#>(U3'/9/VGP7$:##CC]
M5--5Q^$/=)3[-T;(8/"H:0%LDF".C?*Z28N:R62GBW8W!T[7&,.^#5LX?; F
M9$%?IO=5;NX["D[ H',3:5:DB:$1YN2@#)1G/&OC-DZ1N$O>(["4T5185)53
MNY+3&R0.13.X!*FHV*P"&,RLHX9F]#&\=%48@2)7N<>C&YB#O(;$R27I38AC
M6[T;-]I5+#O90VOK:H4DV,5U!*:VHA>:JDP&)K:2%C0*@F7 8MZ9]5-!2"G9
MOM=*]YCGD$4@;/0.L#IZ-A;B[LX_]2T;W]^>SN^X[G'G[,8[<_'C..SF*]KV
M V(\5Q:C_&L1Y '2MY=E\^!6X>V7:[/_ (S5G6/%NS_5_P"Z/5PMH++#[#UH
M=$T G*H5_P!N*0IH=)S\ISF:D\$GX*9%QN23A$5$2>$LW ,ECR2<2=@ LY*,
M+%X(L5J?9_ V5$#V89&TLFB>TBJQ#)S'M+3G6$',#46) )'.SQ':3:U^'US'
M[2U;FOHJIKFG#L  <U\,@<"YN$-< 02"6N#FYV(*ZDJ6HBR%%05*M+VUO5'D
MZM8$H*(3PW588$@1Q9I&600<KUO5+1%IPYP448I5*%.0 #DX\TSPC!>@MUM[
M[HOK>PO?G=>!M^2VZ)';MK;MW6MRMO6MU66RQ4#9(BU10MO+Y$4M"8%86*%:
MFB+58-!DLS"D&=:?!48,+SD \&X'@8,Y"+&0Y[.06-((LVSK[XW00^XL0[@;
MC(W!N,E(DE!8[I'WBL8B'.!C+3<%AWB6V-B-VUCF,UZPZ]V( ]*J#MO>H5*%
M,)&B4 @VI@3T:,> 8&E2G>QHR8G3"P67@1!(@%"\6# @9P$/9 CC!:[<9O,;
MNL.ZV[&Y7:T@ M:;"X%AD,LE)FG+7LZ:3<E>))6%[RV207M(]N]9SQ<V<X%V
M9SS*VK3U7-=,UXRUVT/;_)4C0KDCD<_R@3,)_>'262AZE[VX.6(ZS1YB+-4O
M3\X&%D-3(V(DQ&2DY"4 "\9S]JFMF\(G"*A'>WW=3Y^"G1GZ6=EN:!MSIAO;
M5^L4_?S+T1[ O_.C7]9O_$^>7?L4?><^^+AGW^*R]$)QW[]_,B<(G")PA[WS
M5R/3;]PYKGW=G]A*CNS\4C?.=VH?>5'^]:?\BQ> \=^&\9_A;$OYY-\6BF_R
MZ6+3A$X1.$3A%6HLZ76G9SF].!9UNM!CW()#(UR!FV.MYG:R':3/:^0/64+4
MBFA*-N3GN[DM4 1)"24R;QN2B"BRP! ''2X3ALTCY9:.&21Y+GO<V[G..I)O
MJ5L5+M;M+0T\-)1XU7T]-3L$<,$4N['&P&X:T;N0N3Z3U6_/CI;Z?X[?Z\7A
MWY[?=/W/]>.4_$F$_M?3?@?2JYVWVM/Z_P")9?Y;_P#E3/H2CJWUUK1KJVJ$
MKHEAC:[RM_3X>Y,]3!U4O$TE#O,)*X+I%(5[F[."APD3VYK!B5+#<$^.\G)P
M62466')1QQPQLBB:&1QM#6,;D&M&0 '(+7*BHGJZB:JJI7SU%1(Z6::0W?)(
M[-SW&PNYQS)MF5&/;/4&,W5:U,WU)MJK>H-RICQT;K5NC.==%L 1SZQWE#'T
M<M(9;[I2U$ [9>C%;;!(@^(3D[T@2.2EAB92-5*G[#U]JCWULIYMJ4]"W($2
MEQ5NZE&B2I5#LX 0EKW0].064:XK2VQ&WMI:M:8 2E2!O0(4(3C1A2(TQ&"R
M0$7[>$7+/U&_[8(Z97S?UE^EJ\N9^B^!J_[]_P"3B6(J_A&B[!^.Y=3', LN
MN9_KO6S'I-8VM.M<3WIIG6B8/*2VFNVX]8-Z2&H<QZN[%8X.TJK-=CF%$J:%
MSH@KK%FQ"OHY-W"/E/SO82IYB2Y0ZQ-7Y*ZN??/O\J*Q[HU.J-XZ=U)*VN=(
MK 9"I!>#?''1KE$JG3.PQ=JOJS&V,UZQSR:I4DCG;'6+"E;Z^9YHK+,32ANC
M:9Y:E:YI6(5JAK;AWXJ.?;Z,@K0N%*<(J;.HG[O[HK_A-["_R8YEPBN3X1.$
M7.-<=&7-96X6ZC]7T\J^,LB:YH VGM\S@,ME#J8X$:OZ_GGJBG!BL.*(RT1A
M"I,64D,;C3P&E*#!JC &EEE:9M!105%:Q\KI@_P=C1T;F!NZ))2/KXWF_E&^
M=K:#)=K]CG&\1P_!)Z>D;1.B=B,\A-3'.]X>8:=K@.BGB;NV: +MWKW))%@L
M<]B3M#^[!07F[,_[CUB]_O\ ]VG/G_C[^8+Q71Y>759?^W%GV^XKH/MJQK/W
M+"[BWZC67'+2KX=0([5&.].DQ:.P,A8)+,KLK%J7M#"KASN")5S/F=--H$X2
M)AEBZ!S )]KN!ZR-*I#&FEQ&%J4,[L484>6F=B"5:@ [ZECBHV/CC=*YKGMD
M:9.C<8I@R2)LT5HV@2!DKF^4'-T):2T$:_B\U5C4\$]6RDC?%"^ED\&%5$VL
MHWU$%0^CJKU#W.IW3T\3_<S%(TAP;* \WQZY^CS:5[.KP^3:_*V"ZNS]%W$I
M8UU7*"S&=@B\6D$5)@[,!RLAS)11M>7+Y>^*S\%CD2>22)0[M;ZWFH&D"#[I
M6Q4C6MBZ3=:V06<YAWGR2,DZ5VZQI+V]%$P"^X8XPUS';SRZABHJ\8DDFJO!
MA)+/3R!\<<H,4-/334[:2,/ED#*=PJJJ5S@.G;43NDCFC+(@R7@=2-H XP'%
MP4%X(0X#C&:?L?/=C'9CMSFZNW/=V8[^_/GSG/?S'>*J/]G5?AP_U-N_6;[.
M-J<:^U84+9#W&L-K6 UJ^JW$=>86"6GJELRCK&QE:JVZ(.2I()+U*DE-4=AD
M*#DZ>/.)AQ1!QMR'EDG&%A& HP9!I8!B"(1)@<9!FI%A=()8R'U-P]AS?"1D
MX',=#\RMJO:C&G4M4UT6%EKJ>9KB(:L&SXG EOU78$Y@9$7 .0&?2+1GM)4[
M\UE??FDT<Z8O+BVGPB<(G")PB<(J$M[,9SO4^=F,Y_:IT9YL?]+.RW^WF@;<
MZ8;VU7]'7HCV!==J.S!L_P"4_I^GA'[P1?\ %%^3/.?+T1W[\/5\2\>"+WL_
MDSPG?OZT\$7_ !<^_P";/F]_A$\$7=^QS^3/?PB>"+/F#G/XL\7^;OWTRT17
M(=-OW#FN?^)"CW\?\(WSW^=VH?>5'^]:?\BQ> \<^&\9_A;$OYY-WZM%-_ET
ML6G")PB<(G"+G"AU"U\Q('U!:'3KF4TG6;%MEQ?):;JK%9J*28>;1F#PUO(9
M4I1J5#X2X,R]O4IUQJ@PP1!A8!>#D'@!UZIH\2DGE?$]PC<\E@$Y:-V^0L'"
MW9;S'1=$PO&-F8,.I(JN"%U2R%K9B[#Q(XOSN72&([QM87WB3Q*RS[CE =G_
M )L66]O9\"Z'^?O_ /AF>['=\?;\6>ZAX!BOVR3_ %DGXW'^WSJ_&.[(7][T
MX_ZK;U\>AR]&AZBK*>G1 W6N=9D\<<ZX=:E3G7'L9(XY7SRP)8HNCL+EM]6)
M)86GS&D6<I6%,?%W5J5HFHD)84:1023XDG(<EAV*G;(R"%DI)D;&UKR7;QW@
M,_*N;Y\5SG$9*>:OK):5H;32U$CX6M9T;1&X^2&QV&X ,MVPMH!:RQ#J,4*V
MVW$]?YJEA4CFT]I[;'5.2PTAE/E+@GC3<KV?I4VPIDIB3.KRQKCV&"L[R(Z6
M/;.M50V*J9:) X-#8\R$2RLK)6+\(G"+EGZC?]L$=,KYOZR_2U>7,_1? U?]
M^_\ )Q+$5?PC1=@_'<NICF 677/IUM*>?YI8^F4M8*?V0F<>0+KK:+7F^G.L
MM6WM?T=:!1F,C@* 3W9D7D3='(6K?U3V!<T=A!KR:H-6(1X,9U!9Y%9YT^&S
M++J'433Y)L0WEMZ64)2$.UD!B=87LC3%S6183)YI!8.VM$68"BB? #&B&IN3
M%J8KAE6G!$I4G&"*!GZ>]LSWX*&O7+M2WJOU+K$BI9@=7I5H;;:]U%9LX!8K
MM3Z2/5?-I"XD/N7JW(^@<7^KXX].R-@CTBF[(1AV:&9V6@0#PI5%A$4KFUL_
M<ZU55+Q\!>U&PE5CURTKV3L+7IU]DVZR]-=VW-6[]JZ:2IFBRTS)!U&S\ *A
MC.WL]>1>:L4A7B@\F.(=\/R]$ND2R/1\?K^A1V?V=74KR]TYU?[WU1^CM'9I
M1[+&:J;[AL5XBMM)[/;71YF,T?-5I0;.HNNK J/)G&(IH<H,4@2/"J0.14@\
M3C"=*B\+'9*E=#'")PBJ)9/='[PX].=A8;\?=C5'6W\G;Z<>;N[\]^>:KC=_
M"V6-O<&=OU\FBZOL,/THFS%O#I38_P":AX$<[^FXN2MG<Q'?S\.]_3=;L.',
M@BYX'UDYV!X7(%KY!R5(( &N74>P&XR.7;?AR3COW[\0OG@+6L#Q//K!-LKW
MOKRT <*?.1J,M!UVMD,AJ<KG34ZUN?VGK7^;6=_FNZ_;]7/N/[(S[]OXP5"J
M][5-@?L$Q)!M<=&^^5R<S];ZK:JQ^C/:2IWYK*^_-)HYOJ\\K:?")PB<(G")
MPBIOV8I6GK@WJG ;8JNN[,PP:IZ]Y8L3Z&1Z789LN=L[28<LM>'YN7X09<,(
M$.%N4OBO*<(TN#O#\05X&O8\][/!=QSFWZ>]B0#;H;7'5<V\ZWS8F&*7QETL
M;'[O@EMYH-K^$WM?FL<]A3IU\%777'_T8KO\G9ZW??YKO3S?;'_A'YUO7@5(
M,_!HK_>-3V%.G?P5==L>CVF*\^KWR?P<=/-]L?\ A%3X'2?<\7X 3V%.G?P5
M==?]#%=_)_@][W=\G'3S?;'_ (13P.E^YXOP O'L*=.^[]JMKMY_W&*\]/\
MD][_ &9[N.GF^VO_  C\_6G@=+]SQ?@#YEY]A3IUZ-5==O\ 0Q7?R_X/>_\
MS\=/-]M?^$4\#I?N>+\ ?,IQ=.]O0-&E]"-+4B2-K8V1=T;FUN0)RDB%O0(I
M9($R-$C2D! 0F2)$Y1:=.G)  HDDL!980@"'&-^@SAAO]JC_ ! N(58 JZH
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MLC7MS>&ANZ ^YM*>HKW0-G96NG\#JFQ2$5!FBKY)F4IB93N;3Q[[27/@?$\
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M!R(8QC%G 0  '&1"$+. A#C.<YQC'"+6'W<:4]3H.[_=@JWU)LU=ZEULZ?=
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MJH8SC#E*I<Z/#BO=7->L/4+7!Q6JEJP\Y2>:8+Y<]TCB][BYQU<=386'+(
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M\GQ35<XOPS^:H.UV%?L:O2UC TZ9 _7\K=>NEUX]>5T]W[339KX_Z=KEW?\
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MF1)\8JNHF";+H XVTTQ.YVI YS5'*7)<H)C3(E"Z#?\ $<&\-:,AY7N^??\
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MB)F*=+(O%-3ZL)PR9,*",XBG3*]2=6)ZYDOD_P!;J(GS^2UM;*&0SBHX#+I
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7]'")PB<(G")PB<(G")PB<(G")PB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g773514g98f32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773514g98f32.jpg
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M 0$! 0$! 0$!_\  $0@ S (S P$1  (1 0,1 ?_$ !\  0 !! (# 0
M       %! 8'" (# 0D*"__$ 'P0  $$ @ "! <'!A0,$ L&!P4" P0& 0<
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M403JI2W 28!UT //3A7G< [GV#WKFT(=PJV=[RVAO;)H%F=VTS:V+B6DR0
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M(Q!4E(0@L .*1O&L_66WMTZ@VS:\ID7G(WX=M>T8^[)-- B-HE4D"+>@S%H
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M346[7D'4ULY?-+V+6PZHZ@JL:H3]JT!H>B1HJ)=1FM;>B4.V;!+LVP.&V->
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MXIZRM;!2$K&&EU+0MK.W"6MX6]Z@/E)? <&-4=#;TU+%PUU=H6H=?#2^G*0
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MF+Z,?"GY,<9+XCR?*:YJ.!\OR"IEKW/^#C_-QFK@?(?BKL6N7X0^2I9CW?\
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M-VUX]/O;GT:>3M6_5 %?<*T?Q5PWKOVLOWQGZ=-VUX]/O;GT:\XKU6Z\?^,
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M8_-U/V1.Z!_TZVQ_[SXW^G5RQR,<D./1RN<K6/@Y>-;X_P"YG#U-P[[0LO\
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MPT[WYQ:2[P=,5,-8:WO.(./ TPVJ](;M$BIL53?)+0D=^JX%"0><DB.N0K+
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M)4TH (WA)$ (S9<TD\ KHGJ40DP2!60?:) #B22O( -25@9LL=>7I <T@D:
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M?_\ >*%1F<BN*3&G(<./.D#K'P_-4HRPUC..J6RKX$OX]W[+6.*2?:GX/GI
M]L/A^;_=4JRVC'5U/-J]WS87[F<^;SHQZ>,E<>$<?C/^ZM !''D1Y.BG7X!U
M<>OC06%EMT<VAR2S'3B6TKPCJ7E)SGP4C'8QAIIQ?:SUYSCK3C'4G/7G&>K&
M:U>K)[C%];0O93OHG"E.XQ?6T+V4[Z)PI3N,7UM"]E.^B<*4[C%];0O93OHG
M"E.XQ?6T+V4[Z)PI3N,7UM"]E.^B<*5(#X<9"I?9)1'.T/F(SA+<S'82IK.%
M.*[49/6E&/.K">M6<?E4YSYN%*C^XQ?6T+V4[Z)PI3N,7UM"]E.^B<*4[C%]
M;0O93OHG"E.XQ?6T+V4[Z)PI3N,7UM"]E.^B<*4[C%];0O93OHG"E2 N'&1,
M2I).([G$>;CL(;F85G"H4A*E8[<9*>I&,Y6K'7UY2G.$X4KJQE2H_N,7UM"]
ME.^B<*4[C%];0O93OHG"E.XQ?6T+V4[Z)PI3N,7UM"]E.^B<*4[C%];0O93O
MHG"E.XQ?6T+V4[Z)PI4@_#C9'0$9)Q$I2].RES+<SLN95F-VDIQB-E>,HZL=
MKM)3C/:QV<JZL]2E1_<8OK:%[*=]$X4IW&+ZVA>RG?1.%*=QB^MH7LIWT3A2
MG<8OK:%[*=]$X4J0S#C>*DH\9Q.SXP6KPO@YG8[7=F\>#ZN[=OM8Q^2SGL=C
MJSC&%9SUXPI4?W&+ZVA>RG?1.%*=QB^MH7LIWT3A2G<8OK:%[*=]$X4IW&+Z
MVA>RG?1.%*=QB^MH7LIWT3A2G<8OK:%[*=]$X4IW&+ZVA>RG?1.%*=QB^MH7
MLIWT3A2G<8OK:%[*=]$X4IW&+ZVA>RG?1.%*=QB^MH7LIWT3A2G<8OK:%[*=
M]$X4IW&+ZVA>RG?1.%*=QB^MH7LIWT3A2G<8OK:%[*=]$X4K)09"6QD-"'4/
M)2WG&'6\+PA>.VO/6G#B4+QCS]7Y).,]>,^;A2OA)Z2/\^;S)?W6[)^_./MO
M8S^)&SGXFM?ZM-?Q@[L'_++W1?\ //$_Z\5H+HC\]_RR?WR>D?\ *=6N//;6
M?P3BGXMOOZEROT/N5?QEV9_SDP?^WVM?8US@$]AHH.P:IIXJ^"VY?<W&M:\/
MQ\!U>39M DZ8S8I&3LX<-9BCHPMQK$I^4CN\^8/4VEUY332_F=@ A)(D)2DD
M<9D #3RF>K36*_J(Z3*P#!*E 'JU/,Z5ZZ[[N3F/OE!K7,]IQB^=XA<N5<D[
MKY5,Y+!CLGRJ?OHV]GM<QI68Q,5M_3EC #20%N"Y%S>JGX4;AS,PW5I+VP2D
M2E0 !5T50"1P,'RZC7M\V1)/2!X)U&HXSK$3(&OETUJZ+E;MNZ\YF;J$JEGV
M7?=9[$"6MS4C,@Q92HW7G-/KW7K[D?65@EK*.Y>TO>VK"/+0WC;:A#>V1ODG
M*(HA>+1;P %(E*0J1.@$I)CTQKKK&M"2%$9B1&FNH4!PTY>C736M61&U^D(4
MT)3#9V',K^!U/>U^3*"B22EGVI)$\@SMAJ]M<D1&Y3X!@Y;.:-B6.+I:&P>Y
M;#C2&X476XOQ!;*W][SGAH.E!_7V"JRK0=*2.T:@)D3U3/6-5=6GL,Y*&N9Y
M@MN*)OZR>6-?$+U\#IMP:<(J$W:Y0(%DD;2N5.9,APA&%1S"9]&B"QT2&JK0
M3PJT1ZI+)#$9*3LG @9<L3K($<-(G4_MQK1$ZR9X0>W6>4>C3JK??C*KTX4J
M];E_2:;_ &E"_P!_%>%OP=_GE?DHJ'^+?\TCXU5BZ+9J]-L)BI0S0V39J^,!
MFC@%B6RZ4$B;,^;BU\@0AH5EZ+&,OUL\T/<>2G$E0J;X/M895GCD0>,:==85
M(/D1\:9"'R)\.//)XDY'07I3#4PAB$VEZ9F%&6M+TK$1E:'9.6$.88;6E;O8
M2K&<HX]G&E1F+37\VA=*P4C9M2 #=I6$_HG?$U]TBZ);*9QV/!=V619=B8_H
MGA/"HSUHPGJ5F8,3RF//2K@3Z<?#CY>(I54CTY^#_/CA5D\OPD_+4BQ[G_,X
M5"N)\I^.I-GTX^'/R<0>*?+\AJ>7^C_MU),^C'P9^7C$\$^3Y36HXJ\OR"I-
MCW/^9Q%34DU[G_"Q_FXCF?(/C56J.'F'QJJ48]*?Y_U6.**\$?@_*FKU+L^C
M'P9^7C.E237H_P "?DSQFOZ/^U6GMO\ 3_V:E&?3CX<_)QG5QQ5Y?D%33/HQ
M\&?EX5-3#/HQ\&?EXS/A'\)'Q&E3+'I3_/\ JL<9TJ9C^C'PX^7/&*N/I_*5
M6@X'\$_DHKTJ]/#SY;QZ/GE7U9MC0L>CR;3;^8 'KHLB^@)UB%IK\[7>RK*\
MJ)$@&P3K)#!&LC<(DKE.MIC9DM9CJ4ZEQOJ\4NW;-AMQD(*E.A!S@J$%"U<
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MR]'9UU?L[D0Y@%6VWVL#N("):L5YLEQDUM)BSK%V840YJAF]@- LBI8 C!C
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MX^>''AA1JXHW0A]*&VC&%\KLC&>O&?\ 7?T%GY-J9XXZ]G\7)TM.7VQ:]O\
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M$.3'9$[H]AO*#FPTEN[PYU8=>LJ"=C:JZXH#>(S:[JF)+-?;.M29(X=D0UA
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MW=L*9OW@F\QAO$7_ %6MVL05<M&[<PYM(M[:W<NUH:9S+!64;QO%JMXD;9S
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MY#=_V=RO3;(_PM@_XRL?[6U7Z,VR;37*0U=[?;C0VN5>M.'C)X\7E-0A@D7
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M:F6QKR"*U8A9\/PW#P25%I>5*]V3E.BYC+PF9!$=>G&HWK<A.\1*DE8&8:I
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M8QUF-K]T)6$\P[D>/5+'/D9V"W+Q6:W+F18MY(MPEOAEO8DCH9H>T_-:L&Y
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MZU':NYK]7[&A--&ESM1W%>P+5K%S7&TB-0&V]-PJ5I>ILR%#56;3:JR<B$[
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M[N6^7;IS9>%JDM69^2&M=,:O) 7*N0U;(#01$L5H#5YUB4(BCK($LP)Z?6K
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M660/YD0?V)7^,7PI7YI_2Q?[(3S?_P!W&Z?O_CZZV2_BA@'XKM_R!7PKMO\
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MC.624B!(@)C@)2X9"4EPE*C>%C@2ZXU%-DE8T!0!,D#4%0C4CT\M >(J^\$
MB2%E40"=" 9T!Y>323P!K85GTX^'/R<85L.*O+\@J:9]&/@S\O"IJ89]&/@S
M\O&9\(_A(^(TJ98]*?Y_U6.,Z5,Q_1CX<?+GC%7'T_E*K0<#^"?R45\Q?U4;
MN7<&F>6WEC*Z?VMLG5!0SO ^.,$M:WJT46>5'LT0E):@DIE7*"Y$Z&U(QA]N
M-*<=90]C#J487C"N.BQQUQIADM.+;)=()0M2"1D48)202)UBOVSN*X;AV)8Q
MB[>(V%E?MMX<RMMN]M6+I"%FZ0DK0A]MQ*5%)*2I(!()$Q7Q:P^>?G95A.5<
MXG-,K/5GSYY@]M9]S[-NX\R;N[@_NJXX'^6<^E7U ULELJ<L[,[/GCQP;#NW
M_!JNB+SP<Z:NQVN;[FB5U]77VM_[7SU^GZ]MXXRKV\'"[N>!_EW>M/W]=HSL
M?LD0)V6V</EP3##['MM:N:+SM<YRL_DN;GF=5Z/3OS:N?ZK[-KXQ5?7H&EY=
M#CPN'1R/W]=S;;%['*RYMD]FCT3QP+"S\=K5S1.=/G&5U]KFSYF%>;/Y;>^T
ML^[CZ]JXXRL0OX/[NO/"^V7O:_AUW;>P^Q64?\#]E_"'_P!/X3UG_!*FV.<_
MG#SCS\U_,KGS>[O7:.?<Q]>T\9*Q"_ )%]> ]8N7@>(^_KG-;"[$'+.QVRIX
M\=GL(/7_ ('4S'YR^;_.<=?-9S)Y\V?3O/9^?EM'%#B%_P#;UYX /_&7N,C7
MP^-=DWL#L*3KL5LD=4\=G,'/,_X'4S&YRN;Y..M/-7S))RKM(5E.\]GXRI"O
M,I.<XM'7E*L>;*<^;./-G'%/5'$/MZ\_UE_Z==FUW/\ 8(C78C9$Z'CLU@QY
M_P"15[L.2KI)]];<@N4"][0V#(NM;$KFXL63A)8\T!%MI>DRS,A1 ='A3F&V
M),DP0GEQ,=4)XH]-/U<#E%XT]Z_!L9N+P=[O+<+[:,V]DY5MI@2LZ!*Q[(J(
M!$G,C53?ROW7>XW@&RCJ,<P:PPYO!\1NMR</4AH/V5ZZ%*#=H@I<6_:K! 8:
M::>6RXEI 8N7,MKB?L$7OS=6&W6WMHWE#B<2$.IDV(A'PAIELVF;F8N5,I[D
M1R.@;:N_JE2*4N'D?<5DI>JW:7:"O(9WN_=YK5YU$1$S,Y ."YU21"\Q:*%J
MLOPX8)A!.F&V<'+E*64*DJ+)1E"$W06"7+;($)N\Y<M4MIQ%-W;-;9\7M_;K
MPY);D;2O*,,HF8FKDV$A#\%E";"DEF=EYVD]P6QB-<,3L/>0&1"QEN7,QJ%R
MA&T]'=.^=/\ **$ S*B/;22>A'!<_O9$+'K10KO"!@F$=$IPZT,Y<@2RA4R6
M-WD@7F<'-:Y,O?V]WEJ$'%>_F?KZ\N[]W9GPV)>T+RVI>9F):7K$1A.,I_TQ
MMS\N^$S4>X.,YS;>]>&CTE0Q^!84O1=5N427!Y Q>=F"ZOF5"8(\+L3'!6D-
MZYI#64BRD8)A&F7#K,QDRD,(6"?6"V!'?6<$=[985>;Q*V"%8D+U"]M><G?F
MZ_\ 1"WMI7OLJ[VA65GB43+BUO&V9>5MM)".PWFY! TT['1"K\D;+:=AH&TV
M95@]>Y>!>=\8OB9U(XR.R(D@@!,$1"2D):@8+A *0G#;/V!!W*%1 9*=5;T+
M3E0T0HK?2XDA9<NDW+KV-\%;^W<_UISM"]]N0IWMX2?(-.X[RY.2XIM$9"%,
MN+=,NMQFHL)K,9UT7%'#FI@ZKA0T%YWQB]=1"O*9CJ,D#30QIHE*8]1,)3J,
M/LX $ LH(Z(;B2HF0 T"I2ED$!Q:UE+ERX[[$.3'F8.[ -HUO>4S3)_ PZ3!
M6J)#7*Q,&0Q2I<IBR*@H>CPT1F9T!8^PJ7@;);)!1T^6I\]13VQN9;/J7T%R
M502E0UD#B%1,1(A7 R 3)07/%[3;/M62/5"TR-,%:6WK=2PG*XLJ2A5N%D%6
M8H7G8 WB=VZXA(2S=LV.\_',KQ=.%*<*4X4IPI3A2I.1^98S]G(_+$X4J,X4
MIPI3A2G"E5,^=$&5F42(2&XD ?)F3ILIY799C1(@_$B3(=5Y^RVRRVMQQ7N)
M3G/$@$D :DF .LFA, D\!J:Q9I_<&M]^:XK&W-16F)===7*/.DUJS0HA.!')
MLC"L\&0RF&9A#2D9R(7%D(#[,V#&>0_%=3EOLX2K-W6G&7%-.I*'$$!2208D
M C4$@R"#H3QJB%H<0%H5F0K4$2)@D<P#Q!Y5K7OGG3&Z*V]&U+)UK8;L1D:Y
MJ>R(R:F3CRK.:@6?<8#3B@=4IZQ_>+%814^PM6F5!:*1&EU<89EXD-R(28[^
M[-H7FMZ%A(WBFSF!R@I:4[F4J=$D)*9CPB!P,UD[<!M>3(5'(E8RF2<S@; "
M8U,F8GP03V5?/+SS7T;F/HQ*Q4P<3;N0$ S8+!K*0E<<_ BE#%T!U=40J9C
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MI\^]:O\ ;B- I>L+A+NC@S8V:P L9$)4)!.SZD!:'-;$J]C>+/=VISM;_!^
MQ9$V4X3R\NH7G+,)3L.O1[)95DI" XMQ(1+>9205 )=4\$*3&JLVY)@ >$F3
MQBJ;I*U9$H5F(64I40F2V&BM*B=$Y=ZD3K.54<IN?7W.4.O%PY8JK.UT7IJN
M:+4MAV=5&K+9J_&LH-ZL5\#9200G5\*PX0BR1IQ60Q4*3FD".!!@BNMQ*]!>
M.)JY:%";A06%][NI;64I.0YE%((5R,@2" !(&;-"39%QF4RDH*=\@K2"H9A
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M %* X Q5P20">) )\L5ECBM33A2G"E7K<OZ33?[2A?[^*\+?@[_/*_)14/\
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M!PB:N['*OK-G8-7V\%P4"[6IPO:PL-=XC\=N=.8W$3C&;@U;XL.-!CW6'@O
M%$@HZQ=\A@98B ^(:ANH><>SSG*4Z%)(,'K&FG,:<8ID$YO9 * /X7&>N.4\
M*R[4=3TNETS5- K@MN)5--#:V(HXZ1US5#1U4I\RE 6^\R,J>5)A!Y79[ZK*
MI#KB%*6K*G5JXS6HRL\U@ ^<E1^$5H$   <$9HGL2$CX#67F?3CX<_)QC6HX
MJ\OR"IIGT8^#/R\*FIAGT8^#/R\9GPC^$CXC2IECTI_G_58XSI4S']&/AQ\N
M>,5<?3^4JM!P/X)_)17J Z9CHT#_ $F.G]/T$!MH/J1[6FR"%QD$S%2FVUHL
MT2K,\(F S&A' 2XCC2W,2%/K>?2M./!X:3G/:XZW$+(WS;;8<#>1>>2DJGHE
M,0%)CC,S7Z'W/]M&MBK^^O'K!S$$WEJBW#;=PFW+90\EW,5*:="@0F( !!UD
MU\]K'U*=L9G&,9YS:2KJQU?ZS)W'7U_]86>.H.SZR([Z1J(/K1T_\>OP5^OH
M^J#L4Q_P8NC$_P!TV>?_ -GVU,,_4L6Q&NKKYQZ6KJZO]IPYCKZNO_T_S]?C
M)6S2SPNT</$GK!\9V5S6_JC;! '_  5O#'^-&>J/M*I9GZEUV&UGS\X-,S\&
MGSF/=Z_T_<9G9=P_\\1S_D5<P1XSMKG-?5,X>W'_  2O# C^%F!/_P""?VZJ
MEV/J8C8+/IYNZ:KS9_VHC>/3G&?T]Y^MQDK9-P@Q>HU,_O"NJ/&5V"?JI\.2
M /K-O3!!_AE@<)_Q?VU(-_4RM_;QU?AN*?GS?J1FL?6_].\_6XH=D'"([^0)
M_P '4?\ ^T5R4?578:F/^!=\8G^[-OSG_%_;4@W]30WUO.,_AM*AGJQG'^M*
M9QZ?_CK/%?K/=/\ SYOP0/WA7(SXT5RT?5;X8DS]9%\=1_=NWY?]FU+0OJ:2
M^O9=3^&SJ"? QWY.<_@3&<]K#*.WE&/]/6.K*NKJQGSXQZ>K/%?K-=^WV_\
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M:A$WD(0AZ3/D00D&1.(."1+I @^T\0)F3)0_;CUGLYWE--):3 U)\)41)^&
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M"8Y=M1OX ]$_LS]T4?1>+^J#_4W[D_2JO>;/4KW1I^ /1/[,_=%'T7AZH/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g773539v1_page1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773539v1_page1.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( !D V@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MO4/B5X=TKQS8>%[K7M%MO$FJ6\EU9:3+>QI?7<,?WY(X2=[HO=E! [U^>7[
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MSK#-<>)(?C&_PY\46P/WM*T2X-W/\O7;';O: 9X_=$]J^RO^"T7C63Q-\(O
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MG?\ !&&3]GC]@CXR?"75O&5KXB\2?%BRGTYO$#63JMG E@MI81F-G+,EN0S
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g773539v2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g773539v2.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE
M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( "(!+ ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M9U.940_>*MMX(QS6+_P0[_;X\7?MD?!3Q-I?Q)N[>3XB>!M5.GZC"J".8Q
M+(ZC@%F#],#BLGBJ:K>PZ[GH1X=Q4LK_ +727L^;EWU];=O,^YQP=I'?K0#E
M..Q]:XG]H3XC/\)/@EXM\312)&=!TFXO59_N@QQEAG\J_-3_ ((L?\%;_B1^
MT]^U?X@\"_$?4X;K3=<M[G5O#<TL*Q.Z+)M$4>  RA5<YY/%%?&0I58T9;RV
M#+>',5CL%7Q]"SC2UEWMY+\S]83)M']!3U.5[=*_+K_@O9_P4U^('[*M_P"%
M_#7PE\11:;K%N9-3\1S0Q)/):6RE%575@0JL95YZ\"OOK]DSXG7GQE_9D\ ^
M*[N9;B\\1:!::A.ZXP\DD2LQ'XDT4\52G6E16\;!CN'<7A,NHYG52Y*K:CKK
MIW73R[GI#MYB_+2$C=M]O6O$I/V_/AC_ ,+/;PC'XDWZD-0_LG[0L#&R%_G'
MV,SX\OS_ /IGG=[5D?\ !37QGXV^&7[$'C[Q-X!UB71?$_AO3SJ<,\<22[8X
M?GD&&!'*@BMY5%RN:Z'FT<#5G7AA[<KFTDWHM=#Z%)P/I[4>:-FZOB?X?_\
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MV1C<!T[9KZ0_X+*?M$^//V3?^">.K>*O"'B!M+\6Z7):0?VBD"L7+,%<[&!
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M@W4)+^XT'7O M^-1TNZM J>7)O1N?E.?N"N:6&K27M.M[K_+[CWL-Q#E=-K
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9W\AY7$/2DBY-%%(.@YES'TIPZ445('__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
